Clustering O 0 0.00012341329420451075
of O 0 1.6027857782319188e-05
missense O 0 0.00014732565614394844
mutations O 0 6.856690106360475e-06
in O 0 4.3243680920568295e-06
the O 0 0.0001514609029982239
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999697208404541
telangiectasia I-Disease 1 0.9999996423721313
gene O 0 2.0423745809239335e-05
in O 0 1.1805303756773355e-06
a O 0 9.384794793731999e-06
sporadic B-Disease 0 0.06464002281427383
T I-Disease 1 0.9999463558197021
- I-Disease 1 0.9596644043922424
cell I-Disease 1 0.9954278469085693
leukaemia I-Disease 1 0.9999866485595703
. O 0 0.00018262275261804461

Ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9998910427093506
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.025603365153074265
A B-Disease 1 0.9999945163726807
- I-Disease 1 0.9999487400054932
T I-Disease 1 0.9999828338623047
) O 0 5.620179877041664e-07
is O 0 2.2108665120867954e-07
a O 0 9.786904229258653e-07
recessive B-Disease 0 9.804104774957523e-05
multi I-Disease 0 0.29910194873809814
- I-Disease 1 0.9904656410217285
system I-Disease 0 0.2228279560804367
disorder I-Disease 1 0.999951958656311
caused O 0 0.00022870348766446114
by O 0 4.6174037038326787e-07
mutations O 0 5.316176157066366e-07
in O 0 2.426874630145903e-07
the O 0 6.640200922447548e-07
ATM O 0 5.626436905004084e-05
gene O 0 1.772969085322984e-06
at O 0 1.1736377700799494e-06
11q22 O 0 0.00010514323366805911
- O 0 3.844477396341972e-05
q23 O 0 0.0002125932223862037
( O 0 1.6798049955468741e-06
ref O 0 4.729607826448046e-05
. O 0 6.465210731221305e-07
3 O 0 3.093238774454221e-06
) O 0 2.4742785171838477e-06
. O 0 1.4001174349687062e-05

The O 0 4.365257700555958e-05
risk O 0 5.433851765701547e-05
of O 0 0.00011109679326182231
cancer B-Disease 1 0.9999849796295166
, O 0 3.988779280916788e-05
especially O 0 5.762455839430913e-05
lymphoid B-Disease 1 0.9999866485595703
neoplasias I-Disease 1 0.9512268304824829
, O 0 1.481392928326386e-06
is O 0 4.6933925545999955e-07
substantially O 0 2.6037064344563987e-06
elevated O 0 6.046700582373887e-05
in O 0 3.6364533571031643e-06
A B-Disease 1 0.9999942779541016
- I-Disease 1 0.9999991655349731
T I-Disease 1 0.9999998807907104
patients O 0 8.834905202093069e-06
and O 0 6.572348070221778e-07
has O 0 5.482439178194909e-07
long O 0 6.639529601670802e-07
been O 0 4.769249244418461e-07
associated O 0 9.040752502187388e-07
with O 0 3.5392711197346216e-06
chromosomal O 1 0.9999779462814331
instability O 1 0.999993085861206
. O 0 0.00043736150837503374

By O 0 2.4776765712886117e-05
analysing O 0 0.0003712767211254686
tumour B-Disease 1 0.999998927116394
DNA O 0 4.3711599573725834e-05
from O 0 1.3818863635606249e-06
patients O 0 2.3635254819964757e-06
with O 0 1.2720436188828899e-06
sporadic B-Disease 0 0.21869227290153503
T I-Disease 1 0.9998971223831177
- I-Disease 1 0.59562748670578
cell I-Disease 1 0.9892637133598328
prolymphocytic I-Disease 1 0.9999868869781494
leukaemia I-Disease 1 0.9999998807907104
( O 0 0.005135730840265751
T B-Disease 1 0.9996113181114197
- I-Disease 0 0.014615636318922043
PLL I-Disease 1 0.9973364472389221
) O 0 2.7521556944520853e-07
, O 0 2.1392271776221605e-07
a O 0 5.954254334028519e-07
rare O 0 5.346307261788752e-06
clonal B-Disease 0 0.002292992314323783
malignancy I-Disease 0 0.01857931911945343
with O 0 2.813267201418057e-07
similarities O 0 1.2267568081369973e-06
to O 0 2.2705380331444758e-07
a O 0 6.892071723996196e-06
mature B-Disease 0 7.232617645058781e-05
T I-Disease 0 0.44520658254623413
- I-Disease 0 0.0003785779990721494
cell I-Disease 0 0.024124443531036377
leukaemia I-Disease 1 0.9441683292388916
seen O 0 8.443745969088923e-07
in O 0 8.015646812964405e-07
A B-Disease 1 0.5743939876556396
- I-Disease 0 0.13248810172080994
T I-Disease 1 0.895111083984375
, O 0 1.6436349881132628e-07
we O 0 2.4322401870335852e-08
demonstrate O 0 4.879862558482273e-08
a O 0 8.569588771933923e-08
high O 0 1.6891659981865814e-07
frequency O 0 3.0128029493425856e-07
of O 0 7.87755482178909e-07
ATM O 0 6.61101148580201e-05
mutations O 0 3.991005996795138e-06
in O 0 1.1125310265924782e-05
T B-Disease 1 0.9979128241539001
- I-Disease 0 0.3270711302757263
PLL I-Disease 1 0.9994526505470276
. O 0 0.00012187066749902442

In O 0 7.978483154147398e-06
marked O 0 1.1493337296997197e-05
contrast O 0 1.6907209783312283e-06
to O 0 2.561242808951647e-07
the O 0 8.78905382251105e-07
ATM O 0 4.121341771678999e-05
mutation O 0 2.1134001144673675e-06
pattern O 0 2.667310127435485e-06
in O 0 7.048921588648227e-07
A B-Disease 1 0.9295651912689209
- I-Disease 1 0.6810267567634583
T I-Disease 1 0.9848964214324951
, O 0 2.303928425817503e-07
the O 0 1.1624678819543988e-07
most O 0 5.498404576087523e-08
frequent O 0 2.1244669312636688e-07
nucleotide O 0 4.501468993112212e-07
changes O 0 1.08163952461382e-07
in O 0 2.264500409410175e-07
this O 0 1.4567148127753171e-06
leukaemia B-Disease 1 0.9686989188194275
were O 0 4.940960025123786e-06
missense O 0 0.00025230576284229755
mutations O 0 3.855301110888831e-05
. O 0 6.714805931551382e-05

These O 0 2.430525682939333e-06
clustered O 0 4.19996831624303e-06
in O 0 4.724437019376637e-07
the O 0 3.938466193176282e-07
region O 0 4.524123937699187e-07
corresponding O 0 2.1409741179923003e-07
to O 0 1.0011757467509597e-07
the O 0 2.4052025082710315e-07
kinase O 0 7.839647651053383e-07
domain O 0 1.332954013832932e-07
, O 0 3.060433684254349e-08
which O 0 1.5007337594852288e-08
is O 0 2.0100774378306596e-08
highly O 0 9.89851471899783e-08
conserved O 0 2.826213005846512e-07
in O 0 2.4724261038500117e-07
ATM O 0 4.639345206669532e-05
- O 0 4.315641945140669e-06
related O 0 7.098504966052133e-07
proteins O 0 3.2788827297736134e-07
in O 0 5.275151693240332e-07
mouse O 0 6.327553364826599e-06
, O 0 8.201210448532947e-07
yeast O 0 1.4454680240305606e-05
and O 0 3.6705991988128517e-06
Drosophila O 0 7.678698602830991e-05
. O 0 2.3162549041444436e-05

The O 0 2.1337074940674938e-05
resulting O 0 2.964564373542089e-05
amino O 0 7.50137269278639e-06
- O 0 1.867721766757313e-05
acid O 0 5.367222001950722e-06
substitutions O 0 9.78952698460489e-07
are O 0 2.58501557937052e-08
predicted O 0 2.811279955494683e-07
to O 0 6.431719867805441e-08
interfere O 0 4.568834697238344e-07
with O 0 4.653476253224653e-07
ATP O 0 0.0016838954761624336
binding O 0 3.3653941500233486e-06
or O 0 1.2927422403663513e-06
substrate O 0 2.0520074031082913e-05
recognition O 0 2.1961279344395734e-05
. O 0 3.193219527020119e-05

Two O 0 3.795518523475039e-06
of O 0 2.2520516722579487e-05
seventeen O 0 0.00031710127950645983
mutated O 0 0.20570266246795654
T B-Disease 1 0.9879521727561951
- I-Disease 0 0.00404402706772089
PLL I-Disease 1 0.8774314522743225
samples O 0 1.8717677221502527e-06
had O 0 1.1065146736655151e-06
a O 0 9.882251106319018e-07
previously O 0 2.308010834894958e-06
reported O 0 1.1055957656935789e-05
A B-Disease 1 0.9786416292190552
- I-Disease 1 0.9998151659965515
T I-Disease 1 0.9999864101409912
allele O 0 0.0001881813514046371
. O 0 4.552623795461841e-05

In O 0 1.6043331925175153e-05
contrast O 0 1.0967003618134186e-05
, O 0 1.7313269609076087e-06
no O 0 5.552357151827891e-07
mutations O 0 4.912894837616477e-07
were O 0 1.7586202716302068e-07
detected O 0 5.653833454744017e-07
in O 0 9.162525316241954e-08
the O 0 3.513768263019301e-07
p53 O 0 2.160060830647126e-06
gene O 0 3.820755694050604e-07
, O 0 9.306370429840172e-08
suggesting O 0 2.1199051047915418e-07
that O 0 1.0358527191556277e-07
this O 0 1.0784685855469434e-06
tumour B-Disease 1 1.0
suppressor O 1 0.950108528137207
is O 0 4.2814349399122875e-07
not O 0 4.993060898073054e-08
frequently O 0 9.764327302264064e-08
altered O 0 5.514830831998552e-07
in O 0 6.768506750631786e-07
this O 0 4.44032957602758e-06
leukaemia B-Disease 1 0.9996877908706665
. O 0 0.00011299179459456354

Occasional O 0 0.00011037220974685624
missense O 0 0.00014722568448632956
mutations O 0 8.832260391500313e-06
in O 0 1.9677859199873637e-06
ATM O 0 4.5054392103338614e-05
were O 0 3.105547534687503e-07
also O 0 1.2110507441320806e-07
found O 0 1.1067724869917583e-07
in O 0 2.592959447156318e-07
tumour B-Disease 1 0.9999997615814209
DNA O 0 6.186661721585551e-06
from O 0 1.6390735879667773e-07
patients O 0 2.9191289740992943e-07
with O 0 4.4170812429911166e-07
B B-Disease 0 0.3870362937450409
- I-Disease 0 0.0038112085312604904
cell I-Disease 0 0.06163114309310913
non I-Disease 0 0.00026877198251895607
- I-Disease 1 0.9999165534973145
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 1 0.9999946355819702
( O 0 6.8330541580508e-06
B B-Disease 0 0.00012078236613888294
- I-Disease 0 3.821356585831381e-06
NHL I-Disease 0 4.154720954829827e-06
) O 0 9.810848666802485e-08
and O 0 8.934721051900851e-08
a O 0 1.4221424180504982e-06
B B-Disease 0 6.733979535056278e-05
- I-Disease 0 3.579235271899961e-05
NHL I-Disease 0 0.00017364410450682044
cell O 0 0.00013344100443646312
line O 0 4.5591976231662557e-05
. O 0 3.449110590736382e-05

The O 0 5.344772944226861e-06
evidence O 0 8.666666531098599e-07
of O 0 6.433762678170751e-07
a O 0 6.220562909220462e-07
significant O 0 3.449553958034812e-07
proportion O 0 4.1491796309856e-07
of O 0 9.257080364477588e-07
loss O 0 0.0002719442709349096
- O 0 6.264293006097432e-06
of O 0 1.8113341866410337e-06
- O 0 2.4939936338341795e-06
function O 0 4.2947951328642375e-07
mutations O 0 1.310062600623496e-07
and O 0 2.7142348812958517e-08
a O 0 1.248143064458418e-07
complete O 0 6.499050186903332e-07
absence O 0 7.539230750808201e-07
of O 0 1.96230530491448e-07
the O 0 2.140026964525532e-07
normal O 0 2.894724957513972e-07
copy O 0 6.373164751494187e-07
of O 0 3.2871014354896033e-07
ATM O 0 3.955064130423125e-06
in O 0 1.1444378600344862e-07
the O 0 1.5820948817690805e-07
majority O 0 5.434832814898982e-07
of O 0 4.919326784147415e-06
mutated O 0 0.0011659780284389853
tumours B-Disease 1 0.9999892711639404
establishes O 0 3.445428956183605e-05
somatic O 0 3.252064561820589e-05
inactivation O 0 0.0001024738303385675
of O 0 7.347586574724119e-07
this O 0 1.436483216821216e-07
gene O 0 2.6603925107338e-07
in O 0 9.514987908687544e-08
the O 0 5.310009214554157e-07
pathogenesis O 0 0.015206619165837765
of O 0 7.039952379273018e-06
sporadic B-Disease 1 0.8033649325370789
T I-Disease 1 0.9999548196792603
- I-Disease 0 0.09883453696966171
PLL I-Disease 1 0.9926020503044128
and O 0 6.860620942461537e-07
suggests O 0 8.015753678591864e-07
that O 0 1.9500188841448107e-07
ATM O 0 1.1491889381431974e-05
acts O 0 1.5434883380294195e-06
as O 0 1.9682665879372507e-06
a O 0 6.618619954679161e-05
tumour B-Disease 1 0.9999998807907104
suppressor O 1 0.9917318820953369
. O 0 0.00011235809506615624

As O 0 1.1146273209305946e-05
constitutional O 0 2.4449989723507315e-05
DNA O 0 1.2302691175136715e-05
was O 0 3.0029802928766003e-06
not O 0 7.797283529953347e-08
available O 0 6.935999152801742e-08
, O 0 1.7493100301635423e-07
a O 0 1.7958709577214904e-06
putative O 0 0.00018082729366142303
hereditary O 1 0.9991015195846558
predisposition O 1 0.997150719165802
to O 0 4.1532803152222186e-05
T B-Disease 1 0.9999644756317139
- I-Disease 0 0.013918370939791203
PLL I-Disease 1 0.9097623825073242
will O 0 1.365532682484627e-07
require O 0 6.929652585085933e-08
further O 0 1.799013205072697e-07
investigation O 0 1.3161428569219424e-06
. O 0 1.7456882233091164e-06
. O 0 1.4064714378037024e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00014891613682266325
kinase O 0 2.0781406419700943e-05
is O 0 3.128484138414933e-07
involved O 0 1.334794603735645e-07
in O 0 6.156241028065779e-08
the O 0 2.1997870192080882e-07
modulation O 0 1.3336726851775893e-06
of O 0 3.7260383578541223e-07
the O 0 1.3825664382238756e-06
Ca2 O 0 2.954745286842808e-05
+ O 0 2.290823067596648e-05
homeostasis O 0 0.0003319314564578235
in O 0 1.0214066605840344e-05
skeletal O 1 0.9999949932098389
muscle O 1 0.9998799562454224
cells O 0 0.03363747522234917
. O 0 8.336134487763047e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997610449790955
DM B-Disease 1 1.0
) O 0 9.841368409979623e-06
, O 0 7.755928663755185e-07
the O 0 8.314003707710071e-07
most O 0 1.6815841945572174e-06
prevalent O 1 0.9886852502822876
muscular B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 1.2538673217932228e-05
adults O 0 7.700916739850072e-07
, O 0 2.8637327886826824e-07
is O 0 1.8987888950050547e-07
caused O 0 1.3630153716803761e-06
by O 0 2.0695618729860144e-07
( O 0 6.864024157948734e-07
CTG O 0 8.533208892913535e-05
) O 0 5.958747451018098e-08
n O 0 1.7451010592139937e-07
- O 0 1.7009018904445838e-07
repeat O 0 3.2277313266604324e-07
expansion O 0 3.291104064828687e-07
in O 0 7.696116455235824e-08
a O 0 2.4506206841579115e-07
gene O 0 3.2992932119668694e-07
encoding O 0 2.4044180690907524e-07
a O 0 5.93669369663985e-07
protein O 0 1.7129232219303958e-06
kinase O 0 4.915903446089942e-06
( O 0 1.3687547379959142e-06
DM B-Disease 1 0.9995493292808533
protein O 0 2.3101513306755805e-06
kinase O 0 1.9457570488157216e-06
; O 0 2.41866757733078e-07
DMPK O 0 0.00018465970060788095
) O 0 1.2871568344507978e-07
and O 0 7.943491908690703e-08
involves O 0 1.9464255274215247e-07
changes O 0 2.0987991433685238e-07
in O 0 6.219264037099492e-07
cytoarchitecture O 0 0.00010334800026612356
and O 0 5.085395059722941e-06
ion O 0 0.00046675195335410535
homeostasis O 0 0.02709568850696087
. O 0 6.909955118317157e-05

To O 0 2.9540842660935596e-06
obtain O 0 2.1021296561229974e-06
clues O 0 1.0487405006642803e-06
to O 0 8.143352658862568e-08
the O 0 1.5802100961082033e-07
normal O 0 2.508304817183671e-07
biological O 0 4.4657485887000803e-07
role O 0 2.1795024451876088e-07
of O 0 5.377685852181457e-07
DMPK O 0 0.021211424842476845
in O 0 1.7530570630697184e-06
cellular O 0 3.782354906434193e-05
ion O 0 6.631621545238886e-06
homeostasis O 0 1.7335081793135032e-05
, O 0 1.1667862054309808e-07
we O 0 1.918040304360602e-08
have O 0 1.0219152635215778e-08
compared O 0 6.806439500905981e-08
the O 0 3.3247957276216766e-07
resting O 0 1.0599138477118686e-05
[ O 0 3.209325768693816e-06
Ca2 O 0 4.00100498154643e-06
+ O 0 1.372150109091308e-06
] O 0 7.532152039857465e-07
i O 0 8.201416079600676e-08
, O 0 3.308342044761048e-08
the O 0 5.7415761034462776e-08
amplitude O 0 8.176594974429463e-07
and O 0 9.232608988440916e-08
shape O 0 1.2195920362501056e-06
of O 0 1.4809111235081218e-06
depolarization O 0 0.0004531476879492402
- O 0 4.8286481614923105e-05
induced O 0 0.0035111429169774055
Ca2 O 0 2.3625774701940827e-05
+ O 0 4.433660251379479e-06
transients O 0 3.6949384139006725e-06
, O 0 3.929225300680628e-08
and O 0 2.967796497443942e-08
the O 0 7.364683796140525e-08
content O 0 1.3767650841600698e-07
of O 0 5.677114813806838e-07
ATP O 0 0.005743249785155058
- O 0 9.298487384512555e-06
driven O 0 5.296846666169586e-06
ion O 0 6.477766874013469e-06
pumps O 0 3.5515888612280833e-06
in O 0 7.343082302213588e-07
cultured O 0 0.03584607318043709
skeletal O 1 0.9999796152114868
muscle O 0 0.4876866340637207
cells O 0 5.742327175539685e-06
of O 0 6.058277790543798e-07
wild O 0 2.5547296900185756e-06
- O 0 3.9586943785252515e-06
type O 0 3.0069581953284796e-06
and O 0 4.592039033468609e-07
DMPK O 1 0.900299608707428
[ O 0 2.313927689101547e-05
- O 0 0.00021692243171855807
/ O 0 0.008108838461339474
- O 0 0.0035374928265810013
] O 0 0.00026610668282955885
knockout O 1 0.8144708871841431
mice O 0 0.000268614967353642
. O 0 4.3184245441807434e-05

In O 0 1.9795385014731437e-05
vitro O 0 7.396218279609457e-05
- O 0 9.22346516745165e-05
differentiated O 0 0.0001853850990300998
DMPK O 1 0.9611412286758423
[ O 0 6.763325654901564e-05
- O 0 0.00017291844415012747
/ O 0 0.0003293630143161863
- O 0 6.036359627614729e-05
] O 0 1.877411523310002e-05
myotubes O 0 2.509276419004891e-05
exhibit O 0 2.3058944407239323e-06
a O 0 5.895670369682193e-07
higher O 0 6.443347047024872e-07
resting O 0 1.2340703506197315e-05
[ O 0 3.3612341212574393e-06
Ca2 O 0 4.7683938646514434e-06
+ O 0 1.933937483045156e-06
] O 0 1.1130052826047176e-06
i O 0 1.7121885775850387e-07
than O 0 4.880178749999686e-08
do O 0 5.3176311354263817e-08
wild O 0 5.390357955548097e-07
- O 0 1.2555752846310497e-06
type O 0 3.125968987660599e-06
myotubes O 0 1.5415349480463192e-05
because O 0 4.522484431390694e-08
of O 0 7.579227201404137e-08
an O 0 9.720621108044725e-08
altered O 0 2.1286265905473556e-07
open O 0 1.519638459512862e-07
probability O 0 7.389885325892465e-08
of O 0 1.5831922439701884e-07
voltage O 0 2.817391077769571e-06
- O 0 3.8783955460530706e-06
dependent O 0 1.0917881354544079e-06
l O 0 3.8319544728437904e-06
- O 0 2.8580027446878375e-06
type O 0 5.18903880220023e-06
Ca2 O 0 8.499187970301136e-06
+ O 0 4.085973159817513e-06
and O 0 1.0623886055327603e-06
Na O 0 0.00023095263168215752
+ O 0 2.038560705841519e-05
channels O 0 1.0143330655409954e-05
. O 0 1.8690545402932912e-05

The O 0 6.710676825605333e-05
mutant O 0 0.00041151922778226435
myotubes O 0 0.00035025892429985106
exhibit O 0 1.1089781764894724e-05
smaller O 0 7.38882022233156e-07
and O 0 2.947280961507204e-07
slower O 0 3.14754333885503e-06
Ca2 O 0 2.2897702365298755e-06
+ O 0 5.147766728441638e-07
responses O 0 8.945599461185338e-08
upon O 0 1.48799074395356e-07
triggering O 0 1.2814130059268791e-06
by O 0 4.0723432448430685e-07
acetylcholine O 0 7.812645890226122e-06
or O 0 3.148823282117519e-07
high O 0 2.9028822154941736e-06
external O 0 1.596686342963949e-05
K O 0 8.860480011207983e-05
+ O 0 5.0507929699961096e-05
. O 0 1.4933011698303744e-05

In O 0 5.8550363064568955e-06
addition O 0 1.4731299415871035e-06
, O 0 5.23731614521239e-07
we O 0 7.591727779754365e-08
observed O 0 8.301257281573271e-08
that O 0 3.994025732367845e-08
these O 0 8.273216423049234e-08
Ca2 O 0 2.9424520562315593e-06
+ O 0 4.979246114089619e-06
transients O 0 7.756499144306872e-06
partially O 0 7.595963325002231e-07
result O 0 8.52944097573527e-08
from O 0 5.0652808170070784e-08
an O 0 6.898188331661004e-08
influx O 0 3.746140748717153e-07
of O 0 3.389945106846426e-07
extracellular O 0 2.7233049877395388e-06
Ca2 O 0 1.4721342722623376e-06
+ O 0 4.5954826077831967e-07
through O 0 5.3159578072836666e-08
the O 0 3.3741213201210485e-07
l O 0 6.263838713493897e-06
- O 0 6.511012543342076e-06
type O 0 1.2593330211529974e-05
Ca2 O 0 2.3608095943927765e-05
+ O 0 1.242417965841014e-05
channel O 0 1.3201755791669711e-05
. O 0 1.0417615158075932e-05

Neither O 0 2.682253580132965e-05
the O 0 3.1613872124580666e-06
content O 0 7.892286362221057e-07
nor O 0 7.95135747466702e-07
the O 0 2.9722275485255523e-07
activity O 0 4.270286240171117e-07
of O 0 1.2442466186257661e-06
Na O 0 0.00037543283542618155
+ O 0 1.7604470485821366e-05
/ O 0 2.5302830181317404e-05
K O 0 1.5607769455527887e-05
+ O 0 7.921559699752834e-06
ATPase O 0 1.1948392966587562e-05
and O 0 1.064516368387558e-06
sarcoplasmic O 0 0.0001613427302800119
reticulum O 0 8.839128713589162e-05
Ca2 O 0 3.373149593244307e-05
+ O 0 1.2326308024057653e-05
- O 0 1.3821058018947951e-05
ATPase O 0 1.558203985041473e-05
are O 0 9.871685335838265e-08
affected O 0 4.773863224727393e-07
by O 0 1.930804501171224e-06
DMPK O 1 0.767747163772583
absence O 0 0.0004266863106749952
. O 0 0.00012121745385229588

In O 0 1.0091363947140053e-05
conclusion O 0 5.953935215075035e-06
, O 0 9.93101934909646e-07
our O 0 4.0507219978280773e-07
data O 0 2.4582607238698984e-07
suggest O 0 3.0024366992620344e-07
that O 0 2.834623842318251e-07
DMPK O 0 0.00020396690524648875
is O 0 2.340509155374093e-07
involved O 0 1.323272158515465e-07
in O 0 1.2006572092104761e-07
modulating O 0 3.3068640732381027e-06
the O 0 3.0829673391963297e-07
initial O 0 4.390346077798313e-07
events O 0 1.0017410545515304e-07
of O 0 6.1463975953302e-07
excitation O 0 2.1998379452270456e-05
- O 0 0.00012928950309287757
contraction O 0 0.015777502208948135
coupling O 0 0.00012400711420923471
in O 0 1.620822149561718e-05
skeletal O 1 0.9999922513961792
muscle O 1 0.9605859518051147
. O 0 1.8255081158713438e-05
. O 0 6.0669161030091345e-05

Constitutional O 0 0.002784073818475008
RB1 O 1 0.9986642599105835
- O 0 0.0013486319221556187
gene O 0 9.831047646002844e-05
mutations O 0 1.1155205356772058e-05
in O 0 3.3449064176238608e-06
patients O 0 9.8017026175512e-06
with O 0 5.645003966492368e-06
isolated O 0 0.00034341964055784047
unilateral B-Disease 0 0.0006767399609088898
retinoblastoma I-Disease 1 0.9968546628952026
. O 0 0.00024354312336072326

In O 0 1.2279915608814918e-05
most O 0 3.3447663554397877e-06
patients O 0 5.231573140918044e-06
with O 0 1.7337623603452812e-06
isolated O 0 4.140870078117587e-05
unilateral B-Disease 0 5.84773879381828e-05
retinoblastoma I-Disease 1 0.9758906960487366
, O 0 7.704098607064225e-06
tumor B-Disease 1 0.9824544787406921
development O 0 1.3875476270186482e-06
is O 0 2.1634902225287078e-07
initiated O 0 7.593347959300445e-07
by O 0 2.0936974465257663e-07
somatic O 0 5.154278369445819e-06
inactivation O 0 2.3572345526190475e-05
of O 0 5.432102057056909e-07
both O 0 1.6121393286994135e-07
alleles O 0 5.439774213300552e-07
of O 0 1.3987303191242972e-06
the O 0 3.944845593650825e-05
RB1 O 1 0.9986598491668701
gene O 0 7.837104931240901e-05
. O 0 3.8649639463983476e-05

However O 0 2.092115391860716e-05
, O 0 2.1047294467280153e-06
some O 0 3.0696068620272854e-07
of O 0 1.3108615348755848e-06
these O 0 6.443249276344432e-07
patients O 0 2.9773243568342878e-06
can O 0 7.306994120881427e-07
transmit O 0 1.1031787835236173e-05
retinoblastoma B-Disease 0 0.31785064935684204
predisposition O 0 0.0002939476107712835
to O 0 1.1749066288757604e-06
their O 0 2.0250950001354795e-06
offspring O 0 3.474789627944119e-05
. O 0 4.5632208639290184e-05

To O 0 1.2880179838248296e-06
determine O 0 3.9070673096830433e-07
the O 0 3.930035177290847e-07
frequency O 0 4.793288326254697e-07
and O 0 1.3759093064891204e-07
nature O 0 4.3076551037302124e-07
of O 0 1.1435611213528318e-06
constitutional O 0 5.938853428233415e-05
RB1 O 1 0.9862017035484314
- O 0 3.431538425502367e-05
gene O 0 3.358305775691406e-06
mutations O 0 7.08299182861083e-07
in O 0 3.420451264446456e-07
patients O 0 1.3619395531350165e-06
with O 0 9.392686024511931e-07
isolated O 0 3.5512843169271946e-05
unilateral B-Disease 0 1.4439139704336412e-05
retinoblastoma I-Disease 0 0.006842251401394606
, O 0 7.189882467173447e-07
we O 0 1.6106979217056505e-07
analyzed O 0 4.0235633491647604e-07
DNA O 0 3.51152789335174e-06
from O 0 2.0568522813846357e-06
peripheral O 1 0.8582962155342102
blood O 0 2.215345375589095e-05
and O 0 2.530209030737751e-06
from O 0 6.496160494862124e-05
tumor B-Disease 1 0.9999997615814209
tissue O 1 0.9999642372131348
. O 0 0.0003655223990790546

The O 0 5.233020146988565e-06
analysis O 0 1.6443042341052205e-06
of O 0 6.918373856024118e-06
tumors B-Disease 1 0.9765154123306274
from O 0 1.124316895584343e-06
54 O 0 3.2364530397899216e-06
( O 0 3.365543932432047e-07
71 O 0 1.721954504319001e-06
% O 0 1.9446109433829406e-07
) O 0 5.44307034999747e-08
of O 0 2.6712430667430453e-07
76 O 0 4.4941093619854655e-06
informative O 0 2.462104475853266e-06
patients O 0 1.1170470770593965e-06
showed O 0 1.5346289501394494e-06
loss O 0 8.024206181289628e-06
of O 0 3.7505844829865964e-06
constitutional O 0 0.00012675783364102244
heterozygosity O 1 0.9998611211776733
( O 0 0.00011538821854628623
LOH O 1 0.9999960660934448
) O 0 3.3716746656864416e-06
at O 0 1.862851422629319e-05
intragenic O 0 0.001608781865797937
loci O 0 0.00014645529154222459
. O 0 6.576108717126772e-05

Three O 0 8.998166777018923e-06
of O 0 1.8243854356114753e-05
13 O 0 7.691956125199795e-05
uninformative O 0 0.480103075504303
patients O 0 5.544232772081159e-05
had O 0 3.955445936298929e-05
constitutional O 0 0.00015310563321691006
deletions O 0 0.0007753363461233675
. O 0 0.00019123991660308093

For O 0 6.7178984863858204e-06
39 O 0 2.0135472368565388e-05
randomly O 0 6.335566013149219e-06
selected O 0 2.04471707547782e-05
tumors B-Disease 1 0.9998860359191895
, O 0 8.215871275751851e-06
SSCP O 1 0.9991804957389832
, O 0 1.9241420886828564e-05
hetero O 0 0.002998368814587593
- O 0 1.3228436728240922e-05
duplex O 0 4.401469777803868e-05
analysis O 0 1.9136248852191784e-07
, O 0 1.2431347329311393e-07
sequencing O 0 4.690018613473512e-07
, O 0 9.21246794405306e-08
and O 0 1.0045536669167632e-07
Southern O 0 1.3708317965210881e-06
blot O 0 4.169482963334303e-06
analysis O 0 1.508038423025937e-07
were O 0 1.2979364782950142e-07
used O 0 1.5099479355740186e-07
to O 0 2.867072339540755e-07
identify O 0 1.3736244000028819e-06
mutations O 0 1.1042954611184541e-05
. O 0 1.9946075553889386e-05

Mutations O 0 2.1101732272654772e-05
were O 0 2.2327872102323454e-06
detected O 0 2.2043368517188355e-06
in O 0 2.9575468829534657e-07
21 O 0 1.1565689419512637e-06
( O 0 2.31750732382352e-07
91 O 0 1.4415447822102578e-06
% O 0 2.2592242032715149e-07
) O 0 1.197537642383395e-07
of O 0 6.836644388386048e-07
23 O 0 3.4854696423280984e-05
tumors B-Disease 1 0.9999785423278809
with O 0 7.114840263966471e-05
LOH O 1 0.9999997615814209
. O 0 0.0004186866863165051

In O 0 5.512414645636454e-06
6 O 0 5.196110578253865e-06
( O 0 8.423855888395337e-07
38 O 0 1.3932798310634098e-06
% O 0 3.2455849918733293e-07
) O 0 1.360302377406697e-07
of O 0 5.247114813755616e-07
16 O 0 1.3256864804134239e-05
tumors B-Disease 1 0.9999911785125732
without O 0 4.121405709156534e-06
LOH O 1 0.9999284744262695
, O 0 3.8840340721435496e-07
one O 0 1.2209054034428846e-07
mutation O 0 5.999071390760946e-07
was O 0 1.5520288343395805e-06
detected O 0 2.8036708954459755e-07
, O 0 2.3527858772354193e-08
and O 0 1.1612729444721026e-08
in O 0 2.789896491606214e-08
9 O 0 1.343129270026111e-07
( O 0 6.579510625215335e-08
56 O 0 1.7008596842060797e-07
% O 0 9.610836571027903e-08
) O 0 3.2976004149531946e-08
of O 0 2.5782162538234843e-07
the O 0 5.347469596017618e-06
tumors B-Disease 1 0.9999983310699463
without O 0 8.909557436709292e-06
LOH O 1 0.9999923706054688
, O 0 5.248966772342101e-07
both O 0 2.4882393745429e-07
mutations O 0 1.25987048704701e-06
were O 0 1.1784043181251036e-06
found O 0 5.1985889513161965e-06
. O 0 1.802366205083672e-05

Thus O 0 9.526866051601246e-06
, O 0 8.386174386032508e-07
a O 0 6.483820698122145e-07
total O 0 6.358594077937596e-07
of O 0 6.370527216859045e-07
45 O 0 1.203614374389872e-06
mutations O 0 5.741488280364138e-07
were O 0 2.719220333347039e-07
identified O 0 1.5480701449632761e-06
in O 0 1.8393111531622708e-06
tumors B-Disease 1 0.999846339225769
of O 0 2.1587678929790854e-05
36 O 0 6.257663335418329e-05
patients O 0 0.00022548146080225706
. O 0 0.00010573270992608741

Thirty O 0 3.895313057000749e-05
- O 0 6.7042283262708224e-06
nine O 0 2.1011294393247226e-06
of O 0 1.6582108628426795e-06
the O 0 2.1858209038327914e-06
mutations O 0 1.2227177421664237e-06
- O 0 1.3983168400955037e-06
including O 0 3.693905910040485e-07
34 O 0 1.045586714099045e-06
small O 0 2.2786987585732277e-07
mutations O 0 1.468152390771138e-07
, O 0 6.384844652984611e-08
2 O 0 2.6656800855562324e-07
large O 0 4.2091244267794536e-07
structural O 0 1.1464786439319141e-05
alterations O 0 1.6535537724848837e-05
, O 0 3.611958447891084e-07
and O 0 3.0770104331168113e-07
hypermethylation O 0 0.00066355150192976
in O 0 1.2433072242856724e-06
3 O 0 2.5152632588287815e-05
tumors O 1 0.9999343156814575
- O 0 5.18490924150683e-06
were O 0 1.9045997134981008e-07
not O 0 3.380381841111557e-08
detected O 0 2.0073578355095378e-07
in O 0 5.122154433934156e-08
the O 0 5.796549089609471e-07
corresponding O 0 1.7560792912263423e-05
peripheral O 1 0.9960806965827942
blood O 0 0.0002495734952390194
DNA O 0 0.00017556519014760852
. O 0 3.6146415368421e-05

In O 0 3.256913259974681e-06
6 O 0 2.9693196665903088e-06
( O 0 3.868050555411173e-07
17 O 0 4.1525836991240794e-07
% O 0 1.8674656132589007e-07
) O 0 6.424963316931098e-08
of O 0 1.3557615829995484e-07
the O 0 2.8082496328352136e-07
36 O 0 8.132453785947291e-07
patients O 0 5.496097514878784e-07
, O 0 9.859678584689391e-08
a O 0 3.467020519565267e-07
mutation O 0 8.137496365634433e-07
was O 0 1.2567973044497194e-06
detected O 0 2.8981196464883396e-07
in O 0 8.02870090410579e-08
constitutional O 0 8.268277156275872e-07
DNA O 0 5.143261887496919e-07
, O 0 4.84202580253168e-08
and O 0 2.8650486427750366e-08
1 O 0 1.3767834161626524e-07
of O 0 1.1531300003753131e-07
these O 0 2.6092834559676703e-08
mutations O 0 2.0490078611601348e-07
is O 0 9.108300247362422e-08
known O 0 1.2749860900385102e-07
to O 0 3.0935929373754334e-08
be O 0 5.353738785629503e-08
associated O 0 5.94702953549131e-07
with O 0 1.4958403653508867e-06
reduced O 0 0.0001399813627358526
expressivity O 0 0.09832756966352463
. O 0 7.32700718799606e-05

The O 0 8.539696864318103e-06
presence O 0 2.871794777092873e-06
of O 0 9.463889796279545e-07
a O 0 1.7270264152102754e-06
constitutional O 0 4.0197837734012865e-06
mutation O 0 3.8369130379578564e-06
was O 0 3.496206772979349e-06
not O 0 3.663446790369562e-08
associated O 0 7.674802304791228e-08
with O 0 4.6322671920506764e-08
an O 0 3.2264509286505927e-07
early O 0 5.128786142449826e-06
age O 0 1.232435715792235e-05
at O 0 3.4701333788689226e-05
treatment O 0 0.0011438668007031083
. O 0 6.905780173838139e-05

In O 0 2.189173028455116e-05
1 O 0 3.7642115785274655e-05
patient O 0 5.297556344885379e-05
, O 0 1.1988465303147677e-05
somatic O 0 0.0007035576272755861
mosaicism O 1 0.7527798414230347
was O 0 9.940761628968176e-06
demonstrated O 0 1.5486400570807746e-06
by O 0 1.054815399470499e-07
molecular O 0 3.923657914128853e-07
analysis O 0 6.646371986107624e-08
of O 0 4.15835387457264e-07
DNA O 0 2.716667040658649e-06
and O 0 5.838514880451839e-07
RNA O 0 2.6117437300854363e-05
from O 0 7.640778676432092e-06
peripheral O 1 0.9854450821876526
blood O 0 0.00037133623845875263
. O 0 6.357916572596878e-05

In O 0 9.908165338856634e-06
2 O 0 1.1364334568497725e-05
patients O 0 4.3802101572509855e-06
without O 0 6.22712207132281e-07
a O 0 1.9569990854506614e-06
detectable O 0 7.306459156097844e-05
mutation O 0 9.562083505443297e-06
in O 0 2.943448635051027e-06
peripheral O 1 0.9923195242881775
blood O 0 2.7590391255216673e-05
, O 0 3.478284497759887e-06
mosaicism O 1 0.9753902554512024
was O 0 6.467618277383735e-06
suggested O 0 4.223346650178428e-07
because O 0 5.713609851909496e-08
1 O 0 1.8590661454709334e-07
of O 0 3.792685845382948e-07
the O 0 2.3567304197058547e-06
patients O 0 0.00017250969540327787
showed O 1 0.9604552984237671
multifocal O 1 1.0
tumors B-Disease 1 0.9999996423721313
and O 0 1.148496721725678e-06
the O 0 1.5888082316450891e-06
other O 0 3.064382951833977e-07
later O 0 3.506274197206949e-06
developed O 0 1.4517897398036439e-05
bilateral B-Disease 0 5.5002292356221005e-05
retinoblastoma I-Disease 0 0.33783626556396484
. O 0 0.00014764221850782633

In O 0 9.61409205046948e-06
conclusion O 0 6.282486538111698e-06
, O 0 1.0670544270396931e-06
our O 0 2.8618791247936315e-07
results O 0 1.4720696128733834e-07
emphasize O 0 5.394348931986315e-07
that O 0 8.503531745418513e-08
the O 0 3.822746066362015e-07
manifestation O 0 4.910253846901469e-05
and O 0 6.551416049660475e-07
transmissibility O 0 5.124299059389159e-05
of O 0 1.201190229949134e-06
retinoblastoma B-Disease 0 4.368947702459991e-05
depend O 0 1.3078481231332262e-07
on O 0 7.306228866355013e-08
the O 0 9.75375513689869e-08
nature O 0 1.2063338772350107e-07
of O 0 6.900951632360375e-08
the O 0 1.1591092174967343e-07
first O 0 1.9086581914962153e-07
mutation O 0 2.8591045975190355e-07
, O 0 3.107946966451891e-08
its O 0 2.087807082773452e-08
time O 0 1.95807245972901e-08
in O 0 3.8450412631618747e-08
development O 0 1.1420272727491465e-07
, O 0 3.135646409191395e-08
and O 0 1.4972341588759264e-08
the O 0 2.9925910638439746e-08
number O 0 3.054153552284333e-08
and O 0 3.8754865983037234e-08
types O 0 8.77987460512486e-08
of O 0 6.79251002111414e-07
cells O 0 1.1651776503640576e-06
that O 0 5.999437036052768e-08
are O 0 5.234270261667007e-08
affected O 0 7.160472250689054e-07
. O 0 1.8173069520344143e-06
. O 0 1.2060239896527492e-05

Hereditary B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999997615814209
of I-Disease 0 0.00017191428923979402
the I-Disease 0 4.161614197073504e-05
fifth I-Disease 0 0.001289147767238319
component I-Disease 0 3.604813537094742e-05
of I-Disease 0 3.4548056646599434e-06
complement I-Disease 0 1.1570606147870421e-05
in O 0 8.745878403715324e-06
man O 0 0.00024222684442065656
. O 0 6.26843684585765e-05

I O 0 0.007284524850547314
. O 0 0.0009810952469706535

Clinical O 0 0.001694433856755495
, O 0 8.164317841874436e-05
immunochemical O 0 0.17380690574645996
, O 0 9.587961358192842e-06
and O 0 2.7220717129239347e-06
family O 0 1.2397241334838327e-05
studies O 0 1.969580989680253e-05
. O 0 6.087414294597693e-05

The O 0 9.89068030321505e-06
first O 0 6.372930783982156e-06
recognized O 0 8.460943718091585e-06
human O 0 5.489666818903061e-06
kindred O 0 0.035854049026966095
with O 0 6.168265827000141e-05
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 0 0.026789462193846703
the I-Disease 0 3.3780721423681825e-05
fifth I-Disease 0 0.00043917755829170346
component I-Disease 0 1.1415188964747358e-05
of I-Disease 0 1.9744479686778504e-06
complement I-Disease 0 1.362417151540285e-05
( O 0 6.964301974221598e-06
C5 O 1 0.886690080165863
) O 0 8.58709313433792e-07
is O 0 1.6121898624987807e-06
described O 0 1.8385413568466902e-05
. O 0 3.2427247788291425e-05

The O 0 2.1351894247345626e-05
proband O 0 0.00024006514286156744
, O 0 2.161068323403015e-06
a O 0 1.834199792938307e-06
20 O 0 1.0742128324636724e-06
- O 0 6.289578777796123e-06
year O 0 4.4938092287338804e-06
- O 0 8.622804307378829e-05
old O 0 0.0002357394405407831
black O 0 0.00010244804434478283
female O 0 1.6421401596744545e-05
with O 0 0.013977735303342342
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.002209069672971964
age O 0 3.96271025238093e-05
11 O 0 1.5288242138922215e-05
, O 0 1.0794897207233589e-05
lacked O 0 0.03941114991903305
serum O 0 0.16813476383686066
hemolytic O 1 0.9999840259552002
complement O 0 1.704655005596578e-05
activity O 0 2.3058723854774144e-06
, O 0 4.260629395957949e-07
even O 0 6.643342658207985e-07
during O 0 8.849662663124036e-06
remission O 0 0.05158671364188194
. O 0 8.578564302297309e-05

C5 O 1 0.9983832836151123
was O 0 0.00041043516830541193
undetectable O 0 0.00026075090863741934
in O 0 2.4933610802690964e-06
her O 0 2.7877292723132996e-06
serum O 0 1.5125382560654543e-05
by O 0 1.0632501243890147e-06
both O 0 3.016050641235779e-06
immunodiffusion O 0 0.3254857361316681
and O 0 4.147070285398513e-05
hemolytic O 1 0.999998927116394
assays O 0 0.0009564994252286851
. O 0 0.00015452419756911695

Other O 0 2.551219040469732e-06
complement O 0 6.16759825788904e-06
components O 0 2.1506261873582844e-06
were O 0 3.435568203258299e-07
normal O 0 4.990309321328823e-07
during O 0 1.0704137594075291e-06
remission O 0 0.0015086468774825335
of O 0 0.00012078616418875754
lupus O 1 0.999998927116394
, O 0 6.3866505115584005e-06
but O 0 3.2052575988927856e-06
C1 O 1 0.9903884530067444
, O 0 8.082328349701129e-06
C4 O 1 0.9996689558029175
, O 0 3.701208925122046e-06
C2 O 0 0.011738365516066551
, O 0 1.1383881428628229e-06
and O 0 1.8930892338175909e-06
C3 O 0 0.496955931186676
levels O 0 7.238541911647189e-06
fell O 0 0.00011123704462079331
during O 0 6.749891326762736e-05
exacerbations O 1 0.9759324789047241
. O 0 9.797936218092218e-05

A O 0 0.0002923774009104818
younger O 0 5.144790338817984e-05
half O 0 1.0597602340567391e-05
- O 0 0.00015518451982643455
sister O 0 6.497945287264884e-05
, O 0 1.6504566247022012e-06
who O 0 1.1761879932237207e-06
had O 0 2.385962261541863e-06
no O 0 8.049896678130608e-06
underlying O 1 0.9998668432235718
disease O 1 0.9999914169311523
, O 0 3.1679935545980697e-06
was O 0 2.5912120690918528e-05
also O 0 3.4516929758865444e-07
found O 0 2.1707610642351938e-07
to O 0 2.4226983441621996e-07
lack O 0 2.237537228211295e-05
immunochemically O 1 0.7998907566070557
detectable O 1 0.7163198590278625
C5 O 1 0.9995394945144653
. O 0 8.438975783064961e-05

By O 0 7.599166565341875e-05
hemolytic O 1 0.9999830722808838
assay O 0 0.00012739980593323708
, O 0 2.4145638235495426e-06
she O 0 7.074054337863345e-07
exhibited O 0 1.3824728739564307e-06
1 O 0 7.363580607488984e-07
- O 0 4.1448134879829013e-07
2 O 0 1.6105812505884387e-07
% O 0 4.3659039050680803e-08
of O 0 6.83035565884893e-08
the O 0 2.2052439874187257e-07
normal O 0 1.8045718661596766e-06
serum O 0 2.57984283962287e-05
C5 O 0 0.0008291039266623557
level O 0 2.636740248362912e-07
and O 0 4.7189388396873255e-08
normal O 0 1.360011623319224e-07
concentrations O 0 3.1950901302479906e-07
of O 0 2.2182287295891e-07
other O 0 1.7913913552547456e-07
complement O 0 1.2600263289641589e-05
components O 0 4.632351192412898e-05
. O 0 3.512583862175234e-05

C5 O 0 0.03078599087893963
levels O 0 5.561839770962251e-06
of O 0 2.8387701149767963e-06
other O 0 2.263999334672917e-07
family O 0 5.021483957534656e-07
members O 0 1.2974278718047572e-07
were O 0 1.8647641297775408e-07
either O 0 1.9113502958134632e-07
normal O 0 3.1172623948805267e-07
or O 0 1.0871059430428431e-07
approximately O 0 2.3281272376607376e-07
half O 0 3.255554474890232e-07
- O 0 1.94692074728664e-06
normal O 0 4.677841900502244e-07
, O 0 2.1306045994151646e-07
consistent O 0 8.564945233047183e-07
with O 0 6.961711846997787e-07
autosomal O 0 0.00018386098963674158
codominant O 1 0.5134509801864624
inheritance O 0 2.809063153108582e-05
of O 0 6.553148978127865e-06
the O 0 1.0691297575249337e-05
gene O 0 9.413637599209324e-05
determining O 0 0.00032028084388002753
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0011652368120849133

Normal O 0 0.0008422393584623933
hemolytic O 1 0.9998557567596436
titers O 0 0.0011046717409044504
were O 0 3.923806161765242e-06
restored O 0 9.794722245715093e-06
to O 0 3.5300510603519797e-07
both O 0 9.916312819768791e-07
homozygous O 0 0.0003508004010654986
C5 B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999388456344604
deficient I-Disease 1 0.9999951124191284
( O 0 2.3371339921141043e-05
C5D B-Disease 1 0.9999973773956299
) O 0 6.83427117564861e-07
sera O 0 3.5336183827894274e-06
by O 0 2.2189884418821748e-07
addition O 0 3.1769323527441884e-07
of O 0 1.3159670970708248e-06
highly O 0 1.4525153346767183e-05
purified O 0 8.18227490526624e-05
human O 0 2.076672353723552e-05
C5 O 1 0.9554311633110046
. O 0 7.52662235754542e-05

In O 0 2.586136179161258e-05
specific O 0 1.7773127183318138e-05
C5 O 1 0.7877039909362793
titrations O 0 0.00019250923651270568
, O 0 9.83344875749026e-07
however O 0 4.5235026391310384e-07
, O 0 1.4728868791280547e-07
it O 0 5.9279816611024216e-08
was O 0 4.7401562142113107e-07
noted O 0 1.543943284332272e-07
that O 0 2.5556595062425913e-08
when O 0 4.6826180266634765e-08
limited O 0 9.835655845336078e-08
amounts O 0 1.285964259523098e-07
of O 0 5.871212351848953e-07
C5 O 0 0.00032583196298219264
were O 0 3.188083326222113e-07
assayed O 0 2.412264393569785e-06
in O 0 8.824162733844787e-08
the O 0 1.300505090284787e-07
presence O 0 3.353775639425294e-07
of O 0 4.4168962176627247e-07
low O 0 2.166745616705157e-06
dilutions O 0 2.5485305741312914e-05
of O 0 2.079367504848051e-06
either O 0 8.230222192651127e-06
C5D B-Disease 1 0.9999982118606567
serum O 0 0.00010321129957446828
, O 0 6.333635269584192e-07
curving O 0 2.449282192173996e-06
rather O 0 1.343167639333842e-07
than O 0 7.17783947834505e-08
linear O 0 9.467825634601468e-07
dose O 0 3.4978975236299448e-06
- O 0 1.9104077182419132e-06
response O 0 6.45487261863309e-07
plots O 0 4.3136489580319903e-07
were O 0 8.873969647993363e-08
consistently O 0 1.8288430680968304e-07
obtained O 0 1.4625040023474867e-07
, O 0 1.7944451258244953e-07
suggesting O 0 7.385685307781387e-07
some O 0 3.383736952855543e-07
inhibitory O 0 1.86199522431707e-05
effect O 0 9.406407116330229e-06
. O 0 2.7127680368721485e-05

Further O 0 7.142860795283923e-06
studies O 0 2.670631829460035e-06
suggested O 0 2.274580765515566e-06
that O 0 2.5083167543016316e-07
low O 0 2.1322093743947335e-06
dilutions O 0 6.558180029969662e-05
of O 0 8.774851266935002e-06
C5D B-Disease 1 0.9999994039535522
serum O 0 8.316094317706302e-05
contain O 0 6.336976525744831e-07
a O 0 4.5769292000841233e-07
factor O 0 5.102078262098075e-07
( O 0 7.876325724964772e-08
or O 0 3.4767939638413736e-08
factors O 0 4.146844645447345e-08
) O 0 4.129070774183674e-08
interfering O 0 1.4439937956467475e-07
at O 0 1.0802684613508973e-07
some O 0 3.612646892747762e-08
step O 0 2.524994897612487e-07
in O 0 1.4034507955784647e-07
the O 0 1.3527617284125881e-06
hemolytic O 1 0.9987655878067017
assay O 0 9.441845577384811e-06
of O 0 5.227961992204655e-06
C5 O 1 0.9555683732032776
, O 0 3.6210013831805554e-07
rather O 0 1.1585278514303354e-07
than O 0 9.381972887467782e-08
a O 0 1.2542707281681942e-06
true O 0 2.2077991161495447e-05
C5 O 1 0.9990988969802856
inhibitor O 0 0.001028823433443904
or O 0 8.01478381617926e-06
inactivator O 0 0.0018302778480574489
. O 0 8.581837028032169e-05

Of O 0 2.0176801626803353e-05
clinical O 0 3.202884181519039e-05
interest O 0 1.653897697906359e-06
are O 0 8.278867369426735e-08
( O 0 2.0662763233758596e-07
a O 0 3.4455590025572747e-07
) O 0 9.487695962206999e-08
the O 0 2.4578693569310417e-07
documentation O 0 2.7996361495752353e-06
of O 0 3.756376463570632e-05
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 1 0.7963764071464539
vasculitis B-Disease 1 1.0
, O 0 0.00017769954865798354
and O 0 0.00012061155575793236
arthritis B-Disease 1 1.0
in O 0 1.37436597924534e-06
an O 0 5.985344841974438e-07
individual O 0 3.930522325390484e-07
lacking O 0 0.0006872921949252486
C5 O 1 0.9357975125312805
( O 0 1.6451248541216046e-07
and O 0 5.001095715329029e-08
its O 0 6.934888574505749e-08
biologic O 0 7.079891474859323e-06
functions O 0 4.1978076126270025e-08
) O 0 2.628900830359271e-08
, O 0 3.157697037181606e-08
and O 0 2.6162702226883994e-08
( O 0 9.343382600945915e-08
b O 0 5.564310185945942e-07
) O 0 6.496719606730039e-08
a O 0 3.370680019543215e-07
remarkable O 0 2.959788844236755e-06
propensity O 0 1.2112799595342949e-05
to O 0 4.914966211799765e-07
bacterial B-Disease 1 0.9999903440475464
infections I-Disease 1 0.9623236656188965
in O 0 4.333886920449004e-07
the O 0 9.864435241979663e-07
proband O 0 0.0025829742662608624
, O 0 1.4892599153881747e-07
even O 0 4.991813185029059e-08
during O 0 1.8840125903807348e-07
periods O 0 4.0586644445284037e-07
of O 0 9.541864756101859e-07
low O 0 3.237385271859239e-06
- O 0 1.4421386367757805e-05
dose O 0 1.8887718397309072e-05
or O 0 4.078184474565205e-07
alternate O 0 2.0443987978069345e-06
- O 0 3.7454916309798136e-05
day O 0 4.8969173803925514e-05
corticosteroid O 1 0.9983097314834595
therapy O 0 0.03442063182592392
. O 0 9.646452963352203e-05

Other O 0 3.6852886751148617e-06
observations O 0 2.772550715235411e-06
indicate O 0 1.350413185718935e-06
that O 0 2.7867116614288534e-07
the O 0 1.343430653832911e-06
C5D B-Disease 1 0.9837530851364136
state O 0 2.5149108751065796e-07
is O 0 8.082322722202662e-08
compatible O 0 1.7168434851555503e-07
with O 0 4.981864165642946e-08
normal O 0 4.190104334611533e-07
coagulation O 0 1.737156935632811e-06
function O 0 1.0179297049717206e-07
and O 0 2.6473777836599766e-08
the O 0 1.2799200987956283e-07
capacity O 0 5.062933610133769e-07
to O 0 1.668932725351624e-07
mount O 0 2.4873592337826267e-05
a O 0 1.581350625201594e-05
neutrophilic O 1 0.9990411400794983
leukocytosis O 1 0.6464487314224243
during O 0 0.00018587752128951252
pyogenic B-Disease 1 0.9995311498641968
infection I-Disease 0 0.07890314608812332
. O 0 1.2319914276304189e-05
. O 0 4.02804471377749e-05

Susceptibility O 1 0.999125063419342
to O 0 0.007391239516437054
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00011279792670393363
twins O 0 0.0001210459231515415
: O 0 5.622871412924724e-07
the O 0 4.020349138045276e-07
role O 0 3.9522183215012774e-07
of O 0 1.1015597465302562e-06
genes O 0 1.25433530229202e-06
, O 0 3.213926220269059e-06
HLA O 1 0.9985907673835754
, O 0 1.1454997093096608e-06
and O 0 7.056212325551314e-07
the O 0 4.8575798246019986e-06
environment O 0 4.1024377424037084e-05
. O 0 5.632127795252018e-05

OBJECTIVE O 0 4.628474562196061e-05
To O 0 4.4454120029513433e-07
determine O 0 3.0399962724914076e-07
the O 0 2.947483324078348e-07
relative O 0 1.5950723764035502e-06
effects O 0 2.6237621568725444e-06
of O 0 1.2200248420413118e-06
genetic O 0 6.637176738877315e-06
and O 0 3.318131120977341e-07
environmental O 0 2.2911967789696064e-06
factors O 0 7.019592658252805e-07
in O 0 1.7028021375153912e-06
susceptibility O 1 0.8341183662414551
to O 0 0.0008576501277275383
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0409487746655941
AS B-Disease 1 0.817661464214325
) O 0 9.075540219782852e-06
. O 0 2.344782478758134e-05

METHODS O 0 7.506222755182534e-05
Twins O 0 8.216240530600771e-05
with O 0 2.151368789782282e-06
AS B-Disease 0 4.592071854858659e-05
were O 0 5.832114879922301e-07
identified O 0 3.2091679713630583e-07
from O 0 1.476459061677815e-07
the O 0 6.620838917115179e-07
Royal O 0 0.0052917469292879105
National O 0 0.00020012811000924557
Hospital O 1 0.9980359673500061
for O 0 0.002627571811899543
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.04726824164390564
. O 0 0.00029348389944061637

Clinical O 0 0.00022674891806673259
and O 0 9.6652984211687e-06
radiographic O 0 0.00034727115416899323
examinations O 0 1.4281892617873382e-05
were O 0 1.207889681609231e-06
performed O 0 1.8396340237814002e-06
to O 0 2.0345811435618089e-07
establish O 0 1.6934644690991263e-06
diagnoses O 0 0.0004709319327957928
, O 0 3.3538856314407894e-06
and O 0 4.850168807024602e-06
disease O 1 0.9979483485221863
severity O 0 0.04086177051067352
was O 0 5.667558070854284e-05
assessed O 0 1.1192214515176602e-06
using O 0 9.845040693789997e-08
a O 0 2.628101753998635e-07
combination O 0 1.0741821370174875e-06
of O 0 1.0080698302772362e-06
validated O 0 7.473952791769989e-06
scoring O 0 5.111417522130068e-06
systems O 0 4.4901091314386576e-05
. O 0 2.5704466679599136e-05

HLA O 1 0.9857345819473267
typing O 0 0.00017873816250357777
for O 0 3.237662895116955e-05
HLA O 1 0.9999743700027466
- O 0 0.03395197167992592
B27 O 1 0.8727636337280273
, O 0 6.071975076338276e-05
HLA O 1 0.9994550347328186
- O 0 0.00012524409976322204
B60 O 0 0.0027622184716165066
, O 0 2.295389322171104e-06
and O 0 4.900606199953472e-06
HLA O 1 0.9999887943267822
- O 0 0.03591781109571457
DR1 O 1 0.9958142638206482
was O 0 6.703805865981849e-06
performed O 0 9.6506403224339e-07
by O 0 3.1027056479615567e-07
polymerase O 0 5.775857061962597e-06
chain O 0 1.946011252584867e-06
reaction O 0 3.101611127931392e-07
with O 0 9.163276359913652e-08
sequence O 0 2.4655719244037755e-07
- O 0 6.615625238737266e-07
specific O 0 9.488130103818548e-08
primers O 0 9.811295740291825e-07
, O 0 1.6265509827917413e-07
and O 0 3.7736938907073636e-07
zygosity O 0 5.30668294231873e-05
was O 0 7.4630834205891006e-06
assessed O 0 6.0019715419912245e-06
using O 0 4.102868388144998e-06
microsatellite O 0 0.0002637709549162537
markers O 0 6.858030246803537e-05
. O 0 3.4803808375727385e-05

Genetic O 0 4.9919908633455634e-05
and O 0 1.2749001143674832e-06
environmental O 0 1.7987815681408392e-06
variance O 0 4.434969866906613e-07
components O 0 5.773532620878541e-07
were O 0 8.332650480724624e-08
assessed O 0 2.0083400897874526e-07
with O 0 5.1453120875066816e-08
the O 0 2.3306419905111397e-07
program O 0 5.511328708962537e-07
Mx O 0 2.8408990146999713e-06
, O 0 3.8946193825495357e-08
using O 0 1.449481690229959e-08
data O 0 1.3551250788168545e-08
from O 0 1.910923330683545e-08
this O 0 2.1611223033346505e-08
and O 0 3.1370220199278265e-08
previous O 0 9.501403752665283e-08
studies O 0 1.4015060401106894e-07
of O 0 6.614426411033492e-07
twins O 0 1.7281650798395276e-05
with O 0 3.150976226606872e-06
AS B-Disease 0 0.04323428496718407
. O 0 9.564310312271118e-05

RESULTS O 0 9.6795592980925e-06
Six O 0 2.2579479264095426e-06
of O 0 3.669507123049698e-06
8 O 0 4.742045348393731e-05
monozygotic O 0 0.37868601083755493
( O 0 2.9241236916277558e-05
MZ O 1 0.9999706745147705
) O 0 3.7571030588878784e-06
twin O 0 2.6903231628239155e-05
pairs O 0 1.029264467433677e-06
were O 0 1.239679363607138e-06
disease O 0 0.016517452895641327
concordant O 0 1.7039317754097283e-05
, O 0 1.4692139416183636e-07
compared O 0 1.4313634721929702e-07
with O 0 5.2821192753071955e-08
4 O 0 4.7303657879638195e-07
of O 0 4.961552804161329e-07
15 O 0 1.1448487384768669e-06
B27 O 0 3.903959077433683e-05
- O 0 7.0561313805228565e-06
positive O 0 1.692947535048006e-06
dizygotic O 0 0.00020117020176257938
( O 0 2.9603309030790115e-06
DZ O 0 0.38711392879486084
) O 0 4.987074362361454e-07
twin O 0 1.521757326372608e-06
pairs O 0 1.2391458881211292e-07
( O 0 3.887791422130249e-08
27 O 0 1.7506852145743323e-07
% O 0 8.094109915646186e-08
) O 0 2.3022234785230467e-08
and O 0 2.513140806570391e-08
4 O 0 1.6831167215514142e-07
of O 0 3.981172653766407e-07
32 O 0 2.60183219324972e-06
DZ O 1 0.8135009407997131
twin O 0 4.345161869423464e-06
pairs O 0 1.904022184362475e-07
overall O 0 5.897396704312996e-07
( O 0 1.0442956721590235e-07
12 O 0 1.6797780233446247e-07
. O 0 5.750256093506323e-08
5 O 0 4.543806255696836e-07
% O 0 7.807088877598289e-07
) O 0 1.6645914229229675e-06
. O 0 9.896086339722387e-06

Nonsignificant O 0 0.0006754017085768282
increases O 0 4.375250682642218e-06
in O 0 5.123317805555416e-07
similarity O 0 1.3613785085908603e-06
with O 0 3.138596866847365e-07
regard O 0 8.357926049029629e-07
to O 0 1.8058993589420425e-07
age O 0 1.4334947991301306e-05
at O 0 0.006934999022632837
disease O 1 0.999997615814209
onset O 1 0.9999731779098511
and O 0 6.282405138335889e-07
all O 0 9.952392332479576e-08
of O 0 1.1624207445493084e-06
the O 0 2.8388267310219817e-05
disease O 1 0.9998841285705566
severity O 0 0.000588242313824594
scores O 0 1.500243456575845e-06
assessed O 0 8.186972308976692e-07
were O 0 2.473027507221559e-07
noted O 0 1.8974471913679736e-06
in O 0 5.922945092606824e-06
disease O 1 0.9999914169311523
- O 1 0.9960643649101257
concordant O 1 0.9997242093086243
MZ O 1 0.9999991655349731
twins O 0 0.0008944408036768436
compared O 0 1.158113718702225e-05
with O 0 1.0521954209252726e-05
concordant O 1 0.9775102734565735
DZ O 1 0.9999969005584717
twins O 0 0.031633391976356506
. O 0 0.00010288055636920035

HLA O 1 0.9999673366546631
- O 0 0.0024746726267039776
B27 O 0 0.013128953985869884
and O 0 5.571708697971189e-06
B60 O 0 0.00023720540048088878
were O 0 6.241640448934049e-07
associated O 0 5.133436502546829e-07
with O 0 3.256249954119994e-07
the O 0 7.3894298111554235e-06
disease O 1 0.998473584651947
in O 0 2.393750037299469e-06
probands O 0 0.39364537596702576
, O 0 3.301389597254456e-07
and O 0 7.441497018589871e-08
the O 0 1.0436107800160244e-07
rate O 0 2.053669874158004e-07
of O 0 7.0388784934039e-07
disease O 0 0.0026020598597824574
concordance O 0 2.0214123651385307e-05
was O 0 7.117932000255678e-06
significantly O 0 5.438648713607108e-07
increased O 0 6.867291517664853e-07
among O 0 7.996482054295484e-07
DZ O 1 0.9989011287689209
twin O 0 8.055924809013959e-06
pairs O 0 1.5054072832754173e-07
in O 0 7.662939793817714e-08
which O 0 7.606903551504729e-08
the O 0 7.354919375757163e-07
co O 0 2.4052438675425947e-05
- O 0 3.517340519465506e-05
twin O 0 3.786548040807247e-05
was O 0 3.3196929507539608e-06
positive O 0 1.49729771692364e-07
for O 0 2.2804205457305216e-07
both O 0 7.797846706125711e-07
B27 O 0 0.00033544155303388834
and O 0 2.434064299450256e-05
DR1 O 1 0.9956600069999695
. O 0 8.889559103408828e-05

Additive O 0 9.699822840048e-05
genetic O 0 2.230185600637924e-05
effects O 0 6.994445811869809e-06
were O 0 5.340510824680678e-07
estimated O 0 5.753942105002352e-07
to O 0 7.610038466054903e-08
contribute O 0 1.5199211134131474e-07
97 O 0 8.400045885537111e-07
% O 0 1.8976520266278385e-07
of O 0 2.932416123258008e-07
the O 0 7.819532470421109e-07
population O 0 7.800189791851153e-07
variance O 0 4.652438747143606e-06
. O 0 1.480924584029708e-05

CONCLUSION O 0 0.00024213630240410566
Susceptibility O 0 0.00042513193329796195
to O 0 1.3844294244336197e-06
AS B-Disease 0 3.4483440686017275e-05
is O 0 6.432173904613592e-07
largely O 0 9.516863883618498e-07
genetically O 0 7.095242722243711e-07
determined O 0 1.6842695060859114e-07
, O 0 5.449427931125683e-08
and O 0 3.2697922591751194e-08
the O 0 2.4047528768278426e-07
environmental O 0 1.98779071070021e-06
trigger O 0 1.1494588534333161e-06
for O 0 2.165897399208916e-07
the O 0 5.778143531642854e-06
disease O 1 0.9940274953842163
is O 0 4.66940537080518e-06
probably O 0 2.8866916181868874e-05
ubiquitous O 0 0.00011157102562719956
. O 0 2.9349215765250847e-05

HLA O 1 0.9999619722366333
- O 0 0.0005394942709244788
B27 O 0 0.00019734074885491282
accounts O 0 7.711455509706866e-07
for O 0 2.689527605070907e-07
a O 0 7.321105499613623e-07
minority O 0 3.9675353491475107e-07
of O 0 5.663125648425194e-07
the O 0 1.1765896488213912e-06
overall O 0 2.1882295186514966e-05
genetic O 0 7.63547868700698e-05
susceptibility O 0 0.0010177971562370658
to O 0 1.974180577235529e-06
AS B-Disease 0 0.0008888680604286492
. O 0 4.186811565887183e-05

Cell O 0 0.0013904559891670942
cycle O 0 0.0001239106641151011
- O 0 0.00010029729310190305
dependent O 0 7.883169928390998e-06
colocalization O 0 0.0003607093240134418
of O 0 1.0119639227923471e-05
BARD1 O 1 0.9874513745307922
and O 0 2.6925865768134827e-06
BRCA1 O 0 2.181819945690222e-05
proteins O 0 6.519722433040442e-07
in O 0 5.133314289196278e-07
discrete O 0 6.8611443566624075e-06
nuclear O 0 2.599498475319706e-05
domains O 0 3.2166557502932847e-05
. O 0 3.1064089853316545e-05

Germ O 1 0.9944890737533569
- O 0 8.769429405219853e-05
line O 0 1.3071193279756699e-05
mutations O 0 2.11141605177545e-06
of O 0 1.3196467989473604e-06
the O 0 4.93093830300495e-06
BRCA1 O 0 0.02848137356340885
gene O 0 8.143792001646943e-06
predispose O 0 8.0517393143964e-06
women O 0 2.934407916654891e-07
to O 0 2.0007716727832303e-07
early O 0 2.0892563043162227e-05
- O 1 0.9598418474197388
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9999793767929077
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.6874262655619532e-05
compromising O 0 7.13412810000591e-05
the O 0 3.8002090150257573e-06
genes O 0 1.8081964299199171e-06
presumptive O 0 0.00010666732850950211
function O 0 1.355906761091319e-06
as O 0 1.8180592178396182e-06
a O 0 3.1124494853429496e-05
tumor B-Disease 1 0.9999518394470215
suppressor O 1 0.8992717862129211
. O 0 8.196644193958491e-05

Although O 0 1.9819828594336286e-05
the O 0 9.496468919678591e-06
biochemical O 0 7.581512909382582e-05
properties O 0 1.4047770491742995e-05
of O 0 1.051894469128456e-05
BRCA1 O 0 0.00019396851712372154
polypeptides O 0 4.351805273472564e-06
are O 0 5.1365066866537745e-08
not O 0 7.250545763781702e-08
understood O 0 3.178241456680553e-07
, O 0 8.559950259723337e-08
their O 0 5.972059113901196e-08
expression O 0 4.1053323229789385e-07
pattern O 0 1.7083552847907413e-06
and O 0 4.464641278900672e-07
subcellular O 0 2.579434476501774e-05
localization O 0 1.9419181626290083e-05
suggest O 0 4.2329028815402125e-07
a O 0 3.034296014448046e-07
role O 0 7.455959121216438e-07
in O 0 1.244994450644299e-06
cell O 0 6.26172186457552e-05
- O 0 3.451703014434315e-05
cycle O 0 3.7236884963931516e-05
regulation O 0 3.663464667624794e-05
. O 0 3.6529712815536186e-05

When O 0 6.972307164687663e-05
resting O 0 0.0013874811120331287
cells O 0 1.714195059321355e-05
are O 0 2.0875168615930306e-07
induced O 0 5.366249297367176e-06
to O 0 1.9869554535034695e-07
proliferate O 0 1.0868794788621017e-06
, O 0 8.969963261051817e-08
the O 0 1.2658171044677147e-07
steady O 0 1.1219508451176807e-06
- O 0 2.891538031235541e-07
state O 0 2.4514848817602797e-08
levels O 0 5.4326569909335376e-08
of O 0 8.587178257357664e-08
BRCA1 O 0 1.226777726515138e-06
increase O 0 9.444489990073635e-08
in O 0 1.033232308600418e-07
late O 0 1.34687616082374e-06
G1 O 0 3.527226363075897e-05
and O 0 4.670513575888435e-08
reach O 0 1.0227677904595112e-07
a O 0 1.7256749629268597e-07
maximum O 0 7.840021680749487e-07
during O 0 3.479870656519779e-06
S O 0 7.268473564181477e-05
phase O 0 6.223622767720371e-05
. O 0 2.9614624509122223e-05

Moreover O 0 3.839732744381763e-05
, O 0 3.6571921100403415e-06
in O 0 2.9162788450776134e-06
S O 0 9.855425014393404e-05
phase O 0 8.874635386746377e-05
cells O 0 9.172085810860153e-06
, O 0 1.6481978946103482e-06
BRCA1 O 0 2.6070603780681267e-05
polypeptides O 0 3.2118550734594464e-06
are O 0 1.5243776374518347e-07
hyperphosphorylated O 0 1.8539189113653265e-05
and O 0 3.980405836045975e-07
accumulate O 0 1.5026447499622009e-06
into O 0 1.0651074262568727e-06
discrete O 0 6.429404038499342e-06
subnuclear O 0 0.00024506833869963884
foci O 0 0.0002853951882570982
termed O 0 0.00016148664872162044
" O 0 3.924965130863711e-05
BRCA1 O 0 0.0003416713734623045
nuclear O 0 8.971876377472654e-05
dots O 0 9.25660424400121e-05
. O 0 4.403741331771016e-05

" O 0 0.00035424731322564185
BRCA1 O 0 0.0022177568171173334
associates O 0 0.00012111381511203945
in O 0 4.566205461742356e-06
vivo O 0 3.390765778021887e-05
with O 0 2.425736965960823e-06
a O 0 2.281285014760215e-05
structurally O 0 0.00029460102086886764
related O 0 3.266632847953588e-05
protein O 0 0.0001426920498488471
termed O 0 0.0009139690082520247
BARD1 O 1 0.9948023557662964
. O 0 0.00025152802118100226

Here O 0 5.906621481699403e-06
we O 0 4.456848046174855e-07
show O 0 2.497048967597948e-07
that O 0 3.8127108581420543e-08
the O 0 1.857797116144866e-07
steady O 0 1.5982075183273992e-06
- O 0 5.163855121281813e-07
state O 0 7.132026524914181e-08
levels O 0 1.765063899483721e-07
of O 0 4.0877282003748405e-07
BARD1 O 0 0.06651214510202408
, O 0 1.9718727628514898e-07
unlike O 0 1.6697987348379684e-07
those O 0 2.3616024691364146e-08
of O 0 4.832236868423934e-07
BRCA1 O 0 4.248760888003744e-05
, O 0 2.1546260597915534e-07
remain O 0 2.665990166406118e-07
relatively O 0 2.3362140666449704e-07
constant O 0 1.0671999461919768e-06
during O 0 5.188915110920789e-06
cell O 0 0.00011916700896108523
cycle O 0 4.657919271267019e-05
progression O 0 0.0218107420951128
. O 0 4.312930104788393e-05

However O 0 6.974974530749023e-05
, O 0 2.514915649953764e-05
immunostaining O 0 0.001002258388325572
revealed O 0 4.1078128560911864e-05
that O 0 2.7509795472724363e-06
BARD1 O 0 0.02512587234377861
resides O 0 1.4407433809537906e-05
within O 0 2.139301841452834e-06
BRCA1 O 0 5.1847935537807643e-05
nuclear O 0 5.835603587911464e-06
dots O 0 1.9612739379226696e-06
during O 0 9.363716912957898e-07
S O 0 3.094891098953667e-06
phase O 0 1.313107532041613e-06
of O 0 3.0151022656355053e-07
the O 0 4.385642284887581e-07
cell O 0 3.639284386736108e-06
cycle O 0 6.458000711973e-07
, O 0 7.457013140310664e-08
but O 0 2.18737703505667e-08
not O 0 1.8432528392509084e-08
during O 0 4.6721709168195957e-07
the O 0 3.218477559130406e-06
G1 O 0 0.008113042451441288
phase O 0 0.00011445947166066617
. O 0 2.6325711587560363e-05

Nevertheless O 0 0.00018675137835089117
, O 0 2.3923919798107818e-05
BARD1 O 0 0.004531480837613344
polypeptides O 0 1.1516333870531525e-05
are O 0 1.0896947344463115e-07
found O 0 1.0841097974889635e-07
exclusively O 0 6.092857063322299e-08
in O 0 6.642544292390085e-08
the O 0 1.1498454455249885e-07
nuclear O 0 5.543118959394633e-07
fractions O 0 1.9632636849564733e-07
of O 0 1.6253507340024953e-07
both O 0 2.6919576612272067e-07
G1 O 0 0.0005432855687104166
- O 0 6.1636706050194334e-06
and O 0 9.714187854115153e-07
S O 0 9.037859126692638e-05
- O 0 6.15866738371551e-05
phase O 0 0.00032184680458158255
cells O 0 8.198223076760769e-05
. O 0 1.8139468011213467e-05

Therefore O 0 2.3174236048362218e-05
, O 0 4.251490736351116e-06
progression O 0 3.090152677032165e-05
to O 0 6.334795443763142e-07
S O 0 1.282269113289658e-05
phase O 0 5.142122518009273e-06
is O 0 2.1834884478266758e-07
accompanied O 0 4.3651334635796957e-07
by O 0 1.165653955581547e-07
the O 0 3.3412609923288983e-07
aggregation O 0 2.036681053141365e-06
of O 0 1.6587882782914676e-06
nuclear O 0 5.186475027585402e-05
BARD1 O 0 0.0025299531407654285
polypeptides O 0 2.52694317168789e-05
into O 0 5.031040927860886e-06
BRCA1 O 0 0.00023479665105696768
nuclear O 0 0.00010519537318032235
dots O 0 0.00010739194840425625
. O 0 4.036804602947086e-05

This O 0 2.1445684978971258e-05
cell O 0 0.0002031939511653036
cycle O 0 3.681732778204605e-05
- O 0 4.390352842165157e-05
dependent O 0 6.490251507784706e-06
colocalization O 0 0.00011086567246820778
of O 0 6.1746486608171836e-06
BARD1 O 1 0.9249279499053955
and O 0 2.1306545932020526e-06
BRCA1 O 0 2.9269469450809993e-05
indicates O 0 1.2976645393791841e-06
a O 0 5.222711934038671e-07
role O 0 6.333369242383924e-07
for O 0 8.142371257235936e-07
BARD1 O 0 0.39337489008903503
in O 0 8.4121147665428e-06
BRCA1 O 0 0.3459222614765167
- O 0 0.1380501687526703
mediated O 1 0.6771668791770935
tumor B-Disease 1 0.9999884366989136
suppression O 1 0.9987584352493286
. O 0 0.00021919947175774723

Ethnic O 0 4.482742224354297e-05
differences O 0 1.6316002074745484e-05
in O 0 1.0109742106578778e-05
the O 0 2.3937634978210554e-05
HFE O 0 0.15392668545246124
codon O 0 9.219552885042503e-05
282 O 0 0.00012515932030510157
( O 0 5.713814971386455e-05
Cys O 1 0.9994820952415466
/ O 0 0.17978686094284058
Tyr O 0 0.0026863072998821735
) O 0 1.54916870087618e-05
polymorphism O 0 0.00020726122602354735
. O 0 6.81728997733444e-05

Recent O 0 5.998664164508227e-06
studies O 0 1.6462248595416895e-06
have O 0 4.1345410295434704e-07
shown O 0 1.4797986978010158e-06
that O 0 1.754296499711927e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9913280606269836
HH B-Disease 1 0.9999997615814209
) O 0 1.346182784800476e-06
is O 0 1.4683428162243217e-07
likely O 0 5.745344822116749e-08
to O 0 2.130012966006234e-08
be O 0 3.604394649414644e-08
caused O 0 5.388374120229855e-07
by O 0 1.7689549736132903e-07
homozygosity O 0 1.0495135938981548e-05
for O 0 1.5351632498550316e-07
a O 0 1.3359144759306218e-06
Cys282Tyr O 0 5.458084342535585e-05
mutation O 0 1.2203087180751027e-06
in O 0 5.547281034523621e-07
the O 0 3.6332994568510912e-06
HFE O 1 0.7786524295806885
gene O 0 7.125246156647336e-06
located O 0 4.4272969716985244e-06
4 O 0 1.86759698408423e-05
. O 0 2.6486704882699996e-05

5 O 0 0.0004535204207058996
Mb O 0 0.269631028175354
telomeric O 0 0.007945048622786999
to O 0 3.6210134567227215e-05
HLA O 1 0.9999736547470093
- O 0 0.016879314556717873
A O 0 0.000824697723146528
. O 0 0.00015105144120752811

Population O 0 3.4434117424098076e-06
studies O 0 8.224927796618431e-07
of O 0 1.159444650511432e-06
this O 0 4.867554821430531e-07
polymorphism O 0 3.0451749353233026e-06
are O 0 3.6568145844739774e-08
facilitated O 0 5.846131330144999e-07
by O 0 9.506008780135744e-08
the O 0 2.1505019276446546e-07
fact O 0 2.3251715219885227e-07
that O 0 8.36890308164584e-08
the O 0 9.329239674116252e-07
Cys282Tyr O 0 0.00036663530045188963
mutation O 0 1.4916700820322149e-05
creates O 0 8.771011380304117e-06
a O 0 7.867653948778752e-06
Rsal O 0 0.0008057396626099944
restriction O 0 4.284002716303803e-05
site O 0 3.097658554906957e-05
. O 0 1.9233915736549534e-05

We O 0 3.917577032552799e-06
have O 0 8.048615995903674e-07
studied O 0 3.813507646555081e-06
the O 0 2.7469634460430825e-06
codon O 0 2.421933641016949e-05
282 O 0 7.084137905621901e-05
( O 0 3.3076950785471126e-05
Cys O 1 0.9943546056747437
/ O 0 0.0036360539961606264
Tyr O 0 0.00028048467356711626
) O 0 9.95668187897536e-07
polymorphism O 0 3.3241947221540613e-06
in O 0 4.059663183397788e-07
different O 0 1.0146363393914726e-07
ethnic O 0 2.7808177947008517e-06
groups O 0 4.784592874784721e-06
. O 0 2.9965558496769518e-05

In O 0 3.87556337955175e-06
agreement O 0 3.1645754461351316e-06
with O 0 6.555759455295629e-07
previous O 0 1.3548223023462924e-06
observations O 0 9.517698345007375e-07
the O 0 1.7158547507278854e-06
Tyr O 0 0.0001873174187494442
allele O 0 4.826617896469543e-06
appeared O 0 1.0264933507642127e-06
to O 0 7.399913926064983e-08
be O 0 1.0983480791537659e-07
rare O 0 7.86632426752476e-07
or O 0 2.2635461505160492e-07
absent O 0 2.390184590694844e-06
in O 0 1.1972650781899574e-06
Asiatic O 0 0.19136632978916168
( O 0 1.8358342686042306e-06
Indian O 0 4.708968390332302e-06
, O 0 8.495505881001009e-07
Chinese O 0 2.5807648853515275e-06
) O 0 1.5466209788428387e-06
populations O 0 5.060142484580865e-06
. O 0 2.7876050808117725e-05

The O 0 9.03964064491447e-06
highest O 0 7.126734999474138e-06
allele O 0 3.932073923351709e-06
frequency O 0 6.303410486907524e-07
( O 0 1.192577627762148e-07
7 O 0 2.7046621653425973e-07
. O 0 4.34131592896847e-08
5 O 0 1.7947273533991392e-07
% O 0 1.682148962345309e-07
) O 0 9.130529576850677e-08
was O 0 1.4574889064533636e-06
found O 0 4.727416182959132e-07
in O 0 1.3375245089264354e-06
Swedes O 0 0.00010261914576403797
. O 0 4.233993240632117e-05

Saamis O 0 0.0003449350188020617
( O 0 4.4009657358401455e-06
2 O 0 1.9497340417728992e-06
% O 0 8.663650419293845e-07
) O 0 1.8253406608437217e-07
and O 0 1.4664284719856369e-07
Mordvinians O 0 6.1272057791939005e-06
( O 0 8.258696482243977e-08
1 O 0 1.1145853306970821e-07
. O 0 2.391245779165274e-08
8 O 0 1.2463945608942595e-07
% O 0 1.0404804129393597e-07
) O 0 5.526139901235183e-08
had O 0 1.8566281312359934e-07
significantly O 0 1.8503443754980253e-07
lower O 0 2.611559466458857e-07
frequencies O 0 1.3887439820337022e-07
of O 0 7.426495471918315e-07
the O 0 6.47855767965666e-06
Tyr O 0 0.0010211820481345057
allele O 0 5.9982630773447454e-05
. O 0 2.522758222767152e-05

Comparisons O 0 1.743542088661343e-05
with O 0 3.280979854025645e-06
allele O 0 8.091876225080341e-06
frequencies O 0 6.878821068312391e-07
based O 0 2.44213310907071e-07
on O 0 3.980557323757239e-07
prevalence O 0 8.35697392176371e-06
estimates O 0 5.984671247460938e-07
of O 0 1.3484287819665042e-06
HH B-Disease 0 0.35526537895202637
showed O 0 1.7650467043495155e-06
some O 0 9.220079277838522e-08
disagreements O 0 7.40145139843662e-07
with O 0 2.1731575827743654e-07
the O 0 2.345318080188008e-06
RFLP O 0 3.494491829769686e-05
data O 0 2.9145223834348144e-07
, O 0 3.0461779942925205e-07
particularly O 0 5.606016202364117e-07
in O 0 1.8233969285574858e-06
Finns O 0 0.0001011096901493147
. O 0 3.2777825254015625e-05

The O 0 5.171470547793433e-05
newly O 0 0.0001525856350781396
described O 0 0.00016103305097203702
HFE O 1 0.9866281151771545
marker O 0 3.516947981552221e-05
provides O 0 5.549535444515641e-07
a O 0 2.2904617935637361e-07
new O 0 8.38361700061796e-08
approach O 0 7.29841502788986e-08
to O 0 1.6551357617800022e-08
the O 0 7.915391364576863e-08
screening O 0 5.51381049263e-07
of O 0 9.705315733299358e-07
HH B-Disease 0 0.4039195775985718
as O 0 2.546901214373065e-07
well O 0 4.626342686719909e-08
as O 0 3.9271871088431e-08
studies O 0 3.939866743962739e-08
of O 0 1.0267336136848826e-07
the O 0 2.1924734028289095e-07
relationship O 0 3.020887504590064e-07
between O 0 7.860947448534716e-07
the O 0 3.366591045050882e-05
HFE O 1 0.9999939203262329
Tyr O 1 0.679970383644104
allele O 0 1.458039059798466e-05
and O 0 1.0560066812104196e-06
different O 0 1.5030160511741997e-06
disorders O 1 0.9999650716781616
including O 0 0.1804121434688568
cancer B-Disease 1 0.9999998807907104

Autosomal B-Disease 1 0.9992345571517944
dominant I-Disease 1 0.9999717473983765
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999991655349731
associated O 0 2.409619810350705e-05
with O 0 1.524252525086922e-06
a O 0 8.55734742799541e-06
missense O 0 7.124691182980314e-05
mutation O 0 6.082121672079666e-06
encoding O 0 5.084910299046896e-06
Gly23 O 0 0.008664676919579506
- O 0 0.0002767023688647896
- O 0 0.003260584780946374
> O 0 0.00025566128897480667
Val O 0 9.897664858726785e-05
in O 0 5.389461421145825e-06
neurophysin O 0 0.2774837613105774
II O 1 0.9998748302459717
. O 0 0.00010788338840939105

Autosomal B-Disease 1 0.9996486902236938
dominant I-Disease 1 0.9999796152114868
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.35816776752471924
ADNDI B-Disease 1 0.9999983310699463
) O 0 3.613657554524252e-06
is O 0 1.1459803772595478e-06
an O 0 7.28423910913989e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.9981096982955933
by O 0 0.00020114296057727188
progressive O 1 0.9999985694885254
degeneration O 1 1.0
of O 0 0.0002710241242311895
the O 0 9.715199121274054e-05
magnocellular O 1 0.9947901964187622
neurons O 0 6.374760687322123e-06
of O 0 4.287596766516799e-07
the O 0 6.899344953126274e-07
hypothalamus O 0 4.560495654004626e-06
leading O 0 5.064827064416022e-07
to O 0 5.550382908836582e-08
decreased O 0 9.503785349807004e-07
ability O 0 7.106606147999628e-08
to O 0 5.461518526317377e-08
produce O 0 2.6142831188735727e-07
the O 0 1.018973307509441e-06
hormone O 0 1.6980176951619796e-05
arginine O 0 2.088756264129188e-05
vasopressin O 0 5.206013156566769e-05
( O 0 9.560734724800568e-06
AVP O 0 0.011468565091490746
) O 0 9.969117854780052e-06
. O 0 2.888575181714259e-05

Affected O 0 3.879654104821384e-05
individuals O 0 1.586263238095853e-06
are O 0 2.3162301943102648e-07
not O 0 4.3360861923247285e-07
symptomatic O 0 0.0002826553536579013
at O 0 5.981002232147148e-06
birth O 0 1.875326779554598e-05
, O 0 9.888443628369714e-07
but O 0 3.715117031788395e-07
usually O 0 9.902438478093245e-07
develop O 0 1.7995012967730872e-05
diabetes B-Disease 1 0.9999897480010986
insipidus I-Disease 1 0.9635948538780212
at O 0 3.593494966480648e-06
1 O 0 6.2066592363407835e-06
- O 0 1.8059621652355418e-05
6 O 0 1.453948425478302e-05
yr O 0 0.00032997396192513406
of O 0 5.560646513913525e-06
age O 0 3.964342249673791e-05
. O 0 5.0568949518492445e-05

The O 0 1.4574941815226339e-05
genetic O 0 1.8784696294460446e-05
locus O 0 1.9648721718112938e-05
of O 0 4.0435070332023315e-06
the O 0 2.86264403257519e-05
disease O 1 0.999402642250061
is O 0 2.59015905612614e-06
the O 0 1.5071992493176367e-05
AVP O 1 0.9996867179870605
- O 0 0.0009110980900004506
neurophysin O 1 0.9784090518951416
II O 1 0.9999915361404419
( O 0 9.22417348192539e-06
NPII O 1 0.9143174886703491
) O 0 5.169979999664065e-07
gene O 0 3.8707148064531793e-07
, O 0 9.685550850235813e-08
and O 0 1.1427267310182287e-07
mutations O 0 4.441945407052117e-07
that O 0 2.5903668188220763e-07
cause O 0 3.155473677907139e-05
ADNDI B-Disease 1 0.9112110733985901
have O 0 1.3553659528042772e-07
been O 0 6.565294086158247e-08
found O 0 3.2330298438409955e-08
in O 0 2.0626412577939846e-08
both O 0 1.7968282861602347e-08
the O 0 1.2003984295461123e-07
signal O 0 1.133406271947024e-06
peptide O 0 1.2570609442263958e-06
of O 0 3.576427047846664e-07
the O 0 2.885977892219671e-06
prepro O 1 0.947944700717926
- O 1 0.9659010171890259
AVP O 1 0.9999226331710815
- O 0 0.011587374843657017
NPII O 1 0.9838258624076843
precursor O 0 9.939545270754024e-05
and O 0 2.0874581423413474e-06
within O 0 7.693834049860016e-06
NPII O 0 0.175192728638649
itself O 0 7.282530714292079e-05
. O 0 6.911978562129661e-05

An O 0 3.2640826248098165e-05
affected O 0 1.4993715012678877e-05
girl O 0 1.2910980331071187e-05
who O 0 9.538288168187137e-07
presented O 0 1.0413008340037777e-06
at O 0 6.873443680888158e-07
9 O 0 5.113398628964205e-07
months O 0 2.235085077018084e-07
of O 0 3.3645460462139454e-07
age O 0 1.3598993291452643e-06
and O 0 2.9264404588502657e-07
her O 0 9.840136954153422e-07
similarly O 0 4.241342139721382e-06
affected O 0 1.0791641216201242e-06
younger O 0 2.6972409159498056e-06
brother O 0 1.5398598407045938e-05
and O 0 2.961388076982985e-07
father O 0 2.4065016077656765e-06
were O 0 1.483903844246015e-07
all O 0 3.177446927793426e-08
found O 0 4.443979051416136e-08
to O 0 1.9434832410070157e-08
have O 0 2.58007517572878e-08
a O 0 1.9149337049384485e-07
novel O 0 1.4487349062619614e-06
missense O 0 6.52840981274494e-06
mutation O 0 1.2854361557401717e-06
( O 0 3.8312495576064975e-07
G1758 O 0 3.426914554438554e-05
- O 0 1.513744609837886e-05
- O 0 4.422266283654608e-05
> O 0 4.5010408939560875e-05
T O 0 8.166221050487366e-06
) O 0 4.769967532070041e-08
encoding O 0 9.252282495708641e-08
the O 0 1.6934370705712354e-07
amino O 0 5.011351049688528e-07
acid O 0 3.119732582490542e-06
substitution O 0 1.1151834769407287e-05
Gly23 O 0 0.0016716246027499437
- O 0 0.0002570169453974813
- O 0 0.0008726190426386893
> O 0 0.0003577164898160845
Val O 0 0.00013636061339639127
within O 0 1.8280343283549882e-05
NPII O 0 0.11401324719190598
. O 0 9.181536734104156e-05

The O 0 2.273893369419966e-05
mutation O 0 3.41127670253627e-05
was O 0 1.565762431710027e-05
confirmed O 0 2.66579695562541e-06
by O 0 1.869323796199751e-06
restriction O 0 3.0488035918097012e-05
endonuclease O 0 0.00015191157581284642
analysis O 0 9.94074343907414e-06
. O 0 3.315451249363832e-05

A O 0 0.0014851790620014071
T1 O 1 0.8904451131820679
- O 0 0.00010002908675232902
weighted O 0 1.8941254893434234e-05
magnetic O 0 2.8552824005600996e-05
resonance O 0 9.548159141559154e-06
imaging O 0 8.474082278553396e-06
of O 0 2.63241918219137e-06
the O 0 1.1428631296439562e-05
fathers O 0 0.00013804316404275596
pituitary O 1 0.999042809009552
gland O 1 0.9306529760360718
demonstrates O 0 5.6167555158026516e-05
an O 0 1.3203644812165294e-05
attenuated O 1 0.8972563743591309
posterior O 1 0.8527854084968567
pituitary O 1 0.999913215637207
bright O 0 0.037791088223457336
spot O 0 0.0004131774476263672
. O 0 8.308310498250648e-05

This O 0 5.465402409754461e-06
mutation O 0 8.972374416771345e-06
may O 0 6.014698783474159e-07
be O 0 1.2319345898959e-07
valuable O 0 3.3837272894743364e-07
for O 0 9.116747889947874e-08
developing O 0 3.248250948217901e-07
models O 0 3.351077282331971e-07
of O 0 2.7354712983651552e-06
dominantly B-Disease 1 0.9998183846473694
inherited I-Disease 1 0.9999995231628418
neurodegeneration I-Disease 1 1.0
, O 0 2.389747123743291e-06
as O 0 1.5065216985021834e-07
the O 0 1.5010577669727354e-07
early O 0 4.6858701807650505e-07
age O 0 6.505114811261592e-07
of O 0 1.6449473605462117e-06
onset O 1 0.9999889135360718
of O 0 0.05168986693024635
symptoms O 1 0.9995368719100952
suggests O 0 4.581358098221244e-06
that O 0 1.2151508599345107e-07
this O 0 1.046742497123887e-07
mutation O 0 6.740036155861162e-07
may O 0 1.8456933048582869e-07
be O 0 1.1020792101135157e-07
particularly O 0 3.782795658935356e-07
deleterious O 0 2.6972691102855606e-06
to O 0 3.4763968415063573e-07
the O 0 5.486040208779741e-06
magnocellular O 1 0.8655588030815125
neuron O 0 0.004750346299260855
. O 0 7.009531145740766e-06
. O 0 2.691405825316906e-05

Frequent O 0 0.00013993597531225532
inactivation O 0 0.014165570959448814
of O 0 0.0008616202976554632
PTEN O 1 0.9999982118606567
/ O 1 0.9969518184661865
MMAC1 O 1 0.9997159838676453
in O 0 6.881062290631235e-05
primary O 1 0.9586330056190491
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0028423271141946316

Sporadic B-Disease 1 0.9998997449874878
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 7.356629066634923e-05
the O 0 1.0302121154381894e-05
most O 0 9.97200004348997e-07
common O 0 6.543881227116799e-06
male B-Disease 0 2.4870532797649503e-05
cancer I-Disease 1 0.9374978542327881
in O 0 7.906682526481745e-07
the O 0 1.5880734736128943e-06
Western O 0 8.086399247986265e-06
world O 0 1.2816049093089532e-06
, O 0 1.0024827190591168e-07
yet O 0 6.935324847745505e-08
many O 0 1.3203345972101488e-08
of O 0 1.0203225286886664e-07
the O 0 1.686666024625083e-07
major O 0 1.28990859593614e-06
genetic O 0 1.586986513757438e-06
events O 0 5.931057600605527e-08
involved O 0 1.0606438394233919e-07
in O 0 5.576752570846111e-08
the O 0 2.7523654466676817e-07
progression O 0 0.0009821183048188686
of O 0 2.8278702757233987e-06
this O 0 1.9940412130381446e-06
often O 0 2.5176229883072665e-06
fatal O 1 0.9935715198516846
cancer B-Disease 1 0.9986769556999207
remain O 0 3.547120513758273e-06
to O 0 6.893103545735357e-07
be O 0 2.491302666385309e-06
elucidated O 0 0.00031452070106752217
. O 0 4.638734753825702e-05

Numerous O 0 7.721366273472086e-05
cytogenetic O 0 0.0013723726151511073
and O 0 1.3376902643358335e-05
allelotype O 0 0.0015090714441612363
studies O 0 3.5455952911433997e-06
have O 0 2.8024678044857865e-07
reported O 0 1.331657017544785e-06
frequent O 0 1.7945047829925898e-06
loss O 0 4.5423243136610836e-05
of O 0 1.8022545191342942e-05
heterozygosity O 1 0.9988616704940796
on O 0 1.5273128155968152e-05
chromosomal O 1 0.9034724235534668
arm O 0 0.22253282368183136
10q O 0 0.2649795711040497
in O 0 4.1250299545936286e-05
sporadic B-Disease 1 0.9999055862426758
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.010490283370018005

Deletion O 0 0.00022177238133735955
mapping O 0 3.167621252941899e-05
studies O 0 5.288472493703011e-06
have O 0 7.225502258734195e-07
unambiguously O 0 4.622519554686733e-06
identified O 0 7.958215064718388e-07
a O 0 1.0756614301499212e-06
region O 0 1.2609991699719103e-06
of O 0 1.953029823198449e-06
chromosome O 0 1.2080108717782423e-05
10q23 O 0 2.2149522919789888e-05
to O 0 1.3688209321571776e-07
be O 0 7.285480307928083e-08
the O 0 1.8719447325565852e-07
minimal O 0 4.166978669672972e-06
area O 0 2.0516254153335467e-06
of O 0 4.684217401518254e-06
loss O 0 0.004969335161149502
. O 0 8.94562472240068e-05

A O 0 0.00011590364738367498
new O 0 5.193413016968407e-05
tumor B-Disease 1 0.9881552457809448
suppressor O 0 0.35659945011138916
gene O 0 4.216582601657137e-05
, O 0 2.0724444766528904e-05
PTEN O 1 0.9999308586120605
/ O 0 0.07055046409368515
MMAC1 O 1 0.9932147264480591
, O 0 1.7676222796580987e-06
was O 0 1.1610996807576157e-05
isolated O 0 2.2117278604127932e-06
recently O 0 4.778974016517168e-07
at O 0 2.3441637608812016e-07
this O 0 6.668123120334712e-08
region O 0 3.839270732441946e-07
of O 0 7.872733931435505e-07
chromosome O 0 1.842719029809814e-05
10q23 O 0 0.00010050983837572858
and O 0 1.689214315092613e-07
found O 0 8.053562794430036e-08
to O 0 1.6432988303449747e-08
be O 0 2.562185308363496e-08
inactivated O 0 1.4150749620966963e-06
by O 0 1.536494664833299e-07
mutation O 0 7.680014277866576e-07
in O 0 5.684455572918523e-07
three O 0 2.2569967768504284e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9998537302017212
lines O 0 0.00027185562066733837
. O 0 5.5724423873471096e-05

We O 0 1.8654112864169292e-05
screened O 0 9.023115853779018e-05
80 O 0 0.00013084251258987933
prostate B-Disease 1 0.9999995231628418
tumors I-Disease 1 0.9999946355819702
by O 0 7.218502560135676e-06
microsatellite O 0 0.0005425941199064255
analysis O 0 8.59810711517639e-07
and O 0 4.5803349735251686e-07
found O 0 7.95072025994159e-07
chromosome O 0 4.592906861944357e-06
10q23 O 0 1.143852114182664e-05
to O 0 1.4412324844670366e-07
be O 0 9.298101844024131e-08
deleted O 0 5.914812959417759e-07
in O 0 3.321322310512187e-07
23 O 0 5.895220510865329e-06
cases O 0 8.240132956416346e-06
. O 0 3.782340354518965e-05

We O 0 4.24974359702901e-06
then O 0 1.4930640190868871e-06
proceeded O 0 1.7041538740159012e-06
with O 0 1.3434738832529547e-07
sequence O 0 1.6854103535024478e-07
analysis O 0 6.562365229001443e-08
of O 0 2.8696268827843596e-07
the O 0 1.5195471405604621e-06
entire O 0 3.8091915484983474e-05
PTEN O 1 0.9989547729492188
/ O 0 0.0012542789336293936
MMAC1 O 1 0.6923413872718811
coding O 0 6.313105131994234e-06
region O 0 4.907865331915673e-07
and O 0 9.046869564599547e-08
tested O 0 1.7556442344357492e-07
for O 0 8.564033038283014e-08
homozygous O 0 1.5348630313383183e-06
deletion O 0 1.9119279386359267e-06
with O 0 2.0975426195946056e-07
new O 0 9.832596106207347e-07
intragenic O 0 0.0005816668854095042
markers O 0 1.4831725820840802e-06
in O 0 1.0020965390822312e-07
these O 0 1.7073661595645717e-08
23 O 0 3.8364814258784463e-07
cases O 0 1.478395006415667e-07
with O 0 7.042115726108022e-07
10q23 O 0 0.012938741594552994
loss O 0 0.021008681505918503
of O 0 0.0005158949643373489
heterozygosity O 1 0.9999003410339355
. O 0 0.0002955674135591835

The O 0 6.753188245056663e-06
identification O 0 4.385685770103009e-06
of O 0 1.0179185210290598e-06
the O 0 1.1574749123610673e-06
second O 0 4.463825916900532e-06
mutational O 0 5.162630623090081e-05
event O 0 1.6963448388196412e-06
in O 0 1.4339251208639325e-07
10 O 0 9.53208072473899e-08
( O 0 1.306494255004509e-07
43 O 0 6.054852974557434e-07
% O 0 1.0478026979399147e-06
) O 0 3.189322796970373e-06
tumors B-Disease 1 0.999244213104248
establishes O 0 0.0005314380396157503
PTEN O 1 0.9998576641082764
/ O 0 0.00036987211205996573
MMAC1 O 0 0.03788990527391434
as O 0 3.731101969606243e-07
a O 0 4.220970595270046e-07
main O 0 1.029011286846071e-06
inactivation O 0 1.618066744413227e-05
target O 0 4.0054430883174064e-07
of O 0 6.138302524050232e-07
10q O 0 7.919548806967214e-05
loss O 0 4.944319880451076e-05
in O 0 1.0815691894094925e-05
sporadic B-Disease 1 0.9998213648796082
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.45496217859909e-05
. O 0 8.898702071746811e-05

Risk O 0 0.00021499941067304462
reversals O 0 0.00024851071066223085
in O 0 1.1937914678128436e-05
predictive O 0 4.8830810555955395e-05
testing O 0 4.2064613808179274e-05
for O 0 9.173957369057462e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 0.0009304729173891246

The O 0 1.0217095223197248e-05
first O 0 4.731620265374659e-06
predictive O 0 6.7125188252248336e-06
testing O 0 3.5337127428647364e-06
for O 0 1.0749942703114357e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 2.497430386938504e-06
HD B-Disease 0 3.177435792167671e-05
) O 0 8.273894991361885e-08
was O 0 3.9227262504937244e-07
based O 0 2.817441568936374e-08
on O 0 4.7354483001527115e-08
analysis O 0 4.514185292237016e-08
of O 0 2.11697567920055e-07
linked O 0 1.9494700609357096e-06
polymorphic O 0 5.036503807787085e-06
DNA O 0 8.316137041219918e-07
markers O 0 3.471659226761403e-07
to O 0 2.775581897651591e-08
estimate O 0 9.363988340282958e-08
the O 0 8.590176037159836e-08
likelihood O 0 5.550414243771229e-07
of O 0 5.355720418265264e-07
inheriting O 0 6.059437964722747e-06
the O 0 1.491288003308e-06
mutation O 0 4.569385055219755e-06
for O 0 3.647637413450866e-06
HD B-Disease 0 0.0014775552554056048
. O 0 3.179263512720354e-05

Limits O 0 4.151841494604014e-06
to O 0 4.3973605556857365e-07
accuracy O 0 9.224535801877209e-07
included O 0 5.623461447612499e-07
recombination O 0 1.171669509858475e-06
between O 0 2.6553459520073375e-07
the O 0 5.918627152823319e-07
DNA O 0 1.2540363059088122e-06
markers O 0 5.642693849949865e-07
and O 0 8.845293564263557e-08
the O 0 2.196831019318779e-07
mutation O 0 1.167750724562211e-06
, O 0 3.4969662010553293e-07
pedigree O 0 2.604356950541842e-06
structure O 0 1.8300884221389424e-06
, O 0 1.4619628529999318e-07
and O 0 8.141644514125801e-08
whether O 0 8.13394578358384e-08
DNA O 0 4.1681050788611174e-07
samples O 0 6.053818424334168e-08
were O 0 7.263959389547381e-08
available O 0 1.0233005554027841e-07
from O 0 4.014632679627539e-07
family O 0 2.852872057701461e-06
members O 0 3.7744457586086355e-06
. O 0 2.5882136469590478e-05

With O 0 1.883058075691224e-06
direct O 0 1.0411290531919803e-06
tests O 0 3.7427415122692764e-07
for O 0 1.7578054212208372e-07
the O 0 6.000089456392743e-07
HD B-Disease 0 1.5689071005908772e-05
mutation O 0 5.411362167251355e-07
, O 0 5.578550599238952e-08
we O 0 1.17996998838521e-08
have O 0 4.285844568130415e-09
assessed O 0 2.421667488761159e-08
the O 0 2.0346524465253424e-08
accuracy O 0 8.809027463030361e-08
of O 0 6.320867385056772e-08
results O 0 4.622135563181473e-08
obtained O 0 9.189319882807467e-08
by O 0 8.933186990134345e-08
linkage O 0 1.4506509842249216e-06
approaches O 0 2.784857429105614e-07
when O 0 8.930273764917729e-08
requested O 0 1.537800784490173e-07
to O 0 2.8909912686003736e-08
do O 0 1.6773920918922158e-08
so O 0 1.9201888079578566e-08
by O 0 5.2464141475638826e-08
the O 0 3.8765145404795476e-07
test O 0 1.7673728507361375e-06
individuals O 0 1.3701325087822624e-06
. O 0 2.2616830392507836e-05

For O 0 2.117027179338038e-06
six O 0 9.025598615153285e-07
such O 0 3.0043847232263943e-07
individuals O 0 1.5441655421000178e-07
, O 0 4.839403686673904e-07
there O 0 3.8507261024278705e-07
was O 0 4.257390173734166e-06
significant O 0 1.9066329741690424e-06
disparity O 0 1.1720958354999311e-05
between O 0 5.178630431146303e-07
the O 0 3.5690682125277817e-06
tests O 0 5.245961347100092e-06
. O 0 2.293179204571061e-05

Three O 0 4.64061668026261e-06
went O 0 4.677088782045757e-06
from O 0 8.239782118835137e-07
a O 0 2.357638550165575e-06
decreased O 0 8.387139132537413e-06
risk O 0 3.8457716300399625e-07
to O 0 3.544076321304601e-08
an O 0 7.2613687507328e-08
increased O 0 5.265255822450854e-07
risk O 0 3.058718789361592e-07
, O 0 5.495479271644399e-08
while O 0 4.1197960598537975e-08
in O 0 4.2543604195088847e-08
another O 0 1.6925135071232944e-07
three O 0 6.746364533682936e-08
the O 0 9.231919761987228e-07
risk O 0 5.92107062402647e-06
was O 0 4.021220956929028e-05
decreased O 0 0.00012048051576130092
. O 0 3.2029911380959675e-05

Knowledge O 0 1.936651096912101e-05
of O 0 3.0703436095791403e-06
the O 0 1.5005355180619517e-06
potential O 0 1.269366634915059e-06
reasons O 0 2.3009289407127653e-07
for O 0 3.433392237184307e-08
these O 0 1.6167669869560086e-08
changes O 0 4.096914452134115e-08
in O 0 5.07859176934744e-08
results O 0 4.666987152290858e-08
and O 0 3.598734110710211e-08
impact O 0 2.4023643163673114e-07
of O 0 2.2208895700259745e-07
these O 0 4.5029803885654474e-08
risk O 0 4.3083741729788017e-07
reversals O 0 2.503105179130216e-06
on O 0 2.020363893961985e-07
both O 0 1.5372742723229749e-07
patients O 0 5.206718469707994e-07
and O 0 1.8750860419913806e-07
the O 0 7.477778467546159e-07
counseling O 0 2.5953343083529035e-06
team O 0 2.2988191972217464e-07
can O 0 1.549908645870346e-08
assist O 0 4.8221824755501075e-08
in O 0 2.4807890852684977e-08
the O 0 4.674862452702655e-08
development O 0 9.549714263812348e-08
of O 0 7.179495753462106e-08
strategies O 0 4.638456019279147e-08
for O 0 2.9286031377750987e-08
the O 0 2.2481425787646003e-07
prevention O 0 3.928224487026455e-06
and O 0 4.16481391596335e-08
, O 0 4.40303402626796e-08
where O 0 3.5177237123207306e-08
necessary O 0 5.095377630937037e-08
, O 0 3.778684387611975e-08
management O 0 1.42258443247556e-07
of O 0 1.1418649847882989e-07
a O 0 5.085425982542802e-07
risk O 0 5.507944820237753e-07
reversal O 0 1.155201971414499e-06
in O 0 7.991850026201064e-08
any O 0 1.1219525219985371e-07
predictive O 0 6.291908789535228e-07
testing O 0 6.690787586194347e-07
program O 0 1.1853361456815037e-06
. O 0 1.3339297311176779e-06
. O 0 1.72519612533506e-05

A O 0 0.00015703368990216404
novel O 0 6.503052281914279e-05
common O 0 9.616146599000785e-06
missense O 0 4.0888142393669114e-05
mutation O 0 6.0497950471471995e-06
G301C O 0 1.795058597053867e-05
in O 0 5.668723588314606e-07
the O 0 1.0107710295415018e-06
N O 0 1.5095265553100035e-05
- O 0 1.8125807400792837e-05
acetylgalactosamine O 0 0.0003261299862060696
- O 0 6.950055831111968e-05
6 O 0 0.00010860405745916069
- O 0 0.15598076581954956
sulfate O 1 0.7862120866775513
sulfatase O 1 0.9333615303039551
gene O 0 2.1787200239486992e-05
in O 0 1.4034487321623601e-05
mucopolysaccharidosis B-Disease 1 0.9952404499053955
IVA I-Disease 1 0.9999992847442627
. O 0 0.000398805714212358

Mucopolysaccharidosis B-Disease 1 0.9996026158332825
IVA I-Disease 1 0.9999997615814209
( O 0 0.1558080017566681
MPS B-Disease 1 0.9999804496765137
IVA I-Disease 1 1.0
) O 0 7.104097221599659e-06
is O 0 1.327624659097637e-06
an O 0 3.401043159101391e-06
autosomal B-Disease 1 0.9122253656387329
recessive I-Disease 1 0.9999992847442627
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.8900578022003174
by O 0 4.99404086440336e-06
a O 0 0.0005866331048309803
genetic B-Disease 1 0.9974924325942993
defect I-Disease 1 0.999025821685791
in O 0 1.5404001487695496e-06
N O 0 2.6271714887116104e-05
- O 0 2.5956884201150388e-05
acetylgalactosamine O 0 0.001265924540348351
- O 0 0.00011721930786734447
6 O 0 0.00016750987560953945
- O 1 0.7761013507843018
sulfate O 1 0.9790194630622864
sulfatase O 1 0.9996929168701172
( O 0 3.1528961699223146e-05
GALNS O 1 0.9410312175750732
) O 0 2.2083382646087557e-05
. O 0 5.138969936524518e-05

In O 0 4.822205937671242e-06
previous O 0 2.8834197109972592e-06
studies O 0 1.799932874746446e-06
, O 0 9.891641639114823e-07
we O 0 1.845825181590044e-07
have O 0 4.7543625925072774e-08
found O 0 9.409733081611193e-08
two O 0 4.1310716625275745e-08
common O 0 5.691127284990216e-07
mutations O 0 8.86736927441234e-07
in O 0 9.422697075933684e-07
Caucasians O 0 8.931943739298731e-05
and O 0 1.2280162309252773e-06
Japanese O 0 2.892991506087128e-05
, O 0 4.400500074552838e-06
respectively O 0 3.466220368864015e-05
. O 0 3.437939449213445e-05

To O 0 6.927181402716087e-06
characterize O 0 1.9537545085768215e-05
the O 0 6.3995753407652956e-06
mutational O 0 0.0002804510004352778
spectrum O 0 6.301826488197548e-06
in O 0 2.7108879407933273e-07
various O 0 1.1090526186308125e-07
ethnic O 0 3.810043835983379e-07
groups O 0 2.0233950692727376e-07
, O 0 1.7010819419738255e-07
mutations O 0 2.9951098667879705e-07
in O 0 2.3401653947985324e-07
the O 0 1.3781984762317734e-06
GALNS O 0 0.2511373460292816
gene O 0 2.536768988647964e-06
in O 0 9.726377356855664e-07
Colombian O 0 8.15482489997521e-05
MPS B-Disease 1 0.9994930028915405
IVA I-Disease 1 1.0
patients O 0 2.135486647603102e-05
were O 0 8.915159241951187e-07
investigated O 0 2.827562639140524e-06
, O 0 4.894824314760626e-07
and O 0 2.635393059335911e-07
genetic O 0 1.2436072438504198e-06
backgrounds O 0 4.634140680082055e-07
were O 0 1.5609022341322998e-07
extensively O 0 4.2427723201399203e-07
analyzed O 0 1.33349800535143e-07
to O 0 2.80593841495147e-08
identify O 0 7.576581850798902e-08
racial O 0 6.446482530009234e-07
origin O 0 2.014055837662454e-07
, O 0 7.236108956476528e-08
based O 0 1.5152708954246918e-07
on O 0 4.5721870378656604e-07
mitochondrial O 0 8.019080269150436e-06
DNA O 0 2.5144029223156394e-06
( O 0 1.1102247299277224e-06
mtDNA O 0 2.8678152830252657e-06
) O 0 1.9935087038902566e-06
lineages O 0 2.4099714210024104e-05
. O 0 3.0051638532313518e-05

Three O 0 1.4151400137052406e-05
novel O 0 5.6773918913677335e-05
missense O 0 0.00027611342375166714
mutations O 0 1.2112765034544282e-05
never O 0 2.134793476216146e-06
identified O 0 4.690465971179947e-07
previously O 0 4.23006980554419e-07
in O 0 7.121246881069965e-08
other O 0 2.2658175780065903e-08
populations O 0 5.429021143754653e-08
and O 0 3.636754541957998e-08
found O 0 3.7976292333041783e-08
in O 0 3.0794346628226776e-08
16 O 0 1.387505079719631e-07
out O 0 5.1685447033378296e-08
of O 0 5.095416781841777e-07
19 O 0 7.618455128977075e-06
Colombian O 0 0.00012201869685668498
MPS B-Disease 1 0.5370181202888489
IVA I-Disease 1 0.9999996423721313
unrelated O 0 1.7263086192542687e-05
alleles O 0 2.0116824543947587e-06
account O 0 6.396974185918225e-07
for O 0 2.1742550870840205e-06
84 O 0 0.00011999862181255594
. O 0 6.48824279778637e-05

2 O 0 1.4569103768735658e-05
% O 0 2.366793978580972e-06
of O 0 1.778883301994938e-06
the O 0 1.6505699704794097e-06
alleles O 0 1.425968207513506e-06
in O 0 5.462945296130783e-07
this O 0 9.321644824922259e-07
study O 0 6.970933100092225e-06
. O 0 3.314053901704028e-05

The O 0 8.198504656320438e-05
G301C O 0 0.0008294011349789798
and O 0 1.6929419871303253e-05
S162F O 0 0.00029873353196308017
mutations O 0 7.799269951647148e-06
account O 0 1.7298118564212928e-06
for O 0 2.6660054572857916e-06
68 O 0 0.0001780954480636865
. O 0 0.00010373524128226563

4 O 0 6.517846486531198e-05
% O 0 2.04050556931179e-05
and O 0 7.319672022276791e-06
10 O 0 2.0674267943832092e-05
. O 0 5.105485979584046e-05

5 O 0 1.1219840416742954e-05
% O 0 2.7249807317275554e-06
of O 0 1.8503033061278984e-06
mutations O 0 1.982258936550352e-06
, O 0 6.773647100999369e-07
respectively O 0 8.297061526718608e-07
, O 0 2.7930411761190044e-07
whereas O 0 2.675342614111287e-07
the O 0 3.337426903726737e-07
remaining O 0 1.821999376261374e-06
F69V O 0 0.0072553688660264015
is O 0 3.6504664535641496e-07
limited O 0 1.810860936757308e-07
to O 0 9.630250730197076e-08
a O 0 1.9357382825546665e-06
single O 0 8.201530363294296e-06
allele O 0 5.242945917416364e-05
. O 0 2.8007418222841807e-05

The O 0 3.641469083959237e-05
skewed O 0 2.829035474860575e-05
prevalence O 0 4.2153926187893376e-05
of O 0 5.545437034015777e-06
G301C O 0 0.00017279777966905385
in O 0 8.33466856420273e-07
only O 0 4.120810501717642e-07
Colombian O 0 3.2609907520964043e-06
patients O 0 7.503023198296432e-07
and O 0 1.8187479611242452e-07
haplotype O 0 5.571549081651028e-06
analysis O 0 1.1708770131235724e-07
by O 0 1.3060707715339959e-07
restriction O 0 7.384008995359181e-07
fragment O 0 7.045050551823806e-07
length O 0 2.347420888781926e-07
polymorphisms O 0 6.595165018552507e-07
in O 0 1.3953952304746053e-07
the O 0 8.899511385607184e-07
GALNS O 1 0.7561277151107788
gene O 0 1.9327187601447804e-06
suggest O 0 2.964770544622297e-07
that O 0 1.5468555147890584e-07
G301C O 0 1.9299492123536766e-05
originated O 0 1.4747084833288682e-06
from O 0 4.4391507003638253e-07
a O 0 3.2927973734331317e-06
common O 0 6.65650350128999e-06
ancestor O 0 0.00014661040040664375
. O 0 5.580589277087711e-05

Investigation O 0 1.663741932134144e-05
of O 0 3.975461822847137e-06
the O 0 2.5685715172585333e-06
genetic O 0 4.644335149350809e-06
background O 0 1.3633091384690488e-06
by O 0 3.926978138224513e-07
means O 0 6.54006100830884e-07
of O 0 7.71457393966557e-07
mtDNA O 0 1.931158067236538e-06
lineages O 0 8.290101050079102e-07
indicate O 0 1.4633884859449608e-07
that O 0 3.9675875029843155e-08
all O 0 5.7473723558132406e-08
our O 0 2.6676332254282897e-07
patients O 0 7.598535489705682e-07
are O 0 7.652540290337129e-08
probably O 0 1.6946146388363559e-06
of O 0 2.793549811030971e-06
native O 0 2.78647530649323e-05
American O 0 0.00014777673641219735
descent O 0 0.008805093355476856

Low O 0 2.66323440882843e-05
frequency O 0 1.0314565770386253e-05
of O 0 1.2232902918185573e-05
BRCA1 O 0 0.0005636911955662072
germline O 0 0.00029664329485967755
mutations O 0 1.6300757579301717e-06
in O 0 8.182320812011312e-07
45 O 0 9.8362270364305e-06
German O 1 0.9999630451202393
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0003003479214385152
. O 0 0.000445668090833351

In O 0 3.446999699008302e-06
this O 0 5.258416422293521e-07
study O 0 3.6238412803868414e-07
we O 0 1.7801072260681394e-07
investigated O 0 1.5179887213889742e-06
45 O 0 4.503110176301561e-06
German O 1 0.9986866116523743
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.2018358524510404e-06
for O 0 2.3050502022670116e-06
germline O 0 0.18533682823181152
mutations O 0 1.9763772343139863e-06
in O 0 1.1971544608968543e-06
the O 0 1.6374848200939596e-05
BRCA1 O 0 0.06164919212460518
gene O 0 0.0001408250827807933
. O 0 8.606981282355264e-05

We O 0 5.684819370799232e-06
identified O 0 4.090698894287925e-06
four O 0 1.6935708799792337e-06
germline O 0 0.00016711598436813802
mutations O 0 1.9673543647513725e-06
in O 0 8.566252063246793e-07
three O 0 2.3899658572190674e-06
breast B-Disease 1 0.9999936819076538
cancer I-Disease 1 0.999886155128479
families O 0 7.667310342185374e-07
and O 0 5.521113735085237e-07
in O 0 3.0345240702445153e-06
one O 0 0.004312021192163229
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.020774738863110542
. O 0 5.816362431687594e-07
among O 0 1.3758240413608291e-07
these O 0 4.0093674158470094e-08
were O 0 2.566818011473515e-07
one O 0 6.416403834919038e-07
frameshift O 0 0.00010649333853507414
mutation O 0 3.29664658238471e-06
, O 0 4.801798354492348e-07
one O 0 3.1057547289492504e-07
nonsense O 0 3.18658203468658e-05
mutation O 0 2.5940994419215713e-06
, O 0 3.819335177013272e-07
one O 0 5.057326575297338e-07
novel O 0 4.2320252759964205e-06
splice O 0 8.684341082698666e-06
site O 0 1.969490767805837e-06
mutation O 0 1.3034393759880913e-06
, O 0 2.7581225481299043e-07
and O 0 6.271916959121882e-07
one O 0 2.398356627963949e-06
missense O 0 0.00017970471526496112
mutation O 0 8.552459621569142e-05
. O 0 5.138661072123796e-05

The O 0 4.3718853703467175e-05
missense O 0 0.0003149774274788797
mutation O 0 4.5960230636410415e-05
was O 0 3.667722558020614e-05
also O 0 1.1416062761782086e-06
found O 0 5.532182285605813e-07
in O 0 1.2483875480029383e-06
2 O 0 2.0569485059240833e-05
. O 0 3.17090998578351e-05

8 O 0 1.550768138258718e-05
% O 0 3.2342313716071658e-06
of O 0 1.1190132909177919e-06
the O 0 8.393903385695012e-07
general O 0 1.376892669213703e-06
population O 0 2.669557090939634e-07
, O 0 1.6442432126950735e-07
suggesting O 0 2.368974776345567e-07
that O 0 4.6308187506838294e-08
it O 0 6.354424186838514e-08
is O 0 3.6691605487249035e-07
not O 0 8.091730023807031e-07
disease O 0 0.10672691464424133
associated O 0 3.9660742913838476e-05
. O 0 5.014147245674394e-05

The O 0 1.3048625987721607e-05
average O 0 6.37704715700238e-06
age O 0 3.3259457268286496e-05
of O 0 0.0007722452864982188
disease O 1 0.9999996423721313
onset O 1 0.9999985694885254
in O 0 1.2735373275063466e-05
those O 0 1.229758936460712e-06
families O 0 2.0613608739949996e-06
harbouring O 1 0.9462378025054932
causative O 0 0.006828315556049347
mutations O 0 7.494179499190068e-06
was O 0 1.9475339286145754e-05
between O 0 5.991031684970949e-06
32 O 0 6.212521839188412e-05
. O 0 6.4378822571598e-05

3 O 0 0.00013863520871382207
and O 0 3.5815948649542406e-05
37 O 0 0.000238789725699462
. O 0 0.00020536531519610435

4 O 0 3.0698327464051545e-05
years O 0 9.235670404450502e-06
, O 0 4.499495844356716e-06
whereas O 0 2.9568293484771857e-06
the O 0 1.9313572465762263e-06
family O 0 4.6790028136456385e-06
harbouring O 0 0.0008785202517174184
the O 0 3.960507001465885e-06
missense O 0 5.01474023621995e-05
mutation O 0 3.1088297873793636e-06
had O 0 6.606307465517602e-07
an O 0 1.0957889884366523e-07
average O 0 2.0153834157099482e-07
age O 0 1.086969632524415e-06
of O 0 2.3795721517672064e-06
onset O 1 0.8394801616668701
of O 0 4.364629421615973e-05
51 O 0 0.0002467197773512453
. O 0 8.232364052673802e-05

2 O 0 0.00032398951589129865
years O 0 0.00018442266446072608
. O 0 0.0003725108690559864

These O 0 1.6135495570779312e-06
findings O 0 2.0714112451969413e-06
show O 0 1.9036459661947447e-06
that O 0 9.962911917682504e-07
BRCA1 O 0 5.09594137838576e-05
is O 0 4.779156483891711e-07
implicated O 0 1.737668981149909e-06
in O 0 2.461178780777118e-07
a O 0 9.418762374480139e-07
small O 0 5.800177405035356e-07
fraction O 0 2.7736350602936e-06
of O 0 0.00011862361134262756
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.795943373712362e-06
suggesting O 0 2.510152626200579e-06
the O 0 6.606130682484945e-07
involvement O 0 5.328552560968092e-06
of O 0 2.917642177635571e-06
another O 0 5.599492214969359e-05
susceptibility O 1 0.7938286662101746
gene O 0 8.192972018150613e-05
( O 0 1.6562526070629247e-05
s O 0 0.00025060237385332584
) O 0 5.27507254446391e-05

Paternal O 0 0.061463747173547745
transmission O 1 0.9726066589355469
of O 1 0.9999544620513916
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9994736313819885

We O 0 1.4683509107271675e-05
report O 0 4.24226436734898e-06
a O 0 7.594024282298051e-06
rare O 0 1.5158596397668589e-05
case O 0 1.4388252566277515e-05
of O 0 0.00016929868434090167
paternally O 1 0.9999611377716064
transmitted O 1 0.9999992847442627
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 0.0018608439713716507
. O 0 0.00014197219570633024

The O 0 2.5986755645135418e-05
proband O 0 0.0003393247607164085
is O 0 1.772329937921313e-06
a O 0 1.516741235718655e-06
23 O 0 3.2363354875997175e-06
year O 0 4.514005922828801e-06
old O 0 0.0006657587946392596
, O 0 0.000116099210572429
mentally B-Disease 1 0.9999970197677612
retarded I-Disease 1 0.9999957084655762
male O 0 0.19525204598903656
who O 1 0.9374312162399292
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9884130358695984

He O 0 4.2831939936149865e-05
presented O 0 5.857869837200269e-05
with O 0 8.96908895811066e-05
respiratory O 1 1.0
and O 0 0.0004867514071520418
feeding O 0 0.010176826268434525
difficulties O 0 0.008726884610950947
at O 0 0.0001221497805090621
birth O 0 0.0007916095783002675
. O 0 0.00013783945178147405

His O 0 0.00011229608207941055
two O 0 4.8871341277845204e-05
sibs O 1 0.9999792575836182
suffer O 1 0.9628188014030457
from O 0 0.0006435438408516347
childhood O 1 0.9999982118606567
onset O 1 1.0
DM B-Disease 1 1.0
. O 1 0.8590232133865356

Their O 0 7.145599738578312e-06
late O 0 2.5701207050587982e-05
father O 0 2.079609657812398e-05
had O 0 2.4384287371503888e-06
the O 0 1.0343853773520095e-06
adult O 0 1.1892446991623729e-06
type O 0 7.830853974155616e-06
of O 0 4.180180621915497e-05
DM B-Disease 1 1.0
, O 0 1.9615827113739215e-06
with O 0 6.926216542524344e-07
onset O 1 0.5654534101486206
around O 0 2.6407494715385837e-06
30 O 0 4.923945652990369e-06
years O 0 7.101861683622701e-06
. O 0 3.195385215803981e-05

Only O 0 3.267771262471797e-06
six O 0 1.0589070598143735e-06
other O 0 1.7480526537383412e-07
cases O 0 2.116479151936801e-07
of O 0 2.1540990928770043e-06
paternal O 0 0.005872939247637987
transmission O 1 0.9719142317771912
of O 1 0.9999922513961792
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 3.886767808580771e-05
been O 0 4.162522145634284e-06
reported O 0 9.941549251379911e-06
recently O 0 4.330615411163308e-05
. O 0 4.648654430638999e-05

We O 0 2.0784279968211195e-06
review O 0 1.3575383945862995e-06
the O 0 9.57569454840268e-07
sex O 0 6.776929240004392e-07
related O 0 8.240355668931443e-07
effects O 0 5.023044195695547e-06
on O 0 5.104967840452446e-06
transmission O 0 0.0038048806600272655
of O 1 0.9244771003723145
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9742297530174255

Decreased O 0 0.0003607605758588761
fertility O 0 0.00012743371189571917
of O 0 4.612211341736838e-06
males O 0 1.258653924196551e-06
with O 0 8.304312473228492e-07
adult O 0 6.080921957618557e-05
onset O 1 1.0
DM B-Disease 1 1.0
and O 0 4.362068466434721e-06
contraction O 0 2.3512715415563434e-05
of O 0 4.52326105460088e-07
the O 0 3.5995927305521036e-07
repeat O 0 1.6169292393897194e-06
upon O 0 4.859707019022608e-07
male O 0 6.835372801106132e-07
transmission O 0 6.173985411805916e-07
contribute O 0 1.844343699985984e-07
to O 0 3.492559486062419e-08
the O 0 1.5137543130094855e-07
almost O 0 4.705295850726543e-07
absent O 0 1.6025389868445927e-06
occurrence O 0 1.7931430420503602e-06
of O 0 3.6702840588986874e-06
paternal O 0 0.0012235356261953712
transmission O 1 0.6477048397064209
of O 1 0.9995782971382141
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9965426325798035

Also O 0 7.851568625483196e-06
the O 0 2.8177939839224564e-06
fathers O 0 2.2550534595211502e-06
of O 0 1.4339773315441562e-06
the O 0 3.849154381896369e-06
reported O 0 2.4080507500912063e-05
congenitally O 0 0.06202620267868042
affected O 0 1.1772069683502195e-06
children O 0 2.426342291528272e-07
showed O 0 4.2697976709860086e-07
, O 0 9.586268134853526e-08
on O 0 1.1657339626935936e-07
average O 0 2.0108679166241927e-07
, O 0 4.154556449975644e-07
shorter O 0 3.5146101708960487e-06
CTG O 0 0.0003572981513570994
repeat O 0 2.316337258889689e-06
lengths O 0 2.2768747385271126e-06
and O 0 3.2263648108710186e-07
hence O 0 1.4453689800575376e-06
less O 0 1.3099804618832422e-06
severe O 1 0.9918922185897827
clinical O 1 0.7479214668273926
symptoms O 1 0.8553597331047058
than O 0 5.755538836638152e-07
the O 0 1.934590500241029e-06
mothers O 0 1.26073223327694e-06
of O 0 4.215035460219951e-06
children O 0 1.659824738453608e-05
with O 1 0.9699838161468506
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9996864795684814

We O 0 6.608931016671704e-06
conclude O 0 9.092485015571583e-06
that O 0 1.4045530178918852e-06
paternal O 0 5.156549013918266e-05
transmission O 0 0.0013148485450074077
of O 1 0.999189555644989
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.46553754806518555
rare O 0 5.901536496821791e-05
and O 0 5.067242341283418e-07
preferentially O 0 6.372119401021337e-07
occurs O 0 8.997722744652492e-08
with O 0 1.93676001458698e-07
onset O 1 0.9968439340591431
of O 0 0.007122022099792957
DM B-Disease 1 1.0
past O 0 8.993250162347977e-07
30 O 0 2.7816668080049567e-07
years O 0 2.0871664219157537e-07
in O 0 3.059879816191824e-07
the O 0 1.2169383580840076e-06
father O 0 1.0236271009489428e-05
. O 0 5.13917120770202e-06
. O 0 1.919267015182413e-05

The O 0 0.00021562846086453646
RB1 O 1 0.9520572423934937
gene O 0 2.6972646082867868e-05
mutation O 0 1.2473958122427575e-05
in O 0 1.5968684010658762e-06
a O 0 1.1009002264472656e-05
child O 0 3.283056867076084e-05
with O 0 4.8905239964369684e-05
ectopic B-Disease 1 0.9999964237213135
intracranial I-Disease 1 0.9999998807907104
retinoblastoma I-Disease 1 0.9999957084655762
. O 0 0.0012807931052520871

The O 0 0.00023455990594811738
RB1 O 1 0.6228814721107483
gene O 0 4.979899313184433e-05
mutation O 0 1.3224286703916732e-05
was O 0 1.5037363482406363e-05
investigated O 0 6.3942802626115736e-06
in O 0 9.498565987087204e-07
a O 0 4.083943167643156e-06
child O 0 1.3941868928668555e-05
with O 0 8.857042303134222e-06
ectopic B-Disease 1 0.9999445676803589
intracranial I-Disease 1 0.9999994039535522
retinoblastoma I-Disease 1 0.9879376292228699
using O 0 1.132549414251116e-06
DNA O 0 7.410209263980505e-07
obtained O 0 1.2304788299388747e-07
from O 0 7.512188204827908e-08
both O 0 1.80307026198534e-07
the O 0 5.266965672490187e-06
pineal B-Disease 1 0.9986007809638977
and I-Disease 0 0.00010484707308933139
retinal I-Disease 1 1.0
tumours I-Disease 1 0.9999997615814209
of O 0 0.0001596775691723451
the O 0 0.0001845604128902778
patient O 0 0.14891937375068665
. O 0 0.00020407934789545834

A O 0 0.00018827180610969663
nonsense O 0 0.0002293909783475101
mutation O 0 1.6118383427965455e-05
in O 0 2.8998831567150773e-06
exon O 0 3.463213943177834e-05
17 O 0 2.6686154797062045e-06
( O 0 6.578205216101196e-07
codon O 0 2.2379226720659062e-06
556 O 0 3.7911991057626437e-06
) O 0 2.0255920674117078e-07
of O 0 3.347212498283625e-07
the O 0 1.951467766048154e-06
RB1 O 0 0.1353171467781067
gene O 0 2.019009116338566e-06
was O 0 1.5868320133449743e-06
found O 0 7.163464488257887e-08
to O 0 1.9117544880487003e-08
be O 0 2.494611095471555e-08
present O 0 8.608644463947712e-08
homozygously O 0 6.418315479095327e-06
in O 0 1.2973140428584884e-07
both O 0 1.8153308189994277e-07
the O 0 3.331344714752049e-06
retinal B-Disease 1 0.9999945163726807
and I-Disease 0 6.68595430397545e-06
the I-Disease 0 0.00026953622000291944
pineal I-Disease 1 0.9999980926513672
tumours I-Disease 1 0.9999997615814209
. O 0 0.0003578975156415254

The O 0 9.494983714830596e-06
same O 0 2.597022785266745e-06
mutation O 0 6.1396463024721015e-06
was O 0 5.488583155965898e-06
present O 0 1.1704946700774599e-06
heterozygously O 0 2.113117625412997e-05
in O 0 3.0024310149201483e-07
the O 0 4.381846281376056e-07
DNA O 0 4.5540531345977797e-07
from O 0 6.767049143263648e-08
the O 0 1.9677061402489926e-07
constitutional O 0 1.1950098723900737e-06
cells O 0 6.473983944488282e-07
of O 0 2.1544884987179103e-07
the O 0 8.600878800280043e-07
patient O 0 4.010096745332703e-06
, O 0 6.031920634086418e-07
proving O 0 4.475871264730813e-06
it O 0 7.600551299447034e-08
to O 0 5.003357017585586e-08
be O 0 1.3200580895045277e-07
of O 0 2.6195716600341257e-06
germline O 0 0.0004959551733918488
origin O 0 3.5330063838046044e-05
. O 0 4.1535655327606946e-05

The O 0 1.4102617569733411e-05
initial O 0 1.224357129103737e-05
mutation O 0 1.0444174222357105e-05
was O 0 6.477420356532093e-06
shown O 0 4.1604164380260045e-07
to O 0 9.462539196647413e-08
have O 0 7.148383218691379e-08
occurred O 0 6.886421601848269e-07
in O 0 2.8132808438385837e-07
the O 0 5.5290197451540735e-06
paternally O 0 0.0001586814469192177
derived O 0 2.958204822789412e-05
RB1 O 0 0.23108527064323425
allele O 0 0.00011742201604647562
. O 0 4.216888191876933e-05

The O 0 1.9537508705980144e-05
mutation O 0 1.0609352102619596e-05
is O 0 7.273254709616594e-07
in O 0 2.634395457334904e-07
an O 0 2.558786889039766e-07
area O 0 4.548046490526758e-07
of O 0 2.3126148107621702e-07
the O 0 3.0868858402754995e-07
gene O 0 3.7163576394050324e-07
that O 0 3.7280852183130264e-08
encodes O 0 2.5827051786109223e-07
the O 0 1.6897138266358525e-07
protein O 0 4.956170300829399e-07
- O 0 1.055605935107451e-06
binding O 0 2.2925664211470576e-07
region O 0 2.740066804562957e-07
known O 0 2.8216049940965604e-07
as O 0 2.2597455995310156e-07
the O 0 9.901665407596738e-07
pocket O 0 0.0003908390935976058
region O 0 1.0166592119276174e-06
and O 0 1.4669599579519854e-07
has O 0 1.4218969113244384e-07
been O 0 9.01412633425025e-08
detected O 0 2.2778210961860168e-07
in O 0 9.08654129716524e-08
other O 0 4.593081115444875e-08
cases O 0 1.5069930725530867e-07
of O 0 3.697021384141408e-06
retinoblastoma B-Disease 0 0.15009567141532898
. O 0 1.2381349733914249e-05
. O 0 3.485087290755473e-05

Low O 0 1.378636898152763e-05
levels O 0 2.7533471893548267e-06
of O 0 2.2204985725693405e-06
beta O 0 1.3194682651374023e-05
hexosaminidase O 0 0.0006589419790543616
A O 0 9.91117940429831e-06
in O 0 5.37952246304485e-07
healthy O 0 1.6915629430513945e-06
individuals O 0 1.7198145485508576e-07
with O 0 2.0040613435412524e-06
apparent O 1 0.9981206059455872
deficiency O 1 0.9999998807907104
of O 0 0.0021236753091216087
this O 0 4.0635321056470275e-05
enzyme O 0 0.00015549467934761196
. O 0 4.470652129384689e-05

Appreciable O 0 0.0010063982335850596
beta O 0 0.00017525344446767122
hexosaminidase O 0 0.004569992423057556
A O 0 7.13262488716282e-05
( O 0 3.82610096494318e-06
hex O 0 4.2047813622048125e-05
A O 0 5.798037364002084e-06
) O 0 3.218823110273661e-07
activity O 0 2.7248484002484474e-07
has O 0 1.4878460774525593e-07
been O 0 2.0722993099298037e-07
detected O 0 1.3176196489439462e-06
in O 0 2.558855385359493e-06
cultured O 1 0.9962073564529419
skin O 1 0.9999995231628418
fibroblasts O 1 0.9999973773956299
and O 0 0.19228217005729675
melanoma B-Disease 1 1.0
tissue O 1 0.9999943971633911
from O 0 5.946076726104366e-06
healthy O 0 6.328325525828404e-06
individuals O 0 1.1336976513121044e-07
previously O 0 8.200279921766196e-07
reported O 0 8.789305070422415e-07
as O 0 8.036267331590352e-07
having O 0 1.5695175534347072e-05
deficiency B-Disease 1 0.9999750852584839
of I-Disease 0 5.449586024042219e-05
hex I-Disease 0 0.006978804245591164
A I-Disease 0 9.152669917966705e-06
activity O 0 4.956057182425866e-07
indistinguishable O 0 3.957090939366026e-07
from O 0 3.818118088361189e-08
that O 0 4.538747688798139e-08
of O 0 6.430296934922808e-07
patients O 0 9.321741345047485e-06
with O 0 0.004325965419411659
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 1 0.5902357697486877
TSD B-Disease 1 0.9999948740005493
) O 0 3.164867666782811e-05
. O 0 5.161375520401634e-05

Identification O 0 5.5661006626905873e-05
and O 0 5.8803179854294285e-06
quantitation O 0 0.00035221001598984003
of O 0 1.1144424206577241e-05
hex O 0 0.00016606602002866566
A O 0 1.359904035780346e-05
, O 0 1.0724297681008466e-06
amounting O 0 5.3865223890170455e-06
to O 0 1.1719600934156915e-06
3 O 0 1.6662317648297176e-05
. O 0 2.3151329514803365e-05

5 O 0 9.358824900118634e-05
% O 0 5.375554974307306e-05
- O 0 0.00027361209504306316
6 O 0 0.0003410962817724794
. O 0 0.00014841558004263788

9 O 0 9.445726391277276e-06
% O 0 2.0867455532425083e-06
of O 0 1.3251479913378716e-06
total O 0 3.1183255941868993e-06
beta O 0 9.181274435832165e-06
hexosaminidase O 0 4.2317369661759585e-05
activity O 0 7.85932058988692e-07
, O 0 1.1892771567545424e-07
has O 0 6.025158683087284e-08
been O 0 5.980528783311456e-08
obtained O 0 3.231303935535834e-07
by O 0 1.282287030335283e-06
cellulose O 0 0.18087799847126007
acetate O 0 0.02082407847046852
gel O 0 0.0003641732328105718
electrophoresis O 0 3.450584699749015e-05
, O 0 2.9886634820286417e-06
DEAE O 0 0.1625238060951233
- O 0 0.00016218678501900285
cellulose O 0 0.067005954682827
ion O 0 2.4526445486117154e-05
- O 0 8.163900929503143e-06
exchange O 0 3.693127382575767e-06
chromatography O 0 2.5450090106460266e-05
, O 0 2.0197949197608978e-06
radial O 0 3.8242458685999736e-05
immunodiffusion O 0 0.00027292376034893095
, O 0 3.1665376809542067e-06
and O 0 4.0206045923696365e-06
radioimmunoassay O 0 0.0020676751155406237
. O 0 0.0001009862608043477

Previous O 0 3.4970355045516044e-05
family O 0 6.547839348058915e-06
studies O 0 1.6907242752495222e-06
suggested O 0 1.2659152162086684e-06
that O 0 1.0377710424336328e-07
these O 0 3.658412239815334e-08
individuals O 0 4.0675608659057616e-08
may O 0 2.1818856055233482e-07
be O 0 1.704376728639545e-07
compound O 0 2.8821054911531974e-06
heterozygotes O 0 1.4397985523828538e-06
for O 0 5.4073193922477e-08
the O 0 4.5319055175241374e-07
common O 0 2.564818942119018e-06
mutant O 0 0.00026087224250659347
TSD B-Disease 1 0.9054768085479736
gene O 0 1.0280048172717215e-06
and O 0 1.4881213417083927e-07
a O 0 1.0628547215674189e-06
rare O 0 4.971061571268365e-06
( O 0 2.533321321607218e-06
allelic O 0 0.00010636109800543636
) O 0 3.7993320347595727e-06
mutant O 0 7.667210593353957e-05
gene O 0 3.826354441116564e-05
. O 0 2.7616319130174816e-05

Thus O 0 8.892708137864247e-06
, O 0 1.2573893855005736e-06
the O 0 9.589887213223847e-07
postulated O 0 1.0957071935990825e-05
rate O 0 1.2525757711046026e-06
mutant O 0 5.851190508110449e-06
gene O 0 4.677529545915604e-07
appears O 0 1.0180131226888989e-07
to O 0 8.861061218112809e-09
code O 0 1.8907833521097928e-08
for O 0 1.423168782821449e-08
the O 0 7.406747926097523e-08
expression O 0 2.3881833044470113e-07
of O 0 2.2658831255739642e-07
low O 0 1.1776011206166004e-06
amounts O 0 8.246636866715562e-07
of O 0 2.321556394235813e-06
hex O 0 0.00011343722144374624
A O 0 6.577124440809712e-05
. O 0 4.1154784412356094e-05

Heterozygotes O 0 0.0005622311728075147
for O 0 6.325254616967868e-06
the O 0 9.960887837223709e-06
rare O 0 3.602747528930195e-05
mutant O 0 7.25462450645864e-05
may O 0 1.1888625977007905e-06
be O 0 2.6388534024590626e-07
indistinguishable O 0 1.6838789633766282e-06
from O 0 2.4697729372746835e-07
heterozygotes O 0 6.565183866769075e-06
for O 0 5.653067773891962e-07
the O 0 5.533941475732718e-06
common O 0 3.5931032471125945e-05
TSD B-Disease 1 0.9964368343353271
mutant O 0 0.0007949936552904546
. O 0 5.019970194553025e-05

However O 0 9.501360182184726e-06
, O 0 2.044307166215731e-06
direct O 0 1.2915431852889014e-06
visualization O 0 1.0193843991146423e-05
and O 0 7.423138868034584e-07
quantitation O 0 8.047092705965042e-05
of O 0 2.426854734949302e-06
hex O 0 2.960869278467726e-05
A O 0 1.8690207070903853e-06
by O 0 1.5190327928849e-07
the O 0 1.900448438618696e-07
methods O 0 2.789886650589324e-07
described O 0 8.337180474882189e-07
may O 0 2.515462824703718e-07
prevent O 0 1.0245793191643315e-06
false O 0 1.0700239272409817e-06
- O 0 3.7425024856929667e-06
positive O 0 6.960609653106076e-07
prenatal O 0 1.7812188161769882e-05
diagnosis O 0 0.0001723332970868796
of O 0 5.3688334446633235e-05
TSD B-Disease 1 0.9999886751174927
in O 0 2.491749455657555e-06
fetuses O 0 5.541974587686127e-06
having O 0 1.0271738801748143e-06
the O 0 9.622500556361047e-07
incomplete O 0 7.501773779949872e-06
hex B-Disease 0 0.19866971671581268
A I-Disease 1 0.7285912036895752
deficiency I-Disease 1 0.999994158744812
of O 0 5.77015907765599e-06
the O 0 3.715978436957812e-06
type O 0 2.4271752408822067e-05
described O 0 2.3505219814978773e-06
in O 0 2.9072160145915404e-07
the O 0 1.142394694397808e-06
four O 0 4.500997874856694e-06
healthy O 0 5.226542634773068e-05
individuals O 0 2.7643985959002748e-05

The O 0 0.0003316410584375262
tumor B-Disease 1 0.9991834759712219
suppressor O 1 0.9825862646102905
gene O 0 0.00046540796756744385
Smad4 O 1 0.9380913376808167
/ O 0 0.014551405794918537
Dpc4 O 0 0.0009464866598136723
is O 0 5.074240334579372e-07
required O 0 1.1624256757158946e-07
for O 0 1.5343918846610904e-07
gastrulation O 0 0.00016682781279087067
and O 0 2.0985790172289853e-07
later O 0 6.184321819091565e-07
for O 0 2.0982949422432284e-07
anterior O 0 1.3352634596230928e-05
development O 0 1.4487637827187427e-06
of O 0 2.0723757643281715e-06
the O 0 7.770952834107447e-06
mouse O 0 0.00010957209451589733
embryo O 0 6.169459084048867e-05
. O 0 3.115250001428649e-05

Mutations O 0 4.293294841772877e-05
in O 0 9.05901561054634e-06
the O 0 4.033464574604295e-05
SMAD4 O 1 0.9999840259552002
/ O 1 0.9998445510864258
DPC4 O 1 0.9999957084655762
tumor B-Disease 1 0.9999715089797974
suppressor O 0 0.01561212819069624
gene O 0 1.736913532113249e-06
, O 0 1.415243531255328e-07
a O 0 2.713671278797847e-07
key O 0 9.584400686435401e-07
signal O 0 2.8204851787450025e-06
transducer O 0 5.049941137258429e-06
in O 0 2.244445056476252e-07
most O 0 3.539881845426862e-07
TGFbeta O 0 0.001849543652497232
- O 0 2.1335650671971962e-05
related O 0 1.659171175560914e-06
pathways O 0 1.8523619473853614e-06
, O 0 5.55252164247122e-08
are O 0 7.580019278918826e-09
involved O 0 3.429184403103136e-08
in O 0 6.192394863546724e-08
50 O 0 4.400406510285393e-07
% O 0 1.3488300965036615e-06
of O 0 4.804881609743461e-05
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999966621398926
. O 0 0.0009085925994440913

Homozygous O 0 0.0029240597505122423
Smad4 O 1 0.7212997674942017
mutant O 0 0.14842848479747772
mice O 0 0.001886270591057837
die O 0 0.00011458473454695195
before O 0 9.912748282658868e-06
day O 0 1.8696713596000336e-05
7 O 0 0.0001053793093888089
. O 0 7.92125501902774e-05

5 O 0 0.00015227007679641247
of O 0 0.00021779055532533675
embryogenesis O 0 0.015034971758723259
. O 0 0.0002982380974572152

Mutant O 0 0.00014979610568843782
embryos O 0 7.662268217245582e-06
have O 0 5.074302862340119e-07
reduced O 0 1.564959575262037e-06
size O 0 6.906362841618829e-07
, O 0 5.082362122266204e-07
fail O 0 8.008632335076982e-07
to O 0 1.6147181725045812e-07
gastrulate O 0 5.673992927768268e-05
or O 0 5.261998126115941e-07
express O 0 2.7795238111139042e-06
a O 0 4.146539140492678e-06
mesodermal O 0 0.08944546431303024
marker O 0 3.75755516870413e-05
, O 0 5.731815804210783e-07
and O 0 3.8664279600197915e-07
show O 0 5.521363618754549e-06
abnormal O 0 0.0003157380851916969
visceral O 1 0.5273000597953796
endoderm O 1 0.9956654906272888
development O 0 0.00014210275548975915
. O 0 5.838606011820957e-05

Growth B-Disease 0 0.23029574751853943
retardation I-Disease 1 0.9993095397949219
of O 0 2.7053431040258147e-05
the O 0 4.02997357014101e-05
Smad4 O 1 0.9973880648612976
- O 0 0.010734792798757553
deficient O 0 0.00030771963065490127
embryos O 0 6.63449100102298e-07
results O 0 1.6239842182130815e-07
from O 0 1.749490223801331e-07
reduced O 0 3.248512712161755e-06
cell O 0 2.086663880618289e-05
proliferation O 0 6.0304173530312255e-06
rather O 0 2.6921836138171784e-07
than O 0 2.4179988145078823e-07
increased O 0 7.482539331249427e-06
apoptosis O 0 0.00048549307393841445
. O 0 2.3792068532202393e-05

Aggregation O 0 0.00010519547504372895
of O 0 5.8494621043791994e-05
mutant O 0 0.0016546138795092702
Smad4 O 1 0.9789634943008423
ES O 1 0.9845733046531677
cells O 0 2.1298466890584677e-05
with O 0 1.6032466874094098e-06
wild O 0 4.2700819903984666e-05
- O 0 0.00031481709447689354
type O 0 0.000283309374935925
tetraploid O 0 0.0008646773640066385
morulae O 0 0.01197703368961811
rescues O 0 0.00029497654759325087
the O 0 4.411260306369513e-05
gastrulation B-Disease 1 0.9997205138206482
defect I-Disease 1 0.9867664575576782
. O 0 0.0001414897124050185

These O 0 2.015961399592925e-06
results O 0 1.0931343012998695e-06
indicate O 0 1.2805907090296387e-06
that O 0 3.241551098653872e-07
Smad4 O 0 2.7575582862482406e-05
is O 0 2.613143976759602e-07
initially O 0 2.610658214052819e-07
required O 0 3.665564562993495e-08
for O 0 1.716656150563267e-08
the O 0 8.226216152706911e-08
differentiation O 0 8.049199209381186e-07
of O 0 3.092148119776539e-07
the O 0 1.1525872878337395e-06
visceral O 0 0.002444607438519597
endoderm O 0 0.002159151481464505
and O 0 1.2325457987572008e-07
that O 0 9.559537517134231e-08
the O 0 1.1485493587315432e-06
gastrulation B-Disease 1 0.9062085747718811
defect I-Disease 0 0.00035910974838770926
in O 0 2.9811064905516105e-07
the O 0 1.831996996770613e-06
epiblast O 1 0.5455130338668823
is O 0 3.1810463951842394e-07
secondary O 0 1.5503956092288718e-06
and O 0 5.399557494456531e-07
non O 0 9.52907430473715e-06
- O 0 0.0001399511966155842
cell O 0 0.00024861452402547
autonomous O 0 5.8931120292982087e-05
. O 0 4.707514017354697e-05

Rescued O 0 0.0013159329537302256
embryos O 0 0.00010598830704111606
show O 0 8.319220069097355e-05
severe O 1 0.9991481304168701
anterior O 1 0.9939028024673462
truncations O 1 0.9983880519866943
, O 0 5.234272975940257e-06
indicating O 0 5.3668481996282935e-06
a O 0 1.0798723906191299e-06
second O 0 9.950624644261552e-07
important O 0 3.085879427544569e-07
role O 0 6.3216992884918e-07
for O 0 5.741301833950274e-07
Smad4 O 0 0.0009027085616253316
in O 0 7.808660484442953e-06
anterior O 0 0.04621328413486481
patterning O 0 0.14774805307388306
during O 0 0.0002312968426849693
embryogenesis O 0 0.08031345903873444
. O 0 7.528789137722924e-05

Prevalence O 0 0.0007314649992622435
of O 0 5.7078676036326215e-05
p16 O 0 0.0016471524722874165
and O 0 3.193959855707362e-05
CDK4 O 1 0.9991868138313293
germline O 0 0.3563706874847412
mutations O 0 7.956553417898249e-06
in O 0 2.8495928745542187e-06
48 O 0 0.00044171480112709105
melanoma B-Disease 1 1.0
- O 1 0.9948370456695557
prone O 0 0.007104227319359779
families O 0 1.2263683402125025e-06
in O 0 4.935510787618114e-06
France O 0 0.000244610826484859
. O 0 0.0001059804271790199

The O 0 0.0002483510470483452
French O 0 0.020536908879876137
Familial B-Disease 1 0.9999388456344604
Melanoma I-Disease 1 0.9999998807907104
Study O 0 0.00050033611478284
Group O 0 0.0008437216747552156
. O 0 0.0002172310050809756

Germline O 0 0.0025342926383018494
mutations O 0 1.3440197108138818e-05
in O 0 2.570806373114465e-06
the O 0 6.756847596989246e-06
p16 O 0 0.000248017895501107
and O 0 2.242475375169306e-06
CDK4 O 1 0.7859326601028442
genes O 0 4.793662924384989e-07
have O 0 5.369876632244086e-08
been O 0 6.16226714100776e-08
reported O 0 7.951465619271403e-08
in O 0 5.15275644374924e-08
a O 0 5.152452331458335e-07
subset O 0 7.5928078331344295e-06
of O 0 1.452429478376871e-05
melanoma B-Disease 1 0.9999997615814209
pedigrees O 0 7.933713641250506e-05
, O 0 6.348439569592301e-07
but O 0 1.0780598813653341e-07
their O 0 1.052815434832155e-07
prevalence O 0 1.8478753190720454e-05
is O 0 3.9733021139909397e-07
not O 0 1.4541261350586865e-07
well O 0 7.81458254550671e-07
known O 0 9.013650924316607e-06
. O 0 1.8626382370712236e-05

We O 0 4.795977019966813e-06
searched O 0 5.9239960137347225e-06
for O 0 5.634337298943137e-07
such O 0 1.162686771749577e-06
germline O 0 9.553772542858496e-05
mutations O 0 1.6621104350633686e-06
in O 0 6.043493954166479e-07
48 O 0 9.524012966721784e-06
French O 1 0.9364850521087646
melanoma B-Disease 1 1.0
- O 1 0.9532210230827332
prone O 0 0.00025172860478051007
families O 0 1.0847054454643512e-07
selected O 0 1.000282452423562e-07
according O 0 3.989959651562458e-08
to O 0 1.6546465531064314e-08
two O 0 1.4798782643765662e-08
major O 0 1.964630911288623e-07
criteria O 0 1.0836735242492068e-07
families O 0 2.506310003980161e-08
with O 0 3.788643354596388e-08
at O 0 2.0048399562710983e-07
least O 0 4.569453437852644e-08
three O 0 3.625506650450916e-08
affected O 0 7.913428845540693e-08
members O 0 5.259599333840015e-08
( O 0 5.0915399896211966e-08
n O 0 2.0760140273523575e-07
= O 0 1.5659790619793057e-07
20 O 0 7.379884436886641e-08
) O 0 2.004510690767347e-08
or O 0 1.8372578125536165e-08
families O 0 7.871711282803062e-09
with O 0 1.6265502722490055e-08
two O 0 3.273161652828094e-08
affected O 0 8.079209834477297e-08
members O 0 3.837457995814475e-08
, O 0 3.163514605830642e-08
one O 0 2.9032806381223963e-08
of O 0 6.46991082930981e-08
them O 0 2.015528899335095e-08
affected O 0 4.3426741314078754e-08
before O 0 3.068324261334965e-08
the O 0 2.5691683447348623e-08
age O 0 7.826024983614843e-08
of O 0 5.956316329047695e-08
50 O 0 9.6392561488301e-08
( O 0 4.652109808489513e-08
n O 0 1.6461699203773605e-07
= O 0 1.511558878064534e-07
28 O 0 2.293078154025352e-07
) O 0 5.375666844997795e-08
, O 0 3.77539208784583e-08
and O 0 3.4983266061772156e-08
one O 0 1.0146383289111327e-07
additional O 0 5.692321565220482e-07
minor O 0 1.6994674297166057e-05
criterion O 0 0.000376906362362206
. O 0 6.596766615984961e-05

Sixteen O 0 0.00014576928515452892
different O 0 8.141306352626998e-06
p16 O 0 0.0008390488801524043
germline O 0 0.0016196150099858642
mutations O 0 4.501890998653835e-06
were O 0 4.88710043100582e-07
found O 0 1.7485729131294647e-07
in O 0 1.6504898781022348e-07
21 O 0 5.465321919473354e-07
families O 0 1.210690356856503e-07
, O 0 1.5889779092503886e-07
while O 0 2.188454146789809e-07
one O 0 4.172670458046923e-07
germline O 0 0.0004951530136168003
mutation O 0 3.821247446467169e-06
, O 0 1.0394702485427842e-06
Arg24His O 0 0.00027743467944674194
, O 0 7.351371209551871e-07
was O 0 5.525856977328658e-06
detected O 0 1.6401288576162187e-06
in O 0 6.683147830699454e-07
the O 0 4.869616532232612e-06
CDK4 O 1 0.972556471824646
gene O 0 9.978291200241074e-05
. O 0 3.522496626828797e-05

The O 0 6.129941084509483e-06
frequency O 0 5.941966719547054e-06
of O 0 4.7038561206136364e-06
p16 O 0 5.954816879238933e-05
gene O 0 1.917991085065296e-06
mutation O 0 5.602499300039199e-07
in O 0 8.484965263733102e-08
our O 0 6.076875536109583e-08
sample O 0 4.6043876267276573e-08
( O 0 4.835224132193616e-08
44 O 0 2.093342033049339e-07
% O 0 1.6759632615048758e-07
) O 0 4.679465703816277e-08
is O 0 2.4996692715717472e-08
among O 0 1.5279033149795396e-08
the O 0 8.095808112784653e-08
highest O 0 4.106350104393641e-07
rates O 0 1.1075094619172887e-07
yet O 0 1.2480312250318093e-07
reported O 0 2.0712008108603186e-07
and O 0 1.0622736823506784e-07
the O 0 5.912094707127835e-07
CDK4 O 0 0.08419657498598099
mutation O 0 2.1168314106034813e-06
is O 0 1.1142367384309182e-07
the O 0 1.4536962567035516e-07
second O 0 7.726472972535703e-07
mutation O 0 1.1387943459340022e-06
detected O 0 5.198199914957513e-07
in O 0 1.7812128305649821e-07
this O 0 6.200147595336603e-07
gene O 0 6.58261251373915e-06
worldwide O 0 1.063570107362466e-05
. O 0 2.406716885161586e-05

In O 0 5.163828518561786e-06
summary O 0 9.74271915765712e-06
, O 0 1.2621168252735515e-06
our O 0 2.607816327326873e-07
results O 0 1.1048405212932266e-07
show O 0 1.4065727782508475e-07
frequent O 0 1.7754754821908136e-07
involvement O 0 6.172713824525999e-07
of O 0 5.161580247659003e-07
the O 0 2.016678536165273e-06
p16 O 0 0.00014423317043110728
gene O 0 2.621876092234743e-06
in O 0 1.2371095863272785e-06
familial B-Disease 1 0.9935702085494995
melanoma I-Disease 1 0.9999998807907104
and O 0 1.5459573887710576e-06
confirm O 0 6.392107252395363e-07
the O 0 2.334031705686357e-07
role O 0 3.0341863066496444e-07
of O 0 6.295119874266675e-07
the O 0 3.7403899568744237e-06
CDK4 O 1 0.9932830333709717
gene O 0 6.873338861623779e-06
as O 0 1.2627078831428662e-06
a O 0 9.490575757808983e-05
melanoma B-Disease 1 0.9999997615814209
- O 0 0.2729223966598511
predisposing O 0 0.009546793065965176
gene O 0 3.913005639333278e-05
. O 0 4.9253499128099065e-06
. O 0 2.897116428357549e-05

Progression O 0 0.0015781020047143102
of O 0 9.867743210634217e-05
somatic O 0 0.1759207844734192
CTG O 0 0.37244921922683716
repeat O 0 1.3341204066819046e-05
length O 0 2.5382837520737667e-06
heterogeneity O 0 1.2131261428294238e-05
in O 0 7.659036782570183e-07
the O 0 2.7771445729740663e-06
blood O 0 0.00015487911878153682
cells O 0 0.0011953959474340081
of O 1 0.7561731338500977
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9998050332069397
. O 0 0.0010967932175844908

The O 0 1.4293965250544716e-05
genetic O 0 2.2066309611545876e-05
basis O 0 9.229338502336759e-06
of O 1 0.9958510398864746
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9992627501487732
DM B-Disease 1 1.0
) O 0 8.853004942466214e-07
is O 0 8.139222273939595e-08
the O 0 5.3299377356097466e-08
expansion O 0 3.3772050755942473e-07
of O 0 2.597699051420932e-07
an O 0 8.523828114448406e-07
unstable O 0 4.37710878031794e-05
CTG O 0 0.00036775603075511754
repeat O 0 7.507160262321122e-07
in O 0 9.570976544637233e-08
the O 0 2.0582795912105212e-07
34 O 0 1.1380516298231669e-06
UTR O 0 0.0001582485274411738
of O 0 1.4443671716435347e-06
the O 0 7.897573595982976e-06
DM B-Disease 1 0.9999953508377075
protein O 0 1.2581625924212858e-05
kinase O 0 4.857890417042654e-06
gene O 0 1.385930090691545e-06
on O 0 1.0903449947363697e-06
chromosome O 0 2.1356576326070353e-05
19 O 0 4.311667726142332e-05
. O 0 7.689271296840161e-05

One O 0 3.677782160593779e-06
of O 0 2.5851002192212036e-06
the O 0 1.495729179623595e-06
principal O 0 4.932988758810097e-06
features O 0 6.832069061601942e-07
of O 0 1.5132333146539168e-06
the O 0 1.5785797586431727e-05
DM B-Disease 1 1.0
mutation O 0 1.877654722193256e-05
is O 0 1.932892530476238e-07
an O 0 1.3905304285799502e-07
extraordinarily O 0 1.3045199693806353e-06
high O 0 3.658280149920756e-07
level O 0 3.881975203512411e-07
of O 0 2.016390226344811e-06
somatic O 0 0.0038629176560789347
mosaicism O 1 0.9222107529640198
, O 0 3.6038039752384066e-07
due O 0 2.903165352563519e-07
to O 0 3.400318249191514e-08
an O 0 8.570781773187264e-08
extremely O 0 2.2979249081345188e-07
high O 0 1.7506134497580206e-07
degree O 0 1.2020256008327124e-06
of O 0 2.8952847515029134e-06
somatic O 0 0.00032877104240469635
instability O 0 3.5771568946074694e-05
both O 0 1.3057518799541867e-07
within O 0 2.478358851476514e-07
and O 0 1.8251822098136472e-07
between O 0 8.935229516282561e-07
different O 0 1.6367226862712414e-06
tissues O 0 0.00015537180297542363
. O 0 4.3526084482437e-05

This O 0 1.466573667130433e-05
instability O 0 0.00016053233412094414
appears O 0 4.098015779163688e-06
to O 0 1.207579316542251e-07
be O 0 7.11525984797845e-08
biased O 0 2.171440058873486e-07
towards O 0 6.376739491997796e-08
further O 0 4.470281922408503e-08
expansion O 0 3.4966262774105417e-07
and O 0 3.9125630735270533e-08
continuous O 0 3.8389813994399447e-07
throughout O 0 4.58496742794523e-08
the O 0 5.593744489829078e-08
life O 0 6.439059063723107e-08
of O 0 8.317629607290655e-08
an O 0 7.948554525682994e-08
individual O 0 4.7317282536596394e-08
, O 0 1.0773938186048326e-07
features O 0 1.5202212466647325e-07
that O 0 4.2238777808734085e-08
could O 0 3.774038859205575e-08
be O 0 2.593139214468465e-08
associated O 0 7.07695662072183e-08
with O 0 6.996441470619175e-08
the O 0 8.885502325028938e-07
progressive O 0 0.005340998526662588
nature O 0 4.839925168198533e-06
of O 0 6.883119112899294e-06
the O 0 0.0001361728791380301
disease O 1 0.999920129776001
. O 0 0.00020429583673831075

Although O 0 9.631786269892473e-06
increasing O 0 3.7969305139995413e-06
measured O 0 1.812028699532675e-06
allele O 0 2.554685806899215e-06
size O 0 4.817126750822354e-07
between O 0 5.734319756811601e-07
patients O 0 2.0192901502014138e-06
clearly O 0 6.133445253908576e-07
correlates O 0 5.393314381763048e-07
with O 0 5.221775722930033e-08
an O 0 2.2310601366370975e-07
increased O 0 1.1109608522019698e-06
severity O 0 0.00025129097048193216
of O 0 1.2697366400971077e-05
symptoms O 0 0.11136253923177719
and O 0 3.367576084656321e-07
an O 0 1.5940534581204702e-07
earlier O 0 4.65774320446144e-07
age O 0 6.822855880272982e-07
of O 0 9.18029570584622e-07
onset O 1 0.9403475522994995
, O 0 3.343103287534177e-07
this O 0 6.236964367190012e-08
correlation O 0 1.557555009412681e-07
is O 0 4.180094137495871e-08
not O 0 1.402080407331141e-08
precise O 0 6.091624982218491e-08
and O 0 3.4248049729512786e-08
measured O 0 1.2308308328101703e-07
allele O 0 3.926023168787651e-07
length O 0 1.1164662083729127e-07
cannot O 0 3.595138764467265e-08
be O 0 7.272940028002495e-09
used O 0 9.424818259162748e-09
as O 0 1.569785368360499e-08
an O 0 2.6913049566701375e-08
accurate O 0 1.7233855942322407e-07
predictor O 0 1.5696857644798001e-06
of O 0 6.809983688071952e-07
age O 0 3.78071422346693e-06
of O 0 2.232000588264782e-05
onset O 1 0.9999715089797974
. O 0 0.00030314846662804484

In O 0 5.288094143907074e-06
order O 0 1.1175266081409063e-06
to O 0 2.6975652644978254e-07
further O 0 4.5122746428205573e-07
characterize O 0 3.3645244457147783e-06
the O 0 1.002656404125446e-06
dynamics O 0 1.7789812773116864e-05
of O 0 9.075080015463755e-05
DM B-Disease 1 1.0
CTG O 1 0.9999634027481079
repeat O 0 0.00016617641085758805
somatic O 0 0.00025115086464211345
instability O 0 3.954947897000238e-05
, O 0 2.510262504529237e-07
we O 0 4.308895640292576e-08
have O 0 2.2083245454496137e-08
studied O 0 1.6274043446173891e-07
repeat O 0 4.832384092878783e-07
length O 0 1.4755890731521504e-07
changes O 0 6.940459940096844e-08
over O 0 1.2866340171058255e-07
time O 0 3.168309490320098e-07
in O 0 3.0097580747678876e-06
111 O 1 0.9979100823402405
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 7.709389319643378e-05
with O 0 5.708260459869052e-07
varying O 0 1.0262006071570795e-06
clinical O 0 5.269220855552703e-05
severity O 0 0.017214486375451088
and O 0 3.108533519480261e-06
CTG O 0 0.02550327405333519
repeat O 0 1.151432570623001e-06
size O 0 1.2673778826410853e-07
over O 0 3.4168056828320914e-08
time O 0 2.690796918614069e-08
intervals O 0 7.55763167603618e-08
of O 0 1.5570441291856696e-07
1 O 0 9.622775678508333e-07
- O 0 3.221990937163355e-06
7 O 0 5.117509772389894e-06
years O 0 8.662950676807668e-06
. O 0 3.56812852260191e-05

We O 0 3.3293313208559994e-06
have O 0 2.656994695371395e-07
found O 0 1.3624237737985823e-07
a O 0 2.487513199866953e-07
direct O 0 3.662818244265509e-07
progression O 0 4.607665232470026e-06
of O 0 3.849620782148122e-07
the O 0 3.1475113360102114e-07
size O 0 2.641733942709834e-07
heterogeneity O 0 1.4504877299259533e-06
over O 0 1.0338434464074453e-07
time O 0 6.125704743453753e-08
related O 0 1.2115866354633908e-07
to O 0 9.649300380942805e-08
initial O 0 1.612308210496849e-06
CTG O 0 0.00011328568507451564
repeat O 0 5.495919026543561e-07
size O 0 8.628715875147464e-08
and O 0 2.7403167734973977e-08
the O 0 4.0631327635765047e-08
time O 0 8.048188249176746e-08
interval O 0 8.367783266294282e-07
and O 0 2.4426384470643825e-07
always O 0 4.250767347002693e-07
biased O 0 4.411187717323628e-07
towards O 0 8.342891533175134e-07
further O 0 9.527316251478624e-07
expansion O 0 2.5513172658975236e-05
. O 0 2.4932467567850836e-05

Attempts O 0 1.7721522453939542e-05
to O 0 1.2603451295944978e-06
mathematically O 0 3.7020843137725024e-06
model O 0 1.103330191654095e-06
the O 0 6.163984380691545e-07
dynamics O 0 2.271964149258565e-06
have O 0 1.560317315352222e-07
proved O 0 1.6841231627040543e-06
only O 0 1.431265133078341e-07
partially O 0 1.6103427924463176e-06
successful O 0 4.609827328749816e-07
suggesting O 0 2.0327638594608288e-07
that O 0 1.5594299185295313e-08
individual O 0 1.6763589627544206e-08
specific O 0 4.305576339902473e-08
genetic O 0 1.254987523680029e-06
and O 0 3.0991034805083473e-07
/ O 0 5.417966531240381e-05
or O 0 3.6482043697105837e-07
environmental O 0 9.789405339688528e-07
factors O 0 1.3678943844297464e-07
also O 0 8.952136454354331e-08
play O 0 8.31415647439826e-08
a O 0 3.6854606833003345e-07
role O 0 9.790488775252015e-07
in O 0 2.451691671012668e-06
somatic O 0 0.005517729092389345
mosaicism O 1 0.9459924697875977
. O 0 1.450840227334993e-05
. O 0 4.1412178688915446e-05

Aspartylglucosaminuria B-Disease 1 0.9814456105232239
among O 0 0.00015915058611426502
Palestinian O 0 0.00038532051257789135
Arabs O 0 0.0013248231261968613
. O 0 0.0004689099150709808

Aspartylglucosaminuria B-Disease 1 0.9999960660934448
( O 1 0.8961074352264404
AGU B-Disease 1 0.9999998807907104
) O 0 6.427834250644082e-06
is O 0 1.8893739479608485e-06
a O 0 8.02217073214706e-06
rare O 0 0.00605804193764925
disorder B-Disease 1 0.9998842477798462
of I-Disease 0 0.019019020721316338
glycoprotein I-Disease 1 0.9999916553497314
metabolism I-Disease 1 0.7634588479995728
caused O 0 0.00015620977501384914
by O 0 8.061674634518567e-07
the O 0 1.630449332878925e-05
deficiency B-Disease 1 0.9999862909317017
of I-Disease 0 2.1535821360885166e-05
the I-Disease 0 7.348706276388839e-05
lysosomal I-Disease 1 0.999984622001648
enzyme I-Disease 0 8.445302955806255e-05
aspartylglucosaminidase I-Disease 0 0.49950626492500305
( O 0 3.117151572951116e-05
AGA O 1 0.9972255825996399
) O 0 1.4263518096413463e-05
. O 0 3.572643254301511e-05

AGU B-Disease 1 0.9999998807907104
is O 0 0.00010918555199168622
inherited O 1 0.6816384196281433
as O 0 1.3885304724681191e-05
an O 0 4.171444379608147e-05
autosomal O 1 0.9997395873069763
recessive O 1 0.999923825263977
trait O 0 0.3133271336555481
and O 0 1.6198927141886088e-06
occurs O 0 3.132442998321494e-07
with O 0 8.344483859445972e-08
a O 0 4.277521270523721e-07
high O 0 3.0305423592835723e-07
frequency O 0 2.0137966316724487e-07
in O 0 8.331650036552674e-08
Finland O 0 8.782367899584642e-07
because O 0 1.2663822701597383e-07
of O 0 5.679426635651907e-07
a O 0 1.0119532817043364e-05
founder O 0 0.0004946578992530704
effect O 0 5.8799763792194426e-05
. O 0 4.3564956285990775e-05

While O 0 1.8229646229883656e-05
very O 0 7.084490789566189e-06
few O 0 2.7744868020818103e-06
patients O 0 7.960743459989317e-06
with O 0 1.8209331756224856e-05
AGU B-Disease 1 1.0
have O 0 3.747466621462081e-07
been O 0 3.171235505305958e-07
reported O 0 2.2118703668638773e-07
from O 0 1.5838250533306564e-07
non O 0 1.1343739743097103e-06
- O 0 5.214408247411484e-06
Finnish O 0 5.125809184391983e-05
origin O 0 9.250320545106661e-07
, O 0 4.814495468963287e-07
we O 0 4.348476352333819e-07
diagnosed O 1 0.7743449807167053
the O 0 5.241880899120588e-06
disorder O 1 0.998708963394165
in O 0 2.449564817652572e-06
8 O 0 2.5162373276543804e-05
patients O 0 1.6072591506599565e-06
originating O 0 4.7429145411115314e-07
from O 0 1.6677775249718252e-07
3 O 0 8.958607509157446e-07
unrelated O 0 7.57955092467455e-07
families O 0 5.8423022863962615e-08
, O 0 6.57402807746621e-08
all O 0 3.178240959300638e-08
Palestinian O 0 6.88447755692323e-07
Arabs O 0 6.699049208691576e-07
from O 0 2.0886918150608835e-07
the O 0 6.344250778056448e-07
region O 0 1.979846501853899e-06
of O 0 3.0971880278229946e-06
Jerusalem O 0 8.503301069140434e-05
. O 0 6.07750698691234e-05

The O 0 5.160159707884304e-05
clinical O 0 0.008691936731338501
diagnosis O 1 0.9998670816421509
of O 1 0.999649167060852
AGU B-Disease 1 1.0
is O 0 3.3633528801146895e-05
often O 0 2.2960759338275238e-07
difficult O 0 2.135358556643041e-07
, O 0 6.661106510819081e-08
in O 0 3.661322978132375e-08
particular O 0 3.746819388084077e-08
early O 0 9.823899915772927e-08
in O 0 3.143491156265554e-08
the O 0 8.871787571251843e-08
course O 0 6.013046913722064e-07
of O 0 6.079066565689573e-07
the O 0 9.421130016562529e-06
disease O 1 0.9893863201141357
, O 0 1.809129628327355e-07
and O 0 6.515582384736263e-08
most O 0 5.133098923693069e-08
of O 0 5.531359192900709e-07
the O 0 7.072057542245602e-06
patients O 0 1.501715541962767e-05
are O 0 1.5676916120810347e-07
diagnosed O 0 0.4445047676563263
after O 0 1.4049013543626643e-06
the O 0 8.97947813882638e-07
age O 0 1.2930023558510584e-06
of O 0 1.7725260477163829e-06
5 O 0 9.682928066467866e-06
years O 0 1.2723586223728489e-05
. O 0 3.114881837973371e-05

However O 0 2.766183933999855e-05
, O 0 4.554097813525004e-06
since O 0 2.9345608254516264e-06
these O 0 5.935765443609853e-07
patients O 0 2.9977754820720293e-06
excrete O 0 8.779044947004877e-06
early O 0 8.701118190401758e-07
large O 0 4.698838438343955e-07
amounts O 0 2.3003389060249901e-07
of O 0 4.647001787816407e-07
aspartylglucosamine O 0 6.0615722759393975e-05
in O 0 4.259410388840479e-07
urine O 0 9.523427593194356e-07
, O 0 1.8687912017867347e-07
biochemical O 0 3.232156359445071e-06
screening O 0 7.541158311141771e-07
is O 0 2.5394530211997335e-07
easy O 0 3.141345814583474e-07
by O 0 3.340649357141956e-07
urine O 0 4.4595958570425864e-06
chromatography O 0 3.7528781831497326e-05
. O 0 2.674687038961565e-06
. O 0 1.557421092002187e-05

Detection O 0 5.482220876729116e-05
of O 0 6.668633432127535e-06
heterozygous O 0 9.679669346951414e-06
carriers O 0 3.297498551546596e-06
of O 0 3.5492353163135704e-06
the O 0 8.691330731380731e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999959468841553
telangiectasia I-Disease 1 0.9999998807907104
( O 0 3.739966268767603e-05
ATM O 0 0.00029448617715388536
) O 0 4.951540972797375e-07
gene O 0 6.871988489365322e-07
by O 0 8.66663356191566e-07
G2 O 1 0.6856867074966431
phase O 0 5.308079926180653e-05
chromosomal O 0 0.00032618531258776784
radiosensitivity O 1 0.5497664213180542
of O 0 0.0014565150486305356
peripheral O 1 0.9999961853027344
blood O 1 0.7280188202857971
lymphocytes O 0 0.10086242109537125
. O 0 5.861870158696547e-05

In O 0 0.0005945223965682089
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999912977218628
telangiectasia I-Disease 1 1.0
( O 0 0.20672324299812317
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999973773956299
T I-Disease 1 0.9999994039535522
) O 0 8.257686090473726e-07
patients O 0 3.3552279887771874e-07
, O 0 7.698245241272161e-08
mutations O 0 7.49837383295926e-08
in O 0 6.279422137822621e-08
a O 0 4.506434549966798e-07
single O 0 8.144251069097663e-07
gene O 0 1.6746449773563654e-06
, O 0 3.9894581504995585e-07
ATM O 0 1.8369888493907638e-05
, O 0 1.8342753094202635e-07
result O 0 2.577493489752669e-07
in O 0 4.94145979246241e-07
an O 0 5.618298382614739e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 0.0006776705849915743
embraces O 0 9.656328620621935e-05
a O 0 1.6067151591414586e-06
variety O 0 3.4264326131960843e-07
of O 0 5.476518367686367e-07
clinical O 0 1.6127734852489084e-05
features O 0 1.8385745761406724e-06
and O 0 5.596475602942519e-07
manifests O 0 1.1460785572126042e-05
extreme O 0 3.583340367185883e-05
radiosensitivity O 0 0.005868569947779179
and O 0 5.893527941225329e-07
a O 0 2.5250481030525407e-06
strong O 0 4.073950094607426e-06
pre O 0 0.0002575168909970671
- O 0 0.0002132245572283864
disposition O 0 0.00038715972914360464
to O 0 8.620228982181288e-06
malignancy B-Disease 1 0.9994046688079834
. O 0 6.908480281708762e-05

Heterozygotes O 0 0.00018136377912014723
for O 0 3.770984449147363e-06
the O 0 7.823024134268053e-06
ATM O 0 0.0001257486001122743
gene O 0 1.6819545862745144e-06
have O 0 7.374649868552297e-08
no O 0 1.2132539950471255e-07
clinical O 0 9.932458624462015e-07
expression O 0 1.1723982424882706e-06
of O 0 6.5418844314990565e-06
A B-Disease 1 0.9999860525131226
- I-Disease 1 0.9999607801437378
T I-Disease 1 0.9999980926513672
but O 0 3.760186473300564e-07
may O 0 5.941666927355982e-07
be O 0 3.961648360473191e-07
cancer B-Disease 0 0.49831995368003845
prone O 0 9.811794370762073e-06
with O 0 1.6851981854415499e-07
a O 0 1.5451524859599886e-06
moderate O 0 4.229656951793004e-06
increase O 0 6.706387694066507e-07
in O 0 6.719550356137916e-07
in O 0 2.2126307612779783e-06
vitro O 0 6.361038686009124e-05
radiosensitivity O 0 0.0030360317323356867
. O 0 5.346093894331716e-05

We O 0 6.50341689834022e-06
performed O 0 1.4936003026377875e-05
a O 0 9.017803677124903e-06
blind O 0 3.283267142251134e-05
chromosomal O 0 1.626613266125787e-05
analysis O 0 8.076411290858232e-07
on O 0 1.7607694644539151e-06
G2 O 0 0.4696294367313385
- O 0 7.4515482992865145e-06
phase O 0 9.349510037282016e-06
lymphocytes O 0 3.1000606668385444e-06
from O 0 8.920246585830682e-08
7 O 0 9.060474894795334e-07
unrelated O 0 6.010735887684859e-06
A B-Disease 1 0.9681711792945862
- I-Disease 1 0.9986100196838379
T I-Disease 1 0.9999871253967285
patients O 0 1.7549356243762304e-06
, O 0 3.685130138819659e-07
13 O 0 1.3739597761741607e-06
obligate O 0 7.406955319311237e-06
A B-Disease 1 0.9898717999458313
- I-Disease 1 0.9996334314346313
T I-Disease 1 0.9999983310699463
heterozygotes O 0 2.20218462345656e-05
( O 0 1.2157164519521757e-07
parents O 0 3.6166664330039566e-08
of O 0 1.0880975764848699e-07
the O 0 4.3794608473035623e-07
patients O 0 5.84033614359214e-07
) O 0 7.971601689860108e-08
, O 0 5.6414460658515964e-08
and O 0 3.5180054425154594e-08
14 O 0 1.1251069054196705e-07
normal O 0 1.279107522123013e-07
controls O 0 2.610155149795901e-07
following O 0 1.4482731103271362e-07
X O 0 1.9491205875965534e-06
- O 0 7.010989406808221e-07
irradiation O 0 1.1720338761733728e-06
with O 0 1.251381291922371e-07
1 O 0 9.842615327215753e-07
Gy O 0 7.301210644072853e-06
in O 0 4.0559243075222184e-08
order O 0 2.9458526284997788e-08
to O 0 1.0969784192127463e-08
evaluate O 0 4.6312777612911304e-08
this O 0 3.901973144593285e-08
cytogenetic O 0 2.309622686880175e-06
method O 0 1.1156360102404506e-07
as O 0 7.11608763026561e-08
a O 0 2.614191032535018e-07
tool O 0 7.969835564836103e-07
for O 0 1.3993157210734353e-07
detection O 0 3.038911472685868e-06
of O 0 4.851445737585891e-06
ATM O 0 0.0007120257942005992
carriers O 0 5.761774446000345e-05
. O 0 2.235737156297546e-05

Both O 0 7.068273407639936e-05
A B-Disease 1 0.9972420930862427
- I-Disease 1 0.9996883869171143
T I-Disease 1 0.9999814033508301
homozygotes O 0 0.0006017311825416982
and O 0 2.6123018415091792e-06
heterozygotes O 0 2.106505780830048e-05
showed O 0 2.3251880065799924e-06
significantly O 0 4.727596660814015e-07
increased O 0 2.0862391636455868e-07
levels O 0 1.7234611959793256e-07
of O 0 1.4033372508492903e-06
radiation O 1 0.5112411379814148
- O 0 0.32687604427337646
induced O 1 0.9996778964996338
chromatid O 1 0.9947372078895569
damage O 0 6.475255941040814e-05
relative O 0 8.702006084604363e-07
to O 0 6.908642546932242e-08
that O 0 6.208217939729366e-08
of O 0 9.517943908576854e-07
normal O 0 7.33154729459784e-06
controls O 0 2.522859358577989e-05
. O 0 2.6504843845032156e-05

These O 0 1.1565490467546624e-06
results O 0 4.771441695083922e-07
show O 0 4.0598683881398756e-07
that O 0 1.4750487764558784e-07
the O 0 1.3521297432816937e-06
G2 O 1 0.9609538316726685
- O 0 1.9910079572582617e-05
phase O 0 3.601604112191126e-05
chromosomal O 0 9.737393702380359e-05
radiosensitivity O 0 0.00010714952804846689
assay O 0 1.4537864672092837e-06
can O 0 1.109045921765528e-08
be O 0 6.23936502464062e-09
used O 0 8.448513000303137e-09
for O 0 8.977011134447821e-09
the O 0 1.0223485702454127e-07
detection O 0 1.317765509156743e-06
of O 0 3.6440214898902923e-06
A B-Disease 1 0.9995922446250916
- I-Disease 1 0.999969482421875
T I-Disease 1 0.9999942779541016
heterozygotes O 0 0.001380732748657465
. O 0 5.375980617827736e-05

In O 0 9.361339834867977e-06
combination O 0 9.906473678711336e-06
with O 0 9.314233579971187e-07
molecular O 0 1.0443795872561168e-05
genetic O 0 2.932954885181971e-06
analyses O 0 3.1444929504687025e-07
, O 0 7.935087609212133e-08
this O 0 2.768713436296366e-08
test O 0 7.853059713625044e-08
may O 0 2.854586611533705e-08
be O 0 6.454205614403463e-09
of O 0 2.112324537506538e-08
value O 0 2.3469189258662482e-08
in O 0 2.3675738702877425e-08
studies O 0 5.2414232953879036e-08
of O 0 2.94002148848449e-07
familial B-Disease 0 0.00012771168258041143
and I-Disease 0 1.5625226978954743e-06
sporadic I-Disease 0 0.00020117116218898445
cancers I-Disease 0 0.005281967576593161
aimed O 0 7.710160616625217e-07
at O 0 3.1305972925110837e-07
determination O 0 3.005473274697579e-07
of O 0 1.2613885758128163e-07
the O 0 2.493774502454471e-07
potential O 0 4.6565662614739267e-07
involvement O 0 1.5804014310560888e-06
of O 0 1.838511479945737e-06
ATM O 0 0.004863234236836433
mutations O 0 2.5370688945258735e-06
in O 0 2.286069729962037e-06
tumor B-Disease 1 0.9999932050704956
risk O 0 1.5031269867904484e-05
or O 0 7.111948434612714e-07
development O 0 4.447453193279216e-06
. O 0 4.09423091696226e-06
. O 0 1.900882307381835e-05

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9997487664222717
telangiectasia I-Disease 1 0.9999953508377075
: O 0 7.651307896594517e-06
identification O 0 3.3124254059657687e-06
and O 0 5.726985250475991e-07
detection O 0 3.20431331601867e-06
of O 0 1.8069208636006806e-06
founder O 0 0.0003835485549643636
- O 0 5.729182248614961e-06
effect O 0 1.1339878938088077e-06
mutations O 0 2.7135109803566593e-07
in O 0 1.1098249785845837e-07
the O 0 7.279242595359392e-07
ATM O 0 6.72762471367605e-05
gene O 0 1.3583179452325567e-06
in O 0 4.6743991788389394e-07
ethnic O 0 3.259069444538909e-06
populations O 0 9.470641089137644e-06
. O 0 2.2753511075279675e-05

To O 0 2.828218157446827e-06
facilitate O 0 2.880451347664348e-06
the O 0 1.4018163483342505e-06
evaluation O 0 4.096253633179003e-06
of O 0 5.460077773022931e-06
ATM O 0 0.0007210090407170355
heterozygotes O 0 4.267024633008987e-05
for O 0 7.277701570274075e-07
susceptibility O 0 0.00040053282282315195
to O 0 2.2495625273677433e-07
other O 0 3.046677647944307e-07
diseases O 1 0.8622469902038574
, O 0 5.217524972067622e-07
such O 0 3.3439451385675056e-07
as O 0 1.0324928553018253e-05
breast B-Disease 1 0.9999973773956299
cancer I-Disease 1 0.9999955892562866
, O 0 1.4109244830251555e-06
we O 0 6.124174234400925e-08
have O 0 1.3017181110797083e-08
attempted O 0 2.0312677406764124e-07
to O 0 1.5395961838748917e-08
define O 0 4.902897288161512e-08
the O 0 6.393619145228513e-08
most O 0 3.9631327553024676e-08
common O 0 1.2499130264131963e-07
mutations O 0 7.53204503212146e-08
and O 0 2.9687420521895547e-08
their O 0 2.7360499643691583e-08
frequencies O 0 2.1953439954813803e-07
in O 0 1.736022454679187e-06
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999364614486694
telangiectasia I-Disease 1 1.0
( O 0 0.002622497035190463
A B-Disease 1 0.9999918937683105
- I-Disease 1 0.9998924732208252
T I-Disease 1 0.9999788999557495
) O 0 1.1991299970759428e-06
homozygotes O 0 1.4167848348733969e-05
from O 0 3.688168135340675e-07
10 O 0 9.295350764659815e-07
ethnic O 0 4.351481493358733e-06
populations O 0 1.1599176104937214e-05
. O 0 2.8024704079143703e-05

Both O 0 1.1850856026285328e-05
genomic O 0 2.86935392068699e-05
mutations O 0 4.394720690470422e-06
and O 0 5.375081286729255e-07
their O 0 3.190431243638159e-07
effects O 0 3.4757115372485714e-06
on O 0 1.9330670966155594e-06
cDNA O 0 2.8710512196994387e-05
were O 0 3.141788056382211e-06
characterized O 0 6.12275252933614e-05
. O 0 3.889233630616218e-05

Protein O 0 3.616148387663998e-05
- O 0 1.902652184071485e-05
truncation O 0 7.452716090483591e-05
testing O 0 1.3523141433324781e-06
of O 0 4.5254355995894e-07
the O 0 8.004066671674082e-07
entire O 0 5.691252681572223e-06
ATM O 0 3.502890103845857e-05
cDNA O 0 7.747465133434162e-06
detected O 0 8.704521405888954e-07
92 O 0 1.5012110452516936e-06
( O 0 3.2810879702083184e-07
66 O 0 3.5198424939153483e-06
% O 0 7.912000796750362e-07
) O 0 6.185513257150888e-07
truncating O 0 7.977707355166785e-06
mutations O 0 1.0816472695296397e-06
in O 0 6.20205184986844e-07
140 O 0 6.238764399313368e-06
mutant O 0 4.204736978863366e-05
alleles O 0 9.252709787688218e-06
screened O 0 5.399398651206866e-05
. O 0 4.7653098590672016e-05

The O 0 5.34490063728299e-05
haplotyping O 0 0.008606677874922752
of O 0 1.743651955621317e-05
patients O 0 9.287285138270818e-06
with O 0 1.3474672186930547e-06
identical O 0 7.542289495177101e-06
mutations O 0 1.8881418100136216e-06
indicates O 0 9.863475725069293e-07
that O 0 2.911832197582953e-08
almost O 0 4.6116824137243384e-08
all O 0 1.5837306577282106e-08
of O 0 1.1314067904777403e-07
these O 0 3.2250355275209586e-08
represent O 0 1.9489033320496674e-07
common O 0 3.263107828388456e-07
ancestry O 0 7.704838935751468e-07
and O 0 1.442127484097e-07
that O 0 1.8501536658277473e-07
very O 0 4.714413819328911e-07
few O 0 1.0746514362836024e-06
spontaneously O 0 2.0927460354869254e-05
recurring O 0 0.0005814656033180654
ATM O 0 0.01934867724776268
mutations O 0 1.949269244505558e-05
exist O 0 1.0203561032540165e-05
. O 0 2.326571302546654e-05

Assays O 0 4.560684465104714e-05
requiring O 0 5.11082316734246e-06
minimal O 0 8.002609320101328e-06
amounts O 0 9.809396033233497e-07
of O 0 5.23666642493481e-07
genomic O 0 2.119263399436022e-06
DNA O 0 9.183885936181468e-07
were O 0 6.685162645680975e-08
designed O 0 1.7961606602057145e-07
to O 0 2.8658575956796994e-08
allow O 0 6.564167875922067e-08
rapid O 0 1.1319513077978627e-06
screening O 0 6.819927875767462e-07
for O 0 1.586099926953466e-07
common O 0 9.132147056334361e-07
ethnic O 0 5.310482265485916e-06
mutations O 0 2.1904785171500407e-05
. O 0 3.4226293792016804e-05

These O 0 3.0735661766811972e-06
rapid O 0 2.182652497140225e-05
assays O 0 6.343479981296696e-06
detected O 0 2.412105686744326e-06
mutations O 0 3.887813875280699e-07
in O 0 1.4142045756670996e-07
76 O 0 1.0628872360030073e-06
% O 0 3.0134984285723476e-07
of O 0 7.027671244941303e-07
Costa O 0 1.9022631931875367e-06
Rican O 0 3.5682412544701947e-06
patients O 0 3.5409823340160074e-07
( O 0 7.489640552194032e-08
3 O 0 1.0645636194794861e-07
) O 0 2.0152675972440193e-08
, O 0 8.039331866882549e-09
50 O 0 1.419108297540106e-08
% O 0 1.326799736744988e-08
of O 0 5.042338813154856e-08
Norwegian O 0 1.2123373380745761e-06
patients O 0 2.2428808676977496e-07
( O 0 3.872235154744885e-08
1 O 0 1.0850365583792154e-07
) O 0 1.1575268743513334e-08
, O 0 8.113674176968289e-09
25 O 0 2.729466785922341e-08
% O 0 4.567153055745621e-08
of O 0 1.5291344368506543e-07
Polish O 0 2.9586646633106284e-05
patients O 0 6.093670776863291e-07
( O 0 1.0352641766075976e-07
4 O 0 2.102180616248006e-07
) O 0 2.50833291914887e-08
, O 0 1.9768995329627614e-08
and O 0 1.3649800401083212e-08
14 O 0 6.332113855478383e-08
% O 0 4.9353040765254264e-08
of O 0 1.7570143029388419e-07
Italian O 0 4.8646452341927215e-06
patients O 0 7.760611993035127e-07
( O 0 1.5025844390947896e-07
1 O 0 4.382903568966867e-07
) O 0 5.908520961384056e-08
, O 0 4.3702691243652225e-08
as O 0 2.4922520935888315e-08
well O 0 2.6894269922195235e-08
as O 0 6.174091282673544e-08
in O 0 1.7954481279502943e-07
patients O 0 8.117313541333715e-07
of O 0 4.61359240944148e-06
Amish O 0 0.004622669890522957
/ O 0 0.011293040588498116
Mennonite O 0 0.0029129923786967993
and O 0 2.480210469002486e-06
Irish O 0 5.297344614518806e-05
English O 0 6.115768337622285e-05
backgrounds O 0 4.376879587653093e-05
. O 0 6.206386751728132e-05

Additional O 0 1.153381890617311e-05
mutations O 0 4.2508745536906645e-06
were O 0 7.217733468678489e-07
observed O 0 8.885823490345501e-07
in O 0 6.77046955388505e-07
Japanese O 0 6.777655016776407e-06
, O 0 1.1291157306914101e-06
Utah O 0 5.6928056437755e-06
Mormon O 0 4.425836323207477e-06
, O 0 4.912548661195615e-07
and O 0 7.301143227778084e-07
African O 0 8.672737749293447e-06
American O 0 2.3652331947232597e-05
patients O 0 8.361803338630125e-05
. O 0 7.336417911574244e-05

These O 0 2.0855281945841853e-06
assays O 0 3.2832710985530866e-06
should O 0 2.9094016440467385e-07
facilitate O 0 4.0206634821515763e-07
screening O 0 9.34927982143563e-07
for O 0 1.187227667287516e-06
A B-Disease 1 0.9987280964851379
- I-Disease 1 0.9995298385620117
T I-Disease 1 0.9999772310256958
heterozygotes O 0 1.2493697795434855e-05
in O 0 1.5170552103427326e-07
the O 0 3.0745698609280225e-07
populations O 0 5.097603548165353e-07
studied O 0 3.0269370654423255e-06
. O 0 2.8743922939611366e-06
. O 0 3.1338011467596516e-05

The O 0 0.00020919222151860595
von B-Disease 0 0.12443222105503082
Hippel I-Disease 1 0.9980515241622925
- I-Disease 1 0.9960123300552368
Lindau I-Disease 1 0.9999760389328003
tumor I-Disease 1 0.9999921321868896
suppressor O 0 0.03266511857509613
gene O 0 1.3983235476189293e-06
is O 0 1.0770548186656015e-07
required O 0 6.395266183290005e-08
for O 0 9.984068327639761e-08
cell O 0 3.956958153139567e-06
cycle O 0 2.5248555175494403e-06
exit O 0 5.130581484991126e-06
upon O 0 1.9033336684515234e-06
serum O 0 4.950066067976877e-05
withdrawal O 0 9.930355736287311e-05
. O 0 3.411146462894976e-05

The O 0 3.295881106168963e-05
inactivation O 0 0.00042377968202345073
of O 0 1.7956304873223417e-05
the O 0 2.3827175027690828e-05
von B-Disease 0 0.3874414265155792
Hippel I-Disease 1 0.9996127486228943
- I-Disease 1 0.9452275633811951
Lindau I-Disease 1 0.9999270439147949
( I-Disease 0 0.00023310228425543755
VHL I-Disease 1 0.9999096393585205
) I-Disease 0 1.857777351688128e-05
tumor I-Disease 1 0.9998892545700073
suppressor O 1 0.9984245300292969
gene O 0 9.174919978249818e-05
predisposes O 0 6.56416013953276e-05
affected O 0 3.7707221167693206e-07
individuals O 0 6.81683332004468e-08
to O 0 1.3830832301664486e-07
the O 0 2.757154788923799e-06
human O 0 0.39268311858177185
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 6.535155262099579e-05
is O 0 2.5798101432883414e-06
associated O 0 2.4002031295822235e-06
with O 0 4.3070572246506345e-06
sporadic B-Disease 1 0.9999879598617554
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.9673347473144531
RCC B-Disease 1 1.0
) O 0 1.897332549560815e-05
and O 0 1.748684371705167e-05
brain B-Disease 1 0.978919267654419
hemangioblastomas I-Disease 1 0.9898228645324707
. O 0 0.00010992016177624464

VHL O 1 0.8636254072189331
- O 0 0.00037078437162563205
negative O 0 3.766563895624131e-05
786 O 0 0.0021210669074207544
- O 0 0.0023996306117624044
0 O 0 0.00031795224640518427
RCC B-Disease 1 0.9999986886978149
cells O 0 1.6616635548416525e-05
are O 0 1.2393066128879582e-07
tumorigenic O 0 2.346540532016661e-05
in O 0 9.387841259922425e-07
nude O 0 8.606970368418843e-06
mice O 0 3.541816795404884e-06
which O 0 1.3372525131671864e-07
is O 0 1.5137428022171662e-07
suppressed O 0 1.1320613566567772e-06
by O 0 2.453267597957165e-07
the O 0 1.9010117284778971e-06
reintroduction O 0 0.00010059076157631353
of O 0 3.262538666604087e-05
VHL B-Disease 1 0.9833674430847168
. O 0 7.041503704385832e-05

Remarkably O 0 0.00019945680105593055
, O 0 3.895217105309712e-06
this O 0 6.333852979878429e-07
occurs O 0 4.678261404933437e-07
without O 0 2.319382446103191e-07
affecting O 0 2.4863226144589134e-07
the O 0 1.525851018868707e-07
growth O 0 3.5969469536212273e-07
rate O 0 1.6137175862240838e-07
and O 0 1.541209826427803e-07
cell O 0 2.494790578566608e-06
cycle O 0 5.274684440337296e-07
profile O 0 2.8774371685358346e-07
of O 0 3.986658896337758e-07
these O 0 1.9344932411513582e-07
cells O 0 2.5577332962711807e-06
in O 0 1.148555952568131e-06
culture O 0 3.923011536244303e-05
. O 0 4.533124956651591e-05

The O 0 4.8820238589541987e-05
786 O 0 0.0005663068150170147
- O 0 6.825538002885878e-05
0 O 0 1.984752088901587e-05
cell O 0 3.425731847528368e-05
line O 0 2.680910483832122e-06
, O 0 4.885012572231062e-07
like O 0 4.927534860144078e-07
many O 0 3.796141641032591e-07
cancer B-Disease 1 0.9327905774116516
cells O 0 9.684203178039752e-06
, O 0 3.3745493510650704e-07
fails O 0 3.0123203487164574e-07
to O 0 3.605845222409698e-08
exit O 0 6.846842666163866e-07
the O 0 5.006077685720811e-07
cell O 0 5.546145985135809e-06
cycle O 0 2.1448704501381144e-06
upon O 0 2.8996616947551956e-06
serum O 0 6.480604497483e-05
withdrawal O 0 0.00013566805864684284
. O 0 3.8153284549480304e-05

Here O 0 1.2192745998618193e-05
, O 0 1.4312203120425693e-06
it O 0 2.2040605074380437e-07
is O 0 1.8008807955993689e-07
shown O 0 2.247685984002601e-07
that O 0 9.631757080796888e-08
reintroduction O 0 2.3743946258036885e-06
of O 0 4.8147842335311e-07
the O 0 1.067511448127334e-06
wild O 0 8.711150258022826e-06
- O 0 4.506096593104303e-05
type O 0 0.00011470630124676973
VHL B-Disease 0 0.3120523989200592
gene O 0 3.5067689623247134e-06
restores O 0 7.277948952832958e-06
the O 0 5.603632189377095e-07
ability O 0 5.026121243645321e-07
of O 0 2.945664164144546e-06
VHL O 1 0.9999043941497803
- O 0 0.08125604689121246
negative O 0 0.00022783639724366367
RCC B-Disease 1 1.0
cancer I-Disease 1 0.998084545135498
cells O 0 2.810866817526403e-06
to O 0 1.1440002367635316e-07
exit O 0 1.1591814654821064e-06
the O 0 6.316130907180195e-07
cell O 0 4.614014869730454e-06
cycle O 0 2.748546194197843e-06
and O 0 7.426580737046606e-07
enter O 0 1.0180361641687341e-05
G0 O 1 0.9869725108146667
/ O 0 7.525000546593219e-05
quiescence O 0 0.00012673002493102103
in O 0 2.17635033550323e-06
low O 0 3.1541047064820305e-05
serum O 0 0.000254036218393594
. O 0 4.136031566304155e-05

Both O 0 7.246487075462937e-05
VHL O 1 0.9827605485916138
- O 0 0.00016700910055078566
positive O 0 1.0224659490631893e-05
and O 0 9.915604096022435e-06
VHL O 1 0.9995511174201965
- O 0 0.000766198558267206
negative O 0 1.9262144633103162e-05
RCC B-Disease 1 0.9999951124191284
cells O 0 8.838631401886232e-06
exit O 0 2.292484168719966e-06
the O 0 8.811218208393257e-07
cell O 0 9.66924380918499e-06
cycle O 0 1.6252917021120084e-06
by O 0 1.0645651400409406e-06
contact O 0 9.116483852267265e-06
inhibition O 0 9.352293272968382e-05
. O 0 3.767120506381616e-05

The O 0 7.350773375947028e-05
cyclin O 0 0.0002684610662981868
- O 0 7.130550511647016e-05
dependent O 0 1.0536312402109616e-05
kinase O 0 2.4194936486310326e-05
inhibitor O 0 2.668883462320082e-05
, O 0 1.3368027111937408e-06
p27 O 0 4.569809607346542e-05
, O 0 4.516407159371738e-07
accumulates O 0 1.4779454886593157e-06
upon O 0 2.205412386047101e-07
serum O 0 2.8900406050524907e-06
withdrawal O 0 1.321066065429477e-06
, O 0 5.887821430405893e-08
only O 0 1.2076111666203815e-08
in O 0 2.433298007531448e-08
the O 0 1.0176307085885128e-07
presence O 0 4.1750388390937587e-07
of O 0 1.2575355867738836e-06
VHL B-Disease 0 0.23367315530776978
, O 0 1.6779944189693197e-07
as O 0 1.0598107280657132e-07
a O 0 1.230512793881644e-07
result O 0 1.560751883289413e-07
of O 0 1.673044067729279e-07
the O 0 3.6992076957176323e-07
stabilization O 0 7.926229955046438e-06
of O 0 1.584606025062385e-06
the O 0 5.9814924497914035e-06
protein O 0 2.8923901481903158e-05
. O 0 1.7557260434841737e-05

We O 0 2.508422312530456e-06
propose O 0 2.234063231298933e-06
that O 0 2.431099801469827e-07
the O 0 5.28058819782018e-07
loss O 0 1.2144191714469343e-05
of O 0 5.7524562180333305e-06
wild O 0 4.62158459413331e-05
- O 0 0.00018942152382805943
type O 0 0.0006183308432810009
VHL B-Disease 1 0.8202313184738159
gene O 0 1.1080953754571965e-06
results O 0 1.267484179834355e-07
in O 0 1.0986749288122155e-07
a O 0 4.5661866465707135e-07
specific O 0 3.1879676498647314e-07
cellular O 0 9.791128104552627e-05
defect O 0 0.0002558807609602809
in O 0 9.561230172039359e-07
serum O 0 8.25690949568525e-05
- O 0 9.297813448938541e-06
dependent O 0 7.796181193953089e-07
growth O 0 1.1185896937604412e-06
control O 0 6.838548074483697e-07
, O 0 1.5362090266535233e-07
which O 0 1.5018368060282228e-07
may O 0 9.069803468264581e-07
initiate O 0 1.5169817743299063e-05
tumor B-Disease 0 0.04950625076889992
formation O 0 0.0002023139677476138
. O 0 7.496865146094933e-05

This O 0 6.6997795329371e-06
is O 0 1.7835377548180986e-06
corrected O 0 4.11738710681675e-06
by O 0 5.388065460465441e-07
the O 0 8.73002647949761e-07
reintroduction O 0 2.050845250778366e-05
of O 0 2.8369461233523907e-06
wild O 0 4.2888994357781485e-05
- O 0 0.006429473403841257
type O 0 0.19855545461177826
VHL B-Disease 1 0.9999284744262695
, O 0 4.658556918002432e-06
implicating O 0 0.0005893759080208838
VHL B-Disease 0 0.25158095359802246
as O 0 4.617967590547778e-07
the O 0 5.85126826990745e-07
first O 0 3.444791445872397e-06
tumor B-Disease 1 0.9481855630874634
suppressor O 0 3.6796194763155654e-05
involved O 0 1.3552057964716369e-07
in O 0 4.3604689636822513e-08
the O 0 9.292623559531421e-08
regulation O 0 3.8816233427496627e-07
of O 0 4.7559137783537153e-07
cell O 0 6.8001204454049e-06
cycle O 0 1.209310880767589e-06
exit O 0 7.888298227953783e-07
, O 0 6.24887164235588e-08
which O 0 1.7015857167734794e-08
is O 0 2.2731070359327532e-08
consistent O 0 6.50742322250153e-08
with O 0 4.0697258896216226e-08
its O 0 1.8666430889879848e-07
gatekeeper O 0 3.2494044717168435e-05
function O 0 2.782749390917161e-07
in O 0 2.1540240879858175e-07
the O 0 2.7779233278124593e-06
kidney O 1 0.999235987663269
. O 0 9.94730453385273e-06
. O 0 3.764505891012959e-05

Piebaldism B-Disease 1 0.9999587535858154
with O 0 0.0013677431270480156
deafness B-Disease 1 1.0
: O 0 2.0238428987795487e-05
molecular O 0 1.3931222383689601e-05
evidence O 0 1.1226101150896284e-06
for O 0 3.6312999895926623e-07
an O 0 6.1364339671854395e-06
expanded O 0 0.0007457623723894358
syndrome O 1 0.9999996423721313
. O 0 0.0004486462858039886

In O 0 2.4167815354303457e-05
a O 0 3.0351196983247064e-05
South O 0 5.939601396676153e-05
African O 0 4.650419214158319e-05
girl O 0 3.830947389360517e-05
of O 0 1.749569855746813e-05
Xhosa O 1 0.9955396056175232
stock O 0 1.8736946003627963e-05
with O 0 7.863827704568394e-06
severe O 1 0.9999514818191528
piebaldism B-Disease 1 0.9999905824661255
and O 0 0.10608865320682526
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.00010744122846517712
identified O 0 6.9023071773699485e-06
a O 0 1.8797280745275202e-06
novel O 0 3.3004751003318233e-06
missense O 0 5.269025677989703e-06
substitution O 0 2.96549342237995e-06
at O 0 5.741060817854304e-07
a O 0 5.789632382402488e-07
highly O 0 6.140820119071577e-07
conserved O 0 7.641760362275818e-07
residue O 0 9.994143965741387e-07
in O 0 9.947363110995866e-08
the O 0 3.8710066974090296e-07
intracellular O 0 2.1992889287503203e-06
kinase O 0 1.156237999566656e-06
domain O 0 3.50433111862003e-07
of O 0 4.5948075921842246e-07
the O 0 7.215474397526123e-06
KIT O 1 0.9575948119163513
proto O 1 0.7214681506156921
- O 0 0.011162587441504002
oncogene O 1 0.6131923198699951
, O 0 2.7183878046344034e-05
R796G O 0 0.0013816389255225658
. O 0 9.740152017911896e-05

Though O 0 0.0001429143885616213
auditory B-Disease 0 0.4498082399368286
anomalies I-Disease 0 0.0003887377679347992
have O 0 2.8877019531137194e-07
been O 0 2.26685983761854e-07
observed O 0 2.660869427018042e-07
in O 0 3.4249885061399254e-07
mice O 0 2.692116822800017e-06
with O 0 5.693716502719326e-07
dominant O 0 6.0089580074418336e-05
white O 0 0.00010692416253732517
spotting O 0 0.0009656400070525706
( O 0 3.1026897886476945e-06
W O 0 0.016325030475854874
) O 0 1.663510857952133e-07
due O 0 6.52436256132205e-07
to O 0 3.168133844155818e-07
KIT O 0 0.2925339341163635
mutations O 0 7.444147286150837e-06
, O 0 2.0955656509613618e-05
deafness B-Disease 1 1.0
is O 0 1.9106264517176896e-06
not O 0 1.5699193056661898e-07
typical O 0 1.7343263607472181e-06
in O 0 1.1180575256730663e-06
human O 0 7.651877240277827e-06
piebaldism B-Disease 0 0.002777016256004572
. O 0 5.919414616073482e-05

Thus O 0 1.3333215974853374e-05
, O 0 1.6422700355178677e-06
the O 0 1.1661870757961879e-06
occurrence O 0 1.2563942618726287e-05
of O 0 0.0012665123213082552
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 8.342162618646398e-05
this O 0 2.430613903925405e-06
patient O 0 1.1108316357422154e-05
extends O 0 1.8528547798268846e-06
considerably O 0 8.071060051406675e-07
the O 0 1.9724294020306843e-07
phenotypic O 0 1.2026114291074919e-06
range O 0 1.518528733868152e-07
of O 0 4.471279737572331e-07
piebaldism B-Disease 0 7.645592995686457e-05
due O 0 4.434675247466657e-06
to O 0 7.087992344168015e-07
KIT O 0 0.03946184366941452
gene O 0 1.7256879800697789e-06
mutation O 0 6.928145239726291e-07
in O 0 2.0218364227275742e-07
humans O 0 1.9529817052443832e-07
and O 0 1.0479431011845008e-07
tightens O 0 2.821964926624787e-06
the O 0 2.1790658877307578e-07
clinical O 0 2.1182611362746684e-06
similarity O 0 1.5066984815348405e-06
between O 0 6.134685577308119e-07
piebaldism B-Disease 0 0.0007475141901522875
and O 0 3.226703597647429e-07
the O 0 3.055284309994022e-07
various O 0 2.1123413773693756e-07
forms O 0 3.7362760849646293e-06
of O 0 0.029720451682806015
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0006890044896863401
. O 0 0.0003192614240106195

Cycloheximide O 0 0.0008948133909143507
facilitates O 0 2.647440487635322e-05
the O 0 1.7068309716705699e-06
identification O 0 1.5938483102218015e-06
of O 0 1.2056408422722598e-06
aberrant O 0 1.093190712708747e-05
transcripts O 0 3.336161626066314e-06
resulting O 0 1.3160524758859538e-06
from O 0 3.4485736932765576e-07
a O 0 2.5707893200888066e-06
novel O 0 6.692805982311256e-06
splice O 0 1.2420566235959996e-05
- O 0 6.029692940501263e-06
site O 0 1.214550024997152e-06
mutation O 0 8.173881838047237e-07
in O 0 5.301508849697711e-07
COL17A1 O 0 0.02555392123758793
in O 0 8.858832529767824e-07
a O 0 5.798003712698119e-06
patient O 0 3.3564701880095527e-05
with O 0 2.8766777177224867e-05
generalized O 1 0.9999841451644897
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999992847442627
. O 0 0.0014662432949990034

Patients O 0 0.0006727866712026298
with O 0 0.00017268957162741572
generalized O 1 0.9999953508377075
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999996423721313
often O 0 4.455464022612432e-06
show O 0 1.3042898672210868e-06
decreased O 0 4.639253347704653e-06
expression O 0 1.0263651120112627e-06
of O 0 2.1393384486145806e-06
type O 0 0.11365431547164917
XVII O 1 0.9999998807907104
collagen O 1 0.9994791150093079
, O 0 2.092345084747649e-06
a O 0 5.724250513594598e-06
transmembrane O 0 0.00021865632152184844
hemidesmosomal O 0 0.00014851042942609638
protein O 0 4.310640179028269e-06
encoded O 0 1.395165213580185e-06
by O 0 3.517466666380642e-06
COL17A1 O 0 0.21946537494659424
. O 0 8.163484744727612e-05

This O 0 5.161489752936177e-06
report O 0 2.3472825887438376e-06
documents O 0 1.673217866482446e-06
a O 0 2.610785259093973e-06
novel O 0 1.0281883078278042e-05
splice O 0 1.6785859770607203e-05
- O 0 9.592588867235463e-06
site O 0 2.8502452096290654e-06
mutation O 0 1.3349668961382122e-06
in O 0 5.691463798029872e-07
COL17A1 O 0 0.008940033614635468
in O 0 6.650911359429301e-07
a O 0 2.428208972560242e-06
patient O 0 1.0311614460079e-05
with O 0 1.3604280866275076e-05
generalized O 1 0.9999929666519165
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999996423721313
, O 0 2.188860207752441e-06
and O 0 2.1616135370550182e-07
applies O 0 1.4465354070125613e-07
a O 0 1.7740637758834055e-07
new O 0 9.526974054097082e-08
methodology O 0 2.0907643261125486e-07
to O 0 4.2107984654649044e-08
define O 0 1.3122934205966885e-07
and O 0 1.6289415327719325e-07
characterize O 0 1.61642674356699e-06
the O 0 9.097845463656995e-07
resulting O 0 8.342991350218654e-06
mRNA O 0 2.6634172172634862e-05
splice O 0 8.755574526730925e-05
variants O 0 3.436716360738501e-05
. O 0 3.2993717468343675e-05

Mutational O 0 0.0005543921724893153
analysis O 0 8.202741810237058e-06
of O 0 1.315816643909784e-05
COL17A1 O 0 0.18919898569583893
identified O 0 1.4474902854999527e-05
a O 0 1.3702638170798309e-05
maternally O 0 0.0002085827582050115
inherited O 0 0.12126826494932175
G O 0 0.017489274963736534
- O 0 2.4411683625658043e-05
to O 0 1.1822382930404274e-06
- O 0 0.00013247443712316453
T O 0 0.002348223002627492
transversion O 0 1.4075824765313882e-05
at O 0 3.936674772830884e-07
the O 0 2.6247630557918455e-07
- O 0 1.092580760087003e-06
1 O 0 1.012841835290601e-06
position O 0 8.35352750527818e-07
of O 0 3.5386974559514783e-06
exon O 0 0.00014318271132651716
32 O 0 2.628414767968934e-05
. O 0 3.277532596257515e-05

This O 0 2.501966810086742e-05
acceptor O 0 5.5450840591220185e-05
splice O 0 4.334449113230221e-05
- O 0 1.5042526683828328e-05
site O 0 2.599706704131677e-06
mutation O 0 8.221853704526438e-07
led O 0 4.114315572678606e-07
to O 0 4.1414377704995786e-08
the O 0 1.6063137309174635e-07
formation O 0 8.525990438101871e-07
of O 0 4.907763013761723e-07
aberrant O 0 3.979167559009511e-06
transcripts O 0 1.1266481578786625e-06
present O 0 3.846211598101945e-07
at O 0 2.0844345272053033e-06
extremely O 0 4.149394953856245e-06
low O 0 8.414585863647517e-06
levels O 0 1.7014879631460644e-05
. O 0 3.104803909081966e-05

Based O 0 6.659106929873815e-06
on O 0 2.214171672676457e-06
our O 0 1.1055294635298196e-06
recent O 0 1.0851871365957777e-06
finding O 0 1.8832754449249478e-06
that O 0 1.6323283489327878e-06
cycloheximide O 0 0.00033683329820632935
stabilized O 0 0.0001538722572149709
mutant O 0 7.449943950632587e-05
COL17A1 O 0 0.0008364003151655197
transcripts O 0 2.9539094157371437e-06
in O 0 4.1709881770657375e-07
keratinocytes O 0 1.1410052138671745e-05
homozygous O 0 1.0225509186057025e-06
for O 0 1.1601863292298731e-07
a O 0 1.2584857813635608e-06
frameshift O 0 4.025467933388427e-05
mutation O 0 7.120132750060293e-07
, O 0 1.1664323551485722e-07
the O 0 1.2534439974842826e-07
effects O 0 3.6951882975699846e-07
of O 0 4.6886594873285503e-07
the O 0 9.176916933029133e-07
splice O 0 5.609360414382536e-06
- O 0 2.083742856484605e-06
site O 0 1.0448391094541876e-06
mutation O 0 3.051516443974833e-07
on O 0 1.05269293726451e-07
splicing O 0 7.903983600954234e-07
of O 0 4.605687990988372e-07
COL17A1 O 0 9.837406105361879e-05
transcripts O 0 9.397515441378346e-07
were O 0 8.184444766357046e-08
determined O 0 1.5834775979328697e-07
using O 0 1.5224293292703805e-07
reverse O 0 1.3903185163144371e-06
transcriptase O 0 5.62595778319519e-06
polymerase O 0 3.1005336040834663e-06
chain O 0 1.076598323379585e-06
reaction O 0 1.5022348520687956e-07
of O 0 1.461401240021587e-07
total O 0 6.373408041326911e-07
RNA O 0 3.231040636819671e-06
from O 0 3.9091025882953545e-07
keratinocytes O 0 1.5440209608641453e-05
incubated O 0 4.217665718897479e-06
for O 0 1.101578618545318e-06
2 O 0 2.4667537218192592e-05
. O 0 2.5553108571330085e-05

5 O 0 2.327436777704861e-05
h O 0 3.5561442928155884e-05
in O 0 1.3879804328098544e-06
the O 0 1.080843048839597e-06
presence O 0 1.7685159718894283e-06
or O 0 5.430915734905284e-07
absence O 0 2.912218405981548e-06
of O 0 3.6240871850168332e-06
10 O 0 1.5105058992048725e-05
microg O 0 0.010299026034772396
cycloheximide O 0 0.0027908815536648035
per O 0 3.50325062754564e-05
ml O 0 0.000883495609741658
. O 0 6.939208833500743e-05

Using O 0 2.8494025627878727e-06
this O 0 7.359508913395985e-07
approach O 0 1.1837908004963538e-06
, O 0 3.914646242719755e-07
an O 0 3.5821071264763304e-07
abnormally O 0 1.1772040124924388e-05
spliced O 0 4.81969118482084e-06
transcript O 0 5.1508095566532575e-06
was O 0 2.14144915844372e-06
identified O 0 1.4616924204347015e-07
that O 0 2.5290958660662e-08
contains O 0 6.051705980780753e-08
an O 0 5.756928800337846e-08
extra O 0 1.3510066310118418e-07
264 O 0 5.376660396905208e-07
bases O 0 2.741838898145943e-07
upstream O 0 3.127833565486071e-07
from O 0 8.650005867139043e-08
exon O 0 2.427375420666067e-06
32 O 0 1.9313299048917543e-07
, O 0 7.884743524755322e-08
resulting O 0 2.963566316793731e-07
in O 0 1.9651369598250312e-07
a O 0 1.8370427596892114e-06
premature O 0 1.235962008649949e-05
termination O 0 1.2749956113111693e-05
codon O 0 3.5500647754815873e-06
27 O 0 3.2504156024515396e-06
bp O 0 5.491976025950862e-06
downstream O 0 1.5206430816760985e-06
from O 0 3.58777555220513e-07
the O 0 5.1121778597007506e-06
cryptic O 0 0.00011968151375185698
splice O 0 0.00010715268581407145
site O 0 6.253844185266644e-05
. O 0 5.217747457209043e-05

Three O 0 5.8006639847008046e-06
other O 0 1.5560837027805974e-06
splice O 0 1.8645823729457334e-05
variants O 0 2.750308340182528e-06
, O 0 4.227722740779427e-07
including O 0 2.190822101511003e-07
one O 0 1.384219245892382e-07
derived O 0 1.4030426598310441e-07
from O 0 6.614502723323312e-08
the O 0 2.922048167874891e-07
skipping O 0 2.3559034616482677e-06
of O 0 1.1397405614843592e-06
exon O 0 1.764969238138292e-05
32 O 0 9.242031637768378e-07
, O 0 3.641738715032261e-07
were O 0 8.437081646661682e-07
also O 0 2.176167754441849e-06
identified O 0 1.414725738868583e-05
. O 0 2.7517497073858976e-05

These O 0 1.704443093331065e-06
results O 0 9.502779221293167e-07
indicate O 0 9.444702868677268e-07
the O 0 6.840498372184811e-07
usefulness O 0 4.6292566366901156e-06
of O 0 1.7886784462461947e-06
cycloheximide O 0 0.032218001782894135
treatment O 0 6.1717291828244925e-06
in O 0 3.21535623015734e-07
evaluating O 0 4.3024326146223757e-07
the O 0 2.9542431434492755e-07
abnormal O 0 1.8735214553089463e-06
processing O 0 4.982734367331432e-07
of O 0 2.8508711125141417e-07
mRNA O 0 7.884695492066385e-07
due O 0 2.871143465199566e-07
to O 0 6.739753644069424e-08
splice O 0 1.7766183191270102e-06
- O 0 9.867812877928372e-07
site O 0 5.344944042917632e-07
mutations O 0 1.8479741470400768e-07
, O 0 8.371505089144193e-08
because O 0 7.023410120154949e-08
( O 0 1.9969972697708727e-07
i O 0 4.795547283720225e-07
) O 0 1.956635742317303e-07
aberrant O 0 1.8779487618303392e-06
splicing O 0 1.15686452772934e-06
often O 0 7.30377607283117e-08
generates O 0 1.7330933133052895e-07
a O 0 3.660562697405112e-07
premature O 0 2.214868800365366e-06
termination O 0 3.2548730359849287e-06
codon O 0 1.6262761164398398e-06
, O 0 1.1099456997953894e-07
( O 0 1.4243070722841367e-07
ii O 0 9.258385034627281e-06
) O 0 1.0811877615424237e-07
transcripts O 0 4.509478515046794e-07
with O 0 2.889327390676044e-07
premature O 0 1.2566183613671456e-05
termination O 0 9.127748853643425e-06
codons O 0 9.604366368876072e-07
can O 0 2.361710649267934e-08
occur O 0 2.9637577725338815e-08
at O 0 1.442039518906313e-07
low O 0 4.0640637166688975e-07
or O 0 7.973046223241909e-08
undetectable O 0 1.7119466519943671e-06
levels O 0 1.2550589190141181e-07
due O 0 1.8527104828081065e-07
to O 0 7.004587132541928e-08
nonsense O 0 2.4199282506742748e-06
- O 0 7.816773859303794e-07
mediated O 0 9.03645968719502e-07
mRNA O 0 5.091287675895728e-07
decay O 0 1.2153587931607035e-06
, O 0 5.067696662308663e-08
and O 0 5.020477900075093e-08
( O 0 1.2199835452975094e-07
iii O 0 5.904639237996889e-06
) O 0 4.062109937308378e-08
the O 0 4.5371034929075904e-08
levels O 0 2.3225162237849872e-08
of O 0 3.50477122879056e-08
these O 0 1.1812894662455165e-08
transcripts O 0 1.743889868066617e-07
can O 0 1.7229936588591954e-08
be O 0 4.9001581459151566e-08
increased O 0 6.673129746559425e-07
by O 0 3.3106632599810837e-06
cycloheximide O 0 0.0009933875408023596
. O 0 6.98519143043086e-05

A O 0 0.0001824766950448975
deletion O 0 0.0002878101367969066
mutation O 0 4.5993205276317894e-05
in O 0 4.187127160548698e-06
COL17A1 O 1 0.7012252807617188
in O 0 2.0114023300266126e-06
five O 0 1.167865434581472e-06
Austrian O 0 4.822950722882524e-05
families O 0 1.3548817605624208e-06
with O 0 1.5356245057773776e-05
generalized O 1 0.9999761581420898
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999974966049194
represents O 0 4.007974348496646e-05
propagation O 0 5.560620775213465e-05
of O 0 7.661684321647044e-06
an O 0 1.0427077540953178e-05
ancestral O 0 0.0005482602282427251
allele O 0 0.00023315142607316375
. O 0 8.619079017080367e-05

Patients O 0 0.0010356855345889926
with O 0 0.00026831598370335996
generalized O 1 0.9999872446060181
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999995231628418
, O 0 1.9904175132978708e-05
a O 0 6.6257675825909246e-06
usually O 0 2.501854851288954e-06
nonlethal O 0 5.655529093928635e-05
form O 0 6.82013705954887e-06
of O 0 0.0002293549187015742
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999936819076538
, O 0 3.79046878151712e-06
have O 0 6.131562031441717e-07
generalized O 0 7.844866195227951e-05
blistering B-Disease 1 0.9401800632476807
, O 0 0.003241460071876645
nail B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
, O 1 0.8046610355377197
patchy B-Disease 1 0.9999997615814209
alopecia I-Disease 1 1.0
, O 0 0.00021983636543154716
and O 0 0.0004931798321194947
dental B-Disease 1 0.9999997615814209
abnormalities I-Disease 1 0.9999985694885254
. O 0 0.002285065595060587

Skin B-Disease 1 0.999994158744812
fragility I-Disease 1 0.9994738698005676
in O 0 1.1518387509568129e-05
most O 0 9.119423225456558e-07
cases O 0 2.6328154945076676e-07
is O 0 1.998420344762053e-07
due O 0 3.682024782847293e-07
to O 0 6.987067280306292e-08
mutations O 0 1.5275632847533416e-07
in O 0 8.877305646137756e-08
the O 0 5.267551159704453e-07
gene O 0 3.4374204460618785e-06
encoding O 0 6.8321419348649215e-06
type O 0 0.008231892250478268
XVII O 1 0.9999998807907104
collagen O 1 0.9999951124191284
( O 0 9.411231440026313e-05
COL17A1 O 1 0.9984152317047119
) O 0 1.8959795852424577e-05
. O 0 2.957051037810743e-05

Recently O 0 9.716913336887956e-05
, O 0 5.947698355157627e-06
we O 0 1.4184704468789278e-06
reported O 0 2.0721781766042113e-06
five O 0 1.9829112716251984e-06
Austrian O 0 5.567077823798172e-05
families O 0 4.6525360630766954e-06
with O 0 2.5043969799298793e-05
generalized O 1 0.9999713897705078
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
who O 0 8.474752576148603e-06
share O 0 1.0420250191600644e-06
the O 0 1.9657384200399974e-06
same O 0 5.0864769036707e-06
COL17A1 O 1 0.9923117756843567
mutation O 0 0.00016609419253654778
. O 0 4.5458433305611834e-05

Affected O 0 2.1478002963704057e-05
individuals O 0 1.0884457424253924e-06
in O 0 7.933928145575919e-07
three O 0 2.72874132178913e-07
families O 0 1.7996447354562406e-07
are O 0 4.103554473999793e-08
homozygous O 0 1.0032016461991589e-06
for O 0 3.313726040232723e-07
4003delTC O 0 9.486775525147095e-05
, O 0 4.513401847816567e-07
whereas O 0 2.5237429213120777e-07
those O 0 1.9673528584007727e-08
in O 0 5.269469838253826e-08
two O 0 1.0366373714987276e-07
others O 0 6.948949931029347e-07
are O 0 4.7333392672044283e-07
compound O 0 0.00016002218762878329
heterozygotes O 0 0.00038183352444320917
. O 0 5.878204683540389e-05

To O 0 3.566533223420265e-06
determine O 0 8.029617788452015e-07
if O 0 1.7403145591288194e-07
the O 0 2.1616835965687642e-07
occurrence O 0 2.0093891635042382e-06
of O 0 1.2630993069251417e-06
4003delTC O 0 4.238926339894533e-05
in O 0 4.5904539547336753e-07
these O 0 9.264679334819448e-08
unrelated O 0 6.686883580186986e-07
families O 0 1.753542591131918e-07
signifies O 0 4.405312211019918e-06
propagation O 0 4.175347839918686e-06
of O 0 7.665467478545906e-07
an O 0 6.892834107929957e-07
ancestral O 0 2.0238776414771564e-05
allele O 0 3.731689275809913e-06
or O 0 4.374648199245712e-07
a O 0 3.892231688951142e-06
mutational O 0 0.009727601893246174
hot O 0 2.9374668883974664e-05
spot O 0 4.60088540421566e-06
, O 0 4.26808810516377e-07
haplotypes O 0 1.981856257771142e-06
were O 0 1.5496283367610886e-07
determined O 0 2.1367314673170767e-07
for O 0 1.3053546865648968e-07
polymorphisms O 0 1.4689383078803075e-06
both O 0 1.665234634629087e-07
within O 0 1.0494458138055052e-06
and O 0 5.305384092935128e-06
flanking O 0 0.016719002276659012
COL17A1 O 1 0.99915611743927
. O 0 0.0001136077189585194

Five O 0 4.5590062654810026e-05
intragenic O 0 0.0007938853232190013
polymorphisms O 0 4.609207826433703e-05
were O 0 1.4082696679906803e-06
chosen O 0 1.177168769572745e-06
based O 0 7.831592938600807e-07
on O 0 2.45276737587119e-06
their O 0 6.2569260990130715e-06
informativeness O 0 0.0016703121364116669
. O 0 0.0001380662142764777

One O 0 4.647130481316708e-06
of O 0 1.6222147678490728e-06
these O 0 2.383305286457471e-07
, O 0 3.6825375104854174e-07
not O 0 8.379093685562111e-08
previously O 0 2.6529994556767633e-07
reported O 0 2.0449475357509073e-07
, O 0 1.7228794035872852e-07
was O 0 3.5068926536041545e-06
2988 O 0 4.1692608647281304e-05
A O 0 6.949175258341711e-06
or O 0 3.005478959039465e-07
C O 0 5.518199486687081e-06
that O 0 1.6116045742364804e-07
introduces O 0 7.325190836127149e-07
a O 0 2.3337557308877876e-07
new O 0 1.6357132892608206e-07
restriction O 0 1.194609922094969e-06
site O 0 1.6769911326264264e-06
for O 0 1.364745344289986e-06
Eco0109 O 0 0.00043027292122133076
I O 0 0.0002500887494534254
. O 0 6.860555004095659e-05

All O 0 7.255052878463175e-06
the O 0 1.1073422683693934e-05
4003delTC O 0 0.00013406887592282146
alleles O 0 6.487101472885115e-06
showed O 0 2.9631160032295156e-06
the O 0 8.509533699907479e-07
same O 0 6.863185717520537e-07
haplotype O 0 8.724618965061381e-06
for O 0 2.6731697744253324e-07
these O 0 2.0077406759355654e-07
five O 0 1.6015366099964012e-06
polymorphic O 0 7.254900992847979e-05
markers O 0 0.00013728509657084942
. O 0 5.694563878932968e-05

Fourteen O 0 0.00021064432803541422
microsatellite O 0 0.00047072721645236015
polymorphisms O 0 2.8858108635176904e-05
were O 0 6.139414949757338e-07
selected O 0 4.072125818765926e-07
based O 0 2.1979123232540587e-07
on O 0 2.993416501340107e-07
their O 0 1.9616129520727554e-07
high O 0 2.4207613478210988e-06
heterozygosity O 0 0.00017346373351756483
and O 0 3.518341884500842e-07
their O 0 1.768836881410607e-07
location O 0 1.5296756146199186e-06
within O 0 2.683222646737704e-06
10q23 O 0 0.0003934540436603129
- O 0 0.00032903411192819476
q25 O 0 0.009208164177834988
near O 0 0.0005737325409427285
COL17A1 O 0 0.3953734040260315
. O 0 0.00020446129201445729

Three O 0 9.477307685301639e-06
families O 0 2.4908181330829393e-06
shared O 0 1.016065198200522e-05
microsatellite O 0 0.00024414315703324974
polymorphisms O 0 3.41187187586911e-05
covering O 0 1.1278456440777518e-05
at O 0 2.293033048772486e-06
most O 0 3.005252722232399e-07
19 O 0 1.8262962839799002e-06
cM O 0 7.777662176522426e-06
, O 0 1.5881569481734914e-07
whereas O 0 2.1105613257077493e-07
the O 0 9.194334182893726e-08
others O 0 8.800278550324947e-08
shared O 0 1.3309089297308674e-07
smaller O 0 6.86808405703232e-08
regions O 0 9.96508120465478e-08
consistent O 0 1.8218520381196868e-07
with O 0 8.581741894886363e-08
cross O 0 3.736396649856033e-07
- O 0 8.066151053753856e-07
over O 0 2.1013669027070137e-07
events O 0 1.2663629433973256e-07
during O 0 3.022561827492609e-07
passage O 0 3.749028678612376e-07
of O 0 1.8744458429864608e-07
this O 0 1.4221544120118779e-07
mutation O 0 6.794460318815254e-07
through O 0 2.1244304093670507e-07
several O 0 5.783804795100878e-07
generations O 0 1.0784875485114753e-05
. O 0 2.1049194401712157e-05

These O 0 3.10900759359356e-06
results O 0 1.5619818896084325e-06
indicate O 0 1.5524698255831026e-06
that O 0 3.029392416920018e-07
4003delTC O 0 1.4143749467621092e-05
occurs O 0 3.815956404196186e-07
on O 0 2.2053829695778404e-07
a O 0 1.256500127055915e-06
single O 0 2.948972451122245e-06
ancestral O 0 3.8935973861953244e-05
allele O 0 1.1848075700982008e-05
. O 0 4.3623385863611475e-06
. O 0 2.558460801083129e-05

The O 0 0.00016318843699991703
haptoglobin O 0 0.0037974149454385042
- O 0 0.0003054354165215045
gene O 0 4.5152799430070445e-05
deletion O 0 3.5799112083623186e-05
responsible O 0 1.4990068848419469e-05
for O 0 1.5621440979884937e-05
anhaptoglobinemia B-Disease 1 0.5297194719314575
. O 0 0.00018784361600410193

We O 0 3.974741503043333e-06
have O 0 7.58031035275053e-07
found O 0 3.835537825125357e-07
an O 0 4.6535561182281526e-07
allelic O 0 1.7409965948900208e-05
deletion O 0 5.929196049692109e-06
of O 0 2.125185346812941e-06
the O 0 5.063386197434738e-06
haptoglobin O 0 0.0006473566172644496
( O 0 1.6294898159685545e-06
Hp O 0 5.457261522678891e-06
) O 0 2.028551762123243e-07
gene O 0 4.2447393866495986e-07
from O 0 1.665920734694737e-07
an O 0 4.221417384542292e-07
individual O 0 4.917930027659168e-07
with O 0 6.142100119177485e-06
anhaptoglobinemia B-Disease 1 0.6402294635772705
. O 0 0.00015717136557213962

The O 0 3.1108560506254435e-05
Hp O 0 0.00010160706733586267
gene O 0 1.0818219379871152e-05
cluster O 0 1.107411844714079e-05
consists O 0 1.6567930742894532e-06
of O 0 4.994927849111264e-07
coding O 0 1.198953896164312e-06
regions O 0 9.603599693264186e-08
of O 0 1.738425083885886e-07
the O 0 4.625804308489023e-07
alpha O 0 2.313365939698997e-06
chain O 0 7.880846624175319e-07
and O 0 6.052860612726363e-08
beta O 0 4.308246559503459e-07
chain O 0 4.887929776486999e-07
of O 0 2.0050045179687004e-07
the O 0 6.401709811143519e-07
haptoglobin O 0 2.14547872019466e-05
gene O 0 5.972856911284907e-07
( O 0 1.46494684827303e-07
Hp O 0 5.944636995991459e-07
) O 0 3.008432614137746e-08
and O 0 2.4252083008491354e-08
of O 0 7.180933891959285e-08
the O 0 2.5129907044174615e-07
alpha O 0 2.0763100110343657e-06
chain O 0 6.66438438656769e-07
and O 0 5.4299739815633075e-08
beta O 0 4.706040783730714e-07
chain O 0 7.585763341921847e-07
of O 0 2.9761642394987575e-07
the O 0 1.4151424920783029e-06
haptoglobin O 0 0.00012613531725946814
- O 0 5.982816219329834e-06
related O 0 1.4354221775647602e-06
gene O 0 2.203903704867116e-06
( O 0 4.800104420610296e-07
Hpr O 0 9.837502148002386e-06
) O 0 1.229071386887881e-07
, O 0 1.1684208089945969e-07
in O 0 1.6645549294480588e-07
tandem O 0 1.9915362372557865e-06
from O 0 1.882839626432542e-07
the O 0 1.7605480024940334e-06
5 O 0 1.0946000656986143e-05
side O 0 3.0210048862500116e-05
. O 0 3.49613546859473e-05

Southern O 0 0.00027019050321541727
blot O 0 0.0003348750760778785
and O 0 3.1945828595780768e-06
PCR O 0 9.90670105238678e-06
analyses O 0 9.205527362610155e-07
have O 0 6.159094567692591e-08
indicated O 0 1.5976208089796273e-07
that O 0 2.215171335251398e-08
the O 0 5.280829640241791e-08
individual O 0 2.4826682931688993e-08
with O 0 1.3675213494934724e-07
anhaptoglobinemia B-Disease 0 8.75639307196252e-05
was O 0 3.393889301150921e-06
homozygous O 0 4.4492634287962574e-07
for O 0 4.049747914791624e-08
the O 0 1.9830406472465256e-07
gene O 0 6.483375614152465e-07
deletion O 0 7.480517183466873e-07
and O 0 6.461130652724023e-08
that O 0 3.868263576123354e-08
the O 0 2.0864659688868414e-07
gene O 0 6.159066288091708e-07
deletion O 0 1.5797174910403555e-06
was O 0 1.3767981954515562e-06
included O 0 1.7359218418278033e-07
at O 0 3.096232319421688e-07
least O 0 1.0555781670973374e-07
from O 0 6.720870970866599e-08
the O 0 4.895225629297784e-07
promoter O 0 7.195695070549846e-05
region O 0 7.914007937870338e-07
of O 0 4.933883133162453e-07
Hp O 0 3.0268215596152004e-06
to O 0 2.5040884565896704e-07
Hpr O 0 1.1551443094504066e-05
alpha O 0 2.677037400644622e-06
but O 0 7.398488577337048e-08
not O 0 6.07020282927806e-08
to O 0 2.4823140165608493e-07
Hpr O 0 2.609458169899881e-05
beta O 0 1.2694098586507607e-05
( O 0 5.432642865343951e-06
Hpdel O 0 0.0003879056021105498
) O 0 1.3574394870374817e-05
. O 0 3.906987330992706e-05

In O 0 5.042030352342408e-06
addition O 0 3.0308885925478535e-06
, O 0 9.211771612172015e-07
we O 0 1.79208171857681e-07
found O 0 8.857584532506735e-08
seven O 0 4.98950036842416e-08
individuals O 0 2.554295086554248e-08
with O 0 1.5618090287716768e-07
hypohaptoglobinemia B-Disease 0 0.0006877816049382091
in O 0 3.0942484841034457e-07
three O 0 8.625869440948009e-08
families O 0 9.196929795507458e-08
, O 0 1.0826199314806217e-07
and O 0 4.9027381265887016e-08
the O 0 1.4894885680405423e-07
genotypes O 0 9.242331771019963e-07
of O 0 1.070666399982656e-07
six O 0 1.1261428056741352e-07
of O 0 1.91713013464323e-07
the O 0 3.190875474956556e-07
seven O 0 1.8622299080561788e-07
individuals O 0 5.422925397624567e-08
were O 0 2.341084979207153e-07
found O 0 3.0656104854642763e-07
to O 0 3.5615059346127964e-07
be O 0 3.8044915982027305e-06
Hp2 O 0 0.033714767545461655
/ O 0 0.2938993573188782
Hpdel O 0 0.3890068531036377
. O 0 0.00015238426567520946

The O 0 1.8161070329369977e-05
phenotypes O 0 3.734595520654693e-05
and O 0 1.323952915299742e-06
genotypes O 0 6.373429187078727e-06
in O 0 2.3263250170657557e-07
one O 0 7.715649985584605e-08
of O 0 2.0044117832185293e-07
these O 0 1.5810837084018203e-08
three O 0 2.149558220310155e-08
families O 0 3.395179248855129e-08
showed O 0 2.473787219514634e-07
the O 0 1.8770593612771336e-07
father O 0 5.785857410955941e-07
to O 0 6.574279609594669e-08
be O 0 1.569070633422598e-07
hypohaptoglobinemic B-Disease 0 2.4482909793732688e-05
( O 0 5.296737981552724e-07
Hp2 O 0 5.701285772374831e-05
) O 0 4.6651541651954176e-07
and O 0 4.7482998866144044e-07
Hp2 O 0 0.0007725007017143071
/ O 0 9.593147115083411e-05
Hpdel O 0 0.0002325424284208566
, O 0 3.4429609740982414e-07
the O 0 2.8649975547523354e-07
mother O 0 4.096079351256776e-07
to O 0 3.597546793798756e-08
be O 0 5.281061277173649e-08
Hp2 O 0 5.89164574194001e-06
- O 0 1.3401074738794705e-06
1 O 0 1.1508145689731464e-06
and O 0 5.591866170107096e-07
Hp1 O 0 0.001095450483262539
/ O 0 7.518623169744387e-05
Hp2 O 0 0.00017442472744733095
, O 0 1.0497495850358973e-07
one O 0 3.16481205686614e-08
of O 0 9.442273807280799e-08
the O 0 9.0070457758884e-08
two O 0 3.7907540217929636e-08
children O 0 5.525633994807322e-08
to O 0 5.4515275849098543e-08
be O 0 1.7039866406776127e-07
hypohaptoglobinemic B-Disease 0 2.804702853609342e-05
( O 0 1.0598405424389057e-06
Hp2 O 0 8.791818254394457e-05
) O 0 5.159877787264122e-07
and O 0 4.954705445925356e-07
Hp2 O 0 0.006101831328123808
/ O 0 0.0001854250585893169
Hpdel O 0 0.001596949645318091
, O 0 4.778741526934027e-07
and O 0 1.0365683067448117e-07
the O 0 1.6383360446070583e-07
other O 0 5.955282134095796e-08
child O 0 2.954581077574403e-07
to O 0 1.1980607439454616e-07
be O 0 2.2825744849797047e-07
Hp1 O 0 3.683524118969217e-05
and O 0 1.3682013104698854e-06
Hp1 O 1 0.6712254881858826
/ O 0 0.0036269959527999163
Hpdel O 0 0.0005372262094169855
, O 0 4.849438255405403e-07
showing O 0 8.606868391325406e-07
an O 0 5.653100174640713e-07
anomalous O 0 2.102463986375369e-05
inheritance O 0 9.620053788239602e-06
of O 0 4.119327059015632e-06
Hp O 0 6.0485002904897556e-05
phenotypes O 0 6.266611308092251e-06
in O 0 4.994794835511129e-07
the O 0 2.256098923680838e-06
child O 0 5.512692951015197e-06
with O 0 8.840906957630068e-06
Hp1 O 1 0.9742019176483154
. O 0 0.00020472325559239835

The O 0 8.901536784833297e-05
Hp2 O 0 0.12260346859693527
/ O 0 0.0013631032779812813
Hpdel O 0 0.0004444106307346374
individuals O 0 7.8675248005311e-07
had O 0 1.342518771707546e-06
an O 0 2.3953319328029465e-07
extremely O 0 4.623299503236922e-07
low O 0 1.4152381311305362e-07
level O 0 1.5311482570723456e-07
of O 0 1.9983309584858944e-07
Hp O 0 1.030769340104598e-06
( O 0 9.556766400464767e-08
mean O 0 2.9858011885153246e-07
+ O 0 6.163020316307666e-07
/ O 0 1.4805891623836942e-06
- O 0 1.3497887039193301e-06
SD O 0 7.13852978151408e-06
= O 0 3.966574411151669e-07
0 O 0 1.7923755990523205e-07
. O 0 1.2335100052496273e-07
049 O 0 5.484303073899355e-06
+ O 0 5.002584089197626e-07
/ O 0 6.465889441642503e-07
- O 0 5.842525183652469e-07
0 O 0 2.167509052242167e-07
. O 0 1.986936410958151e-07
043 O 0 5.892443368793465e-06
mg O 0 2.666976797627285e-06
/ O 0 1.0286207725584973e-06
ml O 0 4.6071374981693225e-07
; O 0 1.1703185087696966e-08
n O 0 4.856389779206438e-08
= O 0 4.5059529441005e-08
6 O 0 3.8649599076734376e-08
) O 0 1.033921837034768e-08
, O 0 5.618591814027241e-09
compared O 0 6.566218679893154e-09
with O 0 7.321402595295012e-09
the O 0 2.582059011047022e-08
level O 0 1.0854608945010114e-07
( O 0 4.1968309716367e-08
1 O 0 7.425589387821674e-08
. O 0 3.2782537573439186e-08
64 O 0 3.444993978973798e-07
+ O 0 4.719317132639844e-07
/ O 0 4.1248799220738874e-07
- O 0 2.759946085006959e-07
1 O 0 2.385943389526801e-07
. O 0 1.0860034649340378e-07
07 O 0 5.989203600620385e-06
mg O 0 8.524416443833616e-06
/ O 0 4.182744760328205e-06
ml O 0 1.8546597857493907e-06
) O 0 7.24106570260119e-08
obtained O 0 1.6479795306167944e-07
from O 0 1.4090835520619294e-07
52 O 0 1.7256533055842738e-06
healthy O 0 2.402759037067881e-06
volunteers O 0 3.2954048947431147e-06
having O 0 3.537084467097884e-06
phenotype O 0 4.4684526073979214e-05
Hp2 O 0 0.00018627991084940732
, O 0 5.736397952205152e-07
whereas O 0 5.255478185972606e-07
the O 0 4.6713955725863343e-07
serum O 0 6.569543074874673e-06
Hp O 0 1.3687024420505622e-06
level O 0 1.9847661292260455e-07
of O 0 1.412913093190582e-07
an O 0 1.534413911485899e-07
individual O 0 1.5407131570555066e-07
with O 0 1.1807936743934988e-06
Hp1 O 1 0.75457763671875
/ O 0 0.07522565871477127
Hpdel O 0 0.013984084129333496
was O 0 5.109927951707505e-05
0 O 0 2.218303234258201e-05
. O 0 2.6812791475094855e-05

50 O 0 8.417733624810353e-05
mg O 0 0.0004209965991321951
/ O 0 9.822726860875264e-05
ml O 0 2.4331175154657103e-05
, O 0 4.826019903703127e-07
which O 0 6.842796551609354e-08
was O 0 4.0176507809519535e-07
approximately O 0 5.5286172084834106e-08
half O 0 3.1292653801529013e-08
the O 0 3.863515374291637e-08
level O 0 9.318696214677402e-08
of O 0 1.4014125326866633e-07
Hp O 0 7.511442277063907e-07
in O 0 1.2400016657920787e-07
control O 0 4.0566058601143595e-07
sera O 0 1.6437304566352395e-06
from O 0 1.0255632076905385e-07
the O 0 3.98099786025341e-07
Hp1 O 0 1.9948547560488805e-05
phenotype O 0 2.2214983346202644e-06
( O 0 6.870848778817162e-08
1 O 0 1.5770125116887357e-07
. O 0 3.770016832049805e-08
26 O 0 2.1090200164053385e-07
+ O 0 3.6759200838787365e-07
/ O 0 3.6906237710354617e-07
- O 0 2.970334378460393e-07
0 O 0 1.8386886324606166e-07
. O 0 5.1071310736006126e-08
33 O 0 3.8352197861968307e-07
mg O 0 2.3234038053487893e-06
/ O 0 1.0612292271616752e-06
ml O 0 6.731596045028709e-07
; O 0 2.8055744394350768e-08
n O 0 1.400477316337856e-07
= O 0 1.6859762297372072e-07
9 O 0 1.1510677921933166e-07
) O 0 2.9553467228993213e-08
, O 0 4.610723891573798e-08
showing O 0 3.4014411198768357e-07
a O 0 8.968634688244492e-07
gene O 0 5.409533969213953e-06
- O 0 2.73847472271882e-05
dosage O 0 5.788986527477391e-05
effect O 0 3.546606603777036e-05
. O 0 2.750645398919005e-05

The O 0 1.609460923646111e-05
other O 0 1.7635358062761952e-06
allele O 0 1.2299534319026861e-05
( O 0 2.0055563254572917e-06
Hp2 O 0 6.661772931693122e-05
) O 0 3.2807690786285093e-07
of O 0 3.2993625609378796e-07
individuals O 0 8.250886907035238e-08
with O 0 8.96390645266365e-07
Hp2 O 1 0.9988868832588196
/ O 1 0.8835675716400146
Hpdel O 1 0.9556680917739868
was O 0 3.535301220836118e-05
found O 0 1.5083072923971486e-07
to O 0 2.078263605653774e-08
have O 0 1.4019520655494944e-08
, O 0 2.4127002618001825e-08
in O 0 2.5231647882151265e-08
all O 0 6.656178896946585e-08
exons O 0 1.7885216720969765e-06
, O 0 1.677437495573031e-07
no O 0 2.7577991090765863e-07
mutation O 0 1.1309499541312107e-06
, O 0 2.9355385322560323e-07
by O 0 9.570152315063751e-07
DNA O 0 1.701656947261654e-05
sequencing O 0 2.4324772311956622e-05
. O 0 2.3350799892796203e-05

On O 0 2.6226161935483105e-06
the O 0 5.131004172653775e-07
basis O 0 1.9708650711436349e-07
of O 0 2.784928767596284e-07
the O 0 2.113501977873966e-07
present O 0 1.528516264670543e-07
study O 0 1.1862074700275116e-07
, O 0 7.460911177759044e-08
the O 0 1.0791522697672917e-07
mechanism O 0 3.868157705255726e-07
of O 0 8.709171197551768e-07
anhaptoglobinemia B-Disease 0 5.245997090241872e-05
and O 0 1.645102827296796e-07
the O 0 3.084208231030061e-07
mechanism O 0 1.0864173418667633e-06
of O 0 1.2020656185995904e-06
anomalous O 0 2.064038380922284e-05
inheritance O 0 1.0424234460515436e-05
of O 0 4.29884175900952e-06
Hp O 0 6.341718108160421e-05
phenotypes O 0 1.0455614756210707e-05
were O 0 9.73945589066716e-07
well O 0 2.00773047254188e-06
explained O 0 3.269023363827728e-05
. O 0 2.8361288059386425e-05

However O 0 2.72998986474704e-05
, O 0 5.337462880561361e-06
the O 0 4.829578301723814e-06
mechanism O 0 1.8923054085462354e-05
of O 0 3.073682091780938e-05
hypohaptoglobinemia B-Disease 1 0.7148950695991516
remains O 0 0.0012469663051888347
unknown O 0 0.000938132987357676

ATM O 0 0.0009556704317219555
mutations O 0 3.051223757211119e-05
and O 0 5.766439699073089e-06
phenotypes O 0 0.0002438328374410048
in O 0 0.00022412235557567328
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999884366989136
telangiectasia I-Disease 1 0.9999995231628418
families O 0 1.3853897371518542e-06
in O 0 7.725551540715969e-07
the O 0 9.106595939556428e-07
British O 0 8.55632697494002e-06
Isles O 0 4.618082584784133e-06
: O 0 1.5530770269833738e-07
expression O 0 3.050142822758062e-07
of O 0 4.378796916171268e-07
mutant O 0 9.363071512780152e-06
ATM O 0 1.5175432054093108e-05
and O 0 1.1112294373560871e-07
the O 0 3.238627925838955e-07
risk O 0 1.7922437791639823e-06
of O 0 5.9917569160461426e-05
leukemia B-Disease 1 1.0
, O 1 0.9999722242355347
lymphoma B-Disease 1 1.0
, O 1 0.9549106955528259
and O 1 0.7916203141212463
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.0653582438826561

We O 0 3.9145520531747025e-06
report O 0 7.440204967679165e-07
the O 0 6.163149919302668e-07
spectrum O 0 1.9140879885526374e-06
of O 0 1.1395471801733947e-06
59 O 0 5.5185414566949476e-06
ATM O 0 3.4416192647768185e-05
mutations O 0 8.986040143099672e-07
observed O 0 8.583654107496841e-07
in O 0 5.434715603769291e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999841451644897
telangiectasia I-Disease 1 1.0
( O 0 0.05015849322080612
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999983310699463
T I-Disease 1 0.9999997615814209
) O 0 1.0869583775274805e-06
patients O 0 5.299128247315821e-07
in O 0 3.228747118555475e-07
the O 0 2.3731404326099437e-06
British O 0 0.00011422025272622705
Isles O 0 0.00030536175472661853
. O 0 5.9565605624811724e-05

Of O 0 5.821610466227867e-05
51 O 0 0.00013497679901774973
ATM O 0 0.0009019149583764374
mutations O 0 6.57191139907809e-06
identified O 0 1.5393090961879352e-06
in O 0 3.8693826809321763e-07
families O 0 2.1058566801457346e-07
native O 0 5.97384826050984e-07
to O 0 8.128517947625369e-08
the O 0 3.0945670914661605e-07
British O 0 4.502526280703023e-06
Isles O 0 2.896577370847808e-06
, O 0 1.3328751435892627e-07
11 O 0 2.9456708716679714e-07
were O 0 2.773402343336784e-07
founder O 0 1.2337738553469535e-05
mutations O 0 4.009826852779952e-07
, O 0 1.352907190721453e-07
and O 0 8.055329203671135e-08
2 O 0 1.8764741582799616e-07
of O 0 1.719458708748789e-07
these O 0 2.4997694580974894e-08
11 O 0 3.28733960941463e-07
conferred O 0 3.793455789491418e-06
a O 0 2.040362915067817e-06
milder O 0 9.161088200926315e-06
clinical O 0 1.0805712008732371e-05
phenotype O 0 1.1429285223130137e-05
with O 0 1.2778637881183386e-07
respect O 0 4.536285587164457e-07
to O 0 3.193877375906595e-07
both O 0 3.662479684862774e-06
cerebellar B-Disease 1 0.9999998807907104
degeneration I-Disease 1 1.0
and O 0 0.00021930880029685795
cellular O 0 0.35958778858184814
features O 0 4.799733869731426e-05
. O 0 4.636390440282412e-05

We O 0 2.4826458684401587e-06
report O 0 6.136756951491407e-07
, O 0 1.9360730618700472e-07
in O 0 1.795249602309923e-07
two O 0 2.955624154310499e-07
A B-Disease 0 0.11212838441133499
- I-Disease 0 0.04062361642718315
T I-Disease 1 0.5997551679611206
families O 0 2.1213875811554317e-07
, O 0 1.2280965222544182e-07
an O 0 2.94192858518727e-07
ATM O 0 2.5913355784723535e-05
mutation O 0 1.0770318112918176e-06
( O 0 3.7618863757415966e-07
7271T O 0 2.9510816602851264e-05
- O 0 8.471964974887669e-06
- O 0 1.6975916878436692e-05
> O 0 4.050292773172259e-05
G O 0 2.3759126634104177e-05
) O 0 4.90401035335708e-08
that O 0 1.4214732502182414e-08
may O 0 1.807504723672082e-08
be O 0 5.761066290688177e-09
associated O 0 2.3084497868808285e-08
with O 0 2.636000395739302e-08
an O 0 1.0299994102069832e-07
increased O 0 1.0948797353194095e-06
risk O 0 1.3314235047801048e-06
of O 0 8.22873153083492e-06
breast B-Disease 1 0.9999562501907349
cancer I-Disease 1 0.9991746544837952
in O 0 1.6461243603771436e-06
both O 0 8.815176784082723e-07
homozygotes O 0 0.00032281604944728315
and O 0 5.835609044879675e-07
heterozygotes O 0 1.0671737982193008e-05
( O 0 2.1962696905575285e-07
relative O 0 3.894293172379548e-07
risk O 0 1.5331237079863058e-07
12 O 0 7.663217616027396e-08
. O 0 2.2363979113038113e-08
7 O 0 1.8026265991011314e-07
; O 0 9.782147714076928e-08
P O 0 5.1074116527161095e-06
= O 0 5.74804573716392e-07
. O 0 1.1098419605559684e-07
0025 O 0 7.611570708832005e-06
) O 0 5.710330697183963e-08
, O 0 3.5562784717058094e-08
although O 0 2.6285398746495048e-08
there O 0 3.8147987879710854e-08
is O 0 4.7368843070216826e-08
a O 0 2.9552012392741744e-07
less O 0 1.046195166054531e-06
severe O 1 0.9999094009399414
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999914169311523
T I-Disease 1 0.9999961853027344
phenotype O 0 9.84326470643282e-06
in O 0 8.573839949121975e-08
terms O 0 8.403020501646097e-08
of O 0 1.6259771484783414e-07
the O 0 4.880309347754519e-07
degree O 0 2.232047336292453e-05
of O 0 0.003411930985748768
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.03671487420797348

This O 0 1.2627690921362955e-05
mutation O 0 2.17510387301445e-05
( O 0 3.1377428513224004e-06
7271T O 0 0.00011422712123021483
- O 0 2.3724078346276656e-05
- O 0 3.123102942481637e-05
> O 0 5.347184560378082e-05
G O 0 1.3153875443094876e-05
) O 0 7.110565292123283e-08
also O 0 1.7342831171163198e-08
allows O 0 6.130858043462695e-09
expression O 0 2.737782978101677e-08
of O 0 5.199850861004052e-08
full O 0 2.543784489716927e-07
- O 0 1.0089469242302584e-06
length O 0 5.380456400416733e-07
ATM O 0 5.509739366971189e-06
protein O 0 1.7609548308428202e-07
at O 0 8.788184402419574e-08
a O 0 9.385427546249048e-08
level O 0 1.6851467421474808e-07
comparable O 0 2.084083661202385e-07
with O 0 7.705413906933245e-08
that O 0 1.8813911140114215e-07
in O 0 1.4592189927498112e-06
unaffected O 0 5.0230206397827715e-05
individuals O 0 3.4657020933082094e-06
. O 0 3.7773948861286044e-05

In O 0 4.6876943997631315e-06
addition O 0 1.3986995099912747e-06
, O 0 5.323319101080415e-07
we O 0 9.334546291484003e-08
have O 0 5.77894212483443e-08
studied O 0 4.62245282051299e-07
18 O 0 5.693511411664076e-06
A B-Disease 1 0.9999696016311646
- I-Disease 1 0.9999940395355225
T I-Disease 1 0.9999995231628418
patients O 0 1.403096462126996e-06
, O 0 1.1615137651688201e-07
in O 0 6.540821573253197e-08
15 O 0 1.6016238646443526e-07
families O 0 7.722628225792505e-08
, O 0 2.391894042830245e-07
who O 0 2.1368791749409866e-06
developed O 0 0.007401396054774523
leukemia B-Disease 1 1.0
, O 1 0.9959478974342346
lymphoma B-Disease 1 1.0
, O 1 0.9580643177032471
preleukemic O 1 0.9999998807907104
T O 1 0.9999985694885254
- O 1 0.7618920207023621
cell O 1 0.6304506063461304
proliferation O 1 0.7571679353713989
, O 0 2.266193405375816e-05
or O 0 0.034531913697719574
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 0.04206422343850136
mostly O 0 6.768856565031456e-06
in O 0 1.0572164683253504e-05
childhood O 0 0.18085825443267822
. O 0 0.000154265682795085

A O 0 5.496558878803626e-05
wide O 0 8.373919627047144e-06
variety O 0 2.1670741716661723e-06
of O 0 6.642634616582654e-06
ATM O 0 0.0004424543585628271
mutation O 0 4.155485385126667e-06
types O 0 3.828590422472189e-07
, O 0 1.485678069457208e-07
including O 0 2.257156666019e-07
missense O 0 1.06847128336085e-05
mutations O 0 4.576732521854865e-07
and O 0 1.52394875385653e-07
in O 0 5.198432404540654e-07
- O 0 2.0918361769872718e-05
frame O 0 4.55406989203766e-05
deletions O 0 5.113869974593399e-06
, O 0 2.3364746937204472e-07
were O 0 1.9273261386842933e-07
seen O 0 3.401759158805362e-07
in O 0 3.348764323618525e-07
these O 0 4.6899339167794096e-07
patients O 0 1.415683982486371e-05
. O 0 3.07364716718439e-05

We O 0 2.2747349248675164e-06
also O 0 3.4504225254750054e-07
show O 0 1.8497584619581176e-07
that O 0 2.7394911228384444e-08
25 O 0 1.2110784552987752e-07
% O 0 1.1883066974860412e-07
of O 0 2.1372736114244617e-07
all O 0 5.02197224250267e-07
A B-Disease 1 0.9918136596679688
- I-Disease 1 0.999404788017273
T I-Disease 1 0.9999876022338867
patients O 0 1.0797467666634475e-06
carried O 0 4.5836821982447873e-07
in O 0 5.198184567234421e-07
- O 0 1.3777064850728493e-05
frame O 0 5.419734225142747e-05
deletions O 0 1.005658668873366e-05
or O 0 4.5969292727932043e-07
missense O 0 1.2999537830182817e-05
mutations O 0 4.871465080213966e-07
, O 0 6.647931627412618e-08
many O 0 1.7030727050837413e-08
of O 0 8.719229072085e-08
which O 0 7.6319288666582e-08
were O 0 1.1487275486388171e-07
also O 0 5.395131452701207e-08
associated O 0 9.32273209741652e-08
with O 0 1.2848487074279547e-07
expression O 0 1.8619188040247536e-06
of O 0 5.571060228248825e-06
mutant O 0 0.00033919731504283845
ATM O 0 0.0010210741311311722
protein O 0 5.113427323522046e-05
. O 0 2.654273521329742e-05

The O 0 0.00012647722905967385
DMPK O 1 0.9706526398658752
gene O 0 0.0002036491787293926
of O 0 0.0006765588186681271
severely O 1 0.9999885559082031
affected O 1 0.9999964237213135
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9999744892120361
is O 0 0.000687653839122504
hypermethylated O 1 0.9895920753479004
proximal O 0 0.0015393714420497417
to O 0 5.306010280037299e-07
the O 0 1.4153976053421502e-06
largely O 0 6.351446245389525e-06
expanded O 0 2.08563324122224e-05
CTG O 0 0.0029181838035583496
repeat O 0 0.00012465479085221887
. O 0 3.8895006582606584e-05

Using O 0 1.739194522087928e-05
methylation O 0 7.852604903746396e-05
- O 0 2.3320622858591378e-05
sensitive O 0 3.57138355866482e-06
restriction O 0 2.1593357359961374e-06
enzymes O 0 5.37910182174528e-07
, O 0 1.9705755960330862e-07
we O 0 5.432667293803206e-08
characterized O 0 3.2319510978595645e-07
the O 0 1.3533535536680574e-07
methylation O 0 7.937295549709233e-07
pattern O 0 3.4999689546566515e-07
on O 0 7.14309393856638e-08
the O 0 9.161913538946465e-08
5 O 0 1.8631644138622505e-07
side O 0 1.4371026679782517e-07
of O 0 2.230817557347109e-07
the O 0 7.758843594274367e-07
CTG O 0 0.00027637783205136657
repeat O 0 1.1960770507357665e-06
in O 0 2.0539165745958599e-07
the O 0 1.0105686669703573e-06
DMPK O 0 0.011448645032942295
gene O 0 1.614220650481002e-06
of O 0 3.858721697724832e-07
normal O 0 5.514551730811945e-07
individuals O 0 5.139887804261889e-08
and O 0 1.5692860699800804e-07
of O 0 3.480342002148973e-06
patients O 0 9.601401688996702e-05
affected O 0 8.713969873497263e-05
with O 1 0.9802947044372559
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.2365942641044967e-05
showing O 0 5.947454155830201e-06
expansions O 0 5.532790964934975e-06
of O 0 2.2335900666803354e-06
the O 0 5.7895613281289116e-06
repetitive O 0 0.0001678125117905438
sequence O 0 2.0756526282639243e-05
. O 0 3.216373443137854e-05

The O 0 2.2293033907772042e-05
gene O 0 1.6927257092902437e-05
segment O 0 8.130274181894492e-06
analyzed O 0 1.2069258445990272e-06
corresponds O 0 1.021897674036154e-06
to O 0 1.819063726316017e-07
the O 0 8.190424409804109e-07
genomic O 0 1.3846374713466503e-05
SacI O 0 0.00028147935518063605
- O 0 2.3032633180264384e-05
HindIII O 0 0.00011721013288479298
fragment O 0 1.687271833361592e-05
carrying O 0 5.4922588788031135e-06
exons O 0 9.222853805113118e-06
11 O 0 4.309941687097307e-06
- O 0 3.09261740767397e-05
15 O 0 3.216523691662587e-05
. O 0 4.277266998542473e-05

There O 0 1.4518202078761533e-05
is O 0 3.7546499243035214e-06
constitutive O 0 3.523957639117725e-05
methylation O 0 7.174517577368533e-06
in O 0 6.249824764381628e-07
intron O 0 2.7157861040905118e-05
12 O 0 6.199426252351259e-07
at O 0 5.881209972358192e-07
restriction O 0 5.047925242251949e-07
sites O 0 8.115813443509978e-08
of O 0 2.1494932411769696e-07
SacII O 0 1.4935118997527752e-05
and O 0 2.687538085410779e-07
HhaI O 0 1.9404962586122565e-05
, O 0 2.668416811957286e-07
localized O 0 1.1883876140927896e-06
1 O 0 4.4651437747234013e-07
, O 0 1.1892102946831073e-07
159 O 0 3.4279884175703046e-07
- O 0 6.651723083450634e-07
1 O 0 5.272240173326281e-07
, O 0 1.4884363963574287e-07
232 O 0 5.188655336496595e-07
bp O 0 6.707628585900238e-07
upstream O 0 1.4514021984268766e-07
of O 0 9.269133727229928e-08
the O 0 5.321151661519252e-07
CTG O 0 0.0002362889499636367
repeat O 0 1.0813379276441992e-06
, O 0 1.481683682413859e-07
whereas O 0 1.310914967689314e-07
most O 0 3.322709218878117e-08
, O 0 4.42573337977592e-08
if O 0 1.2499937085408419e-08
not O 0 6.477922198655506e-09
all O 0 5.925446355803388e-09
, O 0 2.146059685514956e-08
of O 0 4.954043930638363e-08
the O 0 1.2140804983573616e-07
other O 0 1.6014613635206842e-08
sites O 0 3.618377419911667e-08
of O 0 3.129134711343795e-07
SacII O 0 0.00016301081632263958
, O 0 8.936704034567811e-07
HhaI O 0 0.0001867438986664638
, O 0 3.446804726081609e-07
and O 0 1.739474839723698e-07
HpaII O 0 2.4522794774384238e-05
in O 0 2.1960266849418986e-07
this O 0 1.3822709377109277e-07
region O 0 7.341374157476821e-07
are O 0 4.52790480665044e-08
unmethylated O 0 7.4084391599171795e-06
, O 0 7.244062771860627e-08
in O 0 6.23592910642401e-08
normal O 0 2.0018443080971338e-07
individuals O 0 2.1844584807695355e-08
and O 0 6.362657956060502e-08
most O 0 9.167629855255655e-08
of O 0 1.4492931086351746e-06
the O 0 1.0044031114375684e-05
patients O 0 6.851591751910746e-05
. O 0 3.986593219451606e-05

In O 0 5.827705990668619e-06
a O 0 2.1613755052385386e-06
number O 0 8.518919685229775e-07
of O 0 3.162937218803563e-06
young O 0 1.5797226296854205e-05
and O 0 8.885011084203143e-06
severely O 1 0.9005273580551147
affected O 0 4.544197508948855e-06
patients O 0 2.7213163775741123e-06
, O 0 3.088823916641559e-07
however O 0 2.0021612101572828e-07
, O 0 5.7809597109326205e-08
complete O 0 2.4572810275458323e-07
methylation O 0 3.555085470452468e-07
of O 0 1.071898481086464e-07
these O 0 1.6327014407124807e-08
restriction O 0 1.8421640390897664e-07
sites O 0 3.874000853443249e-08
was O 0 5.083961696072947e-07
found O 0 1.3928132602814003e-07
in O 0 1.847879076422032e-07
the O 0 2.8455492611101363e-06
mutated O 0 5.856791904079728e-05
allele O 0 9.426051110494882e-05
. O 0 3.7100773624842986e-05

In O 0 8.774215530138463e-06
most O 0 1.0744854535005288e-06
of O 0 1.5082080153661082e-06
these O 0 3.387175411262433e-07
patients O 0 1.8195510165242013e-06
, O 0 3.0796525152254617e-07
the O 0 8.428211231148452e-07
onset O 1 0.9543034434318542
of O 0 6.0721835325239226e-05
the O 0 0.4458869397640228
disease O 1 1.0
was O 1 0.9999986886978149
congenital O 1 1.0
. O 1 0.839354395866394

Preliminary O 0 2.017279803112615e-05
in O 0 7.578975328215165e-06
vivo O 0 5.508375761564821e-05
footprinting O 0 0.00011531023483257741
data O 0 3.146454901070683e-07
gave O 0 3.3853734748845454e-07
evidence O 0 1.8772259124943957e-07
for O 0 9.366935671550891e-08
protein O 0 5.54559903775953e-07
- O 0 1.2507447308962583e-06
DNA O 0 8.493731229464174e-07
contact O 0 1.0605832301280316e-07
in O 0 6.404945906979265e-08
normal O 0 1.5903060557320714e-07
genes O 0 6.682281394887468e-08
at O 0 1.253463182138148e-07
an O 0 1.929014246115912e-07
Sp1 O 0 9.379784387419932e-06
consensus O 0 3.3342325878038537e-07
binding O 0 1.2504067115060025e-07
site O 0 1.3430869216790597e-07
upstream O 0 1.1059832871751496e-07
of O 0 9.345877316491169e-08
the O 0 5.849259991919098e-07
CTG O 0 9.431203943677247e-05
repeat O 0 5.039493089498137e-07
and O 0 3.842584916924352e-08
for O 0 3.5783646268328084e-08
a O 0 1.3115652564010816e-07
significant O 0 2.2189946946582495e-07
reduction O 0 5.541581344914448e-07
of O 0 1.364345507681719e-07
this O 0 4.550649634893489e-08
interaction O 0 9.404960366055093e-08
in O 0 1.0810186523713128e-07
cells O 0 5.314700501912739e-07
with O 0 2.276708954696005e-07
a O 0 1.1436393833719194e-05
hypermethylated O 1 0.9610281586647034
DMPK O 1 0.9991635084152222
gene O 0 2.991279325215146e-05
. O 0 5.366403001971776e-06
. O 0 1.8176249795942567e-05

The O 0 0.0007781268795952201
hemochromatosis B-Disease 1 0.999998927116394
gene O 0 3.473361357464455e-05
product O 0 5.007709205528954e-06
complexes O 0 3.00863325719547e-06
with O 0 3.15978780918158e-07
the O 0 2.3656768917135196e-06
transferrin O 0 0.00018895343237090856
receptor O 0 1.9969984350609593e-06
and O 0 3.448303971254063e-07
lowers O 0 3.3472583709226456e-06
its O 0 2.2616775652295473e-07
affinity O 0 1.6387436971854186e-06
for O 0 5.619472744911036e-07
ligand O 0 3.807426764979027e-05
binding O 0 1.7650028894422576e-05
. O 0 3.0021674319868907e-05

We O 0 6.591847522940952e-06
recently O 0 5.7696192925504874e-06
reported O 0 1.6427275113528594e-06
the O 0 1.0206675824520062e-06
positional O 0 2.277376552228816e-05
cloning O 0 2.9257446385599906e-06
of O 0 7.571178457510541e-07
a O 0 1.8841000155589427e-06
candidate O 0 5.332415639713872e-06
gene O 0 1.4924725292075891e-05
for O 0 4.243958028382622e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999803304672241
HFE O 1 0.999998927116394
. O 0 0.00045683427015319467

The O 0 2.295574995514471e-05
gene O 0 9.825595043366775e-06
product O 0 1.671511199674569e-06
, O 0 3.1421549806509574e-07
a O 0 3.3896054674187326e-07
member O 0 2.16806725461538e-07
of O 0 2.63850125747922e-07
the O 0 7.641031629646022e-07
major O 0 7.648668542969972e-05
histocompatibility O 1 0.9999781847000122
complex O 0 3.476817437331192e-05
class O 0 1.1018897566827945e-05
I O 0 1.0116262274095789e-05
- O 0 2.853699470506399e-06
like O 0 4.7010973958094837e-07
family O 0 6.562990506608912e-07
, O 0 2.1522664894746413e-07
was O 0 1.3715143722947687e-06
found O 0 6.122130713492879e-08
to O 0 1.5800527108922324e-08
have O 0 1.552183626074566e-08
a O 0 1.9840962295347708e-07
mutation O 0 7.953662475301826e-07
, O 0 5.779415914730635e-07
Cys O 0 0.0002268916432512924
- O 0 2.0530076653813012e-05
282 O 0 3.579662006814033e-05
- O 0 0.00015230840654112399
- O 0 0.0008470897446386516
> O 0 0.0005786741967312992
Tyr O 0 0.0002751300926320255
( O 0 8.175409789146215e-07
C282Y O 0 6.9618181441910565e-06
) O 0 7.187922079765485e-08
, O 0 3.993744002173116e-08
in O 0 6.215326919800646e-08
85 O 0 5.970362622065295e-07
% O 0 5.455958103084413e-07
of O 0 2.7322384994477034e-06
patient O 0 5.907583181397058e-05
chromosomes O 0 3.3653966966085136e-05
. O 0 3.7793473893543705e-05

This O 0 8.233472726715263e-06
mutation O 0 1.4693287084810436e-05
eliminates O 0 1.1441411515988875e-05
the O 0 1.0185661949435598e-06
ability O 0 3.213930597212311e-07
of O 0 9.625089205655968e-07
HFE O 0 0.016625991091132164
to O 0 1.4456223595971096e-07
associate O 0 1.5547811926808208e-06
with O 0 7.672502988498309e-07
beta2 O 1 0.6016008257865906
- O 0 0.029198404401540756
microglobulin O 1 0.9738810062408447
( O 0 4.001104116468923e-06
beta2m O 0 0.0005704722716473043
) O 0 6.594033266082988e-07
and O 0 6.590738621525816e-07
prevents O 0 7.80507343733916e-06
cell O 0 0.00013287494948599488
- O 0 5.735148806707002e-05
surface O 0 3.3628461096668616e-05
expression O 0 3.2257423299597576e-05
. O 0 2.0976573068764992e-05

A O 0 5.470214819069952e-05
second O 0 1.0943997040158138e-05
mutation O 0 4.403169896249892e-06
that O 0 1.8958431269311404e-07
has O 0 1.4813954862802348e-07
no O 0 9.483280649646986e-08
effect O 0 1.8213516739251645e-07
on O 0 4.4725337033924006e-07
beta2m O 0 0.003588357474654913
association O 0 4.571450972434832e-06
, O 0 8.366842507712136e-07
H63D O 0 0.2539004683494568
, O 0 4.2272631617379375e-07
was O 0 1.5984559240678209e-06
found O 0 8.504213866444843e-08
in O 0 5.3435265101597906e-08
eight O 0 1.0439053710342705e-07
out O 0 8.590453859369518e-08
of O 0 7.673293680454663e-07
nine O 0 3.2684069992683362e-06
patients O 0 3.137709882139461e-06
heterozygous O 0 2.307768681930611e-06
for O 0 8.039348244892608e-07
the O 0 9.75316834228579e-06
C282Y O 0 0.00747227668762207
mutant O 0 0.0005741491913795471
. O 0 6.585604569409043e-05

In O 0 4.88726709590992e-06
this O 0 6.215884127414029e-07
report O 0 3.9547819596919e-07
, O 0 1.4268712789089477e-07
we O 0 9.127500533168131e-08
demonstrate O 0 4.438828682395979e-07
in O 0 6.722254966007313e-07
cultured O 0 2.788790880003944e-05
293 O 0 4.641557825380005e-05
cells O 0 4.5157579734222963e-05
overexpressing O 0 0.0002827561693266034
wild O 0 4.175793947069906e-06
- O 0 5.661453087668633e-06
type O 0 7.69106100051431e-06
or O 0 1.1362709528839332e-06
mutant O 0 2.608913382573519e-05
HFE O 0 0.0009253923199139535
proteins O 0 8.856756750219574e-08
that O 0 1.7943623475957793e-08
both O 0 2.6063887048621837e-08
the O 0 3.255157139392395e-07
wild O 0 1.5912526123429416e-06
- O 0 4.630872354027815e-06
type O 0 7.238169473566813e-06
and O 0 1.4297060033641174e-06
H63D O 1 0.9994572997093201
HFE O 1 0.9740351438522339
proteins O 0 6.894800321788352e-07
form O 0 8.183850468412857e-07
stable O 0 3.3693538625811925e-06
complexes O 0 1.9789988527918467e-06
with O 0 2.847512519110751e-07
the O 0 2.599766276034643e-06
transferrin O 0 0.0005493933567777276
receptor O 0 1.3828400369675364e-05
( O 0 5.2304553719295654e-06
TfR O 0 0.0038052715826779604
) O 0 7.4773106462089345e-06
. O 0 3.0450060876319185e-05

The O 0 8.884890121407807e-05
C282Y O 0 0.0015654251910746098
mutation O 0 5.4105523304315284e-05
nearly O 0 1.1930243999813683e-05
completely O 0 9.528256669000257e-06
prevents O 0 1.5433838598255534e-06
the O 0 6.722152079419175e-07
association O 0 1.3628515489472193e-06
of O 0 1.0283009714839864e-06
the O 0 3.3411445201636525e-06
mutant O 0 0.00012531386164482683
HFE O 0 0.09362607449293137
protein O 0 2.6244101718475576e-06
with O 0 1.061382022271573e-06
the O 0 2.160139410989359e-05
TfR O 1 0.9682875275611877
. O 0 8.187925413949415e-05

Studies O 0 1.1273466952843592e-05
on O 0 4.768034614244243e-06
cell O 0 2.2862526748212986e-05
- O 0 6.652639058302157e-06
associated O 0 2.5450126486248337e-06
transferrin O 0 1.3992177628097124e-05
at O 0 3.550260885276657e-07
37 O 0 4.5640055645890243e-07
degrees O 0 5.495698474078381e-07
C O 0 3.293287363703712e-06
suggest O 0 1.7550013353684335e-07
that O 0 3.544130677823887e-08
the O 0 5.314021223057352e-07
overexpressed O 0 3.83986443921458e-05
wild O 0 3.986053798143985e-06
- O 0 1.2823926226701587e-05
type O 0 2.5531086066621356e-05
HFE O 0 0.03934454545378685
protein O 0 9.140598535850586e-07
decreases O 0 4.1158068597724196e-07
the O 0 1.1822276491102457e-07
affinity O 0 5.125203870193218e-07
of O 0 5.879886089132924e-07
the O 0 5.211614734434988e-06
TfR O 0 0.028890404850244522
for O 0 1.2175129995739553e-05
transferrin O 0 0.004120464436709881
. O 0 9.119861351791769e-05

The O 0 0.0001070994621841237
overexpressed O 0 0.006690771784633398
H63D O 1 0.518473744392395
protein O 0 5.001371391699649e-06
does O 0 1.8688179181935993e-07
not O 0 2.8714056909961982e-08
have O 0 1.5655663432312394e-08
this O 0 2.3210946054064152e-08
effect O 0 1.153076212290216e-07
, O 0 4.189752900174426e-08
providing O 0 7.620263886565226e-08
the O 0 4.0060115225060144e-08
first O 0 7.489983744335404e-08
direct O 0 5.675897085666293e-08
evidence O 0 7.548656100198059e-08
for O 0 4.786618745811211e-08
a O 0 5.642790483761928e-07
functional O 0 2.1484511307789944e-06
consequence O 0 3.5786626995104598e-06
of O 0 2.0942657101841178e-06
the O 0 1.3670086445927154e-05
H63D O 1 0.9985085129737854
mutation O 0 0.00027075057732872665
. O 0 5.035173307987861e-05

Addition O 0 2.1266219846438617e-05
of O 0 4.382943734526634e-05
soluble O 0 0.001357648870907724
wild O 0 0.00018625523080118
- O 0 0.026525819674134254
type O 1 0.7221458554267883
HFE O 1 0.9999970197677612
/ O 0 0.49745792150497437
beta2m O 0 0.02391640469431877
heterodimers O 0 0.00010170079622184858
to O 0 5.777795877293102e-07
cultured O 0 9.8610044005909e-06
cells O 0 8.433718790001876e-07
also O 0 6.294939680628886e-08
decreased O 0 4.893013283435721e-07
the O 0 1.398896785076431e-07
apparent O 0 8.229784498325898e-07
affinity O 0 3.6819403703702847e-07
of O 0 1.4815819326940982e-07
the O 0 5.167559606888972e-07
TfR O 0 7.22314725862816e-05
for O 0 8.881895041668031e-08
its O 0 1.1103288954927848e-07
ligand O 0 1.0796325113915373e-06
under O 0 5.95293101923744e-07
steady O 0 2.9686966627195943e-06
- O 0 6.428334700103733e-07
state O 0 8.674457774304756e-08
conditions O 0 3.428570209962345e-07
, O 0 6.47029310130165e-08
both O 0 2.8964443288259645e-08
in O 0 1.45225229175594e-07
293 O 0 7.90978447184898e-06
cells O 0 2.3624238565389533e-06
and O 0 4.746004833577899e-07
in O 0 4.9594314077694435e-06
HeLa O 1 0.9252760410308838
cells O 0 9.581161430105567e-05
. O 0 2.230804784630891e-05

Furthermore O 0 1.3692137144971639e-05
, O 0 9.123459108195675e-07
at O 0 5.41689757938002e-07
4 O 0 6.125203526607947e-07
degrees O 0 7.792850738042034e-07
C O 0 7.3771216193563305e-06
, O 0 2.5698454919620417e-07
the O 0 3.7468163327503134e-07
added O 0 3.4290976600459544e-06
soluble O 0 1.2908025382785127e-05
complex O 0 4.453042492968962e-06
of O 0 9.081582902581431e-06
HFE O 1 0.9997822642326355
/ O 0 0.0008210618980228901
beta2m O 0 0.0003051158564630896
inhibited O 0 8.835309927235357e-06
binding O 0 4.1058567035179294e-07
of O 0 1.0252400670651696e-06
transferrin O 0 7.943093805806711e-05
to O 0 1.3849206652594148e-06
HeLa O 0 0.004681513644754887
cell O 0 2.9707087378483266e-05
TfR O 0 0.00012961514585185796
in O 0 5.458070972963469e-07
a O 0 4.1414491533942055e-06
concentration O 0 0.0001266982581000775
- O 0 4.0066748624667525e-05
dependent O 0 4.326157977629919e-06
manner O 0 1.1791860742960125e-05
. O 0 3.185876994393766e-05

Scatchard O 0 0.0002582638699095696
plots O 0 1.7545142327435315e-05
of O 0 1.7871149111670093e-06
these O 0 1.8377735955255048e-07
data O 0 1.250110983619379e-07
indicate O 0 1.422043283128005e-07
that O 0 3.638176693243622e-08
the O 0 1.945145129411685e-07
added O 0 1.0662273552952684e-06
heterodimer O 0 1.2855518434662372e-05
substantially O 0 9.06079492324352e-07
reduced O 0 5.689347517545684e-07
the O 0 3.052203396691766e-07
affinity O 0 2.4535254397051176e-06
of O 0 3.2303289572155336e-06
TfR O 0 0.018246939405798912
for O 0 1.1683973752951715e-05
transferrin O 0 0.011281370185315609
. O 0 7.856342563172802e-05

These O 0 2.207605803050683e-06
results O 0 1.2646590903386823e-06
establish O 0 1.6044749600041541e-06
a O 0 8.644263971291366e-07
molecular O 0 1.6585698858762044e-06
link O 0 1.4556983387592481e-06
between O 0 7.959437766658084e-07
HFE O 1 0.9083292484283447
and O 0 3.0280523333203746e-07
a O 0 4.7166355443550856e-07
key O 0 7.199872698038234e-07
protein O 0 2.528406923829607e-07
involved O 0 1.4132433534541633e-07
in O 0 2.492020030331332e-07
iron O 0 0.06982825696468353
transport O 0 2.3229340513353236e-06
, O 0 1.6904132849049347e-07
the O 0 3.4876708809861157e-07
TfR O 0 0.00018494937103241682
, O 0 1.2976555296972947e-07
and O 0 3.002682902319975e-08
raise O 0 4.5050764896359397e-08
the O 0 3.1965463165306574e-08
possibility O 0 1.048290982907929e-07
that O 0 1.8043598615236078e-08
alterations O 0 5.283318387228064e-07
in O 0 5.531011737502922e-08
this O 0 4.5578243401678264e-08
regulatory O 0 6.476676617239718e-07
mechanism O 0 3.780263853059296e-07
may O 0 7.162740445210147e-08
play O 0 4.128314756712825e-08
a O 0 1.2009950012270565e-07
role O 0 1.6018040582821413e-07
in O 0 1.810275733760136e-07
the O 0 2.11765927815577e-06
pathogenesis O 1 0.9999639987945557
of O 1 0.9304778575897217
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.04616465047001839
. O 0 0.0004760219599120319

Genomic O 0 9.375778608955443e-05
organization O 0 1.3947307706985157e-05
of O 0 1.115116447181208e-05
the O 0 6.096668585087173e-05
UBE3A O 1 0.9999961853027344
/ O 1 0.9974326491355896
E6 O 1 0.998636782169342
- O 0 0.0002540430286899209
AP O 0 6.163285434013233e-05
gene O 0 7.848079803807195e-06
and O 0 1.3715743989450857e-06
related O 0 1.0510681931918953e-05
pseudogenes O 0 0.0002081647253362462
. O 0 6.289070006459951e-05

The O 0 0.00013540568761527538
UBE3A O 0 0.00986829400062561
gene O 0 2.985434366564732e-05
encodes O 0 1.5125960089790169e-05
the O 0 1.2621935638890136e-05
E6 O 0 0.0928327813744545
- O 0 6.405798922060058e-05
AP O 0 7.110817387001589e-05
ubiquitin O 0 8.860640809871256e-05
- O 0 2.858802690752782e-05
protein O 0 5.70782049180707e-06
ligase O 0 8.217775757657364e-06
and O 0 2.1444235187573213e-07
has O 0 1.9655080052416452e-07
recently O 0 3.5101575690532627e-07
been O 0 7.489840925245517e-08
shown O 0 9.126716804530588e-08
to O 0 4.8604483993131e-08
be O 0 1.725632188254167e-07
mutated O 0 3.075048516620882e-05
in O 0 0.050625137984752655
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998407363891602
who O 0 0.004350369796156883
lack O 1 0.5270942449569702
15q11 O 1 0.9997772574424744
- O 0 0.4446972608566284
q13 O 1 0.783386766910553
deletions O 0 0.0001134755220846273
or O 0 3.7104296097822953e-06
chromosome O 0 8.278463792521507e-05
15 O 0 8.534568041795865e-05
paternal O 0 0.4378264546394348
uniparental B-Disease 1 0.9999884366989136
disomy I-Disease 1 0.9995361566543579
. O 0 0.0003408456686884165

Previous O 0 0.0001017529793898575
UBE3A O 0 0.008900949731469154
cDNA O 0 4.818859451916069e-05
analysis O 0 1.0055762231786503e-06
has O 0 2.3433857165855443e-07
shown O 0 2.7209065933675447e-07
a O 0 5.405302090366604e-07
coding O 0 1.2320656423980836e-06
region O 0 4.1343596990373044e-07
of O 0 5.269027951726457e-07
approximately O 0 1.8071656313622952e-06
2 O 0 1.3909636436437722e-05
. O 0 1.3611716894956771e-05

6 O 0 0.00010478260810486972
kb O 0 0.0001548856234876439
and O 0 2.121872284988058e-06
a O 0 3.2873001600819407e-06
3 O 0 5.1839251682395115e-06
- O 0 1.8916109183919616e-05
untranslated O 0 0.0001240404526470229
region O 0 1.8077826098306105e-06
( O 0 4.4739499571733177e-07
UTR O 0 3.590534470276907e-05
) O 0 1.021068172235573e-07
of O 0 1.8133617629700893e-07
< O 0 2.3957941266417038e-06
50 O 0 2.630401354508649e-07
bp O 0 7.998000342013256e-07
, O 0 8.252665395502845e-08
whereas O 0 9.891927987837335e-08
Northern O 0 9.817175339321693e-08
analysis O 0 6.025330634429338e-08
has O 0 6.119095274925712e-08
indicated O 0 9.74652039076318e-08
mRNA O 0 1.1316323167420705e-07
sizes O 0 3.005249382681541e-08
of O 0 1.37650260967348e-07
5 O 0 1.4179564686855883e-06
- O 0 1.7404388927388936e-05
8 O 0 2.7377249352866784e-05
kb O 0 0.000395067036151886
. O 0 4.3748052121372893e-05

We O 0 5.446088835014962e-06
have O 0 7.849777148294379e-07
analyzed O 0 1.3584332236860064e-06
additional O 0 1.3310400390764698e-06
cDNA O 0 1.722710112517234e-05
clones O 0 3.1605520689481637e-06
and O 0 1.0480751200248051e-07
provide O 0 7.80975639713688e-08
evidence O 0 9.772711706546033e-08
for O 0 5.248966417070733e-08
an O 0 2.696047829431336e-07
additional O 0 1.4153962411000975e-06
0 O 0 1.1674473171296995e-05
. O 0 1.6783009414211847e-05

5 O 0 3.030798507097643e-05
kb O 0 5.8793033531401306e-05
of O 0 4.5418410081765614e-06
5 O 0 6.6897050601255614e-06
- O 0 3.5688433854375035e-05
UTR O 0 0.000992737477645278
and O 0 7.06110654391523e-07
> O 0 3.83738188247662e-06
2 O 0 1.425819959877117e-06
kb O 0 1.398441418132279e-05
of O 0 2.4840715013851877e-06
3 O 0 2.5706794986035675e-05
- O 0 0.0014042844995856285
UTR O 1 0.9271594882011414
. O 0 6.856827531009912e-05

We O 0 3.2934190130617935e-06
have O 0 3.684223486288829e-07
established O 0 1.2385095260469825e-06
the O 0 6.972176720410062e-07
genomic O 0 3.8045786823204253e-06
organization O 0 1.0767174671855173e-06
of O 0 1.435869876331708e-06
UBE3A O 0 0.02514706179499626
and O 0 3.348917516632355e-07
the O 0 5.949117394266068e-07
sequence O 0 1.1383773426132393e-06
of O 0 6.65679590383661e-06
intron O 0 0.1301611214876175
- O 0 0.00425528222694993
exon O 0 0.002406297018751502
borders O 0 3.386228854651563e-05
. O 0 4.657266617869027e-05

We O 0 5.947539648332167e-06
have O 0 5.080850087324507e-07
also O 0 3.7254628182381566e-07
mapped O 0 9.64522996582673e-07
two O 0 2.0785616072771518e-07
highly O 0 1.4116541251496528e-06
homologous O 0 2.03179229174566e-06
processed O 0 1.6149413113453193e-06
pseudogenes O 0 5.3172220759734046e-06
, O 0 1.1206365115867811e-06
UBE3AP1 O 0 0.019147593528032303
and O 0 1.5668829291826114e-06
UBE3AP2 O 0 0.005773383192718029
, O 0 2.54595391879775e-07
to O 0 5.976777117666643e-08
chromosomes O 0 1.440435539734608e-07
2 O 0 1.2233809343342728e-07
and O 0 5.571808614490692e-08
21 O 0 3.688104754928645e-07
, O 0 1.6635394217701105e-07
respectively O 0 3.2633877822263457e-07
, O 0 1.5441051459674782e-07
and O 0 1.5815504639249411e-07
determined O 0 4.0746195395513496e-07
their O 0 2.977674569137889e-07
genomic O 0 1.1243211702094413e-05
organization O 0 1.654904190218076e-05
. O 0 2.5405613996554166e-05

These O 0 1.3238443443697179e-06
results O 0 3.7849065392947523e-07
will O 0 1.1467627558658933e-07
form O 0 9.878711182409461e-08
the O 0 7.619507869094377e-08
basis O 0 6.766146043446497e-08
for O 0 3.723657826526505e-08
studies O 0 8.555625186090765e-08
of O 0 4.0511625343242486e-07
mutation O 0 3.935056156478822e-06
and O 0 1.163021693173505e-06
imprinting O 0 0.0001576627983013168
of O 0 6.822779687354341e-05
UBE3A O 1 0.9997830986976624
. O 0 0.0001837102900026366

Mutation O 0 0.00020211671653669327
spectrum O 0 0.00012043859896948561
and O 0 1.2861429240729194e-05
genotype O 0 0.0006801241543143988
- O 0 0.0016456029843539
phenotype O 0 0.0004318869032431394
analyses O 0 7.794852535880636e-06
in O 0 1.9760680515901186e-05
Cowden B-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999946355819702
and O 0 0.000102747515484225
Bannayan B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.523917621350847e-05
two O 0 2.0586636310326867e-05
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 0.9999988079071045
with O 1 0.5095866918563843
germline O 1 1.0
PTEN O 1 0.9999997615814209
mutation O 0 0.0029161907732486725
. O 0 0.00011721930786734447

The O 0 0.0008812487940303981
tumour B-Disease 1 0.9999998807907104
suppressor O 1 0.9998425245285034
gene O 0 0.0008866577409207821
PTEN O 1 0.8967821598052979
, O 0 1.0783472816910944e-06
which O 0 2.468592867899133e-07
maps O 0 1.535606770630693e-06
to O 0 1.6273761502816342e-06
10q23 O 0 0.0004398538148961961
. O 0 4.490357605391182e-05

3 O 0 2.456816037010867e-05
and O 0 3.47490276908502e-06
encodes O 0 6.861570000182837e-06
a O 0 2.2415069906855933e-06
403 O 0 4.9584100452193525e-06
amino O 0 2.588149072835222e-06
acid O 0 4.098969384358497e-06
dual O 0 6.204440069268458e-06
specificity O 0 1.0322832167730667e-05
phosphatase O 0 0.00010303223825758323
( O 0 9.582372513250448e-07
protein O 0 1.9342546693223994e-06
tyrosine O 0 3.231475147913443e-06
phosphatase O 0 1.7728470993461087e-05
; O 0 1.039470660657571e-07
PTPase O 0 5.730248176405439e-06
) O 0 7.784667843679927e-08
, O 0 7.143407998455586e-08
was O 0 7.616179118485888e-07
shown O 0 1.4084749011544773e-07
recently O 0 1.7862838319615548e-07
to O 0 3.730959363679176e-08
play O 0 9.692758595747364e-08
a O 0 4.6100558392936364e-07
broad O 0 2.180929868700332e-06
role O 0 1.408210550835065e-06
in O 0 1.6471701655973447e-06
human O 0 2.0883519027847797e-05
malignancy B-Disease 1 0.9997631907463074
. O 0 0.0001311621890636161

Somatic O 1 0.7426236867904663
PTEN O 1 0.9952091574668884
deletions O 0 0.00010966376430587843
and O 0 2.4457274321321165e-06
mutations O 0 1.478455828873848e-06
were O 0 3.1514881015937135e-07
observed O 0 3.51239464180253e-07
in O 0 5.242192742116458e-07
sporadic B-Disease 0 0.0004118249053135514
breast I-Disease 1 0.9999620914459229
, I-Disease 0 0.0017288177041336894
brain I-Disease 1 0.9999743700027466
, I-Disease 0 0.009238125756382942
prostate I-Disease 1 1.0
and I-Disease 1 0.9998188614845276
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999896287918091
lines O 0 5.790256636828417e-06
and O 0 2.8310333277659083e-07
in O 0 2.8085841563552094e-07
several O 0 5.272305543257971e-07
primary O 0 9.446928015677258e-05
tumours B-Disease 1 0.9999924898147583
such O 0 2.680895249795867e-06
as O 0 0.000262058136286214
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.999997615814209
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999992847442627
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.8877739310264587

In O 0 1.3073935406282544e-05
addition O 0 2.2275733499554917e-05
, O 0 2.156668961106334e-05
PTEN O 1 0.5653185248374939
was O 0 8.841447197482921e-06
identified O 0 1.0179651326325256e-06
as O 0 3.6889841226184217e-07
the O 0 6.762267616977624e-07
susceptibility O 0 3.15573561238125e-05
gene O 0 1.3040511248618714e-06
for O 0 5.406926106843457e-07
two O 0 1.090686328097945e-05
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.00015893251111265272
CD B-Disease 0 0.1744881570339203
; O 0 2.9514314974221634e-06
MIM O 1 0.9972902536392212
158350 O 0 0.00018743712280411273
) O 0 7.066677767397778e-07
and O 0 7.651269129382854e-07
Bannayan B-Disease 0 0.002176135778427124
- I-Disease 0 0.008469250984489918
Zonana I-Disease 1 0.9793844223022461
( I-Disease 0 8.493889254168607e-06
BZS I-Disease 0 0.007525274995714426
) I-Disease 0 1.115271629714698e-06
or I-Disease 0 2.1591135919152293e-06
Ruvalcaba I-Disease 0 0.02983739599585533
- I-Disease 0 0.004791207145899534
Riley I-Disease 1 0.7697176933288574
- I-Disease 1 0.9993851184844971
Smith I-Disease 1 0.9922671914100647
syndrome I-Disease 1 1.0
( O 1 0.8391026258468628
MIM O 1 0.9999997615814209
153480 O 1 0.9974543452262878
) O 0 3.609963459894061e-05
. O 0 5.3793548431713134e-05

Constitutive O 0 0.0010600393870845437
DNA O 0 3.2286134228343144e-05
from O 0 2.7430864975031e-06
37 O 0 7.620787982887123e-06
CD B-Disease 0 2.761908581305761e-05
families O 0 6.4572122937534e-07
and O 0 5.158607905286772e-07
seven O 0 3.1958627459971467e-06
BZS B-Disease 0 0.002265942981466651
families O 0 9.697156428956077e-07
was O 0 7.396452019747812e-06
screened O 0 1.382813661621185e-05
for O 0 6.4820492298167665e-06
germline O 1 0.9763754606246948
PTEN O 1 0.9987238049507141
mutations O 0 0.00010245877638226375
. O 0 5.161597073310986e-05

PTEN O 0 0.018996285274624825
mutations O 0 1.622909985599108e-05
were O 0 1.2037347687510191e-06
identified O 0 7.805421660123102e-07
in O 0 1.5849160206471424e-07
30 O 0 1.2168672469670128e-07
of O 0 1.6220401732880418e-07
37 O 0 4.885366706730565e-07
( O 0 1.3604760340513167e-07
81 O 0 1.008303456728754e-06
% O 0 2.184329872534363e-07
) O 0 1.701963014966168e-07
CD B-Disease 0 1.7732818378135562e-06
families O 0 5.7643671169671507e-08
, O 0 1.0284858831255406e-07
including O 0 2.461981694068527e-07
missense O 0 5.899235929973656e-06
and O 0 3.881590089349629e-07
nonsense O 0 1.7011796444421634e-05
point O 0 1.7375994048052235e-06
mutations O 0 6.601734980904439e-07
, O 0 3.0772804393564e-07
deletions O 0 2.49421714215714e-06
, O 0 4.525841177382972e-07
insertions O 0 5.293392405292252e-06
, O 0 4.588178228459583e-07
a O 0 4.118828201171709e-06
deletion O 0 7.299216667888686e-05
/ O 0 0.0005236736033111811
insertion O 0 2.7645568479783833e-05
and O 0 2.9363384328462416e-06
splice O 0 6.409300112864003e-05
site O 0 1.3280501661938615e-05
mutations O 0 1.61566749738995e-05
. O 0 1.866678212536499e-05

These O 0 2.646002712936024e-06
mutations O 0 2.429077540000435e-06
were O 0 6.763177111679397e-07
scattered O 0 8.785718819126487e-07
over O 0 4.1254662619394367e-07
the O 0 3.561499113402533e-07
entire O 0 1.095698735298356e-06
length O 0 5.837980552314548e-07
of O 0 1.6108865565911401e-06
PTEN O 0 0.10387647897005081
, O 0 1.1195625404525344e-07
with O 0 3.1796719923704586e-08
the O 0 1.0296518127006493e-07
exception O 0 1.5385460017114383e-07
of O 0 7.623680176038761e-08
the O 0 1.376476319592257e-07
first O 0 3.4539255011623027e-07
, O 0 3.056543391721789e-07
fourth O 0 6.034064426785335e-06
and O 0 1.869544803412282e-06
last O 0 1.63823915499961e-05
exons O 0 0.00015475982218049467
. O 0 3.432239100220613e-05

A O 0 0.00010892972932197154
hot O 0 4.625120709533803e-05
spot O 0 1.2477075870265253e-05
for O 0 2.9968321086926153e-06
PTEN O 0 0.028280798345804214
mutation O 0 2.9314476250874577e-06
in O 0 4.674220974720811e-07
CD B-Disease 0 8.417066055699252e-06
was O 0 3.091864300586167e-06
identified O 0 3.2644553016325517e-07
in O 0 1.2065018495377444e-07
exon O 0 3.077783958360669e-06
5 O 0 1.7437933763631008e-07
that O 0 3.894990996400338e-08
contains O 0 1.0885438683772009e-07
the O 0 2.495211219866178e-07
PTPase O 0 2.2599904696107842e-05
core O 0 5.87146450925502e-06
motif O 0 2.997403953486355e-06
, O 0 6.297125310084084e-08
with O 0 1.692574258527202e-08
13 O 0 1.1047583825529728e-07
of O 0 9.508185172535377e-08
30 O 0 2.0158987013019214e-07
( O 0 9.236396181222517e-08
43 O 0 3.4025703143925057e-07
% O 0 2.352194172772215e-07
) O 0 1.7142814101589465e-07
CD B-Disease 0 4.206237917969702e-06
mutations O 0 6.490867576758319e-07
identified O 0 3.784859643474192e-07
in O 0 3.0689892582813627e-07
this O 0 1.588088707649149e-06
exon O 0 0.0003452508826740086
. O 0 4.376799915917218e-05

Seven O 0 2.42683836404467e-06
of O 0 1.1912720765394624e-06
30 O 0 7.796880368005077e-07
( O 0 2.271140147058759e-07
23 O 0 5.600384156423388e-07
% O 0 1.7305036692505382e-07
) O 0 3.844293416932487e-08
were O 0 3.1218014839851094e-08
within O 0 4.450832946645278e-08
the O 0 1.2103187430057005e-07
core O 0 2.44728357756685e-06
motif O 0 1.6051453712861985e-06
, O 0 3.4561388417841954e-08
the O 0 5.643070721816912e-08
majority O 0 6.026882459764238e-08
( O 0 2.526116560375158e-08
five O 0 3.291724937071194e-08
of O 0 9.199087713795961e-08
seven O 0 8.323137024035532e-08
) O 0 3.740535703400383e-08
of O 0 8.495280923170867e-08
which O 0 7.005228042089584e-08
were O 0 2.5785948309930973e-07
missense O 0 5.780347692052601e-06
mutations O 0 6.681171953459852e-07
, O 0 2.3766776280353952e-07
possibly O 0 3.1222128882291145e-07
pointing O 0 2.7120725576423865e-07
to O 0 2.1528611782173357e-08
the O 0 8.909704973802945e-08
functional O 0 4.0526424527342897e-07
significance O 0 5.441346502266242e-07
of O 0 7.442376386279648e-07
this O 0 1.164231321126863e-06
region O 0 2.136755756509956e-05
. O 0 2.931545168394223e-05

Germline O 1 0.9895380735397339
PTEN O 1 0.7613334655761719
mutations O 0 1.3666124687006231e-05
were O 0 1.022076958179241e-06
identified O 0 6.648318162660871e-07
in O 0 1.3689984257325705e-07
four O 0 8.056235856201965e-08
of O 0 2.636046474435716e-07
seven O 0 5.635003503812186e-07
( O 0 6.652103934357001e-07
57 O 0 2.6681777853809763e-06
% O 0 2.6091747713508084e-06
) O 0 2.543071559557575e-06
BZS B-Disease 0 0.0005389158613979816
families O 0 1.1334753935443587e-06
studied O 0 1.6840631360537373e-05
. O 0 2.781179136945866e-05

Interestingly O 0 0.00020155766105744988
, O 0 7.35851517674746e-06
none O 0 2.177845317419269e-06
of O 0 9.256179964722833e-07
these O 0 1.8814053248661367e-07
mutations O 0 7.226805109894485e-07
was O 0 2.7120154300064314e-06
observed O 0 4.898093379779311e-07
in O 0 3.678167672660493e-07
the O 0 4.2751948967634235e-06
PTPase O 0 0.057624343782663345
core O 0 0.0008100889972411096
motif O 0 0.0006590572302229702
. O 0 5.366786353988573e-05

It O 0 5.117514774610754e-06
is O 0 1.5160123894020217e-06
also O 0 5.510193545887887e-07
worthy O 0 1.6265461226794287e-06
of O 0 4.6419521027019073e-07
note O 0 5.938103413427598e-07
that O 0 7.004145885503021e-08
a O 0 3.7675661701541685e-07
single O 0 7.346171742028673e-07
nonsense O 0 1.0856491826416459e-05
point O 0 8.059599281295959e-07
mutation O 0 8.258772936642345e-07
, O 0 1.8444140437168244e-07
R233X O 0 4.2043166104122065e-06
, O 0 1.299292620160486e-07
was O 0 4.755002294132282e-07
observed O 0 9.773270903679077e-08
in O 0 6.3369107294875e-08
the O 0 4.899004011349462e-07
germline O 0 5.688246892532334e-05
DNA O 0 7.991870347723307e-07
from O 0 1.1142218880877408e-07
two O 0 1.504747046965349e-07
unrelated O 0 3.483463160591782e-06
CD B-Disease 0 2.286477138113696e-05
families O 0 4.4210682403900137e-07
and O 0 1.2354789760138374e-06
one O 0 1.2251303814991843e-05
BZS B-Disease 1 0.9979479908943176
family O 0 2.6647634513210505e-05
. O 0 3.110820398433134e-05

Genotype O 0 0.0023275986313819885
- O 0 0.0002602718013804406
phenotype O 0 9.749425225891173e-05
studies O 0 8.601026593169081e-07
were O 0 1.928569162146232e-07
not O 0 4.852491741758058e-08
performed O 0 2.1314318132681365e-07
on O 0 8.939561269016849e-08
this O 0 1.4600706776946026e-07
small O 0 4.341167141319602e-07
group O 0 2.4805347038636683e-06
of O 0 1.0943976121779997e-05
BZS B-Disease 1 0.9096322655677795
families O 0 1.147796956502134e-05
. O 0 2.862071050913073e-05

However O 0 1.94058520719409e-05
, O 0 1.1706391887855716e-05
genotype O 0 8.69958967086859e-05
- O 0 3.796852979576215e-05
phenotype O 0 5.561293801292777e-05
analysis O 0 1.271297833227436e-06
inthe O 0 2.686116386030335e-05
group O 0 9.721592277855962e-07
of O 0 1.1507980843816767e-06
CD B-Disease 0 2.1097548597026616e-05
families O 0 1.2306266228279128e-07
revealed O 0 4.919224352306628e-07
two O 0 2.192000536638261e-08
possible O 0 1.125961333059422e-07
associations O 0 1.7134904339854984e-07
worthy O 0 9.230942055182823e-07
of O 0 4.481482847040752e-07
follow O 0 2.2718246839303902e-07
- O 0 1.5204574310700991e-06
up O 0 3.73056820990314e-07
in O 0 3.4925270142593945e-07
independent O 0 8.88560350631451e-07
analyses O 0 7.309194188565016e-06
. O 0 1.7812732039601542e-05

The O 0 1.1590308531594928e-05
first O 0 9.952666005119681e-06
was O 0 2.2792017261963338e-05
an O 0 1.4576543208022485e-06
association O 0 2.389273049629992e-06
noted O 0 6.509167178592179e-07
in O 0 1.2022934470223845e-07
the O 0 2.9041763127679587e-07
group O 0 7.063867997203488e-07
of O 0 1.1887798336829292e-06
CD B-Disease 0 0.00019939651247113943
families O 0 8.978801702141936e-07
with O 0 2.9916500352555886e-05
breast B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999998807907104
. O 0 0.01898489147424698

A O 0 2.361113547522109e-05
correlation O 0 3.840848876279779e-06
was O 0 3.994256985606626e-06
observed O 0 3.0902378966857214e-07
between O 0 9.827704872122922e-08
the O 0 2.663428517735156e-07
presence O 0 1.044175746756082e-06
/ O 0 7.097663456079317e-06
absence O 0 1.7125033764386899e-06
of O 0 1.2432193443601136e-06
a O 0 2.1014217054471374e-05
PTEN O 1 0.9951424598693848
mutation O 0 9.52555353705975e-07
and O 0 8.235337389805863e-08
the O 0 1.8543755686550867e-07
type O 0 3.522038468872779e-06
of O 0 4.986749900126597e-06
breast O 1 0.9945664405822754
involvement O 0 0.008099455386400223
( O 0 7.58690875954926e-05
unaffected O 1 0.6966114044189453
versus O 1 0.9398382306098938
benign O 1 0.9999783039093018
versus O 1 0.9978095889091492
malignant O 1 0.9999994039535522
) O 0 6.470008520409465e-05
. O 0 6.482088065240532e-05

Specifically O 0 1.014907866192516e-05
and O 0 1.5798289041413227e-06
more O 0 1.96750917780264e-07
directly O 0 1.7569774968251295e-07
, O 0 2.874184588108619e-07
an O 0 2.8639729521273694e-07
association O 0 2.5610163447709056e-06
was O 0 2.841289187927032e-06
also O 0 5.49659020521176e-08
observed O 0 3.5723839886259157e-08
between O 0 3.738082554605171e-08
the O 0 1.5159648114604352e-07
presence O 0 3.7841738276256365e-07
of O 0 1.0301669135515112e-06
a O 0 2.73905443464173e-05
PTEN O 1 0.9999736547470093
mutation O 0 0.0018057756824418902
and O 0 0.0005795636679977179
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.6869473457336426

Secondly O 0 0.00017752530402503908
, O 0 3.404768449399853e-06
there O 0 6.101603275965317e-07
appeared O 0 1.2875242418886046e-06
to O 0 1.4944416193429788e-07
be O 0 1.0393399207941911e-07
an O 0 2.872554034638597e-07
interdependent O 0 4.726694896817207e-06
association O 0 1.0062218507300713e-06
between O 0 3.349134658492403e-07
mutations O 0 7.918333722045645e-07
upstream O 0 4.028447335713281e-07
and O 0 5.0704812792901066e-08
within O 0 1.1018921952654637e-07
the O 0 3.233406289382401e-07
PTPase O 0 0.00014772306894883513
core O 0 1.4611945516662672e-05
motif O 0 5.738516847486608e-06
, O 0 1.960165576520012e-07
the O 0 3.4359021583441063e-07
core O 0 3.6129508771409746e-06
motif O 0 3.0344835977302864e-06
containing O 0 1.4977517537317908e-07
the O 0 1.0744427925146738e-07
majority O 0 1.1651226827780192e-07
of O 0 4.1480873846921895e-07
missense O 0 1.1820030522358138e-05
mutations O 0 5.442166184366215e-07
, O 0 8.04903237394683e-08
and O 0 4.6396063879683425e-08
the O 0 9.872079687056612e-08
involvement O 0 5.199175916459353e-07
of O 0 1.9026137465516513e-07
all O 0 9.662689137712732e-08
major O 0 5.618311661237385e-06
organ O 1 0.9755707383155823
systems O 0 0.00020678808505181223
( O 0 4.453289420780493e-06
central O 0 3.5693297832040116e-05
nervous O 0 0.00910876877605915
system O 0 7.774414370942395e-06
, O 0 2.225335265393369e-05
thyroid O 1 1.0
, O 0 0.00942896492779255
breast O 1 0.9999998807907104
, O 1 0.9843370318412781
skin O 1 1.0
and O 1 0.9999510049819946
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 0.004917430691421032
. O 0 0.0002480110269971192

However O 0 1.0056970495497808e-05
, O 0 6.218510861799587e-07
these O 0 5.945759795622507e-08
observations O 0 1.3335591120267054e-07
would O 0 4.2192397131657344e-08
need O 0 3.6497560529369366e-08
to O 0 1.602261612276834e-08
be O 0 1.5254604690539963e-08
confirmed O 0 5.309938444497675e-08
by O 0 3.321530783750859e-08
studying O 0 2.3305862839606561e-07
a O 0 2.908186615968589e-07
larger O 0 1.8405869184334733e-07
number O 0 2.1363116786687897e-07
of O 0 1.7143498780569644e-06
CD B-Disease 0 9.749416494742036e-05
families O 0 7.264995474542957e-06
. O 0 2.2071737475926057e-05

Molecular O 0 0.014558800496160984
defects O 0 0.2859773337841034
leading O 0 2.0709705495391972e-05
to O 0 1.3599355952464975e-06
human O 0 4.11828978030826e-06
complement B-Disease 0 0.00018080124573316425
component I-Disease 1 0.9999799728393555
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.114771061518695e-06
an O 0 2.7805206173070474e-06
African O 0 3.165827365592122e-05
- O 0 0.00011575101234484464
American O 0 6.178184412419796e-05
family O 0 4.0263239498017356e-05
. O 0 6.69990258757025e-05

Complement B-Disease 0 0.0023245876654982567
component I-Disease 1 0.9999725818634033
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.0013842579210177064
C6D B-Disease 1 0.999984622001648
) O 0 3.6107330743107013e-06
was O 0 6.344524445012212e-05
diagnosed O 0 0.0022559661883860826
in O 0 2.2507339281219174e-07
a O 0 7.15929786565539e-07
16 O 0 6.426324148378626e-07
- O 0 5.612619588646339e-06
year O 0 1.9759813767450396e-06
- O 0 2.2546862965100445e-05
old O 0 4.680133133661002e-05
African O 0 1.2708656868198887e-05
- O 0 3.4830238291760907e-05
American O 0 1.7277301594731398e-05
male O 0 2.754961133177858e-05
with O 0 0.00036011525662615895
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.13065670430660248

The O 0 8.091861673165113e-05
patients O 0 5.3201507398625836e-05
father O 0 2.576643782958854e-05
and O 0 1.8330597413296346e-06
two O 0 1.1334440159771475e-06
brothers O 0 7.797468424541876e-05
also O 0 3.305221525806701e-06
had O 0 7.962185918586329e-06
C6D B-Disease 1 0.6415814161300659
, O 0 9.556107443131623e-07
but O 0 1.699995380022301e-07
gave O 0 5.822400908073178e-07
no O 0 3.81697560669636e-07
history O 0 1.7134950667241355e-06
of O 0 0.00013635125651489943
meningitis B-Disease 1 0.9999998807907104
or O 0 9.164863513433374e-06
other O 0 6.67705899104476e-06
neisserial B-Disease 1 0.9999715089797974
infection I-Disease 1 0.9999563694000244
. O 0 0.0004082251980435103

By O 0 1.6842270269989967e-05
using O 0 7.688349796808325e-06
exon O 0 7.244053995236754e-05
- O 0 6.41731185169192e-06
specific O 0 1.0688102065614657e-06
polymerase O 0 1.2847380276070908e-05
chain O 0 4.759625426231651e-06
reaction O 0 9.813521728574415e-07
( O 0 4.019705102109583e-07
PCR O 0 2.9700418053835165e-06
) O 0 1.5886355697602994e-07
/ O 0 1.2691451729551773e-06
single O 0 3.4197927334389533e-07
- O 0 1.8389076785751968e-06
strand O 0 2.0032816792081576e-06
conformation O 0 4.874272008237313e-07
polymorphism O 0 4.798447434950504e-07
as O 0 1.1165599289597594e-07
a O 0 2.88997227926302e-07
screening O 0 4.370469639525254e-07
step O 0 2.6766900873553823e-07
and O 0 8.448081700862531e-08
nucleotide O 0 6.714860774081899e-07
sequencing O 0 4.987778083886951e-07
of O 0 2.180941152118976e-07
target O 0 5.016400450585934e-07
exons O 0 1.1253854381720885e-06
, O 0 4.184569490917056e-08
we O 0 1.514108838307493e-08
determined O 0 5.3750820683262646e-08
that O 0 1.9778800819381104e-08
the O 0 2.2035159474853572e-07
proband O 0 2.8006403226754628e-05
was O 0 5.718510692531709e-06
a O 0 4.233970685163513e-06
compound O 0 1.645144948270172e-05
heterozygote O 0 1.5913839888526127e-05
for O 0 6.379646606546885e-07
two O 0 3.0745748063054634e-06
C6 O 1 0.9997363686561584
gene O 0 6.386463792296126e-05
mutations O 0 2.9469787477864884e-05
. O 0 3.1648134608985856e-05

The O 0 8.293838618556038e-06
first O 0 4.9178120207216125e-06
, O 0 1.5572564961985336e-06
1195delC O 0 2.2502226784126833e-05
located O 0 2.009385525525431e-06
in O 0 3.0645290394204494e-07
exon O 0 8.932247510529123e-06
7 O 0 9.785383099369938e-07
, O 0 1.502022968224992e-07
is O 0 5.313909667847838e-08
a O 0 1.2579900499076757e-07
novel O 0 7.907527788120206e-07
mutation O 0 3.216589163912431e-07
, O 0 6.293702625725928e-08
while O 0 3.6677256787243095e-08
the O 0 1.0951934825698117e-07
second O 0 4.46036011680917e-07
, O 0 1.4259734371080413e-07
1936delG O 0 2.523572447898914e-06
in O 0 2.125757987414545e-07
exon O 0 5.2108689487795345e-06
12 O 0 1.9797866457338387e-07
, O 0 1.0472338374256651e-07
has O 0 4.428900268749203e-08
been O 0 4.313294610369667e-08
described O 0 1.1093298013520325e-07
before O 0 1.4726677477483463e-07
to O 0 1.517674519391221e-07
cause O 0 1.1826684385596309e-05
C6D B-Disease 0 0.11888234317302704
in O 0 5.852853632859478e-07
an O 0 8.532010156159231e-07
unrelated O 0 1.0521121112105902e-05
African O 0 1.3769721590506379e-05
- O 0 3.6341454688226804e-05
American O 0 2.1147343431948684e-05
individual O 0 7.903419827925973e-06
. O 0 5.3659776312997565e-05

Both O 0 2.3759988835081458e-05
mutations O 0 2.6962718038703315e-05
result O 0 1.36974522320088e-05
in O 0 7.328696028707782e-06
premature O 0 0.00020303300698287785
termination O 0 0.00035859725903719664
codons O 0 6.121433398220688e-05
and O 0 1.2924519069201779e-05
C6 O 1 0.9972520470619202
null O 0 0.00015536868886556476
alleles O 0 3.1237788789439946e-05
. O 0 4.927816553390585e-05

Allele O 0 0.00012982827320229262
- O 0 1.4058868146094028e-05
specific O 0 9.231637818629679e-07
PCR O 0 5.752873221354093e-06
indicated O 0 8.955651651376684e-07
that O 0 7.332894114142618e-08
the O 0 4.067692884746066e-07
probands O 0 2.80486074188957e-05
two O 0 3.2985698794618656e-07
brothers O 0 2.1219946575001813e-05
also O 0 1.4543356883223169e-06
inherited O 0 2.9019720386713743e-05
the O 0 2.1201649360591546e-06
1195delC O 0 8.119604171952233e-05
mutation O 0 2.178132035624003e-06
from O 0 2.1482880185885733e-07
their O 0 1.8028690362825728e-07
heterozygous O 0 1.3712958661926677e-06
mother O 0 1.3615214129458764e-06
and O 0 1.9398248696234077e-07
the O 0 1.0526172218305874e-06
1936delG O 0 4.250689744367264e-05
mutation O 0 2.232201723018079e-06
from O 0 3.49963869439307e-07
their O 0 4.5594765651912894e-07
homozygous O 0 1.4542187273036689e-05
father O 0 2.044845859927591e-05
. O 0 6.447702162404312e-06
. O 0 3.536420990712941e-05

PAX6 O 1 0.9051607251167297
mutations O 0 0.0011364222737029195
reviewed O 0 0.0005149244097992778
. O 0 0.0006245166878215969

Mutations O 0 0.00011898987577296793
in O 0 1.631286068004556e-05
PAX6 O 1 0.5126203894615173
are O 0 5.486325562742422e-07
responsible O 0 1.3539749943447532e-06
for O 0 4.149369488004595e-07
human O 0 2.9780710519844433e-06
aniridia B-Disease 1 0.9998360872268677
and O 0 8.948719596446608e-07
have O 0 1.6789147139206761e-07
also O 0 2.0277181533856492e-07
been O 0 2.170620234664966e-07
found O 0 1.5261916530562303e-07
in O 0 2.8579268018802395e-07
patients O 0 1.9121869172522565e-06
with O 0 3.676530468510464e-06
Peters B-Disease 1 0.9999991655349731
anomaly I-Disease 1 1.0
, O 0 0.004140031058341265
with O 1 0.9972720742225647
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.975779116153717
with O 0 0.03775188699364662
autosomal B-Disease 1 0.9999982118606567
dominant I-Disease 1 0.9999997615814209
keratitis I-Disease 1 1.0
, O 0 6.380814738804474e-05
and O 0 5.674885869666468e-06
with O 0 5.2263032557675615e-05
isolated B-Disease 1 0.9994194507598877
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.015741445124149323

No O 0 3.0278952181106433e-05
locus O 0 3.095431748079136e-05
other O 0 6.782619266232359e-07
than O 0 9.25042684229993e-07
chromosome O 0 3.8228237826842815e-05
11p13 O 0 0.0032997503876686096
has O 0 1.2804906646124437e-06
been O 0 6.701234838146775e-07
implicated O 0 3.45427542924881e-06
in O 0 1.703224484117527e-06
aniridia B-Disease 1 0.9999808073043823
, O 0 4.033628101751674e-06
and O 0 1.5264054127328563e-06
PAX6 O 1 0.9919924736022949
is O 0 4.611172528257157e-07
clearly O 0 1.1405557387433873e-07
the O 0 1.045577278091514e-07
major O 0 5.707362333851052e-07
, O 0 1.3052589054041164e-07
if O 0 3.211102139744071e-08
not O 0 3.629187261822153e-08
only O 0 1.0467844901995704e-07
, O 0 5.340501161299471e-07
gene O 0 3.0146586595947156e-06
responsible O 0 9.657447662902996e-06
. O 0 2.5837254725047387e-05

Twenty O 0 3.195305907865986e-05
- O 0 9.965468052541837e-06
eight O 0 1.4573929547623266e-06
percent O 0 1.0279205753249698e-06
of O 0 1.8205611240773578e-06
identified O 0 5.056765530753182e-06
PAX6 O 0 0.008446256630122662
mutations O 0 1.3701678653887939e-06
are O 0 1.1432063473648668e-07
C O 0 2.7221181881031953e-05
- O 0 1.8067474229610525e-05
T O 0 2.7115836928714998e-05
changes O 0 1.8184219641170785e-07
at O 0 6.601973723263654e-07
CpG O 0 1.0130125701834913e-05
dinucleotides O 0 9.23302741284715e-06
, O 0 1.0221360469131469e-07
20 O 0 8.537188023183262e-08
% O 0 7.753119746212178e-08
are O 0 9.562195479873026e-09
splicing O 0 3.699144031088508e-07
errors O 0 3.6522911273095815e-07
, O 0 5.62532882497635e-08
and O 0 1.3829652090180389e-08
more O 0 7.710894145418479e-09
than O 0 1.8200314144678487e-08
30 O 0 1.4270972314989194e-07
% O 0 1.871555639354483e-07
are O 0 5.60766366675125e-08
deletion O 0 3.677494532894343e-06
or O 0 6.768597700101964e-07
insertion O 0 1.7836680854088627e-05
events O 0 7.955734872666653e-06
. O 0 3.085847129113972e-05

There O 0 7.749179530947004e-06
is O 0 2.7397138637752505e-06
a O 0 4.556673957267776e-06
noticeably O 0 1.5520405213464983e-05
elevated O 0 1.994984268094413e-05
level O 0 8.593450502303313e-07
of O 0 5.224584924690134e-07
mutation O 0 8.642136890557595e-07
in O 0 1.4824766481069673e-07
the O 0 2.9113112987033674e-07
paired O 0 8.507553275194368e-07
domain O 0 4.936749178341415e-07
compared O 0 1.8466035101027956e-07
with O 0 9.109707832521963e-08
the O 0 3.39971592211441e-07
rest O 0 8.852515520629822e-07
of O 0 1.317375904363871e-06
the O 0 6.3513675740978215e-06
gene O 0 4.4833494030172005e-05
. O 0 3.235052281524986e-05

Increased O 0 2.4713666789466515e-05
mutation O 0 1.3218234926171135e-05
in O 0 1.3240248790680198e-06
the O 0 2.401031906629214e-06
homeodomain O 0 0.00011276017175987363
is O 0 3.0512137527693994e-07
accounted O 0 5.242393399385037e-07
for O 0 8.197052636660374e-08
by O 0 6.143221753518446e-07
the O 0 4.476699359656777e-06
hypermutable O 0 0.04604736715555191
CpG O 0 0.0011001176899299026
dinucleotide O 0 0.0002801081573124975
in O 0 2.8827787446061848e-06
codon O 0 3.550139444996603e-05
240 O 0 3.703601396409795e-05
. O 0 3.8570182368857786e-05

Very O 0 1.1558121514099184e-05
nearly O 0 3.115228537353687e-06
all O 0 3.385641491604474e-07
mutations O 0 1.332946681031899e-06
appear O 0 3.5074072002316825e-07
to O 0 1.2775981872437114e-07
cause O 0 3.585050535548362e-06
loss O 0 4.983535745850531e-06
of O 0 4.0938064671536267e-07
function O 0 2.3715018926395715e-07
of O 0 2.292111531687624e-07
the O 0 5.643651661557669e-07
mutant O 0 7.121027920220513e-06
allele O 0 6.388030442394665e-07
, O 0 3.6361853972266545e-08
and O 0 1.8347469321611243e-08
more O 0 8.527680783743108e-09
than O 0 1.847779707020436e-08
80 O 0 1.8038700488887116e-07
% O 0 2.5982538431890134e-07
of O 0 8.512423050888174e-07
exonic O 0 9.305838466389105e-05
substitutions O 0 5.507953119376907e-06
result O 0 2.582687784524751e-06
in O 0 4.582489964377601e-06
nonsense O 0 0.0001883772056316957
codons O 0 5.0730366638163105e-05
. O 0 2.2810108930571005e-05

In O 0 8.172009074769448e-06
a O 0 5.1914594223489985e-06
gene O 0 2.2963877199799754e-06
with O 0 3.2004453487388673e-07
such O 0 6.933591976121534e-07
extraordinarily O 0 1.0476554962224327e-05
high O 0 1.1864964335472905e-06
sequence O 0 4.759916123475705e-07
conservation O 0 4.547360958895297e-07
throughout O 0 1.0422720464475788e-07
evolution O 0 3.0136246209622186e-07
, O 0 1.1252142684270439e-07
there O 0 7.467061635679784e-08
are O 0 7.52770787926238e-08
presumed O 0 8.517916285200045e-06
undiscovered O 0 8.163647726178169e-05
missense O 0 3.1799369025975466e-05
mutations O 0 1.44879834351741e-06
, O 0 2.1306716746494203e-07
these O 0 4.108394335844423e-08
are O 0 2.5309150331054298e-08
hypothesized O 0 6.562802923326672e-07
to O 0 2.6831093791201965e-08
exist O 0 6.292454912681933e-08
in O 0 1.1864948845641266e-07
as O 0 6.1036399756631e-07
- O 0 9.297990800405387e-06
yet O 0 2.861872872017557e-06
unidentified O 0 1.0980190381815191e-05
phenotypes O 0 1.629546022741124e-05
. O 0 4.563158199744066e-06
. O 0 2.7256610337644815e-05

Genetic O 0 0.0002537847321946174
heterogeneity O 0 0.0003412748337723315
and O 0 7.296664989553392e-06
penetrance O 0 7.281210855580866e-05
analysis O 0 9.782582992556854e-07
of O 0 2.5630656637076754e-06
the O 0 6.869957360322587e-06
BRCA1 O 0 0.0029901734087616205
and O 0 4.655642896977952e-06
BRCA2 O 0 0.00018530733359511942
genes O 0 2.5574577193765435e-06
in O 0 1.3219696484156884e-05
breast B-Disease 1 0.9999974966049194
cancer I-Disease 1 0.9999966621398926
families O 0 7.65648583183065e-05
. O 0 0.00025847175857052207

The O 0 0.006830388680100441
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9995983242988586
Consortium O 0 0.10455943644046783
. O 0 0.00034766035969369113

The O 0 1.4141160136205144e-05
contribution O 0 2.6483041438041255e-05
of O 0 2.0990903067286126e-05
BRCA1 O 0 0.015029487200081348
and O 0 8.953978976933286e-06
BRCA2 O 0 0.10168217867612839
to O 0 1.3174136256566271e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9893878698348999
assessed O 0 5.834819148731185e-06
by O 0 8.162772928699269e-07
linkage O 0 2.3866108676884323e-05
and O 0 2.155065885744989e-07
mutation O 0 2.909457066380128e-07
analysis O 0 5.9141918029581575e-08
in O 0 6.37944026493642e-08
237 O 0 4.823125436814735e-07
families O 0 4.544560283648025e-08
, O 0 3.4318279773515314e-08
each O 0 7.147411995589437e-09
with O 0 3.674853843449455e-08
at O 0 2.1966424412767083e-07
least O 0 5.5228628781378575e-08
four O 0 4.631092309637097e-08
cases O 0 1.270613836368284e-07
of O 0 2.3219916329253465e-05
breast B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.9999676942825317
, O 0 1.6583375099799014e-06
collected O 0 3.8956042658355727e-07
by O 0 9.693845868241624e-07
the O 0 0.0003914812405128032
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.999901294708252
Consortium O 0 0.0038098616059869528
. O 0 0.00011945884034503251

Families O 0 8.402189450862352e-06
were O 0 2.6104316930286586e-06
included O 0 2.091431497319718e-06
without O 0 7.488368396479927e-07
regard O 0 8.647314757581626e-07
to O 0 1.429036586841903e-07
the O 0 4.492368645969691e-07
occurrence O 0 7.828060915926471e-06
of O 0 0.0001748076465446502
ovarian B-Disease 1 1.0
or I-Disease 0 4.126458225073293e-05
other I-Disease 0 1.3054922419541981e-05
cancers I-Disease 1 0.999834418296814
. O 0 0.00043295451905578375

Overall O 0 0.00033590555540286005
, O 0 0.00013389947707764804
disease O 1 0.9964654445648193
was O 0 0.00016583039541728795
linked O 0 5.493191565619782e-06
to O 0 3.0359981906258326e-07
BRCA1 O 0 3.2974608075164724e-06
in O 0 6.065966573487458e-08
an O 0 5.861455676381411e-08
estimated O 0 1.4283143912052765e-07
52 O 0 2.0037236936332192e-07
% O 0 6.310579436785702e-08
of O 0 1.2352192868547718e-07
families O 0 5.5106781360336754e-08
, O 0 5.963237725836734e-08
to O 0 7.62740413051688e-08
BRCA2 O 0 9.811762993194861e-07
in O 0 4.3922721459921377e-08
32 O 0 1.2694003714841529e-07
% O 0 5.980620443324369e-08
of O 0 1.2910933833154559e-07
families O 0 6.599607615953573e-08
, O 0 3.9196738299551726e-08
and O 0 2.761330186729083e-08
to O 0 3.256236880133656e-08
neither O 0 1.1579512460002661e-07
gene O 0 5.127882829469854e-08
in O 0 1.8423635950171047e-08
16 O 0 6.947956165959113e-08
% O 0 5.767281407997871e-08
( O 0 3.25341247275901e-08
95 O 0 1.4015942895184708e-07
% O 0 1.135948721753266e-07
confidence O 0 8.36176866414462e-07
interval O 0 2.1265598206809955e-06
[ O 0 3.1264191875379765e-06
CI O 0 0.00010305375326424837
] O 0 6.677528290310875e-07
6 O 0 2.658120195064839e-07
% O 0 1.2888544631550758e-07
- O 0 3.4137221405217133e-07
28 O 0 4.3713947661672137e-07
% O 0 2.7109555844617717e-07
) O 0 1.8878073149153352e-07
, O 0 3.147523273128172e-07
suggesting O 0 1.3794582400805666e-06
other O 0 5.807649472444609e-07
predisposition O 0 0.00015157763846218586
genes O 0 1.4520638615067583e-05
. O 0 3.774643482756801e-05

The O 0 1.1795527825597674e-05
majority O 0 5.262988906906685e-06
( O 0 1.3587455214292277e-06
81 O 0 3.3187304779858096e-06
% O 0 5.080830760562094e-07
) O 0 1.3648308083702432e-07
of O 0 5.613784423985635e-07
the O 0 3.136809027637355e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3402467402556795e-06
were O 0 5.044128670306236e-07
due O 0 1.7070166222765693e-06
to O 0 2.443283904085547e-07
BRCA1 O 0 3.133729478577152e-05
, O 0 9.229879793792861e-08
with O 0 3.8794727430513376e-08
most O 0 4.84984532533872e-08
others O 0 7.869688545270037e-08
( O 0 5.981065243076955e-08
14 O 0 2.8649239425249107e-07
% O 0 1.9201930001599976e-07
) O 0 2.051064740271613e-07
due O 0 1.6949800283327932e-06
to O 0 2.3440168206434464e-06
BRCA2 O 0 0.00034674181370064616
. O 0 3.7012287066318095e-05

Conversely O 0 6.180164200486615e-05
, O 0 2.0798931927856756e-06
the O 0 8.343495778717624e-07
majority O 0 8.028001730053802e-07
of O 0 6.736000841556233e-07
families O 0 2.1492388668775675e-07
with O 0 5.124050517224532e-07
male B-Disease 0 8.785426871327218e-06
and I-Disease 0 6.452758498198818e-06
female I-Disease 0 0.16414774954319
breast I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
were O 0 2.686753532543662e-06
due O 0 8.691334187460598e-06
to O 0 5.813589609715564e-07
BRCA2 O 0 1.8236305550090037e-05
( O 0 5.504059572558617e-07
76 O 0 1.1513105164340232e-05
% O 0 3.996425220975652e-06
) O 0 5.2801929086854216e-06
. O 0 2.4136881620506756e-05

The O 0 1.3623522136185784e-05
largest O 0 1.1437462489993777e-05
proportion O 0 3.600946001824923e-06
( O 0 8.328104854626872e-07
67 O 0 3.097920853178948e-06
% O 0 3.9896255543681036e-07
) O 0 8.234631110326518e-08
of O 0 2.2247752440307522e-07
families O 0 7.154289249911017e-08
due O 0 2.726683874243463e-07
to O 0 3.86017831033314e-08
other O 0 1.734421850585477e-08
genes O 0 6.644635419661427e-08
was O 0 9.652222843214986e-07
found O 0 8.676477136759786e-08
in O 0 4.787303353737116e-08
families O 0 2.409384691759442e-08
with O 0 3.7636798566609286e-08
four O 0 1.295303917459023e-07
or O 0 1.0641311831705025e-07
five O 0 8.067660672850252e-08
cases O 0 1.1774523045460228e-07
of O 0 1.114363840315491e-05
female O 0 0.47353264689445496
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999990463256836
only O 0 6.580568879144266e-05
. O 0 0.00020477949874475598

These O 0 1.6851770396897336e-06
estimates O 0 1.425254367859452e-06
were O 0 4.88558100641967e-07
not O 0 1.3960899991616316e-07
substantially O 0 9.151955282504787e-07
affected O 0 1.4751248045286047e-07
either O 0 8.611912249989473e-08
by O 0 4.7927208868259186e-08
changing O 0 1.1971732760684972e-07
the O 0 2.4325100866917637e-07
assumed O 0 2.4673247480677674e-06
penetrance O 0 9.830057024373673e-06
model O 0 3.6811084669352567e-07
for O 0 1.1379199804650852e-07
BRCA1 O 0 4.109361270820955e-06
or O 0 6.745476355263236e-08
by O 0 1.1743549066522974e-07
including O 0 3.644212256403989e-07
or O 0 1.2456689546525013e-06
excluding O 0 1.0849764294107445e-05
BRCA1 O 0 0.000145052166772075
mutation O 0 1.6459656762890518e-05
data O 0 6.3320139815914445e-06
. O 0 2.115460483764764e-05

Among O 0 8.731351954338606e-06
those O 0 1.1639848480626824e-06
families O 0 1.1667010539895273e-06
with O 0 4.932156116410624e-06
disease O 1 0.9999748468399048
due O 0 9.781579865375534e-05
to O 0 8.043643333621731e-07
BRCA1 O 0 1.8439532141201198e-05
that O 0 5.165460237321895e-08
were O 0 6.520393469600094e-08
tested O 0 6.056451695712894e-08
by O 0 3.39661703208094e-08
one O 0 3.523169311847596e-08
of O 0 1.6322506724009145e-07
the O 0 2.6217958293273114e-07
standard O 0 8.19203307855787e-07
screening O 0 5.37571224867861e-07
methods O 0 9.947932966269946e-08
, O 0 4.853981749874947e-08
mutations O 0 9.05037325082958e-08
were O 0 5.531581592777002e-08
detected O 0 1.7494652126970323e-07
in O 0 3.2805616001496674e-08
the O 0 1.5883234993907536e-07
coding O 0 6.146890427771723e-07
sequence O 0 1.5228069116801635e-07
or O 0 4.033605449649258e-08
splice O 0 1.9843649567974353e-07
sites O 0 1.5675652775826165e-08
in O 0 1.2252486136787866e-08
an O 0 1.6931229751548926e-08
estimated O 0 1.2056668197146791e-07
63 O 0 1.7135752727881481e-07
% O 0 6.554284226467644e-08
( O 0 6.21868281314164e-08
95 O 0 4.788591354554228e-07
% O 0 4.4014137756676064e-07
CI O 0 8.629235526314005e-05
51 O 0 1.1928863159482717e-06
% O 0 4.527110490926134e-07
- O 0 3.2085515613289317e-06
77 O 0 5.694325864169514e-06
% O 0 2.722287263168255e-06
) O 0 3.8050795865274267e-06
. O 0 1.3902475075155962e-05

The O 0 1.0724117601057515e-05
estimated O 0 7.918432856968138e-06
sensitivity O 0 1.579385389050003e-05
was O 0 6.615224720007973e-06
identical O 0 5.989284659335681e-07
for O 0 1.740042279152476e-07
direct O 0 3.866988436129759e-07
sequencing O 0 1.6114274785650196e-06
and O 0 4.3547512973418634e-07
other O 0 3.53313623691065e-07
techniques O 0 1.2138078091084026e-05
. O 0 2.0074310668860562e-05

The O 0 4.183084092801437e-05
penetrance O 0 0.00043875834671780467
of O 0 1.680713103269227e-05
BRCA2 O 0 9.228727139998227e-05
was O 0 8.418527613685e-06
estimated O 0 1.0956213145618676e-06
by O 0 2.7480771791488223e-07
maximizing O 0 2.058795189441298e-06
the O 0 7.225723379633564e-07
LOD O 0 0.00012736240751110017
score O 0 1.0559472229942912e-06
in O 0 1.2934489177496289e-06
BRCA2 O 0 3.8475842302432284e-05
- O 0 6.788885002606548e-06
mutation O 0 2.436675913486397e-06
families O 0 1.2907266011552565e-07
, O 0 1.1012996026238397e-07
over O 0 2.037895967532677e-07
all O 0 1.3162001266664447e-07
possible O 0 1.351980131403252e-06
penetrance O 0 9.229034913005307e-05
functions O 0 1.3045962987234816e-05
. O 0 3.926410499843769e-05

The O 0 9.565066648065113e-06
estimated O 0 7.120878308342071e-06
cumulative O 0 1.1971820640610531e-05
risk O 0 3.1387426133733243e-06
of O 0 4.400248144520447e-06
breast B-Disease 1 0.9779343008995056
cancer I-Disease 0 0.3085412383079529
reached O 0 2.460137466187007e-06
28 O 0 7.917367383925011e-07
% O 0 1.820879163005884e-07
( O 0 9.24379790490093e-08
95 O 0 4.41122153915785e-07
% O 0 3.5406111464908463e-07
CI O 0 2.5872932383208536e-05
9 O 0 3.9870388945928426e-07
% O 0 1.2272957405912166e-07
- O 0 1.6940961700129264e-07
44 O 0 1.3987580871344107e-07
% O 0 4.4914262531392524e-08
) O 0 1.3506300078347522e-08
by O 0 2.2058198823060593e-08
age O 0 7.370262267158978e-08
50 O 0 5.969838667851946e-08
years O 0 6.169734945160599e-08
and O 0 3.482209720573337e-08
84 O 0 3.5203487414037227e-07
% O 0 1.3897536632612173e-07
( O 0 6.96621498263994e-08
95 O 0 3.295331225672271e-07
% O 0 3.5961272715212544e-07
CI O 0 2.8863310944871046e-05
43 O 0 3.616714820964262e-07
% O 0 1.4180427854171285e-07
- O 0 3.16836377578511e-07
95 O 0 3.1862413152339286e-07
% O 0 1.7125363171999197e-07
) O 0 6.752672732091014e-08
by O 0 1.2459382503493543e-07
age O 0 1.7117522475018632e-06
70 O 0 4.953990810463438e-06
years O 0 7.370511411863845e-06
. O 0 3.594322697608732e-05

The O 0 0.00019162359239999205
corresponding O 1 0.9379174709320068
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.025018038228154182
were O 0 2.982272781082429e-05
0 O 0 9.012693772092462e-05
. O 0 8.810685540083796e-05

4 O 0 6.976718395890202e-06
% O 0 2.578658722995897e-06
( O 0 6.578932811862614e-07
95 O 0 1.3693814935322735e-06
% O 0 5.366404707274341e-07
CI O 0 2.681542537175119e-05
0 O 0 2.4685130028956337e-07
% O 0 5.4571245300394366e-08
- O 0 1.04462841932218e-07
1 O 0 1.0181413756527036e-07
% O 0 4.6156866773117144e-08
) O 0 1.0543825368358739e-08
by O 0 1.1619597728440567e-08
age O 0 5.8512352296702375e-08
50 O 0 3.906314205437411e-08
years O 0 2.2356003270829206e-08
and O 0 1.1560750579064916e-08
27 O 0 8.488882485835347e-08
% O 0 4.9752170383499106e-08
( O 0 3.3426054812935035e-08
95 O 0 2.6272121544934635e-07
% O 0 2.1478619771642116e-07
CI O 0 1.8459624698152766e-05
0 O 0 2.7361184606888855e-07
% O 0 7.311372485219181e-08
- O 0 2.07877576485771e-07
47 O 0 2.949136899133009e-07
% O 0 1.2356268541680038e-07
) O 0 5.0860560207866e-08
by O 0 1.553472657178645e-07
age O 0 2.0567736100929324e-06
70 O 0 4.894245194009272e-06
years O 0 8.2508822742966e-06
. O 0 2.506662167434115e-05

The O 0 1.5397012248286046e-05
lifetime O 0 6.361863779602572e-05
risk O 0 4.8341120418626815e-05
of O 0 0.003973411861807108
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999995231628418
appears O 0 1.9751165382331237e-05
similar O 0 2.4095737671814277e-07
to O 0 6.526067153345139e-08
the O 0 2.8102212468184007e-07
risk O 0 1.3648819958689273e-06
in O 0 7.870542049204232e-07
BRCA1 O 0 9.98940085992217e-05
carriers O 0 8.649302003504999e-07
, O 0 7.394016421358174e-08
but O 0 3.6732142660866884e-08
there O 0 6.100601268599348e-08
was O 0 6.844205131528724e-07
some O 0 5.883790876737294e-08
suggestion O 0 4.4855235614704725e-07
of O 0 3.344040919728286e-07
a O 0 1.4890399597788928e-06
lower O 0 2.523902139728307e-06
risk O 0 1.5664795682823751e-06
in O 0 5.115144858791609e-07
BRCA2 O 0 2.094295086862985e-05
carriers O 0 1.8335946379011148e-06
< O 0 6.0288994063739665e-06
50 O 0 4.440852592324518e-07
years O 0 5.148065724824846e-07
of O 0 3.092869974352652e-06
age O 0 4.804570562555455e-05
. O 0 5.7054294302361086e-05

Eye B-Disease 1 0.9214518070220947
movement I-Disease 0 0.003856341354548931
abnormalities I-Disease 0 0.253353089094162
correlate O 0 1.8244081729790196e-05
with O 0 5.2410809985303786e-06
genotype O 0 0.0007249244372360408
in O 0 4.5730354031547904e-05
autosomal O 1 0.9994879961013794
dominant O 1 0.9999982118606567
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.999998927116394
I I-Disease 1 0.9996827840805054
. O 0 0.0002613358083181083

We O 0 1.4066390576772392e-05
compared O 0 2.443120138195809e-05
horizontal O 0 8.94759432412684e-05
eye O 0 0.00011364023521309718
movements O 0 5.834735475218622e-06
( O 0 1.9757967493205797e-06
visually O 0 4.058059403178049e-06
guided O 0 8.299076398543548e-06
saccades O 0 0.0002734412846621126
, O 0 7.725197974650655e-07
antisaccades O 0 1.5814441212569363e-05
, O 0 1.7321414702564653e-07
and O 0 1.0133444305893136e-07
smooth O 0 1.5032769624667708e-06
pursuit O 0 1.9579288164095487e-06
) O 0 6.373043248686372e-08
in O 0 5.069552955205836e-08
control O 0 1.8017912850609719e-07
subjects O 0 9.145327339865617e-08
( O 0 4.8383423489894994e-08
n O 0 3.0397063710552175e-07
= O 0 2.0923242516346363e-07
14 O 0 1.6605309838269022e-07
) O 0 7.857719452886158e-08
and O 0 7.889767061897146e-08
patients O 0 9.385571075881671e-08
with O 0 5.65019000475786e-08
three O 0 1.3429780665319413e-07
forms O 0 1.0312531912859413e-06
of O 0 8.049113603192382e-06
autosomal O 0 0.2391347438097
dominant O 1 0.9855889678001404
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.9999986886978149
type I-Disease 1 0.9990027546882629
I I-Disease 1 0.750074565410614
spinocerebellar B-Disease 1 0.9999048709869385
ataxias I-Disease 0 0.00012347189476713538
1 I-Disease 0 9.678216201791656e-07
and I-Disease 0 9.99226017484034e-08
2 I-Disease 0 3.081944157656835e-07
( O 0 1.2050232101046277e-07
SCA1 B-Disease 0 9.556959412293509e-06
, O 0 8.56145305760947e-08
n O 0 1.705368504190119e-07
= O 0 1.3502491924555216e-07
11 O 0 7.938811563690251e-08
; O 0 3.857352126601654e-08
SCA2 B-Disease 0 5.33624142917688e-06
, O 0 8.295226905374875e-08
n O 0 2.4308263846251066e-07
= O 0 1.743477469062782e-07
10 O 0 6.350510517449948e-08
) O 0 1.2562922790948505e-07
and O 0 5.355250323191285e-07
SCA3 B-Disease 1 0.9999192953109741
/ O 0 0.0019069077679887414
Machado B-Disease 0 5.4510001064045355e-05
- I-Disease 0 7.26871658116579e-05
Joseph I-Disease 0 0.009172585792839527
disease I-Disease 1 0.9947651624679565
( O 0 5.132994374434929e-06
MJD B-Disease 1 0.9999638795852661
) O 0 4.603711829531676e-07
( O 0 1.729530225702547e-07
n O 0 1.024354560286156e-06
= O 0 1.165922412837972e-06
16 O 0 1.63823267484986e-06
) O 0 1.7511556507088244e-06
. O 0 1.1443299626989756e-05

In O 0 5.093026993563399e-05
SCA1 B-Disease 0 0.005962487310171127
, O 0 1.2181842976133339e-05
saccade O 0 0.00011087454913649708
amplitude O 0 1.78667287400458e-05
was O 0 5.164473805052694e-06
significantly O 0 9.291096603192273e-07
increased O 0 5.00450198614999e-07
, O 0 4.041777401653235e-07
resulting O 0 4.572750185616314e-06
in O 0 4.244652245688485e-06
hypermetria B-Disease 0 0.0023236314300447702
. O 0 5.7179411669494584e-05

The O 0 3.823866427410394e-05
smooth O 0 9.303283877670765e-05
pursuit O 0 0.00017776463937480003
gain O 0 5.237549703451805e-05
was O 0 0.00015633674047421664
decreased O 0 0.00031237330404110253
. O 0 7.639841351192445e-05

In O 0 8.27688563731499e-05
SCA2 B-Disease 0 0.026618173345923424
, O 0 3.4979697375092655e-05
saccade O 0 0.00046161265345290303
velocity O 0 3.348030804772861e-05
was O 0 5.3627903980668634e-05
markedly O 0 8.159134449670091e-05
decreased O 0 0.0001523222163086757
. O 0 5.660092938342132e-05

The O 0 4.313988029025495e-06
percentage O 0 2.019933617702918e-06
of O 0 1.5183505865934421e-06
errors O 0 4.74274247608264e-06
in O 0 1.8194573385699186e-06
antisaccades O 0 0.09273161739110947
was O 0 4.8807956773089245e-05
greatly O 0 1.4220231605577283e-06
increased O 0 3.598618150135735e-07
and O 0 1.0234997205316176e-07
was O 0 1.1626158311628387e-06
significantly O 0 3.420079508487106e-07
correlated O 0 2.3031509499560343e-07
with O 0 1.778095111149014e-07
age O 0 3.505636777845211e-05
at O 0 0.04418326914310455
disease O 1 0.999998927116394
onset O 1 0.9999991655349731
. O 0 0.0019817347638309

In O 0 5.375935870688409e-06
addition O 0 2.014231768043828e-06
, O 0 4.1512376469654555e-07
a O 0 3.6307113759903586e-07
correlation O 0 3.7537870412052143e-07
between O 0 2.146047961559816e-07
smooth O 0 6.108418801886728e-06
pursuit O 0 4.2108172237931285e-06
gain O 0 8.858359024088713e-07
and O 0 9.247624888075734e-08
the O 0 1.6124069190937007e-07
number O 0 2.6896586291513813e-07
of O 0 3.951143298763782e-06
trinucleotide O 1 0.7067772746086121
repeats O 0 2.3068065274856053e-05
was O 0 6.040832886355929e-05
found O 0 1.0652075616235379e-05
. O 0 3.2184660085476935e-05

In O 0 0.0002849675074685365
SCA3 B-Disease 1 0.9999905824661255
, O 0 0.00010142797691514716
gaze B-Disease 0 0.000710649648681283
- I-Disease 0 0.028515035286545753
evoked I-Disease 1 0.7499144077301025
nystagmus I-Disease 1 0.9839683771133423
was O 0 3.5260487493360415e-05
often O 0 2.0421137492121488e-07
present O 0 1.9400727069296408e-07
as O 0 4.195554197394813e-07
was O 0 7.745618859189562e-06
saccade O 0 5.488760143634863e-05
hypometria O 0 4.1595310904085636e-05
and O 0 4.7505059797003923e-07
smooth O 0 4.629503564501647e-06
pursuit O 0 9.279582627641503e-06
gain O 0 4.856834038946545e-06
was O 0 2.987453444802668e-05
markedly O 0 4.892100696451962e-05
decreased O 0 0.00013317748380359262
. O 0 5.13481063535437e-05

Three O 0 5.5605296438443474e-06
major O 0 1.1139005437144078e-05
criteria O 0 5.014959697291488e-06
, O 0 2.3339900963037508e-06
saccade O 0 5.42688176210504e-05
amplitude O 0 9.751438483363017e-06
, O 0 6.596649768653151e-07
saccade O 0 1.1732824532373343e-05
velocity O 0 1.090480054699583e-06
, O 0 1.7980767097469652e-07
and O 0 1.1999554772046395e-07
presence O 0 5.89276396567584e-07
of O 0 1.7105495544456062e-06
gaze B-Disease 0 5.3882162319496274e-05
- I-Disease 0 9.940312884282321e-05
evoked I-Disease 0 0.00021531472157221287
nystagmus I-Disease 0 8.803025411907583e-05
, O 0 1.8461228989963274e-07
permitted O 0 9.205881212892564e-08
the O 0 8.694053832414284e-08
correct O 0 1.1616921113954959e-07
assignment O 0 2.225261255262012e-07
of O 0 8.394322037474922e-08
90 O 0 2.0336906914053543e-07
% O 0 9.16796238925599e-08
of O 0 1.3802068110635446e-07
the O 0 3.6351943322188163e-07
SCA1 B-Disease 0 0.00017141521675512195
, O 0 1.579869604029227e-07
90 O 0 1.501544488746731e-07
% O 0 8.20163492676329e-08
of O 0 1.0163912378402529e-07
the O 0 5.379665708460379e-07
SCA2 B-Disease 0 0.010027391836047173
, O 0 1.6142101344485127e-07
and O 0 6.490589044005901e-08
93 O 0 6.708038426950225e-07
% O 0 8.694501474337812e-08
of O 0 2.2418994660711178e-07
the O 0 6.078997216718562e-07
patients O 0 1.093955006581382e-06
with O 0 1.1407888678149902e-06
SCA3 B-Disease 1 0.999998927116394
to O 0 2.537813941216882e-07
their O 0 2.457548191614478e-07
genetically O 0 3.7925228753010742e-06
confirmed O 0 1.0178855518461205e-06
patient O 0 2.866311433535884e-06
group O 0 1.7581352267370676e-06
and O 0 3.4294990314265306e-07
, O 0 3.5946391108154785e-07
therefore O 0 3.021175416506594e-07
, O 0 2.2026546275810688e-07
may O 0 2.387345432453003e-07
help O 0 2.575483790678845e-07
orient O 0 1.2026082913507707e-05
diagnoses O 0 1.055689062923193e-05
of O 0 5.754431640525581e-06
SCA1 B-Disease 1 0.999941349029541
, O 0 7.928270861157216e-06
SCA2 B-Disease 1 0.9831058382987976
, O 0 1.170043788079056e-06
and O 0 6.964925773900177e-07
SCA3 B-Disease 1 0.999972939491272
at O 0 1.5088136251506512e-06
early O 0 1.2143206049586297e-06
clinical O 0 3.2324830954166828e-06
stages O 0 3.4721135762083577e-06
of O 0 2.5708652628964046e-06
the O 0 2.4968756406451575e-05
diseases O 1 0.9999579191207886
. O 0 1.7122310964623466e-05
. O 0 4.942339364788495e-05

Genetic O 0 4.4764019548892975e-05
basis O 0 4.414072009240044e-06
and O 0 3.5488292269292288e-06
molecular O 0 5.105855962028727e-05
mechanism O 0 7.020049815764651e-05
for O 0 0.00035922310780733824
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9206528067588806

Ventricular B-Disease 1 0.9999998807907104
fibrillation I-Disease 1 0.9999996423721313
causes O 0 0.001247608452104032
more O 0 7.014038487795915e-07
than O 0 3.6079097753827227e-07
300 O 0 9.973806527341367e-07
, O 0 6.807218255744374e-07
000 O 0 3.6426595215743873e-06
sudden O 0 7.799001650710125e-06
deaths O 0 4.013867282992578e-07
each O 0 2.4500078410483184e-08
year O 0 1.8554759151356848e-07
in O 0 2.6971486022375757e-07
the O 0 3.5327761906955857e-06
USA O 0 8.758797775954008e-05
alone O 0 1.345461259916192e-05
. O 0 1.9495981177897193e-05

In O 0 4.217963123664958e-06
approximately O 0 1.5036367813081597e-06
5 O 0 1.084535256268282e-06
- O 0 1.5617659983035992e-06
12 O 0 4.615246496086911e-07
% O 0 1.4392834657428466e-07
of O 0 9.124332223109377e-08
these O 0 1.9352675906247896e-08
cases O 0 3.3418913858440646e-08
, O 0 5.277728121200198e-08
there O 0 3.877534382468184e-08
are O 0 1.8194899809031995e-08
no O 0 4.476126491681498e-07
demonstrable O 1 0.9996381998062134
cardiac O 1 0.9999997615814209
or O 0 1.2042184607707895e-05
non O 0 0.18592576682567596
- O 1 0.999963641166687
cardiac O 1 1.0
causes O 0 0.0008491832995787263
to O 0 1.2986434683170955e-07
account O 0 7.380264577250273e-08
for O 0 4.9118547451598715e-08
the O 0 1.8462232276306167e-07
episode O 0 1.228653445650707e-06
, O 0 7.245168376357469e-08
which O 0 2.6681719944576798e-08
is O 0 8.449934796317393e-08
therefore O 0 1.8017844638507086e-07
classified O 0 1.2049625865984126e-06
as O 0 4.000516128144227e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9995125532150269
IVF B-Disease 1 0.9999998807907104
) O 0 6.262438546400517e-05
. O 0 5.754031735705212e-05

A O 0 6.478992872871459e-05
distinct O 0 8.009472367120907e-06
group O 0 1.1545815141289495e-05
of O 0 0.0015030738431960344
IVF B-Disease 1 1.0
patients O 0 0.013699157163500786
has O 0 8.804826165942359e-07
been O 0 2.741080891155434e-07
found O 0 7.183071204508451e-08
to O 0 3.837414297436226e-08
present O 0 1.7671912644345866e-07
with O 0 3.411212787796103e-07
a O 0 1.0758946700661909e-05
characteristic O 0 0.00047011920833028853
electrocardiographic O 1 0.9489848017692566
pattern O 0 0.00112285022623837
. O 0 6.982660852372646e-05

Because O 0 4.048330538353184e-06
of O 0 2.3703446458966937e-06
the O 0 1.829999519031844e-06
small O 0 4.2679982925619697e-07
size O 0 2.4723792080294515e-07
of O 0 1.6520850465440162e-07
most O 0 1.189025340408989e-07
pedigrees O 0 9.751538527780212e-07
and O 0 1.0389573645852579e-07
the O 0 3.114011519755877e-07
high O 0 1.7955902649191557e-06
incidence O 0 0.0003769579343497753
of O 0 3.763346512641874e-06
sudden B-Disease 0 0.10779470950365067
death I-Disease 0 5.943034193478525e-05
, O 0 4.930439558847866e-07
however O 0 2.534229679440614e-07
, O 0 1.372785902731266e-07
molecular O 0 6.73926535910141e-07
genetic O 0 5.386124257711344e-07
studies O 0 2.087628416802545e-07
of O 0 3.051541398235713e-06
IVF B-Disease 1 0.999826967716217
have O 0 1.5311876211399067e-07
not O 0 5.452078966072804e-08
yet O 0 2.4326305947397486e-07
been O 0 8.230639991779753e-07
done O 0 3.998861302534351e-06
. O 0 1.7176251276396215e-05

Because O 0 0.0003523826599121094
IVF B-Disease 1 0.9999983310699463
causes O 1 0.9998376369476318
cardiac O 1 1.0
rhythm O 1 0.9999998807907104
disturbance O 1 0.9999011754989624
, O 0 1.1811520153059973e-06
we O 0 1.296512550652551e-07
investigated O 0 3.434952020597848e-07
whether O 0 1.3809020060762123e-07
malfunction O 0 3.802383071160875e-05
of O 0 7.360575295933813e-07
ion O 0 3.6898745747748762e-06
channels O 0 2.959296239168907e-07
could O 0 1.282913046907197e-07
cause O 0 1.580579350957123e-06
the O 0 8.453640134575835e-07
disorder O 0 0.006253354717046022
by O 0 3.0399240813494544e-07
studying O 0 8.85307201770047e-07
mutations O 0 4.2913521269838384e-07
in O 0 3.469305909220566e-07
the O 0 4.489080765779363e-06
cardiac O 1 0.9998899698257446
sodium O 0 0.0004000611661467701
channel O 0 4.675395757658407e-05
gene O 0 4.144100967096165e-05
SCN5A O 0 0.02673659287393093
. O 0 6.583350477740169e-05

We O 0 4.154709131398704e-06
have O 0 6.725365437887376e-07
now O 0 5.832627039126237e-07
identified O 0 7.610240118083311e-07
a O 0 1.5743902395115583e-06
missense O 0 1.4965002264943905e-05
mutation O 0 3.0276933102868497e-06
, O 0 5.66443816296669e-07
a O 0 2.4287253381771734e-06
splice O 0 2.8147993361926638e-05
- O 0 2.419811971776653e-05
donor O 0 3.841556008410407e-06
mutation O 0 2.614290679048281e-06
, O 0 2.8815398422921135e-07
and O 0 2.0917255483254849e-07
a O 0 1.437854166397301e-06
frameshift O 0 3.3040600101230666e-05
mutation O 0 7.326630111492705e-07
in O 0 1.165436103178763e-07
the O 0 3.489460596028948e-07
coding O 0 2.4666896933922544e-06
region O 0 9.499970019533066e-07
of O 0 2.103709903167328e-06
SCN5A O 0 0.04647241160273552
in O 0 1.8858886505768169e-06
three O 0 3.119211896773777e-06
IVF B-Disease 1 0.9828242063522339
families O 0 1.4578945410903543e-05
. O 0 4.5485750888474286e-05

We O 0 2.1219773316261126e-06
show O 0 1.4145622344585718e-06
that O 0 3.216555342078209e-07
sodium O 0 9.891887202684302e-07
channels O 0 1.3829763645389903e-07
with O 0 8.749549351705355e-08
the O 0 6.845295388302475e-07
missense O 0 1.4138193364487961e-05
mutation O 0 2.997738420162932e-06
recover O 0 1.3117445405441686e-06
from O 0 1.652461634193969e-07
inactivation O 0 3.0996267014415935e-05
more O 0 4.67797534042802e-08
rapidly O 0 2.826161562552443e-07
than O 0 2.0359799179914262e-08
normal O 0 6.019484288799504e-08
and O 0 2.260840226142591e-08
that O 0 3.3855048542363875e-08
the O 0 2.952806710254663e-07
frameshift O 0 2.1616871890728362e-05
mutation O 0 7.665058205930109e-07
causes O 0 4.37459789282002e-07
the O 0 2.1409415751350025e-07
sodium O 0 6.539212336065248e-07
channel O 0 2.056152794693844e-07
to O 0 2.632428142135268e-08
be O 0 8.221886815817925e-08
non O 0 1.4653759308203007e-06
- O 0 2.106654574163258e-05
functional O 0 4.109387373318896e-05
. O 0 2.4724604372750036e-05

Our O 0 5.626226084132213e-06
results O 0 1.2477329391913372e-06
indicate O 0 7.330306175390433e-07
that O 0 2.018249318780363e-07
mutations O 0 4.109927260742552e-07
in O 0 4.99224199757009e-07
cardiac O 1 0.9602559804916382
ion O 0 2.06445183721371e-05
- O 0 6.136632691777777e-06
channel O 0 9.126888471655548e-07
genes O 0 6.749041148168544e-08
contribute O 0 5.20734388942401e-08
to O 0 2.1595607080371337e-08
the O 0 1.393190558474089e-07
risk O 0 7.003277460171375e-07
of O 0 1.4276214415076538e-06
developing O 0 1.6226778825512156e-05
IVF B-Disease 1 0.9987127780914307
. O 0 1.1436437489464879e-05
. O 0 2.8941283744643442e-05

Molecular O 0 9.621318167774007e-05
heterogeneity O 0 0.00022987199190538377
in O 0 1.4699566236231476e-05
mucopolysaccharidosis B-Disease 1 0.9686285257339478
IVA I-Disease 1 0.9999991655349731
in O 0 2.7069713723903988e-06
Australia O 0 1.654276275075972e-06
and O 0 1.4648237822711963e-07
Northern O 0 7.257131642290915e-07
Ireland O 0 4.910075404040981e-07
: O 0 1.271120595447428e-07
nine O 0 3.0653126259494456e-07
novel O 0 1.1548429483809741e-06
mutations O 0 6.537261469929945e-07
including O 0 5.421580340225773e-07
T312S O 0 0.00015299195365514606
, O 0 7.298442028513819e-07
a O 0 1.562107058816764e-06
common O 0 1.175223701466166e-06
allele O 0 2.988221922350931e-06
that O 0 7.423280408147548e-07
confers O 0 4.640593033400364e-05
a O 0 6.306648720055819e-05
mild O 1 0.9749999642372131
phenotype O 1 0.8870521187782288
. O 0 0.0001224869629368186

Mucopolysaccharidosis B-Disease 1 0.9991182684898376
IVA I-Disease 1 0.9999996423721313
( O 0 0.12830519676208496
MPS B-Disease 1 0.9999377727508545
IVA I-Disease 1 1.0
) O 0 5.5189102567965165e-06
is O 0 1.4699430721520912e-06
an O 0 2.822459919116227e-06
autosomal B-Disease 1 0.9880918264389038
recessive I-Disease 1 0.9999996423721313
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9227506518363953
by O 0 3.808619339906727e-06
a O 0 0.00011104180885013193
genetic B-Disease 1 0.9942556023597717
defect I-Disease 1 0.9995664954185486
in O 0 1.7337872577627422e-06
N O 0 6.112794653745368e-05
- O 0 2.51468281931011e-05
acetylgalactosamine O 0 0.0035576033405959606
- O 0 0.0001260467106476426
6 O 0 0.00014308225945569575
- O 1 0.6580125689506531
sulfate O 1 0.996329128742218
sulfatase O 1 0.9991600513458252
( O 0 2.5482850105618127e-05
GALNS O 1 0.9396824240684509
) O 0 1.4353962797031272e-05
. O 0 2.617897916934453e-05

Previous O 0 9.89044474408729e-06
studies O 0 4.004677521152189e-06
of O 0 4.498324869928183e-06
patients O 0 2.877694669223274e-06
from O 0 4.7266408387258707e-07
a O 0 3.4364338716841303e-06
British O 0 3.2936939533101395e-05
- O 0 1.1733440260286443e-05
Irish O 0 7.242043011501664e-06
population O 0 1.4327483199849667e-07
showed O 0 2.040700479710722e-07
that O 0 3.911503654308035e-08
the O 0 2.6369994543529174e-07
I113F O 0 3.3932043152162805e-05
mutation O 0 9.323192102783651e-07
is O 0 8.93453346861861e-08
the O 0 9.472416451217214e-08
most O 0 9.145257706677512e-08
common O 0 2.4697280309737835e-07
single O 0 7.840156399652187e-07
mutation O 0 7.802171239745803e-06
among O 0 9.367707207275089e-06
MPS B-Disease 1 0.9999980926513672
IVA I-Disease 1 1.0
patients O 0 0.009050276130437851
and O 0 3.0622404665336944e-06
produces O 0 1.3864186257706024e-05
a O 0 2.424186641292181e-05
severe O 1 0.9998695850372314
clinical O 1 0.9975022673606873
phenotype O 1 0.9977661371231079
. O 0 0.00015233892190735787

We O 0 5.6101630434568506e-06
studied O 0 6.593494617845863e-06
mutations O 0 2.5262474991905037e-06
in O 0 8.074809443314734e-07
the O 0 2.705087354115676e-06
GALNS O 0 0.006723765749484301
gene O 0 1.370851464344014e-06
from O 0 1.6467102170736325e-07
23 O 0 1.0967002026518458e-06
additional O 0 2.461184067215072e-06
MPS B-Disease 1 0.8456414341926575
IVA I-Disease 1 1.0
patients O 0 2.351091325181187e-06
( O 0 1.4145729210213176e-07
15 O 0 1.1198785898614005e-07
from O 0 7.031010085256639e-08
Australia O 0 1.5559071186999063e-07
, O 0 3.764721157040185e-08
8 O 0 1.0010572992769085e-07
from O 0 4.79787054530334e-08
Northern O 0 4.37969049471576e-07
Ireland O 0 3.990074617377104e-07
) O 0 5.3746411765587254e-08
, O 0 3.5692032440692856e-08
with O 0 3.172693041619823e-08
various O 0 9.53088061805829e-08
clinical O 0 1.9099752535112202e-05
phenotypes O 0 0.00016011056140996516
( O 0 3.29756471728615e-06
severe O 0 0.18852505087852478
, O 0 4.2183228288195096e-07
16 O 0 4.0133693346433574e-07
cases O 0 8.072154855653935e-08
; O 0 6.85140264522488e-08
intermediate O 0 1.7434455230613821e-06
, O 0 1.2034450946885045e-07
4 O 0 3.0711763088220323e-07
cases O 0 1.1420904399983556e-07
; O 0 2.029817522952726e-07
mild O 0 1.1657440154522192e-05
, O 0 6.880644605189445e-07
3 O 0 1.3078497431706637e-06
cases O 0 1.5515018958467408e-06
) O 0 4.671075657824986e-06
. O 0 2.1499869035324082e-05

We O 0 6.106776254455326e-06
found O 0 1.7147407334050513e-06
two O 0 2.6495555971450813e-07
common O 0 5.159591864867252e-07
mutations O 0 4.660964521008282e-07
that O 0 4.5955960814580976e-08
together O 0 4.221735494525092e-08
accounted O 0 1.300046221786033e-07
for O 0 3.7646277206704326e-08
32 O 0 1.7999538215462962e-07
% O 0 1.108394940274593e-07
of O 0 1.8531257239828847e-07
the O 0 4.383927887374739e-07
44 O 0 2.4375822249567136e-06
unrelated O 0 2.561907649578643e-06
alleles O 0 8.295178304251749e-07
in O 0 7.661024028493557e-07
these O 0 8.769328019297973e-07
patients O 0 3.9558908611070365e-05
. O 0 3.79353114112746e-05

One O 0 9.711856364447158e-06
is O 0 3.5682344332599314e-06
the O 0 3.7706033708673203e-06
T312S O 0 0.00032477069180458784
mutation O 0 1.075713134923717e-05
, O 0 1.0419793170513003e-06
a O 0 1.7247236883122241e-06
novel O 0 5.813651114294771e-06
mutation O 0 3.978116637881612e-06
found O 0 5.04770866882609e-07
exclusively O 0 7.660001415388251e-07
in O 0 1.8087241642206209e-06
milder O 0 0.0001896128960652277
patients O 0 0.00014333923172671348
. O 0 7.417137385345995e-05

The O 0 7.788685252307914e-06
other O 0 6.070886797715502e-07
is O 0 5.13261909418361e-07
the O 0 7.303984261852747e-07
previously O 0 3.0988130674813874e-06
described O 0 4.5056490307615604e-06
I113F O 0 5.709588367608376e-05
that O 0 7.052875616864185e-07
produces O 0 7.215033747343114e-06
a O 0 4.680949859903194e-05
severe O 1 0.999433696269989
phenotype O 1 0.9677438735961914
. O 0 0.00019540176435839385

The O 0 2.018711529672146e-05
I113F O 0 0.0002725264348555356
and O 0 3.459692152318894e-06
T312S O 0 4.6442139137070626e-05
mutations O 0 1.0835386774488143e-06
accounted O 0 5.79962431856984e-07
for O 0 6.877496616652934e-08
8 O 0 1.9929866823531484e-07
( O 0 3.634403711316736e-08
18 O 0 1.0020315954761827e-07
% O 0 5.521893697846281e-08
) O 0 2.237571372631919e-08
and O 0 2.1688650875262283e-08
6 O 0 1.852314710504288e-07
( O 0 7.117268552292444e-08
14 O 0 1.483636395960275e-07
% O 0 1.702105976164603e-07
) O 0 8.549523755618793e-08
of O 0 3.162639927722921e-07
44 O 0 2.407924966973951e-06
unrelated O 0 3.5451623716653557e-06
alleles O 0 2.055465756711783e-06
, O 0 2.7748069442168344e-06
respectively O 0 3.897036731359549e-05
. O 0 4.798809459316544e-05

The O 0 2.5271554477512836e-05
relatively O 0 1.6934878658503294e-05
high O 0 2.0640305592678487e-05
residual O 0 0.0015451757935807109
GALNS O 0 0.3441942632198334
activity O 0 2.2219392121769488e-06
seen O 0 6.576128726010211e-07
when O 0 2.1137600469955942e-07
the O 0 5.308378945301229e-07
T312S O 0 3.38695572281722e-05
mutant O 0 1.3142615898686927e-05
cDNA O 0 8.445046660199296e-06
is O 0 4.0948683022179466e-07
overexpressed O 0 3.07564528156945e-06
in O 0 1.3557590250456997e-07
mutant O 0 4.115840056329034e-06
cells O 0 4.032852132240805e-07
provides O 0 5.0015060537589306e-08
an O 0 3.581437013622235e-08
explanation O 0 1.180091899755098e-07
for O 0 6.940870633798113e-08
the O 0 1.7212976217706455e-06
mild O 0 0.026730593293905258
phenotype O 0 0.0022340475115925074
in O 0 1.0782712251966586e-06
patients O 0 1.1462263955763774e-06
with O 0 4.3152945750080107e-07
this O 0 3.526236241668812e-06
mutation O 0 9.713132749311626e-05
. O 0 4.213769352645613e-05

The O 0 4.269327291694935e-06
distribution O 0 1.4551486628988641e-06
and O 0 2.899313926718605e-07
relative O 0 8.015150001483562e-07
frequencies O 0 1.318557139029508e-07
of O 0 2.3205438992590643e-07
the O 0 5.89815044804709e-07
I113F O 0 4.5824432163499296e-05
and O 0 5.109489507049148e-07
T312S O 0 2.5825922421063296e-05
mutations O 0 3.695255088587146e-07
in O 0 1.2029059348606097e-07
Australia O 0 2.61339806684191e-07
corresponded O 0 1.891766885364632e-07
to O 0 1.9622373059746678e-08
those O 0 1.1239803754392597e-08
observed O 0 6.448991030083562e-08
in O 0 4.32064766187068e-08
Northern O 0 2.8356001280371856e-07
Ireland O 0 3.825645080723916e-07
and O 0 7.410534408336389e-08
are O 0 1.7337338675815772e-08
unique O 0 5.384881873737868e-08
to O 0 9.986920623816786e-09
these O 0 5.727922580689437e-09
two O 0 1.4453543251136125e-08
populations O 0 6.591380241616207e-08
, O 0 3.9607904511740344e-08
suggesting O 0 8.501342563249636e-08
that O 0 2.4531594533527823e-08
both O 0 2.4293285605381243e-08
mutations O 0 1.2845350738643901e-07
were O 0 1.031960010777766e-07
probably O 0 2.722017313772085e-07
introduced O 0 1.655073447182076e-07
to O 0 2.469666249282909e-08
Australia O 0 2.1746689071733272e-07
by O 0 1.750524916133145e-07
Irish O 0 2.2006652216077782e-06
migrants O 0 5.614073188553448e-07
during O 0 8.741606620787934e-07
the O 0 1.180999788630288e-06
19th O 0 3.363747600815259e-05
century O 0 9.722733375383541e-05
. O 0 5.783700544270687e-05

Haplotype O 0 0.0003553886490408331
analysis O 0 6.000231678626733e-06
using O 0 1.8231100966659142e-06
6 O 0 7.96604399511125e-06
RFLPs O 0 2.974853487103246e-05
provides O 0 3.808503379332251e-07
additional O 0 1.349263385463928e-07
data O 0 9.409733081611193e-08
that O 0 4.916841689350804e-08
the O 0 4.244520823704079e-07
I113F O 0 5.040611358708702e-05
mutation O 0 4.511931365414057e-06
originated O 0 1.9474407508823788e-06
from O 0 5.669545544151333e-07
a O 0 4.965906100551365e-06
common O 0 1.1133653060824145e-05
ancestor O 0 0.00021704903338104486
. O 0 4.5278276957105845e-05

The O 0 8.007372343854513e-06
other O 0 4.6421868660218024e-07
9 O 0 3.3472870200057514e-06
novel O 0 4.737959443446016e-06
mutations O 0 9.305328489972453e-07
identified O 0 3.1197245675684826e-07
in O 0 9.809669876403859e-08
these O 0 3.5752606208916404e-08
23 O 0 8.462481559945445e-07
patients O 0 4.0096929865285347e-07
were O 0 6.601961644037146e-08
each O 0 2.030577661571442e-08
limited O 0 1.4123257585652027e-07
to O 0 1.0121989646449947e-07
a O 0 1.4519741853291634e-06
single O 0 4.014489604742266e-06
family O 0 1.2218552910781e-05
. O 0 3.25102882925421e-05

These O 0 8.234589472522202e-07
data O 0 4.440988448095595e-07
provide O 0 1.7279474207043677e-07
further O 0 1.1172565450578986e-07
evidence O 0 1.3162465961613634e-07
for O 0 1.0578315112752534e-07
extensive O 0 3.4553263503767084e-06
allelic O 0 3.0082032026257366e-05
heterogeneity O 0 3.2994943467201665e-05
in O 0 3.2301072678819764e-06
MPS B-Disease 1 0.6048354506492615
IVA I-Disease 1 0.9999998807907104
in O 0 1.7136192127509275e-06
British O 0 5.2857987611787394e-05
- O 0 6.785742152715102e-05
Irish O 0 5.713831342291087e-05
patients O 0 5.503351303559612e-07
and O 0 5.141525605267816e-08
provide O 0 3.2872701893893463e-08
evidence O 0 4.028415645507266e-08
for O 0 1.896522583422211e-08
their O 0 3.2807118799382806e-08
transmission O 0 3.7138065067665593e-07
to O 0 3.3988268199891536e-08
Australia O 0 2.0546904977436498e-07
by O 0 2.1261614335799095e-07
British O 0 1.2778270502167288e-05
- O 0 2.5095465389313176e-05
Irish O 0 2.697763375181239e-05
migrants O 0 6.1910468502901495e-06
. O 0 3.3190028716489905e-06
. O 0 2.709577529458329e-05

Identification O 0 9.318874799646437e-05
of O 0 3.310181273263879e-05
constitutional O 0 0.00037238304503262043
WT1 O 1 0.9991685152053833
mutations O 0 2.0901472453260794e-05
, O 0 1.6638566648907727e-06
in O 0 1.4911599919287255e-06
patients O 0 6.0780448620789684e-06
with O 0 9.178787877317518e-06
isolated O 1 0.9986925721168518
diffuse B-Disease 1 0.9999998807907104
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 2.587366907391697e-06
and O 0 3.3555608069946175e-07
analysis O 0 2.0881778084458347e-07
of O 0 1.8648615878191777e-06
genotype O 0 0.0001270142092835158
/ O 0 0.00020358238543849438
phenotype O 0 6.856454547232715e-06
correlations O 0 5.110259735374711e-07
by O 0 8.994634015380143e-08
use O 0 9.03560888332322e-08
of O 0 3.784520288263593e-07
a O 0 2.467167178110685e-06
computerized O 0 5.283913924358785e-05
mutation O 0 1.227520806423854e-05
database O 0 1.7122491044574417e-05
. O 0 1.8573857232695445e-05

Constitutional O 0 9.384526492794976e-05
mutations O 0 1.6825222701299936e-05
of O 0 4.9530790420249104e-06
the O 0 1.1885500498465262e-05
WT1 O 1 0.9251073598861694
gene O 0 6.5432946030341554e-06
, O 0 1.0103431122843176e-06
encoding O 0 2.9891682515881257e-06
a O 0 1.4311671293398831e-05
zinc O 1 0.9960734844207764
- O 0 0.0002985988394357264
finger O 0 3.1489598768530414e-05
transcription O 0 5.743318524764618e-06
factor O 0 1.1610535466388683e-06
involved O 0 4.916616376249294e-07
in O 0 3.8223411138460506e-06
renal O 1 1.0
and O 0 0.000544496055226773
gonadal O 1 0.9999998807907104
development O 0 2.0053970729350112e-05
, O 0 2.2476538674709445e-07
are O 0 1.394912985119845e-08
found O 0 4.55309780988955e-08
in O 0 6.876276614775634e-08
most O 0 1.4207988385805947e-07
patients O 0 1.110398443415761e-06
with O 0 4.702268597611692e-06
Denys B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9998934268951416
DDS B-Disease 1 1.0
) O 0 4.207758138363715e-06
, O 0 2.626531113492092e-06
or O 0 1.849508043960668e-05
diffuse B-Disease 1 0.9999915361404419
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.16737596690654755
DMS B-Disease 1 0.9999920129776001
) O 0 1.3062990547041409e-06
associated O 0 8.998389375847182e-07
with O 0 1.018408852360153e-06
pseudohermaphroditism B-Disease 1 0.9999927282333374
and O 0 2.5951710995286703e-05
/ O 1 0.9907728433609009
or O 0 0.00028754465165548027
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999997615814209
( O 0 0.0003339848481118679
WT B-Disease 1 0.9999856948852539
) O 0 1.3162207324057817e-05
. O 0 2.8181244488223456e-05

Most O 0 1.4806011677137576e-05
mutations O 0 3.707049836521037e-05
in O 0 4.617012746166438e-05
DDS B-Disease 1 1.0
patients O 0 7.229486800497398e-05
lie O 0 7.344276582443854e-06
in O 0 1.089112402041792e-06
exon O 0 1.7535507140564732e-05
8 O 0 1.0303861017746385e-06
or O 0 5.574954684561817e-07
exon O 0 9.757355655892752e-06
9 O 0 1.1479273780423682e-06
, O 0 5.878490583199891e-07
encoding O 0 2.4735893475735793e-06
zinc O 0 0.00088499701814726
finger O 0 1.3503897207556292e-05
2 O 0 4.621686457539909e-06
or O 0 1.5598247955495026e-06
zinc O 0 0.027410507202148438
finger O 0 3.8618541111645754e-06
3 O 0 3.737554834515322e-07
, O 0 1.0567022457053099e-07
respectively O 0 1.6049784790084232e-07
, O 0 5.498792532421248e-08
with O 0 4.86241411579158e-08
a O 0 1.028656015478191e-06
hot O 0 6.593130365217803e-06
spot O 0 1.9400833934923867e-06
( O 0 3.5001428955183655e-07
R394W O 0 9.99352505459683e-06
) O 0 3.5737136272473435e-07
in O 0 1.0830500514202868e-06
exon O 0 8.044368587434292e-05
9 O 0 2.50000612140866e-05
. O 0 4.098753925063647e-05

We O 0 1.505625505160424e-06
analyzed O 0 7.222911904136708e-07
a O 0 4.599314422648604e-07
series O 0 3.417679863559897e-07
of O 0 4.649820937174809e-07
24 O 0 7.436246960423887e-07
patients O 0 6.142618076410145e-07
, O 0 1.822328101752646e-07
10 O 0 2.037332365034672e-07
with O 0 8.325008025167335e-07
isolated B-Disease 0 0.00041083796531893313
DMS I-Disease 1 0.9999607801437378
( O 0 1.719345891615376e-05
IDMS B-Disease 1 0.9764179587364197
) O 0 2.65784620978593e-07
, O 0 1.226521106900691e-07
10 O 0 2.1282225759478024e-07
with O 0 8.441105592282838e-07
DDS B-Disease 1 0.9999932050704956
, O 0 4.777187996296561e-07
and O 0 2.0362485031455435e-07
4 O 0 1.3202335367168416e-06
with O 0 4.917694695905084e-06
urogenital B-Disease 1 0.9999998807907104
abnormalities I-Disease 1 0.9999864101409912
and O 0 0.0007454896112903953
/ O 1 0.9999440908432007
or O 0 0.0032565828878432512
WT B-Disease 1 0.9999971389770508
. O 0 0.00020873516041319817

We O 0 2.8133606974733993e-05
report O 0 1.6881989722605795e-05
WT1 O 0 0.00142564345151186
heterozygous O 0 1.1186505616933573e-05
mutations O 0 1.5470458265554043e-06
in O 0 4.934993853566993e-07
16 O 0 2.1996204395691166e-06
patients O 0 1.3981901929582818e-06
, O 0 4.7319673512902227e-07
4 O 0 1.7268912415602244e-06
of O 0 1.7612632063901401e-06
whom O 0 3.136994791930192e-06
presented O 0 1.563667319715023e-05
with O 0 6.216053589014336e-05
IDMS B-Disease 1 0.9999110698699951
. O 0 0.00016578580834902823

One O 0 1.8921937225968577e-05
male O 0 2.0305280486354604e-05
and O 0 3.7878885450481903e-06
two O 0 3.602323431550758e-06
female O 0 0.0054664164781570435
IDMS B-Disease 1 0.9999994039535522
patients O 0 0.0003808526962529868
with O 0 6.545683572767302e-05
WT1 O 1 0.9999990463256836
mutations O 0 0.0024683622177690268
underwent O 1 0.9999711513519287
normal O 0 0.0005716364830732346
puberty O 0 0.053151775151491165
. O 0 7.016054587438703e-05

Two O 0 1.0038073924079072e-05
mutations O 0 2.7518284696270712e-05
associated O 0 1.3171399587008636e-05
with O 0 6.556799235113431e-06
IDMS B-Disease 1 0.9998263716697693
are O 0 1.3704131163194688e-07
different O 0 2.5123453539777074e-08
from O 0 2.0841353887135483e-07
those O 0 3.1261399158211134e-07
described O 0 2.919548387581017e-05
in O 0 8.35866158013232e-05
DDS B-Disease 1 1.0
patients O 0 0.03942900896072388
. O 0 0.00020187924383208156

No O 0 0.00020076168584637344
WT1 O 0 0.3502030074596405
mutations O 0 1.1457310392870568e-05
were O 0 1.0714503559938748e-06
detected O 0 1.7032537016348215e-06
in O 0 2.665375120614044e-07
the O 0 2.849566556051286e-07
six O 0 7.757393518659228e-07
other O 0 2.3392065031657694e-06
IDMS B-Disease 1 0.9999948740005493
patients O 0 1.1421930139476899e-05
, O 0 1.246403371624183e-06
suggesting O 0 2.6576740310702007e-06
genetic O 0 4.469891791814007e-06
heterogeneity O 0 5.815423355670646e-05
of O 0 1.4413384633371606e-05
this O 0 3.5120549000566825e-05
disease O 1 0.9999804496765137
. O 0 0.0003065118216909468

We O 0 6.83763028064277e-06
analyzed O 0 1.1547312169568613e-05
genotype O 0 7.800734601914883e-05
/ O 0 8.627425268059596e-05
phenotype O 0 1.5294162949430756e-05
correlations O 0 1.2678918892561342e-06
, O 0 1.298180336561927e-07
on O 0 3.7091830051849684e-08
the O 0 3.0174142295891215e-08
basis O 0 1.9337511147909936e-08
of O 0 4.103507222907865e-08
the O 0 1.327478713619712e-07
constitution O 0 2.437400326016359e-07
of O 0 6.868319815112045e-07
a O 0 4.068630914844107e-06
WT1 O 0 0.0006949595408514142
mutation O 0 1.330654072262405e-06
database O 0 2.768817068954377e-07
of O 0 5.366517825677874e-07
84 O 0 3.066196586587466e-05
germ O 1 0.9998120665550232
- O 0 2.477256020938512e-05
line O 0 2.3096138193068327e-06
mutations O 0 1.4014472071721684e-07
, O 0 3.123802727600378e-08
to O 0 1.0145121187576933e-08
compare O 0 2.7113889800034485e-08
the O 0 4.609642445529971e-08
distribution O 0 6.690481768600876e-08
and O 0 3.787400970622912e-08
type O 0 3.913056332294218e-07
of O 0 2.75823055062574e-07
mutations O 0 2.3045217290018627e-07
, O 0 6.849194278402138e-08
according O 0 4.760006788728788e-08
to O 0 6.303999100509827e-08
the O 0 6.010661763866665e-07
different O 0 5.865548473593662e-07
symptoms O 0 0.0017281756736338139
. O 0 6.942704203538597e-05

This O 0 3.83332917408552e-06
demonstrated O 0 5.995632818667218e-06
( O 0 4.904571824226878e-07
1 O 0 6.52276980872557e-07
) O 0 1.0737360867096868e-07
the O 0 1.2719547726192104e-07
association O 0 2.7272949409962166e-07
between O 0 5.996165697297329e-08
mutations O 0 1.7784527983621956e-07
in O 0 9.114000931731425e-08
exons O 0 5.128430871081946e-07
8 O 0 1.697761149443977e-07
and O 0 5.442966610758049e-08
9 O 0 3.5525710018191603e-07
and O 0 1.277130365906487e-07
DMS B-Disease 0 5.202549436944537e-05
; O 0 5.815386572294301e-08
( O 0 7.883434705036052e-08
2 O 0 2.1232962410522305e-07
) O 0 6.827985288282434e-08
among O 0 6.628508941730615e-08
patients O 0 2.108615717588691e-07
with O 0 2.2983105907314894e-07
DMS B-Disease 0 0.07625220715999603
, O 0 2.6742355885289726e-07
a O 0 1.3012531496769952e-07
higher O 0 1.2755018019561248e-07
frequency O 0 1.242279097368737e-07
of O 0 2.7829668169943034e-07
exon O 0 5.321270236890996e-06
8 O 0 4.813057898900297e-07
mutations O 0 2.4346729787794175e-07
among O 0 1.042504607084993e-07
46 O 0 1.1050382227040245e-06
, O 0 1.6186696711883997e-06
XY O 0 0.003797625657171011
patients O 0 9.333458024229913e-07
with O 0 4.1910556092261686e-07
female O 0 6.471017968578963e-06
phenotype O 0 4.959156649420038e-05
than O 0 1.8534986168106116e-07
among O 0 1.8254554845498205e-07
46 O 0 1.970268385775853e-06
, O 0 2.9948321298434166e-06
XY O 0 0.0065943393856287
patients O 0 9.538961194266449e-07
with O 0 2.53346144063471e-07
sexual O 0 2.839696435330552e-06
ambiguity O 0 3.130700497422367e-05
or O 0 2.5194483441737248e-06
male O 0 6.153808499220759e-06
phenotype O 0 2.2053540305932984e-05
; O 0 7.740028706848534e-08
and O 0 7.234232413111386e-08
( O 0 6.749904457592493e-08
3 O 0 8.313362798162416e-08
) O 0 1.6238317357419874e-08
statistically O 0 1.3233221629604941e-08
significant O 0 2.4718573854443093e-08
evidence O 0 2.9413387281351788e-08
that O 0 1.5693332855448716e-08
mutations O 0 6.406326491514847e-08
in O 0 6.882785186235196e-08
exons O 0 5.390317028286518e-07
8 O 0 1.8286476688444964e-07
and O 0 6.382409623029162e-08
9 O 0 6.144070994196227e-07
preferentially O 0 4.671467195294099e-07
affect O 0 8.157047659551608e-08
amino O 0 1.680005539128615e-07
acids O 0 5.649823364706208e-08
with O 0 3.774700729763936e-08
different O 0 2.986387670489421e-08
functions O 0 2.3546360239379283e-07
. O 0 1.8421795857648249e-06
. O 0 1.651204365771264e-05

The O 0 5.539074481930584e-05
185delAG O 0 0.0016718849074095488
BRCA1 O 0 0.0012193565489724278
mutation O 0 1.0798706171044614e-05
originated O 0 1.8956781104861875e-06
before O 0 2.518583244182082e-07
the O 0 1.5165228717251011e-07
dispersion O 0 9.281761776946951e-07
of O 0 2.1590382459635293e-07
Jews O 0 2.5675427650639904e-07
in O 0 7.658029943513611e-08
the O 0 1.9363648107173503e-07
diaspora O 0 7.444151037816482e-07
and O 0 8.901703552055551e-08
is O 0 1.1084922135751185e-07
not O 0 6.268484753491066e-08
limited O 0 6.460551276177284e-07
to O 0 1.2800999229511945e-06
Ashkenazim O 0 0.00013682155986316502
. O 0 3.125849980278872e-05

The O 0 4.204560900689103e-05
185delAG O 0 0.00037585810059681535
mutation O 0 4.111519956495613e-05
in O 0 6.4745672716526315e-06
BRCA1 O 0 0.000356704113073647
is O 0 1.0649876003299141e-06
detected O 0 1.5549177305729245e-06
in O 0 3.3939690524675825e-07
Ashkenazi O 0 9.642135410103947e-06
Jews O 0 1.2788260619345238e-06
both O 0 1.7692114795408997e-07
in O 0 3.012181650774437e-06
familial B-Disease 1 0.999993085861206
breast I-Disease 1 1.0
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.5183422874542885e-05
in O 0 2.32958063861588e-06
the O 0 4.567898940877058e-06
general O 0 3.431970253586769e-05
population O 0 8.408809662796557e-06
. O 0 3.451953671174124e-05

All O 0 2.5846815333352424e-05
tested O 0 6.898480205563828e-05
Ashkenazi O 0 0.00029842639924027026
mutation O 0 3.822626604232937e-05
carriers O 0 6.248053068702575e-06
share O 0 1.0757772770375595e-06
the O 0 1.087978716896032e-06
same O 0 1.5651847888875636e-06
allelic O 0 5.6825807405402884e-05
pattern O 0 1.3044818842899986e-05
at O 0 6.742345249222126e-06
the O 0 1.396703373757191e-05
BRCA1 O 0 0.0009691570303402841
locus O 0 0.0002969650086015463
. O 0 5.458282248582691e-05

Our O 0 8.292818165500648e-06
previous O 0 2.8612862479349133e-06
study O 0 1.6496823036504793e-06
showed O 0 2.481646788510261e-06
that O 0 1.7432013521556655e-07
this O 0 4.108465532226546e-07
Ashkenazi O 0 3.593055225792341e-05
mutation O 0 2.5017450298037147e-06
also O 0 3.08970754758775e-07
occurs O 0 1.778039120381436e-07
in O 0 1.1918750431050285e-07
Iraqi O 0 6.321325258795696e-07
Jews O 0 6.505933924927376e-07
with O 0 4.1401830230825e-07
a O 0 7.788610673742369e-06
similar O 0 6.428545475500869e-06
allelic O 0 0.0005878264200873673
pattern O 0 0.00026412427541799843
. O 0 7.917329639894888e-05

We O 0 4.298997737350874e-06
extended O 0 3.4356178275629645e-06
our O 0 4.945113118992595e-07
analysis O 0 2.25214691340625e-07
to O 0 1.2916476066493487e-07
other O 0 7.961997994243575e-08
non O 0 1.2166088936282904e-06
- O 0 6.68288157612551e-06
Ashkenazi O 0 1.6352922102669254e-05
subsets O 0 3.6201352031639544e-06
354 O 0 3.127850732198567e-06
of O 0 1.4388609770321636e-06
Moroccan O 0 4.43845237896312e-05
origin O 0 1.3355476085052942e-06
, O 0 9.071385989045666e-07
200 O 0 3.4098995911335805e-06
Yemenites O 0 3.803884465014562e-05
and O 0 1.1080647936978494e-06
150 O 0 5.160505224921508e-06
Iranian O 0 1.4194301002135035e-05
Jews O 0 3.338166789035313e-05
. O 0 5.880671596969478e-05

Heteroduplex O 0 0.0008666066569276154
analysis O 0 1.3833201592206024e-05
complemented O 0 1.652959326747805e-05
by O 0 1.7878769540402573e-06
direct O 0 2.5391070721525466e-06
DNA O 0 5.4289866966428235e-06
sequencing O 0 2.1937503333901986e-06
of O 0 2.5346696475025965e-06
abnormally O 0 5.482236520037986e-05
migrating O 0 4.5999859139556065e-06
bands O 0 9.70899509411538e-06
were O 0 2.1909570477873785e-06
employed O 0 2.849901829904411e-05
. O 0 4.260844434611499e-05

Four O 0 3.3587698453629855e-06
of O 0 2.198731181124458e-06
Moroccan O 0 1.6195210264413618e-05
origin O 0 8.810621920929407e-07
( O 0 2.044666729261735e-07
1 O 0 2.773090272967238e-07
. O 0 3.176465668275341e-08
1 O 0 1.175829709154641e-07
% O 0 6.556984999406268e-08
) O 0 3.278785243310267e-08
and O 0 3.066493192704911e-08
none O 0 1.1025144175391688e-07
of O 0 2.417201017124171e-07
the O 0 8.586651460973371e-07
Yemenites O 0 3.604510857257992e-05
or O 0 2.729563846060046e-07
Iranians O 0 6.162362069517258e-07
was O 0 1.2944348100063507e-06
a O 0 8.448442372355203e-07
carrier O 0 8.1307398431818e-06
of O 0 1.645336396904895e-06
the O 0 7.805416316841729e-06
185delAG O 0 0.0005807644338347018
mutation O 0 0.00012181454803794622
. O 0 5.4458661907119676e-05

BRCA1 O 0 0.02141636610031128
allelic O 0 0.00043551679118536413
patterns O 0 6.423581908165943e-06
were O 0 6.420345926017035e-07
determined O 0 2.528836091642006e-07
for O 0 4.140498077731536e-08
four O 0 4.391719343743716e-08
of O 0 1.1023020363154501e-07
these O 0 1.3142667398824415e-08
individuals O 0 1.0915893966512158e-08
and O 0 2.8744906899191847e-08
for O 0 7.083992414891327e-08
12 O 0 3.9039909438542963e-07
additional O 0 7.025312243058579e-07
non O 0 3.7871011500101304e-06
- O 0 4.310417716624215e-05
Ashkenazi O 0 0.00015428407641593367
185delAG O 0 0.00024414455401711166
mutation O 0 2.0518860765150748e-05
carriers O 0 5.795062861579936e-06
who O 0 5.308021172822919e-06
had O 0 0.0016719071427360177
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9259794354438782

Six O 0 5.370855797082186e-05
non O 0 0.0001228678593179211
- O 0 0.0003187361580785364
Ashkenazi O 0 0.000451501487987116
individuals O 0 1.1886505717484397e-06
shared O 0 2.9757318316114834e-06
the O 0 4.2073165786860045e-06
common O 0 2.1021773136453703e-05
Ashkenazi O 0 0.03809419274330139
haplotype O 0 0.0008019013912416995
, O 0 6.622417458856944e-07
four O 0 2.108456840232975e-07
had O 0 7.441751677106367e-07
a O 0 2.7215449449613516e-07
closely O 0 9.001549727827296e-08
related O 0 1.0838596153917024e-07
pattern O 0 1.1575731377888587e-06
, O 0 9.100381959115111e-08
and O 0 3.696407091524634e-08
the O 0 1.4350675314744876e-07
rest O 0 4.241987596742547e-07
( O 0 1.757046277361951e-07
n O 0 5.108865934744244e-07
= O 0 4.435206619746168e-07
6 O 0 4.278373921806633e-07
) O 0 1.5003307396455057e-07
displayed O 0 1.444466306566028e-06
a O 0 2.767204250631039e-06
distinct O 0 8.868656550475862e-06
BRCA1 O 0 0.0004965951084159315
allelic O 0 0.0013680023839697242
pattern O 0 0.0007426950032822788
. O 0 0.00014635758998338133

We O 0 5.057416274212301e-06
conclude O 0 8.793021152087022e-06
that O 0 5.820169235448702e-07
the O 0 2.2289386834017932e-06
185delAG O 0 0.00024920355645008385
BRCA1 O 0 0.0006271129823289812
mutation O 0 4.048963546665618e-06
occurs O 0 2.59434699501071e-07
in O 0 1.057756833233725e-07
some O 0 1.288163815615917e-07
non O 0 2.4730281893425854e-06
- O 0 1.6056403183029033e-05
Ashkenazi O 0 2.8224170819157735e-05
populations O 0 3.1143679279921344e-07
at O 0 4.163131563927891e-07
rates O 0 2.3044141528316686e-07
comparable O 0 4.979033860763593e-07
with O 0 1.5861770918945695e-07
that O 0 5.368339657252363e-07
of O 0 8.550453458155971e-06
Ashkenazim O 0 0.0009109678212553263
. O 0 5.806213812320493e-05

The O 0 1.3885516636946704e-05
majority O 0 7.570494744868483e-06
of O 0 4.287926458346192e-06
Jewish O 0 1.3989055332785938e-05
185delAG O 0 0.00068567885318771
mutation O 0 3.3585067285457626e-05
carriers O 0 2.6890454591921298e-06
have O 0 1.2668122906234203e-07
a O 0 4.145730372329126e-07
common O 0 6.008581863170548e-07
allelic O 0 2.1432393623399548e-05
pattern O 0 3.095209649472963e-06
, O 0 2.7966476068286283e-07
supporting O 0 4.4770402496396855e-07
the O 0 5.258356168269529e-07
founder O 0 3.680644294945523e-05
effect O 0 8.683113605911785e-07
notion O 0 1.0919079613813665e-06
, O 0 9.58239283477269e-08
but O 0 3.966286143963771e-08
dating O 0 1.607297548389397e-07
the O 0 1.0514207815504051e-07
mutations O 0 1.5190573776635574e-07
origin O 0 5.5901821838233445e-08
to O 0 1.7607977298439437e-08
an O 0 6.718897083146658e-08
earlier O 0 2.7366925792193797e-07
date O 0 5.457779934658902e-07
than O 0 1.9610106960499252e-07
currently O 0 8.506904691785167e-07
estimated O 0 7.439548880938673e-06
. O 0 1.5932821042952128e-05

However O 0 1.5555018762825057e-05
, O 0 1.6672923948135576e-06
the O 0 6.476392400145414e-07
different O 0 1.5724411639439495e-07
allelic O 0 9.88676674751332e-06
pattern O 0 3.6419578464119695e-06
at O 0 1.467137963118148e-06
the O 0 2.7746586965804454e-06
BRCA1 O 0 4.5481410779757425e-05
locus O 0 2.9808500130457105e-06
even O 0 7.49791624343743e-08
in O 0 6.188474799273536e-08
some O 0 4.987035850945176e-08
Jewish O 0 1.0385844007032574e-06
mutation O 0 1.982728008442791e-06
carriers O 0 9.106126981350826e-07
, O 0 1.9394734351863008e-07
might O 0 9.224107344607546e-08
suggest O 0 6.635947613631288e-08
that O 0 4.538375719675969e-08
the O 0 4.222722225222242e-07
mutation O 0 2.0734669305966236e-06
arose O 0 2.147883606085088e-06
independently O 0 1.0462570116942516e-06
. O 0 2.5761419237824157e-06
. O 0 2.0601562937372364e-05

Crystal O 0 0.0008495611837133765
structure O 0 8.001807145774364e-05
of O 0 3.175061283400282e-05
the O 0 0.00031254516215994954
hemochromatosis B-Disease 1 1.0
protein O 0 0.000691121444106102
HFE O 1 0.9897837042808533
and O 0 1.1146453289256897e-06
characterization O 0 4.790802449861076e-06
of O 0 5.534024012376904e-07
its O 0 7.950872031869949e-07
interaction O 0 2.322158707102062e-06
with O 0 3.4287052130821394e-06
transferrin O 0 0.0024140221066772938
receptor O 0 0.000140557560371235
. O 0 3.718216612469405e-05

HFE O 1 0.9836840629577637
is O 0 1.7653967006481253e-05
an O 0 1.1846934285131283e-05
MHC O 1 0.9638128876686096
- O 0 4.14340611314401e-05
related O 0 2.6985580916516483e-06
protein O 0 1.7699281897876062e-06
that O 0 1.0125986449338598e-07
is O 0 1.984646900154985e-07
mutated O 0 1.2008591738776886e-06
in O 0 3.485938293579238e-07
the O 0 2.2328094928525388e-05
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.989231526851654

HFE O 0 0.028288763016462326
binds O 0 3.650544022093527e-05
to O 0 2.7820590275950963e-06
transferrin O 0 0.00015195534797385335
receptor O 0 5.546907686948543e-06
( O 0 7.278451903403038e-07
TfR O 0 6.963716441532597e-05
) O 0 1.1086761730894068e-07
and O 0 8.031059905988513e-08
reduces O 0 3.1686960255683516e-07
its O 0 7.982404071071869e-08
affinity O 0 6.612976335418352e-07
for O 0 5.547815362660913e-07
iron O 1 0.9402972459793091
- O 0 7.977732457220554e-05
loaded O 0 2.097563265124336e-05
transferrin O 0 0.00021755688067059964
, O 0 4.2505180317675695e-06
implicating O 0 0.0003921105235349387
HFE O 1 0.9994198083877563
in O 0 6.087396468501538e-05
iron O 1 0.9999762773513794
metabolism O 0 0.19114632904529572
. O 0 7.302293670363724e-05

The O 0 0.00020392431179061532
2 O 0 0.0005047659506089985
. O 0 0.00035887531703338027

6 O 0 9.846002649283037e-05
A O 0 0.000125338468933478
crystal O 0 0.0007467622635886073
structure O 0 3.9410402678186074e-05
of O 0 2.6903899197350256e-05
HFE O 1 0.998140811920166
reveals O 0 1.0018727152782958e-05
the O 0 6.521525506286707e-07
locations O 0 6.696072887280025e-07
of O 0 1.9402927136979997e-05
hemochromatosis B-Disease 1 1.0
mutations O 0 1.0442421626066789e-05
and O 0 1.5104188832992804e-06
a O 0 1.8039138012682088e-05
patch O 1 0.9652227163314819
of O 0 5.936540219408926e-06
histidines O 0 0.25957679748535156
that O 0 1.8776950128085446e-07
could O 0 6.152906451006857e-08
be O 0 3.5961949862439724e-08
involved O 0 1.3454599923079513e-07
in O 0 4.4832782464254706e-07
pH O 0 2.947130451502744e-05
- O 0 2.61236637015827e-05
dependent O 0 5.439330379886087e-06
interactions O 0 4.424266990099568e-06
. O 0 1.5633408111170866e-05

We O 0 6.272040081967134e-06
also O 0 2.0944573861925164e-06
demonstrate O 0 4.381004146125633e-06
that O 0 2.083011850118055e-06
soluble O 0 0.00013578867947217077
TfR O 1 0.5199840664863586
and O 0 5.075085482530994e-06
HFE O 1 0.807532548904419
bind O 0 2.224636091341381e-06
tightly O 0 1.804238081604126e-06
at O 0 3.352956809976604e-07
the O 0 1.7900472926157818e-07
basic O 0 5.610444873127562e-07
pH O 0 1.0976251587635488e-06
of O 0 2.413492552477692e-07
the O 0 5.114462169331091e-07
cell O 0 4.250720394338714e-06
surface O 0 4.952891003995319e-07
, O 0 6.189265633338437e-08
but O 0 1.4666348135961016e-08
not O 0 1.347938027862483e-08
at O 0 2.0165794012427796e-07
the O 0 9.363663480144169e-07
acidic O 0 9.94285710476106e-06
pH O 0 1.3521977962227538e-05
of O 0 6.400125130312517e-06
intracellular O 0 0.00034654518822208047
vesicles O 0 0.0012628078693524003
. O 0 4.7774949052836746e-05

TfR O 1 0.8878462910652161
HFE O 0 0.34577295184135437
stoichiometry O 0 5.4896230722079054e-05
( O 0 2.126490926457336e-06
2 O 0 1.8144270370612503e-06
1 O 0 1.4391464446816826e-06
) O 0 2.9878350460421643e-07
differs O 0 6.069311666578869e-07
from O 0 5.339594508768641e-07
TfR O 0 0.00011727173114195466
transferrin O 0 2.2790758521296084e-05
stoichiometry O 0 2.5888205072988058e-06
( O 0 9.610342033283814e-08
2 O 0 1.216195357756078e-07
2 O 0 1.7185898570915015e-07
) O 0 5.355076382329571e-08
, O 0 5.1884573082361385e-08
implying O 0 2.2807620325693279e-07
a O 0 6.498331117654743e-08
different O 0 6.930390483717019e-09
mode O 0 1.77205166096428e-07
of O 0 1.1082659767680525e-07
binding O 0 1.8694044001676957e-07
for O 0 2.6662243612918246e-07
HFE O 0 0.005587367806583643
and O 0 5.468241397466045e-07
transferrin O 0 2.0399062123033218e-05
to O 0 2.2631618890045502e-07
TfR O 0 9.926644270308316e-05
, O 0 1.875507962267875e-07
consistent O 0 2.0229204267252499e-07
with O 0 6.472256330880555e-08
our O 0 1.7652507722232258e-07
demonstration O 0 3.846204435831169e-06
that O 0 4.2461238081159536e-07
HFE O 0 0.12513966858386993
, O 0 8.897644647731795e-07
transferrin O 0 3.045073026441969e-05
, O 0 6.378186867550539e-07
and O 0 9.081972507374303e-07
TfR O 0 0.00036219568573869765
form O 0 4.957294095220277e-06
a O 0 1.8221475329482928e-05
ternary O 0 0.0012624050723388791
complex O 0 0.00014721810293849558
. O 0 5.7074648793786764e-05

Identification O 0 1.842536403273698e-05
of O 0 3.776721541726147e-06
three O 0 1.2051971225446323e-06
novel O 0 8.092416464933194e-06
mutations O 0 9.839236554398667e-07
and O 0 1.7348411063267122e-07
a O 0 4.4531262233249436e-07
high O 0 4.701402360751672e-07
frequency O 0 4.67950172833298e-07
of O 0 3.8639544186480634e-07
the O 0 1.021521597976971e-06
Arg778Leu O 0 0.0004060886858496815
mutation O 0 5.2976242841396015e-06
in O 0 1.8375299077888485e-06
Korean O 0 0.0008558031404390931
patients O 0 1.2384856745484285e-05
with O 0 1.3438069800031371e-05
Wilson B-Disease 1 0.9919067621231079
disease I-Disease 1 0.999991774559021
. O 0 0.0005087965400889516

Four O 0 2.815022162394598e-05
mutations O 0 3.677879794850014e-05
- O 0 0.00015436793910339475
- O 0 0.0003760428517125547
R778L O 0 0.011776993982493877
, O 0 3.486042032818659e-06
A874V O 0 4.989491935702972e-05
, O 0 5.392219577515789e-07
L1083F O 0 6.8322979132062756e-06
, O 0 2.471441007401154e-07
and O 0 1.3234917162208149e-07
2304delC O 0 6.627448783547152e-06
- O 0 2.0866777958872262e-06
- O 0 1.847912017183262e-06
in O 0 2.914188996783196e-07
the O 0 1.2464913652365794e-06
copper O 0 0.0001328679791186005
- O 0 4.86059161630692e-06
transporting O 0 4.037149210489588e-06
enzyme O 0 9.310414839092118e-07
, O 0 4.399424256007478e-07
P O 0 3.132352139800787e-05
- O 0 1.0977007150358986e-05
type O 0 1.5183495634119026e-05
ATPase O 0 2.4045419195317663e-05
( O 0 5.889539238523867e-07
ATP7B O 0 0.0009375468362122774
) O 0 1.2848327912706736e-07
, O 0 4.6173333601018385e-08
were O 0 4.757301752533749e-08
identified O 0 1.595081471350568e-07
in O 0 4.44848240022111e-07
Korean O 0 8.842391252983361e-05
Patients O 0 5.243486157269217e-06
with O 0 8.02596696303226e-06
Wilson B-Disease 1 0.9985842704772949
disease I-Disease 1 0.9999967813491821
. O 0 0.00041034258902072906

Arg778Leu O 0 0.005657531321048737
, O 0 6.847078566352138e-06
the O 0 2.033763848885428e-06
most O 0 3.615973582782317e-07
frequently O 0 3.076617360875389e-07
reported O 0 2.5338573550470755e-07
mutation O 0 3.615687376168353e-07
of O 0 2.237802334548178e-07
this O 0 1.1440307901011693e-07
enzyme O 0 5.98003907725797e-07
, O 0 6.357006299140266e-08
was O 0 5.624115715363587e-07
found O 0 4.4763737605535425e-08
in O 0 2.7760901133433435e-08
six O 0 6.186952106190802e-08
of O 0 3.9459962408727733e-07
eight O 0 1.0552384992479347e-06
unrelated O 0 3.723207555594854e-06
patients O 0 5.4411390237874e-07
studied O 0 8.976584240372176e-07
, O 0 2.4172425128199393e-07
an O 0 3.0715278853676864e-07
allele O 0 1.8513924260332715e-06
frequency O 0 1.1081239108534646e-06
of O 0 3.7556237657554448e-06
37 O 0 5.4361480579245836e-05
. O 0 3.693069811561145e-05

5 O 0 1.4443243344430812e-05
% O 0 5.035053618485108e-06
, O 0 7.920131110950024e-07
which O 0 2.3585241137880075e-07
is O 0 1.7113805483859323e-07
considerably O 0 3.2376769354414137e-07
higher O 0 9.885212648441666e-08
than O 0 1.9233045378541647e-08
those O 0 2.5250422197586886e-08
in O 0 1.6874786012976983e-07
other O 0 2.50753942054871e-07
Asian O 0 1.1924487807846162e-05
populations O 0 8.064965186349582e-06
. O 0 2.7731623049476184e-05

The O 0 1.3555611076299101e-05
novel O 0 1.3197073712944984e-05
single O 0 2.339188768019085e-06
nucleotide O 0 7.106726116035134e-06
deletion O 0 1.0345223017793614e-05
, O 0 8.594532800998422e-07
2304delC O 0 3.06127876683604e-05
, O 0 5.238894686954154e-07
was O 0 3.552079760993365e-06
found O 0 3.3578015745661105e-07
in O 0 4.515296438967198e-07
one O 0 2.5550195914547658e-06
patient O 0 0.00010838018351932988
. O 0 5.553969458560459e-05

Since O 0 1.5144637472985778e-05
a O 0 6.05872128289775e-06
mutation O 0 5.697199412679765e-06
at O 0 4.7267581066989806e-06
cDNA O 0 4.6411507355514914e-05
nucleotide O 0 3.177859980496578e-05
2302 O 0 0.012603817507624626
( O 0 9.373223406328179e-07
2302insC O 0 1.2343575690465514e-05
) O 0 2.2525034637510544e-07
had O 0 3.5222564065406914e-07
been O 0 1.572321082221606e-07
previously O 0 3.1880742312750954e-07
described O 0 4.840741780753888e-07
, O 0 6.485515768872574e-08
this O 0 3.208170085144957e-08
region O 0 1.2827209161514475e-07
of O 0 3.2940369010248105e-07
the O 0 2.6516636353335343e-06
ATP7B O 1 0.9996510744094849
gene O 0 6.100425707700197e-06
may O 0 7.457281867573329e-07
be O 0 3.2610046218906064e-07
susceptible O 0 4.245040599926142e-06
to O 0 3.7692984733439516e-07
gene O 0 2.132007102773059e-05
rearrangements O 0 0.20592164993286133
causing O 1 0.914176881313324
Wilson B-Disease 1 0.989456832408905
disease I-Disease 1 0.9999734163284302
. O 0 0.00030828278977423906

Disruption O 0 0.0002615115372464061
of O 0 1.4024184565641917e-05
splicing O 0 1.9739924027817324e-05
regulated O 0 2.1583846319117583e-06
by O 0 6.231506404219544e-07
a O 0 8.007174074009527e-06
CUG O 1 0.7363755702972412
- O 0 6.775913789169863e-05
binding O 0 1.4748064131708816e-05
protein O 0 4.8406353016616777e-05
in O 0 0.00010978523641824722
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0019467754755169153

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995871186256409
DM B-Disease 1 1.0
) O 0 1.662305476202164e-05
is O 0 1.2669345323956804e-06
caused O 0 2.2774697754357476e-06
by O 0 2.5187995333908475e-07
a O 0 2.135088607246871e-06
CTG O 0 0.00012590915139298886
expansion O 0 7.346584993683791e-07
in O 0 7.817222780204247e-08
the O 0 1.2506475854934251e-07
3 O 0 7.833475592633476e-07
untranslated O 0 1.8085265764966607e-05
region O 0 6.971957304813259e-07
of O 0 1.7772198361853953e-06
the O 0 3.9400856621796265e-05
DM B-Disease 1 0.9999997615814209
gene O 0 0.00037593478919006884
. O 0 8.242952026193962e-05

One O 0 1.1895252100657672e-05
model O 0 2.275119004480075e-05
of O 0 0.00022784747125115246
DM B-Disease 1 1.0
pathogenesis O 1 0.999977707862854
suggests O 0 6.981018032092834e-06
that O 0 2.132668015519812e-07
RNAs O 0 1.1105021258117631e-06
from O 0 6.807582053625083e-08
the O 0 1.483936387103313e-07
expanded O 0 4.3632149981931434e-07
allele O 0 2.739329829637427e-07
create O 0 7.338406504686645e-08
a O 0 1.4438394657645404e-07
gain O 0 4.269317628313729e-07
- O 0 7.350831765506882e-07
of O 0 3.8776980204602296e-07
- O 0 1.3296659062689287e-06
function O 0 2.0441169112928037e-07
mutation O 0 1.890437744123119e-07
by O 0 4.639181483412358e-08
the O 0 1.9198928669084125e-07
inappropriate O 0 2.3286023065338668e-07
binding O 0 9.840366033131431e-08
of O 0 2.3360937007055327e-07
proteins O 0 2.593654357951891e-07
to O 0 2.7523654466676817e-07
the O 0 4.911058113066247e-06
CUG O 1 0.7005975246429443
repeats O 0 7.038551120785996e-05
. O 0 2.8643207770073786e-05

Data O 0 5.87060276302509e-06
presented O 0 5.441105258796597e-06
here O 0 1.3623968015963328e-06
indicate O 0 5.81887547923543e-07
that O 0 1.0930982341506024e-07
the O 0 3.21165430250403e-07
conserved O 0 3.5051973554800497e-06
heterogeneous O 0 2.091441274387762e-05
nuclear O 0 5.154828613740392e-05
ribonucleoprotein O 0 0.0012551777763292193
, O 0 1.066404365701601e-06
CUG O 0 0.00011657123104669154
- O 0 3.153561237922986e-06
binding O 0 8.589526032665162e-07
protein O 0 1.0344703014197876e-06
( O 0 4.404008393521508e-07
CUG O 0 0.0008579321438446641
- O 0 1.1094711226178333e-05
BP O 0 2.2701646230416372e-05
) O 0 1.6515792822247022e-07
, O 0 5.660426438680588e-08
may O 0 6.129538832055914e-08
mediate O 0 3.9664152495788585e-07
the O 0 2.249030330858659e-07
trans O 0 7.240350896609016e-06
- O 0 6.548626060975948e-06
dominant O 0 4.75613160233479e-06
effect O 0 7.46649050142878e-07
of O 0 1.3470303201756906e-06
the O 0 6.660770850430708e-06
RNA O 0 0.00012670067371800542
. O 0 2.2476853700936772e-05

CUG O 1 0.9876720905303955
- O 0 0.0011582468869164586
BP O 0 0.000452146225143224
was O 0 1.377091757603921e-05
found O 0 5.399670612860064e-07
to O 0 8.027185316450414e-08
bind O 0 1.4275981641276303e-07
to O 0 7.259804135628656e-08
the O 0 8.689757464708237e-07
human O 0 1.7900294551509432e-05
cardiac O 1 0.9999998807907104
troponin O 1 0.9999998807907104
T O 1 0.9960753321647644
( O 0 1.1588399502215907e-06
cTNT O 0 4.731962690129876e-05
) O 0 3.27799170918297e-07
pre O 0 7.516052846767707e-06
- O 0 1.1115724191768095e-05
messenger O 0 4.861662546318257e-06
RNA O 0 1.739525941957254e-06
and O 0 1.0904847869142031e-07
regulate O 0 3.585230956559826e-07
its O 0 6.143666837488126e-07
alternative O 0 7.974055733939167e-06
splicing O 0 4.7781832108739763e-05
. O 0 2.865747046598699e-05

Splicing O 0 0.00011168449418619275
of O 0 2.0875078917015344e-05
cTNT O 0 0.0026216353289783
was O 0 0.0005965806194581091
disrupted O 0 0.19635669887065887
in O 0 0.0019218260422348976
DM B-Disease 1 1.0
striated O 1 0.9999995231628418
muscle O 1 0.5816451907157898
and O 0 8.00178440840682e-07
in O 0 5.843706389896397e-07
normal O 0 1.881090952338127e-06
cells O 0 2.3603561203344725e-06
expressing O 0 1.300294570683036e-06
transcripts O 0 2.178318709411542e-06
that O 0 5.788793373540102e-07
contain O 0 1.1620800250966568e-05
CUG O 0 0.01830783113837242
repeats O 0 0.00012725569831673056
. O 0 5.717433668905869e-05

Altered O 0 7.107129931682721e-05
expression O 0 9.815612429520115e-06
of O 0 4.181835720373783e-06
genes O 0 2.2438339328800794e-06
regulated O 0 2.277126895933179e-06
posttranscriptionally O 0 5.3256073442753404e-05
by O 0 4.131827154196799e-06
CUG O 1 0.9996991157531738
- O 0 0.00040820479625836015
BP O 0 9.626769315218553e-05
therefore O 0 7.912951218713715e-07
may O 0 6.854741627648764e-07
contribute O 0 2.167683987863711e-06
to O 0 7.354502031375887e-06
DM B-Disease 1 0.9999996423721313
pathogenesis O 1 0.9998044371604919
. O 0 3.831634603557177e-05
. O 0 5.735619197366759e-05

Identification O 0 1.7785368982004002e-05
of O 0 5.6488547670596745e-06
a O 0 7.91628917795606e-06
novel O 0 1.5811470802873373e-05
nonsense O 0 6.077130456105806e-05
mutation O 0 2.0867096282017883e-06
and O 0 1.5090122928995697e-07
a O 0 6.95398796324298e-07
missense O 0 4.269213604857214e-06
substitution O 0 1.7346422964692465e-06
in O 0 2.0194470096157602e-07
the O 0 1.4235210983315483e-06
vasopressin O 0 6.780561670893803e-05
- O 0 8.855073974700645e-05
neurophysin O 1 0.6680469512939453
II O 1 0.9959794282913208
gene O 0 1.1523147804837208e-06
in O 0 1.193253496012403e-07
two O 0 1.7436003929560684e-07
Spanish O 0 4.9448676691099536e-06
kindreds O 0 0.00012651087308768183
with O 0 1.2504651749623008e-05
familial B-Disease 1 0.9999980926513672
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
. O 0 0.005621581804007292

Familial B-Disease 1 0.999994158744812
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 1 0.9960775971412659
FNDI B-Disease 1 1.0
) O 0 5.978070475975983e-06
is O 0 8.780256735008152e-07
an O 0 1.8917158968179137e-06
autosomal B-Disease 1 0.9986787438392639
dominant I-Disease 1 0.9999991655349731
disease I-Disease 1 1.0
caused O 1 0.9999632835388184
by O 0 0.00668081222102046
deficiency O 1 1.0
in O 0 1.0293047125742305e-05
the O 0 3.345636650919914e-05
antidiuretic O 0 0.40254586935043335
hormone O 0 6.050345837138593e-05
arginine O 0 2.3966302251210436e-05
vasopressin O 0 1.9615805285866372e-05
( O 0 1.177311332867248e-06
AVP O 0 4.166768485447392e-05
) O 0 8.377303117867996e-08
encoded O 0 1.029117768780452e-07
by O 0 1.986705342460482e-07
the O 0 3.192067197232973e-06
AVP O 0 0.43112388253211975
- O 0 0.00022800351143814623
neurophysin O 1 0.9864317774772644
II O 1 0.9999984502792358
( O 0 9.203907393384725e-05
AVP O 1 0.9808923602104187
- O 0 0.00019834715931210667
NPII O 1 0.6188972592353821
) O 0 1.8574902469481458e-06
gene O 0 2.955994887088309e-06
on O 0 2.4524142645532265e-06
chromosome O 0 7.76821980252862e-05
20p13 O 0 0.001142130116932094
. O 0 5.717368549085222e-05

In O 0 4.43423550677835e-06
this O 0 5.850542947882786e-07
study O 0 8.925222800826305e-07
, O 0 3.057703565900738e-07
we O 0 7.37728029776008e-08
analyzed O 0 1.151366362250883e-07
two O 0 3.177580509827749e-08
families O 0 9.35897048748302e-08
with O 0 3.2474923727932037e-07
FNDI B-Disease 1 0.7717742323875427
using O 0 2.489596795385296e-07
direct O 0 2.2261123433509056e-07
automated O 0 1.4089695241636946e-06
fluorescent O 0 1.0529696510275244e-06
, O 0 6.72435831461371e-08
solid O 0 3.407460553717101e-07
phase O 0 1.3132265621607075e-06
, O 0 2.0130437405896373e-07
single O 0 3.3559254575266095e-07
- O 0 2.0526508706097957e-06
stranded O 0 2.686582092792378e-06
DNA O 0 9.426687483937712e-07
sequencing O 0 1.1685696108543198e-06
of O 0 1.8026729549092124e-06
PCR O 0 5.922790660406463e-05
- O 0 0.000596989004407078
amplified O 0 0.003242096398025751
AVP O 1 0.9985129237174988
- O 0 0.008389032445847988
NPII O 1 0.9765284657478333
DNA O 0 0.00037544858059845865
. O 0 8.375975448871031e-05

In O 0 3.902549906342756e-06
one O 0 6.150268063720432e-07
of O 0 9.840409802563954e-07
the O 0 8.166759926098166e-07
families O 0 1.782812120154631e-07
, O 0 3.2138478900378686e-07
affected O 0 2.4046519797593646e-07
individuals O 0 5.135301961445293e-08
presented O 0 8.668799864608445e-07
a O 0 1.0226971198790125e-06
novel O 0 2.3405207230098313e-06
nonsense O 0 6.368477897922276e-06
mutation O 0 7.074985433064285e-07
in O 0 1.9796054573362198e-07
exon O 0 3.064004886255134e-06
3 O 0 1.9524900096712372e-07
of O 0 9.944802314976187e-08
the O 0 1.1791784260140048e-07
gene O 0 1.5162365230025898e-07
, O 0 4.0815415047745773e-08
consisting O 0 1.4252420044158498e-07
in O 0 8.543558038809351e-08
a O 0 7.155032335504075e-07
G O 0 6.234512056835229e-06
to O 0 1.644095988240224e-07
T O 0 7.070829724398209e-06
transition O 0 7.293613180081593e-07
at O 0 3.4504225254750054e-07
nucleotide O 0 1.3481844689522404e-06
2101 O 0 1.1882077160407789e-05
, O 0 9.993098615268536e-08
which O 0 3.4806358684136285e-08
produces O 0 1.25823234498057e-07
a O 0 1.3602452497707418e-07
stop O 0 2.3274346006019186e-07
signal O 0 3.7531785324063094e-07
in O 0 1.1289590418073203e-07
codon O 0 1.5646431847926578e-06
82 O 0 3.925191322196042e-06
( O 0 2.5544131858623587e-06
Glu O 0 0.0005349487182684243
) O 0 1.3217048717706348e-06
of O 0 6.415677489712834e-06
NPII O 1 0.5619194507598877
. O 0 8.450684254057705e-05

The O 0 4.3152507714694366e-05
premature O 0 0.00013942093937657773
termination O 0 7.089009886840358e-05
eliminates O 0 1.9787421479122713e-05
part O 0 1.961603402378387e-06
of O 0 1.1434564157752902e-06
the O 0 2.3231998511619167e-06
C O 0 8.300914487335831e-05
- O 0 1.5776227883179672e-05
terminal O 0 1.731139127514325e-05
domain O 0 6.01573162839486e-07
of O 0 3.9241143667823053e-07
NPII O 0 0.0005056220106780529
, O 0 2.546274515680125e-07
including O 0 1.0902829927772473e-07
a O 0 4.6652607466057816e-07
cysteine O 0 5.43708779332519e-07
residue O 0 9.006733989735949e-07
in O 0 8.991323596774237e-08
position O 0 1.927236183973946e-07
85 O 0 4.5603638909597066e-07
, O 0 5.7876565762171595e-08
which O 0 2.6224153515386206e-08
could O 0 2.2503300556309114e-08
be O 0 1.2019857109635268e-08
involved O 0 3.937988424240757e-08
in O 0 6.484921755145479e-08
the O 0 4.465126721697743e-07
correct O 0 2.6227314720017603e-06
folding O 0 2.192332067352254e-05
of O 0 5.805749424325768e-06
the O 0 3.5254906833870336e-05
prohormone O 1 0.9850906133651733
. O 0 9.056838462129235e-05

In O 0 6.3147308537736535e-06
the O 0 3.133388872811338e-06
second O 0 5.515406428457936e-06
family O 0 2.194972466895706e-06
, O 0 6.381959565260331e-07
a O 0 1.3882450957680703e-06
G279A O 0 2.0377754481160082e-05
substitution O 0 2.8956048936379375e-06
at O 0 4.969072051608237e-07
position O 0 3.5472015724735684e-07
- O 0 4.1158460817314335e-07
1 O 0 2.2902673890712322e-07
of O 0 1.6707448935449065e-07
the O 0 2.98269327458911e-07
signal O 0 2.868802994271391e-06
peptide O 0 2.1571663637587335e-06
was O 0 7.706720452915761e-07
observed O 0 1.2658559001010872e-07
in O 0 1.1222199702842772e-07
all O 0 2.997369961121876e-07
affected O 0 1.4618265140597941e-06
individuals O 0 1.7691351104076602e-06
. O 0 3.5733930417336524e-05

This O 0 1.7171336367027834e-05
missense O 0 0.00013700382260140032
mutation O 0 1.810801404644735e-05
, O 0 2.5651370378909633e-06
which O 0 1.4959317695684149e-06
replaces O 0 0.00030538791907019913
Ala O 0 0.3126683831214905
with O 0 3.2164402909984346e-06
Thr O 1 0.9892511963844299
, O 0 2.1540047328016954e-06
is O 0 6.560505880770506e-07
frequent O 0 1.6317509334839997e-06
among O 0 4.491804247663822e-06
FNDI B-Disease 1 1.0
patients O 0 3.0020242775208317e-05
and O 0 4.250734662036848e-07
is O 0 2.673353378668253e-07
thought O 0 1.8851267213904066e-07
to O 0 2.4878541893258443e-08
reduce O 0 1.222401380118754e-07
the O 0 1.0741621281340485e-07
efficiency O 0 5.753370828642801e-07
of O 0 3.985506964454544e-07
cleavage O 0 4.7870667003735434e-06
by O 0 1.0267156085319584e-06
signal O 0 2.573176425357815e-05
peptidases O 0 0.0001243202859768644
. O 0 5.764092293247813e-06
. O 0 2.3403992599924095e-05

Genetic O 0 0.0005211351090110838
heterogeneity O 0 0.0010265440214425325
of O 0 0.0005607116036117077
Saethre B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.1413757571717724e-05
due O 0 4.110755253350362e-05
to O 0 2.2593931134906597e-06
TWIST O 0 0.0004481337673496455
and O 0 8.61687476572115e-06
FGFR O 1 0.9960662722587585
mutations O 0 8.136740507325158e-05
. O 0 4.9350164772477e-05

Thirty O 0 0.00025072667631320655
- O 0 5.9548343415372074e-05
two O 0 2.7011637939722277e-06
unrelated O 0 1.78835034603253e-05
patients O 0 3.893129814969143e-06
with O 0 6.71680822961207e-07
features O 0 1.008084109344054e-05
of O 0 0.0005867304280400276
Saethre B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 0.00018230348359793425
a O 0 0.0003636680485215038
common O 0 0.00022662097762804478
autosomal B-Disease 1 0.7530739307403564
dominant I-Disease 1 0.9516326785087585
condition I-Disease 1 0.9986473917961121
of O 1 0.9949365854263306
craniosynostosis B-Disease 1 1.0
and O 1 0.9974154233932495
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9992693066596985
, O 0 1.9817673546640435e-06
were O 0 2.495987132533628e-07
screened O 0 5.513431915460387e-07
for O 0 1.2363317125618778e-07
mutations O 0 6.57221676192421e-07
in O 0 7.224138016681536e-07
TWIST O 0 0.0020851604640483856
, O 0 5.754003268521046e-06
FGFR2 O 1 0.883781909942627
, O 0 3.0295707347249845e-06
and O 0 7.164582711993717e-06
FGFR3 O 1 0.9582386612892151
. O 0 8.282206545118243e-05

Nine O 0 4.0924503991845995e-05
novel O 0 4.4747295760316774e-05
and O 0 2.788473921100376e-06
three O 0 4.132059530093102e-06
recurrent O 1 0.9941887855529785
TWIST O 0 0.327858567237854
mutations O 0 6.35824608252733e-06
were O 0 5.837958383381192e-07
found O 0 5.056670602243685e-07
in O 0 5.218868182055303e-07
12 O 0 5.647782472806284e-06
families O 0 5.661263912770664e-06
. O 0 5.616091220872477e-05

Seven O 0 1.695983337413054e-05
families O 0 2.573264282546006e-06
were O 0 1.7255645161640132e-06
found O 0 5.724932066186739e-07
to O 0 1.6439328476280934e-07
have O 0 1.1966220370140945e-07
the O 0 1.3713612361243577e-06
FGFR3 O 1 0.8410755395889282
P250R O 0 0.001385939889587462
mutation O 0 3.5081068290310213e-06
, O 0 2.1655978343915194e-07
and O 0 6.166817456687568e-08
one O 0 7.512159783118477e-08
individual O 0 5.259408908386831e-08
was O 0 1.870054802566301e-06
found O 0 1.3466049608723552e-07
to O 0 5.0423771824625874e-08
have O 0 9.240765308504706e-08
an O 0 8.721788162802113e-07
FGFR2 O 1 0.6901376247406006
VV269 O 0 0.011836277320981026
- O 0 0.00031903747003525496
270 O 0 0.00016687858442310244
deletion O 0 0.0005496175144799054
. O 0 0.00010591364116407931

To O 0 2.4698697416170035e-06
date O 0 2.616595565996249e-06
, O 0 4.6102314854579163e-07
our O 0 2.8114465067119454e-07
detection O 0 1.0813625976879848e-06
rate O 0 3.4101589108104235e-07
for O 0 2.0732599637085514e-07
TWIST O 0 1.8276996343047358e-05
or O 0 6.786488597754214e-07
FGFR O 0 0.0008838631911203265
mutations O 0 5.294808715916588e-07
is O 0 1.2946814820224972e-07
68 O 0 1.015873294818448e-06
% O 0 1.755093421706988e-07
in O 0 2.6693484755924146e-07
our O 0 1.804847329367476e-06
Saethre B-Disease 1 0.9997212290763855
- I-Disease 1 0.9999982118606567
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.05710938200354576
, O 0 3.1352901714853942e-06
including O 0 6.709561262141506e-07
our O 0 6.903912890265929e-07
five O 0 1.0007153150581871e-06
patients O 0 3.6089254535909276e-06
elsewhere O 0 1.4122869060884113e-06
reported O 0 1.7651678945185267e-06
with O 0 4.028483999718446e-06
TWIST O 0 0.17748451232910156
mutations O 0 7.62645504437387e-05
. O 0 5.2359762776177377e-05

More O 0 3.163718474752386e-06
than O 0 1.2255125056981342e-06
35 O 0 2.0708582724182634e-06
different O 0 2.831692142990505e-07
TWIST O 0 3.092358019785024e-05
mutations O 0 9.740339237396256e-07
are O 0 8.99336427551134e-08
now O 0 1.7708487121126382e-07
known O 0 3.748135100067884e-07
in O 0 2.280868613979692e-07
the O 0 1.96480868908111e-06
literature O 0 2.5016519430209883e-05
. O 0 3.5034710890613496e-05

The O 0 1.752697971824091e-05
most O 0 2.746607151493663e-06
common O 0 2.4584628590673674e-06
phenotypic O 0 6.975048563617747e-06
features O 0 7.070506171658053e-07
, O 0 1.2831172568894544e-07
present O 0 7.524635492472953e-08
in O 0 3.275378546163665e-08
more O 0 1.0779401371507902e-08
than O 0 1.66098317322394e-08
a O 0 1.5947165366014815e-07
third O 0 4.804555828741286e-07
of O 0 8.377381277568929e-07
our O 0 5.023236440138135e-07
patients O 0 7.075768166941998e-07
with O 0 4.856519240092894e-07
TWIST O 0 0.0036675434093922377
mutations O 0 2.055585355265066e-06
, O 0 4.92217623104807e-07
are O 0 1.953585382352685e-07
coronal B-Disease 0 0.005559138022363186
synostosis I-Disease 0 0.002867802046239376
, O 0 1.733623548716423e-06
brachycephaly B-Disease 0 0.0009282610262744129
, O 0 4.507329322223086e-06
low B-Disease 0 8.161000732798129e-05
frontal I-Disease 1 0.9996696710586548
hairline I-Disease 1 1.0
, O 0 0.0017206765478476882
facial B-Disease 1 0.9999977350234985
asymmetry I-Disease 1 0.9999098777770996
, O 0 0.0011802122462540865
ptosis B-Disease 1 0.9999979734420776
, O 0 0.0001298952556680888
hypertelorism B-Disease 1 0.9878346920013428
, O 0 6.725090770487441e-06
broad B-Disease 0 8.564700692659244e-05
great I-Disease 0 0.0027614880818873644
toes I-Disease 0 0.0003749482275452465
, O 0 5.565590527112363e-06
and O 0 1.15282218757784e-05
clinodactyly B-Disease 0 0.06384217739105225
. O 0 0.00010396082507213578

Significant O 0 6.258187931962311e-05
intra O 0 0.0002554931561462581
- O 0 0.00011200433800695464
and O 0 7.135480245779036e-06
interfamilial O 0 0.000736089248675853
phenotypic O 0 3.5665878385771066e-05
variability O 0 9.242357009497937e-06
is O 0 2.601606468033424e-07
present O 0 3.2142523309630633e-07
for O 0 4.0647461219123215e-07
either O 0 2.7529952149052406e-06
TWIST O 0 0.00014377977640833706
mutations O 0 1.019056981022004e-05
or O 0 7.761990673316177e-06
FGFR O 1 0.9889709949493408
mutations O 0 0.00010709762864280492
. O 0 6.067089270800352e-05

The O 0 8.46359853312606e-06
overlap O 0 3.7268382584443316e-06
in O 0 1.15413160983735e-06
clinical O 0 7.008274224062916e-06
features O 0 1.2428105264916667e-06
and O 0 3.4805569271156855e-07
the O 0 3.0133429618217633e-07
presence O 0 3.831447088487039e-07
, O 0 4.5650981661538026e-08
in O 0 2.555420763883376e-08
the O 0 7.933876844390397e-08
same O 0 6.712120637075714e-08
genes O 0 3.839969764385387e-08
, O 0 1.780697367337325e-08
of O 0 4.582231127869818e-08
mutations O 0 5.606070629937676e-08
for O 0 2.1662602378569318e-08
more O 0 3.084142718989824e-08
than O 0 6.24924041403574e-08
one O 0 4.6783327434241073e-07
craniosynostotic B-Disease 0 0.0350116603076458
condition I-Disease 0 0.0004980614176020026
- O 0 1.1000333870470058e-05
such O 0 5.54653013296047e-07
as O 0 2.2221679500944447e-06
Saethre B-Disease 0 0.20217591524124146
- I-Disease 0 0.00035500936792232096
Chotzen I-Disease 0 0.09172455966472626
, I-Disease 0 2.838304681063164e-06
Crouzon I-Disease 0 0.0008059123647399247
, I-Disease 0 2.752512273218599e-06
and I-Disease 0 5.9014860198658425e-06
Pfeiffer I-Disease 1 0.9997202754020691
syndromes I-Disease 1 0.9995208978652954
- O 0 0.00016085809329524636
support O 0 2.2143997284729267e-06
the O 0 1.1906610097867087e-06
hypothesis O 0 2.547994881751947e-06
that O 0 1.7691506570827187e-07
TWIST O 0 5.564418188441778e-06
and O 0 2.1912318004524423e-07
FGFRs O 0 1.3795470295008272e-05
are O 0 2.2957731715678165e-08
components O 0 1.2832347806579492e-07
of O 0 8.08272346830563e-08
the O 0 1.451161466548001e-07
same O 0 1.7446650701913313e-07
molecular O 0 1.318917156822863e-06
pathway O 0 8.23151935946953e-07
involved O 0 6.127539364797485e-08
in O 0 5.4488559442233964e-08
the O 0 5.478148068505106e-07
modulation O 0 4.44121214968618e-05
of O 0 0.0006348175229504704
craniofacial O 1 1.0
and O 0 0.255226731300354
limb O 1 0.9999997615814209
development O 0 3.281041426816955e-05
in O 0 2.9757432002952555e-06
humans O 0 4.322174390836153e-06
. O 0 3.1567990390612977e-06
. O 0 1.9078306650044397e-05

Mutation O 0 0.0001694946113275364
analysis O 0 2.443527955620084e-05
of O 0 0.00013793069228995591
UBE3A O 1 0.9999996423721313
in O 1 0.9999524354934692
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9999923706054688
. O 0 0.09181579202413559

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.4096274673938751
AS B-Disease 1 0.9976231455802917
) O 0 6.01274223299697e-06
is O 0 1.7626714452489978e-06
caused O 0 8.92247317096917e-06
by O 0 3.3170313145092223e-06
chromosome O 0 0.00015275536861736327
15q11 O 0 0.013084306381642818
- O 0 0.00011479711974970996
q13 O 0 0.0004904098459519446
deletions O 0 1.2588515346578788e-05
of O 0 2.7022485937777674e-06
maternal O 0 1.309394974668976e-05
origin O 0 2.065225544356508e-06
, O 0 8.075625714809576e-07
by O 0 2.954238880192861e-06
paternal O 0 0.0021969613153487444
uniparental B-Disease 1 0.999995231628418
disomy I-Disease 1 0.9999065399169922
( O 0 0.00012324877025093883
UPD B-Disease 1 0.9999746084213257
) O 0 1.909051405846185e-07
15 O 0 1.7728393686411437e-07
, O 0 1.36422571017647e-07
by O 0 5.035159915678378e-07
imprinting O 0 0.09409844875335693
defects O 0 0.05856900289654732
, O 0 3.579662291031127e-07
and O 0 1.2301876495257602e-07
by O 0 3.258442973219644e-07
mutations O 0 9.719246918393765e-07
in O 0 1.0238525192107772e-06
the O 0 1.1019506928278133e-05
UBE3A O 1 0.9988476037979126
gene O 0 0.00010000028123613447
. O 0 3.4435892303008586e-05

UBE3A O 0 0.125408336520195
encodes O 0 0.0001639501570025459
a O 0 5.955083543085493e-05
ubiquitin O 0 0.0005141015280969441
- O 0 0.00013713007501792163
protein O 0 2.592185774119571e-05
ligase O 0 4.201410411042161e-05
and O 0 8.412270631197316e-07
shows O 0 3.236981001464301e-06
brain O 0 0.0009275360498577356
- O 0 5.050012987339869e-05
specific O 0 7.145095423766179e-06
imprinting O 0 0.0007980660884641111
. O 0 5.556766700465232e-05

Here O 0 5.303996294969693e-05
we O 0 9.39052551984787e-06
describe O 0 3.8829406548757106e-05
UBE3A O 0 0.46430084109306335
coding O 0 8.746545790927485e-05
- O 0 2.245579526061192e-05
region O 0 5.54498228666489e-06
mutations O 0 1.198084078168904e-06
detected O 0 1.0890065595958731e-06
by O 0 2.976505015794828e-07
SSCP O 0 0.00022050688858143985
analysis O 0 1.9228576775276451e-07
in O 0 1.2608197152985667e-07
13 O 0 9.436186019229353e-07
AS B-Disease 0 1.4590308637707494e-05
individuals O 0 3.114641344836855e-07
or O 0 1.0433255965835997e-06
families O 0 4.070652721566148e-06
. O 0 3.0206794690457173e-05

Two O 0 3.7859963413211517e-06
identical O 0 4.0405193431070074e-06
de O 0 9.384883924212772e-06
novo O 0 1.1353816262271721e-05
5 O 0 4.393409199110465e-06
- O 0 2.1213918444118463e-05
bp O 0 1.9572120436350815e-05
duplications O 0 2.0744930225191638e-05
in O 0 1.4652461004516226e-06
exon O 0 4.4993510528001934e-05
16 O 0 4.601429736794671e-06
were O 0 3.5348587061889702e-06
found O 0 9.31290014705155e-06
. O 0 3.3426265872549266e-05

Among O 0 8.941076885093935e-06
the O 0 2.842931735358434e-06
other O 0 2.2486786122044577e-07
11 O 0 1.0816554549819557e-06
unique O 0 7.120465852494817e-07
mutations O 0 4.5700417672378535e-07
, O 0 1.4285706129157916e-07
8 O 0 2.65170427837802e-07
were O 0 1.307780763681876e-07
small O 0 1.953790160769131e-07
deletions O 0 1.0797962204378564e-06
or O 0 1.5551030685401201e-07
insertions O 0 3.8199900700419676e-06
predicted O 0 1.948161525433534e-06
to O 0 1.4998957453826733e-07
cause O 0 2.956744765469921e-06
frameshifts O 0 1.5733421605546027e-05
, O 0 1.3886752014968806e-07
1 O 0 3.9127948525674583e-07
was O 0 5.322136189533921e-07
a O 0 1.4919352508968586e-07
mutation O 0 1.6852850137638598e-07
to O 0 1.8309014748751906e-08
a O 0 1.6167058447535965e-07
stop O 0 1.921273877769636e-07
codon O 0 2.238096925566424e-07
, O 0 4.469352532510129e-08
1 O 0 1.6664738211602526e-07
was O 0 7.0297221554938e-07
a O 0 3.115663389507972e-07
missense O 0 2.942101446024026e-06
mutation O 0 2.8479254865487746e-07
, O 0 5.7271609676945445e-08
and O 0 3.65962620207938e-08
1 O 0 5.023677545068495e-07
was O 0 1.4017615512784687e-06
predicted O 0 7.693810744058283e-07
to O 0 7.721656203329985e-08
cause O 0 7.213109824988351e-07
insertion O 0 8.629701255813416e-07
of O 0 4.069629255809559e-07
an O 0 5.169891323930642e-07
isoleucine O 0 4.4779993913834915e-05
in O 0 3.652259863429208e-07
the O 0 6.058607482373191e-07
hect O 0 9.954022061720025e-06
domain O 0 2.7030864657717757e-07
of O 0 1.61576409141162e-07
the O 0 7.53431436351093e-07
UBE3A O 0 0.012381662614643574
protein O 0 2.6680658038458205e-07
, O 0 6.182245471109127e-08
which O 0 1.5480649651067324e-08
functions O 0 4.4676990995640153e-08
in O 0 2.7031950367018e-07
E2 O 0 4.4888845877721906e-05
binding O 0 1.1117949725303333e-06
and O 0 1.2236147313160473e-06
ubiquitin O 0 4.714809620054439e-05
transfer O 0 1.821501246013213e-05
. O 0 3.653897510957904e-05

Eight O 0 1.0138969628314953e-05
of O 0 5.282832262309967e-06
the O 0 2.6748682557808934e-06
cases O 0 9.66923039413814e-07
were O 0 1.0984482514686533e-06
familial O 0 0.00016706166206859052
, O 0 1.9470435290713795e-06
and O 0 7.117267841749708e-07
five O 0 1.505087197983812e-06
were O 0 3.990769982920028e-06
sporadic O 0 0.00011065421858802438
. O 0 6.519357702927664e-05

In O 0 8.511874511896167e-06
two O 0 1.7214683794009034e-06
familial O 0 0.00015815231017768383
cases O 0 1.2153958550698007e-06
and O 0 5.388214958657045e-07
one O 0 6.343216227833182e-07
sporadic O 0 6.685367679892806e-06
case O 0 3.445661832301994e-06
, O 0 1.3669570080310223e-06
mosaicism O 0 0.002290687058120966
for O 0 1.1726722277671797e-06
UBE3A O 1 0.9495466947555542
mutations O 0 1.273730958928354e-06
was O 0 2.2994820483290823e-06
detected O 0 5.248981551631005e-07
in O 0 7.971996751621191e-08
the O 0 2.3477254273984727e-07
mother O 0 5.251440029496734e-07
of O 0 3.9123847273003776e-07
three O 0 2.3951170646796527e-07
AS B-Disease 0 0.009315229021012783
sons O 0 1.5753601473988965e-05
, O 0 2.4559668077017704e-07
in O 0 1.5846892154058878e-07
the O 0 5.652560730595724e-07
maternal O 0 1.0174818271480035e-05
grandfather O 0 1.3126357771398034e-05
of O 0 8.157746265169408e-07
two O 0 1.3692387312858045e-07
AS B-Disease 0 0.00010018964530900121
first O 0 1.1663026953101507e-06
cousins O 0 1.1602587619563565e-06
, O 0 8.633836046101351e-08
and O 0 4.700675759750084e-08
in O 0 1.0561441143863703e-07
the O 0 4.0537750578550913e-07
mother O 0 1.222207174578216e-06
of O 0 1.5274059705916443e-06
an O 0 6.109507921792101e-06
AS B-Disease 1 0.5626336932182312
daughter O 0 0.01757826656103134
. O 0 0.00018797890515998006

The O 0 5.084144049760653e-06
frequencies O 0 9.568491350364638e-07
with O 0 2.2754761630494613e-07
which O 0 1.4864731667785236e-07
we O 0 5.729706487045405e-08
detected O 0 1.7021774567638204e-07
mutations O 0 5.060259411493462e-08
were O 0 2.1585723430916914e-08
5 O 0 4.6595420855055636e-08
( O 0 2.6772307037958853e-08
14 O 0 7.189279926933523e-08
% O 0 5.070248931815513e-08
) O 0 1.613270761424701e-08
of O 0 2.7927661960802652e-08
35 O 0 8.170298571030798e-08
in O 0 5.8194366658881336e-08
sporadic O 0 3.632664515862416e-07
cases O 0 2.408566679434898e-08
and O 0 2.6658980800675636e-08
8 O 0 1.3195042924962763e-07
( O 0 5.383752110788009e-08
80 O 0 1.6156177196080534e-07
% O 0 7.63383596336098e-08
) O 0 3.014359961639457e-08
of O 0 1.0778810377587433e-07
10 O 0 2.0789622112715733e-07
in O 0 4.0543241652812867e-07
familial O 0 4.655912198359147e-05
cases O 0 1.894532374535629e-06
. O 0 5.792554475192446e-06
. O 0 3.727461808011867e-05

The O 0 0.0002442074182908982
hemochromatosis B-Disease 1 0.9999982118606567
845 O 0 0.05114772543311119
G O 0 0.004099460318684578
- O 0 3.1360854336526245e-05
- O 0 1.1983378499280661e-05
> O 0 7.730785910098348e-06
A O 0 1.4516322153212968e-06
and O 0 1.1035452729402095e-07
187 O 0 8.15295493339363e-07
C O 0 4.386969976621913e-06
- O 0 6.633392331423238e-06
- O 0 1.9568797142710537e-05
> O 0 3.333820859552361e-05
G O 0 3.350464248796925e-05
mutations O 0 4.950747438670078e-07
: O 0 2.0790335497622436e-07
prevalence O 0 6.246563771128422e-06
in O 0 1.0072030818264466e-06
non O 0 1.8129696400137618e-05
- O 0 0.0006260601803660393
Caucasian O 0 0.0012076199054718018
populations O 0 4.05596692871768e-05
. O 0 5.414578117779456e-05

Hemochromatosis B-Disease 1 0.9999927282333374
, O 0 0.00013211503392085433
the O 0 0.019520703703165054
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.999993085861206
iron I-Disease 1 1.0
metabolism I-Disease 1 0.999988317489624
, O 0 8.167528903868515e-06
leads O 0 6.36396089248592e-06
, O 0 5.655408017446462e-07
if O 0 3.72370124068766e-07
untreated O 0 2.6162484573433176e-05
, O 0 3.563422126262594e-07
to O 0 8.053975193433871e-07
progressive O 1 0.999893069267273
iron B-Disease 1 1.0
overload I-Disease 1 0.9999984502792358
and O 0 2.343096821277868e-05
premature B-Disease 0 0.030072366818785667
death I-Disease 0 0.00292607513256371
. O 0 9.913004032569006e-05

The O 0 0.0012897650012746453
hemochromatosis B-Disease 1 1.0
gene O 0 0.0010761992307379842
, O 0 5.256573058431968e-05
HFE O 1 0.9999079704284668
, O 0 2.362802206334891e-06
recently O 0 1.4719868204338127e-06
has O 0 1.637108368868212e-07
been O 0 8.202901824461151e-08
identified O 0 1.1319928461261952e-07
, O 0 7.11569398959e-08
and O 0 6.004932373571137e-08
characterization O 0 9.171142778541252e-07
of O 0 2.941289096725086e-07
this O 0 1.5959000165821635e-07
gene O 0 3.1143679279921344e-07
has O 0 3.8973688276655594e-08
shown O 0 2.5831527139530408e-08
that O 0 9.532731937156314e-09
it O 0 9.178928728204028e-09
contains O 0 3.4353906386286326e-08
two O 0 1.3808434395912172e-08
mutations O 0 4.434580702650237e-08
that O 0 1.9885359137106207e-08
result O 0 9.660404742817263e-08
in O 0 1.4117077284936386e-07
amino O 0 4.569061786696693e-07
acid O 0 9.807768037717324e-07
substitutions O 0 7.541287345702585e-07
- O 0 3.6908177207806148e-06
cDNA O 0 8.36241088109091e-06
nucleotides O 0 1.6293779481202364e-06
845 O 0 7.83907398727024e-06
G O 0 1.1017363249266054e-05
- O 0 3.091245162067935e-06
- O 0 5.799950031359913e-06
> O 0 6.8283766267995816e-06
A O 0 2.54833503277041e-06
( O 0 2.429561050121265e-07
C282Y O 0 4.379091024020454e-06
) O 0 8.358534131502893e-08
and O 0 8.612389024165168e-08
187 O 0 7.357438107646885e-07
C O 0 6.8354584072949365e-06
- O 0 1.7109547115978785e-05
- O 0 9.010278154164553e-05
> O 0 0.00042998060234822333
G O 0 0.001610323553904891
( O 0 6.3798811424931046e-06
H63D O 0 0.00447321031242609
) O 0 9.864644198387396e-06
. O 0 2.0382030925247818e-05

Although O 0 0.0007858351455070078
hemochromatosis B-Disease 1 0.9999997615814209
is O 0 8.228291335399263e-06
common O 0 2.4921464500948787e-06
in O 0 1.3202965192249394e-06
Caucasians O 0 2.0916766516165808e-05
, O 0 6.35679953120416e-07
affecting O 0 9.682887593953637e-07
> O 0 4.347487447375897e-06
= O 0 1.1063626743634813e-06
1 O 0 5.69164853914117e-07
/ O 0 1.1252876674916479e-06
300 O 0 1.0610789047404978e-07
individuals O 0 1.0483945267480976e-08
of O 0 1.3758385364326386e-07
northern O 0 5.332998966878222e-07
European O 0 3.782283215514326e-07
origin O 0 3.674959714317083e-07
, O 0 1.676062453270788e-07
it O 0 3.930326997192424e-08
has O 0 4.463159797296612e-08
not O 0 2.3979094265769163e-08
been O 0 6.345025838072615e-08
recognized O 0 1.8068709550789208e-07
in O 0 2.1622608414872957e-07
other O 0 3.476993697404396e-07
populations O 0 4.209524377074558e-06
. O 0 2.5145773179247044e-05

The O 0 9.219301318807993e-06
present O 0 3.2134080356627237e-06
study O 0 9.075747584574856e-07
used O 0 5.573040766648774e-07
PCR O 0 2.4011096684262156e-06
and O 0 3.2402931537944824e-07
restriction O 0 1.9623778371169465e-06
- O 0 2.7297901397105306e-06
enzyme O 0 9.490923957855557e-07
digestion O 0 3.0099366199465294e-07
to O 0 1.2010277217200382e-08
analyze O 0 1.506354330160775e-08
the O 0 1.512408687176503e-08
frequency O 0 4.215797133610977e-08
of O 0 8.676692431208721e-08
the O 0 3.4968260820278374e-07
845 O 0 1.4633002137998119e-05
G O 0 1.8666087271412835e-05
- O 0 3.3003932458086638e-06
- O 0 3.2215484679909423e-06
> O 0 3.0097467060841154e-06
A O 0 6.036558488631272e-07
and O 0 1.0708073716614308e-07
187 O 0 5.530895350602805e-07
C O 0 4.1811176743067335e-06
- O 0 4.92084745928878e-06
- O 0 1.3888268767914269e-05
> O 0 2.5965027816710062e-05
G O 0 2.2444297428592108e-05
mutations O 0 1.5476950920856325e-06
in O 0 8.069474120020459e-07
HLA O 1 0.599019467830658
- O 0 1.0685629604267888e-05
typed O 0 2.657222694324446e-06
samples O 0 2.760330346518458e-07
from O 0 2.330301924757805e-07
non O 0 2.387509994150605e-06
- O 0 2.915508594014682e-05
Caucasian O 0 0.00014241351163946092
populations O 0 6.172243161017832e-07
, O 0 3.1811467238185287e-07
comprising O 0 1.8365698224442895e-06
Australian O 0 2.4893337467801757e-05
Aboriginal O 0 1.0575189662631601e-05
, O 0 6.824573688390956e-07
Chinese O 0 2.302170059920172e-06
, O 0 7.031653126432502e-07
and O 0 1.0282617495249724e-06
Pacific O 0 5.1335478929104283e-05
Islanders O 0 9.899731230689213e-05
. O 0 6.328372546704486e-05

Results O 0 4.4014823288307525e-06
showed O 0 2.687612322915811e-06
that O 0 2.7522605705598835e-07
the O 0 1.1505095471875393e-06
845 O 0 8.08947006589733e-05
G O 0 0.0005851999158039689
- O 0 2.3872138626757078e-05
- O 0 1.9201475879526697e-05
> O 0 9.393516847922001e-06
A O 0 1.5207706383080222e-06
mutation O 0 2.960041456390172e-07
was O 0 3.414532443457574e-07
present O 0 3.650786339903789e-08
in O 0 2.293081813320441e-08
these O 0 8.793848316202002e-09
populations O 0 3.258405456563196e-08
( O 0 2.8148527064786322e-08
allele O 0 7.109806432481491e-08
frequency O 0 3.814646021282897e-08
0 O 0 3.884900223738441e-08
. O 0 9.823128976904627e-09
32 O 0 5.264105951141573e-08
% O 0 7.029065329788864e-08
) O 0 3.485266120151209e-08
, O 0 4.661568908659319e-08
and O 0 3.060924314013391e-08
, O 0 5.678149506138652e-08
furthermore O 0 1.4145203408588714e-07
, O 0 3.751002353169497e-08
it O 0 3.372666412815306e-08
was O 0 5.450362436931755e-07
always O 0 8.577552534916322e-08
seen O 0 9.672388756598593e-08
in O 0 6.967331245277819e-08
conjunction O 0 1.4093833442530013e-06
with O 0 2.2077786070440197e-06
HLA O 1 0.9999659061431885
haplotypes O 0 0.00010701952851377428
common O 0 1.2687614798778668e-06
in O 0 5.418995669970172e-07
Caucasians O 0 8.320568667841144e-06
, O 0 3.6536081893245864e-07
suggesting O 0 6.959228926461947e-07
that O 0 2.380584049888057e-07
845 O 0 4.4445514504332095e-05
G O 0 0.0012845833553001285
- O 0 4.4484906538855284e-05
- O 0 6.600384949706495e-05
> O 0 4.3158226617379114e-05
A O 0 3.70845191355329e-06
may O 0 1.8916243504918384e-07
have O 0 3.517301294664321e-08
been O 0 7.98548072111771e-08
introduced O 0 2.631761333304894e-07
into O 0 8.78955930261327e-08
these O 0 5.742759157101318e-08
populations O 0 3.429159107781743e-07
by O 0 2.043246922767139e-06
Caucasian O 0 0.00036050204653292894
admixture O 0 0.0020911917090415955
. O 0 0.00010616157669574022

187 O 0 8.86670095496811e-05
C O 0 0.00011764605733333156
- O 0 4.442686622496694e-05
- O 0 3.938289955840446e-05
> O 0 5.6498683989048004e-05
G O 0 2.8024356652167626e-05
was O 0 1.6251520946752862e-06
present O 0 1.1497227347945227e-07
at O 0 1.749203306644631e-07
an O 0 1.3059162995432416e-07
allele O 0 8.617118396614387e-07
frequency O 0 7.77640707383398e-07
of O 0 2.4473606572428253e-06
2 O 0 2.975296047225129e-05
. O 0 2.847853465937078e-05

68 O 0 6.485111953224987e-05
% O 0 4.844916929869214e-06
in O 0 6.820806106588861e-07
the O 0 4.978074343853223e-07
two O 0 1.6255135903975315e-07
populations O 0 6.700174139950832e-07
analyzed O 0 8.562633979636303e-07
( O 0 1.1795151522164815e-06
Australian O 0 2.6223431632388383e-05
Aboriginal O 0 2.178800968977157e-05
and O 0 2.3282655092771165e-06
Chinese O 0 1.1957739843637682e-05
) O 0 6.587624739040621e-06
. O 0 3.057346475543454e-05

In O 0 1.3156535715097561e-05
the O 0 7.525118689954979e-06
Australian O 0 2.6575055017019622e-05
Aboriginal O 0 8.569491001253482e-06
samples O 0 7.39247127512499e-07
, O 0 3.191015593984048e-07
187 O 0 1.1865960232171346e-06
C O 0 7.473140158253955e-06
- O 0 7.656081834284123e-06
- O 0 2.420726013951935e-05
> O 0 4.884939698968083e-05
G O 0 7.931143045425415e-05
was O 0 1.570750441715063e-06
found O 0 6.477751668398923e-08
to O 0 1.6617658360473797e-08
be O 0 3.8888146036697435e-08
associated O 0 3.8455624462585547e-07
with O 0 4.145376351516461e-06
HLA O 1 0.9999998807907104
haplotypes O 0 0.10356485098600388
common O 0 2.9459872621373506e-06
in O 0 8.349641120730666e-07
Caucasians O 0 6.353412027237937e-05
, O 0 5.124729796079919e-07
suggesting O 0 6.861235988253611e-07
that O 0 5.937611646800178e-08
it O 0 5.277879466802915e-08
was O 0 1.1073358336943784e-06
introduced O 0 5.274096110952087e-07
by O 0 6.253802098399319e-07
recent O 0 4.878857453149976e-06
admixture O 0 0.00026524977874942124
. O 0 6.353436765493825e-05

In O 0 1.0333912541682366e-05
the O 0 4.153021109232213e-06
Chinese O 0 3.6472965803113766e-06
samples O 0 4.1759386704143253e-07
analyzed O 0 4.325616203004756e-07
, O 0 3.233153620385565e-07
187 O 0 1.091793365048943e-06
C O 0 8.499796422256622e-06
- O 0 5.362407136999536e-06
- O 0 1.6356509149773046e-05
> O 0 4.481913128984161e-05
G O 0 2.3773542125127278e-05
was O 0 1.4722536434419453e-06
present O 0 1.4709385709466005e-07
in O 0 8.535918993857194e-08
association O 0 4.943292992720671e-07
with O 0 1.0118553461779811e-07
a O 0 8.469053796034132e-07
wide O 0 1.3841257668900653e-06
variety O 0 1.0259658438371844e-06
of O 0 9.827226676861756e-06
HLA O 1 0.9999871253967285
haplotypes O 0 5.3924879466649145e-05
, O 0 3.336223812766548e-07
showing O 0 4.990471325072576e-07
this O 0 6.327333323952189e-08
mutation O 0 2.060728689912139e-07
to O 0 3.317466479302311e-08
be O 0 4.81681432518144e-08
widespread O 0 4.938317488267785e-07
and O 0 7.992855444172164e-08
likely O 0 6.741836955370673e-08
to O 0 4.135352327239161e-08
predate O 0 9.863457535175257e-07
the O 0 1.573581158709203e-07
more O 0 7.489898479207113e-08
genetically O 0 1.1378801900718827e-06
restricted O 0 6.889850396873953e-07
845 O 0 8.526206511305645e-05
G O 0 0.005232550669461489
- O 0 0.00015275405894499272
- O 0 0.0002858431253116578
> O 0 0.00017236138228327036
A O 0 5.713814971386455e-05
mutation O 0 5.735553349950351e-05
. O 0 1.8601902411319315e-05

Genotype O 0 0.006186369806528091
- O 0 0.002058228477835655
phenotype O 0 0.0012659147614613175
correlations O 0 0.00017267523799091578
in O 0 0.00012215874448884279
attenuated B-Disease 1 0.999972939491272
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 0.9999984502792358
. O 0 0.006652282550930977

Germ O 1 0.9993777275085449
- O 0 0.0001530647714389488
line O 0 1.717503801046405e-05
mutations O 0 3.2135828860191396e-06
of O 0 3.9292435758397914e-06
the O 0 2.6961251933244057e-05
tumor B-Disease 1 0.9999864101409912
suppressor O 1 0.9994317889213562
APC O 0 0.0019613481126725674
are O 0 3.315442427265225e-07
implicated O 0 9.673975910118315e-06
in O 0 1.426618382538436e-05
attenuated B-Disease 1 0.9998445510864258
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
( O 1 0.9625980854034424
AAPC B-Disease 1 0.9999998807907104
) O 0 2.5268789158872096e-06
, O 0 9.55501377575274e-07
a O 0 2.285912842125981e-06
variant O 0 4.867836105404422e-05
of O 0 0.0001107317948481068
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9993731379508972
FAP B-Disease 1 0.9999973773956299
) O 0 0.00012240197975188494
. O 0 9.153422433882952e-05

AAPC B-Disease 1 0.9995349645614624
is O 0 5.908638286200585e-06
recognized O 0 1.747867145240889e-06
by O 0 3.423509156164073e-07
the O 0 4.671457816129987e-07
occurrence O 0 3.424391707085306e-06
of O 0 2.8505658065114403e-06
< O 0 0.00016178704390767962
100 O 0 7.140899015212199e-06
colonic B-Disease 1 0.988834798336029
adenomas I-Disease 0 0.019125575199723244
and O 0 2.8187511702526535e-07
a O 0 6.410152764146915e-07
later O 0 2.6739576242107432e-06
onset O 1 0.9997708201408386
of O 1 0.9998325109481812
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.8579827155917883e-05
age O 0 2.999088610522449e-05
> O 0 3.9310405554715544e-05
40 O 0 2.4574831058998825e-06
years O 0 2.3919951672723982e-06
) O 0 3.500670800349326e-06
. O 0 1.5642399375792593e-05

The O 0 9.15919281396782e-06
aim O 0 4.546634045254905e-06
of O 0 8.742865702515701e-07
this O 0 2.386466633197415e-07
study O 0 3.062682480958756e-07
was O 0 1.6626194110358483e-06
to O 0 1.880160596101632e-07
assess O 0 1.3723778238272644e-06
genotype O 0 1.7934829884325154e-05
- O 0 5.562221849686466e-05
phenotype O 0 8.502287528244779e-05
correlations O 0 1.6235448129009455e-05
in O 0 1.608377533557359e-05
AAPC B-Disease 1 0.9999866485595703
families O 0 1.0404746717540547e-05
. O 0 4.373099000076763e-05

By O 0 1.0747686246759258e-05
protein O 0 1.1906216059287544e-05
- O 0 1.471985160605982e-05
truncation O 0 7.253600051626563e-05
test O 0 1.7843594832811505e-06
( O 0 8.223923941841349e-07
PTT O 0 1.3080070857540704e-05
) O 0 9.867468264701529e-08
assay O 0 2.356240003109633e-07
, O 0 3.8524703427356144e-08
the O 0 5.711931905238998e-08
entire O 0 3.508380643779674e-07
coding O 0 7.87345470598666e-07
region O 0 2.806726229209744e-07
of O 0 2.3149625860696688e-07
the O 0 1.064445314113982e-06
APC B-Disease 0 5.717777457903139e-05
gene O 0 6.765474154235562e-07
was O 0 1.3433615322355763e-06
screened O 0 7.551513476755645e-07
in O 0 2.0154219271262264e-07
affected O 0 2.3217769751227024e-07
individuals O 0 6.542580877066939e-08
from O 0 7.336271892199875e-07
11 O 0 0.00017396642942912877
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 0.005396760068833828
, O 0 1.1522201930347364e-06
and O 0 2.4558778477512533e-07
their O 0 1.888916756342951e-07
phenotypic O 0 9.89648287941236e-06
differences O 0 1.660928433011577e-06
were O 0 3.3302710562566062e-06
examined O 0 3.7116700696060434e-05
. O 0 3.7818281271029264e-05

Five O 0 4.913682641927153e-05
novel O 0 0.0006220039795152843
germ O 1 0.9999315738677979
- O 0 0.0025633652694523335
line O 0 0.00013398939336184412
APC B-Disease 0 0.000581206928472966
mutations O 0 1.5927937511150958e-06
were O 0 7.288495567081554e-07
identified O 0 1.2856886542067514e-06
in O 0 1.9963699742220342e-06
seven O 0 2.1066265617264435e-05
kindreds O 0 0.002575753489509225
. O 0 7.057181210257113e-05

Mutations O 0 2.2078138499637134e-05
were O 0 1.6964111182460329e-06
located O 0 1.1453128081484465e-06
in O 0 8.900617132212574e-08
three O 0 3.1227486374518776e-08
different O 0 8.169874554653234e-09
regions O 0 4.5350095234653054e-08
of O 0 1.3516510932731762e-07
the O 0 5.967920628791035e-07
APC B-Disease 0 1.4754436961084139e-05
gene O 0 1.7039931776707817e-07
( O 0 3.194230302483447e-08
1 O 0 8.285866215373971e-08
) O 0 1.4356857036545989e-08
at O 0 3.024190320388698e-08
the O 0 2.3678223826095746e-08
5 O 0 5.907517675041163e-08
end O 0 8.713758603562383e-08
spanning O 0 3.254759803894558e-07
exons O 0 4.052128588227788e-07
4 O 0 9.682891288775863e-08
and O 0 2.6528569563311066e-08
5 O 0 7.394368850555111e-08
, O 0 2.2219291295755283e-08
( O 0 1.5211893966693424e-08
2 O 0 5.464978514169161e-08
) O 0 1.7920742223509478e-08
within O 0 4.009191556519909e-08
exon O 0 8.759967045079975e-07
9 O 0 1.2159182460891316e-07
, O 0 3.9297948006833394e-08
and O 0 2.09560262476316e-08
( O 0 3.383445701388155e-08
3 O 0 8.783559479752512e-08
) O 0 2.5348816379278105e-08
at O 0 7.112627287142459e-08
the O 0 1.3503239415513235e-07
3 O 0 7.245195661198522e-07
distal O 0 4.805591743206605e-06
end O 0 6.931872462700994e-07
of O 0 1.119550233852351e-06
the O 0 4.3595146053121425e-06
gene O 0 5.358997077564709e-05
. O 0 3.2962831028271466e-05

Variability O 0 6.217428017407656e-05
in O 0 1.70818918832083e-06
the O 0 1.3101004014970385e-06
number O 0 2.6893967515206896e-06
of O 0 0.17154866456985474
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.19124823808670044
most O 0 3.352905650899629e-07
apparent O 0 2.206298859164235e-06
in O 0 1.0146343498718124e-07
individuals O 0 2.761688122632222e-08
with O 0 9.221908214840369e-08
mutations O 0 3.7876324654462223e-07
in O 0 2.279737714161456e-07
region O 0 7.302772928596823e-07
1 O 0 1.678779995017976e-06
, O 0 4.5388691205516807e-07
and O 0 9.967112646336318e-07
upper O 1 0.7254067659378052
- O 1 0.9984038472175598
gastrointestinal O 1 0.9999997615814209
manifestations O 1 0.932002604007721
were O 0 1.8440250642015599e-06
more O 0 3.4196750675619114e-07
severe O 0 0.04367401450872421
in O 0 3.3220555906154914e-06
them O 0 3.0795165457675466e-06
. O 0 3.776660014409572e-05

In O 0 6.23977621216909e-06
individuals O 0 6.925991442585655e-07
with O 0 6.55952419492678e-07
mutations O 0 1.1641469654932735e-06
in O 0 4.0119383015735366e-07
either O 0 2.9193685691097926e-07
region O 0 5.198502321945853e-07
2 O 0 3.5228407568865805e-07
or O 0 4.905188788484338e-08
region O 0 1.5646655526779796e-07
3 O 0 1.3180076052776712e-07
, O 0 2.8553271747000508e-08
the O 0 2.9298826476065187e-08
average O 0 3.0835430209208425e-08
number O 0 6.255311291170074e-08
of O 0 7.152937087084865e-07
adenomas B-Disease 0 0.05559318885207176
tended O 0 5.501351552084088e-07
to O 0 3.5121793473535945e-08
be O 0 3.193158093495185e-08
lower O 0 9.504068998467119e-08
than O 0 1.9805035833542206e-08
those O 0 1.1319383652619308e-08
in O 0 3.184460695138114e-08
individuals O 0 1.6503506117260258e-08
with O 0 5.6971341422240585e-08
mutations O 0 2.568252739365562e-07
in O 0 8.342638579961204e-08
region O 0 3.5838945677824086e-07
1 O 0 6.527038749482017e-07
, O 0 1.777121951818117e-07
although O 0 1.9558483188575337e-07
age O 0 7.765038958496007e-07
at O 0 2.7267874429526273e-06
diagnosis O 0 0.0004999216180294752
was O 0 4.564687333186157e-05
similar O 0 9.396007044415455e-06
. O 0 3.05161938740639e-05

In O 0 3.789452603086829e-05
all O 0 3.7994395825080574e-05
AAPC B-Disease 1 0.9999606609344482
kindreds O 0 0.0006066556670702994
, O 0 2.985877472383436e-06
a O 0 3.3073183658416383e-06
predominance O 0 0.00011406265548430383
of O 0 2.065871740342118e-05
right O 0 0.0018556311260908842
- O 1 0.9999991655349731
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.4327453374862671
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999998807907104
sparing O 0 0.4144948720932007
was O 0 0.0006466357735916972
observed O 0 4.149210872128606e-05
. O 0 4.3628315324895084e-05

No O 0 0.0007160371751524508
desmoid B-Disease 1 0.9999269247055054
tumors I-Disease 1 0.9999964237213135
were O 0 8.660786079417448e-06
found O 0 2.357215862502926e-06
in O 0 1.9519723082339624e-06
these O 0 2.610344608910964e-06
kindreds O 0 0.00062481255736202
. O 0 4.896692917100154e-05

Our O 0 4.585913302435074e-06
data O 0 7.48525565086311e-07
suggest O 0 7.405956239381339e-07
that O 0 2.1949294648493378e-07
, O 0 5.500779707290349e-07
in O 0 1.6571613059568335e-06
AAPC B-Disease 1 0.9995148181915283
families O 0 2.3317645059250935e-07
, O 0 1.7323463907814585e-07
the O 0 2.092200475090067e-07
location O 0 4.0752374275143666e-07
of O 0 5.693113962479401e-07
the O 0 4.814481599169085e-06
APC B-Disease 0 0.004541262984275818
mutation O 0 4.933214768243488e-06
may O 0 1.0129645033885026e-06
partially O 0 7.018654741841601e-06
predict O 0 1.7598160866327817e-06
specific O 0 5.249727905720647e-07
phenotypic O 0 2.5575534891686402e-05
expression O 0 1.9577983039198443e-05
. O 0 2.5303723305114545e-05

This O 0 3.2647747048031306e-06
should O 0 4.6357936867025273e-07
help O 0 2.408893635674758e-07
in O 0 1.2391198822570004e-07
the O 0 2.1741918487805378e-07
design O 0 1.4107630477155908e-06
of O 0 7.774175401209504e-07
tailored O 0 3.0370110835065134e-06
clinical O 0 1.4894922969688196e-05
- O 0 2.5416811695322394e-05
management O 0 6.233864041860215e-06
protocols O 0 2.800698894134257e-06
in O 0 1.3056360614882578e-07
this O 0 1.4992581043316022e-07
subset O 0 6.147092790342867e-06
of O 0 8.84557084646076e-06
FAP B-Disease 1 0.9857146143913269
patients O 0 5.761614738730714e-05
. O 0 1.666381285758689e-05
. O 0 4.957113560521975e-05

Wilms B-Disease 1 0.9998613595962524
' I-Disease 0 0.00043710143654607236
tumor I-Disease 0 0.009188968688249588
1 O 0 9.212814802594949e-06
and O 0 2.7550411232368788e-06
Dax O 0 0.01913122832775116
- O 0 9.859386409516446e-06
1 O 0 3.5075047435384477e-06
modulate O 0 3.929048489226261e-06
the O 0 9.274134527004207e-07
orphan O 0 2.4575892894063145e-05
nuclear O 0 7.45830220694188e-06
receptor O 0 3.0747155506105628e-06
SF O 0 0.013655858114361763
- O 0 2.1779117105324985e-06
1 O 0 6.955526714591542e-07
in O 0 2.1705871233734797e-07
sex O 0 3.70577538433281e-07
- O 0 2.7999137728329515e-06
specific O 0 9.128698934546264e-07
gene O 0 9.622733159631025e-06
expression O 0 1.9149430954712443e-05
. O 0 2.6231009542243555e-05

Products O 0 1.3011619557801168e-05
of O 0 8.131484719342552e-06
steroidogenic O 0 0.00033825566060841084
factor O 0 5.643410986522213e-06
1 O 0 3.75871218238899e-06
( O 0 1.4752922652405687e-06
SF O 0 0.020226772874593735
- O 0 4.2491560634516645e-06
1 O 0 1.4691428305013687e-06
) O 0 3.551940608303994e-07
and O 0 1.3823067774865194e-06
Wilms B-Disease 1 0.9945145845413208
tumor I-Disease 0 0.18284867703914642
1 O 0 7.850137990317307e-06
( O 0 3.490193648758577e-06
WT1 O 0 0.0034047814551740885
) O 0 1.5520154761361482e-07
genes O 0 4.807718312349607e-08
are O 0 1.2072588262412864e-08
essential O 0 1.9746842383483454e-07
for O 0 1.4443091345128778e-07
mammalian O 0 1.1539837942109443e-05
gonadogenesis O 0 3.663821189547889e-05
prior O 0 2.8821218620578293e-06
to O 0 7.690318852837663e-07
sexual O 0 6.023060450388584e-06
differentiation O 0 0.0001988188159884885
. O 0 5.983820301480591e-05

In O 0 1.1077943781856447e-05
males O 0 9.595543815521523e-06
, O 0 4.044232355226995e-06
SF O 1 0.6404058933258057
- O 0 1.6272802895400673e-05
1 O 0 2.529584207877633e-06
participates O 0 5.864927743459702e-07
in O 0 1.0001775052614903e-07
sexual O 0 1.2723005227144313e-07
development O 0 1.8416861280456942e-07
by O 0 9.63510160545411e-08
regulating O 0 3.210000443232275e-07
expression O 0 3.3401332188987e-07
of O 0 7.098572609720577e-07
the O 0 3.7291561056918e-06
polypeptide O 0 0.024834048002958298
hormone O 0 9.601375495549291e-05
Mullerian O 0 0.18862609565258026
inhibiting O 0 0.000139005045639351
substance O 0 8.825586701277643e-05
( O 0 9.129297723120544e-06
MIS O 0 0.0517820306122303
) O 0 1.0245978955936152e-05
. O 0 2.4749042495386675e-05

Here O 0 1.680530476733111e-05
, O 0 2.4566627416788833e-06
we O 0 5.49904370927834e-07
show O 0 1.899355424939131e-06
that O 0 2.048239366558846e-06
WT1 O 0 0.03026759810745716
- O 0 0.00011599608114920557
KTS O 0 0.002693481044843793
isoforms O 0 6.85574877934414e-06
associate O 0 3.365278871569899e-06
and O 0 7.656423122170963e-07
synergize O 0 3.6458401154959574e-05
with O 0 3.542546664903057e-06
SF O 1 0.9995525479316711
- O 0 2.2337084374157712e-05
1 O 0 5.021463493903866e-06
to O 0 4.58758307786411e-07
promote O 0 4.900213752989657e-06
MIS O 0 0.0008836615597829223
expression O 0 2.653848241607193e-05
. O 0 2.0849312932114117e-05

In O 0 4.8124114982783794e-05
contrast O 0 7.693070801906288e-05
, O 0 3.2952964829746634e-05
WT1 O 1 0.9035537838935852
missense O 0 0.00022285555314738303
mutations O 0 6.423495960916625e-06
, O 0 7.675298547837883e-07
associated O 0 1.0784294772747671e-06
with O 0 8.885137390279851e-07
male B-Disease 0 1.9437040464254096e-05
pseudohermaphroditism I-Disease 1 0.9999885559082031
in O 0 0.0004334496334195137
Denys B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999997615814209
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.2745462047168985e-05
fail O 0 4.808447556570172e-06
to O 0 3.8055117101976066e-07
synergize O 0 3.6218803870724514e-05
with O 0 5.140612302056979e-06
SF O 1 0.9999746084213257
- O 0 0.0011787224793806672
1 O 0 0.0001221798302140087
. O 0 4.547663775156252e-05

Additionally O 0 1.770750168361701e-05
, O 0 1.6438872307844576e-06
the O 0 1.0684728977139457e-06
X O 0 1.609249011380598e-05
- O 0 4.145487309870077e-06
linked O 0 2.7699870770447887e-06
, O 0 3.2603455224489153e-07
candidate O 0 6.601948712159356e-07
dosage O 0 3.897320311807562e-06
- O 0 7.488878509320784e-06
sensitive O 0 1.7766113842299092e-06
sex O 0 4.4782740360460593e-07
- O 0 4.705556875705952e-06
reversal O 0 2.6905385311692953e-05
gene O 0 3.99309965359862e-06
, O 0 1.2357276091279346e-06
Dax O 0 0.0209821630269289
- O 0 7.97141001385171e-06
1 O 0 3.647665607786621e-06
, O 0 7.87112696798431e-07
antagonizes O 0 1.767081266734749e-05
synergy O 0 1.0348646355851088e-05
between O 0 1.6263351199086173e-06
SF O 1 0.8801180124282837
- O 0 7.446021754731191e-06
1 O 0 2.6022962629212998e-06
and O 0 5.139574454915419e-07
WT1 O 0 0.0005410572048276663
, O 0 1.3168290990961395e-07
most O 0 3.3732195703350953e-08
likely O 0 4.070750492246589e-08
through O 0 1.769801194484444e-08
a O 0 1.1929780896480224e-07
direct O 0 9.647827425851574e-08
interaction O 0 3.1601825867255684e-07
with O 0 1.1692428643073072e-06
SF O 1 0.9998576641082764
- O 0 0.0002332350122742355
1 O 0 6.157221650937572e-05
. O 0 3.341443880344741e-05

We O 0 7.813129741407465e-06
propose O 0 8.25005645310739e-06
that O 0 2.6890479603025597e-06
WT1 O 0 0.0013723778538405895
and O 0 3.254261628171662e-06
Dax O 0 0.2539624273777008
- O 0 1.2286052879062481e-05
1 O 0 4.1801768020377494e-06
functionally O 0 3.432876610531821e-06
oppose O 0 2.4401612108704285e-07
each O 0 1.4809710791041653e-08
other O 0 1.4046420027113982e-08
in O 0 1.107581297787874e-07
testis O 0 9.319884156866465e-06
development O 0 5.337415700523707e-07
by O 0 6.722332273056963e-07
modulating O 0 0.00018574712157715112
SF O 1 0.9996708631515503
- O 0 5.8641515352064744e-05
1 O 0 1.2314347259234637e-05
- O 0 3.636711335275322e-05
mediated O 0 3.27705784002319e-05
transactivation O 0 0.00029395040473900735
. O 0 5.8424639064469375e-06
. O 0 2.393564864178188e-05

A O 0 0.00019903844804503024
mouse O 0 4.209110193187371e-05
model O 0 9.072580724023283e-06
for O 0 3.884347825078294e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999995231628418
- O 1 0.9999744892120361
centre O 1 0.9753448963165283
mutations O 0 0.00017330799892079085
. O 0 0.00010412601113785058

Imprinting O 0 0.0005797584308311343
in O 0 1.731707016006112e-05
the O 0 2.383606079092715e-05
15q11 O 0 0.009524879045784473
- O 0 0.00023444343241862953
q13 O 0 0.00047568039735779166
region O 0 2.948710971395485e-06
involves O 0 9.618977401260054e-07
an O 0 6.065134243726789e-07
imprinting O 0 5.7759229093790054e-05
centre O 0 3.718376319739036e-05
( O 0 1.5808295756869484e-06
IC O 0 0.0019377992721274495
) O 0 1.315156197279066e-07
, O 0 3.761132560953229e-08
mapping O 0 7.145806080188777e-08
in O 0 2.7363839194549655e-08
part O 0 1.1079045947326449e-07
to O 0 6.85114116549812e-08
the O 0 5.420737352324068e-07
promoter O 0 2.635869532241486e-05
and O 0 4.7235812417056877e-07
first O 0 3.6160224681225372e-06
exon O 0 0.00016827735817059875
of O 0 2.6716643333202228e-05
SNRPN O 1 0.9771273732185364
. O 0 8.645594061817974e-05

Deletion O 0 0.00016157104982994497
of O 0 2.453407068969682e-05
this O 0 2.0624169337679632e-05
IC O 1 0.8019828796386719
abolishes O 0 0.00034233290352858603
local O 0 4.5482729547075e-06
paternally O 0 2.8693075364571996e-05
derived O 0 9.347550644633884e-07
gene O 0 9.565279697199003e-07
expression O 0 4.028700573144306e-07
and O 0 1.8596779227664229e-07
results O 0 1.081950586012681e-06
in O 0 2.5101449864450842e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999985694885254
PWS B-Disease 1 1.0
) O 0 0.00029934593476355076
. O 0 0.00011127415928058326

We O 0 4.278800588508602e-06
have O 0 6.278739874687744e-07
created O 0 1.3876600633011549e-06
two O 0 2.974932726829138e-07
deletion O 0 1.0225020560028497e-05
mutations O 0 3.815486252278788e-06
in O 0 1.389800331708102e-06
mice O 0 2.921765553764999e-05
to O 0 1.0465682862559333e-06
understand O 0 1.4456776625593193e-05
PWS B-Disease 1 0.9999903440475464
and O 0 6.502881433334551e-07
the O 0 6.598298227800115e-07
mechanism O 0 2.334900727873901e-06
of O 0 2.8443635073927e-06
this O 0 1.5797226296854205e-05
IC O 1 0.9258076548576355
. O 0 7.545759581262246e-05

Mice O 0 0.025930600240826607
harbouring O 0 0.25412511825561523
an O 0 2.2272568457992747e-05
intragenic O 0 0.14582011103630066
deletion O 0 0.00028435877175070345
in O 0 6.6264565248275176e-06
Snrpn O 0 0.12318913638591766
are O 0 5.978408239570854e-07
phenotypically O 0 2.599099389044568e-05
normal O 0 7.463984275091207e-07
, O 0 2.0499852837474464e-07
suggesting O 0 4.4734889570463565e-07
that O 0 8.297411113744602e-08
mutations O 0 2.7773302235800656e-07
of O 0 1.0229799727312638e-06
SNRPN O 0 0.03077261708676815
are O 0 1.0932066629720794e-07
not O 0 2.168584245509919e-07
sufficient O 0 2.126320623574429e-06
to O 0 2.4684616164449835e-06
induce O 0 0.0006057909922674298
PWS B-Disease 1 0.9999972581863403
. O 0 0.00015652558067813516

Mice O 0 0.00010311293590348214
with O 0 1.5233632666422636e-06
a O 0 4.4512767090054695e-06
larger O 0 1.9428960058576195e-06
deletion O 0 6.6288516791246366e-06
involving O 0 1.0684688049877877e-06
both O 0 7.909156920504756e-07
Snrpn O 0 8.867495489539579e-05
and O 0 1.452460310247261e-06
the O 0 1.7602960724616423e-05
putative O 1 0.9811819195747375
PWS O 1 1.0
- O 1 0.9675451517105103
IC O 1 0.9997674822807312
lack O 0 1.0607622243696824e-05
expression O 0 1.0404303338873433e-06
of O 0 7.723673434156808e-07
the O 0 1.7432676031603478e-06
imprinted O 0 2.700540608202573e-05
genes O 0 1.3214048522058874e-06
Zfp127 O 0 0.00034359339042566717
( O 0 2.787179028018727e-06
mouse O 0 1.0976275007124059e-05
homologue O 0 2.5526094759698026e-05
of O 0 1.6588230664638104e-06
ZNF127 O 1 0.5216911435127258
) O 0 1.597514142304135e-06
, O 0 1.621141450414143e-06
Ndn O 0 0.0005502226413227618
and O 0 9.54667939367937e-07
Ipw O 0 4.977928620064631e-05
, O 0 7.094857323863835e-07
and O 0 3.43972516247959e-07
manifest O 0 6.288066742854426e-06
several O 0 5.170556960365502e-07
phenotypes O 0 2.531096470193006e-05
common O 0 9.635553396947216e-06
to O 0 2.4883414880605415e-05
PWS B-Disease 1 1.0
infants O 0 0.08694413304328918
. O 0 0.0001648285979172215

These O 0 9.807066589928581e-07
data O 0 4.547456455838983e-07
demonstrate O 0 5.193645620238385e-07
that O 0 3.4686934213823406e-08
both O 0 2.9028599968228264e-08
the O 0 9.67827489262163e-08
position O 0 1.5706964973105642e-07
of O 0 2.0755032892338932e-07
the O 0 7.750065265099693e-07
IC O 0 0.008650627918541431
and O 0 8.71213003961202e-08
its O 0 5.838181138528853e-08
role O 0 9.745981088826738e-08
in O 0 4.648455487199499e-08
the O 0 7.970963622483396e-08
coordinate O 0 1.591644291920602e-07
expression O 0 1.9457054634131055e-07
of O 0 1.4352400512507302e-07
genes O 0 8.64817479850899e-08
is O 0 4.9558114056935665e-08
conserved O 0 2.32007707268167e-07
between O 0 1.1758925211324822e-07
mouse O 0 1.8534981336415512e-06
and O 0 7.400915791322404e-08
human O 0 1.131942113374862e-07
, O 0 5.442800699029249e-08
and O 0 3.850354346468521e-08
indicate O 0 1.092764634336163e-07
that O 0 2.7634690979994048e-08
the O 0 2.2156029899633722e-07
mouse O 0 7.85650286161399e-07
is O 0 4.537726638886852e-08
a O 0 1.386502219702379e-07
suitable O 0 3.420007601562247e-07
model O 0 1.161672145144621e-07
system O 0 8.650995653169957e-08
in O 0 3.216539568029475e-08
which O 0 1.2505660507144967e-08
to O 0 1.4082634613998835e-08
investigate O 0 7.165404980469248e-08
the O 0 9.2324675904365e-08
molecular O 0 6.498170250779367e-07
mechanisms O 0 1.7833970389347087e-07
of O 0 2.8643992777688254e-07
imprinting O 0 3.820587608061032e-06
in O 0 1.241694036480112e-07
this O 0 7.633632748138552e-08
region O 0 3.8083794606791344e-07
of O 0 3.4726923558991984e-07
the O 0 1.4846004887658637e-06
genome O 0 1.4031837963557336e-05
. O 0 3.538474629749544e-06
. O 0 1.3661328011949081e-05

Mutations O 0 1.4694071069243364e-05
of O 0 5.1231886573077645e-06
the O 0 8.890443496056832e-06
ATM O 0 0.0005649462691508234
gene O 0 5.620101546810474e-06
detected O 0 3.9508117879449856e-06
in O 0 2.4369198854401475e-06
Japanese O 1 0.6128029227256775
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.00015287207497749478
: O 0 5.266275024951028e-07
possible O 0 6.259201654756907e-07
preponderance O 0 5.063969365437515e-05
of O 0 6.494997819572745e-07
the O 0 1.0674870054572239e-06
two O 0 7.858885737732635e-07
founder O 0 0.0011636473936960101
mutations O 0 2.8229336749063805e-05
4612del165 O 0 0.002584328642114997
and O 0 1.3202158697822597e-05
7883del5 O 0 0.10523145645856857
. O 0 0.0001495688920840621

The O 0 6.0934838984394446e-05
ATM O 0 0.00199782382696867
( O 0 4.390897083794698e-05
A O 1 0.9985138773918152
- O 1 0.9989073276519775
T O 1 0.9999731779098511
, O 0 1.7626983890295378e-06
mutated O 0 4.002004970971029e-06
) O 0 2.828469689575286e-07
gene O 0 9.33959313442756e-07
on O 0 7.408315241264063e-07
human O 0 4.936862296744948e-06
chromosome O 0 7.124691182980314e-05
11q22 O 0 0.004354062490165234
. O 0 6.626424874411896e-05

3 O 0 4.805106436833739e-05
has O 0 4.892845026915893e-06
recently O 0 4.375734533823561e-06
been O 0 6.826252842984104e-07
identified O 0 4.867508778261254e-07
as O 0 2.19443137439157e-07
the O 0 2.824011744451127e-07
gene O 0 4.668865756229934e-07
responsible O 0 2.295160896892412e-07
for O 0 1.164838323575168e-07
the O 0 1.8942470205729478e-06
human O 0 0.00016689448966644704
recessive B-Disease 1 0.9999995231628418
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9651203751564026
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999985694885254
T I-Disease 1 0.9999992847442627
) O 0 1.7619588106754236e-05
. O 0 3.140314220217988e-05

In O 0 3.4257177503604908e-06
order O 0 6.680929800495505e-07
to O 0 1.5513495554841938e-07
define O 0 2.801821210596245e-07
the O 0 2.5277557824665564e-07
types O 0 3.0512137527693994e-07
of O 0 4.887807790510124e-06
disease O 1 0.9999759197235107
- O 0 0.16176293790340424
causing O 0 0.02879927307367325
ATM O 0 0.0008821610826998949
mutations O 0 5.542828489524254e-07
in O 0 3.1666479571867967e-07
Japanese O 0 4.42468372057192e-05
A B-Disease 1 0.999984622001648
- I-Disease 1 0.9999665021896362
T I-Disease 1 0.9999994039535522
patients O 0 1.0094233857671497e-06
as O 0 1.1959306789322e-07
well O 0 4.1721527566096483e-08
as O 0 4.782074469744657e-08
to O 0 2.434273049800595e-08
look O 0 4.4478458249841424e-08
for O 0 4.2136182543117684e-08
possible O 0 3.6995183450017066e-07
mutational O 0 3.657104753074236e-05
hotspots O 0 1.4407557500817347e-05
, O 0 4.789879426425614e-07
reverse O 0 1.6682848809068673e-06
- O 0 2.8098966140532866e-06
transcribed O 0 2.428924744890537e-06
RNA O 0 1.5900587868600269e-06
derived O 0 1.2974328456039075e-07
from O 0 6.268592045444166e-08
ten O 0 5.848155524290632e-07
patients O 0 5.520903414435452e-07
belonging O 0 7.790458766976371e-07
to O 0 9.405749068491787e-08
eight O 0 4.4953858946428227e-07
unrelated O 0 3.2581745017523644e-06
Japanese O 0 8.653561235405505e-05
A B-Disease 1 0.9982424974441528
- I-Disease 1 0.9091436266899109
T I-Disease 1 0.9978929162025452
families O 0 1.8970929716033424e-07
was O 0 9.5374616648769e-07
analyzed O 0 1.1852372239218312e-07
for O 0 5.730952779003928e-08
mutations O 0 2.2550267431142856e-07
by O 0 2.2410785049942206e-07
the O 0 1.7829561329563148e-06
restriction O 0 1.3818922525388189e-05
endonuclease O 0 7.944381650304422e-05
fingerprinting O 0 2.8144744646851905e-05
method O 0 6.737286639690865e-06
. O 0 2.1788300728076138e-05

As O 0 9.08244965103222e-06
has O 0 1.7533865275254357e-06
been O 0 3.9389993844451965e-07
reported O 0 2.81208997421345e-07
by O 0 1.6005365921500925e-07
others O 0 2.8544511110339954e-07
, O 0 1.5336149772338104e-07
mutations O 0 1.6745541131513164e-07
that O 0 6.015249454094374e-08
lead O 0 6.210681817719887e-07
to O 0 2.966331749121309e-07
exon O 0 0.00012259307550266385
skipping O 0 9.578621757100336e-06
or O 0 4.3233185920144024e-07
premature O 0 5.470538781082723e-06
protein O 0 1.6340619595212047e-06
truncation O 0 2.1407511667348444e-05
were O 0 2.8196842549732537e-07
also O 0 2.875094651244581e-07
predominant O 0 2.9450488909787964e-06
in O 0 6.97930772730615e-07
our O 0 3.6109290704189334e-06
mutants O 0 7.932549488032237e-05
. O 0 2.0711837350972928e-05

Six O 0 6.7097034843754955e-06
different O 0 5.107701213091786e-07
mutations O 0 1.2715802313323366e-06
were O 0 2.8606376645257114e-07
identified O 0 3.642009573923133e-07
on O 0 1.818189616642485e-07
12 O 0 3.9253382055903785e-07
of O 0 7.107975079634343e-07
the O 0 1.6731139567127684e-06
16 O 0 6.000094344926765e-06
alleles O 0 8.823874850349966e-06
examined O 0 2.5180763259413652e-05
. O 0 4.573523619910702e-05

Four O 0 6.157513325888431e-06
were O 0 3.3670314678602153e-06
deletions O 0 1.1578796147659887e-05
involving O 0 2.1483301679836586e-06
a O 0 4.218976755510084e-06
loss O 0 3.4676490031415597e-05
of O 0 3.236202928746934e-06
a O 0 6.5367457864340395e-06
single O 0 4.825393716600956e-06
exon O 0 7.127002027118579e-05
exon O 0 2.406042221991811e-05
7 O 0 2.2968213215790456e-06
, O 0 7.421483019243169e-07
exon O 0 1.0826827747223433e-05
16 O 0 1.2731019296552404e-06
, O 0 1.3136586858308874e-06
exon O 0 2.0327170204836875e-05
33 O 0 3.98797010348062e-06
or O 0 3.4321401471970603e-06
exon O 0 0.00014626355550717562
35 O 0 3.323685086797923e-05
. O 0 4.425253428053111e-05

The O 0 1.610544859431684e-05
others O 0 4.241746864863671e-06
were O 0 1.3635224149766145e-06
minute O 0 3.2877514968276955e-06
deletions O 0 9.312100701208692e-06
, O 0 1.1013075891241897e-06
4649delA O 0 2.040141771431081e-05
in O 0 2.5358690436405595e-06
exon O 0 5.7458397350274026e-05
33 O 0 5.923262051510392e-06
and O 0 2.288765927005443e-06
7883del5 O 0 0.00010177675721934065
in O 0 7.173429821705213e-06
exon O 0 0.00031745914020575583
55 O 0 5.529458576347679e-05
. O 0 6.65742190903984e-05

The O 0 4.326973794377409e-05
mutations O 0 3.733445191755891e-05
4612del165 O 0 0.00022582440578844398
and O 0 2.7257840429228963e-06
7883del5 O 0 6.747413863195106e-05
were O 0 4.059632487951603e-07
found O 0 1.1751055239983543e-07
in O 0 5.044974926704526e-08
more O 0 2.2032214275213846e-08
than O 0 2.9900466103072176e-08
two O 0 3.8350215447735536e-08
unrelated O 0 2.1308099462657992e-07
families O 0 3.21101012445979e-08
; O 0 2.58252690343852e-08
44 O 0 1.4743007170636702e-07
% O 0 1.3396802955867315e-07
( O 0 5.5095430440132986e-08
7 O 0 1.2567859641876566e-07
of O 0 1.0545981865561771e-07
16 O 0 1.616958797967527e-07
) O 0 3.112592139586923e-08
of O 0 1.0303924824484056e-07
the O 0 3.2311498898707214e-07
mutant O 0 4.638899554265663e-06
alleles O 0 2.760988593308866e-07
had O 0 2.4005069576560345e-07
one O 0 7.712544913829333e-08
of O 0 3.7035283639852423e-07
the O 0 1.6813052070574486e-06
two O 0 1.4410018138732994e-06
mutations O 0 2.167443926737178e-05
. O 0 4.546428317553364e-05

The O 0 2.846430470526684e-05
4612del165 O 0 0.0002209671656601131
mutations O 0 3.950284281017957e-06
in O 0 2.2875083516282757e-07
three O 0 8.499138459683309e-08
different O 0 1.3564775969143739e-08
families O 0 3.8407826252750965e-08
were O 0 4.82175970262233e-08
all O 0 2.5087970811910054e-08
ascribed O 0 5.560544309446414e-07
to O 0 5.481451736955023e-08
the O 0 2.386075266258558e-07
same O 0 4.1962547925322724e-07
T O 0 5.171071461518295e-05
- O 0 2.6188174615526805e-06
- O 0 5.08328093928867e-06
> O 0 8.260740287369117e-06
A O 0 2.043007270913222e-06
substitution O 0 2.764964619927923e-06
at O 0 6.937944476703706e-07
the O 0 5.570448138314532e-07
splice O 0 6.79261529512587e-06
donor O 0 1.6245414826698834e-06
site O 0 2.9262021143949823e-06
in O 0 2.0578920612024376e-06
intron O 0 0.0003210751456208527
33 O 0 3.90974928450305e-05
. O 0 4.600092506734654e-05

Microsatellite O 0 0.004218555521219969
genotyping O 0 0.00040251784957945347
around O 0 5.952697847533273e-06
the O 0 6.771400876459666e-06
ATM O 0 0.00014967031893320382
locus O 0 1.4992971046012826e-05
also O 0 4.024422821657936e-07
indicated O 0 6.307150215434376e-07
that O 0 9.795591182637509e-08
a O 0 6.692217198178696e-07
common O 0 7.984716603459674e-07
haplotype O 0 2.369063804508187e-05
was O 0 5.78948356633191e-06
shared O 0 3.6897830568705103e-07
by O 0 2.0839783587689453e-07
the O 0 6.664435545644665e-07
mutant O 0 1.217118369822856e-05
alleles O 0 6.853421155028627e-07
in O 0 4.2779416276061966e-07
both O 0 1.7588797618373064e-06
mutations O 0 2.8563392334035598e-05
. O 0 5.060763214714825e-05

This O 0 4.547423031908693e-06
suggests O 0 2.8692325031443033e-06
that O 0 1.906798701156731e-07
these O 0 6.434197530325036e-08
two O 0 1.5065893421706278e-07
founder O 0 7.940208161016926e-05
mutations O 0 1.5824209640413756e-06
may O 0 4.4467179804996704e-07
be O 0 2.080410013149958e-07
predominant O 0 3.193973498127889e-06
among O 0 8.853984354573186e-07
Japanese O 0 5.2335148211568594e-05
ATM O 0 0.0012905057519674301
mutant O 0 0.00019890035036951303
alleles O 0 2.587095877970569e-05
. O 0 3.3035274100257084e-05

W474C O 0 0.002088714623823762
amino O 0 7.621090480824932e-05
acid O 0 3.906972415279597e-05
substitution O 0 1.6992406017379835e-05
affects O 0 1.615688347555988e-06
early O 0 5.274794716569886e-07
processing O 0 5.860092073817214e-07
of O 0 1.5034761702281685e-07
the O 0 2.0441207482235768e-07
alpha O 0 1.3275816854729783e-06
- O 0 4.270824263130635e-07
subunit O 0 5.79988977733592e-07
of O 0 2.8606646651496703e-07
beta O 0 2.7816424790216843e-06
- O 0 9.182360372506082e-06
hexosaminidase O 0 9.867084008874372e-05
A O 0 3.309072553747683e-06
and O 0 2.4858459823917656e-07
is O 0 3.5772731621364073e-07
associated O 0 9.311036137660267e-07
with O 0 4.26772385253571e-06
subacute O 1 0.9999969005584717
G B-Disease 1 0.9997878670692444
( I-Disease 0 0.00010947955888696015
M2 I-Disease 1 0.9720855355262756
) I-Disease 0 1.3832805962010752e-05
gangliosidosis I-Disease 0 0.0008043525740504265
. O 0 6.137560558272526e-05

Mutations O 0 2.827239040925633e-05
in O 0 3.4901270282716723e-06
the O 0 7.072839707689127e-06
HEXA O 0 0.020936276763677597
gene O 0 1.5386824543384137e-06
, O 0 1.4782088442188979e-07
encoding O 0 1.751901095303765e-07
the O 0 1.9567923459362646e-07
alpha O 0 7.674778998989495e-07
- O 0 3.7401935060188407e-07
subunit O 0 3.866921929329692e-07
of O 0 1.8359850173510495e-07
beta O 0 1.2314219475229038e-06
- O 0 3.53998325408611e-06
hexosaminidase O 0 0.00015169937978498638
A O 0 3.547164624251309e-06
( O 0 2.5476251153122575e-07
Hex O 0 3.901641321135685e-06
A O 0 8.87886926648207e-07
) O 0 5.629150123809268e-08
, O 0 4.8270045738263434e-08
that O 0 6.404311392316231e-08
abolish O 0 2.6365294161223574e-06
Hex O 0 1.0598087101243436e-05
A O 0 4.36110349255614e-06
enzyme O 0 3.39942153004813e-06
activity O 0 6.5246695157838985e-06
cause O 0 0.3892344832420349
Tay B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
( O 0 0.0002401594683760777
TSD B-Disease 1 0.9999697208404541
) O 0 7.245562301250175e-07
, O 0 4.110095801479474e-07
the O 0 1.0240830761176767e-06
fatal O 0 0.011894828639924526
infantile B-Disease 0 0.03197583928704262
form I-Disease 0 2.525361196603626e-06
of I-Disease 0 3.1542433134745806e-05
G I-Disease 1 0.9805083870887756
( I-Disease 0 4.819295554625569e-06
M2 I-Disease 0 0.05871688947081566
) I-Disease 0 6.335085345199332e-07
gangliosidosis I-Disease 0 3.764699795283377e-05
, I-Disease 0 9.741853546074708e-07
Type I-Disease 0 8.506803169439081e-06
1 I-Disease 0 2.3792546926415525e-05
. O 0 2.8136022592661902e-05

Less O 0 6.927744107088074e-05
severe O 1 0.9789367914199829
, O 0 0.0001556150964461267
subacute O 1 0.9999994039535522
( O 0 0.002022158121690154
juvenile O 1 0.9999620914459229
- O 1 0.9874715209007263
onset O 1 0.9999997615814209
) O 0 5.711864650947973e-05
and O 0 2.459087409079075e-05
chronic O 1 0.9999997615814209
( O 0 2.6053601686726324e-05
adult O 0 2.2515621822094545e-05
- O 0 0.003755663288757205
onset O 1 0.9999750852584839
) O 0 1.2138621059420984e-06
variants O 0 6.317312113424123e-07
are O 0 1.5147326948294904e-08
characterized O 0 2.4139345100593346e-07
by O 0 7.440617366683e-08
a O 0 7.819189704605378e-07
broad O 0 1.722644242363458e-06
spectrum O 0 1.227107759405044e-06
of O 0 5.777806677542685e-07
clinical O 0 2.388675966358278e-05
manifestations O 0 0.0027233490254729986
and O 0 2.0701816083601443e-07
are O 0 1.5394581609484703e-08
associated O 0 1.4457643260357145e-07
with O 0 1.021865045913728e-07
residual O 0 4.174173955107108e-05
levels O 0 8.691538937455334e-07
of O 0 1.8303869637747994e-06
Hex O 0 6.033222598489374e-05
A O 0 1.7090860637836158e-05
enzyme O 0 7.700983587710653e-06
activity O 0 5.629038241750095e-06
. O 0 1.2944043191964738e-05

We O 0 9.364402103528846e-06
identified O 0 4.700721547123976e-06
a O 0 1.01140622064122e-05
1422 O 0 0.002255939180031419
G O 0 0.00021327620197553188
- O 0 1.5089709449966904e-05
- O 0 2.8270556867937557e-05
> O 0 3.101549009443261e-05
C O 0 1.1071331755374558e-05
( O 0 4.0210582596955646e-07
amino O 0 5.860561032022815e-07
acid O 0 8.465871701446304e-07
W474C O 0 2.71430781140225e-06
) O 0 3.621090627348167e-08
substitution O 0 1.600829762082867e-07
in O 0 2.2870539240216203e-08
the O 0 3.5454423397141e-08
first O 0 5.259599333840015e-08
position O 0 8.373485371748757e-08
of O 0 2.8742940116899263e-07
exon O 0 4.8890619837038685e-06
13 O 0 4.975910314897192e-07
of O 0 1.3810351902066031e-06
HEXA O 0 0.19216449558734894
of O 0 1.6790714880698943e-06
a O 0 2.607083160910406e-06
non O 0 4.63152628071839e-06
- O 0 1.7220107110915706e-05
Jewish O 0 7.685622222197708e-06
proband O 0 0.006744306068867445
who O 0 5.418404271040345e-06
manifested O 0 2.7759642762248404e-05
a O 0 2.0603016309905797e-05
subacute O 1 0.9998624324798584
variant O 0 0.0010763310128822923
of O 0 7.140920934034511e-05
G B-Disease 1 0.9969025254249573
( I-Disease 0 2.7924475944018923e-05
M2 I-Disease 1 0.9475817084312439
) I-Disease 0 6.7492997004592326e-06
gangliosidosis I-Disease 0 0.0004842432972509414
. O 0 2.926768320321571e-05

On O 0 1.2331317520875018e-05
the O 0 1.2853949556301814e-05
second O 0 7.372487743850797e-05
maternally O 0 0.0008034976199269295
inherited O 0 0.1030140146613121
allele O 0 2.790813050523866e-05
, O 0 5.888662713005033e-07
we O 0 9.500443809429271e-08
identified O 0 2.816706228259136e-07
the O 0 8.721996209715144e-07
common O 0 7.654448563698679e-05
infantile O 1 0.9999998807907104
disease O 1 0.9999997615814209
- O 1 0.7299849987030029
causing O 0 0.0051090954802930355
4 O 0 2.1424179067253135e-05
- O 0 3.655577529571019e-05
bp O 0 1.1061916666221805e-05
insertion O 0 8.941025953390636e-06
, O 0 1.1983777312707389e-06
+ O 0 1.2542812328319997e-05
TATC O 0 0.0007551292655989528
1278 O 0 0.00047355404240079224
, O 0 1.4001449244460673e-06
in O 0 2.655910520843463e-06
exon O 0 0.00015171717677731067
11 O 0 5.1468610763549805e-05
. O 0 5.4495965741807595e-05

Pulse O 0 0.002220336114987731
- O 0 0.0001038435148075223
chase O 0 1.9358902136445977e-05
analysis O 0 1.1510604736031382e-06
using O 0 1.1227804179725354e-06
proband O 0 0.0002613901160657406
fibroblasts O 0 9.210387361235917e-05
revealed O 0 1.899388053061557e-06
that O 0 8.39212859204963e-08
the O 0 4.0395502765022684e-07
W474C O 0 1.2620515008165967e-05
- O 0 2.1345492768887198e-06
containing O 0 1.4407833077711985e-06
alpha O 0 2.37621134147048e-06
- O 0 1.6767288570918026e-06
subunit O 0 1.7122829376603477e-06
precursor O 0 4.544873718259623e-06
was O 0 1.3850078630639473e-06
normally O 0 1.7312397915247857e-07
synthesized O 0 6.798498475291126e-07
, O 0 5.4002278204734466e-08
but O 0 1.7719528955240094e-08
not O 0 2.3743979227219825e-08
phosphorylated O 0 6.850735303487454e-07
or O 0 9.397070499517213e-08
secreted O 0 2.4048537738963205e-07
, O 0 7.715193106605511e-08
and O 0 7.748463559664742e-08
the O 0 5.499573489942122e-07
mature O 0 4.122290192754008e-06
lysosomal O 0 0.0009331844630651176
alpha O 0 9.181221685139462e-06
- O 0 4.12089093515533e-06
subunit O 0 4.795620043296367e-06
was O 0 4.812356564798392e-06
not O 0 8.363921892851067e-07
detected O 0 1.1088640349043999e-05
. O 0 2.221025170001667e-05

When O 0 1.7984719306696206e-05
the O 0 8.860354682838079e-06
W474C O 0 8.34467718959786e-05
- O 0 1.1539485058165155e-05
containing O 0 2.6292075290257344e-06
alpha O 0 6.1760388234688435e-06
- O 0 3.1262729862646665e-06
subunit O 0 6.489205588877667e-06
was O 0 6.839331945229787e-06
transiently O 0 1.2895006875623949e-05
co O 0 2.5442554942856077e-06
- O 0 1.2159232483099913e-06
expressed O 0 2.0698125524631905e-07
with O 0 4.698094357991067e-08
the O 0 1.6905148925161484e-07
beta O 0 7.278673592736595e-07
- O 0 5.926115704824042e-07
subunit O 0 4.6202228531910805e-07
to O 0 3.7400006647203554e-08
produce O 0 9.8724569852493e-08
Hex O 0 1.5905379768810235e-06
A O 0 8.753469273869996e-07
( O 0 1.8573294369161886e-07
alphabeta O 0 8.756310307944659e-06
) O 0 1.3234034668130334e-07
in O 0 1.9433169029525743e-07
COS O 0 3.596644091885537e-05
- O 0 2.5639653813414043e-06
7 O 0 1.0183301810684497e-06
cells O 0 3.357475009124755e-07
, O 0 3.110461577193746e-08
the O 0 8.021889641440794e-08
mature O 0 1.4932449232674117e-07
alpha O 0 5.810097718494944e-07
- O 0 2.4509526497240586e-07
subunit O 0 4.3093396584481525e-07
was O 0 3.0760364211346314e-07
present O 0 4.9719062644726364e-08
, O 0 2.2967716617472433e-08
but O 0 1.2017014938692228e-08
its O 0 1.5296354405336388e-08
level O 0 9.751020968451485e-08
was O 0 4.092366054919694e-07
much O 0 7.73753399130328e-08
lower O 0 6.078950320898002e-08
than O 0 7.872267282493794e-09
that O 0 1.1012550871214444e-08
from O 0 3.5905408424241614e-08
normal O 0 2.530322262828122e-07
alpha O 0 1.1902682217623806e-06
- O 0 8.387646062146814e-07
subunit O 0 1.8479402115190169e-06
transfections O 0 5.96303834754508e-06
, O 0 8.701834275370857e-08
although O 0 4.474026837897327e-08
higher O 0 4.623255023261663e-08
than O 0 2.496014950281733e-08
in O 0 6.223999093890598e-08
those O 0 7.603349416740457e-08
cells O 0 1.0737212505773641e-06
transfected O 0 4.854564849665621e-06
with O 0 1.210069484613996e-07
an O 0 8.278881864498544e-07
alpha O 0 1.6657679225318134e-05
- O 0 1.0691164789022878e-05
subunit O 0 1.2534273992059752e-05
associated O 0 3.595747330109589e-06
with O 0 1.4347283467941452e-05
infantile O 1 0.9999101161956787
TSD B-Disease 1 0.9999779462814331
. O 0 0.00043046061182394624

Furthermore O 0 2.1374669813667424e-05
, O 0 1.6054025309131248e-06
the O 0 9.667570566307404e-07
precursor O 0 5.3772942010255065e-06
level O 0 4.1867488675961795e-07
of O 0 3.306935525415611e-07
the O 0 5.793687023469829e-07
W474C O 0 2.0749401301145554e-05
alpha O 0 3.19257878800272e-06
- O 0 1.3764791901849094e-06
subunit O 0 1.2773024309353787e-06
was O 0 1.0082409289680072e-06
found O 0 9.382939936131152e-08
to O 0 2.493583473039962e-08
accumulate O 0 9.488130103818548e-08
in O 0 5.537883396300458e-08
comparison O 0 1.1084668471994519e-07
to O 0 3.5462672798303174e-08
the O 0 1.519374706049348e-07
normal O 0 7.694250712120265e-07
alpha O 0 5.420192792371381e-06
- O 0 5.53670770386816e-06
subunit O 0 1.7581371139385737e-05
precursor O 0 3.645241667982191e-05
levels O 0 1.1348327461746521e-05
. O 0 2.8313019356573932e-05

We O 0 4.907359652861487e-06
conclude O 0 7.654271030332893e-06
that O 0 5.51227515188657e-07
the O 0 2.606508587632561e-06
1422 O 0 0.002312772674486041
G O 0 0.0004729617212433368
- O 0 2.9983077183715068e-05
- O 0 4.516089757089503e-05
> O 0 3.0242244974942878e-05
C O 0 1.5413967048516497e-05
mutation O 0 4.842081011702248e-07
is O 0 6.395741536380228e-08
the O 0 1.7798595308704535e-07
cause O 0 1.923548779814155e-06
of O 0 3.217980520275887e-06
Hex B-Disease 0 0.05546710267663002
A I-Disease 0 0.31174805760383606
enzyme I-Disease 1 0.996911883354187
deficiency I-Disease 1 0.9999996423721313
in O 0 3.6008843835588777e-06
the O 0 1.7049087546183728e-05
proband O 0 0.3495112955570221
. O 0 6.963642954360694e-05

The O 0 3.5650744393933564e-05
resulting O 0 5.285022780299187e-05
W474C O 0 0.00021232017024885863
substitution O 0 4.2719108023447916e-05
clearly O 0 3.037677288375562e-06
interferes O 0 1.4454833490162855e-06
with O 0 2.071959386285016e-07
alpha O 0 3.270446086389711e-06
- O 0 1.0219931709798402e-06
subunit O 0 1.0462609907335718e-06
processing O 0 3.227158913432504e-07
, O 0 4.584250490324848e-08
but O 0 2.1314393805482723e-08
because O 0 2.0908673903363706e-08
the O 0 6.503278626723841e-08
base O 0 3.9662339190726925e-07
substitution O 0 9.711927759781247e-07
falls O 0 6.109556238698133e-07
at O 0 8.615707258741168e-08
the O 0 4.74250718696112e-08
first O 0 1.0071705958125676e-07
position O 0 1.8445723526383517e-07
of O 0 5.370674784899165e-07
exon O 0 1.1810993783001322e-05
13 O 0 7.168412139435532e-07
, O 0 2.712806974614068e-07
aberrant O 0 1.924627667904133e-06
splicing O 0 1.1399590675864602e-06
may O 0 1.291140279136016e-07
also O 0 8.379508642519795e-08
contribute O 0 1.7299261401149124e-07
to O 0 1.201145067852849e-07
Hex B-Disease 0 7.388040830846876e-05
A I-Disease 0 0.003316038753837347
deficiency I-Disease 1 0.9996782541275024
in O 0 1.0128939038622775e-06
this O 0 1.0813233757289709e-06
proband O 0 0.0004467944090720266
. O 0 8.772273758950178e-06
. O 0 1.6760743164923042e-05

Two O 0 3.0490973585983738e-05
frequent O 0 0.00011993777297902852
missense O 0 0.0015576569130644202
mutations O 0 0.00027909118216484785
in O 0 0.0018607332604005933
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.53106689453125

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.2263321727514267
an O 1 0.9993273019790649
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999992847442627
by O 0 0.19425174593925476
early O 1 0.9999927282333374
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999967813491821
goiter B-Disease 1 1.0
. O 1 0.9958428740501404

A O 0 6.916021084180102e-05
century O 0 2.836956446117256e-05
after O 0 3.1262820812116843e-06
its O 0 5.946779992882512e-07
recognition O 0 1.9550611796148587e-06
as O 0 1.1138771469632047e-06
a O 0 4.3008756620110944e-05
syndrome O 1 0.9999967813491821
by O 0 5.361890544008929e-06
Vaughan O 1 0.9268621206283569
Pendred O 1 0.9873692393302917
, O 0 2.6261152470397064e-06
the O 0 1.148124283645302e-05
disease O 1 0.9996293783187866
gene O 0 2.6921015887637623e-05
( O 0 3.965518317272654e-06
PDS O 0 0.2070518434047699
) O 0 4.6754155391681707e-07
was O 0 3.5034597658523126e-06
mapped O 0 2.281008619320346e-06
to O 0 6.194935053827066e-07
chromosome O 0 5.419620356406085e-05
7q22 O 0 0.028318921104073524
- O 0 0.02514791488647461
q31 O 0 0.05781290680170059
. O 0 0.00010845285578398034

1 O 0 2.873902667488437e-05
and O 0 2.743764071055921e-06
, O 0 1.5418772818520665e-06
recently O 0 2.180646788474405e-06
, O 0 2.826927243404498e-07
found O 0 1.9858300959185726e-07
to O 0 2.2410102928915876e-07
encode O 0 1.0281244158250047e-06
a O 0 7.252686827996513e-06
putative O 0 0.0003077961737290025
sulfate O 0 0.4666840732097626
transporter O 0 0.38787081837654114
. O 0 0.00013158659567125142

We O 0 6.20933542450075e-06
performed O 0 5.4911170082050376e-06
mutation O 0 1.9949311536038294e-06
analysis O 0 2.48706726324599e-07
of O 0 9.109340339819028e-07
the O 0 3.3650699151621666e-06
PDS B-Disease 1 0.9004570841789246
gene O 0 3.9620026655029505e-06
in O 0 5.102603495288349e-07
patients O 0 1.133427872446191e-06
from O 0 4.834486162508256e-07
14 O 0 3.80265987587336e-06
Pendred B-Disease 0 0.0023987870663404465
families O 0 1.3475633409143484e-07
originating O 0 4.227102010645467e-07
from O 0 9.741484063852113e-08
seven O 0 1.830022426929645e-07
countries O 0 6.290630949479237e-08
and O 0 1.6860244045346917e-07
identified O 0 9.155028237728402e-07
all O 0 7.944626645439712e-07
mutations O 0 1.278119543712819e-05
. O 0 2.5306981115136296e-05

The O 0 1.6825319107738324e-05
mutations O 0 4.935059223498683e-06
include O 0 8.332983156833507e-07
three O 0 2.285347449060282e-07
single O 0 1.2540758689283393e-06
base O 0 4.205198820272926e-06
deletions O 0 5.168435109226266e-06
, O 0 4.898732868241495e-07
one O 0 3.9496862314081227e-07
splice O 0 5.97795633439091e-06
site O 0 1.8844845044441172e-06
mutation O 0 1.1543716027517803e-06
and O 0 2.6228738647660066e-07
10 O 0 3.1897607186692767e-06
missense O 0 0.0001237857068190351
mutations O 0 2.9224956961115822e-05
. O 0 2.8598988137673587e-05

One O 0 3.026757804036606e-05
missense O 0 0.0001999619707930833
mutation O 0 2.6709356461651623e-05
( O 0 2.8424356059986167e-06
L236P O 0 0.00011765772069338709
) O 0 5.767060997641238e-07
was O 0 1.4845281839370728e-06
found O 0 8.575851495606912e-08
in O 0 3.391405911656875e-08
a O 0 1.2983413455458503e-07
homozygous O 0 4.050486381856899e-07
state O 0 3.4288181183228517e-08
in O 0 4.2852583703734126e-08
two O 0 3.699016914993081e-08
consanguineous O 0 2.2283265934675e-06
families O 0 3.7984044354288926e-08
and O 0 4.765539074469416e-08
in O 0 5.8938883995551805e-08
a O 0 3.3190110571013065e-07
heterozygous O 0 1.5133818465074e-07
state O 0 2.7459151397124515e-08
in O 0 3.488085908998073e-08
five O 0 7.650700695194246e-08
additional O 0 4.52337332035313e-07
non O 0 4.550997800834011e-06
- O 0 0.00010605886927805841
consanguineous O 0 0.0002808593271765858
families O 0 7.212021955638193e-06
. O 0 5.4748910770285875e-05

Another O 0 4.8030447942437604e-05
missense O 0 0.0001873951405286789
mutation O 0 2.48480628215475e-05
( O 0 2.5730653305799933e-06
T416P O 0 0.00012170657282695174
) O 0 4.1933026295737363e-07
was O 0 1.586667167430278e-06
found O 0 7.167113835748751e-08
in O 0 4.1221383639822307e-08
a O 0 1.3191331049711152e-07
homozygous O 0 2.9385918765001406e-07
state O 0 4.1698299924064486e-08
in O 0 8.409946872234286e-08
one O 0 8.661066885906621e-08
family O 0 1.252994792366735e-07
and O 0 4.3813699335260026e-08
in O 0 9.819123647503147e-08
a O 0 4.323351845414436e-07
heterozygous O 0 2.8671843210759107e-07
state O 0 6.550546771677546e-08
in O 0 2.4264627995762567e-07
four O 0 1.2480006716941716e-06
families O 0 2.9863190320611466e-06
. O 0 4.294105383451097e-05

Pendred B-Disease 0 0.32347315549850464
patients O 0 3.6642333725467324e-05
in O 0 2.4773762561380863e-06
three O 0 1.2117754977225559e-06
non O 0 1.2361198059807066e-05
- O 0 6.116771692177281e-05
consanguineous O 0 5.798456913908012e-05
families O 0 2.0774162123871065e-07
were O 0 2.1173433140120324e-07
shown O 0 1.8687323688482138e-07
to O 0 1.0933005256674733e-07
be O 0 3.928023204480269e-07
compound O 0 9.99325857264921e-06
heterozygotes O 0 8.111888746498153e-06
for O 0 1.327989366473048e-06
L236P O 0 0.0003001478035002947
and O 0 9.854065865511075e-06
T416P O 0 0.001982534769922495
. O 0 7.939178613014519e-05

In O 0 4.100177193322452e-06
total O 0 2.550416184021742e-06
, O 0 6.888897701173846e-07
one O 0 1.5596715741139633e-07
or O 0 6.4262131616033e-08
both O 0 3.559223316074167e-08
of O 0 1.5636391026419005e-07
these O 0 3.259076564177121e-08
mutations O 0 1.268146831989725e-07
were O 0 8.028670350768152e-08
found O 0 5.534451830158105e-08
in O 0 3.916609969678575e-08
nine O 0 1.0026911212435152e-07
of O 0 3.2926422477430606e-07
the O 0 6.720088663314527e-07
14 O 0 3.0194294140528655e-06
families O 0 1.28210854200006e-06
analyzed O 0 1.310095740336692e-05
. O 0 3.4838809369830415e-05

The O 0 9.63579168455908e-06
identification O 0 3.5934162951889448e-06
of O 0 2.0529053017526167e-06
two O 0 1.1672062782963621e-06
frequent O 0 1.429618896509055e-05
PDS B-Disease 1 0.7872381806373596
mutations O 0 1.7351816268273978e-06
will O 0 1.0470120770378344e-07
facilitate O 0 3.7727653534602723e-07
the O 0 8.517619676240429e-07
molecular O 0 3.957267836085521e-05
diagnosis O 0 0.28592661023139954
of O 1 0.8198660612106323
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.8115386366844177

Insertional O 0 0.0018904191674664617
mutation O 0 4.208491736790165e-05
by O 0 3.460153948253719e-06
transposable O 0 0.0010450348490849137
element O 0 2.979151759063825e-05
, O 0 2.197423100369633e-06
L1 O 0 0.00021913426462560892
, O 0 3.565312169939716e-07
in O 0 5.235238518253027e-07
the O 0 4.015178546978859e-06
DMD B-Disease 1 0.9999992847442627
gene O 0 4.549817731458461e-06
results O 0 5.282623192215397e-07
in O 0 1.6240288687185966e-06
X B-Disease 1 0.8349747657775879
- I-Disease 1 0.9954202771186829
linked I-Disease 1 0.972132682800293
dilated I-Disease 1 0.9999922513961792
cardiomyopathy I-Disease 1 1.0
. O 0 0.031046994030475616

X B-Disease 1 0.9760144352912903
- I-Disease 1 0.9991509914398193
linked I-Disease 1 0.9996795654296875
dilated I-Disease 1 0.9999995231628418
cardiomyopathy I-Disease 1 1.0
( O 0 0.12337157875299454
XLDCM B-Disease 1 0.9999920129776001
) O 0 1.8474012222213787e-06
is O 0 3.500489924590511e-07
a O 0 5.957679150014883e-07
clinical O 0 5.276543561194558e-06
phenotype O 0 3.384711453691125e-05
of O 0 2.814112121996004e-06
dystrophinopathy B-Disease 0 0.12268766760826111
which O 0 3.500940692902077e-07
is O 0 3.025748469553946e-07
characterized O 0 2.4135715648299083e-06
by O 0 1.0821032674357411e-06
preferential O 0 0.0007690441561862826
myocardial B-Disease 1 1.0
involvement I-Disease 0 0.00022204976994544268
without O 0 1.4488412034552312e-06
any O 0 7.826687919987307e-07
overt O 0 1.3572608622780535e-05
clinical O 0 0.00019525294192135334
signs O 0 0.19173835217952728
of O 1 0.9942317605018616
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.7723967432975769

To O 0 2.0644772575906245e-06
date O 0 4.416067440615734e-06
, O 0 9.143458896687662e-07
several O 0 2.9951928581795073e-07
mutations O 0 8.535720326108276e-07
in O 0 1.4751643675481318e-06
the O 0 0.005183876492083073
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.999984860420227
, O 1 0.9071159958839417
DMD O 1 1.0
, O 0 2.6852526389120612e-06
have O 0 9.180087801041736e-08
been O 0 1.8544569968526048e-07
identified O 0 3.232783569728781e-07
in O 0 2.6007282372120244e-07
patients O 0 1.6058849041655776e-06
with O 0 2.120055796694942e-06
XLDCM B-Disease 1 0.9999970197677612
, O 0 1.0720524414864485e-06
but O 0 1.0569885233735477e-07
a O 0 3.20017676358475e-07
pathogenic O 0 8.739472718843899e-07
correlation O 0 3.172403069129359e-07
of O 0 2.9241695642667764e-07
these O 0 1.358036598730905e-07
cardiospecific O 0 0.00014073941565584391
mutations O 0 2.776024530248833e-06
in O 0 2.307253680555732e-06
DMD O 1 0.9999998807907104
with O 0 2.0287213828851236e-06
the O 0 3.5403689253143966e-05
XLDCM B-Disease 1 0.9999934434890747
phenotype O 0 0.001297612558118999
has O 0 6.832401595602278e-07
remained O 0 3.1564802611683263e-06
to O 0 3.052913655210432e-07
be O 0 1.6566128806516645e-06
elucidated O 0 0.00015758270455989987
. O 0 4.82180985272862e-05

We O 0 6.015048256813316e-06
report O 0 1.3591912875199341e-06
here O 0 5.981841582070047e-07
the O 0 2.712232856083574e-07
identification O 0 4.831342721445253e-07
of O 0 4.33891983675494e-07
a O 0 9.535970093565993e-07
unique O 0 1.3171523960409104e-06
de O 0 5.350897936295951e-06
novo O 0 2.1008565454394557e-05
L1 O 0 5.9402413171483204e-05
insertion O 0 3.5150558232999174e-06
in O 0 5.31964985839295e-07
the O 0 1.972938434846583e-06
muscle O 0 0.00012033137318212539
exon O 0 8.487608283758163e-05
1 O 0 3.6026463021698873e-06
in O 0 2.4961971121229e-06
DMD O 1 0.9999943971633911
in O 0 1.210285631714214e-06
three O 0 1.5861679685258423e-06
XLDCM B-Disease 1 0.9999064207077026
patients O 0 9.296430107497144e-06
from O 0 9.963159754988737e-07
two O 0 1.2256995205461862e-06
unrelated O 0 2.205475902883336e-05
Japanese O 0 8.445021376246586e-05
families O 0 1.4355509847518988e-05
. O 0 6.0534737713169307e-05

The O 0 1.2540814168460201e-05
insertion O 0 3.4645683626877144e-05
was O 0 1.3138743270246778e-05
a O 0 2.4761739041423425e-06
5 O 0 1.6898376316021313e-06
- O 0 2.993516091009951e-06
truncated O 0 2.740568334047566e-06
form O 0 1.415480994637619e-07
of O 0 4.0650715504852997e-07
human O 0 8.68795098085684e-07
L1 O 0 2.4168506570276804e-05
inversely O 0 1.3074244407107471e-06
integrated O 0 9.188231615553377e-07
in O 0 6.773131389081755e-08
the O 0 1.6754199805291137e-07
5 O 0 6.470947369052737e-07
- O 0 3.652037321444368e-06
untranslated O 0 2.5913057470461354e-05
region O 0 3.3517676456540357e-07
in O 0 1.1580628012097804e-07
the O 0 5.307396691023314e-07
muscle O 0 2.1947711502434686e-05
exon O 0 1.1043935046473052e-05
1 O 0 4.4578766278391413e-07
, O 0 5.777366141046514e-08
which O 0 1.3221994166201512e-08
affected O 0 2.062649073764078e-08
the O 0 3.9784392669162116e-08
transcription O 0 2.519919064525311e-07
or O 0 2.1303257824456523e-08
the O 0 7.924212752641324e-08
stability O 0 8.392198651563376e-07
of O 0 3.7841448374820175e-07
the O 0 1.069501536221651e-06
muscle O 0 2.3235223125084303e-05
form O 0 6.812147148593795e-07
of O 0 1.8275123920830083e-06
dystrophin O 0 0.000501857663039118
transcripts O 0 1.0226151516690152e-06
but O 0 3.578774254719974e-08
not O 0 1.0252029447599398e-08
that O 0 1.2933357496081044e-08
of O 0 1.9218622071548452e-07
the O 0 3.0057196909183403e-06
brain O 1 0.807223916053772
or O 0 8.134004929161165e-06
Purkinje O 1 0.9999585151672363
cell O 0 0.0001916623441502452
form O 0 7.823135774742696e-07
, O 0 4.99522343488934e-07
probably O 0 5.487979137797083e-07
due O 0 2.449256157888158e-07
to O 0 3.3139880173393976e-08
its O 0 5.692344018370932e-08
unique O 0 2.1154821183699823e-07
site O 0 5.870249424333451e-07
of O 0 1.0118820910065551e-06
integration O 0 3.912125248461962e-05
. O 0 2.363862222409807e-05

We O 0 4.658068064600229e-06
speculate O 0 4.16848070017295e-06
that O 0 1.983080295531181e-07
this O 0 1.6303775396409037e-07
insertion O 0 1.641368157834222e-06
of O 0 5.645955525324098e-07
an O 0 1.1074774874941795e-06
L1 O 0 0.0002603718312457204
sequence O 0 9.765907407199848e-07
in O 0 1.7625924328967812e-06
DMD O 1 0.9999986886978149
is O 0 2.1290142626639863e-07
responsible O 0 1.3292242329043802e-07
for O 0 2.1756846990683698e-08
some O 0 1.8384602284982066e-08
of O 0 8.338215451431097e-08
the O 0 1.5962898203270015e-07
population O 0 1.0400933803111911e-07
of O 0 8.387102070628316e-07
Japanese O 0 4.1974097257480025e-05
patients O 0 7.537228157161735e-06
with O 0 4.020167580165435e-06
XLDCM B-Disease 1 0.9997759461402893
. O 0 2.873540870496072e-05
. O 0 6.25007669441402e-05

Severe O 1 0.9974060654640198
early O 0 0.08436892181634903
- O 1 0.9999496936798096
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.999996542930603
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9991940855979919
red O 1 1.0
hair O 1 0.9999992847442627
pigmentation O 1 0.9999992847442627
caused O 1 0.9365730881690979
by O 0 0.00012480693112593144
POMC O 1 0.9999967813491821
mutations O 0 1.1884049854415935e-05
in O 0 4.8922101996140555e-06
humans O 0 1.2132639312767424e-05
. O 0 2.6504792913328856e-05

Sequential O 0 4.278923734091222e-05
cleavage O 0 1.8069353245664388e-05
of O 0 1.894510774036462e-06
the O 0 1.8999278381670592e-06
precursor O 0 1.9782590243266895e-05
protein O 0 2.9526474918384338e-06
pre O 0 1.7773263607523404e-05
- O 0 3.473467586445622e-05
pro O 0 8.495381916873157e-05
- O 0 0.00017637106066104025
opiomelanocortin O 0 0.026622068136930466
( O 0 8.042408808250912e-06
POMC O 0 0.005355812609195709
) O 0 6.089209705351095e-07
generates O 0 1.4265897334553301e-06
the O 0 2.0529250832623802e-06
melanocortin O 0 0.0004810169921256602
peptides O 0 9.798834071261808e-06
adrenocorticotrophin O 0 0.00013483081420417875
( O 0 4.263887149136281e-06
ACTH O 0 0.00026885836268775165
) O 0 1.1349929991411045e-06
, O 0 1.650119770602032e-06
melanocyte O 0 0.0007925161626189947
- O 0 5.174243051442318e-05
stimulating O 0 5.1431521569611505e-05
hormones O 0 3.2882721825444605e-06
( O 0 7.634672556378064e-07
MSH O 0 0.00015299793449230492
) O 0 1.1692222301462607e-07
alpha O 0 2.672165635431156e-07
, O 0 2.6354124216254604e-08
beta O 0 1.0369913638896833e-07
and O 0 2.4080797800252185e-08
gamma O 0 1.8925753408893797e-07
as O 0 4.458990332523172e-08
well O 0 4.175567980269079e-08
as O 0 9.651066790183904e-08
the O 0 5.170103349882993e-07
opioid O 0 1.7303138520219363e-05
- O 0 9.921033779392019e-06
receptor O 0 6.943623702682089e-06
ligand O 0 1.4142226063995622e-05
beta O 0 3.8613165088463575e-05
- O 0 0.0006754680653102696
endorphin O 0 0.060219865292310715
. O 0 3.4773285733535886e-05

While O 0 1.6343317838618532e-05
a O 0 9.04773060028674e-06
few O 0 1.3273803460833733e-06
cases O 0 9.996966809922014e-07
of O 0 2.5126213586190715e-05
isolated O 1 0.9994884729385376
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 8.206358756979171e-07
been O 0 7.587586310364713e-07
reported O 0 2.405304030617117e-06
( O 0 5.090091690362897e-06
OMIM O 1 0.9962540864944458
201400 O 0 0.00046022122842259705
) O 0 8.172984848897613e-07
, O 0 7.650597808606108e-07
an O 0 4.764512141264277e-06
inherited O 1 0.9999985694885254
POMC O 1 1.0
defect O 1 0.999825656414032
has O 0 8.917386935536342e-07
not O 0 1.0572021835741907e-07
been O 0 2.2706853997078724e-07
described O 0 1.288251382902672e-06
so O 0 5.779553475804278e-07
far O 0 3.0875032734911656e-06
. O 0 1.8526538042351604e-05

Recent O 0 1.2922152563987765e-05
studies O 0 4.272080786904553e-06
in O 0 1.7411740600437042e-06
animal O 0 2.8661229407589417e-06
models O 0 7.23423170256865e-07
elucidated O 0 7.60294460633304e-06
a O 0 5.66861558581877e-07
central O 0 5.858024110239057e-07
role O 0 3.2508881986359484e-07
of O 0 1.2053809541612281e-06
alpha O 0 1.2183691069367342e-05
- O 0 9.65133494901238e-06
MSH O 0 0.0012052286183461547
in O 0 1.287259863147483e-07
the O 0 9.00225458622117e-08
regulation O 0 1.6647994982577075e-07
of O 0 1.290234337147922e-07
food O 0 1.526421442576975e-07
intake O 0 2.2588321257899224e-07
by O 0 4.8631651594632785e-08
activation O 0 2.893560235861514e-07
of O 0 2.573858068899426e-07
the O 0 8.257914601017546e-07
brain O 0 4.1539773519616574e-05
melanocortin O 0 0.00017792604921851307
- O 0 2.550347971919109e-06
4 O 0 1.3766747315457906e-06
- O 0 3.6568817449733615e-06
receptor O 0 1.633419856261753e-06
( O 0 6.920874966453994e-07
MC4 O 0 0.0004271549405530095
- O 0 2.667668695721659e-06
R O 0 3.5340904105396476e-06
; O 0 8.682138741278322e-08
refs O 0 6.63421303670475e-07
3 O 0 1.263328073264347e-07
- O 0 2.2079166228650138e-07
5 O 0 1.306142962675949e-07
) O 0 2.50627163467243e-08
and O 0 2.1863343135919422e-08
the O 0 7.874913166006081e-08
linkage O 0 2.6712634735304164e-06
of O 0 6.752588888048194e-07
human O 0 9.646444141253596e-07
obesity B-Disease 0 0.009125042706727982
to O 0 7.840024096594789e-08
chromosome O 0 4.769622137246188e-07
2 O 0 2.198648161311212e-07
in O 0 6.913757033544243e-08
close O 0 1.1397489174669317e-07
proximity O 0 2.844923301381641e-07
to O 0 4.2106297115651614e-08
the O 0 9.352133361062442e-07
POMC O 0 0.2325328290462494
locus O 0 1.8284328007212025e-06
, O 0 1.1682670475465784e-07
led O 0 3.2274789418806904e-07
to O 0 4.316051516184416e-08
the O 0 9.403704837041005e-08
proposal O 0 1.5311978529553016e-07
of O 0 2.6994388235834776e-07
an O 0 7.093997851370659e-07
association O 0 7.1555555223312695e-06
of O 0 2.2928839825908653e-05
POMC O 1 0.9999333620071411
with O 0 1.1033933333237655e-05
human O 0 0.0002290264528710395
obesity B-Disease 1 0.9999939203262329
. O 0 0.00034973202855326235

The O 0 1.1348641237418633e-05
dual O 0 1.4800195458519738e-05
role O 0 4.769231054524425e-06
of O 0 9.319812306785025e-06
alpha O 0 0.00022832068498246372
- O 0 0.0004875874728895724
MSH O 1 0.682499349117279
in O 0 5.471684403346444e-07
regulating O 0 1.2745719004669809e-06
food O 0 1.0807316357386298e-06
intake O 0 4.734987669507973e-06
and O 0 6.796566367484047e-07
influencing O 0 1.2842700925830286e-05
hair O 0 0.09119199961423874
pigmentation O 1 0.6854422688484192
predicts O 0 4.087910383532289e-06
that O 0 6.5923735803608e-08
the O 0 3.582558179004991e-07
phenotype O 0 5.709410288545769e-06
associated O 0 3.20348050308894e-07
with O 0 2.8536726404126966e-07
a O 0 2.974884773720987e-05
defect O 1 0.9485113620758057
in O 0 6.34874550087261e-06
POMC O 1 0.9999191761016846
function O 0 6.157979441923089e-07
would O 0 2.4836398893057776e-07
include O 0 6.778422516617866e-07
obesity B-Disease 1 0.9900075197219849
, O 0 2.5716155960253673e-06
alteration O 0 0.0045943958684802055
in O 0 1.80429397005355e-05
pigmentation O 1 0.999995231628418
and O 0 0.0830712765455246
ACTH B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
. O 0 0.0012446928303688765

The O 0 1.3497061445377767e-05
observation O 0 4.3064494093414396e-05
of O 0 3.6059598187421216e-06
these O 0 4.1293708363809856e-07
symptoms O 0 4.11768451158423e-05
in O 0 5.870663812856947e-07
two O 0 4.410127871778968e-07
probands O 0 0.0330621562898159
prompted O 0 4.867039478995139e-06
us O 0 3.224605222840182e-07
to O 0 7.122754652755248e-08
search O 0 1.059378220702456e-07
for O 0 7.649548194876843e-08
mutations O 0 6.168323807287379e-07
within O 0 8.542463660887734e-07
their O 0 2.7050048174714902e-06
POMC O 1 0.844603419303894
genes O 0 1.4952050150895957e-05
. O 0 2.237234184576664e-05

Patient O 0 9.359655086882412e-05
1 O 0 1.4175726391840726e-05
was O 0 1.619094837224111e-05
found O 0 4.6313041934809007e-07
to O 0 6.704303956439617e-08
be O 0 7.579082961228778e-08
a O 0 9.767798019311158e-07
compound O 0 3.948668108932907e-06
heterozygote O 0 2.8435526928660693e-06
for O 0 4.093626060353017e-08
two O 0 3.900983358562371e-08
mutations O 0 1.9841189669023152e-07
in O 0 1.976579682150259e-07
exon O 0 1.0447421118442435e-05
3 O 0 5.178788455850736e-07
( O 0 3.161891868330713e-07
G7013T O 0 1.2378315659589134e-05
, O 0 3.1692522384219046e-07
C7133delta O 0 5.834579496877268e-06
) O 0 7.634360343899971e-08
which O 0 3.4786776126338737e-08
interfere O 0 5.525349777713018e-08
with O 0 2.7148301384727347e-08
appropriate O 0 1.3466896575664578e-07
synthesis O 0 1.8625971733854385e-06
of O 0 2.456958100083284e-06
ACTH O 0 0.0008173866663128138
and O 0 2.633639496707474e-06
alpha O 0 0.0001903819211293012
- O 0 0.01660750061273575
MSH O 1 0.9992488026618958
. O 0 7.584912236779928e-05

Patient O 0 6.427049811463803e-05
2 O 0 1.2393942597554997e-05
was O 0 1.0623263733577915e-05
homozygous O 0 3.744601826838334e-06
for O 0 3.8153521586536954e-07
a O 0 1.2097399348931503e-06
mutation O 0 1.4424042547034333e-06
in O 0 3.6143427450952004e-07
exon O 0 1.5759402231196873e-05
2 O 0 2.0106369902350707e-06
( O 0 1.2677226095547667e-06
C3804A O 0 2.9394728699116968e-05
) O 0 9.72785301200929e-07
which O 0 1.7206641587108606e-06
abolishes O 0 0.0005292597925290465
POMC O 1 0.810515284538269
translation O 0 0.0001320233423030004
. O 0 4.039677151013166e-05

These O 0 1.5561697637167526e-06
findings O 0 1.5780835838086205e-06
represent O 0 4.797532255906845e-07
the O 0 3.63008808790255e-07
first O 0 3.800927004249388e-07
examples O 0 4.879025254922453e-07
of O 0 1.4965652326281997e-06
a O 0 2.7851816412294284e-05
genetic B-Disease 1 0.9962866306304932
defect I-Disease 1 0.999492883682251
within O 0 1.8516766431275755e-06
the O 0 1.0831691724888515e-05
POMC O 1 0.9951946139335632
gene O 0 1.4308163827081444e-06
and O 0 1.271737630759162e-07
define O 0 2.321196888033228e-07
a O 0 1.1723602710844716e-06
new O 0 1.4036093489266932e-05
monogenic B-Disease 1 0.9999998807907104
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
resulting O 0 0.004638348706066608
in O 0 7.697900400671642e-06
early O 0 0.008768806234002113
- O 1 0.9997740387916565
onset O 1 1.0
obesity B-Disease 1 1.0
, O 1 0.999987006187439
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9966611862182617
red O 1 0.9999995231628418
hair O 1 0.9999419450759888
pigmentation O 1 0.9999736547470093
. O 0 1.7670172383077443e-05
. O 0 3.539066165103577e-05

A O 0 0.0001123444817494601
European O 0 2.316555219294969e-05
multicenter O 0 0.00032093405025079846
study O 0 7.988251127244439e-06
of O 0 7.375847781077027e-05
phenylalanine B-Disease 1 0.9999948740005493
hydroxylase I-Disease 1 0.9999963045120239
deficiency I-Disease 1 1.0
: O 0 1.2550580095194164e-06
classification O 0 4.415924649947556e-06
of O 0 5.009678716305643e-07
105 O 0 1.1959333505728864e-06
mutations O 0 2.4799902575978194e-07
and O 0 3.024144135110873e-08
a O 0 2.72586220262383e-07
general O 0 6.179334377520718e-07
system O 0 3.3953224942706584e-07
for O 0 2.424177409920958e-07
genotype O 0 5.8623222685127985e-06
- O 0 3.2097482289827894e-06
based O 0 1.1255356184847187e-06
prediction O 0 2.0782157662324607e-05
of O 0 1.825734398153145e-05
metabolic O 1 0.9836761355400085
phenotype O 0 0.04559842497110367
. O 0 0.00010186161671299487

Phenylketonuria B-Disease 1 0.9999688863754272
( O 0 0.012564349919557571
PKU B-Disease 1 0.9999953508377075
) O 0 2.193825457652565e-05
and O 0 2.5757273760973476e-05
mild B-Disease 1 0.9999051094055176
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9852805733680725
MHP B-Disease 1 1.0
) O 0 3.9222463783517014e-06
are O 0 1.0773368330774247e-06
allelic B-Disease 1 0.9857286810874939
disorders I-Disease 1 0.9999942779541016
caused O 0 0.008360853418707848
by O 0 9.102323588194849e-07
mutations O 0 5.958769975222822e-07
in O 0 1.655951251677834e-07
the O 0 6.237392540242581e-07
gene O 0 4.157499006396392e-06
encoding O 0 3.7373238228610717e-06
phenylalanine O 0 5.569276254391298e-05
hydroxylase O 0 0.0006773865898139775
( O 0 3.415267201489769e-05
PAH O 1 0.999998927116394
) O 0 2.3716884243185632e-05
. O 0 4.479182462091558e-05

Previous O 0 1.2353067177173216e-05
studies O 0 4.271747002349002e-06
have O 0 4.534049367066473e-07
suggested O 0 6.37388211544021e-07
that O 0 1.2662060555612697e-07
the O 0 5.421890136858565e-07
highly O 0 2.041698280663695e-06
variable O 0 4.666569566325052e-06
metabolic O 0 0.011538103222846985
phenotypes O 0 0.0007460567285306752
of O 1 0.9766506552696228
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.02387358993291855
with O 0 0.0029797758907079697
PAH O 1 1.0
genotypes O 1 0.9763033390045166
. O 0 0.0002160192234441638

We O 0 9.85437600320438e-06
identified O 0 5.555637471843511e-06
both O 0 1.4682548226119252e-06
causative O 0 9.30175810935907e-05
mutations O 0 7.6151936809765175e-06
in O 0 4.232900664646877e-06
686 O 0 0.0533415824174881
patients O 0 1.221038655785378e-05
from O 0 2.148957264580531e-06
seven O 0 4.202400759822922e-06
European O 0 1.1067762898164801e-05
centers O 0 3.451400698395446e-05
. O 0 5.248178422334604e-05

On O 0 3.1317188131652074e-06
the O 0 1.001590931082319e-06
basis O 0 4.1853758148135967e-07
of O 0 8.849949040268257e-07
the O 0 1.1858109019158292e-06
phenotypic O 0 7.036307579255663e-06
characteristics O 0 1.8035876792055205e-06
of O 0 2.5564993393345503e-06
297 O 0 8.981840073829517e-05
functionally O 0 0.01612304151058197
hemizygous O 0 0.4792940318584442
patients O 0 2.184430968554807e-06
, O 0 2.3433142359863268e-07
105 O 0 6.742620826116763e-07
of O 0 2.3144330896229803e-07
the O 0 3.462183144620212e-07
mutations O 0 1.8213134467259806e-07
were O 0 8.511320714887916e-08
assigned O 0 1.4385258850779792e-07
to O 0 2.8926681494567674e-08
one O 0 4.53391102439582e-08
of O 0 2.105619643089085e-07
four O 0 4.033052221075195e-07
arbitrary O 0 4.025384896522155e-06
phenotype O 0 7.18386800144799e-05
categories O 0 1.4899809684720822e-05
. O 0 3.1182811653707176e-05

We O 0 3.3561541386006866e-06
proposed O 0 2.4254222807940096e-06
and O 0 8.594548717155703e-07
tested O 0 1.0218460602118284e-06
a O 0 4.141770659771282e-07
simple O 0 2.2435891366967553e-07
model O 0 1.5047154988678813e-07
for O 0 4.9689578673906e-08
correlation O 0 2.328993247147082e-07
between O 0 4.083286455625057e-07
genotype O 0 8.0082891145139e-06
and O 0 1.4643072745457175e-06
phenotypic O 0 3.572881905711256e-05
outcome O 0 1.8043989257421345e-05
. O 0 4.498994894674979e-05

The O 0 2.1325886336853728e-05
observed O 0 1.755123412294779e-05
phenotype O 0 2.959951598313637e-05
matched O 0 3.684536750370171e-06
the O 0 1.1218116924283095e-06
predicted O 0 3.80530445909244e-06
phenotype O 0 1.6582694115641061e-06
in O 0 5.5787317876365705e-08
79 O 0 5.469368034027866e-07
% O 0 6.992092949076323e-08
of O 0 8.63823359509297e-08
the O 0 1.0333820910091163e-07
cases O 0 5.00311827522637e-08
, O 0 3.7509092720711124e-08
and O 0 1.706864694028809e-08
in O 0 2.6121417917579492e-08
only O 0 1.9076894730574168e-08
5 O 0 6.642696348535537e-08
of O 0 1.8746425212157192e-07
184 O 0 1.3811458074997063e-06
patients O 0 5.207076014812628e-07
was O 0 1.4927907159290044e-06
the O 0 2.337511091354827e-07
observed O 0 3.6771399436474894e-07
phenotype O 0 8.952441135079425e-07
more O 0 1.6465742547211448e-08
than O 0 2.769975893102128e-08
one O 0 5.400711700076499e-08
category O 0 3.9730633716317243e-07
away O 0 1.580140747137193e-07
from O 0 1.534437217287632e-07
that O 0 3.237874466321955e-07
expected O 0 6.866957392048789e-06
. O 0 1.931381666508969e-05

Among O 0 5.50713366465061e-06
the O 0 2.485621280357009e-06
seven O 0 1.4569204722647555e-06
contributing O 0 3.6570002066582674e-06
centers O 0 8.3400590256133e-07
, O 0 1.680245844681849e-07
the O 0 1.6981870487597917e-07
proportion O 0 3.568809177068033e-07
of O 0 4.0147708091353707e-07
patients O 0 3.399534591608244e-07
for O 0 1.0697845453933041e-07
whom O 0 3.234880523450556e-07
the O 0 3.3263023624385823e-07
observed O 0 5.533026410375896e-07
phenotype O 0 1.7375214156345464e-06
did O 0 6.645333172627943e-08
not O 0 1.672673377584033e-08
match O 0 7.812646884985952e-08
the O 0 8.296429854226517e-08
predicted O 0 4.121081644825608e-07
phenotype O 0 5.534208753488201e-07
was O 0 2.2996324844370974e-07
4 O 0 1.0477153011834162e-07
% O 0 4.319996804724724e-08
- O 0 1.6175108896732127e-07
23 O 0 2.2387457931927202e-07
% O 0 2.3084767519776506e-07
( O 0 2.3293974038551823e-07
P O 0 1.0489431588212028e-05
< O 0 5.355891062208684e-06
. O 0 1.6201107655433589e-07
0001 O 0 1.016908572637476e-05
) O 0 6.816742370574502e-08
, O 0 5.442758777007839e-08
suggesting O 0 9.440905301971725e-08
that O 0 1.5009311127300862e-08
differences O 0 2.9731280548617178e-08
in O 0 3.9352855196739256e-08
methods O 0 6.762455484476959e-08
used O 0 3.9298097220807904e-08
for O 0 6.541395691783691e-08
mutation O 0 1.0033413673227187e-06
detection O 0 2.849084694389603e-06
or O 0 2.562742906775384e-07
phenotype O 0 8.607775271229912e-06
classification O 0 2.7374910587241175e-06
may O 0 1.2189508424853557e-07
account O 0 2.930782372345675e-08
for O 0 2.9184599625864394e-08
a O 0 1.991265321521496e-07
considerable O 0 1.1252716376475291e-06
proportion O 0 8.04243086349743e-07
of O 0 2.8436420507205185e-06
genotype O 0 0.000756502733565867
- O 0 0.03721991926431656
phenotype O 0 0.010876428335905075
inconsistencies O 0 0.00020160801068414003
. O 0 7.798755541443825e-05

Our O 0 7.55214341552346e-06
data O 0 1.573846816427249e-06
indicate O 0 1.5725025832580286e-06
that O 0 4.7469418973378197e-07
the O 0 6.383776508300798e-06
PAH O 1 0.9999996423721313
- O 0 0.00023653307289350778
mutation O 0 5.875273473066045e-06
genotype O 0 2.074898930004565e-06
is O 0 9.228435970953797e-08
the O 0 8.423479869179573e-08
main O 0 5.668929361490882e-07
determinant O 0 3.208930820619571e-06
of O 0 1.1610445653786883e-06
metabolic O 0 0.4468674957752228
phenotype O 0 6.308808224275708e-05
in O 0 5.172223609406501e-07
most O 0 1.0219347359452513e-06
patients O 0 0.00010408322123112157
with O 1 0.8688363432884216
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.48138055205345154

In O 0 2.947465418401407e-06
the O 0 1.1564056876522955e-06
present O 0 6.692625902360305e-07
study O 0 2.5604271058909944e-07
, O 0 1.701846201740409e-07
the O 0 3.053117438867048e-07
classification O 0 4.312416876928182e-06
of O 0 2.180243427574169e-06
105 O 0 3.956864384235814e-05
PAH O 1 0.9999867677688599
mutations O 0 1.0022797596320743e-06
may O 0 7.235750132394969e-08
allow O 0 2.5951379711841582e-08
the O 0 5.871884312114162e-08
prediction O 0 3.5752270832745126e-07
of O 0 1.1452272730139157e-07
the O 0 2.907182761191507e-07
biochemical O 0 5.596088158199564e-06
phenotype O 0 2.5558654215274146e-06
in O 0 1.442661243800103e-07
> O 0 1.4558510201823083e-06
10 O 0 1.8915774546712782e-07
, O 0 1.610920747907585e-07
000 O 0 8.327842806465924e-07
genotypes O 0 1.4386963584911427e-06
, O 0 8.335385359714564e-08
which O 0 3.667480541480472e-08
may O 0 6.050055390005582e-08
be O 0 1.4942186155053605e-08
useful O 0 2.1679840145338858e-08
for O 0 2.2105412611495012e-08
the O 0 3.1835594427320757e-07
management O 0 4.490960691327928e-06
of O 0 8.600603905506432e-06
hyperphenylalaninemia B-Disease 1 0.9998786449432373
in O 0 3.224370811949484e-05
newborns O 0 0.0002686569932848215
. O 0 6.916614802321419e-05

Somatic O 0 0.0013376575661823153
instability O 0 0.00025465048383921385
of O 0 2.437581315462012e-05
the O 0 4.826153235626407e-05
CTG O 1 0.890941321849823
repeat O 0 2.360784674237948e-05
in O 0 2.447890437906608e-06
mice O 0 1.3763605238636956e-05
transgenic O 0 1.311872256337665e-05
for O 0 9.96333028524532e-07
the O 0 0.021459178999066353
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0003005590115208179
is O 0 8.919853371480713e-07
age O 0 1.5369752190963482e-06
dependent O 0 3.8043793892938993e-07
but O 0 6.053934242800096e-08
not O 0 3.041457574681772e-08
correlated O 0 1.342086903832751e-07
to O 0 3.967103268109895e-08
the O 0 3.443164473537763e-07
relative O 0 2.5604690563341137e-06
intertissue O 0 8.51173754199408e-05
transcription O 0 1.5220710338326171e-05
levels O 0 4.051280939165736e-06
and O 0 3.404950575713883e-06
proliferative O 1 0.9929714798927307
capacities O 0 0.00015809395699761808
. O 0 4.2370469600427896e-05

A O 0 0.0001562215475132689
( O 0 2.043652602878865e-05
CTG O 0 0.0010032032150775194
) O 0 7.049445684970124e-07
nexpansion O 0 6.526616743940394e-06
in O 0 1.1589875725803722e-07
the O 0 3.088028392994602e-07
3 O 0 8.718079698155634e-07
- O 0 4.624808298103744e-06
untranslated O 0 5.338146002031863e-05
region O 0 1.0964115517708706e-06
( O 0 3.3131098575722717e-07
UTR O 0 4.376595461508259e-05
) O 0 1.010647920907104e-07
of O 0 2.408939394626941e-07
the O 0 3.049600763915805e-06
DM O 1 0.9999797344207764
protein O 0 9.188369404000696e-06
kinase O 0 6.582964488188736e-06
gene O 0 1.6769943158578826e-06
( O 0 7.284326102308114e-07
DMPK O 0 0.0011604937026277184
) O 0 1.6828373361477134e-07
is O 0 1.360891417334642e-07
responsible O 0 1.1118353313577245e-06
for O 0 3.9628721424378455e-06
causing O 1 0.9998302459716797
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999349117279053
DM B-Disease 1 1.0
) O 0 0.00018113772966898978
. O 0 9.744147973833606e-05

Major O 0 0.00010870051482925192
instability O 0 0.0004177579830866307
, O 0 2.230158997917897e-06
with O 0 5.076916522739339e-07
very O 0 4.934278194923536e-07
large O 0 4.349330993136391e-07
expansions O 0 1.021250795929518e-06
between O 0 1.9680101104313508e-07
generations O 0 5.331717147782911e-07
and O 0 1.4239404322324845e-07
high O 0 7.154390573305136e-07
levels O 0 4.618117088739382e-07
of O 0 1.92410288946121e-06
somatic O 0 0.006765715312212706
mosaicism O 1 0.9384089112281799
, O 0 4.6982020762698085e-07
is O 0 2.605256099741382e-07
observed O 0 6.462670967266604e-07
in O 0 2.021436557697598e-06
patients O 0 3.337552334414795e-05
. O 0 4.1516806959407404e-05

There O 0 7.16942213330185e-06
is O 0 1.1392114629416028e-06
a O 0 6.94421942171175e-07
good O 0 2.422823115466599e-07
correlation O 0 2.202503281978352e-07
between O 0 1.1723653869921691e-07
repeat O 0 9.253117809748801e-07
size O 0 2.830369396633614e-07
( O 0 8.037741139332866e-08
at O 0 1.8819527269897662e-07
least O 0 8.338501800153608e-08
in O 0 1.2551547001748986e-07
leucocytes O 0 4.292807716410607e-05
) O 0 1.7291904441663064e-07
, O 0 1.904557933585238e-07
clinical O 0 1.9925544165744213e-06
severity O 0 1.8918039131676778e-05
and O 0 9.691951845525182e-07
age O 0 9.953349945135415e-06
of O 0 5.938037793384865e-05
onset O 1 0.9999865293502808
. O 0 0.0006151305860839784

The O 0 0.0003122163761872798
trinucleotide O 1 0.977342963218689
repeat O 0 0.00024253511219285429
instability O 0 0.00048553518718108535
mechanisms O 0 2.044510438281577e-05
involved O 0 7.639189789188094e-06
in O 0 3.901953459717333e-05
DM B-Disease 1 1.0
and O 0 6.757846676919144e-06
other O 0 1.027579514811805e-06
human O 0 8.432331378571689e-05
genetic B-Disease 1 0.9999895095825195
diseases I-Disease 1 1.0
are O 0 2.3461905129806837e-06
unknown O 0 5.472427437780425e-05
. O 0 4.680825077230111e-05

We O 0 8.818525202514138e-06
studied O 0 3.3993361284956336e-05
somatic O 0 9.905803017318249e-05
instability O 0 3.7620724469888955e-05
by O 0 1.176543605652114e-06
measuring O 0 1.3921435311203822e-05
the O 0 6.862518603156786e-06
CTG O 0 0.0030588910449296236
repeat O 0 2.0610700630641077e-06
length O 0 3.219731752324151e-07
at O 0 2.0504583631009154e-07
several O 0 6.94591548722201e-08
ages O 0 1.9131631745494815e-07
in O 0 7.07491878415567e-08
various O 0 1.227288635163859e-07
tissues O 0 4.206723133393098e-06
of O 0 2.836334715539124e-06
transgenic O 0 0.00011756766616599634
mice O 0 3.3792232443374814e-06
carrying O 0 6.141511335044925e-07
a O 0 7.882409818193992e-07
( O 0 1.0390152738182223e-06
CTG O 0 0.0004418013268150389
) O 0 4.010763632322778e-07
55expansion O 0 1.13897658593487e-05
surrounded O 0 2.963412725875969e-06
by O 0 1.8338833740472182e-07
45 O 0 7.552370675512066e-07
kb O 0 7.733764505246654e-06
of O 0 7.746807000330591e-07
the O 0 1.3395107316682697e-06
human O 0 1.0293792911397759e-05
DM B-Disease 1 0.9999992847442627
region O 0 5.99389477429213e-06
, O 0 5.33121919943369e-07
using O 0 4.014724481748999e-07
small O 0 1.7560354308443493e-06
- O 0 5.548020271817222e-05
pool O 0 8.910751057555899e-05
PCR O 0 0.00010967934940708801
. O 0 2.0363437215564772e-05

These O 0 8.081696250883397e-06
mice O 0 2.2243148123379797e-05
have O 0 2.2088602236181032e-07
been O 0 1.798296125343768e-07
shown O 0 1.4475841680905432e-07
to O 0 6.744615177467495e-08
reproduce O 0 1.668391576004069e-07
the O 0 2.5801151082305296e-07
intergenerational O 0 9.761040928424336e-06
and O 0 4.0411066493106773e-07
somatic O 0 9.783258064999245e-06
instability O 0 6.580090030183783e-06
of O 0 8.976156209428154e-07
the O 0 1.789857719813881e-06
55 O 0 9.205060450767633e-06
CTG O 0 0.009705175645649433
repeat O 0 3.5717412174562924e-06
suggesting O 0 1.0328083135391353e-06
that O 0 1.0075203249471087e-07
surrounding O 0 2.445302413889294e-07
sequences O 0 1.4445997464918037e-07
and O 0 8.59645297168754e-08
the O 0 3.360223388426675e-07
chromatin O 0 7.424692284985213e-06
environment O 0 1.1413624179112958e-06
are O 0 4.010200882476056e-08
involved O 0 3.724901489476906e-07
in O 0 1.050545279213111e-06
instability O 0 0.000203181742108427
mechanisms O 0 8.125807653414086e-05
. O 0 7.18541705282405e-05

As O 0 3.352149406055105e-06
observed O 0 1.1859907544931048e-06
in O 0 2.4921220642681874e-07
some O 0 8.968885367721668e-08
of O 0 6.090196507102519e-07
the O 0 1.973136022570543e-06
tissues O 0 0.0035935528576374054
of O 0 0.11252771317958832
DM B-Disease 1 1.0
patients O 0 0.0016456687590107322
, O 0 5.580667448157328e-07
there O 0 1.7492800452600932e-07
is O 0 1.0923665882955902e-07
a O 0 2.637293619045522e-07
tendency O 0 4.3781540171039524e-07
for O 0 1.0162943198110952e-07
repeat O 0 1.2210770137244253e-06
length O 0 6.563391252711881e-07
and O 0 3.523459213283786e-07
somatic O 0 2.0393888917169534e-05
mosaicism O 0 8.827521378407255e-05
to O 0 5.7199994074608185e-08
increase O 0 7.20056050340645e-08
with O 0 8.893829317457858e-08
the O 0 3.4968664408552286e-07
age O 0 1.211519020216656e-06
of O 0 2.0189243059576256e-06
the O 0 1.0956967344100121e-05
mouse O 0 0.00019485308439470828
. O 0 4.2027648305520415e-05

Furthermore O 0 3.580822885851376e-05
, O 0 2.0855918592133094e-06
we O 0 2.1504691005702625e-07
observed O 0 2.7753895892601577e-07
no O 0 9.742301898540973e-08
correlation O 0 2.169738593238435e-07
between O 0 8.953366403829932e-08
the O 0 1.0182164942307281e-06
somatic O 0 2.5231529434677213e-05
mutation O 0 3.7447193790285382e-06
rate O 0 1.9862138742610114e-06
and O 0 3.043882998099434e-06
tissue O 1 0.5523205995559692
proliferation O 0 0.0609421543776989
capacity O 0 0.00010929285053862259
. O 0 2.6110414182767272e-05

The O 0 3.985068906331435e-05
somatic O 0 0.00018942875612992793
mutation O 0 7.997771717782598e-06
rates O 0 7.096372769410664e-07
in O 0 2.9782000865452574e-07
different O 0 5.1820983060224535e-08
tissues O 0 1.6453709577035625e-06
were O 0 7.935224033417398e-08
also O 0 5.3934751775841505e-08
not O 0 1.591027398717415e-08
correlated O 0 6.336306057619367e-08
to O 0 1.6173530070773268e-08
the O 0 1.0589661059157152e-07
relative O 0 5.011503958485264e-07
inter O 0 3.4732861422526184e-06
- O 0 8.45840168040013e-06
tissue O 0 2.5780840587685816e-05
difference O 0 1.8253440714488534e-07
in O 0 5.873822672697315e-08
transcriptional O 0 2.931812161932612e-07
levels O 0 3.921850222354806e-08
of O 0 5.54455290568967e-08
the O 0 7.67048504712875e-08
three O 0 7.041531091545039e-08
genes O 0 3.3721397585395607e-07
( O 0 8.214345257329114e-07
DMAHP O 0 0.4346296787261963
, O 0 1.3978554989080294e-06
DMPK O 0 0.0027929898351430893
and O 0 4.2935707256219757e-07
59 O 0 2.8538408969325246e-06
) O 0 2.565785166552814e-07
surrounding O 0 1.1006712838934618e-06
the O 0 6.317890210993937e-07
repeat O 0 8.841228009259794e-06
. O 0 2.7936484912061132e-06
. O 0 2.0746276277350262e-05

A O 0 0.0002480041584931314
novel O 0 0.00013770321675110608
missense O 0 0.00029291841201484203
mutation O 0 2.696194678719621e-05
in O 0 2.776037945295684e-06
patients O 0 3.5193322673876537e-06
from O 0 8.69789914759167e-07
a O 0 1.8121729226550087e-05
retinoblastoma B-Disease 1 0.9964467883110046
pedigree O 0 9.610132110537961e-05
showing O 0 5.292675723467255e-06
only O 0 5.44204169727891e-07
mild O 0 5.032619446865283e-05
expression O 0 2.622811280161841e-06
of O 0 4.633580829249695e-06
the O 0 7.222361455205828e-05
tumor B-Disease 1 0.9999912977218628
phenotype O 0 0.2970290184020996
. O 0 0.00011620244185905904

We O 0 4.786468707607128e-06
have O 0 3.1045524906403443e-07
used O 0 4.846410206482687e-07
single O 0 8.426001159023144e-07
strand O 0 3.7787460769322934e-06
conformation O 0 1.1253176808168064e-06
polymorphism O 0 6.863317025818105e-07
analysis O 0 3.430152517580609e-08
to O 0 1.742711930319274e-08
study O 0 3.0207196743958775e-08
the O 0 7.611431840359728e-08
27 O 0 5.008828338759486e-07
exons O 0 1.4710326468048152e-06
of O 0 2.941979175830056e-07
the O 0 1.3723438314627856e-06
RB1 O 0 0.14368680119514465
gene O 0 5.609251161331485e-07
in O 0 6.857180778752081e-08
individuals O 0 3.4046856001168635e-08
from O 0 1.4309676998891518e-07
a O 0 1.6564770248805871e-06
family O 0 1.8747011836239835e-06
showing O 0 5.540352049138164e-06
mild O 0 0.0001939834764925763
expression O 0 3.4474007861717837e-06
of O 0 5.06909645991982e-06
the O 0 5.890219108550809e-05
retinoblastoma B-Disease 1 0.9996084570884705
phenotype O 0 0.46994006633758545
. O 0 0.0001460568601032719

In O 0 1.542073005111888e-05
this O 0 2.846594043148798e-06
family O 0 3.6035296488989843e-06
affected O 0 9.039313226821832e-07
individuals O 0 2.693858220936818e-07
developed O 0 1.061672082869336e-05
unilateral B-Disease 0 0.0007276356336660683
tumors I-Disease 1 0.9999991655349731
and O 0 6.457311201302218e-07
, O 0 1.6213658682318055e-07
as O 0 9.914045762116075e-08
a O 0 1.6451970452635578e-07
result O 0 2.2063842664010735e-07
of O 0 4.083426574652549e-07
linkage O 0 7.291148449439788e-06
analysis O 0 3.0993280120128475e-07
, O 0 5.00101009492937e-07
unaffected O 0 6.9075222199899144e-06
mutation O 0 1.7785982890927698e-06
carriers O 0 7.368771548499353e-07
were O 0 1.6290098869831127e-07
also O 0 1.4721510410709016e-07
identified O 0 4.0661259959051677e-07
within O 0 7.401719699373643e-07
the O 0 7.093251497281017e-06
pedigree O 0 0.0002726366219576448
. O 0 7.012100832071155e-05

A O 0 7.061866926960647e-05
single O 0 9.685099030320998e-06
band O 0 2.6127725504920818e-05
shift O 0 6.302595920715248e-06
using O 0 8.973794365374488e-07
SSCP O 0 0.00041519166552461684
was O 0 4.206734956824221e-06
identified O 0 4.863425147050293e-07
in O 0 2.145961985888789e-07
exon O 0 4.292590347176883e-06
21 O 0 3.966574411151669e-07
which O 0 7.56702149828925e-08
resulted O 0 4.3350109990569763e-07
in O 0 1.3496956796643644e-07
a O 0 9.26077120766422e-07
missense O 0 5.6590724852867424e-06
mutation O 0 8.102633728412911e-07
converting O 0 1.3177881328374497e-06
a O 0 3.0982073440100066e-06
cys O 0 0.012538919225335121
- O 0 3.914390617865138e-05
- O 0 8.79470317158848e-05
> O 0 5.2136991143925115e-05
arg O 0 1.0793662113428582e-05
at O 0 4.5927836822556856e-07
nucleotide O 0 7.298915534192929e-07
position O 0 4.5936465653539926e-07
28 O 0 1.3415229886959423e-06
in O 0 1.1207328043383313e-06
the O 0 8.655988494865596e-06
exon O 0 0.0006073834374547005
. O 0 4.7807447117520496e-05

The O 0 3.9904458390083164e-05
mutation O 0 6.009141361573711e-05
destroyed O 0 0.00010696719982661307
an O 0 4.637532583728898e-06
NdeI O 0 0.0008094565710052848
restriction O 0 4.218300091451965e-05
enzyme O 0 1.875421730801463e-05
site O 0 1.7874399418360554e-05
. O 0 1.768308356986381e-05

Analysis O 0 6.192807177285431e-06
of O 0 2.613909373394563e-06
all O 0 4.0304763615495176e-07
family O 0 1.3394596862781327e-06
members O 0 3.378146118393488e-07
demonstrated O 0 8.490985692333197e-07
that O 0 8.786374650071593e-08
the O 0 8.397346391575411e-07
missense O 0 4.768137296196073e-05
mutation O 0 1.4663414731330704e-05
co O 0 7.830515824025497e-05
- O 0 0.0005640894523821771
segregated O 0 0.00014747171371709555
with O 0 1.494783759881102e-06
patients O 0 0.00027545896591618657
with O 0 0.0020270640961825848
tumors B-Disease 1 1.0
or O 0 4.7652574721723795e-06
who O 0 1.443532710254658e-06
, O 0 1.6528272794857912e-07
as O 0 8.549654495482173e-08
a O 0 2.3109789992759033e-07
result O 0 2.122765749845712e-07
of O 0 4.465927645469492e-07
linkage O 0 4.661241291614715e-06
analysis O 0 1.744877948794965e-07
had O 0 3.1320723792305216e-07
been O 0 9.47903160408714e-08
predicted O 0 4.3365824353713833e-07
to O 0 5.3384031417635924e-08
carry O 0 2.705650103962398e-07
the O 0 1.979965418286156e-06
predisposing O 0 0.0001217686731251888
mutation O 0 7.613651541760191e-05
. O 0 5.4069470934337005e-05

These O 0 2.0891588974336628e-06
observations O 0 2.4295734419865767e-06
point O 0 1.3779908840660937e-06
to O 0 1.8795367395796347e-07
another O 0 5.135987635185302e-07
region O 0 5.575672616942029e-07
of O 0 9.483666758569598e-07
the O 0 4.216961769998306e-06
RB1 O 0 0.016396787017583847
gene O 0 9.406006711287773e-07
where O 0 1.0166238695319407e-07
mutations O 0 1.0264771077572732e-07
only O 0 2.3993871778316134e-08
modify O 0 5.8628870647225995e-08
the O 0 4.5410597948603026e-08
function O 0 4.6075324888761315e-08
of O 0 7.929263290407107e-08
the O 0 2.10684888202195e-07
gene O 0 3.5535771303329966e-07
and O 0 7.201452945082565e-08
raise O 0 1.3512875796095614e-07
important O 0 7.215532349391651e-08
questions O 0 5.248165635407531e-08
for O 0 1.3235397489097522e-07
genetic O 0 2.586175241958699e-06
counseling O 0 1.7066097370843636e-06
in O 0 2.9463367923199257e-07
families O 0 1.7995932921621716e-07
with O 0 3.649568327546149e-07
these O 0 7.632743290741928e-07
distinctive O 0 5.576370676863007e-05
phenotypes O 0 8.820950461085886e-05
. O 0 1.129742304328829e-05
. O 0 4.273219019523822e-05

Maternal B-Disease 0 0.08973957598209381
disomy I-Disease 1 0.9993703961372375
and O 0 0.4318488538265228
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.027635851874947548
with O 0 1.557484756631311e-05
gamete O 1 0.8141186833381653
complementation O 1 0.9772312641143799
in O 0 1.0913686310232151e-06
a O 0 1.164765421890479e-06
case O 0 6.963012992855511e-07
of O 0 1.0173255304835038e-06
familial O 0 0.00010460380144650117
translocation O 0 2.376764859945979e-05
( O 0 3.484848036805488e-07
3 O 0 3.367190970493539e-07
; O 0 3.078125132560672e-08
15 O 0 9.315462534686958e-08
) O 0 1.0740104983142373e-07
( O 0 2.3222419542889838e-07
p25 O 0 1.3932231922808569e-05
; O 0 1.3744352145295125e-07
q11 O 0 8.363161214219872e-06
. O 0 3.5596045222519024e-07
2 O 0 2.4091814339044504e-06
) O 0 3.363838004588615e-06
. O 0 1.7014312106766738e-05

Maternal B-Disease 1 0.9605246186256409
uniparental I-Disease 1 0.9999749660491943
disomy I-Disease 1 0.9997947812080383
( I-Disease 0 0.0022777519188821316
UPD I-Disease 1 0.9999396800994873
) I-Disease 0 8.144157845890732e-07
for I-Disease 0 2.531785128212505e-07
chromosome I-Disease 0 1.3436497283692006e-06
15 I-Disease 0 1.7173756816646346e-07
is O 0 5.903688204966784e-08
responsible O 0 7.45536326007823e-08
for O 0 2.3348725619598554e-08
an O 0 5.480207576624707e-08
estimated O 0 2.809495072142454e-07
30 O 0 1.5675210818244523e-07
% O 0 8.96611496159494e-08
of O 0 2.82029219533797e-07
cases O 0 1.098743609873054e-06
of O 0 0.0004825407231692225
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999992847442627
PWS B-Disease 1 1.0
) O 0 0.00033360079396516085
. O 0 0.00013657416275236756

We O 0 2.9452905891957926e-06
report O 0 6.433750172618602e-07
on O 0 3.9950549535205937e-07
an O 0 2.601541950753017e-07
unusual O 0 8.018001835807809e-07
case O 0 4.22384601961312e-07
of O 0 1.226493509420834e-06
maternal B-Disease 0 2.1426365492516197e-05
disomy I-Disease 0 0.005599581636488438
15 I-Disease 0 2.6568377506919205e-06
in O 0 4.8093238547153305e-06
PWS B-Disease 1 0.9999994039535522
that O 0 8.282658114922015e-08
is O 0 3.701515183252013e-08
most O 0 1.1034164693057846e-08
consistent O 0 5.169008332472913e-08
with O 0 3.901057610278258e-08
adjacent O 0 6.103377927502152e-07
- O 0 5.163544756214833e-07
1 O 0 6.562602834492282e-07
segregation O 0 3.6224355426384136e-06
of O 0 2.705072290609678e-07
a O 0 9.154259714705404e-07
paternal O 0 4.238026576786069e-06
t O 0 1.7261668290302623e-06
( O 0 3.958954764016198e-08
3 O 0 6.926467932544256e-08
; O 0 1.487351664053449e-08
15 O 0 4.209537607380298e-08
) O 0 3.97551858100087e-08
( O 0 1.3212469696100015e-07
p25 O 0 9.270923328585923e-06
; O 0 4.9064617257954524e-08
q11 O 0 1.8360863123234594e-06
. O 0 3.534888293188487e-08
2 O 0 1.1078348904902668e-07
) O 0 4.192486713350263e-08
with O 0 5.5474934868016135e-08
simultaneous O 0 1.5276112890205695e-06
maternal O 0 3.640507202362642e-05
meiotic O 0 0.02196202613413334
nondisjunction O 0 0.00024040346033871174
for O 0 2.518804649298545e-06
chromosome O 0 3.8722169847460464e-05
15 O 0 2.20012752834009e-05
. O 0 3.4853834222303703e-05

The O 0 2.160151780117303e-05
patient O 0 4.0427257772535086e-05
( O 0 4.060258106619585e-06
J O 0 0.0030829182360321283
. O 0 4.218926221710717e-07
B O 0 2.6718928438640432e-06
. O 0 6.704188137973688e-08
) O 0 1.90978290959265e-08
, O 0 2.5221927657526066e-08
a O 0 1.3749701111009927e-07
17 O 0 4.1033749198504665e-07
- O 0 2.612740445329109e-06
year O 0 1.1962664530074107e-06
- O 0 1.3689460502064321e-05
old O 0 4.5245040382724255e-05
white O 0 1.987090945476666e-05
male O 0 2.3017880721454276e-06
with O 0 6.129788744146936e-06
PWS B-Disease 1 1.0
, O 0 2.8620613647944992e-06
was O 0 8.87200530996779e-06
found O 0 1.035647372304993e-07
to O 0 1.8181994576593752e-08
have O 0 2.5456474261886797e-08
47 O 0 1.1567768609666018e-07
chromosomes O 0 1.1715807346490692e-07
with O 0 7.410238112015577e-08
a O 0 3.5167688565707067e-06
supernumerary O 1 0.9870850443840027
, O 0 1.8176536968894652e-06
paternal O 0 7.011068646534113e-06
der O 0 9.555667929816991e-05
( O 0 2.1237580938304745e-07
15 O 0 1.7923430561950227e-07
) O 0 5.0381476768279754e-08
consisting O 0 1.1781128250731854e-07
of O 0 1.6171900085737434e-07
the O 0 4.6434087153102155e-07
short O 0 1.6987537492241245e-06
arm O 0 1.514625455456553e-05
and O 0 4.87353815969982e-07
the O 0 4.40814483226859e-06
proximal O 1 0.7574565410614014
long O 0 2.025341018452309e-05
arm O 0 4.486946272663772e-05
of O 0 2.7833011699840426e-06
chromosome O 0 2.1852018107892945e-05
15 O 0 3.1804324862605426e-06
, O 0 1.8551091898189043e-06
and O 0 4.163634002907202e-06
distal O 1 0.7203598618507385
chromosome O 1 0.8664729595184326
arm O 1 0.9987108707427979
3p O 1 0.9999285936355591
. O 0 0.00030415074434131384

The O 0 2.1929134163656272e-05
t O 0 1.5713358152424917e-05
( O 0 5.065203936283069e-07
3 O 0 5.107677338855865e-07
; O 0 4.453312385521713e-08
15 O 0 1.2929318415899616e-07
) O 0 7.686932690376125e-08
was O 0 3.2988435805236804e-07
present O 0 4.3951718708967746e-08
in O 0 2.550823730018692e-08
the O 0 8.73485959118625e-08
balanced O 0 1.3139388954641618e-07
state O 0 2.7492427889797e-08
in O 0 7.08516836311901e-08
the O 0 5.225970198807772e-07
patients O 0 1.863430497905938e-06
father O 0 5.149748631083639e-06
and O 0 2.2226172404771205e-06
a O 0 5.164423055248335e-05
sister O 0 0.0005742692737840116
. O 0 5.752622018917464e-05

Fluorescent O 0 0.00016073728329502046
in O 0 5.8926907513523474e-06
situ O 0 3.569987165974453e-05
hybridization O 0 2.5992478640546324e-06
analysis O 0 5.965935088170227e-07
demonstrated O 0 1.7696731902105967e-06
that O 0 2.9278612601046916e-07
the O 0 3.1642496196582215e-06
PWS B-Disease 1 0.9999954700469971
critical O 0 3.4039503589156084e-06
region O 0 1.2122563930461183e-06
resided O 0 1.0692007208490395e-06
on O 0 7.038349281174305e-08
the O 0 1.1947702205361566e-07
derivative O 0 6.085807626732276e-07
chromosome O 0 4.428393651778606e-07
3 O 0 1.1930576704344276e-07
and O 0 3.070285359285663e-08
that O 0 1.561379470160773e-08
there O 0 2.8282153508030206e-08
was O 0 3.6771120903722476e-07
no O 0 1.174603667664087e-07
deletion O 0 9.204298407894385e-07
of O 0 9.09291827611014e-07
the O 0 1.923373383760918e-05
PWS B-Disease 1 0.9999997615814209
region O 0 1.2060606877639657e-06
on O 0 1.9611005086517252e-07
the O 0 2.603815403290355e-07
normal O 0 6.761706572433468e-07
pair O 0 5.230298256719834e-07
of O 0 6.917067025824508e-07
15s O 0 5.505571607500315e-05
present O 0 1.7708280211081728e-06
in O 0 6.370445589709561e-06
J O 1 0.8179944753646851
. O 0 8.06219395599328e-05

B O 0 0.03999140486121178
. O 0 0.0016839400632306933

Methylation O 0 4.900107887806371e-05
analysis O 0 2.137780256816768e-06
at O 0 3.2240318432741333e-06
exon O 0 1.474471628171159e-05
alpha O 0 2.2283859379967907e-06
of O 0 3.402261938845186e-07
the O 0 5.807355591969099e-07
small O 0 1.4780990795770776e-06
nuclear O 0 2.010339085245505e-05
ribonucleoprotein O 0 0.000608961854595691
- O 0 7.933845154184382e-06
associated O 0 2.6350890038884245e-06
polypeptide O 0 4.4184387661516666e-05
N O 0 1.4491752153844573e-05
( O 0 8.368501767108683e-07
SNRPN O 0 0.0005400283262133598
) O 0 2.896986757150444e-07
gene O 0 3.543982529663481e-07
showed O 0 2.4013885990825656e-07
a O 0 2.2742243288575992e-07
pattern O 0 1.1614611139521003e-06
characteristic O 0 1.0495389233255992e-06
of O 0 2.901183506764937e-07
only O 0 1.434782888054542e-07
the O 0 6.773659606551519e-07
maternal O 0 7.916773029137403e-06
chromosome O 0 5.8216401157551445e-06
15 O 0 3.7269767290126765e-06
in O 0 1.0631757504597772e-05
J O 1 0.9666081070899963
. O 0 6.843383016530424e-05

B O 0 0.10049892216920853
. O 0 0.0029480597004294395

Maternal B-Disease 0 0.001262444769963622
disomy I-Disease 0 0.0028351815417408943
was O 0 3.6013705539517105e-05
confirmed O 0 3.5980110624223016e-06
by O 0 1.3103478977427585e-06
polymerase O 0 1.4409686627914198e-05
chain O 0 3.970187663071556e-06
reaction O 0 4.54991209153377e-07
analysis O 0 1.3301425383360765e-07
of O 0 4.2203626549053297e-07
microsatellite O 0 1.0363747605879325e-05
repeats O 0 1.0777971510833595e-06
at O 0 5.778804279543692e-07
the O 0 1.133835439759423e-06
gamma O 0 1.6948642951319925e-05
- O 0 3.24006614391692e-05
aminobutyric O 0 0.0004589669406414032
acid O 0 2.8671354812104255e-05
receptor O 0 7.5533316703513265e-06
beta3 O 0 7.120894588297233e-05
subunit O 0 1.2663265806622803e-05
( O 0 3.884385023411596e-06
GABRB3 O 0 0.0011956817470490932
) O 0 6.565835064975545e-06
locus O 0 7.400577305816114e-05
. O 0 2.0273295376682654e-05

A O 0 0.0002517233369871974
niece O 0 0.000310486153466627
( O 0 3.6585524867405184e-06
B O 0 3.4690350730670616e-05
. O 0 3.5301087564221234e-07
B O 0 2.7108878839499084e-06
. O 0 5.289297178023844e-08
) O 0 2.9399586765066488e-08
with O 0 3.3625241258050664e-08
45 O 0 1.662090056697707e-07
chromosomes O 0 7.618694297661932e-08
and O 0 2.788460129465875e-08
the O 0 1.2388693448883714e-07
derivative O 0 3.9070451407496876e-07
3 O 0 1.3377321295138245e-07
but O 0 2.8637538562747977e-08
without O 0 3.307552987052986e-08
the O 0 1.3899285988827614e-07
der O 0 1.078863897419069e-05
( O 0 1.375641573986286e-07
15 O 0 2.15275704817941e-07
) O 0 1.0488469825986613e-07
demonstrated O 0 4.7194970420605387e-07
a O 0 4.279671657059225e-07
phenotype O 0 2.622686224640347e-06
consistent O 0 3.5045852087023377e-07
with O 0 6.825238330065986e-08
that O 0 9.694015545846923e-08
reported O 0 2.246492272206524e-07
for O 0 1.7573194099895773e-07
haploinsufficiency O 0 3.7403908208943903e-05
of O 0 7.567593456769828e-06
distal O 0 0.002625634428113699
3 O 0 8.505010919179767e-05
p O 0 0.0008459753589704633
. O 0 5.3393883717944846e-05

Uniparental B-Disease 1 0.9999978542327881
disomy I-Disease 1 0.9993101358413696
associated O 0 5.057107046013698e-05
with O 0 7.970855222083628e-06
unbalanced O 0 0.0005322689539752901
segregation O 0 0.014139617793262005
of O 0 1.3312050214153714e-05
non O 0 7.048585393931717e-05
- O 0 0.0016403774498030543
Robertsonian O 1 0.7894484400749207
translocations O 0 3.989661854575388e-05
has O 0 5.291032607601664e-07
been O 0 2.2774386820856307e-07
reported O 0 1.5321005264468113e-07
previously O 0 2.642409526742995e-07
but O 0 6.226267146303144e-08
has O 0 4.4410981558939966e-08
not O 0 1.810579064454032e-08
, O 0 3.0480897805773566e-08
to O 0 2.0208911877261926e-08
our O 0 4.9193928930435504e-08
knowledge O 0 1.8628374220952537e-07
, O 0 6.406045827134221e-08
been O 0 7.933847001595495e-08
observed O 0 1.1454260118171078e-07
in O 0 1.3286312139371148e-07
a O 0 1.8059388366964413e-06
case O 0 6.629952167713782e-06
of O 0 8.777444600127637e-05
PWS B-Disease 1 0.9999996423721313
. O 0 0.00028199347434565425

Furthermore O 0 7.863935752538964e-05
, O 0 2.9305867883522296e-06
our O 0 6.501505254163931e-07
findings O 0 4.1734347178135067e-07
are O 0 5.2153058760495696e-08
best O 0 2.172082247398066e-07
interpreted O 0 3.293257577752229e-07
as O 0 2.3830689599435573e-07
true O 0 3.5964330891147256e-06
gamete O 0 0.00018706895934883505
complementation O 1 0.5907725691795349
resulting O 0 2.9809392799506895e-05
in O 0 1.0526460755500011e-05
maternal B-Disease 0 0.2682770788669586
UPD I-Disease 1 0.9999890327453613
15 I-Disease 0 0.00023023369431030005
and O 0 0.0003874251851812005
PWS B-Disease 1 0.9999915361404419

Schwartz B-Disease 1 0.9595826268196106
- I-Disease 1 0.9991391897201538
Jampel I-Disease 1 0.9999980926513672
syndrome I-Disease 1 1.0
type I-Disease 0 0.135587677359581
2 I-Disease 0 0.00014697235019411892
and O 0 4.162261029705405e-05
Stuve B-Disease 1 0.9999942779541016
- I-Disease 1 0.9999992847442627
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 3.4676793347898638e-06
a O 0 2.782717047011829e-06
case O 0 9.011786801238486e-07
for O 0 5.182814675208647e-07
" O 0 7.282587375812e-06
lumping O 0 5.7352146541234106e-05
" O 0 2.6262347091687843e-05
. O 0 4.202660420560278e-05

Recent O 0 6.342802407743875e-06
studies O 0 2.6679690563469194e-06
demonstrated O 0 3.9193182601593435e-06
the O 0 4.5582808638755523e-07
existence O 0 1.0284804830007488e-06
of O 0 7.287981702575053e-07
a O 0 2.8901424684590893e-06
genetically O 0 2.980594217660837e-06
distinct O 0 3.3551447131685563e-07
, O 0 1.819410613279615e-07
usually O 0 1.1048490478060558e-07
lethal O 0 4.3048788711530506e-07
form O 0 1.3228154216449184e-07
of O 0 6.32560727353848e-07
the O 0 3.191866198903881e-06
Schwartz B-Disease 0 0.4507852792739868
- I-Disease 1 0.9997420907020569
Jampel I-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.3090220093727112
SJS B-Disease 1 0.9999961853027344
) O 0 3.203610503987875e-06
of O 0 6.447171472245827e-05
myotonia B-Disease 1 0.9999997615814209
and O 0 0.035526126623153687
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.2060366316291038e-05
which O 0 7.641862680429767e-07
we O 0 8.351001952178194e-07
called O 0 9.2984082584735e-06
SJS B-Disease 0 0.04611322283744812
type I-Disease 0 2.6580632038530894e-05
2 I-Disease 0 2.780033537419513e-05
. O 0 2.8788073905161582e-05

This O 0 0.00010238299728371203
disorder O 1 0.9994072914123535
is O 0 5.431141289591324e-06
reminiscent O 0 0.00021579276653937995
of O 0 1.0494535672478378e-05
another O 0 3.43882420565933e-05
rare O 0 0.00012991594849154353
condition O 0 0.0003722446272149682
, O 0 1.2078343161192606e-06
the O 0 8.873943443177268e-06
Stuve B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999988079071045
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.19677194952964783
SWS B-Disease 1 0.9999946355819702
) O 0 9.065228141480475e-07
, O 0 2.3215645228447102e-07
which O 0 1.1637279584419957e-07
comprises O 0 1.4029385511094006e-06
campomelia B-Disease 0 5.209852315601893e-05
at O 0 2.7734870400308864e-06
birth O 0 6.222655065357685e-05
with O 0 0.008082475513219833
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 1 0.780880331993103
contractures B-Disease 1 0.9999970197677612
, O 0 4.293298388802214e-06
and O 0 2.412218691461021e-06
early B-Disease 0 2.9739630917902105e-05
death I-Disease 0 0.0005022108089178801
. O 0 0.00010225147707387805

To O 0 3.2721934530854924e-06
test O 0 2.0855620732618263e-06
for O 0 3.53508426087501e-07
possible O 0 1.3711415931538795e-06
nosologic O 0 0.00015808522584848106
identity O 0 1.3414539807854453e-06
between O 0 8.27401947844919e-07
these O 0 4.0001100387598854e-07
disorders O 1 0.9246270656585693
, O 0 3.6731586305904784e-07
we O 0 4.042038526108627e-08
reviewed O 0 6.233847926750968e-08
the O 0 3.884722232783133e-08
literature O 0 1.1207696815063173e-07
and O 0 3.073830612265738e-08
obtained O 0 7.354548614557643e-08
a O 0 9.200263662023644e-08
follow O 0 4.1762927338595546e-08
- O 0 1.4869949893636658e-07
up O 0 5.5298617240850945e-08
of O 0 8.218782454605389e-08
the O 0 7.755530617714612e-08
only O 0 3.685171989786795e-08
two O 0 4.3597456311772476e-08
surviving O 0 9.623118785384577e-06
patients O 0 7.349086104113667e-07
, O 0 1.256409660754798e-07
one O 0 8.491360148354943e-08
with O 0 3.626779800924851e-07
SJS B-Disease 0 0.1626712530851364
type I-Disease 0 2.1850642042409163e-06
2 I-Disease 0 3.9561248854624864e-07
at O 0 1.8840592019842006e-07
age O 0 1.6629698507131252e-07
10 O 0 6.966135401853535e-08
years O 0 1.0185472376633697e-07
and O 0 7.050226713545271e-08
another O 0 3.272594142345042e-07
with O 0 5.653844254993601e-07
SWS B-Disease 0 0.21864844858646393
at O 0 2.1302257664501667e-06
age O 0 4.45879231847357e-06
7 O 0 1.1757229913200717e-05
years O 0 1.193943990074331e-05
. O 0 3.6775429180124775e-05

Patients O 0 8.985970634967089e-05
reported O 0 8.809187420411035e-06
as O 0 3.160805135848932e-06
having O 0 9.796945960260928e-06
either O 0 4.975973934051581e-05
neonatal O 1 1.0
SJS B-Disease 1 0.9999997615814209
or O 0 1.224863990501035e-05
SWS B-Disease 1 0.9226379990577698
presented O 0 1.9638157482404495e-06
a O 0 7.416035145979549e-07
combination O 0 2.6210834676021477e-06
of O 0 8.739314125705278e-07
a O 0 1.13121504909941e-05
severe O 1 0.9984839558601379
, O 0 4.003122739959508e-05
prenatal O 1 0.9999337196350098
- O 1 0.9999998807907104
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9975016713142395
with O 1 0.9997581839561462
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 0.9999972581863403
respiratory O 1 1.0
and O 0 0.027751341462135315
feeding O 0 0.0200450848788023
difficulties O 0 0.03046487085521221
, O 0 3.34870469487214e-06
tendency O 0 5.781802883575438e-06
to O 0 5.006115770811448e-07
hyperthermia B-Disease 1 0.9996180534362793
, O 0 5.447764124255627e-07
and O 0 1.1215480810733425e-07
frequent O 0 8.659924901621707e-07
death O 0 5.635215075017186e-06
in O 0 1.485410621171468e-06
infancy O 0 3.0195618819561787e-05
) O 0 1.8058753425975738e-07
with O 0 2.470722222369659e-07
a O 0 5.637532012769952e-06
distinct O 0 2.5375542463734746e-05
campomelic B-Disease 1 0.9999864101409912
- I-Disease 1 0.9999977350234985
metaphyseal I-Disease 1 0.9999998807907104
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.12761181592941284

The O 0 1.316549696639413e-05
similarity O 0 1.2964069355803076e-05
of O 0 3.8655389289488085e-06
the O 0 4.435838491190225e-06
clinical O 0 5.0864837248809636e-05
and O 0 2.7322278128849575e-06
radiographic O 0 0.004070995841175318
findings O 0 1.1712081686710007e-06
is O 0 2.875741813568311e-07
so O 0 8.09934448398053e-08
extensive O 0 1.159508769887907e-06
that O 0 2.021148191033717e-07
these O 0 2.4495645334354776e-07
disorders O 0 0.41137370467185974
appear O 0 6.745058271917515e-07
to O 0 1.255054087323515e-07
be O 0 1.1165662527901077e-07
a O 0 1.0840968798220274e-06
single O 0 4.641333362087607e-06
entity O 0 3.180234125466086e-05
. O 0 4.5753033191431314e-05

The O 0 9.580394362274092e-06
follow O 0 2.5445369828958064e-06
- O 0 6.949228009034414e-06
up O 0 1.286198880734446e-06
observation O 0 2.3556699488835875e-06
of O 0 4.096665122688137e-07
an O 0 2.928573223925923e-07
identical O 0 4.186269961792277e-07
and O 0 1.0823721652286622e-07
unique O 0 3.4100352763744013e-07
pattern O 0 8.391122719331179e-06
of O 0 0.0022101369686424732
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 5.534131105378037e-06
the O 0 2.4326682250830345e-06
two O 0 2.950616533325956e-07
patients O 0 1.7439309658584534e-06
( O 0 2.601075550501264e-07
one O 0 2.2360914897490147e-07
with O 0 9.536351512906549e-07
SJS B-Disease 1 0.9132250547409058
type I-Disease 0 5.774210421805037e-06
2 I-Disease 0 4.6380495177800185e-07
, O 0 6.25445224500254e-08
one O 0 9.634752728970852e-08
with O 0 5.132707201482845e-07
SWS B-Disease 1 0.7493844628334045
) O 0 5.967311835775035e-07
surviving O 0 1.873423025244847e-05
beyond O 0 3.958082743338309e-06
infancy O 0 4.808828180102864e-06
adds O 0 3.0856585908622947e-07
to O 0 4.144582987919421e-08
the O 0 1.005005998422348e-07
evidence O 0 1.8632708531640674e-07
in O 0 1.2339523891569115e-07
favor O 0 2.7681809910973243e-07
of O 0 1.3058107697361265e-06
identity O 0 1.7326619854429737e-05
. O 0 4.3744672439061105e-05

The O 0 2.5178505893563852e-05
hypothesis O 0 3.6378278309712186e-05
that O 0 3.7227744087431347e-06
SWS B-Disease 1 0.944311261177063
and O 0 4.209010512568057e-06
SJS B-Disease 1 0.6527760624885559
type I-Disease 0 6.778113402106101e-06
2 I-Disease 0 4.570177054574742e-07
are O 0 2.2531086329991012e-08
the O 0 1.8736272977548651e-07
same O 0 6.833925567661936e-07
disorder O 0 0.3176957666873932
should O 0 1.7912239513862005e-07
be O 0 6.705415955821081e-08
testable O 0 5.459101544147416e-07
by O 0 1.2945950800258288e-07
molecular O 0 2.2391843685909407e-06
methods O 0 7.043633445391606e-07
. O 0 1.7255546254091314e-06
. O 0 1.374184648739174e-05

A O 0 0.0005956207751296461
mouse O 0 0.00013194607163313776
model O 0 1.6792935639386997e-05
of O 0 4.9969345127465203e-05
severe O 1 0.9999996423721313
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9685758948326111
defects O 1 0.9999972581863403
in O 0 0.002249195007607341
hemostasis O 1 0.9999979734420776
and O 0 0.002542815636843443
thrombosis B-Disease 1 0.9999996423721313
. O 0 0.011387119069695473

von B-Disease 0 0.18741369247436523
Willebrand I-Disease 1 0.999550998210907
factor I-Disease 0 0.0008169404463842511
( I-Disease 0 0.0004438594332896173
vWf I-Disease 1 0.999761164188385
) I-Disease 1 0.7092757225036621
deficiency I-Disease 1 1.0
causes O 1 0.9999988079071045
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.02762952260673046
humans O 0 0.00012850067287217826
. O 0 5.7612411183072254e-05

We O 0 1.048524154612096e-05
generated O 0 5.960599082754925e-06
a O 0 3.985278453910723e-06
mouse O 0 5.171324119146448e-06
model O 0 3.011642206729448e-07
for O 0 1.5056168933824665e-07
this O 0 4.285512034130079e-07
disease O 0 9.620327909942716e-05
by O 0 3.768795124869939e-07
using O 0 9.56910298555158e-07
gene O 0 7.296594958461355e-06
targeting O 0 1.0334454600524623e-05
. O 0 2.604009205242619e-05

vWf B-Disease 1 0.8983705639839172
- I-Disease 1 0.9644365906715393
deficient I-Disease 1 0.9948433637619019
mice O 0 0.0001625050645088777
appeared O 0 3.5105231290799566e-06
normal O 0 5.12940914632054e-07
at O 0 6.87678777921974e-07
birth O 0 1.255721372217522e-06
; O 0 1.207813085102316e-07
they O 0 9.623953189930035e-08
were O 0 3.4067915066771093e-07
viable O 0 3.992269739683252e-06
and O 0 4.38838424088317e-06
fertile O 0 0.0001827544328989461
. O 0 4.5219334424473345e-05

Neither O 0 0.0011923322454094887
vWf O 0 0.008980877697467804
nor O 0 0.00031295427470467985
vWf O 0 0.0021824485156685114
propolypeptide O 0 0.004630196839570999
( O 0 4.3203897803323343e-05
von B-Disease 0 0.4718782901763916
Willebrand I-Disease 1 0.9999884366989136
antigen O 1 0.8229129314422607
II O 1 0.9967473745346069
) O 0 6.781933734600898e-07
were O 0 2.842211301867792e-07
detectable O 0 1.7968784504773794e-06
in O 0 1.289721325292703e-07
plasma O 0 3.2011214443627978e-06
, O 0 3.6726052599078685e-07
platelets O 0 4.401595560921123e-06
, O 0 5.183719622436911e-07
or O 0 5.925076038693078e-07
endothelial O 0 0.11064954847097397
cells O 0 1.925319793372182e-06
of O 0 4.670006035212282e-07
the O 0 2.229963456557016e-06
homozygous O 0 4.217201785650104e-05
mutant O 0 0.0009356371592730284
mice O 0 0.0004036825557705015
. O 0 6.102205952629447e-05

The O 0 0.00012864609016105533
mutant O 0 0.042810529470443726
mice O 0 0.002556650200858712
exhibited O 0 0.0008974748780019581
defects O 1 0.9739863872528076
in O 0 8.060435902734753e-06
hemostasis O 1 0.9441074132919312
with O 0 1.4096898439674987e-06
a O 0 5.753219375037588e-05
highly O 0 0.002009054645895958
prolonged O 1 0.9999572038650513
bleeding O 1 0.9999747276306152
time O 0 2.1872931483812863e-06
and O 0 3.0223852718336275e-06
spontaneous O 0 0.003990671131759882
bleeding O 0 0.3171935975551605
events O 0 3.1700139402346394e-07
in O 0 1.7076274616556475e-07
approximately O 0 3.950854079448618e-07
10 O 0 8.480676001454412e-07
% O 0 1.535721139589441e-06
of O 0 1.272847566724522e-05
neonates O 0 0.0006341263651847839
. O 0 5.18719207320828e-05

As O 0 8.38350024423562e-06
in O 0 1.6976426877590711e-06
the O 0 4.124272436456522e-06
human O 0 1.0025264600699302e-05
disease O 0 0.01831251010298729
, O 0 5.222692038842069e-07
the O 0 5.85975044486986e-07
factor O 0 2.004007683353848e-06
VIII O 0 0.001999481813982129
level O 0 6.868175432828139e-07
in O 0 6.925662177081904e-08
these O 0 4.588545721162518e-08
mice O 0 9.229947295352758e-07
was O 0 1.1204998600078397e-06
reduced O 0 3.471944012289896e-07
strongly O 0 8.374859561399717e-08
as O 0 4.7691216309431184e-08
a O 0 6.82115199879263e-08
result O 0 9.376713450137686e-08
of O 0 1.9223074332330725e-07
the O 0 3.60381079644867e-07
lack O 0 1.0305531077392516e-06
of O 0 1.101915927392838e-06
protection O 0 1.358927784167463e-05
provided O 0 4.062144398631062e-06
by O 0 1.3831130672770087e-05
vWf O 0 0.0009192677098326385
. O 0 5.1802664529532194e-05

Defective O 1 0.9997064471244812
thrombosis B-Disease 1 0.9999567270278931
in O 0 9.720656089484692e-05
mutant O 1 0.7230414152145386
mice O 0 0.0005462805856950581
was O 0 1.4220166121958755e-05
also O 0 3.502283050238475e-07
evident O 0 7.85329689279024e-07
in O 0 8.139672047491331e-08
an O 0 1.1211759698426249e-07
in O 0 3.9716920241517073e-07
vivo O 0 7.560956873930991e-06
model O 0 4.16440798289841e-06
of O 0 0.00017855573969427496
vascular B-Disease 1 1.0
injury I-Disease 1 0.9999977350234985
. O 0 0.0012533857952803373

In O 0 5.854796654602978e-06
this O 0 1.149257172983198e-06
model O 0 1.5138451772145345e-06
, O 0 6.808867283325526e-07
the O 0 2.7263192805548897e-06
exteriorized O 0 0.00039449174073524773
mesentery O 0 0.0007382438634522259
was O 0 4.3074101995443925e-05
superfused O 0 0.0018171125557273626
with O 0 1.0490131899132393e-05
ferric O 1 0.9999984502792358
chloride O 0 0.03880176693201065
and O 0 6.148918600956677e-07
the O 0 1.690559770395339e-06
accumulation O 0 5.6566343118902296e-05
of O 0 1.0660225598257966e-05
fluorescently O 0 0.012979851104319096
labeled O 0 1.6737074474804103e-05
platelets O 0 1.2610601515916642e-05
was O 0 4.0846134652383626e-06
observed O 0 1.3462572496791836e-06
by O 0 4.425216047820868e-06
intravital O 0 0.0013026939705014229
microscopy O 0 0.00022379198344424367
. O 0 5.818191493744962e-05

We O 0 5.668449375662021e-06
conclude O 0 1.165370485978201e-05
that O 0 8.700089324520377e-07
these O 0 7.117594122973969e-07
mice O 0 1.2118820450268686e-05
very O 0 4.982311452295107e-07
closely O 0 2.294741307196091e-06
mimic O 0 0.00032387676765210927
severe O 1 0.9996376037597656
human O 0 0.2650006413459778
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 6.3808547565713525e-06
will O 0 2.0481054718857195e-07
be O 0 3.644323243179315e-08
very O 0 2.69193130009171e-08
useful O 0 3.039932039428095e-08
for O 0 1.986526676489575e-08
investigating O 0 2.0739797434998763e-07
the O 0 1.7529306717278814e-07
role O 0 5.082546294943313e-07
of O 0 1.481601998420956e-06
vWf O 0 3.5909553844248876e-05
in O 0 4.3979559904983034e-07
normal O 0 2.656928700162098e-06
physiology O 0 0.000371452362742275
and O 0 6.157093253023049e-07
in O 0 3.0645162496512057e-06
disease O 1 0.9801149964332581
models O 0 4.025227553938748e-06
. O 0 3.391786094653071e-06
. O 0 1.9719303963938728e-05

Oral O 0 0.043029557913541794
contraceptives O 0 0.0018542035249993205
and O 0 8.44972691993462e-06
the O 0 1.6715253877919167e-05
risk O 0 0.0001456655008951202
of O 1 0.5818678140640259
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9990573525428772

Hereditary B-Disease 1 0.9999998807907104
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.9993851184844971
Study O 0 0.001411492470651865
Group O 0 0.0023732269182801247
. O 0 0.00020176936232019216

BACKGROUND O 0 0.0002729149127844721
Women O 0 5.813967163703637e-06
with O 0 1.1401156143620028e-06
mutations O 0 2.4497539925505407e-06
in O 0 6.884700951559353e-07
either O 0 6.26207963705383e-07
the O 0 1.7966452787732123e-06
BRCA1 O 0 8.521621202817187e-05
or O 0 2.910980754222692e-07
the O 0 1.2091896905985777e-06
BRCA2 O 0 3.6749908758793026e-05
gene O 0 5.424859068625665e-07
have O 0 4.239779016756984e-08
a O 0 3.0277345786089427e-07
high O 0 1.4201041267369874e-06
lifetime O 0 1.0483551704965066e-05
risk O 0 3.619956987677142e-05
of O 1 0.8128860592842102
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5215297341346741

Oral O 0 0.0270785354077816
contraceptives O 0 0.1174304187297821
protect O 0 0.0006367886671796441
against O 1 0.9985606074333191
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.7552303688717075e-05
general O 0 0.00011506387090776116
, O 0 4.2818106749109575e-07
but O 0 6.851219325199054e-08
it O 0 2.4825073552392496e-08
is O 0 4.1381294835218796e-08
not O 0 1.2423212680801043e-08
known O 0 8.040593257874207e-08
whether O 0 3.671785009373707e-08
they O 0 4.4619255845645966e-08
also O 0 1.4890129307332245e-07
protect O 0 4.0184937688536593e-07
against O 0 2.330847109988099e-06
hereditary B-Disease 1 0.7441142201423645
forms I-Disease 0 0.00011430229642428458
of I-Disease 1 0.9999510049819946
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7041620016098022

METHODS O 0 3.604276935220696e-05
We O 0 2.581941544121946e-06
enrolled O 0 1.0893724720517639e-05
207 O 0 2.1249432393233292e-05
women O 0 6.558775567100383e-06
with O 0 0.00011324182560201734
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.6901673006941564e-05
161 O 0 1.2081121894880198e-05
of O 0 2.8380341063893866e-06
their O 0 3.949979827666539e-07
sisters O 0 7.151571935537504e-06
as O 0 3.4680587646107597e-07
controls O 0 6.339146239042748e-07
in O 0 1.251229804211107e-07
a O 0 8.750881761443452e-07
case O 0 1.9230021734983893e-06
- O 0 1.8122558685718104e-05
control O 0 8.15885687188711e-06
study O 0 5.680419235432055e-06
. O 0 2.163522549381014e-05

All O 0 4.449417701835046e-06
the O 0 6.466002560046036e-06
patients O 0 5.444172529678326e-06
carried O 0 1.5310810113078333e-06
a O 0 1.7582508462510305e-06
pathogenic O 0 3.748421022464754e-06
mutation O 0 1.700685970718041e-06
in O 0 3.443046523443627e-07
either O 0 1.0999326605087845e-06
BRCA1 O 0 1.3997916539665312e-05
( O 0 4.158806063969678e-07
179 O 0 2.119299779224093e-06
women O 0 8.30258613859769e-07
) O 0 4.3184812170693476e-07
or O 0 5.322227707438287e-07
BRCA2 O 0 1.6869693354237825e-05
( O 0 8.685001944286341e-07
28 O 0 5.084027634438826e-06
women O 0 3.154385694870143e-06
) O 0 4.666556378651876e-06
. O 0 2.0471012248890474e-05

The O 0 1.5541942048002966e-05
control O 0 1.1265621651546098e-05
women O 0 7.56654401357082e-07
were O 0 3.400701871214551e-07
enrolled O 0 1.200767542286485e-06
regardless O 0 4.1176596710101876e-07
of O 0 4.4806793653151544e-07
whether O 0 1.895445507216209e-07
or O 0 1.3024015288465307e-07
not O 0 6.919944439687242e-08
they O 0 9.491333230471355e-08
had O 0 1.0997396202583332e-06
either O 0 3.078838062720024e-06
mutation O 0 3.736216604011133e-05
. O 0 3.235391704947688e-05

Lifetime O 0 0.00010589143494144082
histories O 0 2.8766036848537624e-05
of O 0 2.6302823243895546e-05
oral O 0 0.43941208720207214
- O 1 0.5705516338348389
contraceptive O 0 0.2989574074745178
use O 0 3.1316992021857004e-07
were O 0 9.714264592730615e-08
obtained O 0 1.0706173725338886e-07
by O 0 1.0893995749938767e-07
interview O 0 6.223085051715316e-07
or O 0 4.0750073537765275e-08
by O 0 5.975466166319165e-08
written O 0 5.4836686302905946e-08
questionnaire O 0 1.0788867399469382e-07
and O 0 4.987216684071427e-08
were O 0 6.903729854457197e-08
compared O 0 1.8906469279045268e-07
between O 0 2.2051263215416839e-07
patients O 0 1.2247717222635401e-06
and O 0 3.00332459346464e-07
control O 0 3.167558588756947e-06
women O 0 1.2440195007457078e-07
, O 0 8.220131064717862e-08
after O 0 1.7227989701495972e-07
adjustment O 0 4.944895977132546e-07
for O 0 4.134571440772561e-08
year O 0 1.443052042304771e-07
of O 0 5.853690367985109e-07
birth O 0 6.794973160140216e-06
and O 0 4.043892658955883e-06
parity O 0 0.00043159714550711215
. O 0 3.5420503991190344e-05

RESULTS O 0 3.303748235339299e-05
The O 0 6.685826519969851e-06
adjusted O 0 1.1624379112618044e-05
odds O 0 1.7873888282338157e-05
ratio O 0 1.1554207958397456e-05
for O 0 8.90182564035058e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.6139596482389607e-05
with O 0 3.572452840217011e-07
any O 0 3.8128570167828e-07
past O 0 2.523651687624806e-07
use O 0 1.917674978813011e-07
of O 0 1.1929136007893248e-06
oral O 0 0.00020788706024177372
contraceptives O 0 0.00022158176579978317
was O 0 9.174902515951544e-05
0 O 0 2.9097782316966914e-05
. O 0 2.6630896172719076e-05

5 O 0 8.386403351323679e-06
( O 0 2.267345053041936e-06
95 O 0 2.545029701650492e-06
percent O 0 5.476017008732015e-07
confidence O 0 8.632985668555193e-07
interval O 0 4.575977357035299e-07
, O 0 5.967550009700062e-08
0 O 0 7.225268916499772e-08
. O 0 1.4093973987883146e-08
3 O 0 4.236852646499756e-08
to O 0 1.2065152432683135e-08
0 O 0 1.3212419958108512e-07
. O 0 1.3947273203029908e-07
8 O 0 1.851711999734107e-06
) O 0 2.9495940907509066e-06
. O 0 1.6065165254985914e-05

The O 0 1.5544728739769198e-05
risk O 0 8.217470167437568e-06
decreased O 0 2.805104031722294e-06
with O 0 1.2297067542021978e-07
increasing O 0 2.2948324840399437e-07
duration O 0 3.2037004871199315e-07
of O 0 1.6718956885597436e-07
use O 0 7.649330058256965e-08
( O 0 7.974126248200264e-08
P O 0 1.040186248246755e-06
for O 0 3.063955844595512e-08
trend O 0 2.100855880371455e-07
, O 0 5.2718625909164984e-08
< O 0 4.140854343859246e-07
0 O 0 8.2789938460337e-08
. O 0 4.0426400005344476e-08
001 O 0 1.0067747098219115e-06
) O 0 1.6452965212465642e-08
; O 0 6.919757655765579e-09
use O 0 6.663976037657449e-09
for O 0 7.322967121581314e-09
six O 0 1.923253201141506e-08
or O 0 2.165107915175213e-08
more O 0 1.1020178547482828e-08
years O 0 7.38188390414507e-08
was O 0 9.29028090013162e-07
associated O 0 1.3231485240794427e-07
with O 0 6.046317935215484e-08
a O 0 3.750209032205021e-07
60 O 0 8.01128351213265e-07
percent O 0 8.423855888395337e-07
reduction O 0 8.496886039210949e-06
in O 0 3.1922681955620646e-06
risk O 0 4.304437243263237e-05
. O 0 3.712597390403971e-05

Oral O 0 0.0038368641398847103
- O 0 0.0010743866441771388
contraceptive O 0 0.027043858543038368
use O 0 2.654928039191873e-06
protected O 0 4.435363371158019e-05
against O 0 0.007015481125563383
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999969005584717
both O 0 3.3037139246516745e-07
for O 0 2.0049586169079703e-07
carriers O 0 3.474978313988686e-07
of O 0 2.583577156656247e-07
the O 0 7.548137546109501e-07
BRCA1 O 0 1.6333346138708293e-05
mutation O 0 5.099305440126045e-07
( O 0 7.933801526860407e-08
odds O 0 2.3093575407528988e-07
ratio O 0 6.700506816059715e-08
, O 0 2.2642364427838402e-08
0 O 0 2.581079172614409e-08
. O 0 6.686588172044594e-09
5 O 0 2.0211878393183724e-08
; O 0 6.02317973275035e-09
95 O 0 4.85164015628925e-08
percent O 0 3.602566067684165e-08
confidence O 0 8.780209981296139e-08
interval O 0 9.663555289307624e-08
, O 0 2.883611749382453e-08
0 O 0 2.526323683582632e-08
. O 0 5.382425172228977e-09
3 O 0 1.6714007955442867e-08
to O 0 7.236022891987659e-09
0 O 0 1.9278660445820606e-08
. O 0 1.2970759577513036e-08
9 O 0 6.007796571338986e-08
) O 0 1.3889899008745488e-08
and O 0 8.249341654220643e-09
for O 0 1.2260341186731694e-08
carriers O 0 6.389913664861524e-08
of O 0 8.782320293221346e-08
the O 0 3.9213568925333675e-07
BRCA2 O 0 4.191186235402711e-06
mutation O 0 3.58974006076096e-07
( O 0 8.165687148675715e-08
odds O 0 5.49052856513299e-07
ratio O 0 1.1170285318939932e-07
, O 0 2.7057319940126945e-08
0 O 0 2.6619755288948e-08
. O 0 6.690338505421778e-09
4 O 0 2.2089565732130723e-08
; O 0 6.006453112661347e-09
95 O 0 3.7385671447509594e-08
percent O 0 2.991392733520115e-08
confidence O 0 1.424415927431255e-07
interval O 0 1.4164844230890594e-07
, O 0 2.89069355119409e-08
0 O 0 3.137363435712359e-08
. O 0 8.45354186651548e-09
2 O 0 2.2492313789257423e-08
to O 0 1.4712662199656279e-08
1 O 0 1.9712335586064e-07
. O 0 1.0613440792894835e-07
1 O 0 1.164266791420232e-06
) O 0 1.4997127664173604e-06
. O 0 8.091043127933517e-06

CONCLUSIONS O 0 0.00023788781254552305
Oral O 0 0.007950316183269024
- O 0 0.006211118306964636
contraceptive O 0 0.06375056505203247
use O 0 1.203408942274109e-06
may O 0 3.650592077519832e-07
reduce O 0 4.108543976144574e-07
the O 0 3.2115315207192907e-07
risk O 0 3.1766521715326235e-06
of O 0 0.16668778657913208
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.476738053606823e-05
women O 0 1.5988889572327025e-06
with O 0 8.886179898581759e-07
pathogenic O 0 2.104895429511089e-05
mutations O 0 2.1830169316672254e-06
in O 0 1.4822110188106308e-06
the O 0 1.9791270460700616e-05
BRCA1 O 1 0.5844914317131042
or O 0 5.174795296625234e-05
BRCA2 O 0 0.11775106936693192
gene O 0 0.0015947023639455438

A O 0 0.0003089610254392028
Japanese O 0 0.00014578331320080906
family O 0 1.7636264601605944e-05
with O 0 9.726324606162962e-06
adrenoleukodystrophy B-Disease 1 0.9999990463256836
with O 0 3.8109592424007133e-06
a O 0 1.2461616279324517e-05
codon O 0 1.4762755199626554e-05
291 O 0 8.476555194647517e-06
deletion O 0 6.828767254773993e-06
: O 0 3.1411482837029325e-07
a O 0 5.420463367045159e-07
clinical O 0 6.210294941411121e-06
, O 0 9.838205414780532e-07
biochemical O 0 0.00013526514521799982
, O 0 1.5257359109455138e-06
pathological O 0 0.005344822071492672
, O 0 1.8079274468618678e-06
and O 0 1.7137271015599254e-06
genetic O 0 2.1500523871509358e-05
report O 0 1.7056292563211173e-05
. O 0 4.482083750190213e-05

We O 0 6.522391686303308e-06
report O 0 2.181403942813631e-06
a O 0 3.905133326043142e-06
Japanese O 0 2.1436278984765522e-05
family O 0 7.432528036588337e-06
with O 0 5.2152303396724164e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.7471567392349243
ALD B-Disease 1 1.0
) O 0 6.595013815058337e-07
with O 0 2.2689623335736542e-07
a O 0 7.684395768592367e-07
three O 0 1.6859247864431381e-07
base O 0 2.410318984402693e-06
pair O 0 2.8296076379774604e-06
deletion O 0 7.826075488992501e-06
( O 0 1.2929801869177027e-06
delGAG O 0 5.3557938372250646e-05
291 O 0 4.178973085799953e-06
) O 0 3.1305793868341425e-07
in O 0 9.599823442840716e-07
the O 0 2.4315308110089973e-05
ALD B-Disease 1 0.9999996423721313
gene O 0 0.00022192596225067973
. O 0 5.2439208957366645e-05

A O 0 6.039853906258941e-05
variety O 0 4.8169340516324155e-06
of O 0 3.895945610565832e-06
phenotypes O 0 9.422676157555543e-06
were O 0 4.2871963046309247e-07
observed O 0 6.347967200781568e-07
within O 0 5.783220444754988e-07
this O 0 1.1060187716793735e-06
family O 0 1.3722411495109554e-05
. O 0 5.2995161240687594e-05

While O 0 1.703367888694629e-05
the O 0 1.103274553315714e-05
proband O 0 0.0021775374189019203
( O 0 4.152633209741907e-06
patient O 0 5.473717010318069e-06
1 O 0 2.04768480216444e-06
) O 0 2.5926601665560156e-07
was O 0 1.3018045592616545e-06
classified O 0 3.5232304185228713e-07
as O 0 1.2462733423035388e-07
having O 0 3.146583651414403e-07
a O 0 7.164188104979985e-07
rare O 0 2.6331119897804456e-06
intermediate O 0 3.1281786050385563e-06
type O 0 1.8303101114724996e-06
of O 0 1.3503230320566217e-06
adult O 0 5.934265118412441e-06
cerebral O 1 0.9679051041603088
and O 0 1.3652549569087569e-05
cerebello O 1 0.9999984502792358
- O 1 0.9999595880508423
brain O 1 0.999862790107727
stem O 0 0.00019464176148176193
forms O 0 1.185440169138019e-06
, O 0 3.981582779033488e-07
his O 0 1.749638272485754e-06
younger O 0 5.180258540349314e-06
brother O 0 3.257512071286328e-05
( O 0 9.594405128154904e-07
patient O 0 4.66650726593798e-06
2 O 0 1.6565907117183087e-06
) O 0 2.523673003906879e-07
and O 0 3.747027221834287e-07
nephew O 0 0.00011597992852330208
( O 0 1.0509470484976191e-06
patient O 0 3.2293803542415844e-06
3 O 0 2.5798888145800447e-06
) O 0 1.0823117690961226e-06
had O 0 5.57929115529987e-06
a O 0 7.610400643898174e-05
childhood O 1 0.9999427795410156
ALD B-Disease 1 1.0
type O 1 0.9438056945800781
. O 0 0.0002107761101797223

Another O 0 8.673776756040752e-05
nephew O 0 0.0031551355496048927
( O 0 5.86716578254709e-06
patient O 0 6.647799636994023e-06
4 O 0 2.0486340872594155e-06
) O 0 2.267660050847553e-07
of O 0 5.48679622625059e-07
patient O 0 2.6895556857198244e-06
1 O 0 1.921431248774752e-06
was O 0 6.983441835473059e-06
classified O 0 7.979669476299023e-07
as O 0 3.0710475584783126e-07
having O 0 1.3377311915974133e-06
an O 0 2.519669578759931e-06
adolescent O 0 0.004499261733144522
form O 0 8.032410551095381e-05
. O 0 9.365699224872515e-05

The O 0 9.887237865768839e-06
tau O 0 2.4388855308643542e-05
level O 0 1.6456345974802389e-06
in O 0 4.447371111382381e-07
the O 0 1.7770012163964566e-06
cerebrospinal O 0 0.02502313442528248
fluid O 0 6.042273889761418e-05
( O 0 2.4181404114642646e-06
CSF O 0 0.10428020358085632
) O 0 2.1194847477090661e-07
in O 0 8.92792400009057e-08
patient O 0 3.832163315564685e-07
1 O 0 5.617008014269231e-07
was O 0 1.2918142147100298e-06
as O 0 5.4785772363175056e-08
high O 0 1.5113454310267116e-07
as O 0 3.925569558305142e-08
that O 0 2.9365626375010834e-08
of O 0 7.0567369903074e-07
patients O 0 8.855674423102755e-06
with O 0 0.0010033423313871026
Alzheimers B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.641101208515465e-05
AD B-Disease 0 0.00013335463881958276
) O 0 7.967245437612291e-06
. O 0 2.6935371352010407e-05

His O 0 0.0004147029831074178
brain O 0 0.06276006251573563
magnetic O 0 0.00018065061885863543
resonance O 0 7.634627399966121e-05
image O 0 1.8474171156412922e-05
( O 0 3.914417902706191e-06
MRI O 0 0.0005412637838162482
) O 0 3.996179032128566e-07
showed O 0 2.1323965029296232e-06
abnormalities B-Disease 0 3.926942008547485e-05
in I-Disease 0 2.1208434475283866e-07
the I-Disease 0 8.316501975969004e-07
bilateral I-Disease 0 9.11723545868881e-05
cerebellar I-Disease 1 0.9999995231628418
hemispheres I-Disease 0 0.019469041377305984
and O 0 2.5612267563701607e-05
brain O 1 0.9868805408477783
stem O 0 2.268870230182074e-05
, O 0 1.383203169780245e-07
but O 0 2.9235691201279224e-08
not O 0 1.2617261013758707e-08
in O 0 6.84923406879534e-08
the O 0 1.0578451110632159e-06
cerebral O 1 0.8194023966789246
white O 0 5.553238224820234e-06
matter O 0 2.5324393959635927e-07
, O 0 7.207773933259887e-08
where O 0 7.168809190716274e-08
marked O 0 3.426635259984323e-07
reductions O 0 7.557471803920635e-07
of O 0 3.637184988747322e-07
the O 0 2.8815668429160723e-06
cerebral O 1 0.7607315182685852
blood O 0 7.788707080180757e-06
flow O 0 1.0628303925841465e-06
and O 0 5.951160346739925e-07
oxygen O 0 7.62418267186149e-06
metabolism O 0 2.9495124636014225e-06
were O 0 2.057604433503002e-07
clearly O 0 5.501970576915483e-07
demonstrated O 0 7.539806574641261e-07
by O 0 6.285030167418881e-07
positron O 0 2.595648584247101e-05
emission O 0 7.268543413374573e-06
tomography O 0 1.272262761631282e-05
( O 0 3.3419889859942487e-06
PET O 0 3.243337050662376e-05
) O 0 3.037161604879657e-06
. O 0 1.133091609517578e-05

In O 0 1.2109519957448356e-05
patients O 0 6.389495410985546e-06
2 O 0 1.8168565247833612e-06
and O 0 2.9307889803931175e-07
3 O 0 4.887733666691929e-07
, O 0 1.2636847657176986e-07
the O 0 1.4445087970216264e-07
autopsy O 0 9.554394182487158e-07
findings O 0 3.21090084298703e-07
showed O 0 2.698676553336554e-06
massive O 0 0.005926662124693394
demyelination B-Disease 1 0.9999960660934448
of I-Disease 0 9.851661161519587e-06
the I-Disease 0 5.871862231288105e-05
cerebral I-Disease 1 0.9998788833618164
white I-Disease 0 2.364434658375103e-05
matter I-Disease 0 2.9144001700842637e-07
with O 0 1.1964965551669593e-07
sparing O 0 3.732073537321412e-06
of O 0 2.5961139726859983e-06
the O 0 4.847596210311167e-05
U O 1 0.9999971389770508
- O 1 0.6116833090782166
fibers O 0 0.024578869342803955
, O 0 2.856411924767599e-07
compatible O 0 2.9504843723771046e-07
with O 0 9.009158929984551e-08
the O 0 8.455946272079018e-07
findings O 0 2.5470133095950587e-06
of O 0 2.2516544049722143e-05
childhood O 1 0.999909520149231
ALD B-Disease 1 1.0
. O 0 0.0015203304355964065

Oleic O 0 0.01974373124539852
and O 0 6.799410039093345e-05
erucic O 0 0.4302472770214081
acids O 0 8.892877303878777e-06
( O 0 2.5583481146895792e-06
Lorenzos O 0 0.0001227983011631295
Oil O 0 1.7498884972155793e-06
) O 0 1.1784612041765286e-07
were O 0 5.81085188855468e-08
administered O 0 1.1263780663739453e-07
to O 0 3.402426784759882e-08
patients O 0 1.0613460688091436e-07
1 O 0 1.787503975947402e-07
and O 0 5.047332862773146e-08
4 O 0 2.2271358091074944e-07
, O 0 4.1040475906584106e-08
but O 0 2.6470546643508897e-08
sufficient O 0 1.7500691740224283e-07
effectiveness O 0 4.0673128864909813e-07
was O 0 8.818801688903477e-07
not O 0 1.2038928787205805e-07
obtained O 0 2.1142127479834016e-06
. O 0 1.040050028677797e-05

The O 0 1.0493614354345482e-05
findings O 0 3.5627665511128725e-06
in O 0 6.925819775460695e-07
this O 0 4.914178930448543e-07
family O 0 7.850780434637272e-07
suggest O 0 2.175965363448995e-07
that O 0 9.53437151451908e-08
delGAG291 O 0 3.683384193209349e-06
is O 0 1.516123688816151e-07
part O 0 2.16576097500365e-07
of O 0 4.303585683373967e-07
the O 0 1.990736791412928e-06
cause O 0 2.3489768864237703e-05
of O 0 1.4538485629600473e-05
Japanese O 0 0.4399403929710388
ALD B-Disease 1 0.9999990463256836
with O 0 9.93180674413452e-06
phenotypic O 0 0.00018639575864654034
variations O 0 5.7761706557357684e-05
. O 0 5.397483619162813e-05

Moreover O 0 3.422110603423789e-05
, O 0 2.037928197751171e-06
although O 0 6.893518502693041e-07
the O 0 3.472506762136618e-07
scale O 0 9.360003332403721e-07
of O 0 2.4834005785123736e-07
the O 0 2.388771065398032e-07
study O 0 1.9595749733980483e-07
is O 0 7.077118624465584e-08
limited O 0 7.304821281195473e-08
, O 0 3.576692719775565e-08
there O 0 3.84221152671671e-08
is O 0 5.6931472869337085e-08
a O 0 3.0283868568403705e-07
possibility O 0 1.01552939213434e-06
that O 0 2.473117319823359e-07
PET O 0 2.6142708975385176e-06
can O 0 4.7747100495598715e-08
detect O 0 6.068351012800122e-07
an O 0 9.568291261530248e-07
insidious B-Disease 1 0.9596198201179504
lesion I-Disease 1 0.9950941801071167
which O 0 3.0815209584034164e-07
is O 0 1.932676809701661e-07
undetectable O 0 1.5760954283905448e-06
by O 0 9.307274950742794e-08
computed O 0 8.613774866716994e-07
tomogram O 0 0.00011490444012451917
( O 0 9.132364766628598e-07
CT O 0 0.0005745074013248086
) O 0 1.0268726668982708e-07
or O 0 5.564141147829105e-08
MRI O 0 6.225844799701008e-07
analysis O 0 3.134336878929389e-08
, O 0 2.4242833518428597e-08
and O 0 1.197729115887114e-08
that O 0 9.746832674295547e-09
the O 0 4.176738954697612e-08
higher O 0 8.04969246814835e-08
level O 0 1.569986807226087e-07
of O 0 1.7503180060884915e-07
tau O 0 2.3494103515986353e-06
reflects O 0 1.937155360565157e-07
the O 0 8.72167404963875e-08
process O 0 2.603611903850833e-07
of O 0 6.479286639660131e-06
neuronal B-Disease 1 0.9981378316879272
degeneration I-Disease 1 1.0
in O 0 0.0018596079898998141
ALD B-Disease 1 1.0
. O 0 0.0003536986478138715

Lorenzos O 0 0.002332031959667802
Oil O 0 3.273477705079131e-05
should O 0 6.050033789506415e-07
be O 0 8.156612096854587e-08
given O 0 8.228161618717422e-08
in O 0 8.697006137481367e-08
the O 0 2.6488760340726003e-07
early O 0 2.1113312413945096e-06
stage O 0 1.4926831681805197e-05
. O 0 3.315738013043301e-06
. O 0 1.621721821720712e-05

Nonsense O 0 0.0004491229774430394
mutation O 0 3.876229311572388e-05
in O 0 3.8681500882375985e-06
exon O 0 4.4120180973550305e-05
4 O 0 2.868493538699113e-06
of O 0 1.2760131085087778e-06
human O 0 1.4913606491973042e-06
complement O 0 1.5763609553687274e-05
C9 O 1 0.9927560687065125
gene O 0 2.1308330815372756e-06
is O 0 1.6112539924506564e-07
the O 0 2.433373254007165e-07
major O 0 2.613019432828878e-06
cause O 0 1.677110412856564e-05
of O 0 1.1826029549411032e-05
Japanese O 0 0.001225327025167644
complement B-Disease 0 0.09502314031124115
C9 I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999998807907104
. O 0 0.00040506242658011615

Deficiency B-Disease 1 0.9995020627975464
of I-Disease 0 3.054077023989521e-05
the I-Disease 0 1.1536338206497021e-05
ninth I-Disease 0 0.0003818896075244993
component I-Disease 0 1.422677087248303e-05
of I-Disease 0 1.5303992313420167e-06
human I-Disease 0 1.369227334180323e-06
complement I-Disease 0 4.10936900152592e-06
( O 0 2.5198473849741276e-06
C9 O 1 0.755785346031189
) O 0 2.571875370449561e-07
is O 0 6.660140883241183e-08
the O 0 1.1627107454614816e-07
most O 0 2.1826974716532277e-07
common O 0 5.787711415905505e-06
complement B-Disease 1 0.9993849992752075
deficiency I-Disease 1 1.0
in O 0 5.34476748725865e-06
Japan O 0 9.255171789845917e-06
but O 0 2.339915567972639e-07
is O 0 2.4347102112187713e-07
rare O 0 4.6561933686462e-07
in O 0 2.0313841275765299e-07
other O 0 2.1324525789623294e-07
countries O 0 8.648815423839551e-07
. O 0 2.3913607947179116e-05

We O 0 9.794442121346947e-06
studied O 0 9.678848073235713e-06
the O 0 2.4310311346198432e-06
molecular O 0 3.5049033613177016e-06
basis O 0 1.4587474197469419e-06
of O 0 3.766732334042899e-05
C9 B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999984502792358
in O 0 4.885170710622333e-06
four O 0 7.300827292056056e-06
Japanese O 1 0.924888551235199
C9 B-Disease 1 1.0
- I-Disease 1 0.9999774694442749
deficient I-Disease 1 0.9999504089355469
patients O 0 8.330047421623021e-05
who O 0 1.1605482541199308e-05
had O 0 0.003432700177654624
suffered O 1 0.999998927116394
from O 1 0.997855007648468
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.3620813488960266

Direct O 0 1.4670631571789272e-05
sequencing O 0 2.862065412045922e-05
of O 0 1.8067406927002594e-05
amplified O 0 0.00017139232659246773
C9 O 0 0.013363117352128029
cDNA O 0 3.597021714085713e-05
and O 0 1.1404941915316158e-06
DNA O 0 3.338125225127442e-06
revealed O 0 2.605820100143319e-06
a O 0 1.7488573575974442e-06
nonsense O 0 1.7305879737250507e-05
substitution O 0 9.149180186796002e-06
( O 0 1.9466090179776074e-06
CGA O 0 4.4345004425849766e-05
- O 0 7.5887828643317334e-06
- O 0 1.4501789337373339e-05
> O 0 3.214233220205642e-05
TGA O 0 6.354551442200318e-05
) O 0 1.2747355526698811e-07
at O 0 2.64129056404272e-07
codon O 0 7.067917522363132e-07
95 O 0 5.404657485996722e-07
in O 0 2.519303734516143e-07
exon O 0 3.3522132980579045e-06
4 O 0 2.7805421609627956e-07
in O 0 2.844830930825992e-07
the O 0 1.140520225817454e-06
four O 0 6.4246046349580865e-06
C9 B-Disease 1 0.9996935129165649
- I-Disease 0 0.01439712569117546
deficient I-Disease 0 0.0007118809153325856
individuals O 0 4.1718212742125615e-06
. O 0 3.1907871743896976e-05

An O 0 3.055090564885177e-05
allele O 0 6.023829337209463e-05
- O 0 1.9458482711343095e-05
specific O 0 1.435687750017678e-06
polymerase O 0 2.8959782866877504e-05
chain O 0 1.2671602235059254e-05
reaction O 0 1.5171751783782383e-06
system O 0 4.557528825444024e-07
designed O 0 2.129233678260789e-07
to O 0 3.681167726199419e-08
detect O 0 1.6257321533430513e-07
exclusively O 0 3.637371648324006e-08
only O 0 1.675502225850778e-08
one O 0 1.835888241430439e-08
of O 0 8.801134043778802e-08
the O 0 1.4941851134153694e-07
normal O 0 2.098286984164588e-07
and O 0 9.908657716550806e-08
mutant O 0 2.6848351808439475e-06
alleles O 0 1.8172083571244002e-07
indicated O 0 9.276738666130768e-08
that O 0 1.2796339987630745e-08
all O 0 9.70672253686189e-09
the O 0 4.3631811053046476e-08
four O 0 6.299083565863839e-08
patients O 0 9.450057802951051e-08
were O 0 4.758426896955825e-08
homozygous O 0 1.9104064108432794e-07
for O 0 2.555094269496294e-08
the O 0 1.0710729014817844e-07
mutation O 0 4.401119895192096e-07
in O 0 2.1967512964238267e-07
exon O 0 7.787868526065722e-06
4 O 0 2.845620485913969e-07
and O 0 4.8791179096951964e-08
that O 0 2.6051361956547225e-08
the O 0 1.2615943489890924e-07
parents O 0 7.729878603868201e-08
of O 0 4.1676202044982347e-07
patient O 0 7.097636625985615e-06
2 O 0 7.676582754356787e-06
were O 0 5.269869689072948e-06
heterozygous O 0 3.7245943531161174e-05
. O 0 3.252616443205625e-05

The O 0 1.976637213374488e-05
common O 0 7.379647740890505e-06
mutation O 0 3.825586645689327e-06
at O 0 1.3267083431856008e-06
codon O 0 2.801305299726664e-06
95 O 0 1.1620926443356439e-06
in O 0 3.823566032679082e-07
exon O 0 8.880319001036696e-06
4 O 0 9.639960580898332e-07
might O 0 1.6736248653614894e-07
be O 0 4.790838303847522e-08
responsible O 0 2.679456088117149e-07
for O 0 2.455149399338552e-07
most O 0 1.5143564269237686e-06
Japanese O 0 0.006949584931135178
C9 B-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999998807907104
. O 0 5.251291804597713e-05
. O 0 9.373186912853271e-05

BRCA1 O 0 0.0004050757270306349
required O 0 4.308523784857243e-06
for O 0 1.9209528545616195e-06
transcription O 0 3.768727037822828e-05
- O 0 0.00017452087195124477
coupled O 0 0.00023753198911435902
repair O 0 0.0002777294721454382
of O 0 1.8460961655364372e-05
oxidative O 1 0.9793238639831543
DNA O 0 0.0003991342964582145
damage O 0 0.0013041563797742128
. O 0 6.236413901206106e-05

The O 0 0.00032148370519280434
breast B-Disease 1 0.9999840259552002
and I-Disease 1 0.9949058294296265
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999998807907104
gene O 1 0.6811996102333069
BRCA1 O 1 0.7073310613632202
encodes O 0 3.460576044744812e-05
a O 0 0.00024421417037956417
zinc O 1 0.9999476671218872
finger O 0 0.0003742539556697011
protein O 0 3.1963566016202094e-06
of O 0 1.4887943962094141e-06
unknown O 0 1.292755132453749e-05
function O 0 8.590111065132078e-06
. O 0 2.1900126739637926e-05

Association O 0 5.8435638493392617e-05
of O 0 1.1257868209213484e-05
the O 0 1.0559911061136518e-05
BRCA1 O 0 4.386192813399248e-05
protein O 0 7.834221946723119e-07
with O 0 1.9890828184543352e-07
the O 0 1.44869056839525e-06
DNA O 0 1.393025195284281e-05
repair O 0 3.581669807317667e-05
protein O 0 1.3746923741564387e-06
Rad51 O 0 5.348484592104796e-06
and O 0 3.669026682473486e-08
changes O 0 2.5424398586437746e-08
in O 0 3.4177180197048074e-08
the O 0 9.391229127686529e-08
phosphorylation O 0 1.7927381179561053e-07
and O 0 9.787280674800058e-08
cellular O 0 9.994515721700736e-07
localization O 0 1.514651103207143e-06
of O 0 1.4154082350614772e-07
the O 0 1.694658493534007e-07
protein O 0 5.158007638783602e-07
after O 0 5.80274445383111e-07
exposure O 0 1.8260699334859964e-06
to O 0 2.341049309961818e-07
DNA O 0 3.4033728297799826e-06
- O 0 5.0063054004567675e-06
damaging O 0 6.120612397353398e-06
agents O 0 1.9949300167354522e-07
are O 0 1.0314677112432946e-08
consistent O 0 7.621645181643544e-08
with O 0 6.098996152559266e-08
a O 0 4.578876087180106e-07
role O 0 9.089563377528975e-07
for O 0 7.410661737594637e-07
BRCA1 O 0 8.413664909312502e-05
in O 0 2.605837607916328e-06
DNA O 0 0.00013354602560866624
repair O 0 0.006545503623783588
. O 0 5.5954889830900356e-05

Here O 0 1.2616013918886892e-05
, O 0 1.6246733594016405e-06
it O 0 2.4588140945525083e-07
is O 0 2.592511805232789e-07
shown O 0 3.6908210176989087e-07
that O 0 3.852558734251943e-07
mouse O 0 1.18428906716872e-05
embryonic O 0 2.9453603929141536e-05
stem O 0 4.105600237380713e-05
cells O 0 1.0105578439834062e-05
deficient B-Disease 0 1.1662821634672582e-05
in I-Disease 0 4.344778687936923e-07
BRCA1 I-Disease 0 1.0509809726499952e-05
are O 0 4.028600031347196e-08
defective O 0 1.0762186093415949e-06
in O 0 5.4692538498102294e-08
the O 0 1.0845792530744802e-07
ability O 0 6.239795879992016e-08
to O 0 1.6699827298793934e-08
carry O 0 3.111974677949547e-08
out O 0 5.541666325825645e-08
transcription O 0 1.4475305079031386e-06
- O 0 7.353857654379681e-06
coupled O 0 1.0870528967643622e-05
repair O 0 2.072306233458221e-05
of O 0 2.69618885795353e-06
oxidative O 1 0.8557193279266357
DNA O 0 1.9915243683499284e-05
damage O 0 1.6081996363936923e-05
, O 0 2.513213530619396e-07
and O 0 2.1973129094021715e-07
are O 0 1.7929944817751675e-07
hypersensitive O 0 4.346220885054208e-05
to O 0 9.596492418495473e-07
ionizing O 0 0.00014009168080519885
radiation O 0 0.00010366601782152429
and O 0 4.51357982456102e-06
hydrogen O 0 3.452068631304428e-05
peroxide O 0 0.00022996492043603212
. O 0 5.7764958910411224e-05

These O 0 2.4131757072609616e-06
results O 0 2.5199001356668305e-06
suggest O 0 2.3057339149090694e-06
that O 0 7.87653391398635e-07
BRCA1 O 0 4.336247729952447e-05
participates O 0 1.7326780152870924e-06
, O 0 2.610389060464513e-07
directly O 0 7.988771244527015e-08
or O 0 8.027062392557127e-08
indirectly O 0 2.0362485031455435e-07
, O 0 1.2667108251207537e-07
in O 0 2.1129619653947884e-07
transcription O 0 7.213547633000417e-06
- O 0 4.531101876636967e-05
coupled O 0 3.83029728254769e-05
repair O 0 3.184212255291641e-05
of O 0 3.91654612030834e-06
oxidative O 1 0.7063453793525696
DNA O 0 5.9869824326597154e-05
damage O 0 9.614237205823883e-05
. O 0 4.655510110751493e-06
. O 0 2.210614002251532e-05

Truncation O 0 0.0021289365831762552
mutations O 0 3.0732338927919045e-05
in O 0 2.869027184715378e-06
the O 0 3.972975719079841e-06
transactivation O 0 0.0002140962751582265
region O 0 8.229586455854587e-06
of O 0 5.538661753234919e-06
PAX6 O 1 0.9263544082641602
result O 0 4.757868737215176e-06
in O 0 2.3193081233330304e-06
dominant O 0 4.273646118235774e-05
- O 0 9.875679097604007e-05
negative O 0 2.0162027794867754e-05
mutants O 0 0.0003090111131314188
. O 0 3.665498661575839e-05

PAX6 O 0 0.1030803993344307
is O 0 5.809903996123467e-06
a O 0 2.59440139416256e-06
transcription O 0 2.506382543288055e-06
factor O 0 4.828625037589518e-07
with O 0 8.768293469074706e-08
two O 0 1.5327026403610944e-07
DNA O 0 1.4951730236134608e-06
- O 0 1.0411687298983452e-06
binding O 0 3.57682296225903e-07
domains O 0 4.843180363423016e-07
( O 0 3.1924886911838257e-07
paired O 0 2.467426156727015e-06
box O 0 3.818413460976444e-06
and O 0 5.993529725856206e-07
homeobox O 0 4.590697062667459e-05
) O 0 1.0998805066719797e-07
and O 0 1.9856712185628567e-07
a O 0 2.41575003201433e-06
proline O 0 3.277213909314014e-05
- O 0 1.8464590539224446e-05
serine O 0 3.1389397918246686e-05
- O 0 3.210018257959746e-05
threonine O 0 5.979918205412105e-05
( O 0 3.4308768590562977e-06
PST O 0 0.0103919617831707
) O 0 2.6478783183847554e-06
- O 0 3.263659164076671e-05
rich O 0 1.5505729606957175e-05
transactivation O 0 0.0003187036782037467
domain O 0 3.98466618207749e-05
. O 0 3.876299160765484e-05

PAX6 O 1 0.999091386795044
regulates O 0 0.00046762969577685
eye O 0 0.000816136656794697
development O 0 1.2537801012513228e-05
in O 0 1.9124422578897793e-06
animals O 0 6.727289587615815e-07
ranging O 0 1.5024255617390736e-06
from O 0 1.732103214635572e-06
jellyfish O 0 5.5466803132731e-06
to O 0 4.4575534730029176e-07
Drosophila O 0 6.471320375567302e-06
to O 0 9.968596259568585e-07
humans O 0 7.442302376148291e-06
. O 0 1.6753936506574973e-05

Heterozygous O 0 0.00010726687469286844
mutations O 0 1.3991162632009946e-05
in O 0 2.985569835800561e-06
the O 0 6.019972261128714e-06
human O 0 1.6884887372725643e-05
PAX6 O 1 0.9958743453025818
gene O 0 3.849543645628728e-06
result O 0 4.2640317587938625e-07
in O 0 1.594514174030337e-07
various O 0 1.4345420140671195e-07
phenotypes O 0 3.8068217236286728e-06
, O 0 6.341837206491618e-07
including O 0 2.3952732135512633e-06
aniridia B-Disease 1 0.9999957084655762
, O 0 0.00014157837722450495
Peters B-Disease 1 0.9998231530189514
anomaly I-Disease 1 0.9999828338623047
, O 0 4.456086389836855e-05
autosomal B-Disease 1 0.690097451210022
dominant I-Disease 1 0.9909626841545105
keratitis I-Disease 1 0.9999996423721313
, O 0 0.00010638067760737613
and O 0 0.0001470402057748288
familial B-Disease 1 0.9999970197677612
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9133465886116028

It O 0 7.2400953285978176e-06
is O 0 1.8958807004310074e-06
believed O 0 4.2249116631865036e-06
that O 0 2.5508828116471705e-07
the O 0 1.2769089607900241e-06
mutated O 0 9.2611135187326e-06
allele O 0 6.341967491607647e-06
of O 0 3.8792168197687715e-06
PAX6 O 1 0.9946750402450562
produces O 0 1.8211273982160492e-06
an O 0 4.418513981363503e-07
inactive O 0 1.695249193289783e-05
protein O 0 4.33932700616424e-06
and O 0 1.1443870562288794e-06
aniridia B-Disease 1 0.9995179176330566
is O 0 1.0774220982057159e-06
caused O 0 1.4315111911855638e-05
due O 0 3.634103222793783e-06
to O 0 1.3356660701902001e-06
genetic O 0 7.927210390334949e-05
haploinsufficiency O 1 0.5228143334388733
. O 0 9.30346068344079e-05

However O 0 1.7408339772373438e-05
, O 0 2.268815933348378e-06
several O 0 7.6810908922198e-07
truncation O 0 5.5525557399960235e-05
mutations O 0 8.523161341145169e-07
have O 0 5.653445356301745e-08
been O 0 6.503762506326893e-08
found O 0 3.354721656023685e-08
to O 0 1.479390121517099e-08
occur O 0 1.5364456373845314e-08
in O 0 3.040645424334798e-08
the O 0 2.2577467007067753e-07
C O 0 5.9491925640031695e-05
- O 0 8.668569535075221e-06
terminal O 0 2.7726518965209834e-05
half O 0 3.3660251119727036e-07
of O 0 1.3723988558922429e-06
PAX6 O 0 0.49797624349594116
in O 0 9.456744010094553e-07
patients O 0 8.838570693114889e-07
with O 0 8.788819059191155e-07
Aniridia B-Disease 1 0.9999575614929199
resulting O 0 6.1715404626738746e-06
in O 0 4.356919873771403e-07
mutant O 0 2.323244189028628e-06
proteins O 0 7.173650828917744e-08
that O 0 3.161982320420975e-08
retain O 0 4.5164588868829014e-07
the O 0 3.3842920288407186e-07
DNA O 0 1.2291175153222866e-06
- O 0 7.433517339450191e-07
binding O 0 2.5025704530889925e-07
domains O 0 2.582690115104924e-07
but O 0 6.207969960314585e-08
have O 0 6.005848263157532e-08
lost O 0 1.401979488946381e-06
most O 0 1.1168964419994154e-07
of O 0 1.0286148608429357e-06
the O 0 6.976718395890202e-06
transactivation O 0 0.001131244353018701
domain O 0 6.064971967134625e-05
. O 0 3.920097879017703e-05

It O 0 2.2501405965158483e-06
is O 0 4.1004724948834337e-07
not O 0 6.498640914287535e-08
clear O 0 1.3053235647930705e-07
whether O 0 6.900359750261487e-08
such O 0 1.5685290577494015e-07
mutants O 0 1.3793655853078235e-05
really O 0 7.090899885042745e-07
behave O 0 1.2639884516829625e-07
as O 0 1.737826806902376e-07
loss O 0 7.071659183566226e-06
- O 0 3.3776379950722912e-06
of O 0 1.968348897207761e-06
- O 0 1.1771568097174168e-05
function O 0 1.1542019819898997e-06
mutants O 0 4.551458005153108e-06
as O 0 5.432946181826992e-07
predicted O 0 3.4391716781101422e-06
by O 0 2.667154831215157e-06
haploinsufficiency O 0 0.0013983671087771654
. O 0 6.037666025804356e-05

Contrary O 0 1.4471093891188502e-05
to O 0 5.339899757927924e-07
this O 0 2.6847175149669056e-07
theory O 0 1.3856288205715828e-06
, O 0 2.4536140585951216e-07
our O 0 7.98806993884682e-08
data O 0 5.421022564178202e-08
showed O 0 1.6286030302126164e-07
that O 0 2.756615025134579e-08
these O 0 1.7632949322887725e-08
mutants O 0 5.759761734225322e-07
are O 0 1.5623536242515e-08
dominant O 0 7.875376581978344e-07
- O 0 1.0002726185120991e-06
negative O 0 2.4868347736628493e-07
in O 0 5.316413762557204e-07
transient O 0 2.7430487534729764e-05
transfection O 0 7.530189031967893e-05
assays O 0 7.946096616251452e-07
when O 0 1.3519604635803262e-07
they O 0 2.980026003740477e-08
are O 0 3.818649574327537e-08
coexpressed O 0 9.880772267933935e-06
with O 0 1.2520310974650783e-06
wild O 0 8.88000286067836e-05
- O 0 0.01866317167878151
type O 0 0.0063055092468857765
PAX6 O 1 0.9991266131401062
. O 0 8.401390368817374e-05

We O 0 3.7308636819943786e-06
found O 0 7.586862693642615e-07
that O 0 1.3857726344213006e-07
the O 0 3.8200926155695925e-07
dominant O 0 6.632456461375114e-06
- O 0 2.769065304164542e-06
negative O 0 4.596762437358848e-07
effects O 0 1.431089344805514e-06
result O 0 2.2189777837411384e-07
from O 0 6.797150575721389e-08
the O 0 1.9071298140715953e-07
enhanced O 0 1.0794739182529156e-06
DNA O 0 5.150113793206401e-07
binding O 0 1.0828098595538904e-07
ability O 0 8.005626028761981e-08
of O 0 3.272906212714588e-07
these O 0 4.436822962361475e-07
mutants O 0 5.821582817588933e-05
. O 0 1.635240732866805e-05

Kinetic O 0 3.166237729601562e-05
studies O 0 2.158009920094628e-06
of O 0 1.3632442232847097e-06
binding O 0 1.1439450418038177e-06
and O 0 7.527671073148667e-07
dissociation O 0 3.4202300867036683e-06
revealed O 0 1.0162443686567713e-06
that O 0 4.35850679991745e-08
various O 0 5.883959275365669e-08
truncation O 0 1.1959291441598907e-05
mutants O 0 1.3827273050992517e-06
have O 0 3.025136408041362e-08
3 O 0 1.0891564983239732e-07
- O 0 5.508365461537323e-07
5 O 0 4.635873551706027e-07
- O 0 1.0493047284398926e-06
fold O 0 9.30313660774118e-07
higher O 0 2.2405313870876853e-07
affinity O 0 2.6102247829840053e-07
to O 0 2.4057982273006928e-08
various O 0 3.914876955946056e-08
DNA O 0 3.45875776019966e-07
- O 0 3.549333484897943e-07
binding O 0 7.381039068832251e-08
sites O 0 2.8313024813542143e-08
when O 0 3.649428848007119e-08
compared O 0 1.0620852464171548e-07
with O 0 1.362522539238853e-07
the O 0 2.1902530988882063e-06
wild O 0 6.154123548185453e-05
- O 0 0.0009850496426224709
type O 0 0.0022781183943152428
PAX6 O 1 0.9944878220558167
. O 0 8.124909072648734e-05

These O 0 1.857137704064371e-06
results O 0 7.770705678922241e-07
provide O 0 5.243622922534996e-07
a O 0 1.0627494475556887e-06
new O 0 6.062496709091647e-07
insight O 0 1.5949475482557318e-06
into O 0 1.3331828085938469e-07
the O 0 1.8148011804441921e-07
role O 0 6.363107445395144e-07
of O 0 2.8821548312407685e-06
mutant O 0 0.0005213224212639034
PAX6 O 1 0.9978972673416138
in O 0 7.451335022778949e-06
causing O 0 0.0015639830380678177
aniridia B-Disease 1 0.9997816681861877
. O 0 2.0049514205311425e-05
. O 0 6.0766316892113537e-05

Reversal O 0 0.0025612860918045044
of O 0 0.1294112205505371
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.04658462107181549
excellent O 0 0.0002600530278868973
neuropsychologic O 0 0.03658990561962128
outcome O 0 2.634734755702084e-06
in O 0 4.815859142581758e-07
very B-Disease 0 5.720909825868148e-07
- I-Disease 0 3.542925696820021e-05
long I-Disease 0 5.904717181692831e-05
- I-Disease 1 0.9189317226409912
chain I-Disease 1 0.9873074293136597
acyl I-Disease 1 0.9996777772903442
- I-Disease 1 0.9999185800552368
coenzyme I-Disease 1 0.9997122883796692
A I-Disease 1 0.9986514449119568
dehydrogenase I-Disease 1 0.999355137348175
deficiency I-Disease 1 0.9999988079071045
. O 0 0.000504607567563653

Very B-Disease 0 4.073845047969371e-05
- I-Disease 0 0.00025529248523525894
long I-Disease 0 0.0001554135960759595
- I-Disease 1 0.5063684582710266
chain I-Disease 0 0.3573342561721802
acyl I-Disease 0 0.4305703639984131
- I-Disease 0 0.4691331684589386
coenzyme I-Disease 0 0.2522711157798767
A I-Disease 0 0.003147145500406623
dehydrogenase I-Disease 0 0.00019622044055722654
( I-Disease 0 5.8880564210994635e-06
VLCAD I-Disease 1 0.9999569654464722
) I-Disease 0 1.985925882763695e-05
deficiency I-Disease 1 0.9999969005584717
is O 0 1.3464896255754866e-06
a O 0 9.18069690669654e-06
disorder O 1 0.9990895986557007
of O 0 0.0007976798224262893
fatty O 1 0.9647804498672485
acid O 0 0.001702187699265778
beta O 0 1.1809811439889017e-05
oxidation O 0 1.0822554031619802e-05
that O 0 2.3589515762978408e-07
reportedly O 0 1.4029117210156983e-06
has O 0 8.899208125967562e-08
high O 0 3.537681152465666e-07
rates O 0 3.17243944891743e-07
of O 0 2.653905312399729e-06
morbidity O 0 0.2305947244167328
and O 0 1.4753747564100195e-05
mortality O 0 0.0228409543633461
. O 0 0.0001577163493493572

We O 0 2.272150368298753e-06
describe O 0 1.611249217603472e-06
the O 0 5.05296839037328e-07
outcome O 0 4.4232865548110567e-07
of O 0 4.5189494812802877e-07
a O 0 9.622684729038156e-07
5 O 0 1.1023037131963065e-06
- O 0 5.143907856108854e-06
year O 0 2.0390946247061947e-06
- O 0 2.6926587452180684e-05
old O 0 8.973468356998637e-05
girl O 0 9.845590102486312e-05
with O 0 0.00018225066014565527
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 4.1704577597556636e-05
was O 0 3.5197466786485165e-05
first O 0 8.00516602339485e-07
seen O 0 4.068857037964335e-07
at O 0 1.9055444511195674e-07
5 O 0 2.096932547601682e-07
months O 0 2.288189193677681e-07
of O 0 5.491900196830102e-07
age O 0 8.755107955948915e-06
with O 0 9.085956116905436e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999998807907104
hepatomegaly B-Disease 1 1.0
, O 1 0.9999914169311523
encephalopathy B-Disease 1 1.0
, O 0 0.0041098808869719505
and O 0 0.0003146820527035743
hypotonia B-Disease 1 0.9999014139175415
. O 0 0.00033580121817067266

Biochemical O 0 0.0016104694223031402
studies O 0 0.0002554875100031495
indicated O 1 0.9974092841148376
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 1 0.9984606504440308
by O 0 1.529991095594596e-05
a O 0 5.002054967917502e-05
stable O 0 0.00011007140710717067
yet O 0 1.4659402040706482e-05
inactive O 0 0.00014753005234524608
enzyme O 0 6.185588426887989e-05
. O 0 3.565417500794865e-05

Molecular O 0 0.00015827750030439347
genetic O 0 2.6656682166503742e-05
analysis O 0 3.543539833117393e-06
of O 0 7.888766049291007e-06
her O 0 3.3696036553010345e-05
VLCAD O 1 0.999994158744812
gene O 0 0.0002191842213505879
revealed O 0 4.7993133193813264e-05
a O 0 1.0415200449642725e-05
T1372C O 0 0.009636572562158108
( O 0 5.5902205531310756e-06
F458L O 0 0.00011498729872982949
) O 0 1.8516448108130135e-06
missense O 0 2.10728139791172e-05
mutation O 0 3.5776015465671662e-06
and O 0 1.4987333543103887e-06
a O 0 2.6592648282530718e-05
1668 O 1 0.9956129789352417
ACAG O 1 0.9995912909507751
1669 O 1 0.5991254448890686
splice O 0 0.0007171770557761192
site O 0 7.178485975600779e-05
mutation O 0 0.00010073781595565379
. O 0 7.219386316137388e-05

After O 0 4.3676398490788415e-05
initial O 0 4.497737609199248e-05
treatment O 0 4.876389357377775e-05
with O 0 7.857875971239991e-06
intravenous O 1 0.9730483293533325
glucose O 0 0.11576474457979202
and O 0 1.8141795408155303e-06
carnitine O 0 0.02836308814585209
, O 0 3.5013178489862185e-07
the O 0 3.8600319385295734e-07
patient O 0 1.2858163245255128e-06
has O 0 1.7355048953504593e-07
thrived O 0 1.5086106941453181e-06
on O 0 1.7741247404501337e-07
a O 0 4.5978671892044076e-07
low O 0 1.4513594805976027e-06
- O 0 7.2653970164537895e-06
fat O 0 6.124752417235868e-06
diet O 0 2.3308293748414144e-06
supplemented O 0 5.527066946342529e-07
with O 0 1.919171523923069e-07
medium O 0 7.331561391765717e-06
- O 0 2.1143572666915134e-05
chain O 0 2.5126670152531005e-05
triglyceride O 0 1.857437200669665e-05
oil O 0 2.528807499402319e-06
and O 0 6.55131600524328e-07
carnitine O 0 0.00021139135060366243
and O 0 1.3349350638236501e-06
avoidance O 0 0.00010938605555566028
of O 0 2.9615328458021395e-05
fasting O 0 0.00032669169013388455
. O 0 8.145669562509283e-05

Her O 0 0.002718772040680051
ventricular O 1 0.9999980926513672
hypertrophy O 1 0.999956488609314
resolved O 0 1.9570514268707484e-05
significantly O 0 1.6746911342124804e-06
over O 0 3.3606656302254123e-07
1 O 0 7.547633344984206e-07
year O 0 3.4254654224241676e-07
, O 0 2.1894832968882838e-07
and O 0 3.5483111560097313e-07
cognitively O 0 1.8054557585855946e-05
, O 0 1.9209441859402432e-07
she O 0 1.1715248859900385e-07
is O 0 4.762076954989425e-08
in O 0 7.304027604959629e-08
the O 0 2.832610732639296e-07
superior O 0 2.7967084861302283e-06
range O 0 5.083195446786704e-07
for O 0 7.653641205251915e-07
age O 0 1.971379606402479e-05
. O 0 4.189128230791539e-05

Clinical O 0 0.00034687042352743447
recognition O 0 0.0003242360835429281
of O 1 0.9982572197914124
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.461681965040043e-05
important O 0 1.8715999203777756e-06
because O 0 2.404532608579757e-07
it O 0 5.251069268297215e-08
is O 0 4.08874889501476e-08
one O 0 2.5167434358763785e-08
of O 0 1.5025973709725804e-07
the O 0 6.352436230372405e-07
few O 0 8.806471782918379e-07
directly O 0 2.5208303213730687e-06
treatable O 1 0.9999972581863403
causes O 0 0.30483102798461914
of O 1 0.9271446466445923
cardiomyopathy B-Disease 1 1.0
in O 0 0.00028670969186350703
children O 0 1.574849375174381e-05
. O 0 1.3395770110946614e-05
. O 0 5.267422238830477e-05

Cloning O 0 8.152833470376208e-05
of O 0 3.0099822652118746e-06
a O 0 3.5302839478390524e-06
novel O 0 2.7923031211685156e-06
member O 0 7.233003884721256e-07
of O 0 5.366251798477606e-07
the O 0 1.313647430833953e-06
low O 0 6.385895176208578e-06
- O 0 2.556071376602631e-05
density O 0 1.4914139683241956e-05
lipoprotein O 0 0.0004892551805824041
receptor O 0 2.668883462320082e-05
family O 0 1.0624935384839773e-05
. O 0 2.1484866010723636e-05

A O 0 0.00011002639075741172
gene O 0 1.4027395081939176e-05
encoding O 0 4.219258698867634e-06
a O 0 3.2827920222189277e-06
novel O 0 6.10360302744084e-06
transmembrane O 0 5.0617483793757856e-05
protein O 0 2.6228515253023943e-06
was O 0 1.836857109083212e-06
identified O 0 4.041218346628739e-07
by O 0 1.4747477905530104e-07
DNA O 0 2.809489672017662e-07
sequence O 0 9.116486410221114e-08
analysis O 0 3.6646277123963955e-08
within O 0 8.781147187164606e-08
the O 0 1.2473832384785055e-06
insulin B-Disease 0 0.09791089594364166
- I-Disease 1 0.98455411195755
dependent I-Disease 0 0.3275708556175232
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 0.0006542755872942507
IDDM B-Disease 1 0.9996616840362549
) O 0 7.209848718048306e-06
locus O 0 6.302109977696091e-05
IDDM4 O 0 0.0061842831782996655
on O 0 1.351461742160609e-05
chromosome O 0 0.00016878564201761037
11q13 O 0 0.001810046611353755
. O 0 6.535666761919856e-05

Based O 0 5.393369519879343e-06
on O 0 1.6065266663645161e-06
its O 0 1.076854005077621e-06
chromosomal O 0 1.4603935596824158e-05
position O 0 2.2676044864056166e-06
, O 0 7.306311431420909e-07
this O 0 2.1543773698340374e-07
gene O 0 5.928925475018332e-07
is O 0 8.900260439759222e-08
a O 0 2.610513547551818e-07
candidate O 0 3.326508419831953e-07
for O 0 3.352860744598729e-07
conferring O 0 4.892669676337391e-05
susceptibility O 0 0.14009417593479156
to O 0 1.9199094822397456e-05
diabetes B-Disease 1 0.9999955892562866
. O 0 0.00042784097604453564

The O 0 1.0728658708103467e-05
gene O 0 8.331049684784375e-06
, O 0 1.246375973096292e-06
termed O 0 7.901972821855452e-06
low O 0 2.7291082460578764e-06
- O 0 5.76948195885052e-06
density O 0 1.5824406318643014e-06
lipoprotein O 0 8.307042662636377e-06
receptor O 0 3.7705640920648875e-07
related O 0 8.561289632780245e-08
protein O 0 2.4914425011957064e-07
5 O 0 2.6789936669047165e-07
( O 0 2.3647740476917534e-07
LRP5 O 0 4.4500306103145704e-05
) O 0 9.359131070141302e-08
, O 0 7.763271270277983e-08
encodes O 0 1.6926911428072344e-07
a O 0 1.541995118259365e-07
protein O 0 2.552970954639022e-07
of O 0 2.5222414024028694e-07
1615 O 0 8.233606422436424e-06
amino O 0 2.800784670853318e-07
acids O 0 6.528495077873231e-08
that O 0 1.9100925285897574e-08
contains O 0 7.185564498968233e-08
conserved O 0 2.446305416015093e-07
modules O 0 3.309168903342652e-07
which O 0 1.6442331940424992e-08
are O 0 6.641085459335727e-09
characteristic O 0 8.162822240365131e-08
of O 0 8.32553368468325e-08
the O 0 2.9060325346108584e-07
low O 0 2.2446045022661565e-06
- O 0 8.548562618670985e-06
density O 0 5.836604941578116e-06
lipoprotein O 0 0.0004972201422788203
( O 0 5.020184744353173e-06
LDL O 0 0.0006915246485732496
) O 0 2.305278712810832e-06
receptor O 0 1.367565528198611e-05
family O 0 1.1085530786658637e-05
. O 0 2.8171409212518483e-05

These O 0 1.893405283226457e-06
modules O 0 9.241042789653875e-06
include O 0 9.84513235380291e-07
a O 0 1.3797542806059937e-06
putative O 0 5.413802227849374e-06
signal O 0 1.9255933239037404e-06
peptide O 0 9.401504712513997e-07
for O 0 7.739777885262811e-08
protein O 0 1.830916147582684e-07
export O 0 1.9447072929779097e-07
, O 0 5.247825285437102e-08
four O 0 1.1203251659708258e-07
epidermal O 0 3.3636930311331525e-05
growth O 0 1.3988183127366938e-06
factor O 0 9.819982551562134e-07
( O 0 3.371220032022393e-07
EGF O 0 1.8922242816188373e-05
) O 0 1.1870720584283845e-07
repeats O 0 2.0002070755253953e-07
with O 0 6.918664752220138e-08
associated O 0 8.194706424546894e-07
spacer O 0 7.268467470566975e-06
domains O 0 5.187646365811815e-07
, O 0 2.0751075169300748e-07
three O 0 2.71363518322687e-07
LDL O 0 7.705456664552912e-05
- O 0 7.614344212925062e-06
receptor O 0 2.4498569928255165e-06
( O 0 4.4386553099684534e-07
LDLR O 0 0.0003581940836738795
) O 0 1.871594861313497e-07
repeats O 0 2.5481767806923017e-07
, O 0 6.557409903962252e-08
a O 0 1.8630719011980545e-07
single O 0 2.8657873940574063e-07
transmembrane O 0 7.224129149108194e-06
spanning O 0 2.3660898023081245e-06
domain O 0 9.298914847022388e-07
, O 0 3.055931188100658e-07
and O 0 4.997019118491153e-07
a O 0 6.707707143505104e-06
cytoplasmic O 0 8.73553435667418e-05
domain O 0 2.5744038794073276e-05
. O 0 2.4759332518442534e-05

The O 0 1.7583031876711175e-05
encoded O 0 5.080401933810208e-06
protein O 0 1.6250947965090745e-06
has O 0 3.085808657488087e-07
a O 0 2.9886786023780587e-07
unique O 0 3.483518753455428e-07
organization O 0 5.827856170981249e-07
of O 0 2.0995810245949542e-06
EGF O 0 0.4534054100513458
and O 0 1.6163696727744536e-06
LDLR O 0 0.20761999487876892
repeats O 0 1.4500714087262168e-06
; O 0 2.2666696963824506e-07
therefore O 0 4.194998268758354e-07
, O 0 5.3596954785462e-07
LRP5 O 0 0.0003027155762538314
likely O 0 4.965973516846134e-07
represents O 0 3.006631743573962e-07
a O 0 1.6954345483100042e-07
new O 0 1.883405218450207e-07
category O 0 6.115806172601879e-07
of O 0 1.1713958656400791e-06
the O 0 1.4376058061316144e-05
LDLR O 1 0.9942349791526794
family O 0 6.693299656035379e-05
. O 0 7.68178142607212e-05

Both O 0 1.9056975361309014e-05
human O 0 1.795099706214387e-05
and O 0 1.3262403626868036e-05
mouse O 0 0.0010754731483757496
LRP5 O 1 0.9990837574005127
cDNAs O 0 0.05677953362464905
have O 0 4.7046140139173076e-07
been O 0 3.72943702586781e-07
isolated O 0 6.553447065016371e-07
and O 0 8.719578659110994e-08
the O 0 3.074669621128123e-07
encoded O 0 3.1787021725904197e-07
mature O 0 1.410113270594593e-07
proteins O 0 4.328764191541268e-08
are O 0 8.422849973044322e-09
95 O 0 1.1424259582781815e-07
% O 0 8.94474609935969e-08
identical O 0 8.561600139955772e-08
, O 0 5.3142141354101113e-08
indicating O 0 2.294005412295519e-07
a O 0 1.3375750995692215e-07
high O 0 2.723923557823582e-07
degree O 0 8.050657811509154e-07
of O 0 7.569684044028691e-07
evolutionary O 0 9.403286640008446e-06
conservation O 0 5.666967808792833e-06
. O 0 1.5147984413488302e-06
. O 0 9.895180482999422e-06

The O 0 0.00010459821351105347
APC B-Disease 0 0.002821084577590227
variants O 0 4.518097193795256e-05
I1307K O 0 0.000975023431237787
and O 0 2.686871539481217e-06
E1317Q O 0 0.0006806895253248513
are O 0 3.203236360604933e-07
associated O 0 1.36491798912175e-05
with O 1 0.8482846617698669
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.0006595300510525703
but O 0 4.286027035504958e-07
not O 0 1.0411931583576006e-07
always O 0 1.0231464386833977e-07
with O 0 1.4003650505856058e-07
a O 0 3.5640443911688635e-06
family O 0 6.5979106693703216e-06
history O 0 3.90819477615878e-05
. O 0 6.392526847776026e-05

Classical O 0 0.3128213882446289
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9939960241317749
FAP B-Disease 1 0.9999827146530151
) O 0 2.969132538055419e-06
is O 0 5.709022730115976e-07
a O 0 2.079222895190469e-06
high O 0 4.386569344205782e-05
- O 1 0.9488065242767334
penetrance O 1 0.9999884366989136
autosomal B-Disease 1 0.9999592304229736
dominant I-Disease 1 0.9999970197677612
disease I-Disease 1 0.9999994039535522
that O 0 4.092267317901133e-06
predisposes O 0 4.370084570837207e-05
to O 0 1.2856318676313094e-07
hundreds O 0 2.6814015541276603e-07
or O 0 9.850111837295117e-08
thousands O 0 7.51061179471435e-07
of O 0 0.007857516407966614
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9948887228965759
carcinoma I-Disease 1 1.0
and O 0 2.1369526166381547e-06
that O 0 2.299064618682678e-07
results O 0 1.826007434146959e-07
from O 0 2.8043768907082267e-07
truncating O 0 1.935591353685595e-05
mutations O 0 8.08034087640408e-07
in O 0 6.465593287430238e-07
the O 0 9.83765312412288e-06
APC B-Disease 0 0.010473843663930893
gene O 0 5.1287428505020216e-05
. O 0 4.143469413975254e-05

A O 0 0.0003891994128935039
variant O 0 0.0006189537816680968
of O 0 0.00022153927420731634
FAP B-Disease 1 0.999734103679657
is O 0 0.0003771561896428466
attenuated B-Disease 1 0.9999061822891235
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999997615814209
coli I-Disease 1 0.9997102618217468
, O 0 2.3445534225174924e-06
which O 0 2.0276794998608239e-07
results O 0 3.581068881430838e-07
from O 0 6.438667128350062e-07
germ O 1 0.9928367733955383
- O 0 3.8174666769918986e-06
line O 0 6.246773978091369e-07
mutations O 0 7.361354903423489e-08
in O 0 2.2871542881830464e-08
the O 0 3.955377181341646e-08
5 O 0 8.761205805285499e-08
and O 0 4.140363785154477e-08
3 O 0 1.7300499166594818e-07
regions O 0 1.773678235394982e-07
of O 0 6.735474471497582e-07
the O 0 4.959171292284736e-06
APC B-Disease 0 0.0018928510835394263
gene O 0 5.923174830968492e-05
. O 0 3.0321951271616854e-05

Attenuated B-Disease 1 0.9999710321426392
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999994039535522
patients O 0 0.05536973103880882
have O 0 3.1695892630523304e-06
" O 0 1.3806210517941508e-05
multiple O 0 2.2439740860136226e-05
" O 1 0.9991675615310669
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 2.541238700359827e-06
typically O 0 3.455177477462712e-07
fewer O 0 1.1572270608439794e-07
than O 0 5.279298775917596e-08
100 O 0 2.9913078947174654e-07
) O 0 9.873642881075284e-08
without O 0 1.7877052016501693e-07
the O 0 1.1538091939655715e-06
florid O 0 0.00016344738833140582
phenotype O 0 4.904731395072304e-05
of O 0 9.130369107879233e-06
classical O 0 0.0007637586095370352
FAP B-Disease 1 0.9916063547134399
. O 0 0.0001361004397040233

Another O 0 6.732694600941613e-05
group O 0 1.2729483387374785e-05
of O 0 9.950749699783046e-06
patients O 0 7.414234460156877e-06
with O 0 1.8401321995042963e-06
multiple O 0 3.1330659112427384e-05
adenomas B-Disease 1 0.999935507774353
has O 0 8.561082722735591e-07
no O 0 2.938115528650087e-07
mutations O 0 2.1284357387685304e-07
in O 0 1.5063149305660772e-07
the O 0 1.2488901575125055e-06
APC B-Disease 0 0.0010116184130311012
gene O 0 8.337847816619615e-07
, O 0 1.2108058911053377e-07
and O 0 5.950615644678692e-08
their O 0 6.05429235633892e-08
phenotype O 0 3.8131149722175905e-06
probably O 0 2.5970152250920364e-07
results O 0 3.5260466546560565e-08
from O 0 2.489472805677906e-08
variation O 0 2.7550967729439435e-07
at O 0 2.442053812501399e-07
a O 0 4.138446172419208e-07
locus O 0 4.369146154203918e-06
, O 0 2.5923881707967666e-07
or O 0 1.2353393685771152e-07
loci O 0 5.233162028162042e-07
, O 0 1.3052887481990183e-07
elsewhere O 0 1.7314792444267368e-07
in O 0 2.9872481377424265e-07
the O 0 3.436030965531245e-06
genome O 0 4.405509025673382e-05
. O 0 2.323774970136583e-05

Recently O 0 9.49964887695387e-05
, O 0 5.43412488696049e-06
however O 0 2.002166183956433e-06
, O 0 1.0045476983577828e-06
a O 0 3.5475095501169562e-06
missense O 0 3.117496089544147e-05
variant O 0 2.0765950466739014e-05
of O 0 1.068406072590733e-05
APC B-Disease 0 0.0369734950363636
( O 0 1.810601816032431e-06
I1307K O 0 6.074279372114688e-05
) O 0 2.227522344355748e-07
was O 0 1.0655992355168564e-06
described O 0 2.744387188613473e-07
that O 0 3.518998781260052e-08
confers O 0 5.531296096705773e-07
an O 0 1.4559465455477039e-07
increased O 0 1.3058033800916746e-06
risk O 0 1.622984382265713e-05
of O 1 0.9750455021858215
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.4145692148304079e-05
including O 0 4.572226771415444e-06
multiple O 0 6.74732364132069e-05
adenomas B-Disease 1 0.9999901056289673
, O 0 8.812665328150615e-06
in O 0 1.8404061847832054e-05
Ashkenazim O 0 0.006435684394091368
. O 0 0.00010845813812920824

We O 0 3.4063014027196914e-06
have O 0 5.471422923619684e-07
studied O 0 2.0290813154133502e-06
a O 0 1.0556905181147158e-06
set O 0 8.268876285910665e-07
of O 0 1.0618466603773413e-06
164 O 0 5.169243650016142e-06
patients O 0 3.3013375286827795e-06
with O 0 4.589505351759726e-06
multiple O 1 0.979550302028656
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.4317185878753662
/ I-Disease 1 0.9999805688858032
or I-Disease 0 0.002738308859989047
carcinoma I-Disease 1 1.0
and O 0 5.8236505537934136e-06
analyzed O 0 4.964220352121629e-06
codons O 0 7.90568083175458e-06
1263 O 0 0.00027676651370711625
- O 0 7.093216117937118e-05
1377 O 0 0.0015907108318060637
( O 0 2.104640998368268e-06
exon O 0 3.476134588709101e-05
15G O 0 1.2959853847860359e-05
) O 0 6.753496961664496e-08
of O 0 1.36456151267339e-07
the O 0 1.1000144013451063e-06
APC B-Disease 0 6.03438493271824e-05
gene O 0 3.1137255973590072e-06
for O 0 2.0128222786297556e-06
germ O 1 0.9997914433479309
- O 0 0.0007226517773233354
line O 0 7.241237472044304e-05
variants O 0 5.054117718827911e-05
. O 0 3.683222166728228e-05

Three O 0 1.73370663105743e-05
patients O 0 1.504399006080348e-05
with O 0 2.280625949424575e-06
the O 0 1.1449140401964542e-05
I1307K O 0 0.015585336834192276
allele O 0 1.208734556712443e-05
were O 0 5.080239589005942e-07
detected O 0 1.016784381135949e-06
, O 0 1.966749181292471e-07
each O 0 1.0167304509423047e-07
of O 0 4.2169494918198325e-06
Ashkenazi O 0 0.004474673420190811
descent O 0 0.0007398101151920855
. O 0 0.00010366878268541768

Four O 0 4.752829408971593e-05
patients O 0 7.475806341972202e-05
had O 0 3.0722931114723906e-05
a O 0 0.0001504280517110601
germ O 1 0.9999717473983765
- O 0 0.00026437570340931416
line O 0 2.7945094188908115e-05
E1317Q O 0 0.00016841154138091952
missense O 0 2.3396696633426473e-05
variant O 0 4.463489403860876e-06
of O 0 9.113372243518825e-07
APC O 0 3.589291009120643e-05
that O 0 6.746660830003748e-08
was O 0 5.95923609125748e-07
not O 0 1.5816690179804027e-08
present O 0 4.307868195496667e-08
in O 0 3.76392428336203e-08
controls O 0 1.948364456438867e-07
; O 0 2.1882783585169818e-08
one O 0 2.839566271006788e-08
of O 0 9.073362150502362e-08
these O 0 1.7320218148597633e-08
individuals O 0 1.7795972695466844e-08
had O 0 2.955127911263844e-07
an O 0 1.6264826285805611e-07
unusually O 0 1.1569142088774242e-06
large O 0 2.099676095212999e-07
number O 0 1.825424220669447e-07
of O 0 1.5553640650978195e-06
metaplastic B-Disease 0 0.12772510945796967
polyps I-Disease 0 0.0003339138929732144
of I-Disease 0 5.657027486449806e-06
the I-Disease 0 4.247869219398126e-05
colorectum I-Disease 1 0.9236642718315125
. O 0 0.00018422739231027663

There O 0 4.558982254820876e-06
is O 0 7.859620154704317e-07
increasing O 0 5.917497674090555e-07
evidence O 0 2.6860953994400916e-07
that O 0 5.107306577656345e-08
there O 0 1.3815947852435784e-07
exist O 0 4.481534290334821e-07
germ O 0 0.043503113090991974
- O 0 2.3991253783606226e-06
line O 0 7.248485758282186e-07
variants O 0 1.9814413576568768e-07
of O 0 1.9259867656273855e-07
the O 0 1.2595232874446083e-06
APC B-Disease 0 0.0001111901510739699
gene O 0 4.1126520500256447e-07
that O 0 4.958165078505772e-08
predispose O 0 6.188747079249879e-07
to O 0 3.6894480359705994e-08
the O 0 9.765295772012905e-08
development O 0 6.482065373347723e-07
of O 0 3.386743856026442e-06
multiple O 0 0.04650574177503586
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9998440742492676
carcinoma I-Disease 1 1.0
, O 0 1.052857896866044e-05
but O 0 3.181307590693905e-07
without O 0 3.4257757874911476e-07
the O 0 9.340875521957059e-07
florid O 0 0.0004444241931196302
phenotype O 0 1.4999321138020605e-05
of O 0 1.4269938901634305e-06
classical O 0 0.0006120183388702571
FAP B-Disease 1 0.9952298402786255
, O 0 3.739266389857221e-07
and O 0 9.17420663881785e-08
possibly O 0 1.366733783925156e-07
with O 0 6.088988158126085e-08
importance O 0 3.984951490565436e-06
for O 0 0.015584750100970268
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.0005587352206930518
in O 0 8.671123055137286e-07
the O 0 1.3948857713330653e-06
general O 0 4.742851160699502e-06
population O 0 1.0962234000544413e-06
. O 0 2.3392399270960595e-06
. O 0 2.236381078546401e-05

Genomic O 0 9.124871576204896e-05
structure O 0 3.3601631002966315e-05
of O 0 1.2770326975442003e-05
the O 0 8.415310003329068e-05
human O 1 0.9985742568969727
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999971389770508
CLD B-Disease 1 1.0
) O 0 0.00016900771879591048
gene O 0 0.0001787848595995456
. O 0 6.941512401681393e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999967813491821
CLD B-Disease 1 1.0
) O 0 2.5620867745601572e-05
is O 0 1.4800907592871226e-06
caused O 0 3.6323567655927036e-06
by O 0 3.315749097509979e-07
mutations O 0 4.069516705840215e-07
in O 0 1.6562070470627077e-07
a O 0 1.2657342267630156e-06
gene O 0 1.2883791669082711e-06
which O 0 4.0140048440662213e-07
encodes O 0 3.957093667850131e-06
an O 0 6.745644896000158e-06
intestinal O 1 0.9999970197677612
anion O 1 0.999687671661377
transporter O 1 0.9852113723754883
. O 0 0.00010627359733916819

We O 0 4.596175585902529e-06
report O 0 1.416635882378614e-06
here O 0 7.090061444614548e-07
the O 0 3.8122095702419756e-07
complete O 0 1.7645349998929305e-06
genomic O 0 2.3647498892387375e-06
organization O 0 5.021789775128127e-07
of O 0 4.792639174411306e-07
the O 0 2.0741611024277518e-06
human O 0 6.316242433968e-06
CLD B-Disease 1 0.8656690120697021
gene O 0 3.4399229207338067e-06
which O 0 3.888407320573606e-07
spans O 0 2.5224005639756797e-06
approximately O 0 1.0667623655535863e-06
39kb O 0 2.7992356990580447e-05
, O 0 4.229392231991369e-07
and O 0 4.3943924765699194e-07
comprises O 0 6.027686595189152e-06
21 O 0 2.9318918677745387e-05
exons O 0 0.00018949124205391854
. O 0 2.867786133720074e-05

All O 0 4.1324830817757174e-05
exon O 0 0.001315023167990148
/ O 0 0.00016125400725286454
intron O 0 9.491725359112024e-05
boundaries O 0 1.0464964361744933e-06
conform O 0 7.5389863241071e-07
to O 0 3.880864767324965e-07
the O 0 6.223433047125582e-06
GT O 1 0.6320182681083679
/ O 0 0.08372528105974197
AG O 1 0.7942158579826355
rule O 0 6.519992166431621e-05
. O 0 6.383000436471775e-05

An O 0 5.673176019627135e-06
analysis O 0 2.5906506380124483e-06
of O 0 2.9096670459693996e-06
the O 0 5.817460987600498e-06
putative O 0 7.022888166829944e-05
promoter O 0 0.0002903460117522627
region O 0 2.259815346405958e-06
sequence O 0 5.733346029046515e-07
shows O 0 7.654393243683444e-07
a O 0 5.8820846788876224e-06
putative O 0 0.00031557257170788944
TATA O 1 0.9992458820343018
box O 0 2.7028672775486484e-05
and O 0 8.826356747704267e-07
predicts O 0 4.577550043904921e-06
multiple O 0 8.917480727177463e-07
transcription O 0 6.487497557827737e-06
factor O 0 3.507300789351575e-06
binding O 0 2.536875172154396e-06
sites O 0 3.066653562200372e-06
. O 0 1.3888070498069283e-05

The O 0 1.8185663066105917e-05
genomic O 0 3.555744115146808e-05
structure O 0 1.232694285135949e-05
was O 0 8.676815923536196e-06
determined O 0 7.631899165971845e-07
using O 0 1.2901850254820602e-07
DNA O 0 2.547562019117322e-07
from O 0 3.9344598690149724e-08
several O 0 2.815395205857385e-08
sources O 0 4.675531783959741e-08
including O 0 8.22351822193923e-08
multiple O 0 3.6761090882464487e-07
large O 0 3.770078365050722e-06
- O 0 6.187117105582729e-05
insert O 0 5.4158696002559736e-05
libaries O 0 7.619084499310702e-05
and O 0 5.05652565152559e-07
genomic O 0 5.582644462265307e-06
DNA O 0 4.892145170742879e-06
from O 0 2.2651749986835057e-06
Finnish O 1 0.9737901091575623
CLD B-Disease 1 0.9999992847442627
patients O 0 6.218804628588259e-05
and O 0 5.4351512517314404e-06
controls O 0 7.822500629117712e-05
. O 0 4.49212639068719e-05

Exon O 0 0.0020726053044199944
- O 0 2.6910798624157906e-05
specific O 0 1.3773865248367656e-06
primers O 0 5.938544745731633e-06
developed O 0 9.472756801187643e-07
in O 0 1.1359465901250587e-07
this O 0 4.895571237284457e-08
study O 0 8.652002492226529e-08
will O 0 3.805017456670612e-08
facilitate O 0 1.978131507485159e-07
mutation O 0 3.3078944738917926e-07
screening O 0 2.8622201853067963e-07
studies O 0 1.8619918762396992e-07
of O 0 6.854002663203573e-07
patients O 0 2.2479678136733128e-06
with O 0 1.353045604446379e-06
the O 0 0.0023800078779459
disease O 1 0.9999986886978149
. O 0 0.0006076619611121714

Genomic O 0 8.938896644394845e-05
sequencing O 0 2.8255570214241743e-05
of O 0 1.0360586202295963e-05
a O 0 0.00011016318603651598
BAC O 1 0.9998323917388916
clone O 1 0.761587381362915
H O 1 0.9997112154960632
_ O 0 2.673886228876654e-06
RG364P16 O 0 3.5834702430292964e-05
revealed O 0 1.3541092585001024e-06
the O 0 1.5889673932178994e-07
presence O 0 2.40214234281666e-07
of O 0 2.404835584002285e-07
another O 0 6.210124752215052e-07
, O 0 2.1823851170665876e-07
highly O 0 2.844038817784167e-07
homologous O 0 2.373597283167328e-07
gene O 0 1.687707253950066e-07
3 O 0 1.9278519403087557e-07
of O 0 7.181357659646892e-07
the O 0 4.922170774079859e-06
CLD B-Disease 1 0.9805071353912354
gene O 0 1.3121060646881233e-06
, O 0 1.3856694636160682e-07
with O 0 7.083871622626248e-08
a O 0 3.6189990737511835e-07
similar O 0 1.825615782991008e-07
genomic O 0 1.596927745595167e-06
structure O 0 2.60956289821479e-06
, O 0 2.1869311694899807e-07
recently O 0 2.960730398626765e-07
identified O 0 1.9716847532436077e-07
as O 0 2.6799594365911616e-07
the O 0 4.887260001851246e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.46974971890449524
( O 0 6.33190429653041e-05
PDS B-Disease 1 0.9866753220558167
) O 0 3.3356081985402852e-06
. O 0 4.8409820010419935e-06
. O 0 1.9642950064735487e-05

The O 0 0.00010867491801036522
APCI1307K O 1 0.99980229139328
allele O 0 0.0011160355061292648
and O 0 2.9595848900498822e-05
cancer B-Disease 1 0.9997721314430237
risk O 0 2.1020752683398314e-05
in O 0 1.1097663445980288e-06
a O 0 2.642787649165257e-06
community O 0 8.13444728464674e-07
- O 0 1.9854071524605388e-06
based O 0 1.9360508929366915e-07
study O 0 2.8805948204535525e-07
of O 0 2.2476676804217277e-06
Ashkenazi O 0 0.0005327363614924252
Jews O 0 3.65100713679567e-05
. O 0 5.4531214118469507e-05

Mutations O 0 0.00017710868269205093
in O 0 3.480400482658297e-05
APC O 0 0.0020386651158332825
are O 0 1.984065193028073e-06
classically O 0 0.0008384590619243681
associated O 0 2.8747004762408324e-05
with O 0 0.00011529033508850262
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9997240900993347
FAP B-Disease 1 0.9999983310699463
) O 0 4.692381935456069e-06
, O 0 1.5001591009422555e-06
a O 0 1.3905604646424763e-05
highly O 0 0.011068119667470455
penetrant O 1 0.9999994039535522
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999428987503052
by O 0 0.0018971412209793925
multiple O 1 0.8712598085403442
intestinal O 1 1.0
polyps B-Disease 1 0.9999980926513672
and O 0 1.2076882740075234e-05
, O 0 3.68245355275576e-06
without O 0 2.4716889583942248e-06
surgical O 1 0.9808245897293091
intervention O 0 1.4049833225726616e-05
, O 0 1.8402710111331544e-07
the O 0 2.5142995241367316e-07
development O 0 2.7833832518808777e-06
of O 0 0.01697820983827114
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.966437041759491
CRC B-Disease 1 0.9999958276748657
) O 0 2.3294529455597512e-05
. O 0 4.643909051083028e-05

APC B-Disease 0 0.004664385225623846
is O 0 2.169201798096765e-05
a O 0 0.0002528432523831725
tumour O 1 1.0
- O 1 0.9774991273880005
suppressor O 1 0.9852050542831421
gene O 0 8.292929123854265e-06
, O 0 5.486492682393873e-07
and O 0 9.947892749551102e-07
somatic O 0 0.0006120731122791767
loss O 0 0.020465021952986717
occurs O 0 1.8703134628594853e-05
in O 0 3.712639954756014e-05
tumours B-Disease 1 0.9999992847442627
. O 0 0.00017008715076372027

The O 0 0.00010185616702074185
germline O 1 0.9258813261985779
T O 0 0.0006066047353670001
- O 0 6.666090484941378e-06
to O 0 5.675452712239348e-07
- O 0 3.841984380414942e-06
A O 0 5.381131813919637e-06
transversion O 0 3.417326297494583e-05
responsible O 0 7.350341206802113e-07
for O 0 1.9419645980178757e-07
the O 0 1.5331090708059492e-06
APC O 0 0.00010136474156752229
I1307K O 0 6.276380008785054e-05
allele O 0 2.788053734548157e-06
converts O 0 7.554416470156866e-07
the O 0 4.176938546152087e-07
wild O 0 1.0251295634589042e-06
- O 0 8.151556016855466e-07
type O 0 8.136906899380847e-07
sequence O 0 1.8554759151356848e-07
to O 0 6.42313793264293e-08
a O 0 2.6197465103905415e-06
homopolymer O 1 0.9752305150032043
tract O 1 0.9999611377716064
( O 0 1.440904179617064e-05
A8 O 1 0.9221895933151245
) O 0 3.4423831607455213e-07
that O 0 1.8508313814891153e-07
is O 0 8.048200470511802e-07
genetically O 0 1.3685466001334134e-05
unstable O 0 4.778442962560803e-05
and O 0 1.5939834838718525e-06
prone O 0 4.5535573008237407e-05
to O 0 3.2124676181410905e-06
somatic O 0 0.0004840677138417959
mutation O 0 0.00010546516568865627
. O 0 5.7404009567108005e-05

The O 0 6.271911115618423e-05
I1307K O 0 0.0009497074643149972
allele O 0 5.496993981068954e-05
was O 0 2.4958613721537404e-05
found O 0 2.8854881293227663e-06
in O 0 3.0877770313963993e-06
6 O 0 6.380942795658484e-05
. O 0 6.769777974113822e-05

1 O 0 2.9585236916318536e-05
% O 0 6.809284059272613e-06
of O 0 7.921635187813081e-06
unselected O 0 0.0006973977433517575
Ashkenazi O 0 0.00017944855790119618
Jews O 0 6.442760422942229e-06
and O 0 6.345243264149758e-07
higher O 0 1.0392094509370509e-06
proportions O 0 5.220160346652847e-06
of O 0 2.8184522307128645e-06
Ashkenazim O 0 6.658121128566563e-05
with O 0 6.342980327644909e-07
family O 0 1.6993953977362253e-06
or O 0 4.097540511338593e-07
personal O 0 1.250293962584692e-06
histories O 0 1.4572067357221385e-06
of O 0 3.0388036975637078e-05
CRC B-Disease 1 0.9998660087585449
( O 0 4.334343429945875e-06
ref O 0 0.000256438332144171
. O 0 7.242508104354783e-07
2 O 0 3.08799803860893e-06
) O 0 2.2740666736353887e-06
. O 0 1.1104408258688636e-05

To O 0 2.9301229460543254e-06
evaluate O 0 2.8129959446232533e-06
the O 0 2.040631670752191e-06
role O 0 2.4672474410181167e-06
of O 0 3.4209447221655864e-06
I1307K O 0 0.0018061351729556918
in O 0 6.106391992943827e-06
cancer B-Disease 1 0.7425060272216797
, O 0 1.3952144399809185e-06
we O 0 3.198690592398634e-07
genotyped O 0 2.837443389580585e-05
5 O 0 2.497480636520777e-06
, O 0 2.380035084570409e-06
081 O 0 0.0006040391745045781
Ashkenazi O 0 3.391140853636898e-05
volunteers O 0 2.24744053411996e-06
in O 0 4.32919421200495e-07
a O 0 1.925272044900339e-06
community O 0 3.085454636675422e-06
survey O 0 1.0240489245916251e-05
. O 0 3.0492978112306446e-05

Risk O 0 9.639270865591243e-05
of O 0 6.396110984496772e-05
developing O 0 0.4342655539512634
colorectal B-Disease 1 1.0
, I-Disease 0 0.027215803042054176
breast I-Disease 1 0.9999547004699707
and I-Disease 0 1.1485491086205002e-05
other I-Disease 0 7.985158276824222e-07
cancers I-Disease 0 0.0365988127887249
were O 0 7.136673048080411e-07
compared O 0 1.3754018937106594e-06
between O 0 1.7823236930780695e-06
genotyped O 1 0.7318847179412842
I1307K O 0 0.1266576647758484
carriers O 0 2.4865553314157296e-06
and O 0 1.668916809194343e-07
non O 0 1.008089952847513e-06
- O 0 2.5956189801945584e-06
carriers O 0 7.145580411815899e-07
and O 0 7.563370729712915e-08
their O 0 6.669890950661284e-08
first O 0 1.1358420124452095e-06
- O 0 2.649958878464531e-05
degree O 0 9.013037924887612e-05
relatives O 0 5.491413685376756e-05
. O 0 5.441983012133278e-05

Sperm O 0 5.9153971960768104e-05
DNA O 0 1.355737003905233e-05
analysis O 0 1.4724740822202875e-06
in O 0 3.2792311230878113e-06
a O 0 8.84865949046798e-05
Friedreich B-Disease 1 0.9999823570251465
ataxia I-Disease 1 0.9999971389770508
premutation O 1 0.9997767806053162
carrier O 0 0.018803926184773445
suggests O 0 6.065879006200703e-06
both O 0 4.5806669390913157e-07
meiotic O 0 0.00011570211063371971
and O 0 4.887323825641943e-07
mitotic O 0 1.981621971935965e-05
expansion O 0 6.31253351457417e-06
in O 0 1.02037847682368e-06
the O 0 1.0130241207662039e-05
FRDA B-Disease 1 0.6772650480270386
gene O 0 9.422627044841647e-05
. O 0 5.45754301128909e-05

Friedreich B-Disease 1 0.9999984502792358
ataxia I-Disease 1 0.9999992847442627
is O 0 7.365234341705218e-05
usually O 0 1.9738529317692155e-06
caused O 0 5.7012161960301455e-06
by O 0 2.447224858315167e-07
an O 0 3.6375249123921094e-07
expansion O 0 2.994520855281735e-06
of O 0 8.841749377097585e-07
a O 0 4.021432687295601e-06
GAA O 0 4.753242319566198e-05
trinucleotide O 0 0.0005379559006541967
repeat O 0 2.5473630103078904e-06
in O 0 7.676572408854554e-07
intron O 0 3.748886229004711e-05
1 O 0 2.273195150337415e-06
of O 0 1.8621212802827358e-06
the O 0 9.835532182478346e-06
FRDA B-Disease 1 0.9300496578216553
gene O 0 9.767208393895999e-05
. O 0 3.3112992241512984e-05

Occasionally O 0 2.947006760223303e-05
, O 0 4.707334483100567e-06
a O 0 2.9013544917688705e-06
fully O 0 2.866491968234186e-06
expanded O 0 2.638642172314576e-06
allele O 0 2.141330696758814e-06
has O 0 1.8932179557396012e-07
been O 0 8.983695209963116e-08
found O 0 4.7934616276279485e-08
to O 0 3.326450581653262e-08
arise O 0 1.3664835307736212e-07
from O 0 9.583635574017535e-08
a O 0 9.015258797262504e-07
premutation O 0 3.6787987482966855e-05
of O 0 1.2295981832721736e-06
100 O 0 3.311320142529439e-06
or O 0 1.1584565982047934e-06
less O 0 5.766187314293347e-06
triplet O 0 0.0005925294826738536
repeats O 0 9.844735177466646e-05
. O 0 5.7365708926226944e-05

We O 0 7.742959496681578e-06
have O 0 8.374010462830483e-07
examined O 0 2.5680792532511987e-06
the O 0 1.3529887610275182e-06
sperm O 0 2.407500232948223e-06
DNA O 0 3.6345122680359054e-06
of O 0 3.0560468076146208e-06
a O 0 2.5785539037315175e-05
premutation O 0 0.3437695801258087
carrier O 0 0.004514041822403669
. O 0 0.00011233732220716774

This O 0 1.2731571587210055e-05
mans O 0 0.0001896803587442264
leucocyte O 0 0.0003984758513979614
DNA O 0 1.1218277904845309e-05
showed O 0 2.6921632070298074e-06
one O 0 3.825422538739076e-07
normal O 0 8.366092174583173e-07
allele O 0 9.554557891533477e-07
and O 0 1.5630607208549918e-07
one O 0 2.3160711748460017e-07
allele O 0 9.500477631263493e-07
of O 0 8.154307806762517e-07
approximately O 0 4.576074843498645e-06
100 O 0 1.3846136425854638e-05
repeats O 0 4.745709884446114e-05
. O 0 3.171923162881285e-05

His O 0 5.0145295972470194e-05
sperm O 0 9.76590126811061e-06
showed O 0 3.6208846267982153e-06
an O 0 6.994907266744121e-07
expanded O 0 2.188434336858336e-06
allele O 0 1.4993366903581773e-06
in O 0 2.4461655812046956e-07
a O 0 1.057094891621091e-06
tight O 0 2.1700916477129795e-06
range O 0 3.338732028623781e-07
centering O 0 6.246958719202667e-07
on O 0 1.2766457757606986e-07
a O 0 4.3611680666799657e-07
size O 0 4.6561754629692587e-07
of O 0 8.297140539070824e-07
approximately O 0 4.788390924659325e-06
320 O 0 4.810383325093426e-05
trinucleotide O 0 0.009154191240668297
repeats O 0 9.457401756662875e-05
. O 0 5.270060137263499e-05

His O 0 0.0001552074681967497
affected O 0 4.769106089952402e-05
son O 0 0.0002596056438051164
has O 0 2.5562774226273177e-06
repeat O 0 7.156012998166261e-06
sizes O 0 1.0432937642690376e-06
of O 0 3.910529812856112e-06
1040 O 0 0.00013998791109770536
and O 0 8.386707122554071e-06
540 O 0 0.0002890572650358081
. O 0 9.009840141516179e-05

These O 0 1.3013986972509883e-06
data O 0 6.901306619511161e-07
suggest O 0 5.027180804972886e-07
that O 0 6.910686067840288e-08
expansion O 0 1.029509917316318e-06
occurs O 0 1.0658131088803202e-07
in O 0 3.8901799115365066e-08
two O 0 1.833246265903199e-08
stages O 0 3.075221002291073e-07
, O 0 4.9243123356745855e-08
the O 0 8.28069985914226e-08
first O 0 2.103175091860976e-07
during O 0 5.802700115964399e-07
meiosis O 0 1.643181803956395e-06
followed O 0 2.4335588477697456e-07
by O 0 2.0987351945223054e-07
a O 0 1.1363132443875656e-06
second O 0 7.509203442168655e-06
mitotic O 0 0.00013841871987096965
expansion O 0 8.12459911685437e-05
. O 0 2.998121635755524e-05

We O 0 2.544177732488606e-06
also O 0 6.636820444327896e-07
show O 0 3.0995587962934223e-07
that O 0 6.770031291125633e-08
in O 0 7.994304240810379e-08
all O 0 7.561741455219817e-08
informative O 0 8.641065960546257e-07
carrier O 0 1.0408130947325844e-05
father O 0 3.2181401365960483e-06
to O 0 2.3496069445627654e-07
affected O 0 5.582296580541879e-07
child O 0 4.2874577843576844e-07
transmissions O 0 3.7950158571220527e-07
, O 0 4.0251059374440956e-08
with O 0 1.978491326326548e-08
the O 0 1.0987650256311099e-07
notable O 0 2.2604355365274387e-07
exception O 0 1.996597376319187e-07
of O 0 1.8043878924345336e-07
the O 0 9.217034744324337e-07
premutation O 0 0.0001764206972438842
carrier O 0 6.163352736621164e-06
, O 0 2.08571407256386e-07
the O 0 2.6169797706643294e-07
expansion O 0 2.660894779182854e-06
size O 0 1.4433675232794485e-06
decreases O 0 3.721972234416171e-06
. O 0 2.2078922938817414e-06
. O 0 1.3478153050527908e-05

The O 0 3.143522917525843e-05
R496H O 0 0.0005869391025044024
mutation O 0 3.419207132537849e-05
of O 0 1.8998855011886917e-05
arylsulfatase O 1 0.988465428352356
A O 0 0.0029792827554047108
does O 0 3.099191417277325e-06
not O 0 3.8566831790376455e-06
cause O 0 0.02851623296737671
metachromatic B-Disease 1 0.9999980926513672
leukodystrophy I-Disease 1 0.9999997615814209
. O 0 0.0003379723057150841

Deficiency B-Disease 1 0.9999809265136719
of I-Disease 0 0.000235366853303276
arylsulfatase I-Disease 1 0.999749481678009
A I-Disease 1 0.6840435266494751
( O 0 0.00036351263406686485
ARSA O 1 0.9997872710227966
) O 0 7.26423286323552e-06
enzyme O 0 1.032483942253748e-05
activity O 0 8.67776725499425e-06
causes O 0 0.003166058799251914
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 1.0
( O 0 0.017329009249806404
MLD B-Disease 1 0.9999996423721313
) O 0 2.5150042347377166e-05
. O 0 5.0587277655722573e-05

A O 0 4.8465197323821485e-05
number O 0 5.386316843214445e-06
of O 0 2.2155692931846716e-05
ARSA O 1 0.9934432506561279
gene O 0 1.057109511748422e-05
mutations O 0 1.9177241483703256e-06
responsible O 0 3.002728362844209e-06
for O 0 3.826148258667672e-06
MLD B-Disease 1 0.9999995231628418
have O 0 1.8344796899327775e-06
been O 0 2.641855189722264e-06
identified O 0 1.43267889143317e-05
. O 0 2.9477319912984967e-05

Recently O 0 5.727114694309421e-05
, O 0 4.0352283576794434e-06
the O 0 5.009152118873317e-06
R496H O 0 6.747464794898406e-05
mutation O 0 5.838286597281694e-06
of O 0 6.152423793537309e-06
ARSA O 1 0.7213405966758728
was O 0 7.437342446792172e-06
proposed O 0 3.817135620920453e-07
to O 0 3.473095588901742e-08
be O 0 3.5263898467974286e-08
a O 0 3.4310497198930534e-07
cause O 0 3.1137494715949288e-06
of O 0 7.513315722462721e-06
MLD B-Disease 1 0.9999998807907104
( O 0 2.511708999008988e-06
Draghia O 0 0.0009238643106073141
et O 0 3.87784120903234e-06
al O 0 2.8993133582844166e-06
. O 0 1.2901519141905737e-07
, O 0 1.6682865577877237e-07
1997 O 0 3.972547801822657e-06
) O 0 2.707387011469109e-06
. O 0 1.2510437954915687e-05

We O 0 6.617211056436645e-06
have O 0 9.421331128578458e-07
investigated O 0 3.208187536074547e-06
the O 0 2.2938618258194765e-06
R496H O 0 7.310557703021914e-05
mutation O 0 3.0445562515524216e-06
and O 0 1.8290103298568283e-07
found O 0 1.480442222145939e-07
this O 0 5.3911712427634484e-08
mutation O 0 1.444795429961232e-07
at O 0 1.1412498679419514e-07
a O 0 8.533395146059775e-08
relatively O 0 3.716527174901785e-08
high O 0 5.48845058290226e-08
frequency O 0 3.880220234009357e-08
in O 0 1.4593991792821726e-08
an O 0 3.8652622436075035e-08
African O 0 9.638152675961464e-08
American O 0 1.4324845665214525e-07
population O 0 3.958154692895732e-08
( O 0 4.504921946590912e-08
f O 0 3.6962032368137443e-07
= O 0 1.6005030545329646e-07
0 O 0 8.4752926454712e-08
. O 0 3.635519973954615e-08
09 O 0 1.0837371746674762e-06
, O 0 1.5206852310711838e-07
n O 0 8.21962714780966e-07
= O 0 1.3385019883571658e-06
61 O 0 3.392116013856139e-06
subjects O 0 5.68046289117774e-06
) O 0 6.595809281861875e-06
. O 0 3.401660796953365e-05

The O 0 0.00020469263836275786
ARSA O 1 0.6419346332550049
enzyme O 0 9.249718459614087e-06
activity O 0 7.967061605995696e-07
in O 0 1.8448889704814064e-07
subjects O 0 2.5917307766576414e-07
with O 0 1.2698301077307406e-07
and O 0 2.1335753785933775e-07
without O 0 2.643942025315482e-07
the O 0 1.0088853059642133e-06
R496H O 0 0.0001484336971770972
mutation O 0 3.0348164727911353e-06
was O 0 2.76749960903544e-06
determined O 0 3.949204199216183e-07
and O 0 8.026572118069453e-08
found O 0 2.3225165080020815e-07
to O 0 1.7941576402336068e-07
be O 0 7.206680834315193e-07
normal O 0 6.974962161621079e-06
. O 0 2.4473432858940214e-05

It O 0 4.664376319851726e-06
is O 0 1.3195839301261003e-06
therefore O 0 1.2845268884120742e-06
concluded O 0 1.5995187823136803e-06
that O 0 1.2648156655359344e-07
the O 0 5.79797074351518e-07
R496H O 0 3.171968273818493e-05
mutation O 0 2.449223757139407e-06
of O 0 3.7330987652239855e-06
ARSA O 1 0.9957830905914307
does O 0 1.3664367770616082e-07
not O 0 2.9240542431807626e-08
negatively O 0 4.1079633916751845e-08
influence O 0 6.334964552934252e-08
the O 0 9.396335798328437e-08
activity O 0 3.2475912803420215e-07
of O 0 1.2596337910508737e-06
ARSA O 0 0.27817827463150024
and O 0 2.6949888365379593e-07
is O 0 2.2110900488314655e-07
not O 0 1.220428060833001e-07
a O 0 4.514522515819408e-06
cause O 0 0.00012281820818316191
of O 0 0.0005541646969504654
MLD B-Disease 1 0.9999990463256836

Down O 0 6.47047781967558e-05
- O 0 3.0828294256934896e-05
regulation O 0 1.4657235624326859e-05
of O 0 1.4577387446479406e-05
transmembrane O 0 0.00284848571754992
carbonic O 0 0.11895180493593216
anhydrases O 1 0.506825864315033
in O 0 0.00015628697292413563
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9969348907470703
lines O 0 5.667422101396369e-06
by O 0 1.0357011888117995e-06
wild O 0 1.76091562025249e-05
- O 0 9.392207721248269e-05
type O 0 0.00011120850831503049
von B-Disease 1 0.677876353263855
Hippel I-Disease 1 0.997788667678833
- I-Disease 1 0.7763383984565735
Lindau I-Disease 1 0.9949871301651001
transgenes O 0 0.003162234090268612
. O 0 8.395792247029021e-05

To O 0 1.1061632903874852e-05
discover O 0 1.5148363672778942e-05
genes O 0 1.5124064702831674e-06
involved O 0 1.5630367897756514e-06
in O 0 3.4869731280195992e-06
von B-Disease 0 0.15066209435462952
Hippel I-Disease 1 0.9991317391395569
- I-Disease 1 0.9558072686195374
Lindau I-Disease 1 0.9999330043792725
( O 0 0.0001061368893715553
VHL B-Disease 1 0.9977050423622131
) O 0 1.5480021602343186e-06
- O 0 1.4840420590189751e-05
mediated O 0 4.07084335165564e-05
carcinogenesis O 0 0.07292680442333221
, O 0 5.842435939484858e-07
we O 0 5.228303621152008e-07
used O 0 6.04840488449554e-06
renal B-Disease 1 1.0
cell I-Disease 1 0.9999997615814209
carcinoma I-Disease 1 1.0
cell O 1 0.9965603947639465
lines O 0 7.106411794666201e-05
stably O 0 0.0014283633790910244
transfected O 0 0.00018732242460828274
with O 0 1.7336483324470464e-06
wild O 0 9.055084956344217e-05
- O 0 0.1940162628889084
type O 1 0.843196451663971
VHL O 1 0.9999840259552002
- O 0 0.009719724766910076
expressing O 0 0.00035448785638436675
transgenes O 0 0.0015161170158535242
. O 0 6.0616359405685216e-05

Large O 0 3.1243180274032056e-05
- O 0 2.8488202588050626e-05
scale O 0 2.314589983143378e-05
RNA O 0 1.4251470929593779e-05
differential O 0 6.202753866091371e-06
display O 0 2.3741160930512706e-06
technology O 0 1.0748052545750397e-06
applied O 0 2.4536655018891906e-07
to O 0 4.558415511723979e-08
these O 0 4.2335244643254555e-08
cell O 0 1.8241256611872814e-06
lines O 0 5.790344630440813e-07
identified O 0 4.715457180282101e-07
several O 0 1.4947808324450307e-07
differentially O 0 3.206205292372033e-06
expressed O 0 5.059420118413982e-07
genes O 0 1.432237297649408e-07
, O 0 7.419147607379273e-08
including O 0 2.092008912768506e-07
an O 0 1.6253893591056112e-06
alpha O 0 0.00023543443239759654
carbonic O 0 0.009800807572901249
anhydrase O 0 0.006290968973189592
gene O 0 8.961718776845373e-06
, O 0 3.8644770938844886e-06
termed O 0 0.0001808362576412037
CA12 O 1 0.8121936917304993
. O 0 0.0001116810817620717

The O 0 1.6919704648898914e-05
deduced O 0 2.599770959932357e-05
protein O 0 2.091120222758036e-06
sequence O 0 5.395959306042641e-07
was O 0 1.2868687235823018e-06
classified O 0 2.9853001137780666e-07
as O 0 1.3421305311567266e-07
a O 0 2.877042106774752e-07
one O 0 3.6550787285705155e-07
- O 0 8.576759682910051e-06
pass O 0 3.3363080547132995e-06
transmembrane O 0 0.0012725571868941188
CA O 0 6.820735507062636e-06
possessing O 0 2.153752120648278e-06
an O 0 6.668478818028234e-07
apparently O 0 3.785194621741539e-06
intact O 0 5.055801011621952e-06
catalytic O 0 2.344852873648051e-06
domain O 0 6.130100587142806e-07
in O 0 2.725893182287109e-07
the O 0 2.1369689875427866e-06
extracellular O 0 9.627907274989411e-05
CA O 0 9.654882887843996e-05
module O 0 0.0008096880046650767
. O 0 3.356188608449884e-05

Reintroduced O 0 0.0020544417202472687
wild O 0 0.0004057218902744353
- O 0 0.0015729713486507535
type O 0 0.0019709975458681583
VHL B-Disease 1 0.9651179313659668
strongly O 0 7.5604089033731725e-06
inhibited O 0 9.771416443982162e-06
the O 0 8.599697594036115e-07
overexpression O 0 1.0428708264953457e-05
of O 0 1.2723178315354744e-06
the O 0 2.666735099410289e-06
CA12 O 0 0.2741891145706177
gene O 0 1.1128206551802577e-06
in O 0 3.005639825914841e-07
the O 0 3.169208412145963e-06
parental O 0 0.011242609471082687
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999397993087769
lines O 0 0.0004781648167409003
. O 0 8.302149217342958e-05

Similar O 0 8.159869139490183e-06
results O 0 1.2626707075469312e-06
were O 0 4.244917590767727e-07
obtained O 0 1.2864123846156872e-06
with O 0 8.333205983035441e-07
CA9 O 0 0.2538858950138092
, O 0 2.0714073798444588e-06
encoding O 0 2.220583382950281e-06
another O 0 3.894604105880717e-06
transmembrane O 0 0.00012493539543356746
CA O 0 2.2857884687255137e-06
with O 0 2.15926874602701e-07
an O 0 1.642668053136731e-06
intact O 0 5.05071620864328e-05
catalytic O 0 3.967746306443587e-05
domain O 0 2.1200003175181337e-05
. O 0 2.9611148420372047e-05

Although O 0 6.659818154730601e-06
both O 0 7.729479420959251e-07
domains O 0 2.1918474431004142e-06
of O 0 1.9882911601598607e-06
the O 0 6.926421974640107e-06
VHL B-Disease 0 0.3997160792350769
protein O 0 1.4731159581060638e-06
contribute O 0 2.1963575136396685e-07
to O 0 5.63688544730212e-08
regulation O 0 4.852167876379099e-07
of O 0 8.988799891085364e-07
CA12 O 0 0.18468661606311798
expression O 0 2.3696304651821265e-06
, O 0 2.6326799229536846e-07
the O 0 6.276871999943978e-07
elongin O 0 2.8720667614834383e-05
binding O 0 9.299233738602197e-07
domain O 0 1.5911888340269797e-06
alone O 0 9.549484047965962e-07
could O 0 5.568386995946639e-07
effectively O 0 3.664974428829737e-06
regulate O 0 1.0843701602425426e-05
CA9 O 0 0.006653732620179653
expression O 0 6.361899431794882e-05
. O 0 4.6877939894329756e-05

We O 0 6.869681237731129e-05
mapped O 0 0.0003094990679528564
CA12 O 0 0.21184559166431427
and O 0 7.867993554100394e-05
CA9 O 1 0.750411868095398
loci O 0 4.015185550088063e-05
to O 0 3.2028376608650433e-06
chromosome O 0 6.695482443319634e-05
bands O 0 0.00010003729403251782
15q22 O 0 0.005739332642406225
and O 0 3.157830724376254e-05
17q21 O 0 0.004839595872908831
. O 0 0.00011578435078263283

2 O 0 3.237347846152261e-05
respectively O 0 2.212241815868765e-05
, O 0 5.004673312214436e-06
regions O 0 3.960695721616503e-06
prone O 0 1.079026515071746e-05
to O 0 4.4399547505236114e-07
amplification O 0 1.4874565749778412e-05
in O 0 1.4298615269581205e-06
some O 0 3.306391135993181e-06
human O 0 2.644742744450923e-05
cancers B-Disease 0 0.11837273091077805
. O 0 0.00018101066234521568

Additional O 0 1.057252666214481e-05
experiments O 0 4.14264150094823e-06
are O 0 1.4061973274692718e-07
needed O 0 5.277507284517924e-07
to O 0 7.756240449907637e-08
define O 0 1.3254141606466874e-07
the O 0 2.1752207146619185e-07
role O 0 8.927358976507094e-07
of O 0 2.671926040420658e-06
CA O 0 2.5092118448810652e-05
IX O 0 0.16104687750339508
and O 0 1.2920704648422543e-06
CA O 0 6.929877145012142e-06
XII O 0 0.00011107793397968635
enzymes O 0 2.414832351860241e-07
in O 0 5.7203486392154446e-08
the O 0 1.2091464896002435e-07
regulation O 0 3.886968897859333e-07
of O 0 2.866552790692367e-07
pH O 0 1.5526180732194916e-06
in O 0 1.4371548218150565e-07
the O 0 3.945341688904591e-07
extracellular O 0 6.06013736614841e-06
microenvironment O 0 1.5187767530733254e-05
and O 0 1.232971413855921e-07
its O 0 1.703755998505585e-07
potential O 0 5.830202098877635e-07
impact O 0 1.8298301256436389e-06
on O 0 4.6005825424799696e-06
cancer B-Disease 1 0.9030941128730774
cell O 0 0.0030005546286702156
growth O 0 0.0001259667769772932
. O 0 5.018041338189505e-05

A O 0 0.00010658436076482758
gene O 0 1.6258192772511393e-05
encoding O 0 4.2685296648414806e-06
a O 0 9.132319974014536e-06
transmembrane O 0 0.0008301727939397097
protein O 0 7.63452953833621e-06
is O 0 6.499614073618432e-07
mutated O 0 2.889836650865618e-06
in O 0 7.952130545163527e-07
patients O 0 6.394855881808326e-05
with O 0 0.23540224134922028
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999996423721313
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999990463256836
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 0.0006101027829572558
. O 0 0.00015327829169109464

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 1 0.9879656434059143
WFS B-Disease 1 0.9999991655349731
; O 0 0.00031524902442470193
OMIM O 1 0.9999974966049194
222300 O 1 0.8374715447425842
) O 0 2.093363036692608e-06
is O 0 1.1004550515281153e-06
an O 0 8.323267138621304e-06
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 0.005428930278867483
by O 0 1.5565063222311437e-05
young O 0 0.0003131533449050039
- O 1 0.9759981036186218
onset O 1 1.0
non O 1 0.9995452761650085
- O 1 0.9999995231628418
immune O 1 0.9999997615814209
insulin B-Disease 1 0.9999960660934448
- I-Disease 1 0.9999958276748657
dependent I-Disease 1 0.9861140847206116
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9161365628242493
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.016606442630290985

Linkage O 0 0.0003159723710268736
to O 0 5.149213393451646e-06
markers O 0 2.436470276734326e-05
on O 0 9.431090802536346e-06
chromosome O 0 0.00033007937599904835
4p O 1 0.9996998310089111
was O 0 3.132582060061395e-05
confirmed O 0 3.4141264677600702e-06
in O 0 9.16164879072312e-07
five O 0 2.7823828077089274e-06
families O 0 7.683496733079664e-06
. O 0 5.969634003122337e-05

On O 0 4.02546947952942e-06
the O 0 1.2345425375315244e-06
basis O 0 1.3050986353846383e-06
of O 0 7.713272680121008e-06
meiotic O 1 0.9996402263641357
recombinants O 1 0.9999691247940063
and O 0 0.0008924314752221107
disease O 1 0.9999964237213135
- O 0 0.15932528674602509
associated O 0 6.261387170525268e-05
haplotypes O 0 5.0595092034200206e-05
, O 0 8.160757261066465e-07
the O 0 3.3954690934479004e-06
WFS B-Disease 1 0.9952540397644043
gene O 0 3.5597033729573013e-06
was O 0 3.525620741129387e-06
localized O 0 3.5737443795369472e-06
to O 0 1.9200336964786402e-07
a O 0 5.951358161837561e-06
BAC O 1 0.6682960391044617
/ O 0 0.00043189176358282566
P1 O 0 0.0010943604866042733
contig O 0 4.2467439925530925e-05
of O 0 1.0037394986284198e-06
less O 0 9.310219297731237e-07
than O 0 1.059810188053234e-06
250 O 0 1.6922576833167113e-05
kb O 0 0.00048619008157402277
. O 0 4.601062028086744e-05

Mutations O 0 2.385816515015904e-05
in O 0 3.1954421046975767e-06
a O 0 4.483552856981987e-06
novel O 0 1.5985786376404576e-05
gene O 0 5.1715410336328205e-06
( O 0 1.380160938424524e-06
WFS1 O 0 0.00024246968678198755
) O 0 2.0124430477608257e-07
encoding O 0 3.671708554975339e-07
a O 0 5.880525577595108e-07
putative O 0 6.194584784680046e-06
transmembrane O 0 8.066342161328066e-06
protein O 0 5.065368213763577e-07
were O 0 1.231252184652476e-07
found O 0 4.4026474910197066e-08
in O 0 2.880363147994558e-08
all O 0 3.134288917294725e-08
affected O 0 1.2814982142117515e-07
individuals O 0 3.455038211086503e-08
in O 0 3.838739814909786e-07
six O 0 7.460535925929435e-06
WFS B-Disease 1 0.9999785423278809
families O 0 2.1478210499026318e-07
, O 0 1.479049274166755e-07
and O 0 7.197731122232653e-08
these O 0 3.182001862001016e-08
mutations O 0 3.0180365229171e-07
were O 0 2.0076316786798998e-07
associated O 0 6.425067908821802e-07
with O 0 8.034841698645323e-07
the O 0 0.0003991607518400997
disease O 1 0.9999990463256836
phenotype O 1 0.9984866380691528
. O 0 0.00024695321917533875

WFS1 O 0 0.29104381799697876
appears O 0 2.345070788578596e-05
to O 0 6.360631914503756e-07
function O 0 7.975888252076402e-07
in O 0 5.412121026893146e-07
survival O 0 1.6015725122997537e-05
of O 0 3.100628418906126e-06
islet O 0 0.00032233938691206276
beta O 0 3.573433787096292e-05
- O 0 0.0001371716643916443
cells O 0 1.344214706477942e-05
and O 0 1.433702550457383e-06
neurons O 0 2.4714185201446526e-05
. O 0 3.2926027415669523e-06
. O 0 1.7925098291016184e-05

Stable O 0 5.020156822865829e-05
interaction O 0 2.196781679231208e-06
between O 0 7.315180141631572e-07
the O 0 1.3240918406154378e-06
products O 0 6.415020266103966e-07
of O 0 1.0807646049215691e-06
the O 0 3.6984990856581135e-06
BRCA1 O 0 0.0014493984635919333
and O 0 3.5273831144877477e-06
BRCA2 O 0 0.15860483050346375
tumor B-Disease 1 0.9992550015449524
suppressor O 0 0.0010414989665150642
genes O 0 8.165326903508685e-07
in O 0 9.838448704613256e-07
mitotic O 0 0.00011687930964399129
and O 0 7.766196176817175e-06
meiotic O 1 0.9670339822769165
cells O 0 0.0002715041337069124
. O 0 6.196853792062029e-05

BRCA1 O 0 0.19405923783779144
and O 0 1.6413825505878776e-05
BRCA2 O 0 0.00013952067820355296
account O 0 6.12139615441265e-07
for O 0 1.4357135569298407e-07
most O 0 1.1137438349351214e-07
cases O 0 9.341118811789784e-08
of O 0 7.259803851411561e-07
familial O 0 0.009514281526207924
, O 0 3.0654634883831022e-06
early O 0 0.00021732880850322545
onset O 1 0.9999998807907104
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.5811954736709595
/ I-Disease 1 1.0
or I-Disease 1 0.999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0582392860669643e-05
encode O 0 1.1377478585927747e-06
products O 0 5.402689566835761e-07
that O 0 1.3454828717840428e-07
each O 0 1.1632064911282214e-07
interact O 0 3.447205756401672e-07
with O 0 2.2547437765751965e-06
hRAD51 O 0 0.0007978030480444431
. O 0 8.72243253979832e-05

Results O 0 6.193934950715629e-06
presented O 0 7.540650130977156e-06
here O 0 2.340219452889869e-06
show O 0 2.8838569505751366e-06
that O 0 1.1885894082297455e-06
BRCA1 O 0 5.7244069466833025e-05
and O 0 1.509478579464485e-06
BRCA2 O 0 3.5447035770630464e-05
coexist O 0 1.5883038031461183e-06
in O 0 2.970954824377259e-07
a O 0 1.758494022396917e-06
biochemical O 0 2.9782937417621724e-05
complex O 0 5.1844099289155565e-06
and O 0 7.086154596436245e-07
colocalize O 0 0.0001467739202780649
in O 0 2.0384045456012245e-06
subnuclear O 0 0.001218923251144588
foci O 0 4.4659256673185155e-05
in O 0 9.109957090913667e-07
somatic O 0 1.9049979528062977e-05
cells O 0 7.755735964565247e-07
and O 0 4.387499785707405e-08
on O 0 6.930127938176156e-08
the O 0 1.684067143514767e-07
axial O 0 1.6849166968313511e-06
elements O 0 1.1932094139410765e-06
of O 0 3.2875386750674807e-06
developing O 0 2.7220896299695596e-05
synaptonemal O 0 0.0037262586411088705
complexes O 0 0.0004985646810382605
. O 0 6.943563494132832e-05

Like O 0 0.0002394992916379124
BRCA1 O 0 0.010618982836604118
and O 0 4.9970967666013166e-05
RAD51 O 1 0.9962242841720581
, O 0 4.103822720935568e-05
BRCA2 O 0 0.000270747987087816
relocates O 0 5.039871030021459e-05
to O 0 1.5729885944892885e-06
PCNA O 0 0.0002012876357184723
+ O 0 2.363730800425401e-06
replication O 0 8.646721312288719e-07
sites O 0 6.060218993297894e-08
following O 0 1.145954868775334e-07
exposure O 0 1.0106514309882186e-06
of O 0 7.607003453813377e-07
S O 0 6.53825918561779e-05
phase O 0 2.372317248955369e-05
cells O 0 2.3733284706395352e-06
to O 0 4.169576186541235e-07
hydroxyurea O 0 0.0002179361617891118
or O 0 6.640240826527588e-06
UV O 0 0.024317815899848938
irradiation O 0 0.00034096036688424647
. O 0 3.451505835982971e-05

Thus O 0 5.558584598475136e-05
, O 0 2.053311254712753e-05
BRCA1 O 0 0.00011892487236764282
and O 0 2.4455966922687367e-06
BRCA2 O 0 1.6791687812656164e-05
participate O 0 3.7618468695654883e-07
, O 0 1.85471520808278e-07
together O 0 8.292917641483655e-08
, O 0 8.001336482266197e-08
in O 0 9.50415923739456e-08
a O 0 8.87632097601454e-07
pathway O 0 1.6166795830940828e-06
( O 0 1.1303067992685101e-07
s O 0 2.6488379489819636e-07
) O 0 1.8358042197519353e-08
associated O 0 3.137489201776589e-08
with O 0 1.6238285382996764e-08
the O 0 9.665915712275819e-08
activation O 0 4.67349849486709e-07
of O 0 2.2335549942908983e-07
double O 0 3.7137394883757224e-06
- O 0 2.354920252400916e-05
strand O 0 2.919982944149524e-05
break O 0 6.70557119519799e-06
repair O 0 7.620581891387701e-05
and O 0 1.0066077038572985e-06
/ O 0 2.8894402930745855e-05
or O 0 1.4574110309695243e-06
homologous O 0 1.3405099707597401e-05
recombination O 0 3.468068825895898e-05
. O 0 3.814200681517832e-05

Dysfunction O 1 0.9825282692909241
of O 0 2.7085390684078448e-05
this O 0 3.48330058841384e-06
pathway O 0 4.39918294432573e-05
may O 0 3.3214172390216845e-07
be O 0 3.963737782441967e-08
a O 0 1.792440542658369e-07
general O 0 3.68827016927753e-07
phenomenon O 0 4.005393350325903e-07
in O 0 3.8613496400330405e-08
the O 0 7.15843810894512e-08
majority O 0 8.2730110761986e-08
of O 0 2.227076407734785e-07
cases O 0 2.0944504797171248e-07
of O 0 1.9600325686042197e-05
hereditary B-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
and I-Disease 1 0.9954979419708252
/ I-Disease 1 1.0
or I-Disease 1 0.999987006187439
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0029246339108794928
. O 0 0.0002517600660212338

A O 0 0.00016259773110505193
novel O 0 5.1095768867526203e-05
Arg362Ser O 0 0.00017466771532781422
mutation O 0 6.778301212762017e-06
in O 0 6.446863380915602e-07
the O 0 1.198610902974906e-06
sterol O 0 3.6136243579676375e-05
27 O 0 5.847319243912352e-06
- O 0 2.1400186597020365e-05
hydroxylase O 0 2.458315975673031e-05
gene O 0 1.1378259614502895e-06
( O 0 2.925622766269953e-07
CYP27 O 0 4.571749013848603e-05
) O 0 6.366846605487808e-08
: O 0 3.7916869644050166e-08
its O 0 4.558667754395174e-08
effects O 0 2.9678088253604074e-07
on O 0 2.443204607516236e-07
pre O 0 5.22822119819466e-06
- O 0 5.167730250832392e-06
mRNA O 0 3.453418912613415e-06
splicing O 0 3.47851687365619e-06
and O 0 4.898457746094209e-07
enzyme O 0 5.747367595176911e-06
activity O 0 5.907511422265088e-06
. O 0 1.6945137758739293e-05

A O 0 6.401335122063756e-05
novel O 0 2.2962363800616004e-05
C O 0 2.0727409719256684e-05
to O 0 4.1350298829456733e-07
A O 0 2.0049519662279636e-06
mutation O 0 7.685106311328127e-07
in O 0 2.079596725934607e-07
the O 0 6.07747892900079e-07
sterol O 0 1.9705581507878378e-05
27 O 0 4.766857273352798e-06
- O 0 1.5711681044194847e-05
hydroxylase O 0 4.0514598367735744e-05
gene O 0 1.998922925849911e-06
( O 0 6.784029551454296e-07
CYP27 O 0 0.00010417338489787653
) O 0 3.2765851187832595e-07
was O 0 1.270281018150854e-06
identified O 0 2.8007232799609483e-07
by O 0 4.4932170339961885e-07
sequencing O 0 9.281423444917891e-06
amplified O 0 6.77152129355818e-05
CYP27 O 1 0.927286684513092
gene O 0 4.140082182857441e-06
products O 0 3.862734843096405e-07
from O 0 3.3918982467184833e-07
a O 0 2.1066891804366605e-06
patient O 0 9.399772352480795e-06
with O 0 1.3834258425049484e-05
cerebrotendinous B-Disease 1 0.9999998807907104
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 0.013281451538205147
CTX B-Disease 1 0.9999866485595703
) O 0 1.529918154119514e-05
. O 0 3.022895361937117e-05

The O 0 3.9671864215051755e-05
mutation O 0 4.5644264901056886e-05
changed O 0 1.050683295034105e-05
the O 0 1.1752465070458129e-05
adrenodoxin O 0 0.0009196504834108055
cofactor O 0 0.0002578765561338514
binding O 0 3.1401045816892292e-06
residue O 0 1.1119157534267288e-05
362Arg O 0 1.4944266695238184e-05
to O 0 4.905090804641077e-07
362Ser O 0 4.326322232373059e-05
( O 0 5.297725692798849e-06
CGT O 0 0.028529737144708633
362Arg O 0 4.43189637735486e-05
to O 0 1.7978451296585263e-06
AGT O 1 0.9908280372619629
362Ser O 0 3.335983637953177e-05
) O 0 2.54746481687107e-07
, O 0 6.26427762995263e-08
and O 0 3.180484853260168e-08
was O 0 6.439624939957866e-07
responsible O 0 3.975345066464797e-07
for O 0 3.8054173501222976e-07
deficiency O 1 0.9366074204444885
in O 0 4.1389199623154127e-07
the O 0 1.5238499599945499e-06
sterol O 0 2.6473822799744084e-05
27 O 0 5.204690751270391e-06
- O 0 7.085153356456431e-06
hydroxylase O 0 6.000374924042262e-06
activity O 0 3.274898290328565e-07
, O 0 6.122620987980554e-08
as O 0 3.750709254290996e-08
confirmed O 0 6.709663580295455e-08
by O 0 6.499706728391175e-08
expression O 0 3.30468765241676e-07
of O 0 1.1847224641314824e-06
mutant O 0 1.9744140445254743e-05
cDNA O 0 8.719279321667273e-06
into O 0 1.1240199455642141e-06
COS O 0 0.00020493885676842183
- O 0 3.790074333664961e-05
1 O 0 3.78680088033434e-05
cells O 0 4.250892379786819e-05
. O 0 1.8145905414712615e-05

Quantitative O 0 1.4829131032456644e-05
analysis O 0 1.8737091522780247e-06
showed O 0 1.7120282791438513e-06
that O 0 1.362925416970029e-07
the O 0 3.416206766360119e-07
expression O 0 1.488932070969895e-06
of O 0 3.021647444256814e-06
CYP27 O 0 0.009076785296201706
gene O 0 2.548738621044322e-06
mRNA O 0 1.085234771380783e-06
in O 0 2.835310795035184e-07
the O 0 1.2399679008012754e-06
patient O 0 7.6032420111005194e-06
represented O 0 1.2765699466399383e-05
52 O 0 8.763444202486426e-05
. O 0 0.00010873068094952032

5 O 0 8.964334483607672e-06
% O 0 1.8394655398878967e-06
of O 0 1.8382099824520992e-06
the O 0 3.5945129184256075e-06
normal O 0 7.619414645887446e-06
level O 0 2.1598820239887573e-05
. O 0 3.23904023389332e-05

As O 0 4.751729193230858e-06
the O 0 2.059140797427972e-06
mutation O 0 2.3602144665346714e-06
occurred O 0 1.2062491805409081e-06
at O 0 4.1156377506013087e-07
the O 0 4.605507513133489e-07
penultimate O 0 7.65269487601472e-06
nucleotide O 0 7.92378784808534e-07
of O 0 3.7178460843279026e-07
exon O 0 4.41178690380184e-06
6 O 0 3.5624671568257327e-07
( O 0 5.7797688413074866e-08
- O 0 1.8079879282595357e-07
2 O 0 1.811090726278053e-07
position O 0 1.231173598625901e-07
of O 0 3.8588504480685515e-07
exon O 0 9.527311704005115e-06
6 O 0 1.6573397942920565e-06
- O 0 5.1113006520608906e-06
intron O 0 2.5294075385318138e-05
6 O 0 1.4767449556529755e-06
splice O 0 2.0735776615765644e-06
site O 0 2.7488661658026103e-07
) O 0 2.547177402334455e-08
of O 0 6.252984974253195e-08
the O 0 1.7739453994636278e-07
gene O 0 4.12598552657073e-07
, O 0 9.918149856957825e-08
we O 0 5.380005418942346e-08
hypothesized O 0 3.5336285009179846e-07
that O 0 2.1461948662704344e-08
the O 0 1.5793663976637617e-07
mutation O 0 6.850513045719708e-07
may O 0 1.8584174199531844e-07
partially O 0 5.806364242744166e-07
affect O 0 3.789662628150836e-08
the O 0 5.272657332966446e-08
normal O 0 1.0320879795244764e-07
splicing O 0 3.2461852583764994e-07
efficiency O 0 1.7132518337348301e-07
in O 0 1.0823845286722644e-07
exon O 0 3.138829242743668e-06
6 O 0 2.4295167122545536e-07
and O 0 1.0283329032745314e-07
cause O 0 8.70385747475666e-07
alternative O 0 3.198211686594732e-07
splicing O 0 8.915787930163788e-07
elsewhere O 0 1.5586724089189374e-07
, O 0 4.383960927611952e-08
which O 0 2.0183295035280935e-08
resulted O 0 3.6493037214313517e-07
in O 0 1.715115587330729e-07
decreased O 0 3.4886029425251763e-06
transcript O 0 4.086483841092559e-06
in O 0 7.490354505534924e-07
the O 0 5.794344815512886e-06
patient O 0 0.00010455055598868057
. O 0 5.502201383933425e-05

Transfection O 0 0.0010854314314201474
of O 0 3.733061021193862e-05
constructed O 0 0.0001754162658471614
minigenes O 0 0.0004055165918543935
, O 0 1.1732964821931091e-06
with O 0 1.9616129520727554e-07
or O 0 1.297675424893896e-07
without O 0 1.4530863268191752e-07
the O 0 2.7778546041190566e-07
mutation O 0 8.359377261513146e-07
, O 0 1.883067710650721e-07
into O 0 2.3121143044591008e-07
COS O 0 0.00011726301454473287
- O 0 4.032370270579122e-06
1 O 0 1.5746936696814373e-06
cells O 0 4.4092280404584017e-07
confirmed O 0 7.899554788082241e-08
that O 0 1.2605498866946618e-08
the O 0 1.1377571951243226e-07
mutant O 0 4.057243131683208e-06
minigene O 0 1.1731851373042446e-05
was O 0 9.279177675125538e-07
responsible O 0 1.3702445755825465e-07
for O 0 4.6789391916490786e-08
a O 0 4.792081540472282e-07
mRNA O 0 9.390563491251669e-07
species O 0 5.479737197333634e-08
alternatively O 0 2.3604411580890883e-07
spliced O 0 6.891690986776666e-07
at O 0 4.706355127837014e-07
an O 0 8.489803349220892e-07
activated O 0 2.41644520428963e-05
cryptic O 0 9.454622158955317e-06
5 O 0 1.0872796565308818e-06
splice O 0 3.1542472243017983e-06
site O 0 4.840354677071446e-07
88 O 0 1.2291856137380819e-06
bp O 0 1.1784132993852836e-06
upstream O 0 2.624793182803842e-07
from O 0 4.8672113450720644e-08
the O 0 1.102215918535876e-07
3 O 0 3.9003069218779274e-07
end O 0 8.517408787156455e-07
of O 0 2.939722890005214e-06
exon O 0 0.00016660081746522337
6 O 0 4.383315535960719e-05
. O 0 3.5508030123310164e-05

Our O 0 4.492421339818975e-06
data O 0 6.825445666436281e-07
suggest O 0 2.7888543741028116e-07
that O 0 4.97471432936436e-08
the O 0 1.799315185735395e-07
C O 0 1.468268806092965e-06
to O 0 6.487285020284617e-08
A O 0 4.5791384195581486e-07
mutation O 0 3.0875926881890337e-07
at O 0 2.9746377094852505e-07
the O 0 2.397235618900595e-07
penultimate O 0 5.8724276641441975e-06
nucleotide O 0 6.028872121532913e-07
of O 0 2.3256417591710488e-07
exon O 0 3.9411552279489115e-06
6 O 0 2.689850759907131e-07
of O 0 3.0063733902352396e-07
the O 0 8.167429541572346e-07
CYP27 O 0 0.27931204438209534
gene O 0 8.2351783703416e-07
not O 0 2.7456637852196764e-08
only O 0 4.950171117457103e-08
causes O 0 7.803203061484965e-07
the O 0 1.3814171779813478e-06
deficiency B-Disease 1 0.9992626309394836
in I-Disease 0 4.355158296220907e-07
the I-Disease 0 7.710116847192694e-07
sterol I-Disease 0 1.6435189536423422e-05
27 I-Disease 0 2.223346427854267e-06
- I-Disease 0 3.3170283586514415e-06
hydroxylase I-Disease 0 4.054844794154633e-06
activity I-Disease 0 1.6926395574046182e-07
, O 0 4.6598621850080235e-08
but O 0 3.8757821840817996e-08
also O 0 5.998567331744198e-08
partially O 0 3.787964999446558e-07
leads O 0 1.2875595700734266e-07
to O 0 2.8143963604065902e-08
alternative O 0 2.761741768608772e-07
pre O 0 3.358795765961986e-06
- O 0 2.510379772502347e-06
mRNA O 0 1.896864660011488e-06
splicing O 0 1.2793530004273634e-06
of O 0 4.689464105922525e-07
the O 0 3.2754592211858835e-06
gene O 0 3.117008964181878e-05
. O 0 2.706421582843177e-05

To O 0 4.295342023397097e-06
our O 0 1.9296853679406922e-06
knowledge O 0 2.3768959636072395e-06
, O 0 4.0146443325284054e-07
this O 0 6.889470682835963e-08
is O 0 2.6648050877042806e-08
the O 0 4.6585736157567226e-08
first O 0 7.282798719643324e-08
report O 0 3.34887211295154e-08
regarding O 0 4.2959953816534835e-08
effects O 0 1.9617027646745555e-07
on O 0 1.3145442778750294e-07
pre O 0 1.306071112594509e-06
- O 0 6.0336230944813e-07
mRNA O 0 5.025191853746946e-07
splicing O 0 2.502417544292257e-07
of O 0 7.287495407126698e-08
a O 0 1.18187365671929e-07
mutation O 0 1.6320637996614096e-07
at O 0 1.2528680315426755e-07
the O 0 1.435823122619695e-07
- O 0 5.200247414904879e-07
2 O 0 3.134612427402317e-07
position O 0 1.8341913232688967e-07
of O 0 2.9239686227811035e-07
a O 0 1.5259251995303202e-06
5 O 0 8.454095222987235e-06
splice O 0 6.283986294874921e-05
site O 0 2.44569582719123e-05
. O 0 2.5883027774398215e-05

ATM O 0 0.005604565143585205
germline O 0 0.0030632303096354008
mutations O 0 3.5281951568322256e-05
in O 0 1.7845375623437576e-05
classical O 1 0.9994574189186096
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0004373981792014092
in O 0 3.447394192335196e-06
the O 0 7.865635780035518e-06
Dutch O 0 0.0003186805988661945
population O 0 9.20664933801163e-06
. O 0 3.2387993996962905e-05

Germline O 0 0.0024496023543179035
mutations O 0 2.1463976736413315e-05
in O 0 3.79916900783428e-06
the O 0 5.840948688273784e-06
ATM O 0 0.00016957185289356858
gene O 0 1.7988193121709628e-06
are O 0 3.563074812973355e-08
responsible O 0 3.592870712054719e-07
for O 0 4.854268809140194e-07
the O 0 0.0006344025605358183
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999173879623413
A B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
T I-Disease 1 0.9999992847442627
) O 0 1.680117020441685e-05
. O 0 2.6647530830814503e-05

In O 0 8.8511314970674e-06
our O 0 1.5016863699202077e-06
study O 0 7.531411938543897e-07
, O 0 2.837260808519204e-07
we O 0 6.404555108474597e-08
have O 0 2.6019083776418483e-08
determined O 0 1.0266317929108482e-07
the O 0 2.1049369536285667e-07
ATM O 0 4.643861757358536e-06
mutation O 0 3.6524164670481696e-07
spectrum O 0 4.099627801679162e-07
in O 0 9.291436242619966e-08
19 O 0 1.0529455494179274e-06
classical O 0 8.647309732623398e-05
A B-Disease 1 0.9999877214431763
- I-Disease 1 0.9999939203262329
T I-Disease 1 0.9999997615814209
patients O 0 3.18726415571291e-06
, O 0 1.592055696164607e-07
including O 0 7.67148051750155e-08
some O 0 7.097801102418089e-08
immigrant O 0 5.719595037589897e-07
populations O 0 1.9961174757554545e-07
, O 0 7.786137246057478e-08
as O 0 4.775894169029016e-08
well O 0 4.3835179042162054e-08
as O 0 6.311832123628847e-08
12 O 0 3.046915821869334e-07
of O 0 1.1801836308222846e-06
Dutch O 0 3.973956700065173e-05
ethnic O 0 6.340323125186842e-06
origin O 0 1.3421932635537814e-05
. O 0 2.890231553465128e-05

Both O 0 2.1577013740170514e-06
the O 0 1.621088813408278e-06
protein O 0 1.9081444406765513e-06
truncation O 0 1.7375532479491085e-05
test O 0 8.403130209444498e-07
( O 0 3.580358622912172e-07
PTT O 0 8.488609637424815e-06
) O 0 4.7068933639593524e-08
and O 0 2.990474357034145e-08
the O 0 1.3448723734654777e-07
restriction O 0 1.0859512258321047e-06
endonuclease O 0 1.0342480891267769e-05
fingerprinting O 0 3.647387075034203e-06
( O 0 2.749028737980552e-07
REF O 0 2.4432272766716778e-05
) O 0 2.7348708186991644e-08
method O 0 3.025747830065484e-08
were O 0 1.8080839936374105e-08
used O 0 9.374027776232197e-09
and O 0 7.3919115273213265e-09
compared O 0 3.751574695343152e-08
for O 0 1.733571863837824e-08
their O 0 2.1555360163461046e-08
detection O 0 6.054425512047601e-07
efficiency O 0 1.8943683244287968e-07
, O 0 3.2912915060023806e-08
identifying O 0 7.663348355890776e-08
76 O 0 3.7928919027763186e-07
% O 0 1.2103647861749778e-07
and O 0 4.4758529327282304e-08
60 O 0 8.9263906488668e-08
% O 0 1.282239026068055e-07
of O 0 2.4907416218411527e-07
the O 0 5.982514608149359e-07
mutations O 0 1.8271742874276242e-06
, O 0 1.5037601315270877e-06
respectively O 0 1.6878881069715135e-05
. O 0 3.375508458702825e-05

Most O 0 2.50177599809831e-05
patients O 0 2.1580020984401926e-05
were O 0 2.9974810331623303e-06
found O 0 1.7590037941772607e-06
to O 0 1.4455054042628035e-06
be O 0 4.8924061957222875e-06
compound O 0 0.00034884962951764464
heterozygote O 0 0.0013805689522996545
. O 0 8.052557677729055e-05

Seventeen O 0 8.162885205820203e-05
mutations O 0 1.2452967894205358e-05
were O 0 1.1340398486936465e-06
distinct O 0 4.4603260107578535e-07
, O 0 2.4008161858546373e-07
of O 0 3.1158029401012755e-07
which O 0 1.258592305930506e-07
10 O 0 2.1415540629732277e-07
were O 0 2.340111819876256e-07
not O 0 1.8510220911593933e-07
reported O 0 9.868838333204621e-07
previously O 0 8.975061064120382e-06
. O 0 1.6090772987809032e-05

Mutations O 0 4.895703023066744e-05
are O 0 1.0432081580802333e-06
small O 0 3.3098551739385584e-06
deletions O 0 1.7326141460216604e-05
or O 0 2.0371896880533313e-06
point O 0 6.344883331621531e-06
mutations O 0 5.40194514542236e-06
frequently O 0 2.6387629077362362e-06
affecting O 0 1.0624580681906082e-05
splice O 0 9.752615733304992e-05
sites O 0 1.0578629371593706e-05
. O 0 3.0712650186615065e-05

Moreover O 0 0.00016880834300536662
, O 0 1.9353423340362497e-05
a O 0 2.8799438950954936e-05
16 O 0 9.169908298645169e-05
. O 0 0.00014463934348896146

7 O 0 8.477844676235691e-05
- O 0 7.726037438260391e-05
kb O 0 0.0001011081476463005
genomic O 0 6.910078809596598e-06
deletion O 0 2.975901907120715e-06
of O 0 5.67716313071287e-07
the O 0 3.686655816181883e-07
3 O 0 3.2426208917968324e-07
end O 0 2.5026182015608356e-07
of O 0 1.8616864849718695e-07
the O 0 2.6116890694538597e-07
gene O 0 4.0481887708665454e-07
, O 0 4.9486796882547424e-08
most O 0 1.6492963439418418e-08
likely O 0 3.845818596914796e-08
a O 0 8.766905779111767e-08
result O 0 6.266117935638249e-08
of O 0 1.3918439378812764e-07
recombination O 0 3.3365677154506557e-07
between O 0 3.6332323816168355e-08
two O 0 5.8554441295655124e-08
LINE O 0 3.4219497138110455e-06
elements O 0 1.3371380873650196e-06
, O 0 5.358918997444562e-07
was O 0 1.0581747119431384e-05
identified O 0 9.22507115319604e-06
. O 0 2.5285487936343998e-05

The O 0 9.979619790101424e-06
most O 0 1.4194433788361493e-06
frequently O 0 8.965342885858263e-07
found O 0 5.081450922261865e-07
mutation O 0 8.976601293397835e-07
, O 0 1.9954400443111808e-07
identified O 0 2.1979961672968784e-07
in O 0 1.0806270722696354e-07
three O 0 1.5509974105043511e-07
unrelated O 0 2.9313973755051848e-06
Turkish O 0 1.1292372619209345e-05
A B-Disease 1 0.9991645812988281
- I-Disease 1 0.9957220554351807
T I-Disease 1 0.9995655417442322
individuals O 0 1.0704519581850036e-07
, O 0 1.8099891008205304e-07
was O 0 1.9080553101957776e-06
previously O 0 3.956403986649093e-07
described O 0 2.9274647772581375e-07
to O 0 2.7935227464581658e-08
be O 0 3.321309094417302e-08
a O 0 4.904122761217877e-07
Turkish O 0 1.0381435458839405e-05
A B-Disease 1 0.9973764419555664
- I-Disease 1 0.9995139837265015
T I-Disease 1 0.9999890327453613
founder O 0 0.033602893352508545
mutation O 0 0.00016629372839815915
. O 0 6.749189924448729e-05

The O 0 1.0960145118588116e-05
presence O 0 5.184716428630054e-06
of O 0 3.951965027226834e-06
a O 0 1.3986921658215579e-05
founder O 0 0.0023259692825376987
mutation O 0 1.1314783478155732e-05
among O 0 6.116914050835476e-07
relatively O 0 3.5653459917739383e-07
small O 0 1.5031950795219018e-07
ethnic O 0 1.610390825135255e-07
population O 0 5.673407699191557e-08
groups O 0 3.8655496581441184e-08
in O 0 1.1895335205736046e-07
Western O 0 8.339558235093136e-07
Europe O 0 5.444585440272931e-07
could O 0 7.524176481865652e-08
indicate O 0 1.0278152018372566e-07
a O 0 2.774667109406437e-07
high O 0 4.683430745444639e-07
carrier O 0 1.3558588989326381e-06
frequency O 0 3.784989530686289e-07
in O 0 1.299597442994127e-07
such O 0 3.1405519962390827e-07
communities O 0 1.4803180192757281e-06
. O 0 1.2874192179879174e-05

In O 0 2.891160147555638e-05
patients O 0 1.8215256204712205e-05
of O 0 5.193247034185333e-06
Dutch O 0 0.00013426605437416583
ethnic O 0 3.4558599963929737e-06
origin O 0 1.1852162060677074e-06
, O 0 4.132396327349852e-07
however O 0 2.9842979643035505e-07
, O 0 1.1638300634331245e-07
no O 0 1.5121744922907965e-07
significant O 0 1.276185798815277e-06
founder O 0 6.214572204044089e-05
effect O 0 1.4850153320367099e-06
could O 0 5.851312607774162e-07
be O 0 3.9632695347791014e-07
identified O 0 6.159533313621068e-06
. O 0 1.5561872714897618e-05

The O 0 1.237320429936517e-05
observed O 0 3.87196223528008e-06
genetic O 0 3.3758765312086325e-06
heterogeneity O 0 5.4515448937308975e-06
including O 0 3.651434496987349e-07
the O 0 4.7217122300935443e-07
relative O 0 6.704213433295081e-07
high O 0 4.748372646190546e-07
percentage O 0 2.438353590150655e-07
of O 0 7.428251933561114e-07
splice O 0 1.1222954526601825e-05
- O 0 5.456480721477419e-06
site O 0 2.2217950572667178e-06
mutations O 0 3.769694103539223e-07
had O 0 2.683473780962231e-07
no O 0 1.3788569219741476e-07
reflection O 0 1.186949134535098e-06
on O 0 1.1330106417517527e-06
the O 0 7.662612006242853e-06
phenotype O 0 0.0005432612379081547
. O 0 4.515839464147575e-05

All O 0 1.0580757589195855e-05
patients O 0 2.0205796317895874e-05
manifested O 0 7.113692845450714e-05
classical O 0 0.0007692970102652907
A B-Disease 1 0.9999356269836426
- I-Disease 1 0.999128520488739
T I-Disease 1 0.9995372295379639
and O 0 1.7010492001645616e-06
increased O 0 1.2023032468277961e-05
cellular O 0 0.00011546977475518361
radioresistant O 0 0.00072300317697227
DNA O 0 6.42996747046709e-05
synthesis O 0 0.00011560495477169752
. O 0 3.980355177191086e-05

Determination O 0 6.104027852416039e-05
of O 0 7.360312338278163e-06
the O 0 3.96930226997938e-06
genomic O 0 1.0902704161708243e-05
structure O 0 5.069029157311888e-06
of O 0 1.9773838175751735e-06
the O 0 4.612888460542308e-06
COL4A4 O 1 0.9840108752250671
gene O 0 2.8902195481350645e-06
and O 0 3.5036828194279224e-07
of O 0 2.0589482119248714e-06
novel O 0 9.733624028740451e-05
mutations O 0 0.00026316606090404093
causing O 1 0.9906643629074097
autosomal B-Disease 1 0.9999985694885254
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9995230436325073

Autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.1374754011631012
a O 0 0.491351842880249
progressive O 1 0.9999995231628418
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.9963047504425049
by O 0 0.000263936206465587
glomerular B-Disease 1 1.0
basement I-Disease 1 0.9999995231628418
membrane I-Disease 1 0.9988309741020203
abnormalities I-Disease 1 0.8930761218070984
and O 0 3.449823964274401e-07
associated O 0 5.561381613006233e-07
with O 0 1.7528503803987405e-07
mutations O 0 4.0571705994807417e-07
in O 0 1.6842116679072205e-07
either O 0 2.2323158077597327e-07
the O 0 8.050964197536814e-07
COL4A3 O 1 0.7387381792068481
or O 0 3.5285569310872233e-07
the O 0 1.3587869034381583e-06
COL4A4 O 1 0.6353853940963745
gene O 0 9.551168886900996e-07
, O 0 8.315345212395187e-08
which O 0 4.701115230432151e-08
encode O 0 9.172666892709458e-08
the O 0 3.0916646664991276e-07
alpha3 O 0 6.779048271710053e-05
and O 0 2.703869995457353e-06
alpha4 O 1 0.8389497399330139
type O 1 0.9784414172172546
IV O 1 1.0
collagen O 1 0.9999984502792358
chains O 0 0.00012013877130812034
, O 0 7.518991878896486e-06
respectively O 0 3.046071833523456e-05
. O 0 4.379827078082599e-05

To O 0 2.54289216172765e-06
date O 0 4.76981313113356e-06
, O 0 9.56157691689441e-07
mutation O 0 1.0212118013441795e-06
screening O 0 5.153985398465011e-07
in O 0 1.614853601950017e-07
the O 0 1.9088658120836044e-07
two O 0 6.091334370239565e-08
genes O 0 2.0000773304218455e-07
has O 0 1.4117682667347253e-07
been O 0 1.509314557779362e-07
hampered O 0 2.236147565781721e-06
by O 0 1.140922307740766e-07
the O 0 4.4566354517883155e-07
lack O 0 1.3736924984186771e-06
of O 0 9.773305009730393e-07
genomic O 0 1.0322969501430634e-05
structure O 0 2.1776044377475046e-05
information O 0 5.604729722108459e-06
. O 0 3.725400165421888e-05

We O 0 3.716548917509499e-06
report O 0 8.031884703996184e-07
here O 0 2.2003661115377326e-07
the O 0 1.4502234080282506e-07
complete O 0 1.177060994450585e-06
characterization O 0 1.827221353778441e-06
of O 0 3.246510402732383e-07
the O 0 3.5072397963631374e-07
48 O 0 8.672230933370884e-07
exons O 0 1.431209398106148e-06
of O 0 3.2247530157292204e-07
the O 0 1.0105975434271386e-06
COL4A4 O 0 0.4881349205970764
gene O 0 7.658277354494203e-07
, O 0 9.360737607266856e-08
a O 0 1.6842004413319955e-07
comprehensive O 0 5.28586838299816e-07
gene O 0 3.238831709495571e-07
screen O 0 1.915386604878222e-07
, O 0 5.387995116734601e-08
and O 0 2.945908761375904e-08
the O 0 9.399795430908853e-08
subsequent O 0 4.887799036623619e-07
detection O 0 8.243083016168384e-07
of O 0 1.9035465470551571e-07
10 O 0 2.2138647182146087e-07
novel O 0 1.1113306754850782e-06
mutations O 0 4.986118256056216e-07
in O 0 3.082996613557043e-07
eight O 0 8.648273251310457e-06
patients O 0 0.08485649526119232
diagnosed O 1 0.9999998807907104
with O 1 0.9784881472587585
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999262094497681

Furthermore O 0 5.604823672911152e-05
, O 0 3.41275926984963e-06
we O 0 6.945438144612126e-07
identified O 0 8.323690394718142e-07
a O 0 9.380162850902707e-07
glycine O 0 4.73859245175845e-06
to O 0 1.57665752453795e-07
alanine O 0 1.4681568245578092e-06
substitution O 0 2.2751428332412615e-06
in O 0 1.962110758313429e-07
the O 0 8.818540777610906e-07
collagenous O 0 0.002394831972196698
domain O 0 4.7209195486175304e-07
that O 0 4.426552280278884e-08
is O 0 1.1533840904576209e-07
apparently O 0 3.6274579429118603e-07
silent O 0 8.193994744942756e-07
in O 0 7.528986145644012e-08
the O 0 3.689920049509965e-07
heterozygous O 0 1.450877903153014e-06
carriers O 0 9.217412753059762e-07
, O 0 2.828070648774883e-07
in O 0 7.606307121932332e-07
11 O 0 1.3864952961739618e-05
. O 0 2.985072751471307e-05

5 O 0 8.337217877851799e-06
% O 0 1.7392256950188312e-06
of O 0 1.2954536714460119e-06
all O 0 3.145368623336253e-07
control O 0 1.4724811308042263e-06
individuals O 0 6.362221682820746e-08
, O 0 9.578847937063983e-08
and O 0 5.232612920735846e-08
in O 0 7.763892995171773e-08
one O 0 8.612717294909089e-08
control O 0 4.417569812176225e-07
individual O 0 6.09145089924823e-08
homozygous O 0 8.216578066821967e-07
for O 0 2.265049090510729e-07
this O 0 1.144122961704852e-06
glycine O 0 7.433565042447299e-05
substitution O 0 0.00016087543917819858
. O 0 3.4513413993408903e-05

There O 0 9.917589522956405e-06
has O 0 1.77333254214318e-06
been O 0 4.393764072574413e-07
no O 0 2.1171534569930373e-07
previous O 0 2.6958059606840834e-07
finding O 0 2.2244400099680206e-07
of O 0 3.1067503414305975e-07
a O 0 1.3099343050271273e-06
glycine O 0 7.0574569690506905e-06
substitution O 0 3.477890004432993e-06
that O 0 9.025154668051982e-08
is O 0 5.706769812263701e-08
not O 0 2.253559827636309e-08
associated O 0 9.508185172535377e-08
with O 0 6.70883153475188e-08
any O 0 4.5489358058148355e-07
obvious O 0 6.744602615071926e-06
phenotype O 0 1.728802999423351e-05
in O 0 8.850894346323912e-07
homozygous O 0 1.762735155352857e-05
individuals O 0 2.470161916789948e-06
. O 0 2.9694087061216123e-05

Founder O 1 0.8850340843200684
BRCA1 O 0 0.0748521015048027
and O 0 1.832201814977452e-05
BRCA2 O 0 0.0002561099536251277
mutations O 0 7.574928531539626e-06
in O 0 2.743413233474712e-06
French O 0 0.0069222161546349525
Canadian O 1 0.9344434142112732
breast B-Disease 1 1.0
and I-Disease 1 0.9999198913574219
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.0007084358367137611
. O 0 0.0006309577729552984

We O 0 7.235581051645568e-06
have O 0 6.649865440522262e-07
identified O 0 6.92781497946271e-07
four O 0 1.6729036644846929e-07
mutations O 0 2.389208475506166e-07
in O 0 7.511500399459692e-08
each O 0 3.668320047722773e-08
of O 0 6.141604558251856e-07
the O 0 5.9745209000539035e-05
breast B-Disease 1 0.9999997615814209
cancer I-Disease 1 1.0
- O 1 0.999890923500061
susceptibility O 1 0.9993966817855835
genes O 0 2.3153875190473627e-06
, O 0 1.193393813991861e-06
BRCA1 O 0 7.219868712127209e-05
and O 0 4.4797391751671967e-07
BRCA2 O 0 2.4694300009286962e-05
, O 0 2.2786421993714612e-07
in O 0 4.203704975225264e-07
French O 0 0.0002160853473469615
Canadian O 0 0.46611836552619934
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 1.0
and O 1 0.9998698234558105
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.6832563889911398e-05
from O 0 3.466977796051651e-05
Quebec O 0 0.011214826256036758
. O 0 0.00016561361553613096

To O 0 8.5096344264457e-06
identify O 0 1.0867056516872253e-05
founder O 0 0.0013791832607239485
effects O 0 4.091123628313653e-05
, O 0 1.1159994528497919e-06
we O 0 2.5411898718630255e-07
examined O 0 6.172620032884879e-07
independently O 0 2.1213249112861376e-07
ascertained O 0 5.538830464502098e-06
French O 0 1.537459138489794e-05
Canadian O 0 6.0466314607765526e-05
cancer B-Disease 0 0.009362597018480301
families O 0 9.18434395202894e-08
for O 0 7.014909186864315e-08
the O 0 2.0414478285601945e-07
distribution O 0 1.794458768245022e-07
of O 0 2.2643102681740856e-07
these O 0 1.5354194715655467e-07
eight O 0 1.5802991129021393e-06
mutations O 0 1.2258198694325984e-05
. O 0 2.4239578124252148e-05

Mutations O 0 4.2930085328407586e-05
were O 0 4.460140644368948e-06
found O 0 1.6330679954990046e-06
in O 0 7.169820150920714e-07
41 O 0 3.953668965550605e-06
of O 0 7.713126251474023e-06
97 O 0 9.920739830704406e-05
families O 0 1.333617910859175e-05
. O 0 4.48337486886885e-05

Six O 0 8.146806067088619e-06
of O 0 4.0569489101471845e-06
eight O 0 2.4277783268189523e-06
mutations O 0 1.406958062943886e-06
were O 0 3.720683707797434e-07
observed O 0 8.048461950238561e-07
at O 0 1.9476376564853126e-06
least O 0 3.100705271208426e-06
twice O 0 1.7561111235409044e-05
. O 0 3.511291288305074e-05

The O 0 0.0001650748890824616
BRCA1 O 0 0.023427428677678108
C4446T O 0 0.002307067159563303
mutation O 0 3.298585215816274e-05
was O 0 2.573068741185125e-05
the O 0 1.6752584315327113e-06
most O 0 3.0042585308365233e-07
common O 0 6.073990448385302e-07
mutation O 0 1.1827062280644896e-06
found O 0 2.2659348530851275e-07
, O 0 1.424796209903434e-07
followed O 0 5.243383043307404e-07
by O 0 6.221969215403078e-07
the O 0 7.97655047790613e-06
BRCA2 O 0 0.0004478677292354405
8765delAG O 0 0.0007667943136766553
mutation O 0 0.0001438882463844493
. O 0 4.929385977447964e-05

Together O 0 1.7429119907319546e-05
, O 0 2.958025334010017e-06
these O 0 2.9507233989534143e-07
mutations O 0 7.763891289869207e-07
were O 0 2.1304889230577828e-07
found O 0 1.7548040887049865e-07
in O 0 1.1281152723086052e-07
28 O 0 6.171006816657609e-07
of O 0 9.338622248833417e-07
41 O 0 2.4532751012884546e-06
families O 0 1.6436695204902207e-07
identified O 0 5.4481796496475e-07
to O 0 1.4964267336381454e-07
have O 0 1.8811722668488073e-07
a O 0 3.2738539630372543e-06
mutation O 0 5.0637951062526554e-05
. O 0 3.8792692066635936e-05

The O 0 9.42929182201624e-06
odds O 0 1.3165308700990863e-05
of O 0 2.1487974208866945e-06
detection O 0 6.9371776589832734e-06
of O 0 6.683785045424884e-07
any O 0 2.6549432163847086e-07
of O 0 4.2950944134645397e-07
the O 0 6.79310630857799e-07
four O 0 1.5927085996736423e-06
BRCA1 O 0 9.129711543209851e-05
mutations O 0 4.079793598066317e-06
was O 0 2.3055399651639163e-05
18 O 0 4.260600690031424e-05
. O 0 7.397303124889731e-05

7x O 0 0.003246856853365898
greater O 0 2.664722705958411e-05
if O 0 8.129073307827639e-07
one O 0 3.514666389037302e-07
or O 0 1.8853927485906752e-07
more O 0 7.682755409632591e-08
cases O 0 7.487183779630868e-07
of O 1 0.6715787649154663
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 2.3688942746957764e-05
also O 0 8.823706139082788e-07
present O 0 3.7015720977251476e-07
in O 0 6.232094165170565e-07
the O 0 4.516378339758376e-06
family O 0 2.510664489818737e-05
. O 0 4.7055120376171544e-05

The O 0 1.0944247151201125e-05
odds O 0 9.815051271289121e-06
of O 0 1.481949539083871e-06
detection O 0 3.6773824376723496e-06
of O 0 4.61502651205592e-07
any O 0 1.3106699725540238e-07
of O 0 4.262832078438805e-07
the O 0 8.998680982585938e-07
four O 0 1.5396336721096304e-06
BRCA2 O 0 4.307985363993794e-05
mutations O 0 2.7740263703890378e-06
was O 0 1.9849165255436674e-05
5 O 0 2.051706178463064e-05
. O 0 2.1554043996729888e-05

3x O 0 0.0006358675309456885
greater O 0 1.2573927961057052e-05
if O 0 5.883117069060972e-07
there O 0 2.9094960041220475e-07
were O 0 2.6184923740402155e-07
at O 0 4.4435725499170076e-07
least O 0 1.507194440364401e-07
five O 0 1.1604209504412211e-07
cases O 0 2.590351755316078e-07
of O 0 1.8667209587874822e-05
breast B-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999943971633911
in O 0 1.6949226846918464e-05
the O 0 5.829188012285158e-05
family O 0 0.00012825339217670262
. O 0 8.269295358331874e-05

Interestingly O 0 6.280367961153388e-05
, O 0 1.6869264527485939e-06
the O 0 1.109272147914453e-06
presence O 0 8.236435178332613e-07
of O 0 1.299881660088431e-06
a O 0 8.271409024018794e-05
breast B-Disease 1 0.9999898672103882
cancer I-Disease 1 0.999798595905304
case O 0 6.1555756474263035e-06
< O 0 2.1118201402714476e-05
36 O 0 2.934357610229199e-07
years O 0 1.2283413752811612e-07
of O 0 2.6302055289306736e-07
age O 0 1.049675006470352e-06
was O 0 4.779211394634331e-06
strongly O 0 1.9140354368119006e-07
predictive O 0 9.29349184275452e-08
of O 0 5.159148841471506e-08
the O 0 1.0534582628451972e-07
presence O 0 1.0563073260527744e-07
of O 0 8.492202141496819e-08
any O 0 5.9528407092557245e-08
of O 0 2.882859178043873e-07
the O 0 1.0165186949961935e-06
eight O 0 2.702642859730986e-06
mutations O 0 1.064747448253911e-05
screened O 0 5.6273172958754e-05
. O 0 3.671942977234721e-05

Carriers O 0 2.042086453002412e-05
of O 0 2.5567846932972316e-06
the O 0 1.6730008383092354e-06
same O 0 6.570286359419697e-07
mutation O 0 1.7461144352637348e-06
, O 0 1.5922849172511633e-07
from O 0 7.629761000771396e-08
different O 0 1.2303678964542542e-08
families O 0 4.36280700455427e-08
, O 0 9.923845567527678e-08
shared O 0 3.47825391600054e-07
similar O 0 5.212770020079915e-07
haplotypes O 0 6.108849902375368e-06
, O 0 2.0783873821983434e-07
indicating O 0 4.385433101106173e-07
that O 0 3.8770537003074423e-08
the O 0 2.2645478736649238e-07
mutant O 0 2.306587248313008e-06
alleles O 0 1.5442701339907217e-07
were O 0 5.7159859068178775e-08
likely O 0 7.230176635175667e-08
to O 0 1.6476143116506137e-08
be O 0 1.8090258180336605e-08
identical O 0 6.847862010772587e-08
by O 0 6.900346249949507e-08
descent O 0 1.0302769624104258e-06
for O 0 1.0344508893922466e-07
a O 0 6.794350042582664e-07
mutation O 0 1.0405850616734824e-06
in O 0 2.5803564085435937e-07
the O 0 1.695151240710402e-06
founder O 0 0.00014530618500430137
population O 0 7.163162081269547e-06
. O 0 2.0998530089855194e-05

The O 0 1.2946068636665586e-05
identification O 0 8.678975973452907e-06
of O 0 6.805038538004737e-06
common O 0 2.2370573788066395e-05
BRCA1 O 0 0.0027118187863379717
and O 0 2.9358120627875905e-06
BRCA2 O 0 4.043037915835157e-05
mutations O 0 8.055096714087995e-07
will O 0 1.2527593185041042e-07
facilitate O 0 3.490782205517462e-07
carrier O 0 2.5327801722596632e-06
detection O 0 1.4004788226884557e-06
in O 0 1.909359070850769e-07
French O 0 1.7465741620981134e-05
Canadian O 0 0.0004736962146125734
breast B-Disease 1 0.9999934434890747
cancer I-Disease 1 0.9999997615814209
and O 1 0.9990899562835693
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 0.010867585428059101
. O 0 0.001152531011030078

Are O 0 2.5330522475996986e-05
Dp71 O 0 0.003428443567827344
and O 0 7.453348371200264e-05
Dp140 O 1 0.9969426989555359
brain O 1 0.9978502988815308
dystrophin O 0 0.16096028685569763
isoforms O 0 2.033533382927999e-05
related O 0 4.387919489090564e-06
to O 0 4.210134648019448e-06
cognitive B-Disease 1 0.9341389536857605
impairment I-Disease 1 0.9999994039535522
in O 1 0.999154806137085
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999278783798218

Molecular O 0 6.740635581081733e-05
study O 0 4.097316377738025e-06
and O 0 1.3047676930000307e-06
neuropsychological O 0 1.6863839846337214e-05
analysis O 0 3.3657812537057907e-07
were O 0 2.4077039029180014e-07
performed O 0 5.514373242476722e-07
concurrently O 0 3.8392963119804335e-07
on O 0 3.7134310559849837e-07
49 O 0 4.839560460823122e-06
patients O 0 1.2293107829464134e-05
with O 0 0.4974406361579895
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999877214431763
DMD B-Disease 1 1.0
) O 0 6.48614616238774e-07
in O 0 1.0870292754816546e-07
order O 0 8.528660799811405e-08
to O 0 2.93374107229738e-08
find O 0 5.2634128167028393e-08
a O 0 1.1770077890105313e-07
molecular O 0 5.219246190790727e-07
explanation O 0 1.577916748374264e-07
for O 0 6.92185864181738e-08
the O 0 9.85789029073203e-07
cognitive B-Disease 0 0.0004649752227123827
impairment I-Disease 1 0.9070857167243958
observed O 0 2.7458031581772957e-06
in O 0 4.290159267839044e-06
most O 0 6.45736072328873e-05
DMD B-Disease 1 1.0
patients O 0 0.09447009116411209
. O 0 0.00019360522856004536

Complete O 0 1.2539319868665189e-05
analysis O 0 1.3569986094807973e-06
of O 0 3.0703436095791403e-06
the O 0 5.220867478783475e-06
dystrophin O 0 0.002356941346079111
gene O 0 2.3503157535742503e-06
was O 0 2.7019727895094547e-06
performed O 0 6.273987196436792e-07
to O 0 7.679488334133566e-08
define O 0 1.768620876418936e-07
the O 0 3.683514080421446e-07
localization O 0 8.067311682680156e-06
of O 0 8.488443086207553e-07
deletions O 0 4.250578513165237e-06
and O 0 2.6337045255786506e-07
duplications O 0 5.469928510137834e-06
in O 0 2.5846097173598537e-07
relation O 0 7.348252211158979e-07
to O 0 1.8734807838427514e-07
the O 0 1.9181520656275097e-06
different O 0 3.842058049485786e-06
DMD B-Disease 1 0.9999998807907104
promoters O 0 0.35483983159065247
. O 0 9.572340059094131e-05

Qualitative O 0 2.0373399820527993e-05
analysis O 0 2.722432554946863e-06
of O 0 2.2629080831393367e-06
the O 0 2.4525102162442636e-06
Dp71 O 0 0.00033857181551866233
transcript O 0 9.812692042032722e-06
and O 0 2.1018378504322754e-07
testing O 0 1.8094404197199765e-07
for O 0 4.439988643412107e-08
the O 0 9.357346897331809e-08
specific O 0 5.175035866500366e-08
first O 0 4.5092892264619877e-07
exon O 0 1.2792548659490421e-05
of O 0 1.2266958719919785e-06
Dp140 O 0 4.2721472709672526e-05
were O 0 6.932348810551048e-07
also O 0 4.7185116613945866e-07
carried O 0 1.979568878596183e-06
out O 0 3.4012896321655717e-06
. O 0 2.392118221905548e-05

Neuropsychological O 0 0.0006626834510825574
analysis O 0 1.2080765372957103e-05
assessed O 0 1.3632176887767855e-05
verbal O 0 2.7733552997233346e-05
and O 0 6.439418484660564e-06
visuospatial O 0 0.05253753811120987
intelligence O 0 1.109735694626579e-05
, O 0 2.3967584183992585e-06
verbal O 0 1.814903771446552e-05
memory O 0 0.00463258009403944
, O 0 1.9774515749304555e-06
and O 0 1.3743974704993889e-06
reading O 0 5.0088430725736544e-05
skills O 0 5.349326602299698e-05
. O 0 4.6277109504444525e-05

Comparison O 0 1.9667786546051502e-05
of O 0 7.76012529968284e-06
molecular O 0 1.640240225242451e-05
and O 0 1.2433308711479185e-06
psychometric O 0 4.5259665057528764e-05
findings O 0 1.019152136905177e-06
demonstrated O 0 2.3655099994357442e-06
that O 0 1.7867199630927644e-07
deletions O 0 2.141436880265246e-06
and O 0 3.1090442575987254e-07
duplications O 0 3.837645181192784e-06
that O 0 8.799422346328356e-08
were O 0 1.4772646750316198e-07
localized O 0 1.6262947610812262e-06
in O 0 1.2836166263241466e-07
the O 0 3.4853064789786004e-07
distal O 0 9.838497135206126e-06
part O 0 5.584953441939433e-07
of O 0 6.481336072283739e-07
the O 0 1.4537962442773278e-06
gene O 0 2.699212018342223e-06
seemed O 0 6.483289212155796e-07
to O 0 2.8430454435124375e-08
be O 0 6.352011894250609e-08
preferentially O 0 4.1785639837144117e-07
associated O 0 6.813349386902701e-07
with O 0 3.0222006444091676e-06
cognitive B-Disease 1 0.9670743346214294
impairment I-Disease 1 0.9999958276748657
. O 0 0.0007858710596337914

Two O 0 1.3721573850489222e-05
altered O 0 5.08669727423694e-05
Dp71 O 0 0.00013661467528436333
transcripts O 0 6.237645720830187e-06
and O 0 6.903649705236603e-07
two O 0 4.951144205733726e-07
deleted O 0 4.668991095968522e-06
Dp140 O 0 3.0943192541599274e-05
DNA O 0 1.69834231655841e-06
sequences O 0 1.744705002693081e-07
were O 0 1.0109004477953931e-07
found O 0 1.0733715782862419e-07
in O 0 1.4151382288218883e-07
four O 0 4.3448781639199296e-07
patients O 0 1.5555166100966744e-05
with O 0 0.0007418376626446843
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.9825056791305542

These O 0 2.1249625206110068e-06
findings O 0 1.2744357036353904e-06
suggest O 0 4.448346828667127e-07
that O 0 1.1164449631451134e-07
some O 0 4.3948702455054445e-08
sequences O 0 5.2276750039936815e-08
located O 0 1.7768304871879081e-07
in O 0 7.975738469667704e-08
the O 0 3.599033107093419e-07
distal O 0 6.499733444798039e-06
part O 0 4.798181976184424e-07
of O 0 4.2429667246324243e-07
the O 0 4.4169800617055444e-07
gene O 0 5.648837486660341e-07
and O 0 9.802525369195791e-08
, O 0 9.522776167614211e-08
in O 0 7.785677524907442e-08
particular O 0 2.4157171196748095e-07
, O 0 3.804383084116125e-07
some O 0 3.8618728126493806e-07
DMD B-Disease 1 0.9999769926071167
isoforms O 0 1.2162804523541126e-06
expressed O 0 2.8917420991092513e-07
in O 0 1.429619942427962e-07
the O 0 2.948061364804744e-06
brain O 0 0.0446024127304554
may O 0 1.7447814570914488e-07
be O 0 2.2408556787922862e-08
related O 0 3.990561125988279e-08
to O 0 5.275765602164029e-08
the O 0 1.1986131767116603e-06
cognitive B-Disease 1 0.8824655413627625
impairment I-Disease 1 0.9999902248382568
associated O 0 0.00018625966913532466
with O 0 0.000134516172693111
DMD B-Disease 1 1.0
. O 0 9.260726801585406e-05
. O 0 7.280793943209574e-05

I1307K O 0 0.04549785703420639
APC O 0 0.003908607177436352
and O 0 1.1113169421150815e-05
hMLH1 O 0 0.00019819762383121997
mutations O 0 6.333880719466833e-06
in O 0 1.3378549965636921e-06
a O 0 4.225218162901001e-06
non O 0 8.209495717892423e-06
- O 0 1.8493650713935494e-05
Jewish O 0 6.2995909502205905e-06
family O 0 2.328181153643527e-06
with O 0 4.305693892092677e-06
hereditary B-Disease 1 0.9999991655349731
non I-Disease 1 0.9999983310699463
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9943477511405945

We O 0 1.2559546121337917e-05
describe O 0 1.2437302757462021e-05
a O 0 1.020068066281965e-05
French O 0 8.699846512172371e-05
Canadian O 0 0.0002296890743309632
hereditary B-Disease 1 0.9999816417694092
non I-Disease 1 0.9999700784683228
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9999977350234985
HNPCC B-Disease 1 1.0
) O 0 2.9936194550828077e-05
kindred O 0 0.00035008261329494417
which O 0 4.533980302312557e-07
carries O 0 1.4384727364813443e-06
a O 0 1.7042383433363284e-06
novel O 0 7.059052677504951e-06
truncating O 0 4.308326606405899e-05
mutation O 0 8.275019354186952e-06
in O 0 4.330851879785769e-06
hMLH1 O 0 0.000859720166772604
. O 0 0.00010399205348221585

Interestingly O 0 0.00013069376291241497
, O 0 7.461311270162696e-06
the O 0 7.86547752795741e-06
I1307K O 0 0.0009332902263849974
APC O 0 0.0004411580739542842
polymorphism O 0 1.2278579561098013e-05
, O 0 3.3762938755899086e-07
associated O 0 2.330072987888343e-07
with O 0 5.525982160747844e-08
an O 0 2.325375589862233e-07
increased O 0 2.6897864700003993e-06
risk O 0 1.6438449165434577e-05
of O 1 0.9927869439125061
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.8088062612805516e-05
is O 0 6.552165814355249e-07
also O 0 2.1178480835715163e-07
present O 0 3.421978078677057e-07
in O 0 4.610310782027227e-07
this O 0 1.4953953950680443e-06
family O 0 1.5157280358835123e-05
. O 0 3.8835551094962284e-05

The O 0 2.1359306629165076e-05
I1307K O 0 0.00034638697979971766
polymorphism O 0 5.265503205009736e-05
has O 0 1.4028635177965043e-06
previously O 0 6.321059800029616e-07
only O 0 6.786786599377592e-08
been O 0 9.20340497145844e-08
identified O 0 1.239346687498255e-07
in O 0 6.290343179671254e-08
individuals O 0 5.591952501049491e-08
of O 0 1.4505224044114584e-06
self O 0 0.0001006562088150531
- O 0 0.0018736949423328042
reported O 0 4.881097993347794e-05
Ashkenazi O 0 0.0004915377357974648
Jewish O 0 3.7074107240187004e-05
origins O 0 0.0001633719657547772
. O 0 0.00010628900054143742

In O 0 5.243050964054419e-06
addition O 0 1.7090543451558915e-06
, O 0 5.239429015091446e-07
in O 0 2.2504421792746143e-07
this O 0 2.3052692199598823e-07
family O 0 4.241793476467137e-07
, O 0 1.1191611548611036e-07
there O 0 1.0392606242248803e-07
appears O 0 1.1091879770219748e-07
to O 0 1.2411133454293122e-08
be O 0 1.0775269565499457e-08
no O 0 2.984622327062425e-08
relationship O 0 3.708426277171384e-08
between O 0 7.27613453932463e-08
the O 0 4.327353053668048e-07
I1307K O 0 3.1780844437889755e-05
polymorphism O 0 2.620846089484985e-06
and O 0 1.0828409102714431e-07
the O 0 2.2688951162308513e-07
presence O 0 8.163738698385714e-07
or O 0 2.356707256012669e-07
absence O 0 5.9395529206085484e-06
of O 0 1.954675099113956e-05
cancer B-Disease 1 0.9997028708457947
. O 0 2.492935527698137e-05
. O 0 5.77707432967145e-05

Identification O 0 2.4545071937609464e-05
of O 0 7.547362656623591e-06
a O 0 5.364448043110315e-06
novel O 0 8.202405297197402e-06
mutation O 0 3.3618016459513456e-06
of O 0 1.814705683500506e-06
the O 0 6.743393441865919e-06
CPO O 1 0.618465781211853
gene O 0 2.4588944143033586e-06
in O 0 6.729220558554516e-07
a O 0 7.245393589982996e-06
Japanese O 0 0.0003111048135906458
hereditary B-Disease 1 0.9997690320014954
coproporphyria I-Disease 1 0.9998347759246826
family O 0 0.0005637768772430718
. O 0 0.00017378888151142746

Hereditary B-Disease 1 0.9999469518661499
coproporphyria I-Disease 1 0.9999412298202515
( O 0 0.02170695550739765
HCP B-Disease 1 0.9999896287918091
) O 0 4.299604370316956e-06
is O 0 1.0978397995131672e-06
an O 0 5.036301899963291e-06
autosomal B-Disease 1 0.9998031258583069
dominant I-Disease 1 0.9999957084655762
disease I-Disease 1 0.9999997615814209
characterized O 0 0.3778102695941925
by O 0 6.207085334608564e-06
a O 0 0.059518296271562576
deficiency B-Disease 1 0.9999998807907104
of I-Disease 0 0.011274155229330063
coproporphyrinogen I-Disease 1 0.9999953508377075
oxidase I-Disease 0 0.08335806429386139
( O 0 5.777647402283037e-06
CPO O 1 0.5972168445587158
) O 0 1.8782735367040004e-07
caused O 0 7.279013516381383e-07
by O 0 9.640358911156e-08
a O 0 4.5675020032831526e-07
mutation O 0 7.665921089028416e-07
in O 0 3.063614428810979e-07
the O 0 5.025814061809797e-06
CPO O 1 0.5657779574394226
gene O 0 4.746493141283281e-05
. O 0 2.0444402252906002e-05

Only O 0 5.141082965565147e-06
11 O 0 7.234753411466954e-06
mutations O 0 2.5463089059485355e-06
of O 0 1.681173557699367e-06
the O 0 2.6327052182750776e-06
gene O 0 2.6994641757482896e-06
have O 0 1.502399697983492e-07
been O 0 3.414050695482729e-07
reported O 0 2.5467752493568696e-06
in O 0 1.4094160178501625e-05
HCP B-Disease 1 0.9999758005142212
patients O 0 0.00039456889498978853
. O 0 8.096748206298798e-05

We O 0 6.476098860730417e-06
report O 0 3.3425055789848557e-06
another O 0 4.658192665374372e-06
mutation O 0 7.261434802785516e-06
in O 0 2.026810761890374e-06
a O 0 1.0648825082171243e-05
Japanese O 0 0.0001281563309021294
family O 0 5.242675615590997e-05
. O 0 4.0752478525973856e-05

Polymerase O 0 0.0006296259234659374
chain O 0 0.00010131159069715068
reaction O 0 1.2010483260382898e-05
- O 0 9.815995326789562e-06
single O 0 2.796833996399073e-06
strand O 0 7.540074420830933e-06
conformational O 0 2.4853131890267832e-06
polymorphism O 0 9.313416171607969e-07
and O 0 5.0513396132600974e-08
direct O 0 6.978277156122203e-08
sequence O 0 5.341356512644779e-08
analyses O 0 6.415754683075647e-08
demonstrated O 0 2.8006937213831407e-07
a O 0 2.720372265230253e-07
C O 0 1.7502424043414067e-06
to O 0 1.0214422019316771e-07
T O 0 2.9672389700863278e-06
substitution O 0 4.2061469684995245e-07
in O 0 7.073231955700976e-08
exon O 0 1.7228644537681248e-06
1 O 0 1.1835926017056408e-07
of O 0 1.2965992368663137e-07
the O 0 4.4664042775366397e-07
CPO O 0 3.578405812731944e-05
gene O 0 2.5872606101984275e-07
at O 0 1.8575880744720052e-07
nucleotide O 0 3.871091394103132e-07
position O 0 1.4669936376776604e-07
85 O 0 2.2820087508534925e-07
, O 0 8.17413265963296e-08
which O 0 3.0460729050219015e-08
lies O 0 2.6917086870525964e-07
in O 0 8.017438091201257e-08
the O 0 3.0970471698310575e-07
putative O 0 6.7230130298412405e-06
presequence O 0 1.8374723367742263e-05
for O 0 4.4187666503603396e-07
targeting O 0 3.6781400467589265e-06
to O 0 2.591102884252905e-06
mitochondria O 0 7.76434681029059e-05
. O 0 1.9800030713668093e-05

This O 0 3.922736141248606e-06
mutation O 0 3.0430237529799342e-06
changes O 0 2.9713882554460724e-07
the O 0 3.414597813389264e-07
codon O 0 1.229968802363146e-06
for O 0 1.3524427799893601e-07
glutamine O 0 1.2688861943388474e-06
to O 0 7.656175426973277e-08
a O 0 5.486477334670781e-07
termination O 0 5.589516604231903e-06
codon O 0 3.2326493055734318e-06
at O 0 1.67345717727585e-06
amino O 0 3.0436042379733408e-06
acid O 0 5.606472313957056e-06
position O 0 4.797779638465727e-06
29 O 0 5.2624018280766904e-05
. O 0 5.027203951613046e-05

MaeI O 0 0.0015380020486190915
restriction O 0 5.008489461033605e-05
analysis O 0 4.642914063879289e-06
showed O 0 5.050374966231175e-06
two O 0 2.3876094701336115e-07
other O 0 2.6457934154677787e-07
carriers O 0 2.431712800898822e-06
in O 0 7.561898200947326e-07
the O 0 6.178872354212217e-06
family O 0 2.4416107407887466e-05
. O 0 4.642987551051192e-05

The O 0 4.774120316142216e-05
C O 0 0.008471201173961163
- O 0 0.008268965408205986
T O 0 0.004533290397375822
mutation O 0 1.7476020275353221e-06
is O 0 1.0509877057529593e-07
located O 0 1.5534962471974723e-07
within O 0 6.509098682272452e-08
a O 0 2.0947518919456343e-07
recently O 0 3.148186920043372e-07
proposed O 0 3.0741387035959633e-07
putative O 0 1.4394279332918813e-06
alternative O 0 2.753210992523236e-07
translation O 0 7.651532314412179e-07
initiation O 0 1.9616145436884835e-06
codon O 0 1.9692615751409903e-06
( O 0 2.771139122614841e-07
TIC O 0 2.5367919079144485e-05
- O 0 7.994416364454082e-07
1 O 0 3.781792656809557e-07
) O 0 4.45707684093577e-08
, O 0 3.0682659968306325e-08
supporting O 0 8.084034419653108e-08
that O 0 5.216569221033751e-08
TIC O 0 6.437771662604064e-05
- O 0 1.9826918560283957e-06
1 O 0 8.682600309839472e-07
is O 0 1.0584349752207345e-07
the O 0 3.534309200858843e-07
real O 0 3.2836717309692176e-06
TIC O 0 0.0806434154510498
rather O 0 5.496181074704509e-07
than O 0 6.585196956621076e-07
TIC O 0 0.24694156646728516
- O 0 2.70305790763814e-05
2 O 0 8.308857104566414e-06
. O 0 4.853264272242086e-06
. O 0 1.8343733245274052e-05

Human B-Disease 0 0.00010952571028610691
complement I-Disease 0 0.0003010606160387397
factor I-Disease 0 0.19392865896224976
H I-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 1 0.9960734844207764
with O 1 0.9999926090240479
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999932050704956

This O 0 2.8614690563699696e-06
study O 0 8.68909467044432e-07
reports O 0 3.324668966797617e-07
on O 0 1.583547089012427e-07
six O 0 1.520638761576265e-07
cases O 0 1.126552078289933e-07
of O 0 6.663039584964281e-06
deficiency B-Disease 1 0.9999852180480957
in I-Disease 0 1.1366481658114935e-06
the I-Disease 0 8.335288157468312e-07
human I-Disease 0 3.970540944919776e-07
complement I-Disease 0 1.1292383987893118e-06
regulatory I-Disease 0 1.8479332766219159e-06
protein I-Disease 0 1.3964616982775624e-06
Factor I-Disease 0 2.2015574359102175e-06
H I-Disease 1 0.8633164763450623
( O 0 1.6781941667431965e-06
FH O 0 0.011750933714210987
) O 0 8.52371613291325e-08
in O 0 4.325801228333148e-08
the O 0 9.855524041313402e-08
context O 0 1.900390458331458e-07
of O 0 2.1262555947032524e-06
an O 0 0.011458433233201504
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.9372086524963379

Five O 0 5.310269443725701e-06
of O 0 3.0486355626635486e-06
the O 0 1.4344642522701179e-06
cases O 0 3.7237967376313463e-07
were O 0 2.676996473383042e-07
observed O 0 2.920944837114803e-07
in O 0 2.614420111513027e-07
children O 0 6.303974942056811e-07
presenting O 0 2.5231720428564586e-05
with O 1 0.9750890135765076
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 1 0.704340398311615
. O 0 0.0006221486837603152

Two O 0 2.8648685201915214e-06
of O 0 3.7780289403599454e-06
the O 0 2.771910885712714e-06
children O 0 8.318889399561158e-07
exhibited O 0 2.194595435867086e-05
a O 0 9.447179763810709e-05
homozygous O 1 0.9222360849380493
deficiency O 1 0.9999998807907104
characterized O 0 0.0004926263936795294
by O 0 4.1291818320132734e-07
the O 0 6.419231226573174e-07
absence O 0 1.4813376765232533e-06
of O 0 4.646744571346062e-07
the O 0 6.069520281926089e-07
150 O 0 7.494012379538617e-07
- O 0 4.046824869874399e-06
kD O 0 4.0097482269629836e-05
form O 0 4.787125362781808e-07
of O 0 4.6317106239257555e-07
Factor O 0 2.2359174636221724e-06
H O 0 0.0013000129256397486
and O 0 9.566797132265492e-08
the O 0 1.6064485919287108e-07
presence O 0 2.043091740233649e-07
, O 0 7.609515506601383e-08
upon O 0 1.4515738655518362e-07
immunoblotting O 0 2.2004344373272033e-06
, O 0 7.608906571476837e-08
of O 0 9.185482241491627e-08
the O 0 2.3815354666112398e-07
42 O 0 8.054620366237941e-07
- O 0 3.955765805585543e-06
kD O 0 7.726383046247065e-05
Factor O 0 2.646010216267314e-06
H O 0 5.043727651354857e-05
- O 0 7.27475935491384e-07
like O 0 1.5150902754612616e-07
protein O 0 1.710585735281711e-07
1 O 0 3.910251109573437e-07
( O 0 3.592685686726327e-07
FHL O 0 3.788885078392923e-05
- O 0 7.210001058410853e-07
1 O 0 5.546239094655903e-07
) O 0 9.777185994153115e-08
and O 0 1.0320938770291832e-07
other O 0 2.0505639497514494e-07
FH O 0 0.008919330313801765
- O 0 1.2282139323360752e-05
related O 0 3.129408014501678e-06
protein O 0 6.2141812122717965e-06
( O 0 3.3375395105395e-06
FHR O 0 0.05105412378907204
) O 0 5.762811724707717e-06
bands O 0 7.10448730387725e-05
. O 0 3.728254159796052e-05

Southern O 0 0.00013901593047194183
blot O 0 0.00011541815183591098
and O 0 1.4942122561478755e-06
PCR O 0 3.914294666174101e-06
analysis O 0 1.9575165310925513e-07
of O 0 2.7466387564345496e-07
DNA O 0 8.600420073889836e-07
of O 0 2.6834172217604646e-07
one O 0 2.9504815302061616e-07
patient O 0 2.3400677946483484e-06
with O 0 2.1415919491118984e-06
homozygous O 1 0.8373918533325195
deficiency O 1 0.9999998807907104
ruled O 0 1.4231291061150841e-05
out O 0 1.0720457055413135e-07
the O 0 1.0112206183521266e-07
presence O 0 1.7018851394823287e-07
of O 0 2.134706988954349e-07
a O 0 4.181677297765418e-07
large O 0 4.322659208355617e-07
deletion O 0 1.628008021725691e-06
of O 0 9.439786481379997e-07
the O 0 5.458453415485565e-06
FH O 1 0.9989050626754761
gene O 0 2.4098226276692003e-06
as O 0 3.354082593887142e-07
the O 0 1.5505108876823215e-06
underlying O 0 0.0716390311717987
defect O 0 0.1906612366437912
for O 0 3.732792720256839e-06
the O 0 0.001709494972601533
deficiency O 1 1.0
. O 0 0.000729374005459249

The O 0 1.1205682312720455e-05
other O 0 5.882168920834374e-07
four O 0 6.766635465282889e-07
children O 0 6.578280249414092e-07
presented O 0 2.491502300472348e-06
with O 0 6.256771030166419e-06
heterozygous O 0 0.11759539693593979
deficiency O 1 0.9999997615814209
and O 0 5.647826128551969e-06
exhibited O 0 6.507624493679032e-05
a O 0 5.3213516366668046e-06
normal O 0 3.263678763687494e-06
immunoblotting O 0 6.196912727318704e-05
pattern O 0 2.384654180787038e-06
of O 0 6.213436449797882e-07
proteins O 0 3.057511150927894e-07
of O 0 1.719281272016815e-06
the O 0 3.011279841302894e-05
FH O 1 0.9999240636825562
family O 0 6.755228969268501e-05
. O 0 7.369268132606521e-05

Factor B-Disease 1 0.7715392708778381
H I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.999997615814209
is O 0 3.0381813758140197e-06
the O 0 2.45075648308557e-06
only O 0 4.243259809300071e-06
complement B-Disease 1 0.9999017715454102
deficiency I-Disease 1 1.0
associated O 0 0.003828351618722081
with O 0 0.000897379475645721
HUS B-Disease 1 1.0
. O 0 0.005556426476687193

These O 0 1.4339938161356258e-06
observations O 0 1.730617100292875e-06
suggest O 0 6.76638990171341e-07
a O 0 7.605901259921666e-07
role O 0 1.2442786783140036e-06
for O 0 1.5931992720652488e-06
FH O 1 0.9996910095214844
and O 0 8.365873327420559e-06
/ O 0 0.24628272652626038
or O 0 8.246170182246715e-06
FH O 1 0.964808464050293
receptors O 0 2.2781844108976657e-06
in O 0 2.590811334357568e-07
the O 0 1.891831402645039e-06
pathogenesis O 1 0.9998230338096619
of O 0 0.3941918909549713
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 0.00039318104973062873
. O 0 0.0001291525986744091

Further O 0 9.089892046176828e-06
evidence O 0 2.784533080557594e-06
for O 0 7.629723199897853e-07
a O 0 4.985931809642352e-06
major O 0 2.422469697194174e-05
ancient O 0 0.00016470869013573974
mutation O 1 0.5716639161109924
underlying O 1 0.9999994039535522
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 0.0008374984608963132
linkage O 1 0.9409344792366028
disequilibrium O 1 0.5770812034606934
studies O 0 1.2600278296304168e-06
in O 0 5.111746190777922e-07
the O 0 1.2295876103962655e-06
Japanese O 0 2.0183266315143555e-05
population O 0 3.45122316502966e-06
. O 0 2.022337866947055e-05

The O 1 0.9046777486801147
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9987534284591675
DM B-Disease 1 1.0
) O 0 6.328301424218807e-06
mutation O 0 3.6179540074954275e-06
is O 0 4.989757940165873e-07
an O 0 5.357119903237617e-07
unstable O 0 1.5782306945766322e-05
( O 0 9.073168030226952e-07
CTG O 0 0.00015492222155444324
) O 0 1.0443813636129562e-07
n O 0 2.606339535304869e-07
repeat O 0 2.2312218561637565e-07
, O 0 3.55175018285081e-08
present O 0 2.3016220040972257e-08
at O 0 4.49060379992261e-08
a O 0 8.390384209633339e-08
copy O 0 1.3708719848182227e-07
number O 0 2.1387982940268557e-08
of O 0 6.743444203038962e-08
5 O 0 3.0080371971052955e-07
- O 0 5.763178592133045e-07
37 O 0 3.423159853355173e-07
repeats O 0 2.484549668224645e-07
on O 0 1.0724384225113681e-07
normal O 0 2.0701777714293712e-07
chromosomes O 0 1.682968928662376e-07
but O 0 7.16192047889308e-08
amplified O 0 6.417835720640142e-07
to O 0 9.233876596681512e-08
50 O 0 3.955947818212735e-07
- O 0 3.3472040286142146e-06
3000 O 0 5.795344804937486e-06
copies O 0 3.0620624329458224e-06
on O 0 8.21496269054478e-06
DM B-Disease 1 0.9999693632125854
chromosomes O 0 5.178246647119522e-05
. O 0 2.3576527382829227e-05

Previous O 0 2.1440204363898374e-05
findings O 0 4.491573236009572e-06
in O 0 2.449188741593389e-06
Caucasian O 0 3.0558774597011507e-05
populations O 0 1.6491537735419115e-06
of O 0 6.583127742487704e-06
a O 0 0.10587757080793381
DM B-Disease 1 1.0
founder O 1 0.9918820261955261
chromosome O 0 1.9755743778659962e-05
raise O 0 5.023821358918212e-07
a O 0 3.028912658464833e-07
question O 0 1.165559453397691e-07
about O 0 4.687764842969955e-08
the O 0 1.0297264196879041e-07
molecular O 0 4.633106698292977e-07
events O 0 1.0456410137749117e-07
involved O 0 2.5418685822842235e-07
in O 0 2.094132725005693e-07
the O 0 1.4479475112239015e-06
expansion O 0 4.4616652303375304e-05
mutation O 0 5.923920980421826e-05
. O 0 2.8722175557049923e-05

To O 0 3.5870000374416122e-06
investigate O 0 2.9028074095549528e-06
whether O 0 9.277796948481409e-07
a O 0 2.5468018520768965e-06
founder O 0 6.142339407233521e-05
chromosome O 0 5.382199105952168e-06
for O 0 4.560872639558511e-07
the O 0 1.407222771376837e-05
DM B-Disease 1 1.0
mutation O 0 6.831359769421397e-06
exists O 0 4.092678409506334e-07
in O 0 5.950967363332893e-08
the O 0 1.8283232350313483e-07
Japanese O 0 1.385441237289342e-06
population O 0 1.6033354199862515e-07
, O 0 1.9532424744284071e-07
we O 0 1.2209054034428846e-07
genotyped O 0 6.0611023400269914e-06
families O 0 7.939765822584377e-08
using O 0 9.524175936803658e-08
polymorphic O 0 1.3492906418832717e-06
markers O 0 6.010237711961963e-07
near O 0 6.781972956559912e-07
the O 0 4.519087042353931e-07
( O 0 1.0968341257466818e-06
CTG O 0 0.0001483756786910817
) O 0 2.9564921533165034e-07
n O 0 1.5495353409278323e-06
repeat O 0 2.604118435556302e-06
region O 0 2.448831310175592e-06
and O 0 1.6736726138333324e-06
constructed O 0 8.228424849221483e-05
haplotypes O 0 0.0003060682793147862
. O 0 3.8443053199443966e-05

Six O 0 1.5171669474511873e-05
different O 0 1.7978005644181394e-06
haplotypes O 0 4.1064340621232986e-05
were O 0 2.4041710275923833e-06
found O 0 3.932842901122058e-06
and O 0 1.2777612028003205e-05
DM B-Disease 1 0.9999998807907104
alleles O 0 2.0642724848585203e-05
were O 0 7.155712864914676e-06
always O 0 1.1236266800551675e-05
haplotype O 0 0.00025090531562455
A O 0 0.0001912745792651549
. O 0 9.066949132829905e-05

To O 0 2.185651965191937e-06
find O 0 6.837915975665965e-07
an O 0 2.1421260498755146e-07
origin O 0 4.1661223804112524e-07
of O 0 4.3673861682691495e-07
the O 0 7.138980322451971e-07
( O 0 8.323127076437231e-07
CTG O 0 0.0001701035216683522
) O 0 1.2714332342511625e-07
n O 0 2.7958475357081625e-07
repeat O 0 5.530947646548157e-07
mutation O 0 2.488875168182858e-07
and O 0 2.459498205098498e-08
to O 0 1.838376029184019e-08
investigate O 0 2.772333296263696e-08
the O 0 3.5705511436390225e-08
mechanism O 0 9.811709844598226e-08
of O 0 8.734758694117772e-08
the O 0 9.624668706464945e-08
expansion O 0 6.874367954878835e-07
mutation O 0 1.881312101659205e-07
in O 0 3.168635132055897e-08
the O 0 7.875770080545408e-08
Japanese O 0 5.390666615312512e-07
population O 0 3.723480190842565e-08
we O 0 2.179709568395083e-08
have O 0 2.4287771793751745e-08
studied O 0 5.457540623865498e-07
90 O 0 2.669503828656161e-06
Japanese O 0 7.451805868186057e-05
DM B-Disease 1 0.9999744892120361
families O 0 1.1538586477399804e-06
comprising O 0 4.900493877357803e-06
190 O 0 6.012066023686202e-06
affected O 0 1.7966864334084676e-06
and O 0 1.4811624851063243e-06
130 O 0 2.0004899852210656e-05
unaffected O 0 7.361737516475841e-05
members O 0 9.368475730298087e-06
. O 0 4.839222674490884e-05

The O 0 1.2299652553338092e-05
results O 0 2.799999265334918e-06
suggest O 0 1.691840452622273e-06
that O 0 2.5107891588049824e-07
a O 0 1.0085756230182596e-06
few O 0 4.291761399599636e-07
common O 0 6.056891379557783e-07
ancestral O 0 5.596717983280541e-06
mutations O 0 3.43624975585044e-07
in O 0 1.2477848088110477e-07
both O 0 1.5323796276334178e-07
Caucasian O 0 1.3763067727268208e-05
and O 0 4.6209632387217425e-07
Japanese O 0 3.5071702768618707e-06
populations O 0 2.2086959461375955e-07
have O 0 2.4694541522762847e-08
originated O 0 9.079715113102793e-08
by O 0 3.8754123465878365e-08
expansion O 0 4.845000489694939e-07
of O 0 1.487993586124503e-07
an O 0 1.3177312041534606e-07
ancestral O 0 1.2482328202167992e-06
n O 0 3.260923904235824e-07
= O 0 2.075451845939824e-07
5 O 0 9.863310168611861e-08
repeat O 0 2.1168423813833215e-07
to O 0 5.793930313302553e-08
n O 0 5.713935706808115e-07
= O 0 7.143843276935513e-07
19 O 0 1.0316859970771475e-06
- O 0 6.867547199362889e-06
37 O 0 7.252950126712676e-06
copies O 0 1.2696083103946876e-05
. O 0 2.1837893655174412e-05

These O 0 1.385774112350191e-06
data O 0 8.473157322441693e-07
support O 0 9.56063786361483e-07
multistep O 0 5.499775397765916e-06
models O 0 5.159168949830928e-07
of O 0 1.668459844950121e-06
triplet O 0 0.00010087413102155551
repeat O 0 4.679645371652441e-06
expansion O 0 2.828325932568987e-06
that O 0 8.614343727231244e-08
have O 0 2.0501486730495344e-08
been O 0 3.831672756859916e-08
proposed O 0 9.185271920841842e-08
for O 0 1.4530724001815543e-07
both O 0 2.166981175832916e-06
DM B-Disease 1 0.9999998807907104
and O 0 7.042430661385879e-05
Friedreichs B-Disease 1 0.9998528957366943
ataxia I-Disease 1 0.9999744892120361
. O 0 6.212521839188412e-05
. O 0 0.00010227088205283508

The O 0 7.966181328811217e-06
molecular O 0 7.997848115337547e-06
basis O 0 4.006709787063301e-06
of O 0 0.02393832616508007
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.674007868743502e-06
the O 0 2.512504579499364e-06
western O 0 1.003673423838336e-05
Cape O 0 3.4401557059027255e-05
, O 0 1.2483685623010388e-06
South O 0 6.034387297404464e-06
Africa O 0 1.6948515622061677e-05
. O 0 2.061150735244155e-05

Deficiency B-Disease 1 0.9995135068893433
of I-Disease 0 1.3971350199426524e-05
the I-Disease 0 6.9179518504824955e-06
sixth I-Disease 0 8.564627205487341e-05
component I-Disease 0 1.0875724910874851e-05
of I-Disease 0 1.226493509420834e-06
human I-Disease 0 1.4406692798729637e-06
complement I-Disease 0 5.008139396522893e-06
( O 0 2.563945827205316e-06
C6 O 1 0.9928887486457825
) O 0 1.4765210210043733e-07
has O 0 5.865123853254772e-08
been O 0 3.911488732910584e-08
reported O 0 4.060762393010009e-08
in O 0 2.6591033375211737e-08
a O 0 6.540933839005447e-08
number O 0 3.9438514676248815e-08
of O 0 1.5603382053086534e-07
families O 0 5.476111653024418e-08
from O 0 1.4214710120086238e-07
the O 0 6.478604177573288e-07
western O 0 6.218976977834245e-06
Cape O 0 3.649757127277553e-05
, O 0 1.7901666069519706e-06
South O 0 1.4452723007707391e-05
Africa O 0 2.4816637960611843e-05
. O 0 3.341287811053917e-05

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.999997615814209
is O 0 1.7365924577461556e-05
endemic O 0 2.3007998606772162e-05
in O 0 3.7731683732999954e-07
the O 0 9.284541420129244e-07
Cape O 0 7.292963800864527e-06
and O 0 7.722318429159714e-08
almost O 0 1.1292767254644787e-07
all O 0 4.2828151691765015e-08
pedigrees O 0 1.942040171343251e-06
of O 0 3.1717875117465155e-06
total O 1 0.9559857845306396
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 0.0015035198302939534
C6Q0 O 1 0.9999145269393921
) O 0 5.170053896108584e-07
have O 0 7.806122681586203e-08
been O 0 1.876570792092025e-07
ascertained O 0 2.1475354969879845e-06
because O 0 5.665783646691125e-07
of O 0 1.9540639186743647e-05
recurrent O 1 0.9999997615814209
disease O 1 0.9999998807907104
. O 0 0.00195870827883482

We O 0 6.45186673864373e-06
have O 0 9.297406791120011e-07
sequenced O 0 4.2675687836890575e-06
the O 0 8.918849516703631e-07
expressed O 0 1.6337471606675535e-06
exons O 0 4.676370735978708e-06
of O 0 1.0487494819244603e-06
the O 0 7.3182754931622185e-06
C6 O 1 0.9998138546943665
gene O 0 1.4923735989214038e-06
from O 0 9.170970116656463e-08
selected O 0 1.1182052617186855e-07
cases O 0 3.640765910972732e-08
and O 0 3.621277144816304e-08
have O 0 2.06396340018955e-08
found O 0 5.8386266488241745e-08
three O 0 6.906508787096755e-08
molecular O 0 1.466302273911424e-05
defects O 0 0.001164040295407176
leading O 0 1.9669528228405397e-06
to O 0 1.7935691687398503e-07
total O 0 5.305812737788074e-05
deficiency O 1 1.0
879delG O 1 0.8234851956367493
, O 0 4.098900490134838e-07
which O 0 6.501629457034142e-08
is O 0 6.507075056561007e-08
the O 0 1.8732913531493978e-07
common O 0 9.573000170348678e-07
defect O 0 6.381782441167161e-05
in O 0 1.9324649258578575e-07
the O 0 8.709121175343171e-07
Cape O 0 1.4389253919944167e-05
and O 0 3.5742689874496136e-07
hitherto O 0 5.893055913475109e-06
unreported O 0 1.1358744131939602e-06
, O 0 1.7071846514227218e-07
and O 0 1.6400430524754483e-07
1195delC O 0 1.829957909649238e-05
and O 0 6.700531685055466e-07
1936delG O 0 4.159161835559644e-05
, O 0 2.760119741651579e-07
which O 0 4.457026037130163e-08
have O 0 1.699759621942576e-08
been O 0 4.814554799281723e-08
previously O 0 2.2796682230818988e-07
reported O 0 3.1461308935831767e-07
in O 0 3.9589630773662066e-07
African O 0 1.0520438991079573e-05
- O 0 0.00011026911670342088
Americans O 0 2.7328162104822695e-05
. O 0 4.8524951125727966e-05

We O 0 4.571084446070017e-06
also O 0 7.274426252479316e-07
show O 0 4.1637986214482225e-07
that O 0 1.1548810618933203e-07
the O 0 8.048269819482812e-07
879delG O 0 7.480276690330356e-05
and O 0 4.405450454214588e-06
1195delC O 0 0.3929349184036255
defects O 0 0.3254268169403076
are O 0 1.9114962412913883e-07
associated O 0 1.343944404652575e-06
with O 0 2.9548166367021622e-06
characteristic O 1 0.9998834133148193
C6 O 1 1.0
/ O 1 0.9999990463256836
C7 O 1 0.9999986886978149
region O 0 2.6990628612111323e-05
DNA O 0 1.4886288226989564e-05
marker O 0 2.8760850909748115e-05
haplotypes O 0 1.192280433315318e-05
, O 0 3.2303705665981397e-07
although O 0 3.809829252077179e-07
small O 0 5.129957116878359e-07
variations O 0 1.0691477427826612e-06
were O 0 1.2130451523262309e-06
observed O 0 6.309247055469314e-06
. O 0 1.4326556083688047e-05

The O 0 8.835623157210648e-05
1936delG O 0 0.1046525165438652
defect O 0 0.16391615569591522
was O 0 2.26812426262768e-05
observed O 0 1.024695507112483e-06
only O 0 1.2730299658869626e-07
once O 0 2.622201122903789e-07
in O 0 9.178582160984661e-08
the O 0 3.5406515053182375e-07
Cape O 0 5.488138413056731e-06
, O 0 1.3238931728665193e-07
but O 0 4.236997952489219e-08
its O 0 1.0269608452517787e-07
associated O 0 1.3385759984885226e-06
haplotype O 0 1.9237255401094444e-05
could O 0 8.780927487350709e-07
be O 0 9.420145374861022e-07
deduced O 0 2.6733821869129315e-05
. O 0 2.161033626180142e-05

The O 0 7.231111339933705e-06
data O 0 1.2778652944689384e-06
from O 0 5.8832404192799e-07
the O 0 7.276494216057472e-07
haplotypes O 0 4.21242384618381e-06
indicate O 0 2.5078503540498787e-07
that O 0 4.02164452850684e-08
these O 0 1.780211889013117e-08
three O 0 8.178515287227128e-08
molecular O 0 1.6026939192670397e-05
defects O 0 0.0001351830142084509
account O 0 1.2701741525233956e-07
for O 0 1.6650695044972963e-07
the O 0 1.5038619949336862e-06
defects O 0 0.006470581516623497
in O 0 2.3130780846258858e-07
all O 0 7.584895911350031e-08
the O 0 4.7380228807014646e-07
38 O 0 4.938665369991213e-06
unrelated O 0 1.519437319075223e-05
C6Q0 O 0 0.06162784993648529
individuals O 0 8.026420061924e-08
we O 0 8.547437602146601e-08
have O 0 7.498731946498083e-08
studied O 0 9.100361921809963e-07
from O 0 8.168240128725301e-07
the O 0 9.47250100580277e-06
Cape O 0 0.00038935421616770327
. O 0 4.403611455927603e-05

We O 0 2.8136962555436185e-06
have O 0 3.013009859387239e-07
also O 0 2.0772617403963523e-07
observed O 0 3.1748214723847923e-07
the O 0 7.096636522874178e-07
879delG O 0 6.314321217359975e-05
defect O 0 6.65864790789783e-05
in O 0 5.841243932991347e-07
two O 0 1.1556384151845123e-06
Dutch O 1 0.9991934895515442
C6 B-Disease 1 1.0
- I-Disease 1 0.9999642372131348
deficient I-Disease 1 0.9999814033508301
kindreds O 0 0.000546227500308305
, O 0 3.2584463838247757e-07
but O 0 1.1609124328515463e-07
the O 0 4.361101844096993e-07
879delG O 0 7.670004561077803e-05
defect O 0 8.358151535503566e-05
in O 0 3.5742621662393503e-07
the O 0 1.1084864581789589e-06
Cape O 0 2.9948700102977455e-05
probably O 0 8.610020927335427e-07
did O 0 8.086101388471434e-08
not O 0 2.1179122455805555e-08
come O 0 2.2231075647027865e-08
from O 0 6.001325658644419e-08
The O 0 6.361384521369473e-07
Netherlands O 0 1.6327567209373228e-05
. O 0 6.382668289006688e-06
. O 0 2.733514702413231e-05

Complement B-Disease 1 0.9998283386230469
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.6217712982324883e-05
seven O 0 4.486315901885973e-06
further O 0 8.87364694790449e-06
molecular O 0 0.0005836176569573581
defects O 0 0.1758149266242981
and O 0 1.5778985016368097e-06
their O 0 1.5038505125630763e-06
associated O 0 3.4579861676320434e-05
marker O 0 0.0026172043289989233
haplotypes O 0 0.001284728990867734
. O 0 9.830288036027923e-05

Seven O 0 1.396931111230515e-05
further O 0 8.460321623715572e-06
molecular O 0 3.0634782888228074e-05
bases O 0 3.0093051464064047e-05
of O 0 0.4303155839443207
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.3695741472474765e-05
described O 0 0.00016936971223913133
. O 0 7.624565478181466e-05

All O 0 2.0403163034643512e-06
these O 0 4.939165023643e-07
new O 0 2.2194080884219147e-06
molecular O 0 3.227354682167061e-05
defects O 0 0.00017518225649837404
involve O 0 9.641017868489143e-07
single O 0 1.4905857597113936e-06
- O 0 4.538836037681904e-06
nucleotide O 0 2.402138306933921e-06
events O 0 2.3207496724353405e-07
, O 0 2.343171274787892e-07
deletions O 0 1.3483246448231512e-06
and O 0 7.705061477736308e-08
substitutions O 0 3.7916262840553827e-07
, O 0 6.436824406819142e-08
some O 0 2.908174678850628e-08
of O 0 1.4479611820661376e-07
which O 0 2.4511066953891714e-07
alter O 0 1.231356122843863e-06
splice O 0 2.790508915495593e-06
sites O 0 2.967746581816755e-07
, O 0 2.7554250436878647e-07
and O 0 5.933309239480877e-07
others O 0 2.987276047861087e-06
codons O 0 3.889344588969834e-05
. O 0 1.9842675101244822e-05

They O 0 2.217616383859422e-06
are O 0 1.3727976977406797e-07
distributed O 0 2.4986141511362803e-07
along O 0 3.9634585391468136e-07
the O 0 2.924600948972511e-06
C7 O 1 0.9976894855499268
gene O 0 1.3759764669885044e-06
, O 0 1.7599121804323659e-07
but O 0 5.8304358674377e-08
predominantly O 0 1.0020086449458177e-07
towards O 0 1.2591469555900403e-07
the O 0 3.392739245100529e-07
3 O 0 2.4123060029523913e-06
end O 0 1.2030212019453757e-05
. O 0 1.808047090889886e-05

All O 0 4.113207069167402e-06
were O 0 4.91271657665493e-06
found O 0 3.0587993933295365e-06
in O 0 3.2419209219369804e-06
compound O 0 8.641916792839766e-05
heterozygous O 0 2.2798540157964453e-05
individuals O 0 4.575703769660322e-06
. O 0 3.7480534956557676e-05

The O 0 0.0017969983164221048
C6 O 1 0.9999992847442627
/ O 1 0.9999836683273315
C7 O 1 0.9999955892562866
marker O 0 0.004670290742069483
haplotypes O 0 0.00012177471217000857
associated O 0 4.820196409127675e-06
with O 0 3.55832526111044e-06
most O 0 0.00031575100729241967
C7 B-Disease 1 1.0
defects I-Disease 1 0.9994779229164124
are O 0 1.248853209290246e-06
tabulated O 0 9.417779438081197e-06
. O 0 4.866913968726294e-06
. O 0 2.710239277803339e-05

A O 0 0.00020768890681210905
genome O 0 3.63463768735528e-05
- O 0 1.1938712304981891e-05
wide O 0 2.733473593252711e-06
search O 0 6.987386313994648e-07
for O 0 3.7152022969166865e-07
chromosomal O 0 3.7948411772958934e-05
loci O 0 1.4670771633973345e-05
linked O 0 9.420015885552857e-06
to O 0 2.076731789202313e-06
mental O 1 0.9999699592590332
health O 0 0.0048096454702317715
wellness O 0 0.07083256542682648
in O 0 1.206399929287727e-06
relatives O 0 1.1044133998439065e-06
at O 0 1.0405751709186006e-06
high O 0 1.2410312592692208e-05
risk O 0 2.8501735869213007e-05
for O 0 0.001496163080446422
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.00014719311730004847
the O 0 0.0001299435825785622
Old O 0 0.010781118646264076
Order O 0 3.151945929857902e-05
Amish O 0 0.00046297433436848223
. O 0 5.129251439939253e-05

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9999779462814331
BPAD B-Disease 1 1.0
; O 1 0.999975323677063
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 7.176863437052816e-05
is O 0 1.8936382275569486e-06
characterized O 0 3.5743139505939325e-06
by O 0 4.1520613081047486e-07
episodes O 0 2.7528458304004744e-06
of O 0 3.5786240914603695e-05
mania B-Disease 1 0.9999964237213135
and O 0 9.816452802624553e-05
/ O 1 0.9930516481399536
or O 0 1.5858118786127307e-05
hypomania B-Disease 1 0.9991087317466736
interspersed O 0 1.4620908586948644e-05
with O 0 7.867307090236864e-07
periods O 0 1.4881150491419248e-05
of O 0 0.0001276656548725441
depression B-Disease 1 0.9999819993972778
. O 0 0.0003219668287783861

Compelling O 0 5.2898325520800427e-05
evidence O 0 6.971850780246314e-06
supports O 0 4.536789219855564e-06
a O 0 1.9772028281295206e-06
significant O 0 1.513138045083906e-06
genetic O 0 4.379943220556015e-06
component O 0 4.611054464476183e-06
in O 0 6.573990276592667e-07
the O 0 2.765415501926327e-06
susceptibility O 0 0.00027991057140752673
to O 0 2.2818310299044242e-06
develop O 0 3.739995008800179e-05
BPAD B-Disease 1 0.9999812841415405
. O 0 0.0001560589880682528

To O 0 2.606096131785307e-06
date O 0 4.527180863078684e-06
, O 0 1.0590160854917485e-06
however O 0 8.264997859441792e-07
, O 0 3.9097812987165526e-07
linkage O 0 4.439846634340938e-06
studies O 0 3.6778345702259685e-07
have O 0 7.3689413682132e-08
attempted O 0 1.0867510127354763e-06
only O 0 5.100745070762969e-08
to O 0 6.292754761716424e-08
identify O 0 2.385285995387676e-07
chromosomal O 0 1.1548083421075717e-05
loci O 0 2.231026883237064e-06
that O 0 2.982093292303034e-07
cause O 0 5.34903529114672e-06
or O 0 2.5082474053306214e-07
increase O 0 4.618302398284868e-07
the O 0 1.1205393093405291e-06
risk O 0 4.0827594602887984e-06
of O 0 1.3196444342611358e-05
developing O 0 0.00031704179127700627
BPAD B-Disease 1 0.9999983310699463
. O 0 0.000385237333830446

To O 0 1.5931765346977045e-06
determine O 0 5.471464987749641e-07
whether O 0 2.7970048677161685e-07
there O 0 3.255026967963204e-07
could O 0 1.551319854797839e-07
be O 0 1.59050472348099e-07
protective O 0 6.112696610216517e-06
alleles O 0 2.463165174049209e-07
that O 0 6.455328360743806e-08
prevent O 0 3.7812301911799295e-07
or O 0 9.912457699101651e-08
reduce O 0 3.0200607170627336e-07
the O 0 3.184992749538651e-07
risk O 0 5.047188551543513e-07
of O 0 1.4546797046932625e-06
developing O 0 3.3697611797833815e-05
BPAD B-Disease 1 0.9999983310699463
, O 0 4.7415124981853296e-07
similar O 0 8.51364276854838e-08
to O 0 2.475924887335168e-08
what O 0 2.2476275063354478e-08
is O 0 2.4321241909319724e-08
observed O 0 5.6735160569587606e-08
in O 0 7.151369629809778e-08
other O 0 2.760519919320359e-07
genetic B-Disease 1 0.9999866485595703
disorders I-Disease 1 1.0
, O 0 6.986326297919732e-06
we O 0 4.101715944671014e-07
used O 0 1.280129140468489e-06
mental O 1 0.9713123440742493
health O 0 0.00021145588834770024
wellness O 0 0.27367493510246277
( O 0 1.0490506383575848e-06
absence O 0 3.7968834476487245e-06
of O 0 2.52743325290794e-06
any O 0 2.2710999473929405e-05
psychiatric B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999996423721313
) O 0 1.4679160358355148e-06
as O 0 3.430944843785255e-07
the O 0 5.703798251488479e-07
phenotype O 0 8.893556696421001e-06
in O 0 1.3959461853119137e-07
our O 0 1.9021092612092616e-07
genome O 0 1.287227178181638e-06
- O 0 2.1611590454995167e-06
wide O 0 2.07487323677924e-06
linkage O 0 7.205442670965567e-06
scan O 0 7.63368973366596e-07
of O 0 2.7964074433839414e-07
several O 0 1.0651505988334975e-07
large O 0 1.872974735306343e-06
multigeneration O 0 0.00025635716156102717
Old O 0 1.5135742614802439e-05
Order O 0 2.0386476080602733e-06
Amish O 0 1.996765422518365e-05
pedigrees O 0 6.4429814301547594e-06
exhibiting O 0 3.480179429971031e-06
an O 0 8.774999855631904e-07
extremely O 0 5.621967375191161e-06
high O 0 1.4237996765587013e-05
incidence O 0 0.18807435035705566
of O 0 0.0004759459407068789
BPAD B-Disease 1 0.9999997615814209
. O 0 0.0007996564381755888

We O 0 3.679880364870769e-06
have O 0 5.438306516225566e-07
found O 0 4.1200874534297327e-07
strong O 0 3.88264140838146e-07
evidence O 0 1.724043130479913e-07
for O 0 6.691017517823639e-08
a O 0 6.282183449002332e-07
locus O 0 2.730024334596237e-06
on O 0 6.318486498457787e-07
chromosome O 0 1.3770969417237211e-05
4p O 0 0.3393827974796295
at O 0 2.1746823222201783e-06
D4S2949 O 0 1.8149921743315645e-05
( O 0 3.3882901107062935e-07
maximum O 0 1.1473714494059095e-06
GENEHUNTER O 0 0.00010466446838108823
- O 0 1.4478204093393288e-06
PLUS O 0 1.577257648932573e-06
nonparametric O 0 1.918466750794323e-06
linkage O 0 4.5848011609450623e-07
score O 0 7.744164065570658e-08
= O 0 9.541212619978978e-08
4 O 0 5.399177283038625e-08
. O 0 1.4518557023279755e-08
05 O 0 1.021350044538849e-06
, O 0 5.503209976609469e-08
P O 0 7.214403012767434e-07
= O 0 9.234246789446843e-08
5 O 0 3.152154803842677e-08
. O 0 1.208539757158178e-08
22 O 0 3.7693052234999413e-08
x O 0 5.7984408385891584e-08
10 O 0 2.9841270787756e-08
( O 0 2.6936005426136944e-08
- O 0 1.9618262570020306e-07
4 O 0 1.953048780478639e-07
) O 0 5.510383616069703e-08
; O 0 5.435890670923982e-08
SIBPAL O 0 1.2048858479829505e-05
Pempirical O 0 3.1293482152250363e-06
value O 0 1.1489379403428757e-07
< O 0 6.923904720679275e-07
3 O 0 7.536772983485207e-08
x O 0 1.275599146310924e-07
10 O 0 4.006951570545425e-08
( O 0 3.584943542023211e-08
- O 0 2.2260910270688328e-07
5 O 0 1.643934410822112e-07
) O 0 4.704407174926928e-08
) O 0 2.326603798508131e-08
and O 0 3.4537599447048706e-08
suggestive O 0 1.7079483427551168e-07
evidence O 0 3.9259738571217895e-08
for O 0 4.030975375712842e-08
a O 0 3.039381795133522e-07
locus O 0 2.36604910242022e-06
on O 0 5.139182235325279e-07
chromosome O 0 8.412139322899748e-06
4q O 0 8.324616646859795e-05
at O 0 1.605892521183705e-06
D4S397 O 0 3.0415321816690266e-05
( O 0 5.76656589146296e-07
maximum O 0 1.5600123788317433e-06
GENEHUNTER O 0 0.0001292400702368468
- O 0 2.497563855285989e-06
PLUS O 0 1.5613712776030297e-06
nonparametric O 0 1.9662293198052794e-06
linkage O 0 4.7482188847425277e-07
score O 0 8.450354016531492e-08
= O 0 1.1286425660728128e-07
3 O 0 6.813219499690604e-08
. O 0 1.8994112949144437e-08
29 O 0 1.2151450334840774e-07
, O 0 8.309574184295343e-08
P O 0 8.369555644094362e-07
= O 0 6.40655883898944e-08
2 O 0 2.9267770429441953e-08
. O 0 7.2333734557616935e-09
57 O 0 5.068537589636435e-08
x O 0 5.9457711643062794e-08
10 O 0 2.4436840107000535e-08
( O 0 3.317466479302311e-08
- O 0 1.2279910777124314e-07
3 O 0 1.6132375435518043e-07
) O 0 4.422324195729743e-08
; O 0 5.702069927338016e-08
SIBPAL O 0 1.1302144230285194e-05
Pempirical O 0 3.2507998639630387e-06
value O 0 1.2990471986995544e-07
< O 0 6.317142720035918e-07
1 O 0 1.5795772867477353e-07
x O 0 1.3193910319841962e-07
10 O 0 4.238857442828703e-08
( O 0 4.6803048547872095e-08
- O 0 2.5216499466296227e-07
3 O 0 2.273348229664407e-07
) O 0 4.7836252292654535e-08
) O 0 2.3977721141932307e-08
that O 0 1.0192581889612029e-08
are O 0 3.234954348840802e-08
linked O 0 1.410120148648275e-06
to O 0 1.2466196039895294e-06
mental O 1 0.9699253439903259
health O 0 0.012806466780602932
wellness O 1 0.984503984451294
. O 0 0.00019344266911502928

These O 0 1.237392780240043e-06
findings O 0 1.1030419955204707e-06
are O 0 7.001501245440522e-08
consistent O 0 2.799107789996924e-07
with O 0 1.433891014812616e-07
the O 0 5.766884214608581e-07
hypothesis O 0 1.4773395378142595e-06
that O 0 3.771635093130499e-08
certain O 0 5.990541041001052e-08
alleles O 0 1.957811690544986e-07
could O 0 1.131233062778847e-07
prevent O 0 3.20432377520774e-07
or O 0 8.913053051173847e-08
modify O 0 1.820139630126505e-07
the O 0 1.546255106177341e-07
clinical O 0 3.4890088045358425e-06
manifestations O 0 0.0010757379932329059
of O 0 0.003449993673712015
BPAD B-Disease 1 1.0
and O 0 4.966796495864401e-06
perhaps O 0 4.029637239000294e-06
other O 0 7.649999815839692e-07
related O 0 0.00011923976853722706
affective B-Disease 1 0.9999996423721313
disorders I-Disease 1 1.0
. O 1 0.7005391120910645

Segregation O 1 0.9909633994102478
distortion O 1 0.9997569918632507
in O 1 0.9288191795349121
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.37255150079727173

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999911904335022
DM B-Disease 1 1.0
) O 0 1.769516347849276e-05
is O 0 2.1764769826404518e-06
an O 0 4.369470843812451e-06
autosomal B-Disease 1 0.9987660646438599
dominant I-Disease 1 0.9999450445175171
disease I-Disease 1 0.9999939203262329
which O 0 3.828992305443535e-07
, O 0 1.3030997081386886e-07
in O 0 7.227694709399657e-08
the O 0 3.0978418408267316e-07
typical O 0 1.1730111282304279e-06
pedigree O 0 2.168477976738359e-06
, O 0 9.754796082006578e-08
shows O 0 1.0429759811358963e-07
a O 0 5.434324634734367e-07
three O 0 5.855611107108416e-07
generation O 0 5.1811206503771245e-05
anticipation O 0 0.000223669339902699
cascade O 0 0.0005224440828897059
. O 0 3.134984945063479e-05

This O 0 6.214891982381232e-06
results O 0 5.6044195844151545e-06
in O 0 1.903171323647257e-05
infertility B-Disease 1 0.999998927116394
and O 1 0.9999983310699463
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997487664222717
CDM B-Disease 1 0.9999550580978394
) O 0 5.60138801120047e-07
with O 0 1.2550421502055542e-07
the O 0 5.626293955174333e-07
disappearance O 0 1.719624560791999e-05
of O 0 2.109666274918709e-05
DM B-Disease 1 0.9999998807907104
in O 0 1.1665246347547509e-05
that O 0 6.436237981688464e-06
pedigree O 0 0.00023397515178658068
. O 0 5.2563522331183776e-05

The O 0 8.804894605418667e-06
concept O 0 1.2672689990722574e-05
of O 0 1.1165263458678965e-05
segregation O 0 0.0015920806908980012
distortion O 0 0.0007204733556136489
, O 0 7.613136290274269e-07
where O 0 2.578929354513093e-07
there O 0 9.466655370715671e-08
is O 0 5.726833052221991e-08
preferential O 0 1.921354453315871e-07
transmission O 0 1.9288340524781233e-07
of O 0 5.4827481221764174e-08
the O 0 1.1863771476328111e-07
larger O 0 1.8850404615022853e-07
allele O 0 4.6027943767512625e-07
at O 0 2.8334480361991154e-07
the O 0 1.4991364878369495e-06
DM B-Disease 1 0.9999998807907104
locus O 0 1.9298773622722365e-05
, O 0 1.740043984455042e-07
has O 0 7.003090729540418e-08
been O 0 3.526315595081542e-08
put O 0 7.25108577626088e-08
forward O 0 6.660356888232855e-08
to O 0 3.3480993977264006e-08
explain O 0 1.9579871946007188e-07
partially O 0 7.392661700578174e-07
the O 0 2.393792613020196e-07
maintenance O 0 1.632985549804289e-05
of O 0 1.0819570888997987e-05
DM B-Disease 1 0.9999986886978149
in O 0 1.798517473616812e-06
the O 0 1.938960622283048e-06
population O 0 3.013879677382647e-06
. O 0 1.7866525013232604e-05

In O 0 7.937984264572151e-06
a O 0 4.23610345023917e-06
survey O 0 4.196660938760033e-06
of O 0 1.4479707715508994e-05
DM B-Disease 1 0.9999983310699463
in O 0 4.835140771319857e-06
Northern O 0 1.0458346878294833e-05
Ireland O 0 5.016088834963739e-06
, O 0 1.9160056581313256e-06
59 O 0 1.7524973372928798e-05
pedigrees O 0 5.0085276598110795e-05
were O 0 1.0263630429108161e-05
ascertained O 0 0.00016024116484913975
. O 0 5.3203897550702095e-05

Sibships O 0 0.0005590245127677917
where O 0 4.35290075984085e-06
the O 0 1.5795366152815404e-06
status O 0 1.1839737226182478e-06
of O 0 4.606320089806104e-07
all O 0 7.918939814999248e-08
the O 0 3.259885374973237e-07
members O 0 1.475969071407235e-07
had O 0 7.069319849506428e-07
been O 0 1.4595528341487807e-07
identified O 0 1.0089645030575412e-07
were O 0 3.638058743149486e-08
examined O 0 1.1644429065427175e-07
to O 0 1.2728061271616298e-08
determine O 0 2.7781082323485862e-08
the O 0 1.1266551780408918e-07
transmission O 0 4.985619170838618e-07
of O 0 5.180062885301595e-07
the O 0 6.167409992485773e-06
DM B-Disease 1 0.9999998807907104
expansion O 0 2.1769836166640744e-05
from O 0 6.689677434223995e-07
affected O 0 5.355648795557499e-07
parents O 0 1.6605119412815839e-07
to O 0 1.750484841522848e-07
their O 0 6.531646477014874e-07
offspring O 0 2.296510137966834e-05
. O 0 2.507996396161616e-05

Where O 0 1.8409786207485013e-05
the O 0 1.45211088238284e-05
transmitting O 0 0.00011871651804540306
parent O 0 2.107701584463939e-05
was O 0 5.0267481128685176e-05
male O 0 8.782737495494075e-06
, O 0 5.119110937812366e-06
58 O 0 7.416954031214118e-05
. O 0 5.646905628964305e-05

3 O 0 1.2088036783097778e-05
% O 0 3.3065550724131754e-06
of O 0 2.199049731643754e-06
the O 0 1.3993067113915458e-06
offspring O 0 2.616890014905948e-06
were O 0 3.059232085433905e-07
affected O 0 2.7540275482351717e-07
, O 0 7.570702820203223e-08
and O 0 5.321405538438739e-08
in O 0 5.9516942485515756e-08
the O 0 8.931023387503956e-08
case O 0 1.3658686270900944e-07
of O 0 3.269780393111432e-07
a O 0 2.732493840085226e-06
female O 0 4.883885139861377e-06
transmitting O 0 5.1837549108313397e-05
parent O 0 8.440521014563274e-06
, O 0 5.885153768758755e-06
68 O 0 0.00012571742990985513
. O 0 5.4100983106764033e-05

7 O 0 8.879968663677573e-05
% O 0 3.315852882224135e-05
were O 0 1.953119135578163e-05
affected O 0 8.452103065792471e-05
. O 0 7.446406380040571e-05

Studies O 0 1.6771728041931055e-05
on O 0 9.307013897341676e-06
meiotic O 0 0.004981116391718388
drive O 0 1.757645804900676e-05
in O 0 4.620051640813472e-06
DM B-Disease 1 0.9999606609344482
have O 0 2.1183772958011104e-07
shown O 0 1.5505418105021818e-07
increased O 0 1.9671807649501716e-07
transmission O 0 3.2935216154328373e-07
of O 0 8.564507680830502e-08
the O 0 1.657379442576712e-07
larger O 0 2.788647179841064e-07
allele O 0 5.067126380708942e-07
at O 0 4.430412730016542e-07
the O 0 2.28191356654861e-06
DM B-Disease 1 0.9999978542327881
locus O 0 2.557821608206723e-05
in O 0 2.215348331446876e-06
non O 0 0.00026447654818184674
- O 1 0.9966660141944885
DM O 1 1.0
heterozygotes O 0 0.01091761514544487
for O 0 1.6422842236352153e-05
CTGn O 0 0.052218321710824966
. O 0 9.584359941072762e-05

This O 0 2.9212278604973108e-06
study O 0 1.5476390444746357e-06
provides O 0 5.157319264981197e-07
further O 0 2.6854448265112296e-07
evidence O 0 4.030484035411064e-07
that O 0 1.1855413362127365e-07
the O 0 3.6278081552154617e-06
DM B-Disease 1 0.9999997615814209
expansion O 0 8.400692604482174e-05
tends O 0 9.726646794661065e-07
to O 0 9.389562904971172e-08
be O 0 2.993744772084028e-07
transmitted O 0 4.206963694741717e-06
preferentially O 0 1.200318911287468e-05
. O 0 1.7857666534837335e-05

Diagnosis O 1 0.9989510774612427
of O 1 0.9332241415977478
hemochromatosis B-Disease 1 1.0
. O 0 0.14144787192344666

If O 0 0.00027129659429192543
untreated O 1 0.9999557733535767
, O 1 0.9039075970649719
hemochromatosis B-Disease 1 1.0
can O 0 2.9957784136058763e-05
cause O 1 0.9994766116142273
serious O 1 0.9995326995849609
illness O 1 0.9999878406524658
and O 0 4.208593054499943e-06
early B-Disease 0 6.407088221749291e-05
death I-Disease 0 0.011941622011363506
, O 0 9.633591844249167e-07
but O 0 1.9198122913621773e-07
the O 0 2.1663654479198158e-06
disease O 1 0.905893087387085
is O 0 8.671304954077641e-07
still O 0 6.927431854819588e-07
substantially O 0 6.6293328018218745e-06
under O 0 4.6682001993758604e-05
- O 1 0.9978481531143188
diagnosed O 1 0.9999895095825195
. O 0 0.00020690879318863153

The O 0 2.324074193893466e-05
cornerstone O 0 0.00026308128144592047
of O 0 6.0470151765912306e-06
screening O 0 1.0549292710493319e-05
and O 0 9.554530606692424e-07
case O 0 1.0901474070124095e-06
detection O 0 1.70167550095357e-06
is O 0 1.544043328749467e-07
the O 0 2.0130457301092974e-07
measurement O 0 9.808488812268479e-07
of O 0 1.422666059625044e-06
serum O 0 3.1477349693886936e-05
transferrin O 0 5.737479295930825e-05
saturation O 0 7.766167072986718e-06
and O 0 2.3626213874194946e-07
the O 0 2.0908530586893903e-06
serum O 0 7.919896597741172e-05
ferritin O 0 0.0004760687006637454
level O 0 3.3416257792850956e-05
. O 0 3.495515193208121e-05

Once O 0 5.18774104421027e-05
the O 0 1.9527187760104425e-05
diagnosis O 0 0.01021924614906311
is O 0 3.988023763668025e-06
suspected O 0 1.03097681858344e-05
, O 0 1.6979244037429453e-06
physicians O 0 2.4755670438025845e-06
must O 0 3.05833367519881e-07
use O 0 3.140087869724084e-07
serum O 0 1.5168833670031745e-05
ferritin O 0 0.00026158729451708496
levels O 0 1.7129624438894098e-06
and O 0 1.4694259107272956e-06
hepatic O 1 0.999998927116394
iron O 1 0.9999724626541138
stores O 0 3.5781915812549414e-06
on O 0 2.234668045275612e-06
liver O 1 0.9929647445678711
biopsy O 0 0.09462931752204895
specimens O 0 2.2661388356937096e-06
to O 0 1.1664791088605853e-07
assess O 0 4.078204085544712e-07
patients O 0 2.5703209871608124e-07
for O 0 7.856340289436048e-08
the O 0 6.797292826377088e-07
presence O 0 6.009950539009878e-06
of O 0 6.386164750438184e-05
iron B-Disease 1 0.9999977350234985
overload I-Disease 1 0.9999229907989502
. O 0 0.00024423515424132347

Liver O 1 0.9999828338623047
biopsy O 1 0.9992490410804749
is O 0 7.975166226970032e-06
also O 0 3.7424413790176914e-07
used O 0 6.50335252316836e-08
to O 0 2.7596556151365803e-08
establish O 0 1.401330962380598e-07
the O 0 1.3095068140955846e-07
presence O 0 3.211791863577673e-07
or O 0 9.038366499680706e-08
absence O 0 1.1926224487979198e-06
of O 0 7.834536518203095e-06
cirrhosis B-Disease 1 0.9999991655349731
, O 0 3.229509502489236e-06
which O 0 3.1732261618344637e-07
can O 0 1.7629190551815554e-07
affect O 0 1.1695751709339675e-06
prognosis O 0 0.026851655915379524
and O 0 6.906586804689141e-06
management O 0 0.000277652929071337
. O 0 9.109813981922343e-05

A O 0 9.065272024599835e-05
DNA O 0 1.5495188563363627e-05
- O 0 2.75738875643583e-06
based O 0 4.157616331212921e-07
test O 0 4.3613098910100234e-07
for O 0 1.967589753348875e-07
the O 0 1.982043613679707e-06
HFE O 1 0.9467039108276367
gene O 0 8.975214313977631e-07
is O 0 6.900425120193177e-08
commercially O 0 9.610415929728333e-08
available O 0 1.0612424716782698e-08
, O 0 1.296497220693027e-08
but O 0 6.400864727140743e-09
its O 0 1.1264635446650573e-08
place O 0 5.1088555608203023e-08
in O 0 5.8488804910439285e-08
the O 0 4.701474267676531e-07
diagnosis O 0 0.0470968522131443
of O 0 0.009948082268238068
hemochromatosis B-Disease 1 1.0
is O 0 1.0138843208551407e-05
still O 0 2.4154182938218582e-06
being O 0 2.115467168550822e-06
evaluated O 0 1.4577360161638353e-05
. O 0 2.9281196475494653e-05

Currently O 0 6.672895779047394e-06
, O 0 1.1559579888853477e-06
the O 0 4.1438491393819277e-07
most O 0 8.454851752048853e-08
useful O 0 6.861471746333336e-08
role O 0 1.005621541594337e-07
for O 0 4.7693490046185616e-08
this O 0 5.2482153733990344e-08
test O 0 1.0739818634419862e-07
is O 0 2.7449409856217244e-08
in O 0 2.10279367252042e-08
the O 0 1.6699706861800223e-07
detection O 0 3.7308923310774844e-06
of O 0 7.988151992321946e-06
hemochromatosis B-Disease 1 1.0
in O 0 8.457091666969063e-07
the O 0 1.223800268235209e-06
family O 0 5.925471668888349e-07
members O 0 1.3361866990635463e-07
of O 0 8.773276931606233e-07
patients O 0 1.4871043276798446e-06
with O 0 5.769701374447322e-07
a O 0 1.737571437843144e-05
proven O 0 1.9365308617125265e-05
case O 0 1.8145655076295952e-06
of O 0 4.129290118726203e-06
the O 0 3.9938531699590385e-05
disease O 1 0.999972939491272
. O 0 0.0001770225790096447

It O 0 7.662845746381208e-06
is O 0 3.520970494719222e-06
crucial O 0 1.4031194950803183e-05
to O 0 8.6564004959655e-06
diagnose O 1 0.9999769926071167
hemochromatosis B-Disease 1 1.0
before O 1 0.997431218624115
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9986496567726135
because O 0 0.002947403583675623
phlebotomy O 1 0.9999998807907104
therapy O 1 0.9982144832611084
can O 0 2.6743120997707592e-06
avert O 1 0.9988217949867249
serious O 1 0.9999998807907104
chronic O 1 1.0
disease O 1 1.0
and O 0 2.796969965856988e-05
can O 0 1.8120755385098164e-07
even O 0 1.185929221492188e-07
lead O 0 6.637187084379548e-07
to O 0 2.0936815303684853e-07
normal O 0 1.425738332727633e-06
life O 0 2.5950669169105822e-06
expectancy O 0 2.9664395697182044e-05
. O 0 5.04750505569973e-06
. O 0 1.8692291632760316e-05

Prevalence O 0 0.00043857115088030696
of O 0 3.284331251052208e-05
the O 0 4.951265509589575e-05
I1307K O 1 0.980767011642456
APC B-Disease 1 0.5826172828674316
gene O 0 1.4027368706592824e-05
variant O 0 7.648462997167371e-06
in O 0 2.847083635515446e-07
Israeli O 0 1.0386705753262504e-06
Jews O 0 7.886500270615215e-07
of O 0 3.402255401852017e-07
differing O 0 1.6861112328570016e-07
ethnic O 0 5.043598889642453e-07
origin O 0 7.518925144722743e-07
and O 0 9.865150332188932e-07
risk O 0 5.649146987707354e-05
for O 0 0.0013982834061607718
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.4610559344291687

BACKGROUND O 0 0.0012734811753034592
& O 0 0.0011746101081371307
AIMS O 0 2.9951786927995272e-05
Israeli O 0 3.0788587537244894e-06
Jews O 0 1.721898570394842e-06
of O 0 6.467665230047714e-07
European O 0 1.0581075002846774e-06
birth O 0 4.543053819361376e-06
, O 0 6.307571425168135e-07
i O 0 4.6886054860806325e-07
. O 0 8.100148107814675e-08
e O 0 9.945200929450948e-08
. O 0 6.397327467766445e-08
, O 0 1.6819323889194493e-07
Ashkenazim O 0 2.5072672542592045e-06
, O 0 1.1525659715516667e-07
have O 0 4.421244526042756e-08
the O 0 6.546288204845041e-07
highest O 1 0.9435880184173584
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9963067770004272
of O 0 1.4795031347603071e-05
any O 0 2.9325437935767695e-06
Israeli O 0 1.8844699297915213e-05
ethnic O 0 2.3931312171043828e-05
group O 0 0.00012009363126708195
. O 0 0.00011780332715716213

The O 0 0.00018026246107183397
I1307K O 0 0.21767987310886383
APC B-Disease 0 0.11757766455411911
gene O 0 5.198219514568336e-05
variant O 0 8.62170199980028e-05
was O 0 2.4898656192817725e-05
found O 0 2.003583631449146e-06
in O 0 2.2115634692454478e-06
6 O 0 6.29055721219629e-05
. O 0 5.832529495819472e-05

1 O 0 9.856435099209193e-06
% O 0 2.1825069325132063e-06
of O 0 1.1614013146754587e-06
American O 0 1.2887184084320324e-06
Jews O 0 1.0106130048370687e-06
, O 0 1.8281627944816137e-07
28 O 0 5.292072273732629e-07
% O 0 3.217785717879451e-07
of O 0 7.504998507101845e-07
their O 0 4.1669027268653736e-06
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 0.0002393997710896656
, O 0 2.2599167550652055e-06
but O 0 1.6706269434507703e-07
not O 0 7.18711348213219e-08
in O 0 3.915363322448684e-07
non O 0 6.839834441052517e-06
- O 0 0.00013041750935371965
Jews O 0 7.038510375423357e-05
. O 0 6.946213397895917e-05

We O 0 7.069832008710364e-06
assessed O 0 8.640261512482539e-06
the O 0 4.7275516408262774e-06
I1307K O 0 0.00013142470561433583
prevalence O 0 3.909451334038749e-05
in O 0 4.892835931968875e-07
Israeli O 0 1.2791443850801443e-06
Jews O 0 6.756163770660351e-07
of O 0 2.726324908053357e-07
differing O 0 1.4074946363962226e-07
ethnic O 0 6.701151846755238e-07
origin O 0 9.619674301575287e-07
and O 0 1.0068342817248777e-06
risk O 0 4.2876847146544605e-05
for O 0 0.0024533465038985014
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5181741714477539

METHODS O 0 7.503418601118028e-05
DNA O 0 1.2500204320531338e-05
samples O 0 7.821188319212524e-07
from O 0 5.576422381636803e-07
500 O 0 1.7909555936057586e-06
unrelated O 0 2.2163203539093956e-06
Jews O 0 1.3221133485785685e-06
of O 0 8.15743476323405e-07
European O 0 1.150557864093571e-06
or O 0 2.5355060984111333e-07
non O 0 7.949051905598026e-07
- O 0 2.6731186153483577e-06
European O 0 3.002814707997459e-07
origin O 0 1.831314193623257e-07
, O 0 5.0769358495017514e-08
with O 0 3.6417034721125674e-08
or O 0 1.019861386453158e-07
without O 0 1.3378800645114097e-07
a O 0 5.568758751905989e-07
personal O 0 1.1636540193649125e-06
and O 0 1.015421958072693e-06
/ O 0 0.0001468353730160743
or O 0 4.0441523196932394e-07
family O 0 5.041550821260898e-07
history O 0 8.924091048356786e-07
of O 0 9.760333341546357e-06
neoplasia B-Disease 1 0.9998524188995361
, O 0 5.81537562993617e-07
were O 0 1.374815354893144e-07
examined O 0 3.5475466120260535e-07
for O 0 9.08952273448449e-08
the O 0 6.651977173532941e-07
I1307K O 0 4.439222902874462e-05
variant O 0 2.3712175334367203e-06
by O 0 1.6161756377641723e-07
the O 0 4.5630088152393e-07
allele O 0 2.426924083920312e-06
- O 0 2.3908389721327694e-06
specific O 0 3.893142093147617e-07
oligonucleotide O 0 4.364621054264717e-05
( O 0 3.174120820403914e-06
ASO O 0 0.01373634859919548
) O 0 1.7056203205356724e-06
method O 0 4.403564616950462e-06
. O 0 1.7663802282186225e-05

RESULTS O 0 1.6443747881567106e-05
In O 0 2.0019790554215433e-06
persons O 0 8.501243655700819e-07
at O 0 1.485700977355009e-06
average O 0 1.856627704910352e-06
risk O 0 1.6291327483486384e-05
for O 0 0.0001443252112949267
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 0.0005872412584722042
I1307K O 1 0.7176274657249451
was O 0 4.9405400204705074e-05
found O 0 1.1399895356589695e-06
in O 0 1.148466139966331e-06
5 O 0 1.8522650861996226e-05
. O 0 3.8292382669169456e-05

0 O 0 1.2756523574353196e-05
% O 0 4.039552550239023e-06
of O 0 1.7608232383281575e-06
120 O 0 2.92707295557193e-06
European O 0 3.384054252819624e-06
and O 0 2.343768755963538e-06
1 O 0 4.718768468592316e-05
. O 0 6.69110449962318e-05

6 O 0 2.3290729586733505e-05
% O 0 3.4919316931336652e-06
of O 0 1.8615708086144878e-06
188 O 0 6.87868987370166e-06
non O 0 4.401465048431419e-06
- O 0 5.2019613576703705e-06
European O 0 1.0507746992516331e-06
Jews O 0 1.1836981457236107e-06
( O 0 5.934989530942403e-07
P O 0 9.258270438294858e-06
= O 0 1.366589572171506e-06
0 O 0 9.451622986489383e-07
. O 0 5.626701522487565e-07
08 O 0 1.3196771760703996e-05
) O 0 3.5896896406484302e-06
. O 0 1.943387178471312e-05

It O 0 7.771322998451069e-06
occurred O 0 1.9704359146999195e-05
in O 0 4.90926959173521e-06
15 O 0 3.643403761088848e-05
. O 0 5.3188272431725636e-05

4 O 0 1.9521565263858065e-05
% O 0 4.199435807095142e-06
of O 0 2.9011882816121215e-06
52 O 0 1.1373234883649275e-05
Ashkenazi O 0 3.993815334979445e-05
Israelis O 0 3.4926545140478993e-06
with O 0 2.0326021967775887e-06
familial O 1 0.9847908616065979
cancer B-Disease 1 0.9999216794967651
( O 0 1.0202646080870181e-05
P O 0 0.0005780220380984247
= O 0 1.154933215730125e-06
0 O 0 1.6354385934391757e-07
. O 0 4.503813499923126e-08
02 O 0 2.4003359158086823e-06
) O 0 2.7185352635683557e-08
and O 0 2.1059163302084016e-08
was O 0 3.494042744023318e-07
not O 0 2.7860783902156072e-08
detected O 0 1.8585448913199798e-07
in O 0 9.165846392988897e-08
51 O 0 8.212903708226804e-07
non O 0 1.2028775699945982e-06
- O 0 2.323993157915538e-06
European O 0 9.521393735667516e-07
Jews O 0 1.6693782072252361e-06
at O 0 3.3972764867939986e-06
increased O 0 3.2349780667573214e-05
cancer B-Disease 1 0.998289167881012
risk O 0 0.00047483682283200324
. O 0 0.0001349065569229424

Colorectal B-Disease 1 0.9999978542327881
neoplasia I-Disease 1 0.9999932050704956
occurred O 0 0.0016683334251865745
personally O 0 2.2298370822682045e-05
or O 0 3.7481851222764817e-07
in O 0 2.1529315574753127e-07
the O 0 2.7242248279435444e-07
families O 0 7.49374180486484e-08
of O 0 2.1052039755886653e-07
13 O 0 5.341264568414772e-07
of O 0 7.700534752075328e-07
20 O 0 2.930301661763224e-06
Ashkenazi O 0 5.244631029199809e-05
I1307K O 0 5.977741238893941e-05
carriers O 0 7.231417384900851e-07
, O 0 1.0182579046613682e-07
8 O 0 1.9697149866715336e-07
of O 0 3.5907501683141163e-07
whom O 0 6.426654977076396e-07
also O 0 2.682634203665657e-07
had O 0 9.91882870948757e-07
a O 0 1.3109366818753188e-06
personal O 0 2.3263901312020607e-06
or O 0 8.337847816619615e-07
family O 0 2.4317591851286124e-06
history O 0 9.34953732212307e-06
of O 0 0.00020285171922296286
noncolonic O 1 0.9999556541442871
neoplasia B-Disease 1 0.9999969005584717
. O 0 0.0007243189611472189

CONCLUSIONS O 0 0.00010535680485190824
The O 0 5.4661784815834835e-05
I1307K O 0 0.1427803337574005
APC O 0 0.015339910984039307
variant O 0 3.961240145144984e-05
may O 0 1.0545071518208715e-06
represent O 0 6.553121920660487e-07
a O 0 1.8072723833029158e-06
susceptibility O 0 0.00031849893275648355
gene O 0 3.7786562643304933e-06
for O 0 2.730045252974378e-06
colorectal B-Disease 1 1.0
, I-Disease 0 9.506236892775632e-06
or I-Disease 0 5.506411184796889e-07
other I-Disease 0 1.438962158317736e-07
, I-Disease 0 1.741996243254107e-06
cancers I-Disease 0 0.08300118893384933
in O 0 1.3717733509110985e-06
Ashkenazi O 0 0.007645696867257357
Jews O 0 6.490127361757914e-06
, O 0 6.350595072035503e-07
and O 0 5.448335400615179e-07
partially O 0 7.607405223097885e-06
explains O 0 4.5149258198762254e-07
the O 0 2.2265645327479433e-07
higher O 0 1.1157120525240316e-06
incidence O 0 0.20389844477176666
of O 1 0.9497483968734741
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.28034363721963e-05
European O 0 3.323298369650729e-05
Israelis O 0 6.261208181967959e-05
. O 0 5.021210017730482e-05

Systematic O 0 9.360377589473501e-05
analysis O 0 6.996594493102748e-06
of O 0 2.3372678697342053e-05
coproporphyrinogen O 1 0.9982230067253113
oxidase O 1 0.9643476009368896
gene O 0 0.014195955358445644
defects O 1 0.9970582723617554
in O 0 2.1738696887041442e-05
hereditary B-Disease 1 0.9999924898147583
coproporphyria I-Disease 1 0.9999717473983765
and O 0 5.914409848628566e-05
mutation O 0 0.00018459049169905484
update O 0 0.00018436710524838418
. O 0 8.378428174182773e-05

Hereditary B-Disease 1 0.9999772310256958
coproporphyria I-Disease 1 0.9999752044677734
( O 0 0.21310913562774658
HC B-Disease 1 0.9999996423721313
) O 0 2.1702922822441906e-05
is O 0 4.4742068894265685e-06
an O 0 2.0061297618667595e-05
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.07099573314189911
autosomal O 1 0.9999783039093018
dominant O 1 0.9997190833091736
inheritance O 1 0.9974606037139893
caused O 1 0.9748510718345642
by O 0 9.533810043649282e-06
deficient B-Disease 0 0.00041267534834332764
activity I-Disease 0 1.8325806649954757e-06
of I-Disease 0 3.822800408670446e-06
coproporphyrinogen I-Disease 1 0.8404962420463562
III I-Disease 1 0.9999758005142212
oxidase I-Disease 0 0.0008131348295137286
( O 0 1.0852392733795568e-05
CPO O 0 0.01736537553369999
) O 0 6.414533345378004e-06
. O 0 1.5936544514261186e-05

Clinical O 0 0.001174904522486031
manifestations O 0 0.06358040869235992
of O 0 0.0003618634946178645
the O 1 0.5354521870613098
disease O 1 0.9999992847442627
are O 0 7.863458790779987e-07
characterized O 0 0.00013116630725562572
by O 0 5.184256679058308e-06
acute O 1 0.9999979734420776
attacks O 0 0.02076968550682068
of O 1 0.9998904466629028
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 0.0004270625358913094
precipitated O 1 0.9946933388710022
by O 0 1.0061584362119902e-05
drugs O 0 2.0957895685569383e-05
, O 0 1.1581649914660375e-06
fasting O 0 1.4096392078499775e-05
, O 0 2.8356046186672756e-06
cyclical O 0 0.008401458151638508
hormonal O 0 0.026271870359778404
changes O 0 6.4169935285463e-06
, O 0 9.414448868483305e-06
or O 0 6.214252061909065e-05
infectious B-Disease 1 0.9999996423721313
diseases I-Disease 1 0.9999997615814209
. O 0 0.004937727469950914

Skin O 1 0.9999998807907104
photosensitivity O 1 0.9999909400939941
may O 0 4.982754398952238e-05
also O 0 4.898541192233097e-06
be O 0 1.4739703146915417e-06
present O 0 1.0555702829151414e-05
. O 0 4.505327160586603e-05

The O 0 1.366093783872202e-05
seven O 0 4.906105459667742e-06
exons O 0 1.422567311237799e-05
, O 0 1.1684046512527857e-06
the O 0 2.5346046186314197e-06
exon O 0 9.723540279082954e-05
/ O 0 1.2114994206058327e-05
intron O 0 1.8406659364700317e-05
boundaries O 0 1.4146955606975098e-07
and O 0 5.930921886942997e-08
part O 0 1.624334373673264e-07
of O 0 1.4898536448981758e-07
3 O 0 3.9932189110913896e-07
noncoding O 0 1.2525996453405241e-06
sequence O 0 6.985974465578693e-08
of O 0 1.2564744622522994e-07
the O 0 9.57805923462729e-07
CPO O 0 0.00015480100410059094
gene O 0 4.60007754554681e-07
were O 0 8.822294716992474e-08
systematically O 0 2.174820252776044e-07
analyzed O 0 6.637061034098224e-08
by O 0 8.603867485135197e-08
an O 0 3.6446573403736693e-07
exon O 0 1.60083181981463e-05
- O 0 4.337610334914643e-06
by O 0 2.1387875221989816e-06
- O 0 0.0001177504236693494
exon O 0 0.0003847409097943455
denaturing O 0 0.0002073464129352942
gradient O 0 3.4646309359231964e-05
gel O 0 2.6667921702028252e-05
electrophoresis O 0 6.646740985161159e-06
( O 0 6.298122343650903e-07
DGGE O 0 9.964560740627348e-05
) O 0 1.5270708786374598e-07
strategy O 0 1.732861960590526e-07
followed O 0 6.366457938611347e-08
by O 0 3.482050203729159e-08
direct O 0 8.163195275301405e-08
sequencing O 0 3.1362031904791365e-07
in O 0 7.49328421534301e-08
seven O 0 2.2634208107774612e-07
unrelated O 0 2.874293386412319e-06
heterozygous O 0 1.1548358997970354e-05
HC B-Disease 1 0.9999982118606567
patients O 0 1.1516421182022896e-05
from O 0 6.201555038387596e-07
France O 0 6.172741450427566e-06
, O 0 9.110034966397507e-07
Holland O 0 9.812074495130219e-06
, O 0 6.282752451625129e-07
and O 0 7.808317263879871e-07
Czech O 0 5.4534855735255405e-05
Republic O 0 7.93040162534453e-05
. O 0 0.00010084566019941121

Seven O 0 2.8064983780495822e-05
novel O 0 4.011212877230719e-05
mutations O 0 4.693070877692662e-06
and O 0 8.794805808065576e-07
two O 0 6.672206609437126e-07
new O 0 3.764261691685533e-06
polymorphisms O 0 4.106790220248513e-05
were O 0 5.859639259142568e-06
detected O 0 5.8453584642848e-05
. O 0 4.862704372499138e-05

Among O 0 6.524376658489928e-06
these O 0 7.914363209238218e-07
mutations O 0 1.7071141655833344e-06
two O 0 2.847056350674393e-07
are O 0 2.096886646540952e-07
missense O 0 1.4132074284134433e-05
( O 0 1.1959094763369649e-06
G197W O 0 8.88456852408126e-05
, O 0 8.259229957729985e-07
W427R O 0 1.5293506294256076e-05
) O 0 1.4251088487071684e-07
, O 0 4.8251266093757295e-08
two O 0 2.2502828045389833e-08
are O 0 3.286580607664291e-08
nonsense O 0 5.593632977252128e-06
( O 0 5.062228751739895e-07
Q306X O 0 2.6534737116890028e-05
, O 0 5.618486511593801e-07
Q385X O 0 8.476668881485239e-06
) O 0 1.0764632918380812e-07
, O 0 7.089656151038071e-08
two O 0 2.4904226236799332e-08
are O 0 2.7497621957195406e-08
small O 0 2.2717121339610458e-07
deletions O 0 1.8089259583575767e-06
( O 0 4.4768222551283543e-07
662de14bp O 0 1.9213528503314592e-05
; O 0 2.2535627408615255e-07
1168del3bp O 0 1.7704174751997925e-05
removing O 0 2.4152066089300206e-06
a O 0 6.519473458865832e-07
glycine O 0 1.3310908570929314e-06
at O 0 3.6677818116004346e-07
position O 0 2.8181574407426524e-07
390 O 0 8.945033869167673e-07
) O 0 5.2770637637422624e-08
, O 0 3.212002752661647e-08
and O 0 3.214325161593479e-08
one O 0 3.241649437768501e-08
is O 0 7.942719548736932e-08
a O 0 2.7223808274357e-07
splicing O 0 1.499634095125657e-06
mutation O 0 6.746151939296396e-07
( O 0 3.495359237604134e-07
IVS1 O 0 0.0007566844578832388
- O 0 8.56311908137286e-06
15c O 0 2.6747335141408257e-05
- O 0 5.194128789298702e-06
- O 0 9.404613592778333e-06
> O 0 1.1554307093319949e-05
g O 0 1.6511555713805137e-06
) O 0 1.039732424601425e-07
which O 0 7.587848216417115e-08
creates O 0 5.813290613332356e-07
a O 0 7.054530328787223e-07
new O 0 2.0432682958926307e-06
acceptor O 0 1.9422033801674843e-05
splice O 0 6.40932412352413e-05
site O 0 2.781280090857763e-05
. O 0 2.0434734324226156e-05

The O 0 2.929242509708274e-05
pathological O 0 0.00022073784202802926
significance O 0 1.1131847713841125e-05
of O 0 2.9136158445908222e-06
the O 0 3.307097586002783e-06
point O 0 7.857501259422861e-06
mutations O 0 3.3555011214048136e-06
G197W O 0 5.728097676183097e-05
, O 0 8.773192803346319e-07
W427R O 0 1.5662955775042064e-05
, O 0 1.9491859859499527e-07
and O 0 1.1457165527417601e-07
the O 0 2.2713653891059948e-07
in O 0 5.540429128814139e-07
- O 0 9.309916094935033e-06
frame O 0 2.3233782485476695e-05
deletion O 0 6.007881893310696e-06
390delGly O 0 5.74318119106465e-06
were O 0 1.3302033607942576e-07
assessed O 0 1.5259935537415004e-07
by O 0 4.878494408444567e-08
their O 0 3.2912414127395095e-08
respective O 0 1.1556610246543642e-07
expression O 0 2.1253870841064781e-07
in O 0 1.302719567775057e-07
a O 0 7.199317337835964e-07
prokaryotic O 0 1.7994952941080555e-06
system O 0 1.0115752502315445e-06
using O 0 3.8710766148142284e-07
site O 0 3.3021813123923494e-06
- O 0 1.9766221157624386e-05
directed O 0 2.8195059712743387e-05
mutagenesis O 0 0.000410132430261001
. O 0 4.819622336071916e-05

These O 0 2.5244510197808268e-06
mutations O 0 3.8298794606816955e-06
resulted O 0 3.1521783512289403e-06
in O 0 4.3358713242014346e-07
the O 0 6.124992637523974e-07
absence O 0 4.001524303021142e-06
or O 0 2.6772465844260296e-07
a O 0 1.2135402585045085e-06
dramatic O 0 4.9470750127511565e-06
decrease O 0 5.454009624372702e-06
of O 0 1.768284710124135e-05
CPO O 0 0.49158328771591187
activity O 0 2.2935268134460784e-05
. O 0 2.631639836181421e-05

The O 0 1.069793779606698e-05
two O 0 8.01128351213265e-07
polymorphisms O 0 1.0112229574588127e-05
were O 0 7.717075618529634e-07
localized O 0 2.711324668780435e-06
in O 0 4.87578802221833e-07
noncoding O 0 3.006906581504154e-06
part O 0 2.010012849495979e-07
of O 0 8.80029489280787e-08
the O 0 1.5728041091733758e-07
gene O 0 1.834674066003572e-07
1 O 0 3.175266272137378e-07
) O 0 6.166524002537699e-08
a O 0 3.142706077596813e-07
C O 0 8.037301995500457e-06
/ O 0 5.315771886671428e-06
G O 0 7.0842406785232015e-06
polymorphism O 0 1.7044885680661537e-06
in O 0 2.531432699015568e-07
the O 0 9.778237881619134e-07
promotor O 0 0.00015580517356283963
region O 0 1.1441087508501369e-06
, O 0 2.4471012238791445e-07
142 O 0 1.156617372544133e-06
bp O 0 1.3317560387804406e-06
upstream O 0 1.333042831674902e-07
from O 0 2.921144215406457e-08
the O 0 8.721474387130002e-08
transcriptional O 0 8.323801807819109e-07
initiation O 0 1.2192687108836253e-06
site O 0 4.898420229437761e-07
( O 0 1.6131143354414235e-07
- O 0 2.2835790787212318e-06
142C O 0 2.7640639018500224e-05
/ O 0 1.3081168617645744e-05
G O 0 7.488663868571166e-06
) O 0 5.138103986723763e-08
, O 0 2.1373709913063976e-08
and O 0 1.2835917218012582e-08
2 O 0 5.8692197768550614e-08
) O 0 2.0081653673287292e-08
a O 0 9.033954739834371e-08
6 O 0 2.47623489713078e-07
bp O 0 5.706028787244577e-07
deletion O 0 3.482701913526398e-07
polymorphism O 0 2.7312432848702883e-07
in O 0 5.274719327985622e-08
the O 0 7.79346223112043e-08
3 O 0 3.0899903435965825e-07
noncoding O 0 1.5463997442566324e-06
part O 0 1.3220537198321836e-07
of O 0 2.639835088302789e-07
the O 0 1.140720314651844e-06
CPO O 0 0.0009197039762511849
gene O 0 1.2292558722037938e-06
, O 0 3.904467575921444e-07
574 O 0 4.447109859029297e-06
bp O 0 1.431193027201516e-06
downstream O 0 2.2528729459736496e-07
of O 0 1.0421705809449122e-07
the O 0 9.09382293912131e-08
last O 0 1.96472086599897e-07
base O 0 2.8621519732041634e-07
of O 0 1.398752687009619e-07
the O 0 3.2244699355032935e-07
normal O 0 7.647935262866667e-07
termination O 0 6.886737082822947e-06
codon O 0 3.6071432987228036e-06
( O 0 1.0927495850410196e-06
+ O 0 7.836860277166124e-06
574 O 0 3.53593859472312e-05
delATTCTT O 0 0.00016694588703103364
) O 0 7.807507245161105e-06
. O 0 2.3231919840327464e-05

Five O 0 8.00647831056267e-05
intragenic O 0 0.043044231832027435
dimorphisms O 0 0.00249286787584424
are O 0 7.710175395914121e-07
now O 0 8.789522780716652e-07
well O 0 3.082832051859441e-07
characterized O 0 1.126533220485726e-06
and O 0 1.0261247496146098e-07
the O 0 1.9732082989776245e-07
high O 0 4.656450585116545e-07
degree O 0 8.286717729788506e-07
of O 0 1.0283059737048461e-06
allelic O 0 8.213294495362788e-05
heterogeneity O 0 8.573036029702052e-05
in O 0 1.5088783129613148e-06
HC B-Disease 1 0.9999597072601318
is O 0 7.029440212136251e-07
demonstrated O 0 2.5343069864902645e-07
with O 0 1.7270339824904113e-08
seven O 0 4.1082060420194466e-08
new O 0 2.8729779444347514e-08
different O 0 4.0113543597897205e-09
mutations O 0 3.844373708261628e-08
making O 0 3.846192697665174e-08
a O 0 1.3894792516566667e-07
total O 0 2.700849961456697e-07
of O 0 1.9431181499385275e-06
nineteen O 0 0.0007565492996945977
CPO O 1 0.9999760389328003
gene B-Disease 0 0.0006290063611231744
defects I-Disease 0 0.028510423377156258
reported O 0 2.213895186287118e-06
so O 0 4.934894377583987e-07
far O 0 1.215091060657869e-06
. O 0 2.5693527732073562e-06
. O 0 1.3727581972489133e-05

Coincidence O 0 0.00010416701843496412
of O 0 8.047010851441883e-06
two O 0 1.2465543477446772e-06
novel O 0 2.223975388915278e-05
arylsulfatase O 0 0.00032871056464500725
A O 0 1.4139703125692904e-05
alleles O 0 1.6827536910568597e-06
and O 0 4.963171136296296e-07
mutation O 0 4.6134077820170205e-06
459 O 0 5.588481144513935e-05
+ O 0 9.183655492961407e-05
1G O 0 0.10393937677145004
> O 0 1.1701805306074675e-05
A O 0 2.2016436105332104e-06
within O 0 2.6765445682030986e-07
a O 0 1.4671687722511706e-06
family O 0 2.9494981390598696e-06
with O 0 6.730223503836896e-06
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999994039535522
: O 0 1.9835033526760526e-06
molecular O 0 2.9188054213591386e-06
basis O 0 7.99578117494093e-07
of O 0 3.261276788180112e-06
phenotypic O 0 7.862826169002801e-05
heterogeneity O 0 0.0006456176051869988
. O 0 0.00010957480844808742

In O 0 1.8062892195302993e-05
a O 0 8.460660865239333e-06
family O 0 3.102982873315341e-06
with O 0 4.7551247916999273e-07
three O 0 9.018681339512113e-07
siblings O 0 6.589144959434634e-06
, O 0 5.972560757072642e-07
one O 0 4.3419868234195746e-07
developed O 0 1.511153755018313e-06
classical O 0 2.2169579096953385e-05
late O 0 0.019351406022906303
infantile O 1 0.9999996423721313
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.0011162948794662952
MLD B-Disease 1 0.9999998807907104
) O 0 1.0958847269648686e-06
, O 0 5.88824718761316e-07
fatal O 0 6.690011105092708e-06
at O 0 4.892611968898564e-07
age O 0 5.984043696116714e-07
5 O 0 2.8755579251082963e-07
years O 0 1.578198123297625e-07
, O 0 1.4322482400075387e-07
with O 0 4.943991029904282e-07
deficient O 0 0.001827684580348432
arylsulfatase O 0 0.047810155898332596
A O 0 9.057737042894587e-05
( O 0 1.773175313246611e-06
ARSA O 0 0.001387435244396329
) O 0 8.815582930310484e-08
activity O 0 1.488223517753795e-07
and O 0 6.483153214276172e-08
increased O 0 1.3821919537804206e-06
galactosylsulfatide O 0 0.00027277934714220464
( O 0 1.0072327313537244e-05
GS O 1 0.999742329120636
) O 0 9.103330739890225e-06
excretion O 0 0.0001321762683801353
. O 0 2.6514806449995376e-05

The O 0 8.033837730181403e-06
two O 0 9.341971463072696e-07
other O 0 5.475270654642372e-07
siblings O 0 4.685772637458285e-06
, O 0 1.359777343168389e-06
apparently O 0 2.7454025257611647e-06
healthy O 0 5.061331194156082e-07
at O 0 1.9397693051814713e-07
12 O 0 2.4541475340811303e-07
( O 0 8.715105082046648e-08
1 O 0 2.3082478151081887e-07
/ O 0 4.634109700418776e-07
2 O 0 1.1015118417390113e-07
) O 0 1.9703270126569805e-08
and O 0 1.4962349581537637e-08
15 O 0 4.661213637291439e-08
years O 0 7.597884632559726e-08
, O 0 7.051490769072188e-08
respectively O 0 1.657727182191593e-07
, O 0 6.31450447485804e-08
and O 0 6.680828334992839e-08
their O 0 1.4686762028759404e-07
father O 0 4.403883849590784e-06
, O 0 9.352793313155416e-07
apparently O 0 2.0097074866498588e-06
healthy O 0 4.100910473425756e-07
as O 0 1.2921577763336245e-07
well O 0 1.1726336879291921e-07
, O 0 2.705557449189655e-07
presented O 0 4.278629148757318e-06
ARSA O 0 0.39699509739875793
and O 0 9.521557444713835e-07
GS O 0 0.021178869530558586
values O 0 2.0969386582692096e-07
within O 0 1.3638016582717682e-07
the O 0 3.933365064767713e-07
range O 0 1.418801957697724e-06
of O 0 2.477322232152801e-05
MLD B-Disease 1 0.9999995231628418
patients O 0 0.0006397640099748969
. O 0 0.000104999948234763

Mutation O 0 4.0602084482088685e-05
screening O 0 8.367827831534669e-06
and O 0 6.332390967145329e-07
sequence O 0 4.5906989498689654e-07
analysis O 0 3.1100407227313553e-07
disclosed O 0 8.075879804891883e-07
the O 0 2.877173699289415e-07
involvement O 0 1.4445628266912536e-06
of O 0 3.8018913528503617e-07
three O 0 2.3496875201090006e-07
different O 0 2.582616218660405e-07
ARSA O 0 0.04754423350095749
mutations O 0 8.347730044988566e-07
being O 0 1.8607742902077007e-07
the O 0 2.647110761699878e-07
molecular O 0 8.843604746289202e-07
basis O 0 2.694168870220892e-07
of O 0 2.1686557829525555e-06
intrafamilial O 0 0.0009746184223331511
phenotypic O 0 0.00022364142932929099
heterogeneity O 0 0.0008701232145540416
. O 0 0.00011845123663078994

The O 0 5.6321816373383626e-05
late O 0 0.0008061159169301391
infantile O 1 0.9999758005142212
patient O 1 0.8062139749526978
inherited O 1 0.9962649941444397
from O 0 6.257283985178219e-06
his O 0 2.3351021809503436e-05
mother O 0 1.4415198165806942e-05
the O 0 1.4200445548340213e-06
frequent O 0 1.7992824723478407e-06
0 O 0 1.9247781892772764e-06
- O 0 4.383569830679335e-06
type O 0 3.527046828821767e-06
mutation O 0 2.1047494556114543e-06
459 O 0 1.0021182788477745e-05
+ O 0 1.2023125236737542e-05
1G O 0 0.000387837179005146
> O 0 5.25053610545001e-06
A O 0 1.6090519920908264e-06
, O 0 1.3626211625705764e-07
and O 0 4.799316499770612e-08
from O 0 1.0310687770243021e-07
his O 0 7.864163649173861e-07
father O 0 3.7722759316238808e-06
a O 0 1.0963300383082242e-06
novel O 0 1.5010407423687866e-06
, O 0 1.5508287276588817e-07
single O 0 4.065102530148579e-07
basepair O 0 1.552301000629086e-05
microdeletion O 0 7.229670245578745e-06
of O 0 5.788666612716042e-07
guanine O 0 3.101746187894605e-06
at O 0 4.4122521103417967e-07
nucleotide O 0 7.123189220692439e-07
7 O 0 5.103246394355665e-07
in O 0 3.6172221484775946e-07
exon O 0 1.3391120774031151e-05
1 O 0 2.3822992716304725e-06
( O 0 1.3522432027457398e-06
7delG O 0 4.8194477130891755e-05
) O 0 4.478458777157357e-06
. O 0 1.7333297364530154e-05

The O 0 2.1156763978069648e-05
two O 0 7.615883532707812e-06
clinically O 0 0.0035541870165616274
unaffected O 0 0.00014215086412150413
siblings O 0 6.599672815355007e-06
carried O 0 1.3966961205369444e-06
the O 0 2.282914920215262e-06
maternal O 0 2.0554603906930424e-05
mutation O 0 8.930339390644804e-06
459 O 0 4.6960940380813554e-05
+ O 0 4.936696859658696e-05
1G O 0 0.004717265255749226
> O 0 8.206943675759248e-06
A O 0 1.4776522903048317e-06
and O 0 9.791500588107738e-08
, O 0 8.339249291111628e-08
on O 0 1.2399165427723347e-07
their O 0 9.707615333809372e-08
paternal O 0 1.782296521923854e-06
allele O 0 9.06139121070737e-07
, O 0 1.5995905755517015e-07
a O 0 5.216450063016964e-07
novel O 0 1.329441602138104e-06
cytosine O 0 1.2585819604282733e-06
to O 0 6.652548734109587e-08
thymidine O 0 2.0233210307196714e-06
transition O 0 7.198115667961247e-07
at O 0 4.4277771849010605e-07
nucleotide O 0 2.5647282200225163e-06
2435 O 0 1.9134333342663012e-05
in O 0 2.583192895144748e-07
exon O 0 5.202452030061977e-06
8 O 0 4.973471732228063e-07
, O 0 1.2459524612040696e-07
resulting O 0 1.9862051203745068e-07
in O 0 7.467944129757598e-08
substitution O 0 1.1955080481129698e-06
of O 0 9.514477028460533e-07
alanine O 0 4.5064698497299105e-06
464 O 0 8.470397915516514e-06
by O 0 1.936203716468299e-06
valine O 0 0.0007153073674999177
( O 0 1.2679774044954684e-05
A464V O 0 0.0007540642400272191
) O 0 1.2700757906713989e-05
. O 0 3.273552647442557e-05

The O 0 0.0001239355915458873
fathers O 0 0.00015284513938240707
genotype O 0 0.00017736641166266054
thus O 0 2.1008405383327045e-05
was O 0 0.00017492267943453044
7delG O 0 0.039026081562042236
/ O 1 0.6617606282234192
A464V O 0 0.07661736756563187
. O 0 0.00013074948219582438

Mutation O 0 0.0002668640809133649
A464V O 0 0.0012977872975170612
was O 0 3.792236020672135e-05
not O 0 3.55172375066104e-07
found O 0 3.5977666357212e-07
in O 0 3.861681534544914e-07
18 O 0 9.861492799245752e-06
unrelated O 0 0.005089261569082737
MLD B-Disease 1 1.0
patients O 0 6.330406904453412e-05
and O 0 3.3366388834110694e-06
50 O 0 1.4430659575737081e-05
controls O 0 7.050266140140593e-05
. O 0 3.7262816476868466e-05

A464V O 0 0.0014970245538279414
, O 0 1.750252522469964e-05
although O 0 8.072529453784227e-06
clearly O 0 1.1787453331635334e-05
modifying O 0 4.502346200752072e-05
ARSA O 1 0.8684485554695129
and O 0 1.0574967745924369e-05
GS O 1 0.9999793767929077
levels O 0 1.0443616702104919e-05
, O 0 1.7373176888213493e-06
apparently O 0 4.810195150639629e-06
bears O 0 2.1779449070891133e-06
little O 0 6.777705152671842e-07
significance O 0 7.049836199257697e-07
for O 0 4.71823256020798e-07
clinical O 0 1.8077196727972478e-05
manifestation O 0 0.017091339454054832
of O 0 0.0003626803227234632
MLD B-Disease 1 0.9999998807907104
, O 0 2.0969491743016988e-05
mimicking O 0 8.556015382055193e-05
the O 0 1.7753951397025958e-05
frequent O 0 0.0001554482732899487
ARSA O 1 0.9992577433586121
pseudodeficiency O 1 0.5688056945800781
allele O 0 0.000428305211244151
. O 0 0.00010288378689438105

Our O 0 4.972882379661314e-06
results O 0 1.1283470939815743e-06
demonstrate O 0 8.279671419586521e-07
that O 0 1.1181498393852962e-07
in O 0 1.8445020089075115e-07
certain O 0 4.706628828898829e-07
genetic O 0 1.8331264072912745e-05
conditions O 0 0.007733104284852743
MLD B-Disease 1 1.0
- O 0 0.2614423632621765
like O 0 3.570048284018412e-05
ARSA O 1 0.9983468055725098
and O 0 2.754061370069394e-06
GS O 1 0.9774442315101624
values O 0 3.225977422971482e-07
need O 0 1.4639468304267211e-07
not O 0 3.185256503002165e-08
be O 0 3.530185210820491e-08
paralleled O 0 8.778013125265716e-07
by O 0 4.4488643879958545e-07
clinical O 0 0.09859901666641235
disease O 1 0.9996590614318848
, O 0 1.7318355958195752e-06
a O 0 1.6787608956292388e-06
finding O 0 1.394921810060623e-06
with O 0 7.63680588988791e-07
serious O 0 0.00017667420615907758
diagnostic O 0 0.00010870611731661484
and O 0 8.216514288506005e-06
prognostic O 0 0.4049602448940277
implications O 0 0.00033115956466645
. O 0 7.685210584895685e-05

Moreover O 0 9.74017966655083e-05
, O 0 1.1757577340176795e-05
further O 0 1.6904059521039017e-05
ARSA O 0 0.009412153623998165
alleles O 0 1.3684773875866085e-05
functionally O 0 8.454442649963312e-06
similar O 0 2.9082752917020116e-07
to O 0 1.6414105630246922e-07
A464V O 0 1.6064890587585978e-05
might O 0 1.6268953118014906e-07
exist O 0 4.06298603650157e-08
which O 0 1.536328397833131e-08
, O 0 2.393162112923619e-08
together O 0 2.4247132301979946e-08
with O 0 8.078716717818679e-08
0 O 0 8.111765055218711e-07
- O 0 5.035101821704302e-06
type O 0 3.1524007226835238e-06
mutations O 0 6.380486752277648e-07
, O 0 3.687921719119913e-07
may O 0 1.5082051731951651e-06
cause O 0 0.00023138354299589992
pathological O 1 0.999272882938385
ARSA O 1 0.999980092048645
and O 0 6.82757536196732e-06
GS O 1 0.9999912977218628
levels O 0 2.2765448193240445e-06
, O 0 1.7109285010974418e-07
but O 0 5.17696072677154e-08
not O 0 4.5060303932586976e-08
clinical O 0 1.3170707688914263e-06
outbreak O 0 1.8173372154706158e-05
of O 0 3.816141543211415e-06
the O 0 9.882735321298242e-05
disease O 1 0.9999420642852783
. O 0 1.5341080143116415e-05
. O 0 3.946877404814586e-05

Human O 1 0.7600551843643188
MLH1 O 1 0.9999997615814209
deficiency O 1 1.0
predisposes O 1 0.9990389347076416
to O 0 8.694290590938181e-05
hematological B-Disease 1 0.9999997615814209
malignancy I-Disease 1 1.0
and O 0 0.023883001878857613
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.501626193523407
1 I-Disease 0 0.0007000933401286602
. O 0 6.617723556701094e-05

Heterozygous O 0 0.0017626422923058271
germ O 1 0.9985523819923401
- O 0 0.00011252128751948476
line O 0 1.300248914049007e-05
mutations O 0 1.8120355207429384e-06
in O 0 4.516717240221624e-07
the O 0 2.368738023506012e-06
DNA O 0 5.114793384564109e-05
mismatch O 1 0.5112705826759338
repair O 0 0.00026097000227309763
genes O 0 1.7316439198111766e-06
lead O 0 5.7463043958705384e-06
to O 0 4.648726189770969e-06
hereditary B-Disease 1 0.9999995231628418
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7606812119483948

The O 0 0.00042798317736014724
disease O 1 0.9999626874923706
susceptibility O 1 0.5568713545799255
of O 0 5.895647518627811e-06
individuals O 0 5.227545329944405e-07
who O 0 2.3224179130920675e-06
constitutionally O 0 5.9454246184031945e-06
lack O 0 6.6323045757599175e-06
both O 0 4.832730269299645e-07
wild O 0 1.3930743079981767e-05
- O 0 5.902482371311635e-05
type O 0 3.937982182833366e-05
alleles O 0 3.6931978684151545e-06
is O 0 1.9919675651181024e-06
unknown O 0 1.917871122714132e-05
. O 0 2.0188272173982114e-05

We O 0 6.237099114514422e-06
have O 0 7.202854135357484e-07
identified O 0 1.244457848770253e-06
three O 0 3.6816419424212654e-07
offspring O 0 3.408329121157294e-06
in O 0 1.685938968876144e-06
a O 0 0.0003039935836568475
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.9871765971183777
who O 0 0.02073090709745884
developed O 1 0.8022308349609375
hematological B-Disease 1 0.9999998807907104
malignancy I-Disease 1 0.9999998807907104
at O 0 1.8446637113811448e-05
a O 0 1.44205762353522e-06
very O 0 1.1760338480826249e-07
early O 0 3.1750937523611356e-07
age O 0 3.8126788126646716e-07
, O 0 9.733756911600722e-08
and O 0 4.517269047710215e-08
at O 0 8.757329794661928e-08
least O 0 2.1320575527283836e-08
two O 0 9.55107726241522e-09
of O 0 1.0653700144303002e-07
them O 0 4.579635870527454e-08
displayed O 0 1.087167674995726e-06
signs O 0 3.57617227564333e-06
of O 0 6.066926289349794e-06
neurofibromatosis B-Disease 1 0.9999933242797852
type I-Disease 0 0.00020364063675515354
1 I-Disease 0 4.094760515727103e-05
( O 0 1.5557776350760832e-05
NF1 B-Disease 0 0.05033428966999054
) O 0 9.968139238480944e-06
. O 0 3.110499892500229e-05

DNA O 0 2.1205220036790706e-05
sequence O 0 1.926576032929006e-06
analysis O 0 6.967988497308397e-07
and O 0 4.541969360616349e-07
allele O 0 1.4846725662209792e-06
- O 0 1.3096520206090645e-06
specific O 0 1.7735766277837683e-07
amplification O 0 2.718642008403549e-06
in O 0 1.2966140161552175e-07
two O 0 1.2720639119834232e-07
siblings O 0 2.2783126496506156e-06
revealed O 0 3.818107416009298e-06
a O 0 4.618056209437782e-06
homozygous O 0 5.675410648109391e-05
MLH1 O 1 0.9438392519950867
mutation O 0 1.3655570910486858e-05
( O 0 3.2671046028553974e-06
C676T O 0 0.0011165017494931817
- O 0 0.0009019458666443825
- O 0 0.02925799787044525
> O 0 0.004219304770231247
Arg226Stop O 0 0.0023904365953058004
) O 0 1.3942812074674293e-05
. O 0 3.134055441478267e-05

Thus O 0 3.3720916690072045e-05
, O 0 9.087664693652187e-06
a O 0 2.636080898810178e-05
homozygous O 0 0.0003174557932652533
germ O 1 0.9999618530273438
- O 0 0.015433214604854584
line O 0 0.00014989497140049934
MLH1 O 1 0.9225611686706543
mutation O 0 9.977973604691215e-06
and O 0 2.447271754135727e-06
consequent O 1 0.9987571239471436
mismatch O 1 1.0
repair O 1 0.9999996423721313
deficiency O 1 0.9999998807907104
results O 0 4.348075890447944e-06
in O 0 1.764193370945577e-06
a O 0 4.4839522161055356e-05
mutator O 1 0.9999364614486694
phenotype O 0 0.02251112088561058
characterized O 0 0.00012908389908261597
by O 0 2.1407144231488928e-05
leukemia B-Disease 1 1.0
and O 0 0.36806726455688477
/ O 1 0.9999992847442627
or O 1 0.699204683303833
lymphoma B-Disease 1 1.0
associated O 0 0.18724006414413452
with O 0 0.008350872434675694
neurofibromatosis B-Disease 1 1.0
type I-Disease 0 0.40248918533325195
1 I-Disease 0 9.197432518703863e-05
. O 0 7.442493824783014e-06
. O 0 1.554916161694564e-05

Missense O 0 0.0009266840061172843
mutations O 0 2.0157473045401275e-05
in O 0 2.4949595172074623e-06
the O 0 2.6702473405748606e-06
most O 0 8.098153330138302e-07
ancient O 0 4.175156846031314e-06
residues O 0 1.9487524696160108e-06
of O 0 1.7920455093189958e-06
the O 0 9.368055543745868e-06
PAX6 O 1 0.999153733253479
paired O 0 1.8272516172146425e-05
domain O 0 4.137375071877614e-06
underlie O 0 1.3741505426878575e-05
a O 0 2.076153577945661e-06
spectrum O 0 2.9673845347133465e-05
of O 0 0.0001231462083524093
human O 1 0.9985093474388123
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9765751957893372

Mutations O 0 3.9750484575051814e-05
of O 0 8.213646651711315e-06
the O 0 1.4239912161428947e-05
human O 0 3.4823860914912075e-05
PAX6 O 1 0.9999489784240723
gene O 0 0.03803517669439316
underlie O 1 0.9994947910308838
aniridia B-Disease 1 1.0
( O 1 0.9995343685150146
congenital B-Disease 1 1.0
absence I-Disease 1 0.7111920118331909
of I-Disease 0 0.00061364087741822
the I-Disease 0 0.000580318970605731
iris I-Disease 1 0.9906716346740723
) O 0 4.821143875233247e-07
, O 0 4.7608421027689474e-07
a O 0 1.946629254234722e-06
rare O 0 5.5953289120225236e-05
dominant O 0 0.020316889509558678
malformation B-Disease 1 0.9999954700469971
of I-Disease 0 0.0018498852150514722
the I-Disease 0 0.07539093494415283
eye I-Disease 1 0.9981619715690613
. O 0 0.00013973744353279471

The O 0 1.780616003088653e-05
spectrum O 0 3.096801810897887e-05
of O 0 1.457621965528233e-05
PAX6 O 1 0.9996262788772583
mutations O 0 2.305696216353681e-05
in O 0 1.001124837785028e-05
aniridia B-Disease 1 0.9999996423721313
patients O 0 2.936122655228246e-05
is O 0 5.204202011555026e-07
highly O 0 5.685745918526663e-07
biased O 0 1.6479354769671772e-07
, O 0 2.97394464610079e-08
with O 0 2.1342259515222395e-08
92 O 0 8.682625320943771e-07
% O 0 1.205246036306562e-07
of O 0 1.206788340368803e-07
all O 0 7.342971031221168e-08
reported O 0 4.214703608340642e-07
mutations O 0 2.1712786235639214e-07
leading O 0 3.792085578879778e-07
to O 0 1.250196817181859e-07
premature O 0 2.3688398869126104e-06
truncation O 0 6.772640972485533e-06
of O 0 2.74141541467543e-07
the O 0 5.548254193854518e-07
protein O 0 6.62756065139547e-07
( O 0 2.534621330596565e-07
nonsense O 0 2.3931222585815703e-06
, O 0 1.4673489090455405e-07
splicing O 0 4.342285251368594e-07
, O 0 1.0889010582104675e-07
insertions O 0 8.729460887479945e-07
and O 0 6.890850556828809e-08
deletions O 0 5.321704747984768e-07
) O 0 3.609512688740324e-08
and O 0 2.7001691549344287e-08
just O 0 3.745504528751553e-08
2 O 0 7.562462656096614e-08
% O 0 4.3849983200061615e-08
leading O 0 1.1721351000915092e-07
to O 0 3.054590536066826e-08
substitution O 0 5.177603270567488e-07
of O 0 2.622290935505589e-07
one O 0 1.5930822883092333e-07
amino O 0 4.4426403178476903e-07
acid O 0 1.0902638223342365e-06
by O 0 2.72659519851004e-07
another O 0 1.8744758563116193e-06
( O 0 1.6691664086465607e-06
missense O 0 3.8324167690007016e-05
) O 0 4.970430836692685e-06
. O 0 2.1957677745376714e-05

The O 0 1.0064031812362373e-05
extraordinary O 0 2.338052581762895e-05
conservation O 0 9.832851901592221e-06
of O 0 1.2528408888101694e-06
the O 0 2.0163804492767667e-06
PAX6 O 0 0.0006062013562768698
protein O 0 1.2881212114734808e-06
at O 0 7.494226679227722e-07
the O 0 5.243543341748591e-07
amino O 0 1.3240476164355641e-06
acid O 0 1.8324304846828454e-06
level O 0 1.398154154230724e-06
amongst O 0 3.151288638036931e-06
vertebrates O 0 1.2945970411237795e-05
predicts O 0 3.999456112069311e-06
that O 0 2.4490830696777266e-07
pathological O 0 0.00015604455256834626
missense O 0 2.199382652179338e-05
mutations O 0 4.6555450694540923e-07
should O 0 4.6863974034749845e-08
in O 0 1.031772995929714e-07
fact O 0 1.9425905861680803e-07
be O 0 6.672143371133643e-08
common O 0 2.22544997541263e-07
even O 0 9.686124258223572e-08
though O 0 1.1735644989130378e-07
they O 0 6.196258084401052e-08
are O 0 4.32414353213062e-08
hardly O 0 1.5142120446398621e-06
ever O 0 9.54122697294224e-07
seen O 0 2.8932727218489163e-06
in O 0 5.775840236310614e-06
aniridia B-Disease 1 0.9998956918716431
patients O 0 0.0005256692529655993
. O 0 0.000111029228719417

This O 0 3.026382728421595e-06
indicates O 0 2.69057181867538e-06
that O 0 1.5295077560040227e-07
there O 0 2.127171541133066e-07
is O 0 1.8759159559067484e-07
a O 0 1.042380858962133e-06
heavy O 0 6.543224299093708e-05
ascertainment O 0 0.004032368306070566
bias O 0 1.7647436152401497e-06
in O 0 8.418645336405461e-08
the O 0 1.6208370823278528e-07
selection O 0 4.483013071876485e-07
of O 0 7.410293960674608e-07
patients O 0 1.3419913784673554e-06
for O 0 6.808542707403831e-07
PAX6 O 1 0.7513291239738464
mutation O 0 2.310898480573087e-06
analysis O 0 1.81011685640442e-07
and O 0 1.0993457522090466e-07
that O 0 2.2311792235996109e-07
the O 0 3.522505267028464e-06
missing O 0 5.278202661429532e-05
PAX6 O 1 0.9956099390983582
missense O 0 0.00031869273516349494
mutations O 0 4.857445674133487e-06
frequently O 0 6.599028097298287e-07
may O 0 1.470935899305914e-06
underlie O 0 4.899187115370296e-05
phenotypes O 0 1.8330023522139527e-05
distinct O 0 2.578009798526182e-06
from O 0 7.549558176833671e-06
textbook O 1 0.7106413841247559
aniridia B-Disease 1 0.9999904632568359
. O 0 0.000258724729064852

Here O 0 1.6971094737527892e-05
we O 0 1.5679443094995804e-06
present O 0 1.7744525848684134e-06
four O 0 1.5895857359282672e-06
novel O 0 2.8865264539490454e-05
PAX6 O 1 0.9604235291481018
missense O 0 0.0001024107332341373
mutations O 0 1.4748252397112083e-06
, O 0 1.2020905160170514e-07
two O 0 7.443087213232502e-08
in O 0 5.246224077382067e-07
association O 0 3.4124336707463954e-06
with O 0 1.3713050748265232e-06
atypical O 1 0.8863077163696289
phenotypes O 1 0.5869836807250977
ectopia B-Disease 1 0.9999098777770996
pupillae I-Disease 1 0.9935528039932251
( O 0 4.7349244596262e-06
displaced B-Disease 0 6.853036666143453e-06
pupils I-Disease 0 4.998148142476566e-06
) O 0 3.3522323974466417e-06
and O 0 8.157391857821494e-05
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.99997878074646
( O 0 1.8499242287361994e-05
searching B-Disease 0 9.451810001337435e-06
gaze I-Disease 0 8.443814294878393e-06
) O 0 1.6756756338054402e-07
, O 0 8.822345165526713e-08
and O 0 3.903074841105081e-08
two O 0 5.409444270298991e-08
in O 0 2.979282385240367e-07
association O 0 2.0234965631971136e-06
with O 0 1.0336792684029206e-06
more O 0 2.886795527956565e-06
recognizable O 0 0.0013509811833500862
aniridia B-Disease 1 0.9999599456787109
phenotypes O 0 0.0057005914859473705
. O 0 0.000134053552756086

Strikingly O 0 0.00012749434972647578
, O 0 3.0307382985483855e-06
all O 0 3.0733855282960576e-07
four O 0 4.336735628385213e-07
mutations O 0 5.636906053041457e-07
are O 0 4.392397912056367e-08
located O 0 4.475093646760797e-07
within O 0 2.79833358263204e-07
the O 0 1.4863613841953338e-06
PAX6 O 0 0.12438122183084488
paired O 0 2.173411530748126e-06
domain O 0 4.150018355630891e-07
and O 0 1.0626526858459329e-07
affect O 0 1.2798420812032418e-07
amino O 0 1.7654090811447531e-07
acids O 0 7.9556222942756e-08
which O 0 1.6378665534944048e-08
are O 0 6.824896647827927e-09
highly O 0 8.085422109616047e-08
conserved O 0 1.529058550886475e-07
in O 0 6.02536545102339e-08
all O 0 1.0962635599298665e-07
known O 0 2.8984177333768457e-06
paired O 0 9.785125257621985e-06
domain O 0 1.0820273018907756e-05
proteins O 0 1.1510711374285165e-05
. O 0 1.9456738300505094e-05

Our O 0 5.371348834160017e-06
results O 0 8.335717325280712e-07
support O 0 4.4543750732373155e-07
the O 0 4.2276985823264113e-07
hypothesis O 0 6.154645006972714e-07
that O 0 2.644420327158059e-08
the O 0 9.39004749511696e-08
under O 0 3.514116713176918e-07
- O 0 6.275136001931969e-07
representation O 0 3.978508118507307e-07
of O 0 6.917212544976792e-07
missense O 0 1.5624851585016586e-05
mutations O 0 1.1952778322665836e-06
is O 0 3.340375371863047e-07
caused O 0 2.5671999992482597e-06
by O 0 9.591771004124894e-07
ascertainment O 1 0.591835618019104
bias O 0 5.326601240085438e-06
and O 0 1.898144290635173e-07
suggest O 0 1.2315916819716222e-07
that O 0 3.2451822562507004e-08
a O 0 2.3389159764519718e-07
substantial O 0 2.655697699083248e-06
burden O 0 2.793923340504989e-05
of O 0 0.0004992996109649539
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9969462752342224
related I-Disease 0 0.030896244570612907
disease I-Disease 1 0.9999035596847534
remains O 0 1.4426283996726852e-05
to O 0 2.230770803635096e-07
be O 0 3.727097350747499e-07
uncovered O 0 1.574888483446557e-05
. O 0 3.17668877869437e-06
. O 0 1.5489174984395504e-05

The O 0 2.0260538803995587e-05
chromosomal O 0 5.771634459961206e-05
order O 0 2.6512641397857806e-06
of O 0 2.103306769640767e-06
genes O 0 8.282230510303634e-07
controlling O 0 3.130996219624649e-06
the O 0 1.9381729998713126e-06
major O 0 6.189967098180205e-05
histocompatibility O 1 0.9998975992202759
complex O 0 7.912289220257662e-06
, O 0 7.132379664653854e-07
properdin O 0 4.3038213334511966e-05
factor O 0 2.3879242689872626e-06
B O 0 3.2167474273592234e-05
, O 0 5.925120944993978e-07
and O 0 7.874805874052981e-07
deficiency B-Disease 1 0.9579977989196777
of I-Disease 0 1.2741172668029321e-06
the I-Disease 0 2.049728436759324e-06
second I-Disease 0 3.910328359779669e-06
component I-Disease 0 1.0297691005689558e-05
of I-Disease 0 4.434632955963025e-06
complement I-Disease 0 3.952368933823891e-05
. O 0 3.192187796230428e-05

The O 0 1.0941262189589906e-05
relationship O 0 2.6442346552357776e-06
of O 0 1.46421234603622e-06
the O 0 1.1000836366292788e-06
genes O 0 5.758981842518551e-07
coding O 0 1.2580635484482627e-06
for O 0 2.867017485641554e-07
HLA O 0 0.00040108547545969486
to O 0 4.706112477492752e-08
those O 0 2.908745955210179e-08
coding O 0 4.345901913893613e-07
for O 0 1.1389057874566788e-07
properdin O 0 3.953567647840828e-05
Factor O 0 2.0609325019904645e-06
B O 0 1.821027217374649e-05
allotypes O 0 1.939227331604343e-05
and O 0 1.5419831811414042e-07
for O 0 2.4370285700570093e-07
deficiency B-Disease 0 0.48284634947776794
of I-Disease 0 7.208145120785048e-07
the I-Disease 0 6.401868404282141e-07
second I-Disease 0 9.771777058631415e-07
component I-Disease 0 2.3243123905558605e-06
of I-Disease 0 7.440091849275632e-07
complement I-Disease 0 4.911076757707633e-06
( O 0 2.4554049105063314e-06
C2 O 0 0.00340098119340837
) O 0 1.343346980320348e-07
was O 0 4.5822923766536405e-07
studied O 0 2.63055198956863e-07
in O 0 1.0668789229839604e-07
families O 0 1.1532179655660002e-07
of O 0 3.1651338758820202e-06
patients O 0 0.0005756512982770801
with O 1 0.6837223172187805
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.9979525804519653

Patients O 0 5.311112545314245e-05
were O 0 2.707296744119958e-06
selected O 0 1.691278953330766e-06
because O 0 4.343212651747308e-07
they O 0 9.485958685218066e-08
were O 0 3.239894397211174e-07
heterozygous O 0 1.3461225307764835e-06
or O 0 7.788260063534835e-07
homozygous O 0 4.4952292228117585e-05
for O 0 0.00046321400441229343
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.017113687470555305

12 O 0 2.57386127486825e-05
families O 0 3.504562300804537e-06
with O 0 1.7066080317817978e-06
15 O 0 9.405994205735624e-06
matings O 0 8.424004772678018e-05
informative O 0 2.8190168450237252e-05
for O 0 0.00013592717004939914
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 4.1965653508668765e-05
found O 0 2.7323914764565416e-05
. O 0 3.733637640834786e-05

Of O 0 2.7538262656889856e-05
57 O 0 2.947310531453695e-05
informative O 0 1.2520643394964281e-05
meioses O 0 7.17711664037779e-05
, O 0 6.061259796297236e-07
two O 0 7.61092380230366e-08
crossovers O 0 4.861542493017623e-07
were O 0 1.4594442632187565e-07
noted O 0 4.14627606915019e-07
between O 0 9.900371651383466e-07
the O 0 0.00034488376695662737
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 7.165608167269966e-06
and O 0 5.23592746048962e-07
the O 0 1.0507995284569915e-05
HLA O 1 0.999997615814209
- O 0 0.004690420348197222
B O 0 0.010515592060983181
gene O 0 1.0769824712042464e-06
, O 0 6.260407303670945e-08
with O 0 7.161183646076097e-08
a O 0 9.529369435767876e-07
recombinant O 0 5.363149284676183e-06
fraction O 0 1.2954177464052918e-06
of O 0 2.610389401525026e-06
0 O 0 2.8840282539022155e-05
. O 0 2.7601257897913456e-05

035 O 1 0.7724795341491699
. O 0 0.005461960099637508

A O 0 8.786487887846306e-05
lod O 0 0.00012581577175296843
score O 0 2.2622175492870156e-06
of O 0 9.86165105132386e-07
13 O 0 1.2467219221434789e-06
was O 0 2.1858270429220283e-06
calculated O 0 4.5721824903921515e-07
for O 0 2.8139518803982355e-07
linkage O 0 4.405748768476769e-05
between O 0 0.0002673841081559658
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 0.0003131655976176262
HLA O 1 0.9999991655349731
- O 0 0.0004286487237550318
B O 0 4.173178967903368e-05
at O 0 3.689589220812195e-07
a O 0 2.0948318990576809e-07
maximum O 0 1.7076698100026988e-07
likelihood O 0 2.1515850789910473e-07
value O 0 4.2677783085309784e-08
of O 0 1.5868700131704827e-07
the O 0 4.904450179310516e-07
recombinant O 0 4.190870185993845e-06
fraction O 0 9.640310736358515e-07
of O 0 1.5511320725636324e-06
0 O 0 1.9463826902210712e-05
. O 0 1.8037693735095672e-05

04 O 0 0.06653924286365509
. O 0 0.0023809613194316626

18 O 0 2.3508589947596192e-05
families O 0 2.983944568768493e-06
with O 0 9.223929282597965e-07
21 O 0 4.172522039880278e-06
informative O 0 2.0214404230500804e-06
matings O 0 2.4049002149695298e-06
for O 0 2.2980124469995644e-07
both O 0 3.744012531115004e-07
properdin O 0 9.98668692773208e-05
Factor O 0 1.4230367924028542e-05
B O 0 0.00031111846328713
allotype O 0 0.002539168344810605
and O 0 1.2468427485146094e-05
HLA O 1 0.9999885559082031
- O 0 0.016221916303038597
B O 0 0.00374627485871315
were O 0 5.616201178781921e-06
found O 0 6.5633807935228106e-06
. O 0 1.6693809811840765e-05

Of O 0 3.599598858272657e-05
72 O 0 7.642166019650176e-05
informative O 0 2.6406298275105655e-05
meioses O 0 0.0003104408679064363
, O 0 1.2422357258401462e-06
three O 0 6.951136697352922e-07
recombinants O 0 0.00012213870650157332
were O 0 8.486638876092911e-07
found O 0 4.499958095038892e-07
, O 0 2.2494894835745072e-07
giving O 0 4.6571838652198494e-07
a O 0 1.2131886251154356e-06
recombinant O 0 4.790021193912253e-06
fraction O 0 2.3837060325604398e-06
of O 0 3.159774450978148e-06
0 O 0 2.7422902348916978e-05
. O 0 4.202283889753744e-05

042 O 0 0.15375983715057373
. O 0 0.003317511174827814

A O 0 4.1975261410698295e-05
lod O 0 5.889656677027233e-05
score O 0 1.5931309462757781e-06
of O 0 9.429151646145328e-07
16 O 0 1.977738520508865e-06
between O 0 3.324013960082084e-06
HLA O 1 0.9997285008430481
- O 0 0.00012975250137969851
B O 0 8.678519225213677e-05
and O 0 3.465004283498274e-07
Factor O 0 1.6998540104395943e-06
B O 0 4.786518729815725e-06
allotypes O 0 6.5405865825596265e-06
was O 0 6.80762013871572e-07
calculated O 0 7.281992964180972e-08
at O 0 6.771090710344652e-08
a O 0 5.415700243815991e-08
maximum O 0 1.1142707734279611e-07
likelihood O 0 1.2534081861304003e-07
value O 0 3.5070318205043804e-08
of O 0 5.37389297505797e-08
the O 0 2.3897734990896424e-07
recombinant O 0 1.5926113974273903e-06
fraction O 0 6.244844144021044e-07
of O 0 8.745292916501057e-07
0 O 0 1.2487777894421015e-05
. O 0 1.928240089910105e-05

04 O 0 0.12276960909366608
. O 0 0.003204577136784792

A O 0 5.792266529169865e-05
crossover O 0 3.083781848545186e-05
was O 0 7.875956725911237e-06
shown O 0 2.9860916583857033e-07
to O 0 4.2659472399009246e-08
have O 0 1.3101796092485074e-08
occurred O 0 6.310615674465225e-08
between O 0 2.3006606397757423e-08
genes O 0 2.02545997751713e-08
for O 0 1.6305168770713863e-08
Factor O 0 3.951366522869648e-07
B O 0 6.831229711679043e-06
and O 0 6.872604672025773e-07
HLA O 1 0.8102914690971375
- O 0 2.9251808882690966e-05
D O 0 0.00016214919742196798
, O 0 2.520894781810057e-07
in O 0 2.801912160066422e-07
which O 0 9.71750523603987e-07
HLA O 1 0.9989609718322754
- O 0 0.01099258754402399
D O 1 0.5916202068328857
segregared O 0 0.029922105371952057
with O 0 6.649759143328993e-06
HLA O 1 0.9999980926513672
- O 0 0.009828049689531326
A O 0 0.001077893190085888
and O 0 2.1502206436707638e-05
B O 0 0.011068057268857956
. O 0 5.374048123485409e-05

These O 0 1.279132220588508e-06
studies O 0 1.1186206165803014e-06
suggest O 0 5.064643460173102e-07
that O 0 5.212938702925385e-08
the O 0 9.944233880787579e-08
genes O 0 5.240083567059628e-08
for O 0 7.49276978240232e-08
Factor O 0 2.8919980650243815e-06
B O 0 0.06925341486930847
and O 0 0.00045989276259206235
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 1.0470181166510883e-07
located O 0 2.633463509482681e-07
outside O 0 8.977202980986476e-08
those O 0 2.1529801941255755e-08
for O 0 1.3383203167904867e-07
HLA O 0 0.14612457156181335
, O 0 1.2064167265180004e-07
that O 0 1.9428235020768625e-08
the O 0 4.469744752100269e-08
order O 0 7.391055589778261e-08
of O 0 3.422233021410648e-07
genese O 0 0.00016984064131975174
is O 0 1.141285110861645e-06
HLA O 0 0.3750612735748291
- O 0 4.429561158758588e-06
A O 0 8.356328180525452e-06
, O 0 4.1746207557480375e-07
- O 0 4.4460498429543804e-06
B O 0 1.5956664356053807e-05
, O 0 3.2630921964482695e-07
- O 0 2.75331558441394e-06
D O 0 2.890151517931372e-05
, O 0 5.446034379019693e-07
Factor O 0 2.902361757151084e-06
B O 0 0.00012540481111500412
allotype O 1 0.5004138946533203
, O 0 0.02111447975039482
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 9.462337402510457e-07
that O 0 7.852565175880954e-08
the O 0 1.9464812339720083e-07
genes O 0 2.0015122004224395e-07
coding O 0 3.5596624456957215e-06
for O 0 6.886657956783893e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.6615907725281431e-06
Factor O 0 2.679484396139742e-06
B O 0 1.0814330380526371e-05
allotypes O 0 4.989461103832582e-06
are O 0 1.7820395825651758e-08
approximately O 0 8.06023194854788e-08
3 O 0 1.4595583763821196e-07
- O 0 4.4209585325916123e-07
- O 0 8.825439294923854e-07
5 O 0 5.47426282082597e-07
centimorgans O 0 6.813116215198534e-06
from O 0 2.1674843253549625e-07
the O 0 1.4583216625396744e-06
HLA O 1 0.9643838405609131
- O 0 2.9896251362515613e-05
A O 0 7.350387750193477e-05
and O 0 3.5743614716921e-06
HLA O 1 0.9999748468399048
- O 0 0.000259767024544999
B O 0 0.00019603809050749987
loci O 0 5.704984005205915e-07
, O 0 4.819828447466534e-08
and O 0 1.9494530434371882e-08
that O 0 1.5158658328573438e-08
the O 0 9.578263870935189e-08
apparent O 0 1.8573397255750024e-06
lack O 0 6.286780376285606e-07
of O 0 3.9465535905947036e-07
recombinants O 0 1.545615123177413e-05
between O 0 1.9157812403136631e-07
the O 0 4.891212483926211e-07
Factor O 0 3.2253358313028002e-06
B O 0 0.000235079787671566
gene O 0 4.56129782833159e-05
and O 0 0.07306263595819473
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 4.6805838792352006e-05
suggests O 0 5.618593945655448e-07
that O 0 3.376045398795213e-08
these O 0 1.2965293727518201e-08
two O 0 3.2672360816832224e-08
genes O 0 1.1741555994149167e-07
lie O 0 3.029253718977998e-07
in O 0 1.169226706565496e-07
close O 0 4.5297275619304855e-07
proximity O 0 8.414428975811461e-07
to O 0 2.658186133430718e-07
one O 0 1.0705638260333217e-06
another O 0 1.4345532690640539e-05
. O 0 4.651075505535118e-05

Distribution O 0 1.696491199254524e-05
of O 0 1.8781973267323337e-05
emerin O 0 0.014284257777035236
and O 0 3.8027649225114146e-06
lamins O 0 0.006919725798070431
in O 0 1.2914040325995302e-06
the O 0 3.6916414956067456e-06
heart O 0 0.05776325985789299
and O 0 6.886730261612684e-07
implications O 0 1.0791129170684144e-05
for O 0 8.366336260223761e-06
Emery B-Disease 1 0.9966425895690918
- I-Disease 1 0.9999955892562866
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.30128005146980286

Emerin O 0 0.0012381408596411347
is O 0 6.318683063000208e-06
a O 0 7.612165973114315e-06
nuclear O 0 2.8372702217893675e-05
membrane O 0 1.2119548046030104e-05
protein O 0 6.737433864145714e-07
which O 0 1.0442798270560161e-07
is O 0 3.047752841212059e-07
missing O 0 1.5041343885968672e-06
or O 0 6.64990295717871e-07
defective O 0 3.15663855872117e-05
in O 0 1.002935732685728e-05
Emery B-Disease 1 0.9936560392379761
- I-Disease 1 0.9999995231628418
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9986431002616882
EDMD B-Disease 1 1.0
) O 0 0.00012578039604704827
. O 0 9.707633580546826e-05

It O 0 1.7732970718498109e-06
is O 0 4.359147283139464e-07
one O 0 1.3249618291411025e-07
member O 0 3.639599981397623e-07
of O 0 5.659470616592444e-07
a O 0 2.6529185106483055e-06
family O 0 2.1345106233638944e-06
of O 0 1.7145581296063028e-05
lamina O 1 0.999996542930603
- O 0 0.0002329372218810022
associated O 0 1.5966323871907662e-06
proteins O 0 2.4243948359981005e-07
which O 0 8.15283272004308e-08
includes O 0 7.087803624017397e-07
LAP1 O 0 0.003367434721440077
, O 0 1.8473414229447371e-06
LAP2 O 0 0.009440476074814796
and O 0 3.0562391657440457e-06
lamin O 0 0.0015618541510775685
B O 0 0.00024424027651548386
receptor O 0 1.6908865291043185e-05
( O 0 7.3227574830525555e-06
LBR O 0 0.001984213013201952
) O 0 1.245677049155347e-05
. O 0 3.0095518013695255e-05

A O 0 7.071516301948577e-05
panel O 0 1.4212071619112976e-05
of O 0 4.704928414867027e-06
16 O 0 8.899376553017646e-06
monoclonal O 0 2.856628088920843e-05
antibodies O 0 3.701653668031213e-06
( O 0 1.2951868484378792e-06
mAbs O 0 1.38124132718076e-05
) O 0 1.0058919741595673e-07
has O 0 7.349318309479713e-08
been O 0 3.936261450121492e-08
mapped O 0 1.3918067054419225e-07
to O 0 1.9982808296958865e-08
six O 0 2.9458806949378413e-08
specific O 0 2.3257475945115402e-08
sites O 0 3.6755128718368724e-08
throughout O 0 4.913869489087119e-08
the O 0 2.7671040925270063e-07
emerin O 0 2.3749431420583278e-05
molecule O 0 1.1428066954977112e-06
using O 0 2.0599310346369748e-07
phage O 0 4.9599520934862085e-06
- O 0 2.1319999632396502e-06
displayed O 0 1.2651838687816053e-06
peptide O 0 1.0425717391626677e-06
libraries O 0 1.9994593003502814e-07
and O 0 4.1518937621276564e-08
has O 0 5.2796309546465636e-08
been O 0 6.35055883435598e-08
used O 0 7.281548874971122e-08
to O 0 1.0625574020650674e-07
localize O 0 8.014095328690019e-06
emerin O 0 7.813368574716151e-05
in O 0 1.1079781643275055e-06
human O 0 4.787797024619067e-06
and O 0 7.473482128261821e-06
rabbit O 1 0.7973988652229309
heart O 1 0.9990620017051697
. O 0 0.0002845773415174335

Several O 0 2.137379487976432e-05
mAbs O 0 0.00028736513922922313
against O 0 1.1784913112933282e-05
different O 0 1.5123273442441132e-06
emerin O 0 0.0010439821053296328
epitopes O 0 7.79413094278425e-05
did O 0 7.974899745022412e-07
not O 0 1.4518563773435744e-07
recognize O 0 7.939437978166097e-07
intercalated O 0 2.8447071599657647e-05
discs O 0 5.767325546912616e-06
in O 0 3.5679516940945177e-07
the O 0 2.2434678612626158e-06
heart O 1 0.5102899074554443
, O 0 3.677981794680818e-07
though O 0 1.5018338217487326e-07
they O 0 3.9917409822010086e-08
recognized O 0 3.769622196614364e-07
cardiomyocyte O 0 3.656365515780635e-05
nuclei O 0 2.776212340904749e-06
strongly O 0 4.2071781081176596e-07
, O 0 1.2516260028405668e-07
both O 0 7.952254321708097e-08
at O 0 8.767522103880765e-07
the O 0 1.6674705420882674e-06
rim O 0 3.0138511647237465e-05
and O 0 5.39615996331122e-07
in O 0 1.8874900433729636e-06
intranuclear O 0 0.00036640558391809464
spots O 0 1.062341561919311e-05
or O 0 1.9975889244960854e-06
channels O 0 9.382602002006024e-06
. O 0 2.2349613573169336e-05

A O 0 0.0020583097357302904
polyclonal O 0 0.04323963820934296
rabbit O 0 0.0010567230638116598
antiserum O 0 0.00025098116020672023
against O 0 1.5039570826047566e-05
emerin O 0 0.00015967040963005275
did O 0 1.3253160204840242e-06
recognize O 0 5.347748128770036e-07
both O 0 1.474068653806171e-07
nuclear O 0 3.390990514162695e-06
membrane O 0 3.498391606626683e-06
and O 0 2.2917967612556822e-07
intercalated O 0 1.890094245027285e-05
discs O 0 1.4685405176351196e-06
but O 0 7.296438297998975e-08
, O 0 6.489301540568704e-08
after O 0 3.027353443485481e-07
affinity O 0 9.74107251749956e-07
purification O 0 5.990882982587209e-06
against O 0 7.783967816976656e-07
a O 0 1.5139204379011062e-06
pure O 0 1.2625222552742343e-05
- O 0 9.64167520578485e-06
emerin O 0 0.000489182595629245
band O 0 5.726937160943635e-06
on O 0 2.623486636821326e-07
a O 0 9.95884647636558e-07
western O 0 2.147347004211042e-06
blot O 0 1.3373917681747116e-05
, O 0 3.775976153974625e-07
it O 0 2.2176428160491923e-07
stained O 0 1.156921553047141e-05
only O 0 2.8887265557386854e-07
the O 0 2.457321215842967e-06
nuclear O 0 6.933618715265766e-05
membrane O 0 0.00016287037578877062
. O 0 3.1136580219026655e-05

These O 0 1.2891190408481634e-06
results O 0 5.606732429441763e-07
would O 0 1.7941508190233435e-07
not O 0 4.416996901568382e-08
be O 0 4.28093684945452e-08
expected O 0 1.600551939873185e-07
if O 0 9.808884016138109e-08
immunostaining O 0 8.231062565755565e-06
at O 0 1.2381693750285194e-06
intercalated O 0 2.054870310530532e-05
discs O 0 1.6370083812944358e-06
were O 0 8.574166798780425e-08
due O 0 1.4748209764547937e-07
to O 0 2.7245357969718498e-08
a O 0 1.0749081269523231e-07
product O 0 7.518481481838535e-08
of O 0 1.0510658654538929e-07
the O 0 3.685319995838654e-07
emerin O 0 0.00010884417861234397
gene O 0 6.912715093676525e-07
and O 0 9.136313394719764e-08
, O 0 1.1235285768407266e-07
therefore O 0 8.351139513251837e-08
, O 0 2.9424946035305766e-08
cast O 0 4.072505888075284e-08
some O 0 1.552056261289181e-08
doubt O 0 2.2268916666234873e-07
upon O 0 8.86405757682951e-08
the O 0 2.0351302509880043e-07
hypothesis O 0 3.829937668342609e-06
that O 0 1.2385945638015983e-06
cardiac B-Disease 1 0.9999998807907104
defects I-Disease 1 0.9999794960021973
in O 0 5.403385512181558e-05
EDMD B-Disease 1 1.0
are O 0 2.5441579509788426e-07
caused O 0 1.2169999536126852e-05
by O 0 5.840564085701772e-07
absence O 0 1.596677248016931e-05
of O 0 1.2335738574620336e-05
emerin O 0 0.09403602033853531
from O 0 1.7154183296952397e-05
intercalated O 0 0.4462207555770874
discs O 0 0.0022927424870431423
. O 0 8.462660480290651e-05

Although O 0 5.138205597177148e-05
emerin O 0 0.0006448101485148072
was O 0 3.399611887289211e-05
abundant O 0 3.6960450415790547e-06
in O 0 3.2542320127504354e-07
the O 0 1.0584728897811146e-06
membranes O 0 5.449101990961935e-06
of O 0 1.8964810806210153e-06
cardiomyocyte O 0 0.03222649171948433
nuclei O 0 1.1740234185708687e-05
, O 0 2.811687522807915e-07
it O 0 1.0459822163966237e-07
was O 0 1.6688163668732159e-06
absent O 0 6.443697770919243e-07
from O 0 1.0730092725452778e-07
many O 0 1.7797661655549746e-07
non O 0 4.353872554929694e-06
- O 0 0.016365226358175278
myocyte O 1 0.9998799562454224
cells O 0 1.1682725926220883e-05
in O 0 8.630194656689127e-07
the O 0 1.28118263091892e-05
heart O 1 0.9905192852020264
. O 0 7.538409408880398e-05

This O 0 2.8463500711950473e-06
distribution O 0 2.629235041240463e-06
of O 0 2.7085568490292644e-06
emerin O 0 0.00020358781330287457
was O 0 1.1603557140915655e-05
similar O 0 3.3490385931145283e-07
to O 0 4.362549077541189e-08
that O 0 4.6832788314077334e-08
of O 0 4.630695116247807e-07
lamin O 0 0.0001039960261550732
A O 0 2.6402583443996264e-06
, O 0 2.1200729349857284e-07
a O 0 4.578081700401526e-07
candidate O 0 7.260834991029697e-07
gene O 0 4.382180804896052e-07
for O 0 2.013354816199353e-07
an O 0 1.167640448329621e-06
autosomal O 0 6.137478339951485e-05
form O 0 2.782933006528765e-05
of O 0 0.02636907808482647
EDMD B-Disease 1 1.0
. O 0 0.0013307628687471151

In O 0 2.6372224965598434e-05
contrast O 0 3.691231904667802e-05
, O 0 2.6152132704737596e-05
lamin O 1 0.9695360064506531
B1 O 1 0.9997748732566833
was O 0 7.547839777544141e-05
absent O 0 7.483738045266364e-06
from O 0 1.4851739251753315e-06
cardiomyocyte O 0 0.00036822768743149936
nuclei O 0 7.902282050054055e-06
, O 0 6.313529183898936e-07
showing O 0 2.234143948953715e-06
that O 0 7.521061888837721e-07
lamin O 0 0.05456069856882095
B1 O 0 0.049376700073480606
is O 0 2.1469730882017757e-07
not O 0 2.3928699022235378e-08
essential O 0 1.249077854481584e-07
for O 0 5.961771165630125e-08
localization O 0 7.389768143184483e-06
of O 0 1.052339257512358e-06
emerin O 0 3.178884435328655e-05
to O 0 5.739516950598045e-07
the O 0 8.453821465082001e-06
nuclear O 0 0.0005017596413381398
lamina O 1 0.7294573783874512
. O 0 7.468595140380785e-05

Lamin O 1 0.9996699094772339
B1 O 1 0.9994586110115051
is O 0 1.1596389413170982e-05
also O 0 2.87245757135679e-06
almost O 0 4.2577557906042784e-06
completely O 0 1.6789670553407632e-05
absent O 0 3.9051730709616095e-05
from O 0 3.986452429671772e-05
skeletal O 1 0.999998927116394
muscle O 1 0.9999452829360962
nuclei O 0 0.31923529505729675
. O 0 0.00019043710199184716

In O 0 4.15465074183885e-05
EDMD B-Disease 1 0.9960134029388428
, O 0 2.4477574243064737e-06
the O 0 1.1398329888834269e-06
additional O 0 9.174291903946141e-07
absence O 0 8.141174475895241e-06
of O 0 2.5512832507956773e-05
lamin O 1 0.9999250173568726
B1 O 1 0.9999949932098389
from O 0 3.125271905446425e-05
heart O 1 0.9999964237213135
and O 0 0.03286179527640343
skeletal O 1 1.0
muscle O 1 0.9999152421951294
nuclei O 0 0.0002665528445504606
which O 0 3.73105223161474e-07
already O 0 6.871136974950787e-07
lack O 0 2.0046882127644494e-06
emerin O 0 0.00015403844008687884
may O 0 2.0446628923309618e-07
offer O 0 4.511861462219713e-08
an O 0 5.5015728861462776e-08
alternative O 0 2.1462811616856925e-07
explanation O 0 2.713692310862825e-07
of O 0 2.8786888606191496e-07
why O 0 5.260422994979308e-07
these O 0 1.1645328612530648e-07
tissues O 0 4.95721860716003e-06
are O 0 1.0225630830973387e-07
particularly O 0 1.3153849067748524e-06
affected O 0 3.822873168246588e-06
. O 0 4.497719601204153e-06
. O 0 2.5602181267458946e-05

Genetic O 0 7.038309558993205e-05
mapping O 0 1.6439233149867505e-05
of O 0 7.586828814964974e-06
the O 0 2.682463309611194e-05
copper B-Disease 1 0.9834287762641907
toxicosis I-Disease 1 0.9987579584121704
locus O 0 4.457692921278067e-05
in O 0 2.481452838765108e-06
Bedlington O 0 0.0006067279609851539
terriers O 0 3.083423143834807e-05
to O 0 2.8823671982536325e-07
dog O 0 2.145328835467808e-06
chromosome O 0 8.054144018387888e-07
10 O 0 1.142794232578126e-07
, O 0 8.158277609027209e-08
in O 0 1.066887023171148e-07
a O 0 6.936687100278505e-07
region O 0 1.7080392353818752e-06
syntenic O 0 3.8413370930356905e-05
to O 0 3.385292757229763e-07
human O 0 1.4915100337020704e-06
chromosome O 0 1.962138048838824e-05
region O 0 3.706321876961738e-05
2p13 O 0 0.2359938770532608
- O 0 0.18360616266727448
p16 O 0 0.0076423822902143
. O 0 0.00010453799040988088

Abnormal O 1 0.999987006187439
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999979734420776
accumulation I-Disease 1 0.7308852076530457
is O 0 2.3446202703780727e-06
recognized O 0 1.53091900756408e-06
as O 0 1.1927396599276108e-06
an O 0 8.403818355873227e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.044798579066991806
man O 1 0.9934707880020142
, O 0 5.714425060432404e-05
mouse O 0 0.011090532876551151
, O 0 2.0512405171757564e-05
rat O 0 0.3877875506877899
and O 0 9.617393516236916e-06
dog O 0 0.00015576965233776718
. O 0 4.704690582002513e-05

The O 0 2.6241868908982724e-05
major O 0 5.790532304672524e-05
cause O 0 0.0003871212829835713
of O 0 0.017457513138651848
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999995231628418
accumulation I-Disease 1 0.9899612665176392
in O 0 5.05654361404595e-06
man O 0 2.275305632792879e-05
is O 0 5.31560260697006e-07
a O 0 2.76867967841099e-06
dysfunctional O 0 0.000130747226648964
ATP7B O 1 0.9999052286148071
gene O 0 4.045282912557013e-05
, O 0 3.4897609566542087e-06
causing O 0 0.0030662899371236563
Wilson B-Disease 1 0.5414717197418213
disease I-Disease 1 0.9999744892120361
( O 0 0.00030134947155602276
WD B-Disease 1 0.9999871253967285
) O 0 4.229631304042414e-05
. O 0 7.819024904165417e-05

Mutations O 0 4.9592559662414715e-05
in O 0 4.4762255129171535e-06
the O 0 1.2638822227017954e-05
ATP7B O 1 0.9583367109298706
genes O 0 1.2728834235531394e-06
have O 0 1.2977223207144561e-07
also O 0 2.09665870443132e-07
been O 0 2.303928425817503e-07
demonstrated O 0 1.2082974762961385e-06
in O 0 1.000042743726226e-06
mouse O 0 6.388345354935154e-05
and O 0 1.3522133485821541e-05
rat O 0 0.14935730397701263
. O 0 7.661166455363855e-05

The O 0 0.00012768794840667397
ATP7B O 1 0.9781844019889832
gene O 0 3.590349660953507e-05
has O 0 1.7760456785254064e-06
been O 0 5.083467158328858e-07
excluded O 0 9.912312179949367e-07
in O 0 2.3426082407240756e-07
the O 0 7.759613254165743e-07
much O 0 3.1359659260488115e-06
rarer O 0 0.002134675858542323
human O 0 0.0002810746955219656
copper B-Disease 1 0.9999998807907104
overload I-Disease 1 1.0
disease O 1 0.9999997615814209
non B-Disease 0 0.05767600238323212
- I-Disease 1 0.5283142328262329
Indian I-Disease 0 0.0010562014067545533
childhood I-Disease 1 0.9957006573677063
cirrhosis I-Disease 1 0.9999991655349731
, O 0 3.7539164623012766e-05
indicating O 0 0.00017236056737601757
genetic O 0 0.00036478161928243935
heterogeneity O 0 0.013245576061308384
. O 0 0.00014380773063749075

By O 0 2.0593628505594097e-05
investigating O 0 3.647171979537234e-05
the O 0 1.9064265870838426e-05
common O 0 0.0001697663392405957
autosomal O 1 0.9987114667892456
recessive O 1 0.9999988079071045
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 0.0001299569703405723
CT B-Disease 1 0.8968249559402466
) O 0 1.0093107221109676e-06
in O 0 1.0059301303044776e-06
Bedlington O 0 0.0004548185388557613
terriers O 0 1.5039126083138399e-05
, O 0 2.031926555901009e-07
we O 0 3.4585525554575725e-08
have O 0 1.5627588112465673e-08
identified O 0 6.329106838620646e-08
a O 0 1.733397567704742e-07
new O 0 2.791190638617991e-07
locus O 0 4.880611868429696e-06
involved O 0 8.265218411906972e-07
in O 0 1.4187466149451211e-05
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.6928554177284241

We O 0 5.293281446938636e-06
examined O 0 5.243370651442092e-06
whether O 0 1.188718670164235e-06
the O 0 8.512523891113233e-06
WD B-Disease 1 0.9997169375419617
gene O 0 7.385701610473916e-05
ATP7B O 1 0.9667038917541504
was O 0 1.6046222299337387e-05
also O 0 5.132873752700107e-07
causative O 0 3.3645117127889534e-06
for O 0 2.0580085902111023e-07
CT B-Disease 0 1.4423600987356622e-05
by O 0 2.7955542236668407e-07
investigating O 0 8.689815444995475e-07
the O 0 1.0854065521925804e-06
chromosomal O 0 0.00013407219375949353
co O 0 7.529134018113837e-05
- O 0 6.222803494893014e-05
localization O 0 0.0006910846568644047
of O 0 9.3457565526478e-06
ATP7B O 1 0.7819588780403137
and O 0 1.1889090956174186e-06
C04107 O 0 3.040476622118149e-05
, O 0 4.2731545590868336e-07
using O 0 2.218757799710147e-07
fluorescence O 0 5.917306111768994e-07
in O 0 2.313819464916378e-07
situ O 0 1.2057778803864494e-05
hybridization O 0 4.418119260662934e-06
( O 0 2.145508915418759e-06
FISH O 0 1.7945894796866924e-05
) O 0 4.411912868818035e-06
. O 0 1.612156665942166e-05

C04107 O 0 0.0023918538354337215
is O 0 1.160444207926048e-05
an O 0 5.210074050410185e-06
anonymous O 0 2.116378345817793e-05
microsatellite O 0 0.000575570622459054
marker O 0 7.167848525568843e-05
closely O 0 3.6486744647845626e-06
linked O 0 1.447021077183308e-05
to O 0 7.450872999470448e-06
CT B-Disease 1 0.5322675704956055
. O 0 8.566253382014111e-05

However O 0 0.00010400245810160413
, O 0 9.137044253293425e-05
BAC O 0 0.09462036192417145
clones O 0 0.00011458320659585297
containing O 0 2.4479337298544124e-05
ATP7B O 0 0.09671372920274734
and O 0 3.766484496736666e-06
C04107 O 0 6.770016625523567e-05
mapped O 0 3.5732468859350774e-06
to O 0 3.05755776253136e-07
the O 0 1.3802517742078635e-06
canine O 0 3.952379847760312e-05
chromosome O 0 1.0839100468729157e-05
regions O 0 1.4419146054933663e-06
CFA22q11 O 0 0.00018247461412101984
and O 0 6.351079377964197e-07
CFA10q26 O 0 8.209080988308415e-05
, O 0 3.6545213788485853e-07
respectively O 0 2.49295624143997e-07
, O 0 1.3142108912234107e-07
demonstrating O 0 8.981310770650452e-07
that O 0 3.6385102930580615e-07
WD B-Disease 0 0.023407967761158943
cannot O 0 4.5427100303641055e-07
be O 0 1.7582513578418002e-07
homologous O 0 2.4271300844702637e-06
to O 0 2.656731339811813e-06
CT B-Disease 0 0.005121338181197643
. O 0 6.077790749259293e-05

The O 0 0.00010024498624261469
copper O 0 0.0038863092195242643
transport O 0 7.464622467523441e-05
genes O 0 1.0451795787957963e-05
CTR1 O 0 0.0844612568616867
and O 0 3.1624726943846326e-06
CTR2 O 0 0.14290782809257507
were O 0 9.578525350661948e-07
also O 0 4.780013114213943e-07
excluded O 0 6.827424954281014e-07
as O 0 1.4896662037244823e-07
candidate O 0 3.3156101153508644e-07
genes O 0 1.0445885578747038e-07
for O 0 1.1316323167420705e-07
CT B-Disease 0 6.73275935696438e-05
since O 0 5.612188829218212e-07
they O 0 8.717632482557747e-08
both O 0 9.810512580088471e-08
mapped O 0 1.8066554048346006e-06
to O 0 1.0739527169789653e-06
canine O 0 9.133560524787754e-05
chromosome O 0 6.983533239690587e-05
region O 0 7.20723983249627e-05
CFA11q22 O 0 0.10060174763202667
. O 0 8.8937820692081e-05

2 O 0 0.0002660972822923213
- O 0 0.00045491891796700656
22 O 0 0.000320141960401088
. O 0 0.00022639786766376346

5 O 0 0.0012501135934144258
. O 0 0.0007253674557432532

A O 0 5.781847357866354e-05
transcribed O 0 1.7157815818791278e-05
sequence O 0 1.6517225276402314e-06
identified O 0 1.0647042927303119e-06
from O 0 3.283041110080376e-07
the O 0 8.712826229384518e-07
C04107 O 0 0.0002174705732613802
- O 0 2.0094303181394935e-05
containing O 0 1.0763586033135653e-05
BAC O 0 0.015336461365222931
was O 0 3.843469130515587e-06
found O 0 8.593338662876704e-08
to O 0 2.6788447016201644e-08
be O 0 2.759013639774821e-08
homologous O 0 1.1844180392017734e-07
to O 0 2.9070708507106247e-08
a O 0 2.496706201782217e-07
gene O 0 4.899102350464091e-07
expressed O 0 2.622801389406959e-07
from O 0 1.464277659124491e-07
human O 0 7.349457860073016e-07
chromosome O 0 2.3573560611112043e-05
2p13 O 0 0.11854027956724167
- O 0 0.0010038737673312426
p16 O 0 0.00024437211686745286
, O 0 4.984848942513054e-07
a O 0 5.316251758813451e-07
region O 0 1.2696366411546478e-06
devoid O 0 5.467351911647711e-06
of O 0 5.413912731455639e-07
any O 0 1.0691190936995554e-06
positional O 0 4.708519554696977e-05
candidate O 0 1.1844924301840365e-05
genes O 0 8.298285138153005e-06
. O 0 1.929073187056929e-05

Molecular O 0 1.5096532479219604e-05
analysis O 0 1.1831248230009805e-06
of O 0 1.3076689810986863e-06
the O 0 3.1410959309141617e-06
APC B-Disease 0 5.528599285753444e-05
gene O 0 1.242439566340181e-06
in O 0 2.2941935640119482e-07
205 O 0 1.7246859442821005e-06
families O 0 1.6000544178496057e-07
: O 0 2.0462117333863716e-07
extended O 0 1.6137404372784658e-06
genotype O 0 9.896312803903129e-06
- O 0 9.228485396306496e-06
phenotype O 0 9.281857273890637e-06
correlations O 0 1.0308431228622794e-06
in O 0 3.6727735164276964e-07
FAP B-Disease 0 0.00010148195724468678
and O 0 7.117458977745628e-08
evidence O 0 6.852069134311023e-08
for O 0 3.5325832925536815e-08
the O 0 1.6593848783941212e-07
role O 0 6.763847864021955e-07
of O 0 3.338265287311515e-06
APC B-Disease 0 0.00045308846165426075
amino O 0 3.625106955951196e-06
acid O 0 7.736213774478529e-06
changes O 0 1.971915025933413e-06
in O 0 0.00010125528933713213
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999972581863403
. O 0 0.009385928511619568

BACKGROUND O 0 0.0005405453266575933
/ O 0 0.0002421797253191471
AIMS O 0 2.9882199669373222e-05
The O 0 2.949039753730176e-06
development O 0 6.2786712078377604e-06
of O 0 0.04576285183429718
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.7296182452118956e-06
a O 0 1.7441041109123034e-06
variable O 0 6.999071047175676e-07
range O 0 4.638641826204548e-07
of O 0 1.8376244952378329e-06
extracolonic O 0 0.01938355155289173
manifestations O 0 0.07272885739803314
in O 0 0.00010152725008083507
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9901256561279297
FAP B-Disease 1 0.999995231628418
) O 0 1.115183408728626e-06
is O 0 1.2439909369277302e-07
the O 0 6.847457001413204e-08
result O 0 1.769467843359962e-07
of O 0 2.9540797186200507e-07
the O 0 1.722729621178587e-06
dominant O 0 2.8973981898161583e-05
inheritance O 0 0.00013857877638656646
of O 0 0.06326478719711304
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999994039535522
( O 0 0.031676724553108215
APC B-Disease 1 0.9882907867431641
) O 0 1.074776901077712e-05
gene O 0 2.692530324566178e-05
mutations O 0 2.799636058625765e-05
. O 0 4.37214839621447e-05

In O 0 5.045272246206878e-06
this O 0 7.007085400800861e-07
study O 0 5.497595907399955e-07
, O 0 1.9697638720117538e-07
direct O 0 1.3714839042222593e-07
mutation O 0 1.6470055186346144e-07
analysis O 0 6.272563268794329e-08
of O 0 2.1332539290597197e-07
the O 0 1.4995783885751734e-06
APC B-Disease 0 0.0001341076276730746
gene O 0 1.060918521034182e-06
was O 0 1.4473869214270962e-06
performed O 0 4.321430822074035e-07
to O 0 8.930444295174311e-08
determine O 0 1.4932392389255256e-07
genotype O 0 3.832809852610808e-06
- O 0 3.0221258384699468e-06
phenotype O 0 4.0986760723171756e-06
correlations O 0 4.225046268402366e-07
for O 0 1.4186881003297458e-07
nine O 0 1.2284496051506721e-06
extracolonic O 0 0.0005296882009133697
manifestations O 0 2.509601654310245e-05
and O 0 1.7539372265673592e-07
to O 0 5.3659451992871254e-08
investigate O 0 1.0416876961016897e-07
the O 0 2.5127150138359866e-07
incidence O 0 2.147376289940439e-05
of O 0 6.5319350142090116e-06
APC B-Disease 0 0.005379862617701292
mutations O 0 2.0061188479303382e-06
in O 0 2.5912611363310134e-06
non O 0 0.008496491238474846
- O 1 0.9999991655349731
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.29208680987358093

METHODS O 0 7.068643753882498e-05
The O 0 2.7813250198960304e-05
APC B-Disease 0 0.00024356866197194904
gene O 0 4.623211680154782e-06
was O 0 4.91875471198e-06
analysed O 0 2.1375967662606854e-06
in O 0 6.794454066039179e-07
190 O 0 3.966441454394953e-06
unrelated O 0 6.6593165684025735e-06
FAP B-Disease 0 0.0002163211756851524
and O 0 7.8337438935705e-07
15 O 0 5.049305855209241e-06
non O 0 0.0049522980116307735
- O 1 0.9999983310699463
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.002619146602228284
using O 0 5.762075033999281e-06
denaturing O 0 0.001645935932174325
gradient O 0 8.345584501512349e-05
gel O 0 1.680456625763327e-05
electrophoresis O 0 3.197045316483127e-06
, O 0 1.0389375404429302e-07
the O 0 1.329526071458531e-07
protein O 0 3.67079138641202e-07
truncation O 0 6.094965556258103e-06
test O 0 4.067010479502642e-07
, O 0 1.5959457755343465e-07
and O 0 1.7848432776190748e-07
direct O 0 1.632694193176576e-06
sequencing O 0 2.3657385099795647e-05
. O 0 2.449647945468314e-05

RESULTS O 0 8.245091157732531e-05
Chain O 0 4.646154411602765e-05
terminating O 0 1.378342403768329e-05
signals O 0 2.2753424673283007e-06
were O 0 1.8446216643042135e-07
only O 0 5.5604278514920225e-08
identified O 0 2.822907561039756e-07
in O 0 2.668114120751852e-07
patients O 0 9.945017609425122e-07
belonging O 0 2.8212116376380436e-06
to O 0 2.8260942031010927e-07
the O 0 2.548330257923226e-06
FAP B-Disease 0 0.21200451254844666
group O 0 6.3610482357034925e-06
( O 0 2.079161276924424e-06
105 O 0 1.6163732652785257e-05
patients O 0 1.2651581528189126e-05
) O 0 7.348628059844486e-06
. O 0 2.6852378141484223e-05

Amino O 0 4.808420635527e-05
acid O 0 1.092570528271608e-05
changes O 0 6.849246005913301e-07
were O 0 4.031621756439563e-07
identified O 0 4.793288326254697e-07
in O 0 1.315255246936431e-07
four O 0 2.0794696808934532e-07
patients O 0 6.269465302466415e-07
, O 0 1.107820111201363e-07
three O 0 7.347033204041509e-08
of O 0 5.420008619694272e-07
whom O 0 1.1492527391965268e-06
belonged O 0 7.133350663934834e-06
to O 0 1.3023394274114253e-07
the O 0 1.1861434359161649e-06
non O 0 2.790972575894557e-05
- O 0 0.05406254529953003
FAP O 1 0.9995144605636597
group O 0 0.0003647607518360019
of O 1 0.9969425797462463
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9999701976776123
. O 0 0.012764066457748413

Genotype O 0 0.004236887209117413
- O 0 0.0008319205371662974
phenotype O 0 0.00023633448290638626
correlations O 0 7.138693490560399e-06
identified O 0 1.313031134486664e-06
significant O 0 5.301225201037596e-07
differences O 0 2.6945647846332577e-07
in O 0 2.272613528475631e-07
the O 0 3.235306564874918e-07
nature O 0 7.490232860618562e-07
of O 0 6.928277684892237e-07
certain O 0 1.2339164641161915e-06
extracolonic O 0 0.050639256834983826
manifestations O 0 0.04060046002268791
in O 0 2.9483166144927964e-05
FAP B-Disease 1 0.9999097585678101
patients O 0 1.673375300015323e-05
belonging O 0 6.319677140709246e-06
to O 0 4.222895313432673e-07
three O 0 1.0055924803964444e-06
mutation O 0 4.1813807911239564e-05
subgroups O 0 0.0002102885046042502
. O 0 5.225256609264761e-05

CONCLUSIONS O 0 0.00011623580212472007
Extended O 0 6.0307549574645236e-05
genotype O 0 0.00014119804836809635
- O 0 4.149210872128606e-05
phenotype O 0 3.7467776564881206e-05
correlations O 0 1.3698543170903577e-06
made O 0 2.0774815823187964e-07
in O 0 6.688159714940412e-08
this O 0 4.527663222120282e-08
study O 0 5.49165477536917e-08
may O 0 4.269447373417279e-08
have O 0 1.0580571974116992e-08
the O 0 3.343759757967746e-08
potential O 0 6.414114750441513e-08
to O 0 1.0481966405961884e-08
determine O 0 1.3028780720958366e-08
the O 0 3.01234841515452e-08
most O 0 3.5585649982294854e-08
appropriate O 0 8.359586445294553e-08
surveillance O 0 1.0561254839558387e-06
and O 0 2.8860006295872154e-07
prophylactic O 0 0.0053855557925999165
treatment O 0 0.0005475429352372885
regimens O 0 4.577511936076917e-05
for O 0 4.221059271003469e-07
those O 0 2.727313130890252e-07
patients O 0 7.643859589734348e-07
with O 0 4.768626240547746e-07
mutations O 0 5.376074113883078e-06
associated O 0 5.766120921180118e-06
with O 0 3.3583503409317927e-06
life O 0 0.00015826663002371788
threatening O 0 0.007651899941265583
conditions O 0 0.0014022624818608165
. O 0 0.00018474174430593848

This O 0 2.8497559014795115e-06
study O 0 1.2230408401592285e-06
also O 0 2.905741496306291e-07
provided O 0 2.8934746865161287e-07
evidence O 0 1.51838960960049e-07
for O 0 5.6006197013402925e-08
the O 0 2.82175022903175e-07
pathological O 0 3.554008071660064e-05
nature O 0 5.41474946658127e-07
of O 0 4.898349743598374e-07
amino O 0 1.0080178753923974e-06
acid O 0 1.0014236977440305e-06
changes O 0 1.4932946612589149e-07
in O 0 2.541248136367358e-07
APC O 0 2.5117493350990117e-05
associated O 0 2.8406910246303596e-07
with O 0 2.362603197525459e-07
both O 0 7.991145594132831e-07
FAP B-Disease 0 0.12777665257453918
and O 0 4.207312940707197e-06
non O 0 0.10359787940979004
- O 1 0.9999996423721313
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9956003427505493
. O 0 0.0001237502001458779
. O 0 0.0001397908927174285

Inherited B-Disease 1 0.9999994039535522
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.998497486114502
cancer B-Disease 1 0.9999998807907104
risk O 0 0.016722898930311203
of O 0 0.0005191900418139994
the O 0 0.0017704259371384978
APC O 1 0.9976982474327087
I1307K O 1 0.6579765677452087
polymorphism O 0 0.000754827749915421
. O 0 0.00011668811202980578

Germ O 1 0.9993607401847839
- O 0 0.00025278516113758087
line O 0 3.4130600397475064e-05
and O 0 4.186819751339499e-06
somatic O 0 3.223073508706875e-05
truncating O 0 3.7583435187116265e-05
mutations O 0 1.6523275689905859e-06
of O 0 1.282309085581801e-06
the O 0 4.811498001799919e-06
APC B-Disease 0 0.0009754833299666643
gene O 0 1.0665690979294595e-06
are O 0 4.329284308823844e-08
thought O 0 3.6096372468819027e-07
to O 0 2.098462914545962e-07
initiate O 0 4.6914428821764886e-05
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9999969005584717
formation O 0 0.1626560091972351
in O 0 0.0006603904766961932
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9985066056251526
sporadic O 1 0.9999994039535522
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 0.00029997018282301724
respectively O 0 0.0002658234734553844
. O 0 9.872477676253766e-05

Recently O 0 2.5465624275966547e-05
, O 0 2.6028471893368987e-06
an O 0 3.4145559766329825e-06
isoleucine O 0 0.001462942804209888
- O 0 0.00022522147628478706
- O 0 0.00023768399842083454
> O 0 5.984197196085006e-05
lysine O 0 1.0822667718457524e-05
polymorphism O 0 2.8159965950180776e-06
at O 0 8.881638677848969e-07
codon O 0 2.961643986054696e-06
1307 O 0 1.6844807760207914e-05
( O 0 3.63617914445058e-07
I1307K O 0 2.7893968308490003e-06
) O 0 5.037484385184143e-08
of O 0 1.1148490131063227e-07
the O 0 8.771703505772166e-07
APC B-Disease 0 3.8841404602862895e-05
gene O 0 4.0922918742580805e-07
has O 0 6.034036914570606e-08
been O 0 3.027936301691625e-08
identified O 0 5.223429155876147e-08
in O 0 3.0084727598023164e-08
6 O 0 2.666015461727511e-07
% O 0 1.6129330049352575e-07
- O 0 4.4022198153470526e-07
7 O 0 5.257974748928973e-07
% O 0 1.7831349907737604e-07
of O 0 2.6491969151720696e-07
the O 0 1.5846409269215656e-06
Ashkenazi O 0 3.715912316692993e-05
Jewish O 0 7.291100246220594e-06
population O 0 5.909855644858908e-06
. O 0 3.0929182685213163e-05

To O 0 2.7115547709399834e-06
assess O 0 2.737929889917723e-06
the O 0 1.960967438208172e-06
risk O 0 1.8026385077973828e-06
of O 0 1.2591797258210136e-06
this O 0 1.2614418665179983e-06
common O 0 7.794837983965408e-06
APC B-Disease 0 0.021861355751752853
allelic O 0 0.0023269474040716887
variant O 0 0.002359065692871809
in O 0 4.526005432126112e-05
colorectal O 1 1.0
carcinogenesis O 1 0.9999985694885254
, O 0 2.2185088255355367e-06
we O 0 1.375833136307847e-07
have O 0 3.602868403618231e-08
analyzed O 0 1.650448950840655e-07
a O 0 4.438549581209372e-07
large O 0 1.260988256035489e-06
cohort O 0 2.329426206415519e-05
of O 0 3.7336471905291546e-06
unselected O 0 0.001524689025245607
Ashkenazi O 0 8.142345177475363e-05
Jewish O 0 4.15285512644914e-06
subjects O 0 4.699027613241924e-06
with O 0 7.2656330303289e-06
adenomatous B-Disease 1 0.999995231628418
polyps I-Disease 1 0.9975542426109314
and O 0 3.879054020217154e-06
. O 0 1.1579944839468226e-05
or O 1 0.7179123759269714
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 8.579205314163119e-06
for O 0 3.0043152037251275e-06
the O 0 3.7989615520928055e-05
APC O 0 0.09256010502576828
I1307K O 0 0.016671331599354744
polymorphism O 0 0.0005916916998103261
. O 0 9.593056165613234e-05

The O 0 8.352781151188537e-05
APC O 0 0.001244444982148707
I1307K O 0 0.0002789467107504606
allele O 0 1.4211652342055459e-05
was O 0 4.248025561537361e-06
identified O 0 5.080539722257527e-07
in O 0 1.0651993420651706e-07
48 O 0 2.000245018507485e-07
( O 0 5.341529529800937e-08
10 O 0 5.5343459592904765e-08
. O 0 2.4343751903188604e-08
1 O 0 1.7898048554343404e-07
% O 0 2.0186516280773503e-07
) O 0 1.8539829227393056e-07
of O 0 1.5302066458389163e-06
476 O 0 0.0001072421291610226
patients O 0 6.918976578162983e-05
. O 0 4.476889080251567e-05

Compared O 0 8.070713192864787e-06
with O 0 4.997052656108281e-07
the O 0 6.578537750101532e-07
frequency O 0 4.821897618967341e-07
in O 0 4.8689383191913294e-08
two O 0 1.6137139624561314e-08
separate O 0 5.5851085534186495e-08
population O 0 6.222088444474139e-08
control O 0 3.627579303611128e-07
groups O 0 7.485870412438089e-08
, O 0 2.1784300940907997e-07
the O 0 2.1331898096832447e-06
APC O 0 0.003401165595278144
I1307K O 0 0.00031241620308719575
allele O 0 3.727776629602886e-06
is O 0 1.0228361446706913e-07
associated O 0 9.135755618672192e-08
with O 0 5.6329625408579886e-08
an O 0 2.3451609365565673e-07
estimated O 0 1.1967879345320398e-06
relative O 0 1.2536393114714883e-06
risk O 0 2.034685167018324e-06
of O 0 3.030114157809294e-06
1 O 0 5.492136187967844e-05
. O 0 4.471862848731689e-05

5 O 0 0.0002490348706487566
- O 0 0.0005000026430934668
1 O 0 0.00026996570522896945
. O 0 0.00019610614981502295

7 O 0 5.778595004812814e-05
for O 0 4.112394526600838e-05
colorectal B-Disease 1 0.9999998807907104
neoplasia I-Disease 1 0.9999310970306396
( O 0 7.778441613481846e-06
both O 0 2.0528448203549488e-06
P O 0 0.00022933739819563925
= O 0 7.048100997053552e-06
. O 0 1.1994936812698143e-06
01 O 0 0.00010639070387696847
) O 0 6.503559234261047e-06
. O 0 2.2613550754613243e-05

Furthermore O 0 2.9244807592476718e-05
, O 0 2.9465854822774418e-06
compared O 0 3.074692131121992e-06
with O 0 2.023550678131869e-06
noncarriers O 0 0.025056198239326477
, O 0 1.9019609680981375e-05
APC O 0 0.006016913801431656
I1307K O 0 0.00019892309501301497
carriers O 0 1.5043323173813405e-06
had O 0 3.0008337148501596e-07
increased O 0 2.2529374632540566e-07
numbers O 0 1.1603611937971436e-07
of O 0 1.2664331734413281e-06
adenomas B-Disease 1 0.987518846988678
and O 0 2.7125093765789643e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9998332262039185
per O 0 1.9888373117282754e-06
patient O 0 2.228580524388235e-05
( O 0 9.78009325081075e-07
P O 0 6.58391581964679e-05
= O 0 7.808831696820562e-07
. O 0 6.734703816846377e-08
03 O 0 3.104006964349537e-06
) O 0 3.941820736486079e-08
, O 0 3.0444233800608345e-08
as O 0 2.3994099151991577e-08
well O 0 3.243436808020306e-08
as O 0 9.522177890630701e-08
a O 0 5.089355568088649e-07
younger O 0 1.767101480254496e-06
age O 0 4.9186373871634714e-06
at O 0 2.6602312573231757e-05
diagnosis O 0 0.4955889880657196
. O 0 0.00010543046664679423

We O 0 5.4919864851399325e-06
conclude O 0 7.50608205635217e-06
that O 0 8.308589940497768e-07
the O 0 4.414278009789996e-06
APC O 0 0.0007402000483125448
I1307K O 0 0.00037503259954974055
variant O 0 3.427055344218388e-05
leads O 0 1.8977656282004318e-06
to O 0 2.772952711893595e-07
increased O 0 1.4305926015367731e-05
adenoma B-Disease 1 0.9999985694885254
formation O 0 3.3654550861683674e-06
and O 0 8.124393957587017e-08
directly O 0 2.805274945671954e-08
contributes O 0 6.294243348747841e-08
to O 0 8.658568972919056e-09
3 O 0 6.903439953021007e-08
% O 0 4.0505511833544006e-08
- O 0 1.904403603703031e-07
4 O 0 2.4427666289739136e-07
% O 0 9.811784451585481e-08
of O 0 1.5861921554005676e-07
all O 0 3.357641276124923e-07
Ashkenazi O 0 0.0033861061092466116
Jewish O 1 0.6027177572250366
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.08154819905757904

The O 0 9.480154403718188e-06
estimated O 0 7.58946316636866e-06
relative O 0 4.896831342193764e-06
risk O 0 2.45426031142415e-06
for O 0 4.042409500470967e-07
carriers O 0 1.0791105751195573e-06
may O 0 2.2310706526695867e-07
justify O 0 4.783269105246291e-07
specific O 0 2.5030708172835148e-08
clinical O 0 2.1008096950936306e-07
screening O 0 2.9776180099361227e-07
for O 0 5.569099315039239e-08
the O 0 1.4184161045704968e-07
360 O 0 4.331610057306534e-07
, O 0 1.1438868341429043e-07
000 O 0 3.2797865401335e-07
Americans O 0 6.495741189382898e-08
expected O 0 7.863416584541483e-08
to O 0 6.384236428402801e-08
harbor O 0 3.5923194445786066e-06
this O 0 8.951026586601074e-08
allele O 0 3.837883184587554e-07
, O 0 4.84319890858842e-08
and O 0 3.779210544507805e-08
genetic O 0 1.9784729943239654e-07
testing O 0 9.012115498308049e-08
in O 0 2.5137497416949373e-08
the O 0 5.976218631076335e-08
setting O 0 2.6406107167531445e-07
of O 0 3.4409194427098555e-07
long O 0 5.288652005219774e-07
- O 0 1.5499846313105081e-06
term O 0 7.312361844924453e-07
- O 0 8.510474458489625e-07
outcome O 0 2.2886298722823994e-07
studies O 0 1.254121997362745e-07
may O 0 1.408372867217622e-07
impact O 0 9.345927765025408e-07
significantly O 0 1.9982480807811953e-06
on O 0 6.882329762447625e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 1 0.5932034254074097
in O 0 1.5676093880756525e-06
this O 0 1.3044342495049932e-06
population O 0 3.2133129934663884e-06
. O 0 1.4784537597734015e-05

Localization O 0 0.000588775728829205
of O 0 1.8431233911542222e-05
human O 0 8.049804819165729e-06
BRCA1 O 0 3.8143425626913086e-05
and O 0 4.3302139829393127e-07
its O 0 4.550814480808185e-07
loss O 0 1.3575378943642136e-05
in O 0 6.587094389942649e-07
high O 0 7.667348654649686e-06
- O 0 4.234377411194146e-05
grade O 0 8.535105735063553e-05
, O 0 2.4968637717392994e-06
non B-Disease 0 0.00013355824921745807
- I-Disease 1 0.994484007358551
inherited I-Disease 1 0.9999982118606567
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.31328555941581726

Although O 0 6.2156514104572125e-06
the O 0 2.3076631805452053e-06
link O 0 4.601969521900173e-06
between O 0 1.5096441075002076e-06
the O 0 2.316285826964304e-05
BRCA1 O 1 0.9998348951339722
tumour B-Disease 1 1.0
- O 1 0.965675950050354
suppressor O 1 0.9971032738685608
gene O 0 1.660469024500344e-05
and O 0 3.804767402471043e-06
hereditary B-Disease 1 0.9999998807907104
breast I-Disease 1 1.0
and I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.276948938146234e-05
established O 0 1.7667914562480291e-06
, O 0 1.1810848832283227e-07
the O 0 1.4647288537616987e-07
role O 0 3.7982601952535333e-07
, O 0 8.58136530723641e-08
if O 0 2.783295371955319e-08
any O 0 3.679475923945574e-08
, O 0 7.893982711948411e-08
of O 0 6.336317710520234e-07
BRCA1 O 0 7.430122059304267e-05
in O 0 1.2354200862318976e-06
non B-Disease 0 0.00022745548631064594
- I-Disease 1 0.9930974841117859
familial I-Disease 1 0.9999955892562866
cancers I-Disease 1 0.9999957084655762
is O 0 4.2966410546796396e-05
unclear O 0 6.79558579577133e-05
. O 0 5.256131771602668e-05

BRCA1 O 0 0.01581640914082527
mutations O 0 1.7191983715747483e-05
are O 0 3.193755446773139e-07
rare O 0 3.0454391435341677e-06
in O 0 1.1830052244476974e-06
sporadic B-Disease 0 0.0016431910917162895
cancers I-Disease 1 0.8687686920166016
, O 0 1.3445021522784373e-06
but O 0 3.805874655427033e-07
loss O 0 2.546771429479122e-05
of O 0 8.218026778195053e-06
BRCA1 O 0 0.0028206149581819773
resulting O 0 1.827265009524126e-06
from O 0 3.4934728887492383e-07
reduced O 0 2.038324737441144e-06
expression O 0 7.797668217790488e-07
or O 0 2.2126762644347764e-07
incorrect O 0 1.23907898341713e-06
subcellular O 0 2.054872311418876e-05
localization O 0 2.392608621448744e-05
is O 0 2.4932654696385725e-07
postulated O 0 8.347586799573037e-07
to O 0 2.2034523539105066e-08
be O 0 2.0675489764698796e-08
important O 0 8.960216746345395e-08
in O 0 3.0826615216028586e-07
non B-Disease 0 1.117575720854802e-05
- I-Disease 0 0.3672286868095398
familial I-Disease 1 0.9999841451644897
breast I-Disease 1 1.0
and I-Disease 1 0.9999978542327881
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.8083751201629639

Epigenetic O 0 0.003619808703660965
loss O 0 0.0033285249955952168
, O 0 7.121299404388992e-06
however O 0 1.2342353556960006e-06
, O 0 3.3570012192285503e-07
has O 0 1.1612623751489082e-07
not O 0 2.2523266807183973e-08
received O 0 1.0959436735902273e-07
general O 0 3.6651454138336703e-07
acceptance O 0 6.608777312067105e-07
due O 0 3.5538312204153044e-07
to O 0 6.785324302427398e-08
controversy O 0 6.168618824631267e-07
regarding O 0 1.34204853452502e-07
the O 0 1.927782022903557e-07
subcellular O 0 1.3596770259027835e-05
localization O 0 1.633403189771343e-05
of O 0 9.80674826678296e-07
BRCA1 O 0 1.262687237613136e-05
proteins O 0 1.3030873446950864e-07
, O 0 3.926812652821354e-08
reports O 0 2.473984750395175e-08
of O 0 5.368668354321926e-08
which O 0 2.5414122362121816e-08
have O 0 1.1743299666022722e-08
ranged O 0 1.7704977040011727e-07
from O 0 5.019625604063549e-08
exclusively O 0 1.531466580217966e-07
nuclear O 0 6.631960900449485e-07
, O 0 4.967820643742016e-08
to O 0 3.3112520725353534e-08
conditionally O 0 1.9460781004454475e-06
nuclear O 0 8.22532001620857e-07
, O 0 6.638656913082741e-08
to O 0 7.363208709421087e-08
the O 0 1.4872815654598526e-06
ER O 0 0.17012980580329895
/ O 0 0.0002053939097095281
golgi O 0 0.00023310894903261214
, O 0 5.96802863128687e-07
to O 0 4.123460257687839e-07
cytoplasmic O 0 1.0820014722412452e-05
invaginations O 0 2.765453427855391e-05
into O 0 8.391037908950238e-07
the O 0 4.581113444146467e-06
nucleus O 0 0.00011520802218001336
. O 0 2.7432082788436674e-05

In O 0 6.608502644667169e-06
an O 0 1.8711466509557795e-06
attempt O 0 1.7079986491808086e-06
to O 0 1.5162800082180183e-07
resolve O 0 9.221580512530636e-07
this O 0 1.598934744606595e-07
issue O 0 4.1800865346885985e-07
, O 0 2.329424120262047e-07
we O 0 1.3215280603162682e-07
have O 0 1.0161257080198993e-07
comprehensively O 0 5.459265594254248e-06
characterized O 0 6.698744073219132e-06
19 O 0 2.16820917557925e-05
anti O 0 0.0030555541161447763
- O 0 0.2686844766139984
BRCA1 O 0 0.09093405306339264
antibodies O 0 5.6188771850429475e-05
. O 0 3.471735544735566e-05

These O 0 8.774734851613175e-06
reagents O 0 3.854308306472376e-05
detect O 0 8.498296665493399e-06
a O 0 3.466693897280493e-06
220 O 0 8.189289474103134e-06
- O 0 2.1813644707435742e-05
kD O 0 0.00014061359979677945
protein O 0 1.3091774917484145e-06
localized O 0 1.35178163418459e-06
in O 0 8.312871813132006e-08
discrete O 0 6.383955906130723e-07
nuclear O 0 1.1912311492778827e-06
foci O 0 2.620241275508306e-06
in O 0 1.7926524265021726e-07
all O 0 3.154855789944122e-07
epithelial O 1 0.9984239339828491
cell O 0 0.00013648525055032223
lines O 0 9.217069987244031e-07
, O 0 1.1769134289352223e-07
including O 0 1.668910272201174e-07
those O 0 2.0978026782358938e-07
derived O 0 2.6239472390443552e-06
from O 0 1.0559126167208888e-05
breast B-Disease 1 0.9995197057723999
malignancies I-Disease 1 0.9998641014099121
. O 0 0.0006559288594871759

Immunohistochemical O 1 0.5455252528190613
staining O 0 0.0021525451447814703
of O 0 5.8984529459849e-05
human O 0 0.0001400954060954973
breast O 1 0.9915446043014526
specimens O 0 9.1227499069646e-05
also O 0 8.38254072732525e-06
revealed O 0 0.0001540494558867067
BRCA1 O 0 0.0074214814230799675
nuclear O 0 7.454449951183051e-05
foci O 0 0.00029732505208812654
in O 0 1.2992027222935576e-05
benign O 1 0.999988317489624
breast O 1 0.9999980926513672
, O 0 0.22452417016029358
invasive B-Disease 1 0.9999998807907104
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999940395355225
and O 0 3.1037296139402315e-05
low B-Disease 0 0.21980427205562592
- I-Disease 1 0.9999018907546997
grade I-Disease 1 0.9999879598617554
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00092893693363294

Conversely O 0 0.0001956563937710598
, O 0 1.3533058336179238e-05
BRCA1 O 0 0.0001299666182603687
expression O 0 4.148572315898491e-06
was O 0 6.74134207656607e-06
reduced O 0 1.8269182646690751e-06
or O 0 2.3154220230026112e-07
undetectable O 0 1.7721880567478365e-06
in O 0 7.867587470400395e-08
the O 0 1.2041890329328453e-07
majority O 0 1.2131661719649856e-07
of O 0 4.970911504642572e-07
high O 0 4.705978426500224e-06
- O 0 3.8523201510543004e-05
grade O 0 0.0009139188914559782
, O 0 5.2391773351700976e-05
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 1.256165660379338e-06
suggesting O 0 1.0065538162962184e-06
that O 0 1.0534622418845174e-07
absence O 0 1.3397994962360826e-06
of O 0 2.933047198894201e-06
BRCA1 O 0 0.0005255643045529723
may O 0 1.6421121529219818e-07
contribute O 0 1.262542781432785e-07
to O 0 3.9537553675472736e-08
the O 0 2.329170882831022e-07
pathogenesis O 0 0.0020763445645570755
of O 0 2.1163458541195723e-07
a O 0 4.601086800448684e-07
significant O 0 3.019459029474092e-07
percentage O 0 3.608150507261598e-07
of O 0 1.720449176900729e-06
sporadic B-Disease 0 0.2057957649230957
breast I-Disease 1 0.9999990463256836
cancers I-Disease 1 0.9999915361404419
. O 0 7.069776620483026e-05
. O 0 0.00012145684740971774

